DB00001 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Lepirudin.
DB00001 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.
DB00001 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.
DB00001 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.
DB00001 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.
DB00001 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycochenodeoxycholic Acid.
DB00001 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Cholic Acid.
DB00001 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycocholic acid.
DB00001 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid.
DB00001 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid.
DB00001 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Obeticholic acid.
DB00001 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid.
DB00001 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid.
DB00001 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid.
DB00001 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2.
DB00001 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid.
DB00001 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Hyodeoxycholic Acid.
DB00001 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin.
DB00001 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.
DB00001 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab.
DB00001 DB06228 Rivaroxaban Lepirudin may increase the anticoagulant activities of Rivaroxaban.
DB00001 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.
DB00001 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Lepirudin.
DB00001 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.
DB00001 DB00013 Urokinase Urokinase may increase the anticoagulant activities of Lepirudin.
DB00001 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Lepirudin.
DB00001 DB09030 Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin.
DB00001 DB01381 Ginkgo biloba The therapeutic efficacy of Lepirudin can be increased when used in combination with Ginkgo biloba.
DB00001 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin.
DB00001 DB00468 Quinine The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.
DB00001 DB00908 Quinidine The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine.
DB00001 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin.
DB00001 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin.
DB00001 DB00806 Pentoxifylline The therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline.
DB00001 DB00686 Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Lepirudin.
DB00001 DB00583 Levocarnitine The therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine.
DB00001 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB04573 Estriol Estriol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Lepirudin.
DB00001 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB11674 Equol Equol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Lepirudin.
DB00001 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.
DB00001 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin.
DB00001 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Lepirudin.
DB00001 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.
DB00001 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin.
DB00001 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin.
DB00001 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin.
DB00001 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin.
DB00001 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin.
DB00001 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin.
DB00001 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin.
DB00001 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin.
DB00001 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin.
DB00001 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin.
DB00001 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.
DB00001 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin.
DB00001 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin.
DB00001 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin.
DB00001 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.
DB00001 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Lepirudin.
DB00001 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin.
DB00001 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.
DB00001 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin.
DB00001 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Lepirudin.
DB00001 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Lepirudin.
DB00001 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin.
DB00001 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin.
DB00001 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin.
DB00001 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Lepirudin.
DB00001 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Lepirudin.
DB00001 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin.
DB00001 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin.
DB00001 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin.
DB00001 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin.
DB00001 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin.
DB00001 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin.
DB00001 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin.
DB00001 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin.
DB00001 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin.
DB00001 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin.
DB00001 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin.
DB00001 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Lepirudin.
DB00001 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin.
DB00001 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin.
DB00001 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Lepirudin.
DB00001 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin.
DB00001 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin.
DB00001 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin.
DB00001 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin.
DB00001 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin.
DB00001 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin.
DB00001 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Lepirudin.
DB00001 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin.
DB00001 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin.
DB00001 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin.
DB00001 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin.
DB00001 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin.
DB00001 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin.
DB00001 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin.
DB00001 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin.
DB00001 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin.
DB00001 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin.
DB00001 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin.
DB00001 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin.
DB00001 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin.
DB00001 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin.
DB00001 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Lepirudin.
DB00001 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin.
DB00001 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin.
DB00001 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin.
DB00001 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin.
DB00001 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin.
DB00001 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin.
DB00001 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin.
DB00001 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin.
DB00001 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Lepirudin.
DB00001 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Lepirudin.
DB00001 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin.
DB00001 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin.
DB00001 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin.
DB00001 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin.
DB00001 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin.
DB00001 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin.
DB00001 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin.
DB00001 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Lepirudin.
DB00001 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Lepirudin.
DB00001 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin.
DB00001 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin.
DB00001 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin.
DB00001 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin.
DB00001 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Lepirudin.
DB00001 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Lepirudin.
DB00001 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin.
DB00001 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin.
DB00001 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Lepirudin.
DB00001 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin.
DB00001 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Lepirudin.
DB00001 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin.
DB00001 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin.
DB00001 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin.
DB00001 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin.
DB00001 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin.
DB00001 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin.
DB00001 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin.
DB00001 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Lepirudin.
DB00001 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.
DB00001 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.
DB00001 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.
DB00001 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.
DB00001 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Lepirudin.
DB00001 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Lepirudin.
DB00001 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Lepirudin.
DB00001 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Lepirudin.
DB00001 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Lepirudin.
DB00001 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Lepirudin.
DB00001 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Lepirudin.
DB00001 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Lepirudin.
DB00001 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Lepirudin.
DB00001 DB00834 Mifepristone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mifepristone.
DB00001 DB04066 p-Coumaric acid The therapeutic efficacy of Lepirudin can be decreased when used in combination with p-Coumaric acid.
DB00001 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Lepirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00001 DB05830 Trestolone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trestolone.
DB00001 DB06266 Lonidamine The therapeutic efficacy of Lepirudin can be decreased when used in combination with Lonidamine.
DB00001 DB08867 Ulipristal The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ulipristal.
DB00001 DB09401 Isosorbide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Isosorbide.
DB00001 DB11507 Cloprostenol The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cloprostenol.
DB00001 DB12025 Triptolide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triptolide.
DB00001 DB13044 Gossypol The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gossypol.
DB00001 DB13310 Ormeloxifene The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ormeloxifene.
DB00001 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Lepirudin.
DB00001 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Lepirudin.
DB00001 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Lepirudin.
DB00001 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Lepirudin.
DB00001 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Lepirudin.
DB00001 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Lepirudin.
DB00001 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Lepirudin.
DB00001 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Lepirudin.
DB00001 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.
DB00001 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Lepirudin.
DB00001 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Lepirudin.
DB00001 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin.
DB00001 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin.
DB00001 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin.
DB00001 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Lepirudin.
DB00001 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin.
DB00001 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Lepirudin.
DB00001 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Lepirudin.
DB00001 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.
DB00001 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin.
DB00001 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Lepirudin.
DB00001 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Lepirudin.
DB00001 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin.
DB00001 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.
DB00001 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Lepirudin.
DB00001 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.
DB00001 DB01166 Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Lepirudin.
DB00001 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Lepirudin.
DB00001 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Lepirudin.
DB00001 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.
DB00001 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin.
DB00001 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Lepirudin.
DB00001 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin.
DB00001 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Lepirudin.
DB00001 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Lepirudin.
DB00001 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Lepirudin.
DB00001 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Lepirudin.
DB00001 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin.
DB00001 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Lepirudin.
DB00001 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Lepirudin.
DB00001 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin.
DB00001 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Lepirudin.
DB00001 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.
DB00001 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin.
DB00001 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin.
DB00001 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin.
DB00001 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin.
DB00001 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Lepirudin.
DB00001 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Lepirudin.
DB00001 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Lepirudin.
DB00001 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Lepirudin.
DB00001 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Lepirudin.
DB00001 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin.
DB00001 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Lepirudin.
DB00001 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Lepirudin.
DB00001 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Lepirudin.
DB00001 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Lepirudin.
DB00001 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Lepirudin.
DB00001 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin.
DB00001 DB00374 Treprostinil The risk or severity of bleeding can be increased when Treprostinil is combined with Lepirudin.
DB00001 DB03404 Hemin Hemin may increase the anticoagulant activities of Lepirudin.
DB00001 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Lepirudin.
DB00001 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Lepirudin.
DB00001 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Lepirudin.
DB00001 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Lepirudin.
DB00001 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Lepirudin.
DB00001 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Lepirudin.
DB00001 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Lepirudin.
DB00001 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Lepirudin.
DB00001 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Lepirudin.
DB00001 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Lepirudin.
DB00001 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Lepirudin.
DB00001 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Lepirudin.
DB00001 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Lepirudin.
DB00001 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Lepirudin.
DB00001 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.
DB00001 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.
DB00001 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.
DB00001 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.
DB00001 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.
DB00001 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Lepirudin.
DB00001 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Lepirudin.
DB00001 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Lepirudin.
DB00001 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Lepirudin.
DB00001 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Lepirudin.
DB00001 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Lepirudin.
DB00001 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Lepirudin.
DB00001 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Lepirudin.
DB00001 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Lepirudin.
DB00001 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Lepirudin.
DB00001 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Lepirudin.
DB00001 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Lepirudin.
DB00001 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Lepirudin.
DB00001 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Lepirudin.
DB00001 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin.
DB00001 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Lepirudin.
DB00001 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Lepirudin.
DB00001 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin.
DB00001 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Lepirudin.
DB00001 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.
DB00001 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin.
DB00001 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin.
DB00001 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Lepirudin.
DB00001 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.
DB00001 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Lepirudin.
DB00001 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Lepirudin.
DB00001 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Lepirudin.
DB00001 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Lepirudin.
DB00001 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Lepirudin.
DB00001 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Lepirudin.
DB00001 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Lepirudin.
DB00001 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Lepirudin.
DB00001 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Lepirudin.
DB00001 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Lepirudin.
DB00001 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.
DB00001 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.
DB00001 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Lepirudin.
DB00001 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Lepirudin.
DB00001 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Lepirudin.
DB00001 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Lepirudin.
DB00001 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Lepirudin.
DB00001 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Lepirudin.
DB00001 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Lepirudin.
DB00001 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin.
DB00001 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin.
DB00001 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Lepirudin.
DB00001 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Lepirudin.
DB00001 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Lepirudin.
DB00001 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Lepirudin.
DB00001 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Lepirudin.
DB00001 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Lepirudin.
DB00001 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Lepirudin.
DB00001 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Lepirudin.
DB00001 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.
DB00001 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Lepirudin.
DB00001 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Lepirudin.
DB00001 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Lepirudin.
DB00001 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin.
DB00001 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Lepirudin.
DB00001 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Lepirudin.
DB00001 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.
DB00001 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Lepirudin.
DB00001 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Lepirudin.
DB00001 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Lepirudin.
DB00001 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Lepirudin.
DB00001 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Lepirudin.
DB00001 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lepirudin.
DB00001 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Lepirudin.
DB00001 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Lepirudin.
DB00001 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Lepirudin.
DB00001 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Lepirudin.
DB00001 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Lepirudin.
DB00001 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Lepirudin.
DB00001 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Lepirudin.
DB00001 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Lepirudin.
DB00001 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Lepirudin.
DB00001 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Lepirudin.
DB00001 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Lepirudin.
DB00001 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Lepirudin.
DB00001 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Lepirudin.
DB00001 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Lepirudin.
DB00001 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Lepirudin.
DB00001 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Lepirudin.
DB00001 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Lepirudin.
DB00001 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Lepirudin.
DB00001 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Lepirudin.
DB00001 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Lepirudin.
DB00001 DB00682 Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Lepirudin.
DB00001 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Lepirudin.
DB00001 DB00974 Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Lepirudin.
DB00001 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Lepirudin.
DB00001 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Lepirudin.
DB00001 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.
DB00001 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Lepirudin.
DB00001 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Lepirudin.
DB00001 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Lepirudin.
DB00001 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Lepirudin.
DB00001 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Lepirudin.
DB00001 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Lepirudin.
DB00001 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Lepirudin.
DB00001 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Lepirudin.
DB00001 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Lepirudin.
DB00001 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Lepirudin.
DB00001 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Lepirudin.
DB00001 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Lepirudin.
DB00001 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Lepirudin.
DB00001 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Lepirudin.
DB00001 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Lepirudin.
DB00001 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Lepirudin.
DB00001 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Lepirudin.
DB00001 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Lepirudin.
DB00001 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Lepirudin.
DB00001 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Lepirudin.
DB00001 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Lepirudin.
DB00001 DB13124 Troxerutin The risk or severity of bleeding can be increased when Troxerutin is combined with Lepirudin.
DB00001 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Lepirudin.
DB00001 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Lepirudin.
DB00001 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Lepirudin.
DB00001 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Lepirudin.
DB00001 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Lepirudin.
DB00001 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin.
DB00001 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.
DB00001 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Lepirudin.
DB00001 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Lepirudin.
DB00001 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Lepirudin.
DB00001 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.
DB00001 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Lepirudin.
DB00001 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Lepirudin.
DB00001 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Lepirudin.
DB00001 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Lepirudin.
DB00001 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Lepirudin.
DB00001 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Lepirudin.
DB00001 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Lepirudin.
DB00001 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Lepirudin.
DB00001 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Lepirudin.
DB00001 DB00009 Alteplase The risk or severity of bleeding can be increased when Lepirudin is combined with Alteplase.
DB00001 DB00015 Reteplase The risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.
DB00001 DB00029 Anistreplase The risk or severity of bleeding can be increased when Lepirudin is combined with Anistreplase.
DB00001 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Lepirudin is combined with Tocopherylquinone.
DB00001 DB06679 Amediplase The risk or severity of bleeding can be increased when Lepirudin is combined with Amediplase.
DB00001 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Lepirudin is combined with 4-hydroxycoumarin.
DB00001 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Lepirudin is combined with (R)-warfarin.
DB00001 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Lepirudin is combined with (S)-Warfarin.
DB00001 DB12364 Betrixaban The risk or severity of bleeding can be increased when Lepirudin is combined with Betrixaban.
DB00001 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Lepirudin is combined with Edetate calcium disodium anhydrous.
DB00001 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Lepirudin is combined with Zinc citrate.
DB00001 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.
DB00001 DB04665 Coumarin The risk or severity of bleeding can be increased when Lepirudin is combined with Coumarin.
DB00001 DB14726 Dabigatran The risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran.
DB00001 DB06294 Semuloparin The risk or severity of bleeding can be increased when Lepirudin is combined with Semuloparin.
DB00001 DB12726 Monteplase The risk or severity of bleeding can be increased when Lepirudin is combined with Monteplase.
DB00001 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Lepirudin is combined with Sildenafil.
DB00001 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.
DB00001 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.
DB00001 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3.
DB00001 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.
DB00001 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b.
DB00001 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2a, Recombinant.
DB00001 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin.
DB00001 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.
DB00001 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.
DB00001 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.
DB00001 DB00073 Rituximab The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.
DB00001 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.
DB00001 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.
DB00001 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.
DB00001 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Lepirudin is combined with Phenylalanine.
DB00001 DB00188 Bortezomib The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib.
DB00001 DB00242 Cladribine The risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine.
DB00001 DB00262 Carmustine The risk or severity of bleeding can be increased when Lepirudin is combined with Carmustine.
DB00001 DB00276 Amsacrine The risk or severity of bleeding can be increased when Lepirudin is combined with Amsacrine.
DB00001 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Lepirudin is combined with Chlorambucil.
DB00001 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Lepirudin is combined with Raltitrexed.
DB00001 DB00305 Mitomycin The risk or severity of bleeding can be increased when Lepirudin is combined with Mitomycin.
DB00001 DB00307 Bexarotene The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene.
DB00001 DB00309 Vindesine The risk or severity of bleeding can be increased when Lepirudin is combined with Vindesine.
DB00001 DB00322 Floxuridine The risk or severity of bleeding can be increased when Lepirudin is combined with Floxuridine.
DB00001 DB00352 Tioguanine The risk or severity of bleeding can be increased when Lepirudin is combined with Tioguanine.
DB00001 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Lepirudin is combined with Vinorelbine.
DB00001 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane.
DB00001 DB00398 Sorafenib The risk or severity of bleeding can be increased when Lepirudin is combined with Sorafenib.
DB00001 DB00428 Streptozocin The risk or severity of bleeding can be increased when Lepirudin is combined with Streptozocin.
DB00001 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Lepirudin is combined with Gemcitabine.
DB00001 DB00444 Teniposide The risk or severity of bleeding can be increased when Lepirudin is combined with Teniposide.
DB00001 DB00445 Epirubicin The risk or severity of bleeding can be increased when Lepirudin is combined with Epirubicin.
DB00001 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Lepirudin is combined with Chloramphenicol.
DB00001 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Lepirudin is combined with Lenalidomide.
DB00001 DB00488 Altretamine The risk or severity of bleeding can be increased when Lepirudin is combined with Altretamine.
DB00001 DB00495 Zidovudine The risk or severity of bleeding can be increased when Lepirudin is combined with Zidovudine.
DB00001 DB00515 Cisplatin The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.
DB00001 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.
DB00001 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.
DB00001 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil.
DB00001 DB00552 Pentostatin The risk or severity of bleeding can be increased when Lepirudin is combined with Pentostatin.
DB00001 DB00563 Methotrexate The risk or severity of bleeding can be increased when Lepirudin is combined with Methotrexate.
DB00001 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Lepirudin is combined with Carbamazepine.
DB00001 DB00570 Vinblastine The risk or severity of bleeding can be increased when Lepirudin is combined with Vinblastine.
DB00001 DB00619 Imatinib The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.
DB00001 DB00631 Clofarabine The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine.
DB00001 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Lepirudin is combined with Pemetrexed.
DB00001 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.
DB00001 DB00762 Irinotecan The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.
DB00001 DB00773 Etoposide The risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide.
DB00001 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Lepirudin is combined with Dacarbazine.
DB00001 DB00853 Temozolomide The risk or severity of bleeding can be increased when Lepirudin is combined with Temozolomide.
DB00001 DB00859 Penicillamine The risk or severity of bleeding can be increased when Lepirudin is combined with Penicillamine.
DB00001 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.
DB00001 DB00877 Sirolimus The risk or severity of bleeding can be increased when Lepirudin is combined with Sirolimus.
DB00001 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Lepirudin is combined with Mechlorethamine.
DB00001 DB00928 Azacitidine The risk or severity of bleeding can be increased when Lepirudin is combined with Azacitidine.
DB00001 DB00958 Carboplatin The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.
DB00001 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin.
DB00001 DB00987 Cytarabine The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.
DB00001 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Lepirudin is combined with Doxorubicin.
DB00001 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Lepirudin is combined with Hydroxyurea.
DB00001 DB01008 Busulfan The risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan.
DB00001 DB01030 Topotecan The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.
DB00001 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Lepirudin is combined with Mercaptopurine.
DB00001 DB01041 Thalidomide The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.
DB00001 DB01042 Melphalan The risk or severity of bleeding can be increased when Lepirudin is combined with Melphalan.
DB00001 DB01073 Fludarabine The risk or severity of bleeding can be increased when Lepirudin is combined with Fludarabine.
DB00001 DB01099 Flucytosine The risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine.
DB00001 DB01101 Capecitabine The risk or severity of bleeding can be increased when Lepirudin is combined with Capecitabine.
DB00001 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.
DB00001 DB01177 Idarubicin The risk or severity of bleeding can be increased when Lepirudin is combined with Idarubicin.
DB00001 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.
DB00001 DB01206 Lomustine The risk or severity of bleeding can be increased when Lepirudin is combined with Lomustine.
DB00001 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.
DB00001 DB01248 Docetaxel The risk or severity of bleeding can be increased when Lepirudin is combined with Docetaxel.
DB00001 DB01262 Decitabine The risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine.
DB00001 DB01280 Nelarabine The risk or severity of bleeding can be increased when Lepirudin is combined with Nelarabine.
DB00001 DB01590 Everolimus The risk or severity of bleeding can be increased when Lepirudin is combined with Everolimus.
DB00001 DB02546 Vorinostat The risk or severity of bleeding can be increased when Lepirudin is combined with Vorinostat.
DB00001 DB04572 Thiotepa The risk or severity of bleeding can be increased when Lepirudin is combined with Thiotepa.
DB00001 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Lepirudin is combined with Ixabepilone.
DB00001 DB04868 Nilotinib The risk or severity of bleeding can be increased when Lepirudin is combined with Nilotinib.
DB00001 DB05015 Belinostat The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat.
DB00001 DB05109 Trabectedin The risk or severity of bleeding can be increased when Lepirudin is combined with Trabectedin.
DB00001 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa.
DB00001 DB05472 omega interferon The risk or severity of bleeding can be increased when Lepirudin is combined with omega interferon.
DB00001 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Lepirudin is combined with Trastuzumab emtansine.
DB00001 DB06287 Temsirolimus The risk or severity of bleeding can be increased when Lepirudin is combined with Temsirolimus.
DB00001 DB06616 Bosutinib The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib.
DB00001 DB06769 Bendamustine The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.
DB00001 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel.
DB00001 DB08871 Eribulin The risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin.
DB00001 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.
DB00001 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Lepirudin is combined with Carfilzomib.
DB00001 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.
DB00001 DB08901 Ponatinib The risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib.
DB00001 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.
DB00001 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Lepirudin is combined with Tedizolid phosphate.
DB00001 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.
DB00001 DB09073 Palbociclib The risk or severity of bleeding can be increased when Lepirudin is combined with Palbociclib.
DB00001 DB09074 Olaparib The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.
DB00001 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab.
DB00001 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon beta-1a.
DB00001 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Lepirudin is combined with Cepeginterferon alfa-2B.
DB00001 DB00229 Cefotiam The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotiam.
DB00001 DB00267 Cefmenoxime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmenoxime.
DB00001 DB00274 Cefmetazole The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmetazole.
DB00001 DB00430 Cefpiramide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpiramide.
DB00001 DB00438 Ceftazidime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime.
DB00001 DB00447 Loracarbef The therapeutic efficacy of Lepirudin can be decreased when used in combination with Loracarbef.
DB00001 DB00456 Cefalotin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefalotin.
DB00001 DB00493 Cefotaxime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.
DB00001 DB00535 Cefdinir The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefdinir.
DB00001 DB00567 Cephalexin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephalexin.
DB00001 DB00671 Cefixime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime.
DB00001 DB00689 Cephaloglycin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephaloglycin.
DB00001 DB00833 Cefaclor The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaclor.
DB00001 DB00923 Ceforanide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceforanide.
DB00001 DB01066 Cefditoren The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefditoren.
DB00001 DB01112 Cefuroxime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefuroxime.
DB00001 DB01139 Cefapirin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefapirin.
DB00001 DB01140 Cefadroxil The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefadroxil.
DB00001 DB01150 Cefprozil The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefprozil.
DB00001 DB01212 Ceftriaxone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftriaxone.
DB00001 DB01326 Cefamandole The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole.
DB00001 DB01327 Cefazolin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazolin.
DB00001 DB01328 Cefonicid The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefonicid.
DB00001 DB01329 Cefoperazone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoperazone.
DB00001 DB01330 Cefotetan The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotetan.
DB00001 DB01331 Cefoxitin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoxitin.
DB00001 DB01332 Ceftizoxime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftizoxime.
DB00001 DB01333 Cefradine The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefradine.
DB00001 DB01413 Cefepime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefepime.
DB00001 DB01414 Cefacetrile The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefacetrile.
DB00001 DB01415 Ceftibuten The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftibuten.
DB00001 DB01416 Cefpodoxime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpodoxime.
DB00001 DB04570 Latamoxef The therapeutic efficacy of Lepirudin can be decreased when used in combination with Latamoxef.
DB00001 DB04918 Ceftobiprole The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole.
DB00001 DB06590 Ceftaroline fosamil The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftaroline fosamil.
DB00001 DB09008 Cefaloridine The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaloridine.
DB00001 DB09050 Ceftolozane The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftolozane.
DB00001 DB09062 Cefminox The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefminox.
DB00001 DB11367 Cefroxadine The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefroxadine.
DB00001 DB11935 Flomoxef The therapeutic efficacy of Lepirudin can be decreased when used in combination with Flomoxef.
DB00001 DB13266 Cefatrizine The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefatrizine.
DB00001 DB13461 Cefcapene The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefcapene.
DB00001 DB13470 Cefodizime The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefodizime.
DB00001 DB13499 Cefsulodin The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefsulodin.
DB00001 DB13504 Cefetamet The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefetamet.
DB00001 DB13638 Cefbuperazone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefbuperazone.
DB00001 DB13667 Cefozopran The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefozopran.
DB00001 DB13682 Cefpirome The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpirome.
DB00001 DB13778 Cefazedone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazedone.
DB00001 DB13821 Ceftezole The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftezole.
DB00001 DB14725 Cefamandole nafate The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate.
DB00001 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Lepirudin.
DB00001 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Lepirudin.
DB00001 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin.
DB00001 DB00945 Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.
DB00001 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Lepirudin.
DB00001 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin.
DB00001 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin.
DB00001 DB00620 Triamcinolone The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triamcinolone.
DB00001 DB09079 Nintedanib The risk or severity of bleeding can be increased when Lepirudin is combined with Nintedanib.
DB00001 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Lepirudin.
DB00001 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Lepirudin.
DB00001 DB00232 Methyclothiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methyclothiazide.
DB00001 DB00436 Bendroflumethiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide.
DB00001 DB00562 Benzthiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Benzthiazide.
DB00001 DB00606 Cyclothiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclothiazide.
DB00001 DB00774 Hydroflumethiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroflumethiazide.
DB00001 DB00880 Chlorothiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlorothiazide.
DB00001 DB00999 Hydrochlorothiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydrochlorothiazide.
DB00001 DB01021 Trichlormethiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trichlormethiazide.
DB00001 DB01324 Polythiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Polythiazide.
DB00001 DB13430 Mebutizide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mebutizide.
DB00001 DB13532 Cyclopenthiazide The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclopenthiazide.
DB00002 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cetuximab.
DB00002 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cetuximab.
DB00002 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cetuximab.
DB00002 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cetuximab.
DB00002 DB00255 Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Cetuximab.
DB00002 DB00269 Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Cetuximab.
DB00002 DB00286 Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Cetuximab.
DB00002 DB00655 Estrone Estrone may increase the thrombogenic activities of Cetuximab.
DB00002 DB00783 Estradiol Estradiol may increase the thrombogenic activities of Cetuximab.
DB00002 DB00890 Dienestrol Dienestrol may increase the thrombogenic activities of Cetuximab.
DB00002 DB00977 Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Cetuximab.
DB00002 DB01357 Mestranol Mestranol may increase the thrombogenic activities of Cetuximab.
DB00002 DB04573 Estriol Estriol may increase the thrombogenic activities of Cetuximab.
DB00002 DB04574 Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Cetuximab.
DB00002 DB04575 Quinestrol Quinestrol may increase the thrombogenic activities of Cetuximab.
DB00002 DB07931 Hexestrol Hexestrol may increase the thrombogenic activities of Cetuximab.
DB00002 DB09070 Tibolone Tibolone may increase the thrombogenic activities of Cetuximab.
DB00002 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cetuximab.
DB00002 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cetuximab.
DB00002 DB09369 Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Cetuximab.
DB00002 DB09381 Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Cetuximab.
DB00002 DB11478 Zeranol Zeranol may increase the thrombogenic activities of Cetuximab.
DB00002 DB11674 Equol Equol may increase the thrombogenic activities of Cetuximab.
DB00002 DB12487 Promestriene Promestriene may increase the thrombogenic activities of Cetuximab.
DB00002 DB13143 Methallenestril Methallenestril may increase the thrombogenic activities of Cetuximab.
DB00002 DB13386 Epimestrol Epimestrol may increase the thrombogenic activities of Cetuximab.
DB00002 DB13418 Moxestrol Moxestrol may increase the thrombogenic activities of Cetuximab.
DB00002 DB13952 Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Cetuximab.
DB00002 DB13953 Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Cetuximab.
DB00002 DB13954 Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Cetuximab.
DB00002 DB13956 Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Cetuximab.
DB00002 DB15334 Biochanin A Biochanin A may increase the thrombogenic activities of Cetuximab.
DB00002 DB15335 Formononetin Formononetin may increase the thrombogenic activities of Cetuximab.
DB00002 DB00028 Human immunoglobulin G The risk or severity of adverse effects can be increased when Cetuximab is combined with Human immunoglobulin G.
DB00002 DB00043 Omalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Omalizumab.
DB00002 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Adalimumab.
DB00002 DB00054 Abciximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Abciximab.
DB00002 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.
DB00002 DB00057 Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide.
DB00002 DB00065 Infliximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Infliximab.
DB00002 DB00072 Trastuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab.
DB00002 DB00073 Rituximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rituximab.
DB00002 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab.
DB00002 DB00075 Muromonab The risk or severity of adverse effects can be increased when Cetuximab is combined with Muromonab.
DB00002 DB00076 Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine).
DB00002 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.
DB00002 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab.
DB00002 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.
DB00002 DB00089 Capromab pendetide The risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide.
DB00002 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Efalizumab.
DB00002 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin (rabbit).
DB00002 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Natalizumab.
DB00002 DB00110 Palivizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab.
DB00002 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.
DB00002 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.
DB00002 DB00113 Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab.
DB00002 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Eculizumab.
DB00002 DB01269 Panitumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Panitumumab.
DB00002 DB01270 Ranibizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ranibizumab.
DB00002 DB04901 Galiximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Galiximab.
DB00002 DB04949 Pexelizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pexelizumab.
DB00002 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Afelimomab.
DB00002 DB04958 Epratuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Epratuzumab.
DB00002 DB04962 Bectumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bectumomab.
DB00002 DB04964 Oregovomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Oregovomab.
DB00002 DB04988 IGN311 The risk or severity of adverse effects can be increased when Cetuximab is combined with IGN311.
DB00002 DB05006 Adecatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Adecatumumab.
DB00002 DB05097 Labetuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab.
DB00002 DB05101 Matuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Matuzumab.
DB00002 DB05111 Fontolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fontolizumab.
DB00002 DB05136 Bavituximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bavituximab.
DB00002 DB05139 CR002 The risk or severity of adverse effects can be increased when Cetuximab is combined with CR002.
DB00002 DB05209 Rozrolimupab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rozrolimupab.
DB00002 DB05304 Girentuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Girentuximab.
DB00002 DB05336 Obiltoxaximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Obiltoxaximab.
DB00002 DB05405 XTL-001 The risk or severity of adverse effects can be increased when Cetuximab is combined with XTL-001.
DB00002 DB05437 NAV 1800 The risk or severity of adverse effects can be increased when Cetuximab is combined with NAV 1800.
DB00002 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Briakinumab.
DB00002 DB05496 Otelixizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Otelixizumab.
DB00002 DB05545 AMG 108 The risk or severity of adverse effects can be increased when Cetuximab is combined with AMG 108.
DB00002 DB05550 Iratumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Iratumumab.
DB00002 DB05555 Enokizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Enokizumab.
DB00002 DB05578 Ramucirumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ramucirumab.
DB00002 DB05595 Farletuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Farletuzumab.
DB00002 DB05656 Veltuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Veltuzumab.
DB00002 DB05679 Ustekinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ustekinumab.
DB00002 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab emtansine.
DB00002 DB05793 PRO-542 The risk or severity of adverse effects can be increased when Cetuximab is combined with PRO-542.
DB00002 DB05797 TNX-901 The risk or severity of adverse effects can be increased when Cetuximab is combined with TNX-901.
DB00002 DB05889 Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Cetuximab is combined with Inotuzumab ozogamicin.
DB00002 DB05892 RI 624 The risk or severity of adverse effects can be increased when Cetuximab is combined with RI 624.
DB00002 DB05915 MYO-029 The risk or severity of adverse effects can be increased when Cetuximab is combined with MYO-029.
DB00002 DB05916 CT-011 The risk or severity of adverse effects can be increased when Cetuximab is combined with CT-011.
DB00002 DB05941 Leronlimab The risk or severity of adverse effects can be increased when Cetuximab is combined with Leronlimab.
DB00002 DB05996 Glembatumumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Glembatumumab vedotin.
DB00002 DB06043 Olaratumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Olaratumab.
DB00002 DB06049 IPH 2101 The risk or severity of adverse effects can be increased when Cetuximab is combined with IPH 2101.
DB00002 DB06050 TB-402 The risk or severity of adverse effects can be increased when Cetuximab is combined with TB-402.
DB00002 DB06081 Caplacizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab.
DB00002 DB06101 IMC-1C11 The risk or severity of adverse effects can be increased when Cetuximab is combined with IMC-1C11.
DB00002 DB06116 Eldelumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Eldelumab.
DB00002 DB06162 Lumiliximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lumiliximab.
DB00002 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Canakinumab.
DB00002 DB06186 Ipilimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ipilimumab.
DB00002 DB06192 Nimotuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Nimotuzumab.
DB00002 DB06241 Clenoliximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Clenoliximab.
DB00002 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tocilizumab.
DB00002 DB06304 BIIB015 The risk or severity of adverse effects can be increased when Cetuximab is combined with BIIB015.
DB00002 DB06305 Sonepcizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sonepcizumab.
DB00002 DB06310 Motavizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Motavizumab.
DB00002 DB06317 Elotuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Elotuzumab.
DB00002 DB06318 AVE9633 The risk or severity of adverse effects can be increased when Cetuximab is combined with AVE9633.
DB00002 DB06322 Carotuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Carotuximab.
DB00002 DB06324 XmAb 2513 The risk or severity of adverse effects can be increased when Cetuximab is combined with XmAb 2513.
DB00002 DB06342 Coltuximab ravtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Coltuximab ravtansine.
DB00002 DB06343 Teprotumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Teprotumumab.
DB00002 DB06360 Lucatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lucatumumab.
DB00002 DB06366 Pertuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pertuzumab.
DB00002 DB06371 Siplizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Siplizumab.
DB00002 DB06467 Apolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Apolizumab.
DB00002 DB06474 Sibrotuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sibrotuzumab.
DB00002 DB06550 Bivatuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bivatuzumab.
DB00002 DB06557 Lerdelimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lerdelimumab.
DB00002 DB06599 Lexatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lexatumumab.
DB00002 DB06602 Reslizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Reslizumab.
DB00002 DB06606 Teplizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Teplizumab.
DB00002 DB06607 Catumaxomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Catumaxomab.
DB00002 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Mepolizumab.
DB00002 DB06643 Denosumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Denosumab.
DB00002 DB06647 Volociximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Volociximab.
DB00002 DB06650 Ofatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ofatumumab.
DB00002 DB06674 Golimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Golimumab.
DB00002 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin.
DB00002 DB08879 Belimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.
DB00002 DB08902 Raxibacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Raxibacumab.
DB00002 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Cetuximab is combined with Certolizumab pegol.
DB00002 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Obinutuzumab.
DB00002 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Secukinumab.
DB00002 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Vedolizumab.
DB00002 DB09035 Nivolumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Nivolumab.
DB00002 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Siltuximab.
DB00002 DB09037 Pembrolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pembrolizumab.
DB00002 DB09045 Dulaglutide The risk or severity of adverse effects can be increased when Cetuximab is combined with Dulaglutide.
DB00002 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Blinatumomab.
DB00002 DB09057 Anthrax immune globulin human The risk or severity of adverse effects can be increased when Cetuximab is combined with Anthrax immune globulin human.
DB00002 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dinutuximab.
DB00002 DB09105 Asfotase alfa The risk or severity of adverse effects can be increased when Cetuximab is combined with Asfotase alfa.
DB00002 DB09264 Idarucizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Idarucizumab.
DB00002 DB09302 Alirocumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Alirocumab.
DB00002 DB09303 Evolocumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab.
DB00002 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Cetuximab is combined with Antilymphocyte immunoglobulin (horse).
DB00002 DB09331 Daratumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Daratumumab.
DB00002 DB09559 Necitumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Necitumumab.
DB00002 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ixekizumab.
DB00002 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ravulizumab.
DB00002 DB11595 Atezolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Atezolizumab.
DB00002 DB11604 Tetanus Immune Globulin The risk or severity of adverse effects can be increased when Cetuximab is combined with Tetanus Immune Globulin.
DB00002 DB11608 Eftrenonacog alfa The risk or severity of adverse effects can be increased when Cetuximab is combined with Eftrenonacog alfa.
DB00002 DB11621 Human Varicella-Zoster Immune Globulin The risk or severity of adverse effects can be increased when Cetuximab is combined with Human Varicella-Zoster Immune Globulin.
DB00002 DB11646 Conatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Conatumumab.
DB00002 DB11657 Tabalumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tabalumab.
DB00002 DB11680 Ficlatuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ficlatuzumab.
DB00002 DB11685 Figitumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Figitumumab.
DB00002 DB11714 Durvalumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Durvalumab.
DB00002 DB11715 Bapineuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab.
DB00002 DB11731 Depatuxizumab mafodotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Depatuxizumab mafodotin.
DB00002 DB11746 Onartuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Onartuzumab.
DB00002 DB11756 Solanezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Solanezumab.
DB00002 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sarilumab.
DB00002 DB11771 Tremelimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tremelimumab.
DB00002 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Brodalumab.
DB00002 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sirukumab.
DB00002 DB11826 Lampalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lampalizumab.
DB00002 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Guselkumab.
DB00002 DB11840 Dalotuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dalotuzumab.
DB00002 DB11849 Emibetuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Emibetuzumab.
DB00002 DB11850 Ublituximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ublituximab.
DB00002 DB11856 Ligelizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ligelizumab.
DB00002 DB11857 Seribantumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Seribantumab.
DB00002 DB11862 Landogrozumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Landogrozumab.
DB00002 DB11866 Romosozumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Romosozumab.
DB00002 DB11884 Vadastuximab Talirine The risk or severity of adverse effects can be increased when Cetuximab is combined with Vadastuximab Talirine.
DB00002 DB11914 Lebrikizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lebrikizumab.
DB00002 DB11930 Varlilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Varlilumab.
DB00002 DB11945 Avelumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Avelumab.
DB00002 DB11959 Crenezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Crenezumab.
DB00002 DB11972 Rilotumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rilotumumab.
DB00002 DB11976 Anifrolumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Anifrolumab.
DB00002 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ocrelizumab.
DB00002 DB12023 Benralizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Benralizumab.
DB00002 DB12034 Gantenerumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Gantenerumab.
DB00002 DB12053 Visilizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Visilizumab.
DB00002 DB12077 Urelumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Urelumab.
DB00002 DB12089 Lorvotuzumab mertansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Lorvotuzumab mertansine.
DB00002 DB12090 Patritumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Patritumab.
DB00002 DB12102 Fulranumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fulranumab.
DB00002 DB12104 Tarextumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tarextumab.
DB00002 DB12118 Sotatercept The risk or severity of adverse effects can be increased when Cetuximab is combined with Sotatercept.
DB00002 DB12119 Gevokizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Gevokizumab.
DB00002 DB12142 Duligotuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Duligotuzumab.
DB00002 DB12152 Simtuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Simtuzumab.
DB00002 DB12157 Fasinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fasinumab.
DB00002 DB12159 Dupilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dupilumab.
DB00002 DB12169 Tralokinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tralokinumab.
DB00002 DB12189 Etrolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Etrolizumab.
DB00002 DB12202 Zalutumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Zalutumumab.
DB00002 DB12205 Ganitumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ganitumab.
DB00002 DB12213 Etaracizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Etaracizumab.
DB00002 DB12240 Polatuzumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Polatuzumab vedotin.
DB00002 DB12246 Inclacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Inclacumab.
DB00002 DB12250 Cixutumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Cixutumumab.
DB00002 DB12261 Ascrinvacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ascrinvacumab.
DB00002 DB12274 Aducanumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Aducanumab.
DB00002 DB12281 Luspatercept The risk or severity of adverse effects can be increased when Cetuximab is combined with Luspatercept.
DB00002 DB12296 GS-5745 The risk or severity of adverse effects can be increased when Cetuximab is combined with GS-5745.
DB00002 DB12317 Vanucizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Vanucizumab.
DB00002 DB12331 Labetuzumab govitecan The risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab govitecan.
DB00002 DB12335 Tanezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tanezumab.
DB00002 DB12342 Ensituximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ensituximab.
DB00002 DB12344 Fezakinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fezakinumab.
DB00002 DB12363 Dusigitumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dusigitumab.
DB00002 DB12396 Fresolimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fresolimumab.
DB00002 DB12413 Indusatumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Indusatumab vedotin.
DB00002 DB12456 Bococizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bococizumab.
DB00002 DB12489 Mirvetuximab Soravtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Mirvetuximab Soravtansine.
DB00002 DB12498 Mogamulizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Mogamulizumab.
DB00002 DB12520 Plozalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Plozalizumab.
DB00002 DB12530 Inebilizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Inebilizumab.
DB00002 DB12534 Mavrilimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Mavrilimumab.
DB00002 DB12560 Blosozumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Blosozumab.
DB00002 DB12584 Bimagrumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bimagrumab.
DB00002 DB12589 Dacetuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dacetuzumab.
DB00002 DB12609 Tovetumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tovetumab.
DB00002 DB12683 Lumretuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lumretuzumab.
DB00002 DB12698 Ibalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibalizumab.
DB00002 DB12701 Intetumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Intetumumab.
DB00002 DB12718 Carlumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Carlumab.
DB00002 DB12734 Demcizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Demcizumab.
DB00002 DB12773 Sifalimumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sifalimumab.
DB00002 DB12775 Abituzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Abituzumab.
DB00002 DB12797 Ecromeximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ecromeximab.
DB00002 DB12807 Naptumomab Estafenatox The risk or severity of adverse effects can be increased when Cetuximab is combined with Naptumomab Estafenatox.
DB00002 DB12815 Crotedumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Crotedumab.
DB00002 DB12820 Concizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Concizumab.
DB00002 DB12826 Depatuxizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Depatuxizumab.
DB00002 DB12844 Rontalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rontalizumab.
DB00002 DB12845 Amatuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Amatuximab.
DB00002 DB12849 Clazakizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Clazakizumab.
DB00002 DB12891 Ozanezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ozanezumab.
DB00002 DB12893 Sacituzumab govitecan The risk or severity of adverse effects can be increased when Cetuximab is combined with Sacituzumab govitecan.
DB00002 DB12917 Bimekizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bimekizumab.
DB00002 DB12943 Milatuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Milatuzumab.
DB00002 DB12976 Robatumumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Robatumumab.
DB00002 DB13017 Rovalpituzumab Tesirine The risk or severity of adverse effects can be increased when Cetuximab is combined with Rovalpituzumab Tesirine.
DB00002 DB13037 Namilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Namilumab.
DB00002 DB13045 Racotumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Racotumomab.
DB00002 DB13073 Tregalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tregalizumab.
DB00002 DB13127 Olokizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Olokizumab.
DB00002 DB13140 Bezlotoxumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bezlotoxumab.
DB00002 DB13375 Edrecolomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Edrecolomab.
DB00002 DB13535 Nebacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Nebacumab.
DB00002 DB13886 Human cytomegalovirus immune globulin The risk or severity of adverse effects can be increased when Cetuximab is combined with Human cytomegalovirus immune globulin.
DB00002 DB13923 Emicizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Emicizumab.
DB00002 DB13976 Sulesomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Sulesomab.
DB00002 DB13979 Besilesomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Besilesomab.
DB00002 DB14004 Tildrakizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tildrakizumab.
DB00002 DB14012 Burosumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Burosumab.
DB00002 DB14039 Erenumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Erenumab.
DB00002 DB14040 Eptinezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Eptinezumab.
DB00002 DB14041 Fremanezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fremanezumab.
DB00002 DB14042 Galcanezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Galcanezumab.
DB00002 DB14211 Fanolesomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Fanolesomab.
DB00002 DB14580 Lecanemab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lecanemab.
DB00002 DB14597 Lanadelumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lanadelumab.
DB00002 DB14707 Cemiplimab The risk or severity of adverse effects can be increased when Cetuximab is combined with Cemiplimab.
DB00002 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Emapalumab.
DB00002 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Risankizumab.
DB00002 DB14776 Camrelizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Camrelizumab.
DB00002 DB14778 Setrusumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Setrusumab.
DB00002 DB14784 Gancotamab The risk or severity of adverse effects can be increased when Cetuximab is combined with Gancotamab.
DB00002 DB14809 Anetumab ravtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Anetumab ravtansine.
DB00002 DB14811 Isatuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Isatuximab.
DB00002 DB14824 Icrucumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Icrucumab.
DB00002 DB14843 Codrituzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Codrituzumab.
DB00002 DB14864 Brolucizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Brolucizumab.
DB00002 DB14871 Xentuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Xentuzumab.
DB00002 DB14877 Lintuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Lintuzumab.
DB00002 DB14891 Vobarilizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Vobarilizumab.
DB00002 DB14897 Parsatuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Parsatuzumab.
DB00002 DB14905 Emactuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Emactuzumab.
DB00002 DB14907 Bevacizumab zirconium Zr-89 The risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab zirconium Zr-89.
DB00002 DB14908 Refanezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Refanezumab.
DB00002 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Rozanolixizumab.
DB00002 DB14947 Bermekimab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bermekimab.
DB00002 DB14952 Pamrevlumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pamrevlumab.
DB00002 DB14959 Opicinumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Opicinumab.
DB00002 DB14962 Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab deruxtecan.
DB00002 DB14967 Margetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Margetuximab.
DB00002 DB14988 Dalantercept The risk or severity of adverse effects can be increased when Cetuximab is combined with Dalantercept.
DB00002 DB14997 Pateclizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pateclizumab.
DB00002 DB15014 Gremubamab The risk or severity of adverse effects can be increased when Cetuximab is combined with Gremubamab.
DB00002 DB15022 Apomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Apomab.
DB00002 DB15044 Tafasitamab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tafasitamab.
DB00002 DB15045 Ipafricept The risk or severity of adverse effects can be increased when Cetuximab is combined with Ipafricept.
DB00002 DB15076 Abrilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Abrilumab.
DB00002 DB15089 Frovocimab The risk or severity of adverse effects can be increased when Cetuximab is combined with Frovocimab.
DB00002 DB15090 Tezepelumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tezepelumab.
DB00002 DB15101 Tigatuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tigatuzumab.
DB00002 DB15104 Telisotuzumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Telisotuzumab vedotin.
DB00002 DB15113 Utomilumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Utomilumab.
DB00002 DB15118 Zolbetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Zolbetuximab.
DB00002 DB15135 Ponezumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ponezumab.
DB00002 DB15160 Asunercept The risk or severity of adverse effects can be increased when Cetuximab is combined with Asunercept.
DB00002 DB15172 Suvratoxumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Suvratoxumab.
DB00002 DB15225 Mitazalimab The risk or severity of adverse effects can be increased when Cetuximab is combined with Mitazalimab.
DB00002 DB15252 Nemolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Nemolizumab.
DB00002 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bleselumab.
DB00002 DB15277 Gedivumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Gedivumab.
DB00002 DB15336 Valanafusp alfa The risk or severity of adverse effects can be increased when Cetuximab is combined with Valanafusp alfa.
DB00002 DB15349 Sofituzumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Sofituzumab vedotin.
DB00002 DB15354 Evinacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Evinacumab.
DB00002 DB15363 Istiratumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Istiratumab.
DB00002 DB15383 Pidilizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pidilizumab.
DB00002 DB15397 GMA-161 The risk or severity of adverse effects can be increased when Cetuximab is combined with GMA-161.
DB00002 DB15409 Ladiratuzumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Ladiratuzumab vedotin.
DB00002 DB15415 Tomaralimab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tomaralimab.
DB00002 DB15428 Vesencumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Vesencumab.
DB00002 DB15432 Pinatuzumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Pinatuzumab vedotin.
DB00002 DB15441 Lulizumab pegol The risk or severity of adverse effects can be increased when Cetuximab is combined with Lulizumab pegol.
DB00002 DB15443 Lorukafusp alfa The risk or severity of adverse effects can be increased when Cetuximab is combined with Lorukafusp alfa.
DB00002 DB15453 Naratuximab emtansine The risk or severity of adverse effects can be increased when Cetuximab is combined with Naratuximab emtansine.
DB00002 DB15559 Zenocutuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Zenocutuzumab.
DB00002 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cetuximab.
DB00004 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Denileukin diftitox.
DB00004 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Denileukin diftitox.
DB00004 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Denileukin diftitox.
DB00004 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Denileukin diftitox.
DB00005 DB01281 Abatacept The risk or severity of infection can be increased when Etanercept is combined with Abatacept.
DB00005 DB00026 Anakinra The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.
DB00005 DB08879 Belimumab The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab.
DB00005 DB06168 Canakinumab The risk or severity of infection and neutropenia can be increased when Etanercept is combined with Canakinumab.
DB00005 DB08904 Certolizumab pegol The risk or severity of infection can be increased when Etanercept is combined with Certolizumab pegol.
DB00005 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.
DB00005 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.
DB00005 DB00065 Infliximab Etanercept may increase the immunosuppressive activities of Infliximab.
DB00005 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2a.
DB00005 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n1.
DB00005 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n3.
DB00005 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2b.
DB00005 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon gamma-1b.
DB00005 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2a, Recombinant.
DB00005 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Etanercept is combined with Aldesleukin.
DB00005 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Etanercept is combined with Adalimumab.
DB00005 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Etanercept is combined with Gemtuzumab ozogamicin.
DB00005 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Etanercept is combined with Pegaspargase.
DB00005 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon beta-1b.
DB00005 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfacon-1.
DB00005 DB00073 Rituximab The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.
DB00005 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Etanercept is combined with Basiliximab.
DB00005 DB00075 Muromonab The risk or severity of adverse effects can be increased when Etanercept is combined with Muromonab.
DB00005 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Etanercept is combined with Ibritumomab tiuxetan.
DB00005 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Etanercept is combined with Tositumomab.
DB00005 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Etanercept is combined with Alemtuzumab.
DB00005 DB00092 Alefacept The risk or severity of adverse effects can be increased when Etanercept is combined with Alefacept.
DB00005 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Efalizumab.
DB00005 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Etanercept is combined with Antithymocyte immunoglobulin (rabbit).
DB00005 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2b.
DB00005 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab.
DB00005 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Bevacizumab.
DB00005 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylalanine.
DB00005 DB00242 Cladribine The risk or severity of adverse effects can be increased when Etanercept is combined with Cladribine.
DB00005 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Etanercept is combined with Amsacrine.
DB00005 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Etanercept is combined with Bleomycin.
DB00005 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Etanercept is combined with Chlorambucil.
DB00005 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Etanercept is combined with Raltitrexed.
DB00005 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Etanercept is combined with Mitomycin.
DB00005 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Etanercept is combined with Floxuridine.
DB00005 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Etanercept is combined with Tioguanine.
DB00005 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Etanercept is combined with Dexrazoxane.
DB00005 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Etanercept is combined with Streptozocin.
DB00005 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Etanercept is combined with Trifluridine.
DB00005 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Etanercept is combined with Gemcitabine.
DB00005 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Etanercept is combined with Epirubicin.
DB00005 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Etanercept is combined with Chloramphenicol.
DB00005 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Etanercept is combined with Lenalidomide.
DB00005 DB00488 Altretamine The risk or severity of adverse effects can be increased when Etanercept is combined with Altretamine.
DB00005 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin.
DB00005 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaliplatin.
DB00005 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Etanercept is combined with Propylthiouracil.
DB00005 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Etanercept is combined with Pentostatin.
DB00005 DB00601 Linezolid The risk or severity of adverse effects can be increased when Etanercept is combined with Linezolid.
DB00005 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Etanercept is combined with Clofarabine.
DB00005 DB00763 Methimazole The risk or severity of adverse effects can be increased when Etanercept is combined with Methimazole.
DB00005 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Etanercept is combined with Temozolomide.
DB00005 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Etanercept is combined with Penicillamine.
DB00005 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Etanercept is combined with Mechlorethamine.
DB00005 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Etanercept is combined with Azacitidine.
DB00005 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Etanercept is combined with Carboplatin.
DB00005 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Etanercept is combined with Dactinomycin.
DB00005 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Etanercept is combined with Hydroxyurea.
DB00005 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.
DB00005 DB01030 Topotecan The risk or severity of adverse effects can be increased when Etanercept is combined with Topotecan.
DB00005 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Etanercept is combined with Mercaptopurine.
DB00005 DB01042 Melphalan The risk or severity of adverse effects can be increased when Etanercept is combined with Melphalan.
DB00005 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Etanercept is combined with Fludarabine.
DB00005 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Etanercept is combined with Flucytosine.
DB00005 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Etanercept is combined with Procarbazine.
DB00005 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Etanercept is combined with Arsenic trioxide.
DB00005 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Etanercept is combined with Mitoxantrone.
DB00005 DB01206 Lomustine The risk or severity of adverse effects can be increased when Etanercept is combined with Lomustine.
DB00005 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Eculizumab.
DB00005 DB01262 Decitabine The risk or severity of adverse effects can be increased when Etanercept is combined with Decitabine.
DB00005 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Etanercept is combined with Nelarabine.
DB00005 DB01423 Stepronin The risk or severity of adverse effects can be increased when Etanercept is combined with Stepronin.
DB00005 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.
DB00005 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Etanercept is combined with Vorinostat.
DB00005 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Etanercept is combined with 2-Methoxyethanol.
DB00005 DB03523 Brequinar The risk or severity of adverse effects can be increased when Etanercept is combined with Brequinar.
DB00005 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Etanercept is combined with Afelimomab.
DB00005 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa.
DB00005 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Etanercept is combined with Glatiramer.
DB00005 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Etanercept is combined with Gallium nitrate.
DB00005 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Etanercept is combined with Briakinumab.
DB00005 DB05472 omega interferon The risk or severity of adverse effects can be increased when Etanercept is combined with omega interferon.
DB00005 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Mepolizumab.
DB00005 DB06662 Abetimus The risk or severity of adverse effects can be increased when Etanercept is combined with Abetimus.
DB00005 DB06674 Golimumab The risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.
DB00005 DB06681 Belatacept The risk or severity of adverse effects can be increased when Etanercept is combined with Belatacept.
DB00005 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Etanercept is combined with Pralatrexate.
DB00005 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Etanercept is combined with Wortmannin.
DB00005 DB08871 Eribulin The risk or severity of adverse effects can be increased when Etanercept is combined with Eribulin.
DB00005 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.
DB00005 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Etanercept is combined with Carfilzomib.
DB00005 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Etanercept is combined with Dimethyl fumarate.
DB00005 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Etanercept is combined with Obinutuzumab.
DB00005 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Etanercept is combined with Secukinumab.
DB00005 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Etanercept is combined with Siltuximab.
DB00005 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Etanercept is combined with Blinatumomab.
DB00005 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Etanercept is combined with Dinutuximab.
DB00005 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Etanercept is combined with Tixocortol.
DB00005 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon beta-1a.
DB00005 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Etanercept is combined with Antilymphocyte immunoglobulin (horse).
DB00005 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Etanercept is combined with Tepoxalin.
DB00005 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Ixekizumab.
DB00005 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Ravulizumab.
DB00005 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Etanercept is combined with Pirarubicin.
DB00005 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Etanercept is combined with Voclosporin.
DB00005 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Etanercept is combined with Peficitinib.
DB00005 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Etanercept is combined with Sarilumab.
DB00005 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Etanercept is combined with Brodalumab.
DB00005 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Etanercept is combined with Sirukumab.
DB00005 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Etanercept is combined with Guselkumab.
DB00005 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Ocrelizumab.
DB00005 DB12025 Triptolide The risk or severity of adverse effects can be increased when Etanercept is combined with Triptolide.
DB00005 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Etanercept is combined with Ozanimod.
DB00005 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine.
DB00005 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Etanercept is combined with Gusperimus.
DB00005 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Etanercept is combined with Cepeginterferon alfa-2B.
DB00005 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Etanercept is combined with Trofosfamide.
DB00005 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Etanercept is combined with Doxifluridine.
DB00005 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Etanercept is combined with Deoxyspergualin.
DB00005 DB12996 Acteoside The risk or severity of adverse effects can be increased when Etanercept is combined with Acteoside.
DB00005 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Etanercept is combined with Cortivazol.
DB00005 DB13014 Hypericin The risk or severity of adverse effects can be increased when Etanercept is combined with Hypericin.
DB00005 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Etanercept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00005 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortin.
DB00005 DB13241 Begelomab The risk or severity of adverse effects can be increased when Etanercept is combined with Begelomab.
DB00005 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Etanercept is combined with Fluperolone.
DB00005 DB13664 Formocortal The risk or severity of adverse effects can be increased when Etanercept is combined with Formocortal.
DB00005 DB13728 Halometasone The risk or severity of adverse effects can be increased when Etanercept is combined with Halometasone.
DB00005 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Etanercept is combined with Cloprednol.
DB00005 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Etanercept is combined with Fluclorolone.
DB00005 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Etanercept is combined with Monomethyl fumarate.
DB00005 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Etanercept is combined with Emapalumab.
DB00005 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Risankizumab.
DB00005 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Rozanolixizumab.
DB00005 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Etanercept is combined with Bleselumab.
DB00005 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide.
DB00005 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.
DB00005 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.
DB00005 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone acetonide.
DB00005 DB00635 Prednisone The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisone.
DB00005 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.
DB00005 DB00764 Mometasone The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.
DB00005 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.
DB00005 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.
DB00005 DB01196 Estramustine The risk or severity of adverse effects can be increased when Etanercept is combined with Estramustine.
DB00005 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Etanercept is combined with Corticotropin.
DB00005 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Etanercept is combined with Cortisone acetate.
DB00005 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Etanercept is combined with Paramethasone.
DB00005 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Etanercept is combined with Hydroxychloroquine.
DB00005 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.
DB00005 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednidene.
DB00005 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone.
DB00005 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Etanercept is combined with Vilanterol.
DB00005 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednisolone.
DB00005 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Etanercept is combined with Meprednisone.
DB00005 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone isonicotinate.
DB00005 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Etanercept is combined with Melengestrol.
DB00005 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol.
DB00005 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Etanercept is combined with Baricitinib.
DB00005 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Etanercept is combined with Deflazacort.
DB00005 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Etanercept is combined with Prednylidene.
DB00005 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Etanercept is combined with Tetrandrine.
DB00005 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone furoate.
DB00005 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone succinate.
DB00005 DB01222 Budesonide The risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.
DB00005 DB01394 Colchicine The risk or severity of adverse effects can be increased when Etanercept is combined with Colchicine.
DB00005 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.
DB00005 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.
DB00005 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Etanercept is combined with Rilonacept.
DB00005 DB01656 Roflumilast Etanercept may increase the immunosuppressive activities of Roflumilast.
DB00005 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.
DB00005 DB06273 Tocilizumab Tocilizumab may increase the immunosuppressive activities of Etanercept.
DB00005 DB08895 Tofacitinib The risk or severity of adverse effects can be increased when Etanercept is combined with Tofacitinib.
DB00005 DB09033 Vedolizumab The risk or severity of infection can be increased when Etanercept is combined with Vedolizumab.
DB00005 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Etanercept.
DB00005 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide.
DB00005 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Etanercept.
DB00005 DB08868 Fingolimod Etanercept may increase the immunosuppressive activities of Fingolimod.
DB00005 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Etanercept.
DB00005 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Etanercept.
DB00005 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Etanercept.
DB00005 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Etanercept.
DB00005 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Etanercept.
DB00005 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Etanercept.
DB00005 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Etanercept.
DB00005 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Etanercept.
DB00005 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Etanercept.
DB00005 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Etanercept.
DB00005 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Etanercept.
DB00005 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Etanercept.
DB00005 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Etanercept.
DB00005 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etanercept.
DB00005 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Etanercept.
DB00005 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Etanercept.
DB00005 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etanercept.
DB00005 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Etanercept.
DB00005 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Etanercept.
DB00005 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etanercept.
DB00005 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Etanercept.
DB00005 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Etanercept.
DB00005 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Etanercept.
DB00005 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Etanercept.
DB00005 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Etanercept.
DB00005 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Etanercept.
DB00005 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.
DB00005 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Etanercept.
DB00005 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Etanercept.
DB00005 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Etanercept.
DB00005 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Etanercept.
DB00005 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Etanercept.
DB00005 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Etanercept.
DB00005 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Etanercept.
DB00005 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Etanercept.
DB00005 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Etanercept.
DB00005 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Etanercept.
DB00005 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Etanercept.
DB00005 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Etanercept.
DB00005 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Etanercept.
DB00005 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Etanercept.
DB00005 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Etanercept.
DB00005 DB00795 Sulfasalazine The risk or severity of neutropenia can be increased when Etanercept is combined with Sulfasalazine.
DB00005 DB00201 Caffeine The metabolism of Caffeine can be increased when combined with Etanercept.
DB00005 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Etanercept.
DB00005 DB00195 Betaxolol The metabolism of Betaxolol can be increased when combined with Etanercept.
DB00005 DB00261 Anagrelide The metabolism of Anagrelide can be increased when combined with Etanercept.
DB00005 DB00262 Carmustine The metabolism of Carmustine can be increased when combined with Etanercept.
DB00005 DB00268 Ropinirole The metabolism of Ropinirole can be increased when combined with Etanercept.
DB00005 DB00280 Disopyramide The metabolism of Disopyramide can be increased when combined with Etanercept.
DB00005 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Etanercept.
DB00005 DB00296 Ropivacaine The metabolism of Ropivacaine can be increased when combined with Etanercept.
DB00005 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be increased when combined with Etanercept.
DB00005 DB00316 Acetaminophen The metabolism of Acetaminophen can be increased when combined with Etanercept.
DB00005 DB00334 Olanzapine The metabolism of Olanzapine can be increased when combined with Etanercept.
DB00005 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Etanercept.
DB00005 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be increased when combined with Etanercept.
DB00005 DB00370 Mirtazapine The metabolism of Mirtazapine can be increased when combined with Etanercept.
DB00005 DB00379 Mexiletine The metabolism of Mexiletine can be increased when combined with Etanercept.
DB00005 DB00382 Tacrine The metabolism of Tacrine can be increased when combined with Etanercept.
DB00005 DB00384 Triamterene The metabolism of Triamterene can be increased when combined with Etanercept.
DB00005 DB00442 Entecavir The metabolism of Entecavir can be increased when combined with Etanercept.
DB00005 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be increased when combined with Etanercept.
DB00005 DB00518 Albendazole The metabolism of Albendazole can be increased when combined with Etanercept.
DB00005 DB00544 Fluorouracil The metabolism of Fluorouracil can be increased when combined with Etanercept.
DB00005 DB00629 Guanabenz The metabolism of Guanabenz can be increased when combined with Etanercept.
DB00005 DB00642 Pemetrexed The metabolism of Pemetrexed can be increased when combined with Etanercept.
DB00005 DB00730 Thiabendazole The metabolism of Thiabendazole can be increased when combined with Etanercept.
DB00005 DB00740 Riluzole The metabolism of Riluzole can be increased when combined with Etanercept.
DB00005 DB00787 Acyclovir The metabolism of Acyclovir can be increased when combined with Etanercept.
DB00005 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be increased when combined with Etanercept.
DB00005 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Etanercept.
DB00005 DB00863 Ranitidine The metabolism of Ranitidine can be increased when combined with Etanercept.
DB00005 DB00898 Ethanol The metabolism of Ethanol can be increased when combined with Etanercept.
DB00005 DB00934 Maprotiline The metabolism of Maprotiline can be increased when combined with Etanercept.
DB00005 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be increased when combined with Etanercept.
DB00005 DB00993 Azathioprine The metabolism of Azathioprine can be increased when combined with Etanercept.
DB00005 DB00998 Frovatriptan The metabolism of Frovatriptan can be increased when combined with Etanercept.
DB00005 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Etanercept.
DB00005 DB01012 Cinacalcet The metabolism of Cinacalcet can be increased when combined with Etanercept.
DB00005 DB01056 Tocainide The metabolism of Tocainide can be increased when combined with Etanercept.
DB00005 DB01087 Primaquine The metabolism of Primaquine can be increased when combined with Etanercept.
DB00005 DB01094 Hesperetin The metabolism of Hesperetin can be increased when combined with Etanercept.
DB00005 DB01182 Propafenone The metabolism of Propafenone can be increased when combined with Etanercept.
DB00005 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Etanercept.
DB00005 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Etanercept.
DB00005 DB01367 Rasagiline The metabolism of Rasagiline can be increased when combined with Etanercept.
DB00005 DB01405 Temafloxacin The metabolism of Temafloxacin can be increased when combined with Etanercept.
DB00005 DB01412 Theobromine The metabolism of Theobromine can be increased when combined with Etanercept.
DB00005 DB01482 Fenethylline The metabolism of Fenethylline can be increased when combined with Etanercept.
DB00005 DB01558 Bromazepam The metabolism of Bromazepam can be increased when combined with Etanercept.
DB00005 DB01623 Thiothixene The metabolism of Thiothixene can be increased when combined with Etanercept.
DB00005 DB01645 Genistein The metabolism of Genistein can be increased when combined with Etanercept.
DB00005 DB01667 8-azaguanine The metabolism of 8-azaguanine can be increased when combined with Etanercept.
DB00005 DB02134 Xanthine The metabolism of Xanthine can be increased when combined with Etanercept.
DB00005 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be increased when combined with Etanercept.
DB00005 DB02568 Peldesine The metabolism of Peldesine can be increased when combined with Etanercept.
DB00005 DB02709 Resveratrol The metabolism of Resveratrol can be increased when combined with Etanercept.
DB00005 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be increased when combined with Etanercept.
DB00005 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be increased when combined with Etanercept.
DB00005 DB04871 Lorcaserin The metabolism of Lorcaserin can be increased when combined with Etanercept.
DB00005 DB04948 Lofexidine The metabolism of Lofexidine can be increased when combined with Etanercept.
DB00005 DB04951 Pirfenidone The metabolism of Pirfenidone can be increased when combined with Etanercept.
DB00005 DB06148 Mianserin The metabolism of Mianserin can be increased when combined with Etanercept.
DB00005 DB06210 Eltrombopag The metabolism of Eltrombopag can be increased when combined with Etanercept.
DB00005 DB06216 Asenapine The metabolism of Asenapine can be increased when combined with Etanercept.
DB00005 DB06235 Vadimezan The metabolism of Vadimezan can be increased when combined with Etanercept.
DB00005 DB06479 Propentofylline The metabolism of Propentofylline can be increased when combined with Etanercept.
DB00005 DB06594 Agomelatine The metabolism of Agomelatine can be increased when combined with Etanercept.
DB00005 DB06769 Bendamustine The metabolism of Bendamustine can be increased when combined with Etanercept.
DB00005 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be increased when combined with Etanercept.
DB00005 DB06774 Capsaicin The metabolism of Capsaicin can be increased when combined with Etanercept.
DB00005 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Etanercept.
DB00005 DB09071 Tasimelteon The metabolism of Tasimelteon can be increased when combined with Etanercept.
DB00005 DB09118 Stiripentol The metabolism of Stiripentol can be increased when combined with Etanercept.
DB00005 DB09225 Zotepine The metabolism of Zotepine can be increased when combined with Etanercept.
DB00005 DB09273 Doxofylline The metabolism of Doxofylline can be increased when combined with Etanercept.
DB00005 DB09290 Ramosetron The metabolism of Ramosetron can be increased when combined with Etanercept.
DB00005 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be increased when combined with Etanercept.
DB00005 DB11967 Binimetinib The metabolism of Binimetinib can be increased when combined with Etanercept.
DB00005 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be increased when combined with Etanercept.
DB00005 DB12245 Triclabendazole The metabolism of Triclabendazole can be increased when combined with Etanercept.
DB00005 DB12332 Rucaparib The metabolism of Rucaparib can be increased when combined with Etanercept.
DB00005 DB12406 Lisofylline The metabolism of Lisofylline can be increased when combined with Etanercept.
DB00005 DB12531 Lobucavir The metabolism of Lobucavir can be increased when combined with Etanercept.
DB00005 DB12926 Cafedrine The metabolism of Cafedrine can be increased when combined with Etanercept.
DB00005 DB12927 Theodrenaline The metabolism of Theodrenaline can be increased when combined with Etanercept.
DB00005 DB12945 Dihydralazine The metabolism of Dihydralazine can be increased when combined with Etanercept.
DB00005 DB13203 Bamifylline The metabolism of Bamifylline can be increased when combined with Etanercept.
DB00005 DB13449 Proxyphylline The metabolism of Proxyphylline can be increased when combined with Etanercept.
DB00005 DB13573 Acefylline The metabolism of Acefylline can be increased when combined with Etanercept.
DB00005 DB13592 Etamiphylline The metabolism of Etamiphylline can be increased when combined with Etanercept.
DB00005 DB13634 Pentifylline The metabolism of Pentifylline can be increased when combined with Etanercept.
DB00005 DB13812 Bufylline The metabolism of Bufylline can be increased when combined with Etanercept.
DB00005 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Etanercept.
DB00005 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be increased when combined with Etanercept.
DB00005 DB11757 Istradefylline The metabolism of Istradefylline can be increased when combined with Etanercept.
DB00005 DB04889 Bicifadine The metabolism of Bicifadine can be increased when combined with Etanercept.
DB00005 DB05708 GTS-21 The metabolism of GTS-21 can be increased when combined with Etanercept.
DB00005 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be increased when combined with Etanercept.
DB00005 DB00425 Zolpidem The metabolism of Zolpidem can be increased when combined with Etanercept.
DB00005 DB00458 Imipramine The metabolism of Imipramine can be increased when combined with Etanercept.
DB00005 DB00532 Mephenytoin The metabolism of Mephenytoin can be increased when combined with Etanercept.
DB00005 DB00540 Nortriptyline The metabolism of Nortriptyline can be increased when combined with Etanercept.
DB00005 DB00575 Clonidine The metabolism of Clonidine can be increased when combined with Etanercept.
DB00005 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Etanercept.
DB00005 DB01242 Clomipramine The metabolism of Clomipramine can be increased when combined with Etanercept.
DB00005 DB11689 Selumetinib The metabolism of Selumetinib can be increased when combined with Etanercept.
DB00005 DB00277 Theophylline The metabolism of Theophylline can be increased when combined with Etanercept.
DB00005 DB00564 Carbamazepine The metabolism of Carbamazepine can be increased when combined with Etanercept.
DB00005 DB00682 Warfarin The metabolism of Warfarin can be increased when combined with Etanercept.
DB00005 DB00697 Tizanidine The metabolism of Tizanidine can be increased when combined with Etanercept.
DB00005 DB01100 Pimozide The metabolism of Pimozide can be increased when combined with Etanercept.
DB00005 DB01223 Aminophylline The metabolism of Aminophylline can be increased when combined with Etanercept.
DB00005 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Etanercept.
DB00005 DB09256 Tegafur The metabolism of Tegafur can be increased when combined with Etanercept.
DB00005 DB00851 Dacarbazine The metabolism of Dacarbazine can be increased when combined with Etanercept.
DB00005 DB08910 Pomalidomide The metabolism of Pomalidomide can be increased when combined with Etanercept.
DB00005 DB00238 Nevirapine The metabolism of Nevirapine can be increased when combined with Etanercept.
DB00005 DB00471 Montelukast The metabolism of Montelukast can be increased when combined with Etanercept.
DB00005 DB00690 Flurazepam The metabolism of Flurazepam can be increased when combined with Etanercept.
DB00005 DB00916 Metronidazole The metabolism of Metronidazole can be increased when combined with Etanercept.
DB00005 DB00983 Formoterol The metabolism of Formoterol can be increased when combined with Etanercept.
DB00005 DB01006 Letrozole The metabolism of Letrozole can be increased when combined with Etanercept.
DB00005 DB01028 Methoxyflurane The metabolism of Methoxyflurane can be increased when combined with Etanercept.
DB00005 DB01159 Halothane The metabolism of Halothane can be increased when combined with Etanercept.
DB00005 DB01236 Sevoflurane The metabolism of Sevoflurane can be increased when combined with Etanercept.
DB00005 DB01274 Arformoterol The metabolism of Arformoterol can be increased when combined with Etanercept.
DB00005 DB01544 Flunitrazepam The metabolism of Flunitrazepam can be increased when combined with Etanercept.
DB00005 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be increased when combined with Etanercept.
DB00005 DB06470 Clomethiazole The metabolism of Clomethiazole can be increased when combined with Etanercept.
DB00005 DB09068 Vortioxetine The metabolism of Vortioxetine can be increased when combined with Etanercept.
DB00005 DB09327 Tegafur-uracil The metabolism of Tegafur-uracil can be increased when combined with Etanercept.
DB00005 DB11586 Asunaprevir The metabolism of Asunaprevir can be increased when combined with Etanercept.
DB00005 DB04977 Plitidepsin The metabolism of Plitidepsin can be increased when combined with Etanercept.
DB00005 DB06119 Cenobamate The metabolism of Cenobamate can be increased when combined with Etanercept.
DB00005 DB00193 Tramadol The metabolism of Tramadol can be increased when combined with Etanercept.
DB00005 DB00333 Methadone The metabolism of Methadone can be increased when combined with Etanercept.
DB00005 DB00349 Clobazam The metabolism of Clobazam can be increased when combined with Etanercept.
DB00005 DB00625 Efavirenz The metabolism of Efavirenz can be increased when combined with Etanercept.
DB00005 DB00753 Isoflurane The metabolism of Isoflurane can be increased when combined with Etanercept.
DB00005 DB00818 Propofol The metabolism of Propofol can be increased when combined with Etanercept.
DB00005 DB00835 Brompheniramine The metabolism of Brompheniramine can be increased when combined with Etanercept.
DB00005 DB00836 Loperamide The metabolism of Loperamide can be increased when combined with Etanercept.
DB00005 DB00849 Methylphenobarbital The metabolism of Methylphenobarbital can be increased when combined with Etanercept.
DB00005 DB00865 Benzphetamine The metabolism of Benzphetamine can be increased when combined with Etanercept.
DB00005 DB01069 Promethazine The metabolism of Promethazine can be increased when combined with Etanercept.
DB00005 DB01074 Perhexiline The metabolism of Perhexiline can be increased when combined with Etanercept.
DB00005 DB01221 Ketamine The metabolism of Ketamine can be increased when combined with Etanercept.
DB00005 DB01466 Ethylmorphine The metabolism of Ethylmorphine can be increased when combined with Etanercept.
DB00005 DB01559 Clotiazepam The metabolism of Clotiazepam can be increased when combined with Etanercept.
DB00005 DB04938 Ospemifene The metabolism of Ospemifene can be increased when combined with Etanercept.
DB00005 DB04975 Banoxantrone The metabolism of Banoxantrone can be increased when combined with Etanercept.
DB00005 DB05541 Brivaracetam The metabolism of Brivaracetam can be increased when combined with Etanercept.
DB00005 DB06176 Romidepsin The metabolism of Romidepsin can be increased when combined with Etanercept.
DB00005 DB06209 Prasugrel The metabolism of Prasugrel can be increased when combined with Etanercept.
DB00005 DB06697 Artemether The metabolism of Artemether can be increased when combined with Etanercept.
DB00005 DB06710 Methyltestosterone The metabolism of Methyltestosterone can be increased when combined with Etanercept.
DB00005 DB06738 Ketobemidone The metabolism of Ketobemidone can be increased when combined with Etanercept.
DB00005 DB06739 Seratrodast The metabolism of Seratrodast can be increased when combined with Etanercept.
DB00005 DB11613 Velpatasvir The metabolism of Velpatasvir can be increased when combined with Etanercept.
DB00005 DB13132 Artemisinin The metabolism of Artemisinin can be increased when combined with Etanercept.
DB00005 DB13943 Testosterone cypionate The metabolism of Testosterone cypionate can be increased when combined with Etanercept.
DB00005 DB13944 Testosterone enanthate The metabolism of Testosterone enanthate can be increased when combined with Etanercept.
DB00005 DB13946 Testosterone undecanoate The metabolism of Testosterone undecanoate can be increased when combined with Etanercept.
DB00005 DB01156 Bupropion The metabolism of Bupropion can be increased when combined with Etanercept.
DB00005 DB00956 Hydrocodone The metabolism of Hydrocodone can be increased when combined with Etanercept.
DB00005 DB14975 Voxelotor The metabolism of Voxelotor can be increased when combined with Etanercept.
DB00005 DB11837 Osilodrostat The metabolism of Osilodrostat can be increased when combined with Etanercept.
DB00005 DB13384 Melitracen The metabolism of Melitracen can be increased when combined with Etanercept.
DB00005 DB13411 Lofepramine The metabolism of Lofepramine can be increased when combined with Etanercept.
DB00005 DB00714 Apomorphine The metabolism of Apomorphine can be increased when combined with Etanercept.
DB00005 DB09167 Dosulepin The metabolism of Dosulepin can be increased when combined with Etanercept.
DB00005 DB00213 Pantoprazole The metabolism of Pantoprazole can be increased when combined with Etanercept.
DB00005 DB00215 Citalopram The metabolism of Citalopram can be increased when combined with Etanercept.
DB00005 DB00312 Pentobarbital The metabolism of Pentobarbital can be increased when combined with Etanercept.
DB00005 DB00338 Omeprazole The metabolism of Omeprazole can be increased when combined with Etanercept.
DB00005 DB00347 Trimethadione The metabolism of Trimethadione can be increased when combined with Etanercept.
DB00005 DB00395 Carisoprodol The metabolism of Carisoprodol can be increased when combined with Etanercept.
DB00005 DB00448 Lansoprazole The metabolism of Lansoprazole can be increased when combined with Etanercept.
DB00005 DB00474 Methohexital The metabolism of Methohexital can be increased when combined with Etanercept.
DB00005 DB00582 Voriconazole The metabolism of Voriconazole can be increased when combined with Etanercept.
DB00005 DB00679 Thioridazine The metabolism of Thioridazine can be increased when combined with Etanercept.
DB00005 DB00736 Esomeprazole The metabolism of Esomeprazole can be increased when combined with Etanercept.
DB00005 DB00794 Primidone The metabolism of Primidone can be increased when combined with Etanercept.
DB00005 DB00909 Zonisamide The metabolism of Zonisamide can be increased when combined with Etanercept.
DB00005 DB01129 Rabeprazole The metabolism of Rabeprazole can be increased when combined with Etanercept.
DB00005 DB01131 Proguanil The metabolism of Proguanil can be increased when combined with Etanercept.
DB00005 DB01175 Escitalopram The metabolism of Escitalopram can be increased when combined with Etanercept.
DB00005 DB01259 Lapatinib The metabolism of Lapatinib can be increased when combined with Etanercept.
DB00005 DB01323 St. John's Wort The metabolism of St. John's Wort can be increased when combined with Etanercept.
DB00005 DB01355 Hexobarbital The metabolism of Hexobarbital can be increased when combined with Etanercept.
DB00005 DB01483 Barbital The metabolism of Barbital can be increased when combined with Etanercept.
DB00005 DB05246 Methsuximide The metabolism of Methsuximide can be increased when combined with Etanercept.
DB00005 DB05351 Dexlansoprazole The metabolism of Dexlansoprazole can be increased when combined with Etanercept.
DB00005 DB06218 Lacosamide The metabolism of Lacosamide can be increased when combined with Etanercept.
DB00005 DB06414 Etravirine The metabolism of Etravirine can be increased when combined with Etanercept.
DB00005 DB06605 Apixaban The metabolism of Apixaban can be increased when combined with Etanercept.
DB00005 DB09166 Etizolam The metabolism of Etizolam can be increased when combined with Etanercept.
DB00005 DB12130 Lorlatinib The metabolism of Lorlatinib can be increased when combined with Etanercept.
DB00005 DB12474 Lynestrenol The metabolism of Lynestrenol can be increased when combined with Etanercept.
DB00005 DB13762 Dexrabeprazole The metabolism of Dexrabeprazole can be increased when combined with Etanercept.
DB00005 DB14055 (S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Etanercept.
DB00005 DB00715 Paroxetine The metabolism of Paroxetine can be increased when combined with Etanercept.
DB00005 DB12500 Fedratinib The metabolism of Fedratinib can be increased when combined with Etanercept.
DB00005 DB04861 Nebivolol The metabolism of Nebivolol can be increased when combined with Etanercept.
DB00005 DB06684 Vilazodone The metabolism of Vilazodone can be increased when combined with Etanercept.
DB00005 DB01104 Sertraline The metabolism of Sertraline can be increased when combined with Etanercept.
DB00005 DB11823 Esketamine The metabolism of Esketamine can be increased when combined with Etanercept.
DB00005 DB00252 Phenytoin The metabolism of Phenytoin can be increased when combined with Etanercept.
DB00005 DB00599 Thiopental The metabolism of Thiopental can be increased when combined with Etanercept.
DB00005 DB01174 Phenobarbital The metabolism of Phenobarbital can be increased when combined with Etanercept.
DB00005 DB01320 Fosphenytoin The metabolism of Fosphenytoin can be increased when combined with Etanercept.
DB00005 DB00613 Amodiaquine The metabolism of Amodiaquine can be increased when combined with Etanercept.
DB00005 DB00799 Tazarotene The metabolism of Tazarotene can be increased when combined with Etanercept.
DB00005 DB05229 Beraprost The metabolism of Beraprost can be increased when combined with Etanercept.
DB00005 DB06510 Muraglitazar The metabolism of Muraglitazar can be increased when combined with Etanercept.
DB00005 DB09296 Ombitasvir The metabolism of Ombitasvir can be increased when combined with Etanercept.
DB00005 DB01217 Anastrozole The metabolism of Anastrozole can be increased when combined with Etanercept.
DB00005 DB00255 Diethylstilbestrol The metabolism of Diethylstilbestrol can be increased when combined with Etanercept.
DB00005 DB00295 Morphine The metabolism of Morphine can be increased when combined with Etanercept.
DB00005 DB00359 Sulfadiazine The metabolism of Sulfadiazine can be increased when combined with Etanercept.
DB00005 DB00402 Eszopiclone The metabolism of Eszopiclone can be increased when combined with Etanercept.
DB00005 DB00622 Nicardipine The metabolism of Nicardipine can be increased when combined with Etanercept.
DB00005 DB00912 Repaglinide The metabolism of Repaglinide can be increased when combined with Etanercept.
DB00005 DB01261 Sitagliptin The metabolism of Sitagliptin can be increased when combined with Etanercept.
DB00005 DB06670 Odanacatib The metabolism of Odanacatib can be increased when combined with Etanercept.
DB00005 DB08502 Capravirine The metabolism of Capravirine can be increased when combined with Etanercept.
DB00005 DB08931 Riociguat The metabolism of Riociguat can be increased when combined with Etanercept.
DB00005 DB09198 Lobeglitazone The metabolism of Lobeglitazone can be increased when combined with Etanercept.
DB00005 DB09199 Netoglitazone The metabolism of Netoglitazone can be increased when combined with Etanercept.
DB00005 DB09200 Rivoglitazone The metabolism of Rivoglitazone can be increased when combined with Etanercept.
DB00005 DB09201 Ciglitazone The metabolism of Ciglitazone can be increased when combined with Etanercept.
DB00005 DB11362 Selexipag The metabolism of Selexipag can be increased when combined with Etanercept.
DB00005 DB11901 Apalutamide The metabolism of Apalutamide can be increased when combined with Etanercept.
DB00005 DB11978 Glasdegib The metabolism of Glasdegib can be increased when combined with Etanercept.
DB00005 DB12781 Balaglitazone The metabolism of Balaglitazone can be increased when combined with Etanercept.
DB00005 DB01132 Pioglitazone The metabolism of Pioglitazone can be increased when combined with Etanercept.
DB00005 DB11652 Tucatinib The metabolism of Tucatinib can be increased when combined with Etanercept.
DB00005 DB00946 Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Etanercept.
DB00005 DB01229 Paclitaxel The metabolism of Paclitaxel can be increased when combined with Etanercept.
DB00005 DB00177 Valsartan The metabolism of Valsartan can be increased when combined with Etanercept.
DB00005 DB00184 Nicotine The metabolism of Nicotine can be increased when combined with Etanercept.
DB00005 DB00197 Troglitazone The metabolism of Troglitazone can be increased when combined with Etanercept.
DB00005 DB00214 Torasemide The metabolism of Torasemide can be increased when combined with Etanercept.
DB00005 DB00222 Glimepiride The metabolism of Glimepiride can be increased when combined with Etanercept.
DB00005 DB00285 Venlafaxine The metabolism of Venlafaxine can be increased when combined with Etanercept.
DB00005 DB00304 Desogestrel The metabolism of Desogestrel can be increased when combined with Etanercept.
DB00005 DB00307 Bexarotene The metabolism of Bexarotene can be increased when combined with Etanercept.
DB00005 DB00327 Hydromorphone The metabolism of Hydromorphone can be increased when combined with Etanercept.
DB00005 DB00328 Indomethacin The metabolism of Indomethacin can be increased when combined with Etanercept.
DB00005 DB00343 Diltiazem The metabolism of Diltiazem can be increased when combined with Etanercept.
DB00005 DB00374 Treprostinil The metabolism of Treprostinil can be increased when combined with Etanercept.
DB00005 DB00412 Rosiglitazone The metabolism of Rosiglitazone can be increased when combined with Etanercept.
DB00005 DB00414 Acetohexamide The metabolism of Acetohexamide can be increased when combined with Etanercept.
DB00005 DB00420 Promazine The metabolism of Promazine can be increased when combined with Etanercept.
DB00005 DB00440 Trimethoprim The metabolism of Trimethoprim can be increased when combined with Etanercept.
DB00005 DB00461 Nabumetone The metabolism of Nabumetone can be increased when combined with Etanercept.
DB00005 DB00468 Quinine The metabolism of Quinine can be increased when combined with Etanercept.
DB00005 DB00469 Tenoxicam The metabolism of Tenoxicam can be increased when combined with Etanercept.
DB00005 DB00472 Fluoxetine The metabolism of Fluoxetine can be increased when combined with Etanercept.
DB00005 DB00476 Duloxetine The metabolism of Duloxetine can be increased when combined with Etanercept.
DB00005 DB00482 Celecoxib The metabolism of Celecoxib can be increased when combined with Etanercept.
DB00005 DB00495 Zidovudine The metabolism of Zidovudine can be increased when combined with Etanercept.
DB00005 DB00502 Haloperidol The metabolism of Haloperidol can be increased when combined with Etanercept.
DB00005 DB00533 Rofecoxib The metabolism of Rofecoxib can be increased when combined with Etanercept.
DB00005 DB00549 Zafirlukast The metabolism of Zafirlukast can be increased when combined with Etanercept.
DB00005 DB00554 Piroxicam The metabolism of Piroxicam can be increased when combined with Etanercept.
DB00005 DB00559 Bosentan The metabolism of Bosentan can be increased when combined with Etanercept.
DB00005 DB00568 Cinnarizine The metabolism of Cinnarizine can be increased when combined with Etanercept.
DB00005 DB00580 Valdecoxib The metabolism of Valdecoxib can be increased when combined with Etanercept.
DB00005 DB00586 Diclofenac The metabolism of Diclofenac can be increased when combined with Etanercept.
DB00005 DB00617 Paramethadione The metabolism of Paramethadione can be increased when combined with Etanercept.
DB00005 DB00661 Verapamil The metabolism of Verapamil can be increased when combined with Etanercept.
DB00005 DB00672 Chlorpropamide The metabolism of Chlorpropamide can be increased when combined with Etanercept.
DB00005 DB00678 Losartan The metabolism of Losartan can be increased when combined with Etanercept.
DB00005 DB00701 Amprenavir The metabolism of Amprenavir can be increased when combined with Etanercept.
DB00005 DB00712 Flurbiprofen The metabolism of Flurbiprofen can be increased when combined with Etanercept.
DB00005 DB00731 Nateglinide The metabolism of Nateglinide can be increased when combined with Etanercept.
DB00005 DB00744 Zileuton The metabolism of Zileuton can be increased when combined with Etanercept.
DB00005 DB00749 Etodolac The metabolism of Etodolac can be increased when combined with Etanercept.
DB00005 DB00755 Tretinoin The metabolism of Tretinoin can be increased when combined with Etanercept.
DB00005 DB00758 Clopidogrel The metabolism of Clopidogrel can be increased when combined with Etanercept.
DB00005 DB00783 Estradiol The metabolism of Estradiol can be increased when combined with Etanercept.
DB00005 DB00784 Mefenamic acid The metabolism of Mefenamic acid can be increased when combined with Etanercept.
DB00005 DB00788 Naproxen The metabolism of Naproxen can be increased when combined with Etanercept.
DB00005 DB00796 Candesartan cilexetil The metabolism of Candesartan cilexetil can be increased when combined with Etanercept.
DB00005 DB00812 Phenylbutazone The metabolism of Phenylbutazone can be increased when combined with Etanercept.
DB00005 DB00814 Meloxicam The metabolism of Meloxicam can be increased when combined with Etanercept.
DB00005 DB00839 Tolazamide The metabolism of Tolazamide can be increased when combined with Etanercept.
DB00005 DB00843 Donepezil The metabolism of Donepezil can be increased when combined with Etanercept.
DB00005 DB00857 Terbinafine The metabolism of Terbinafine can be increased when combined with Etanercept.
DB00005 DB00904 Ondansetron The metabolism of Ondansetron can be increased when combined with Etanercept.
DB00005 DB00921 Buprenorphine The metabolism of Buprenorphine can be increased when combined with Etanercept.
DB00005 DB00936 Salicylic acid The metabolism of Salicylic acid can be increased when combined with Etanercept.
DB00005 DB00945 Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be increased when combined with Etanercept.
DB00005 DB00969 Alosetron The metabolism of Alosetron can be increased when combined with Etanercept.
DB00005 DB00972 Azelastine The metabolism of Azelastine can be increased when combined with Etanercept.
DB00005 DB00980 Ramelteon The metabolism of Ramelteon can be increased when combined with Etanercept.
DB00005 DB01016 Glyburide The metabolism of Glyburide can be increased when combined with Etanercept.
DB00005 DB01029 Irbesartan The metabolism of Irbesartan can be increased when combined with Etanercept.
DB00005 DB01036 Tolterodine The metabolism of Tolterodine can be increased when combined with Etanercept.
DB00005 DB01037 Selegiline The metabolism of Selegiline can be increased when combined with Etanercept.
DB00005 DB01041 Thalidomide The metabolism of Thalidomide can be increased when combined with Etanercept.
DB00005 DB01050 Ibuprofen The metabolism of Ibuprofen can be increased when combined with Etanercept.
DB00005 DB01065 Melatonin The metabolism of Melatonin can be increased when combined with Etanercept.
DB00005 DB01067 Glipizide The metabolism of Glipizide can be increased when combined with Etanercept.
DB00005 DB01072 Atazanavir The metabolism of Atazanavir can be increased when combined with Etanercept.
DB00005 DB01075 Diphenhydramine The metabolism of Diphenhydramine can be increased when combined with Etanercept.
DB00005 DB01095 Fluvastatin The metabolism of Fluvastatin can be increased when combined with Etanercept.
DB00005 DB01098 Rosuvastatin The metabolism of Rosuvastatin can be increased when combined with Etanercept.
DB00005 DB01120 Gliclazide The metabolism of Gliclazide can be increased when combined with Etanercept.
DB00005 DB01124 Tolbutamide The metabolism of Tolbutamide can be increased when combined with Etanercept.
DB00005 DB01136 Carvedilol The metabolism of Carvedilol can be increased when combined with Etanercept.
DB00005 DB01154 Thiamylal The metabolism of Thiamylal can be increased when combined with Etanercept.
DB00005 DB01171 Moclobemide The metabolism of Moclobemide can be increased when combined with Etanercept.
DB00005 DB01177 Idarubicin The metabolism of Idarubicin can be increased when combined with Etanercept.
DB00005 DB01198 Zopiclone The metabolism of Zopiclone can be increased when combined with Etanercept.
DB00005 DB01251 Gliquidone The metabolism of Gliquidone can be increased when combined with Etanercept.
DB00005 DB01283 Lumiracoxib The metabolism of Lumiracoxib can be increased when combined with Etanercept.
DB00005 DB01289 Glisoxepide The metabolism of Glisoxepide can be increased when combined with Etanercept.
DB00005 DB01357 Mestranol The metabolism of Mestranol can be increased when combined with Etanercept.
DB00005 DB01424 Aminophenazone The metabolism of Aminophenazone can be increased when combined with Etanercept.
DB00005 DB01435 Antipyrine The metabolism of Antipyrine can be increased when combined with Etanercept.
DB00005 DB01589 Quazepam The metabolism of Quazepam can be increased when combined with Etanercept.
DB00005 DB01628 Etoricoxib The metabolism of Etoricoxib can be increased when combined with Etanercept.
DB00005 DB03756 Doconexent The metabolism of Doconexent can be increased when combined with Etanercept.
DB00005 DB03783 Phenacetin The metabolism of Phenacetin can be increased when combined with Etanercept.
DB00005 DB04557 Arachidonic Acid The metabolism of Arachidonic Acid can be increased when combined with Etanercept.
DB00005 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Etanercept.
DB00005 DB04665 Coumarin The metabolism of Coumarin can be increased when combined with Etanercept.
DB00005 DB04725 Licofelone The metabolism of Licofelone can be increased when combined with Etanercept.
DB00005 DB04841 Flunarizine The metabolism of Flunarizine can be increased when combined with Etanercept.
DB00005 DB04898 Ximelagatran The metabolism of Ximelagatran can be increased when combined with Etanercept.
DB00005 DB06204 Tapentadol The metabolism of Tapentadol can be increased when combined with Etanercept.
DB00005 DB06268 Sitaxentan The metabolism of Sitaxentan can be increased when combined with Etanercept.
DB00005 DB06370 Indisulam The metabolism of Indisulam can be increased when combined with Etanercept.
DB00005 DB06652 Vicriviroc The metabolism of Vicriviroc can be increased when combined with Etanercept.
DB00005 DB06725 Lornoxicam The metabolism of Lornoxicam can be increased when combined with Etanercept.
DB00005 DB06737 Zaltoprofen The metabolism of Zaltoprofen can be increased when combined with Etanercept.
DB00005 DB06803 Niclosamide The metabolism of Niclosamide can be increased when combined with Etanercept.
DB00005 DB07615 Tranilast The metabolism of Tranilast can be increased when combined with Etanercept.
DB00005 DB08439 Parecoxib The metabolism of Parecoxib can be increased when combined with Etanercept.
DB00005 DB08828 Vismodegib The metabolism of Vismodegib can be increased when combined with Etanercept.
DB00005 DB08860 Pitavastatin The metabolism of Pitavastatin can be increased when combined with Etanercept.
DB00005 DB08875 Cabozantinib The metabolism of Cabozantinib can be increased when combined with Etanercept.
DB00005 DB08899 Enzalutamide The metabolism of Enzalutamide can be increased when combined with Etanercept.
DB00005 DB08962 Glibornuride The metabolism of Glibornuride can be increased when combined with Etanercept.
DB00005 DB09048 Netupitant The metabolism of Netupitant can be increased when combined with Etanercept.
DB00005 DB09061 Cannabidiol The metabolism of Cannabidiol can be increased when combined with Etanercept.
DB00005 DB09080 Olodaterol The metabolism of Olodaterol can be increased when combined with Etanercept.
DB00005 DB09288 Propacetamol The metabolism of Propacetamol can be increased when combined with Etanercept.
DB00005 DB11560 Lesinurad The metabolism of Lesinurad can be increased when combined with Etanercept.
DB00005 DB11614 Rupatadine The metabolism of Rupatadine can be increased when combined with Etanercept.
DB00005 DB13406 Carbutamide The metabolism of Carbutamide can be increased when combined with Etanercept.
DB00005 DB13675 Metahexamide The metabolism of Metahexamide can be increased when combined with Etanercept.
DB00005 DB13919 Candesartan The metabolism of Candesartan can be increased when combined with Etanercept.
DB00005 DB13941 Piperaquine The metabolism of Piperaquine can be increased when combined with Etanercept.
DB00005 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Etanercept.
DB00005 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Etanercept.
DB00005 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Etanercept.
DB00005 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Etanercept.
DB00005 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Etanercept.
DB00005 DB14009 Medical Cannabis The metabolism of Medical Cannabis can be increased when combined with Etanercept.
DB00005 DB14011 Nabiximols The metabolism of Nabiximols can be increased when combined with Etanercept.
DB00005 DB00829 Diazepam The metabolism of Diazepam can be increased when combined with Etanercept.
DB00005 DB00514 Dextromethorphan The metabolism of Dextromethorphan can be increased when combined with Etanercept.
DB00005 DB00470 Dronabinol The metabolism of Dronabinol can be increased when combined with Etanercept.
DB00005 DB09213 Dexibuprofen The metabolism of Dexibuprofen can be increased when combined with Etanercept.
DB00005 DB00465 Ketorolac The metabolism of Ketorolac can be increased when combined with Etanercept.
DB00005 DB15233 Avapritinib The metabolism of Avapritinib can be increased when combined with Etanercept.
DB00005 DB00321 Amitriptyline The metabolism of Amitriptyline can be increased when combined with Etanercept.
DB00005 DB01142 Doxepin The metabolism of Doxepin can be increased when combined with Etanercept.
DB00005 DB00216 Eletriptan The metabolism of Eletriptan can be increased when combined with Etanercept.
DB00005 DB00404 Alprazolam The metabolism of Alprazolam can be increased when combined with Etanercept.
DB00005 DB00726 Trimipramine The metabolism of Trimipramine can be increased when combined with Etanercept.
DB00005 DB01101 Capecitabine The metabolism of Capecitabine can be increased when combined with Etanercept.
DB00005 DB00266 Dicoumarol The metabolism of Dicoumarol can be increased when combined with Etanercept.
DB00005 DB00313 Valproic acid The metabolism of Valproic acid can be increased when combined with Etanercept.
DB00005 DB00908 Quinidine The metabolism of Quinidine can be increased when combined with Etanercept.
DB00005 DB13136 Fluindione The metabolism of Fluindione can be increased when combined with Etanercept.
DB00005 DB01224 Quetiapine The metabolism of Quetiapine can be increased when combined with Etanercept.
DB00005 DB00182 Amphetamine The metabolism of Amphetamine can be increased when combined with Etanercept.
DB00005 DB00187 Esmolol The metabolism of Esmolol can be increased when combined with Etanercept.
DB00005 DB00245 Benzatropine The metabolism of Benzatropine can be increased when combined with Etanercept.
DB00005 DB00289 Atomoxetine The metabolism of Atomoxetine can be increased when combined with Etanercept.
DB00005 DB00335 Atenolol The metabolism of Atenolol can be increased when combined with Etanercept.
DB00005 DB00373 Timolol The metabolism of Timolol can be increased when combined with Etanercept.
DB00005 DB00409 Remoxipride The metabolism of Remoxipride can be increased when combined with Etanercept.
DB00005 DB00592 Piperazine The metabolism of Piperazine can be increased when combined with Etanercept.
DB00005 DB00699 Nicergoline The metabolism of Nicergoline can be increased when combined with Etanercept.
DB00005 DB00737 Meclizine The metabolism of Meclizine can be increased when combined with Etanercept.
DB00005 DB00805 Minaprine The metabolism of Minaprine can be increased when combined with Etanercept.
DB00005 DB00866 Alprenolol The metabolism of Alprenolol can be increased when combined with Etanercept.
DB00005 DB00914 Phenformin The metabolism of Phenformin can be increased when combined with Etanercept.
DB00005 DB00933 Mesoridazine The metabolism of Mesoridazine can be increased when combined with Etanercept.
DB00005 DB00960 Pindolol The metabolism of Pindolol can be increased when combined with Etanercept.
DB00005 DB01071 Mequitazine The metabolism of Mequitazine can be increased when combined with Etanercept.
DB00005 DB01079 Tegaserod The metabolism of Tegaserod can be increased when combined with Etanercept.
DB00005 DB01193 Acebutolol The metabolism of Acebutolol can be increased when combined with Etanercept.
DB00005 DB01203 Nadolol The metabolism of Nadolol can be increased when combined with Etanercept.
DB00005 DB01228 Encainide The metabolism of Encainide can be increased when combined with Etanercept.
DB00005 DB01233 Metoclopramide The metabolism of Metoclopramide can be increased when combined with Etanercept.
DB00005 DB01255 Lisdexamfetamine The metabolism of Lisdexamfetamine can be increased when combined with Etanercept.
DB00005 DB01295 Bevantolol The metabolism of Bevantolol can be increased when combined with Etanercept.
DB00005 DB01297 Practolol The metabolism of Practolol can be increased when combined with Etanercept.
DB00005 DB01359 Penbutolol The metabolism of Penbutolol can be increased when combined with Etanercept.
DB00005 DB01403 Methotrimeprazine The metabolism of Methotrimeprazine can be increased when combined with Etanercept.
DB00005 DB01429 Aprindine The metabolism of Aprindine can be increased when combined with Etanercept.
DB00005 DB01454 Midomafetamine The metabolism of Midomafetamine can be increased when combined with Etanercept.
DB00005 DB01472 4-Methoxyamphetamine The metabolism of 4-Methoxyamphetamine can be increased when combined with Etanercept.
DB00005 DB01576 Dextroamphetamine The metabolism of Dextroamphetamine can be increased when combined with Etanercept.
DB00005 DB01577 Metamfetamine The metabolism of Metamfetamine can be increased when combined with Etanercept.
DB00005 DB01580 Oxprenolol The metabolism of Oxprenolol can be increased when combined with Etanercept.
DB00005 DB04840 Debrisoquine The metabolism of Debrisoquine can be increased when combined with Etanercept.
DB00005 DB04844 Tetrabenazine The metabolism of Tetrabenazine can be increased when combined with Etanercept.
DB00005 DB04846 Celiprolol The metabolism of Celiprolol can be increased when combined with Etanercept.
DB00005 DB06217 Vernakalant The metabolism of Vernakalant can be increased when combined with Etanercept.
DB00005 DB06506 Repinotan The metabolism of Repinotan can be increased when combined with Etanercept.
DB00005 DB06608 Tafenoquine The metabolism of Tafenoquine can be increased when combined with Etanercept.
DB00005 DB06678 Esmirtazapine The metabolism of Esmirtazapine can be increased when combined with Etanercept.
DB00005 DB06726 Bufuralol The metabolism of Bufuralol can be increased when combined with Etanercept.
DB00005 DB06727 Sparteine The metabolism of Sparteine can be increased when combined with Etanercept.
DB00005 DB06735 Enclomiphene The metabolism of Enclomiphene can be increased when combined with Etanercept.
DB00005 DB08807 Bopindolol The metabolism of Bopindolol can be increased when combined with Etanercept.
DB00005 DB08808 Bupranolol The metabolism of Bupranolol can be increased when combined with Etanercept.
DB00005 DB08952 Indenolol The metabolism of Indenolol can be increased when combined with Etanercept.
DB00005 DB09013 Befunolol The metabolism of Befunolol can be increased when combined with Etanercept.
DB00005 DB09076 Umeclidinium The metabolism of Umeclidinium can be increased when combined with Etanercept.
DB00005 DB09204 Arotinolol The metabolism of Arotinolol can be increased when combined with Etanercept.
DB00005 DB09351 Levobetaxolol The metabolism of Levobetaxolol can be increased when combined with Etanercept.
DB00005 DB11770 Talinolol The metabolism of Talinolol can be increased when combined with Etanercept.
DB00005 DB11785 Anisodamine The metabolism of Anisodamine can be increased when combined with Etanercept.
DB00005 DB11855 Revefenacin The metabolism of Revefenacin can be increased when combined with Etanercept.
DB00005 DB11979 Elagolix The metabolism of Elagolix can be increased when combined with Etanercept.
DB00005 DB12070 Letermovir The metabolism of Letermovir can be increased when combined with Etanercept.
DB00005 DB12212 Landiolol The metabolism of Landiolol can be increased when combined with Etanercept.
DB00005 DB12752 Bucindolol The metabolism of Bucindolol can be increased when combined with Etanercept.
DB00005 DB13443 Esatenolol The metabolism of Esatenolol can be increased when combined with Etanercept.
DB00005 DB13508 Cloranolol The metabolism of Cloranolol can be increased when combined with Etanercept.
DB00005 DB13530 Mepindolol The metabolism of Mepindolol can be increased when combined with Etanercept.
DB00005 DB13679 Dexchlorpheniramine The metabolism of Dexchlorpheniramine can be increased when combined with Etanercept.
DB00005 DB13757 Epanolol The metabolism of Epanolol can be increased when combined with Etanercept.
DB00005 DB13775 Tertatolol The metabolism of Tertatolol can be increased when combined with Etanercept.
DB00005 DB00850 Perphenazine The metabolism of Perphenazine can be increased when combined with Etanercept.
DB00005 DB09173 Butyrfentanyl The metabolism of Butyrfentanyl can be increased when combined with Etanercept.
DB00005 DB00281 Lidocaine The metabolism of Lidocaine can be increased when combined with Etanercept.
DB00005 DB00598 Labetalol The metabolism of Labetalol can be increased when combined with Etanercept.
DB00005 DB14010 5-methoxy-N,N-dimethyltryptamine The metabolism of 5-methoxy-N,N-dimethyltryptamine can be increased when combined with Etanercept.
DB00005 DB01410 Ciclesonide The metabolism of Ciclesonide can be increased when combined with Etanercept.
DB00005 DB00918 Almotriptan The metabolism of Almotriptan can be increased when combined with Etanercept.
DB00005 DB08918 Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Etanercept.
DB00005 DB08922 Perospirone The metabolism of Perospirone can be increased when combined with Etanercept.
DB00005 DB09183 Dasabuvir The metabolism of Dasabuvir can be increased when combined with Etanercept.
DB00005 DB00185 Cevimeline The metabolism of Cevimeline can be increased when combined with Etanercept.
DB00005 DB00243 Ranolazine The metabolism of Ranolazine can be increased when combined with Etanercept.
DB00005 DB00297 Bupivacaine The metabolism of Bupivacaine can be increased when combined with Etanercept.
DB00005 DB00318 Codeine The metabolism of Codeine can be increased when combined with Etanercept.
DB00005 DB00377 Palonosetron The metabolism of Palonosetron can be increased when combined with Etanercept.
DB00005 DB00589 Lisuride The metabolism of Lisuride can be increased when combined with Etanercept.
DB00005 DB00647 Dextropropoxyphene The metabolism of Dextropropoxyphene can be increased when combined with Etanercept.
DB00005 DB00674 Galantamine The metabolism of Galantamine can be increased when combined with Etanercept.
DB00005 DB00705 Delavirdine The metabolism of Delavirdine can be increased when combined with Etanercept.
DB00005 DB00706 Tamsulosin The metabolism of Tamsulosin can be increased when combined with Etanercept.
DB00005 DB00757 Dolasetron The metabolism of Dolasetron can be increased when combined with Etanercept.
DB00005 DB01149 Nefazodone The metabolism of Nefazodone can be increased when combined with Etanercept.
DB00005 DB01192 Oxymorphone The metabolism of Oxymorphone can be increased when combined with Etanercept.
DB00005 DB01244 Bepridil The metabolism of Bepridil can be increased when combined with Etanercept.
DB00005 DB01392 Yohimbine The metabolism of Yohimbine can be increased when combined with Etanercept.
DB00005 DB01409 Tiotropium The metabolism of Tiotropium can be increased when combined with Etanercept.
DB00005 DB01551 Dihydrocodeine The metabolism of Dihydrocodeine can be increased when combined with Etanercept.
DB00005 DB01591 Solifenacin The metabolism of Solifenacin can be increased when combined with Etanercept.
DB00005 DB01621 Pipotiazine The metabolism of Pipotiazine can be increased when combined with Etanercept.
DB00005 DB02703 Fusidic acid The metabolism of Fusidic acid can be increased when combined with Etanercept.
DB00005 DB04829 Lysergic acid diethylamide The metabolism of Lysergic acid diethylamide can be increased when combined with Etanercept.
DB00005 DB04884 Dapoxetine The metabolism of Dapoxetine can be increased when combined with Etanercept.
DB00005 DB04905 Tesmilifene The metabolism of Tesmilifene can be increased when combined with Etanercept.
DB00005 DB04920 Clevidipine The metabolism of Clevidipine can be increased when combined with Etanercept.
DB00005 DB05271 Rotigotine The metabolism of Rotigotine can be increased when combined with Etanercept.
DB00005 DB06016 Cariprazine The metabolism of Cariprazine can be increased when combined with Etanercept.
DB00005 DB06144 Sertindole The metabolism of Sertindole can be increased when combined with Etanercept.
DB00005 DB06203 Alogliptin The metabolism of Alogliptin can be increased when combined with Etanercept.
DB00005 DB06702 Fesoterodine The metabolism of Fesoterodine can be increased when combined with Etanercept.
DB00005 DB08893 Mirabegron The metabolism of Mirabegron can be increased when combined with Etanercept.
DB00005 DB09128 Brexpiprazole The metabolism of Brexpiprazole can be increased when combined with Etanercept.
DB00005 DB09195 Lorpiprazole The metabolism of Lorpiprazole can be increased when combined with Etanercept.
DB00005 DB09555 Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be increased when combined with Etanercept.
DB00005 DB11130 Opium The metabolism of Opium can be increased when combined with Etanercept.
DB00005 DB11642 Pitolisant The metabolism of Pitolisant can be increased when combined with Etanercept.
DB00005 DB13293 Ipecac The metabolism of Ipecac can be increased when combined with Etanercept.
DB00005 DB00344 Protriptyline The metabolism of Protriptyline can be increased when combined with Etanercept.
DB00005 DB00496 Darifenacin The metabolism of Darifenacin can be increased when combined with Etanercept.
DB00005 DB00543 Amoxapine The metabolism of Amoxapine can be increased when combined with Etanercept.
DB00005 DB00932 Tipranavir The metabolism of Tipranavir can be increased when combined with Etanercept.
DB00005 DB09039 Eliglustat The metabolism of Eliglustat can be increased when combined with Etanercept.
DB00005 DB12930 Opipramol The metabolism of Opipramol can be increased when combined with Etanercept.
DB00005 DB00489 Sotalol The metabolism of Sotalol can be increased when combined with Etanercept.
DB00005 DB01035 Procainamide The metabolism of Procainamide can be increased when combined with Etanercept.
DB00005 DB01195 Flecainide The metabolism of Flecainide can be increased when combined with Etanercept.
DB00005 DB00228 Enflurane The metabolism of Enflurane can be increased when combined with Etanercept.
DB00005 DB06712 Nilvadipine The metabolism of Nilvadipine can be increased when combined with Etanercept.
DB00005 DB06728 Aniline The metabolism of Aniline can be increased when combined with Etanercept.
DB00005 DB00949 Felbamate The metabolism of Felbamate can be increased when combined with Etanercept.
DB00005 DB00593 Ethosuximide The metabolism of Ethosuximide can be increased when combined with Etanercept.
DB00005 DB00186 Lorazepam The metabolism of Lorazepam can be increased when combined with Etanercept.
DB00005 DB00191 Phentermine The metabolism of Phentermine can be increased when combined with Etanercept.
DB00005 DB00207 Azithromycin The metabolism of Azithromycin can be increased when combined with Etanercept.
DB00005 DB00208 Ticlopidine The metabolism of Ticlopidine can be increased when combined with Etanercept.
DB00005 DB00264 Metoprolol The metabolism of Metoprolol can be increased when combined with Etanercept.
DB00005 DB00426 Famciclovir The metabolism of Famciclovir can be increased when combined with Etanercept.
DB00005 DB00433 Prochlorperazine The metabolism of Prochlorperazine can be increased when combined with Etanercept.
DB00005 DB00567 Cephalexin The metabolism of Cephalexin can be increased when combined with Etanercept.
DB00005 DB00590 Doxazosin The metabolism of Doxazosin can be increased when combined with Etanercept.
DB00005 DB01039 Fenofibrate The metabolism of Fenofibrate can be increased when combined with Etanercept.
DB00005 DB01395 Drospirenone The metabolism of Drospirenone can be increased when combined with Etanercept.
DB00005 DB01411 Pranlukast The metabolism of Pranlukast can be increased when combined with Etanercept.
DB00005 DB01431 Allylestrenol The metabolism of Allylestrenol can be increased when combined with Etanercept.
DB00005 DB01624 Zuclopenthixol The metabolism of Zuclopenthixol can be increased when combined with Etanercept.
DB00005 DB06201 Rufinamide The metabolism of Rufinamide can be increased when combined with Etanercept.
DB00005 DB06480 Prucalopride The metabolism of Prucalopride can be increased when combined with Etanercept.
DB00005 DB08882 Linagliptin The metabolism of Linagliptin can be increased when combined with Etanercept.
DB00005 DB09030 Vorapaxar The metabolism of Vorapaxar can be increased when combined with Etanercept.
DB00005 DB09034 Suvorexant The metabolism of Suvorexant can be increased when combined with Etanercept.
DB00005 DB09079 Nintedanib The metabolism of Nintedanib can be increased when combined with Etanercept.
DB00005 DB09299 Tenofovir alafenamide The metabolism of Tenofovir alafenamide can be increased when combined with Etanercept.
DB00005 DB09330 Osimertinib The metabolism of Osimertinib can be increased when combined with Etanercept.
DB00005 DB11094 Vitamin D The metabolism of Vitamin D can be increased when combined with Etanercept.
DB00005 DB11273 Dihydroergocornine The metabolism of Dihydroergocornine can be increased when combined with Etanercept.
DB00005 DB11730 Ribociclib The metabolism of Ribociclib can be increased when combined with Etanercept.
DB00005 DB11952 Duvelisib The metabolism of Duvelisib can be increased when combined with Etanercept.
DB00005 DB12141 Gilteritinib The metabolism of Gilteritinib can be increased when combined with Etanercept.
DB00005 DB12515 9-aminocamptothecin The metabolism of 9-aminocamptothecin can be increased when combined with Etanercept.
DB00005 DB12952 Methylprednisone The metabolism of Methylprednisone can be increased when combined with Etanercept.
DB00005 DB13345 Dihydroergocristine The metabolism of Dihydroergocristine can be increased when combined with Etanercept.
DB00005 DB13385 Dihydroergocryptine The metabolism of Dihydroergocryptine can be increased when combined with Etanercept.
DB00005 DB14126 Tenofovir The metabolism of Tenofovir can be increased when combined with Etanercept.
DB00005 DB15444 Elexacaftor The metabolism of Elexacaftor can be increased when combined with Etanercept.
DB00005 DB06717 Fosaprepitant The metabolism of Fosaprepitant can be increased when combined with Etanercept.
DB00005 DB12825 Lefamulin The metabolism of Lefamulin can be increased when combined with Etanercept.
DB00005 DB12887 Tazemetostat The metabolism of Tazemetostat can be increased when combined with Etanercept.
DB00005 DB00454 Meperidine The metabolism of Meperidine can be increased when combined with Etanercept.
DB00005 DB01151 Desipramine The metabolism of Desipramine can be increased when combined with Etanercept.
DB00005 DB12371 Siponimod The metabolism of Siponimod can be increased when combined with Etanercept.
DB00005 DB00247 Methysergide The metabolism of Methysergide can be increased when combined with Etanercept.
DB00005 DB08827 Lomitapide The metabolism of Lomitapide can be increased when combined with Etanercept.
DB00005 DB11742 Ebastine The metabolism of Ebastine can be increased when combined with Etanercept.
DB00005 DB05015 Belinostat The metabolism of Belinostat can be increased when combined with Etanercept.
DB00005 DB01118 Amiodarone The metabolism of Amiodarone can be increased when combined with Etanercept.
DB00005 DB00675 Tamoxifen The metabolism of Tamoxifen can be increased when combined with Etanercept.
DB00005 DB00204 Dofetilide The metabolism of Dofetilide can be increased when combined with Etanercept.
DB00005 DB00342 Terfenadine The metabolism of Terfenadine can be increased when combined with Etanercept.
DB00005 DB00451 Levothyroxine The metabolism of Levothyroxine can be increased when combined with Etanercept.
DB00005 DB00604 Cisapride The metabolism of Cisapride can be increased when combined with Etanercept.
DB00005 DB00877 Sirolimus The metabolism of Sirolimus can be increased when combined with Etanercept.
DB00005 DB01008 Busulfan The metabolism of Busulfan can be increased when combined with Etanercept.
DB00005 DB01254 Dasatinib The metabolism of Dasatinib can be increased when combined with Etanercept.
DB00005 DB01396 Digitoxin The metabolism of Digitoxin can be increased when combined with Etanercept.
DB00005 DB01590 Everolimus The metabolism of Everolimus can be increased when combined with Etanercept.
DB00005 DB03410 4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be increased when combined with Etanercept.
DB00005 DB04855 Dronedarone The metabolism of Dronedarone can be increased when combined with Etanercept.
DB00005 DB06287 Temsirolimus The metabolism of Temsirolimus can be increased when combined with Etanercept.
DB00005 DB09053 Ibrutinib The metabolism of Ibrutinib can be increased when combined with Etanercept.
DB00005 DB09289 Tianeptine The metabolism of Tianeptine can be increased when combined with Etanercept.
DB00005 DB11633 Isavuconazole The metabolism of Isavuconazole can be increased when combined with Etanercept.
DB00005 DB13275 Clorindione The metabolism of Clorindione can be increased when combined with Etanercept.
DB00005 DB00398 Sorafenib The metabolism of Sorafenib can be increased when combined with Etanercept.
DB00005 DB00444 Teniposide The metabolism of Teniposide can be increased when combined with Etanercept.
DB00005 DB00530 Erlotinib The metabolism of Erlotinib can be increased when combined with Etanercept.
DB00005 DB00541 Vincristine The metabolism of Vincristine can be increased when combined with Etanercept.
DB00005 DB00619 Imatinib The metabolism of Imatinib can be increased when combined with Etanercept.
DB00005 DB00773 Etoposide The metabolism of Etoposide can be increased when combined with Etanercept.
DB00005 DB01248 Docetaxel The metabolism of Docetaxel can be increased when combined with Etanercept.
DB00005 DB01268 Sunitinib The metabolism of Sunitinib can be increased when combined with Etanercept.
DB00005 DB06626 Axitinib The metabolism of Axitinib can be increased when combined with Etanercept.
DB00005 DB08865 Crizotinib The metabolism of Crizotinib can be increased when combined with Etanercept.
DB00005 DB08901 Ponatinib The metabolism of Ponatinib can be increased when combined with Etanercept.
DB00005 DB12483 Copanlisib The metabolism of Copanlisib can be increased when combined with Etanercept.
DB00005 DB00188 Bortezomib The metabolism of Bortezomib can be increased when combined with Etanercept.
DB00005 DB00363 Clozapine The metabolism of Clozapine can be increased when combined with Etanercept.
DB00005 DB01181 Ifosfamide The metabolism of Ifosfamide can be increased when combined with Etanercept.
DB00005 DB05109 Trabectedin The metabolism of Trabectedin can be increased when combined with Etanercept.
DB00005 DB12147 Erdafitinib The metabolism of Erdafitinib can be increased when combined with Etanercept.
DB00005 DB13874 Enasidenib The metabolism of Enasidenib can be increased when combined with Etanercept.
DB00005 DB06589 Pazopanib The metabolism of Pazopanib can be increased when combined with Etanercept.
DB00005 DB05239 Cobimetinib The metabolism of Cobimetinib can be increased when combined with Etanercept.
DB00005 DB09063 Ceritinib The metabolism of Ceritinib can be increased when combined with Etanercept.
DB00005 DB11963 Dacomitinib The metabolism of Dacomitinib can be increased when combined with Etanercept.
DB00005 DB12015 Alpelisib The metabolism of Alpelisib can be increased when combined with Etanercept.
DB00005 DB00309 Vindesine The metabolism of Vindesine can be increased when combined with Etanercept.
DB00005 DB00361 Vinorelbine The metabolism of Vinorelbine can be increased when combined with Etanercept.
DB00005 DB00570 Vinblastine The metabolism of Vinblastine can be increased when combined with Etanercept.
DB00005 DB00694 Daunorubicin The metabolism of Daunorubicin can be increased when combined with Etanercept.
DB00005 DB00987 Cytarabine The metabolism of Cytarabine can be increased when combined with Etanercept.
DB00005 DB00997 Doxorubicin The metabolism of Doxorubicin can be increased when combined with Etanercept.
DB00005 DB01108 Trilostane The metabolism of Trilostane can be increased when combined with Etanercept.
DB00005 DB04572 Thiotepa The metabolism of Thiotepa can be increased when combined with Etanercept.
DB00005 DB04845 Ixabepilone The metabolism of Ixabepilone can be increased when combined with Etanercept.
DB00005 DB04868 Nilotinib The metabolism of Nilotinib can be increased when combined with Etanercept.
DB00005 DB06603 Panobinostat The metabolism of Panobinostat can be increased when combined with Etanercept.
DB00005 DB06616 Bosutinib The metabolism of Bosutinib can be increased when combined with Etanercept.
DB00005 DB08870 Brentuximab vedotin The metabolism of Brentuximab vedotin can be increased when combined with Etanercept.
DB00005 DB08877 Ruxolitinib The metabolism of Ruxolitinib can be increased when combined with Etanercept.
DB00005 DB09073 Palbociclib The metabolism of Palbociclib can be increased when combined with Etanercept.
DB00005 DB08912 Dabrafenib The metabolism of Dabrafenib can be increased when combined with Etanercept.
DB00005 DB12267 Brigatinib The metabolism of Brigatinib can be increased when combined with Etanercept.
DB00005 DB11718 Encorafenib The metabolism of Encorafenib can be increased when combined with Etanercept.
DB00005 DB00563 Methotrexate The metabolism of Methotrexate can be increased when combined with Etanercept.
DB00005 DB05294 Vandetanib The metabolism of Vandetanib can be increased when combined with Etanercept.
DB00005 DB05812 Abiraterone The metabolism of Abiraterone can be increased when combined with Etanercept.
DB00005 DB08881 Vemurafenib The metabolism of Vemurafenib can be increased when combined with Etanercept.
DB00005 DB11363 Alectinib The metabolism of Alectinib can be increased when combined with Etanercept.
DB00005 DB11581 Venetoclax The metabolism of Venetoclax can be increased when combined with Etanercept.
DB00005 DB11641 Vinflunine The metabolism of Vinflunine can be increased when combined with Etanercept.
DB00005 DB11703 Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Etanercept.
DB00005 DB15035 Zanubrutinib The metabolism of Zanubrutinib can be increased when combined with Etanercept.
DB00005 DB00248 Cabergoline The metabolism of Cabergoline can be increased when combined with Etanercept.
DB00005 DB06595 Midostaurin The metabolism of Midostaurin can be increased when combined with Etanercept.
DB00005 DB09143 Sonidegib The metabolism of Sonidegib can be increased when combined with Etanercept.
DB00005 DB11828 Neratinib The metabolism of Neratinib can be increased when combined with Etanercept.
DB00005 DB11986 Entrectinib The metabolism of Entrectinib can be increased when combined with Etanercept.
DB00005 DB12978 Pexidartinib The metabolism of Pexidartinib can be increased when combined with Etanercept.
DB00005 DB14568 Ivosidenib The metabolism of Ivosidenib can be increased when combined with Etanercept.
DB00005 DB09054 Idelalisib The metabolism of Idelalisib can be increased when combined with Etanercept.
DB00005 DB09570 Ixazomib The metabolism of Ixazomib can be increased when combined with Etanercept.
DB00005 DB00199 Erythromycin The metabolism of Erythromycin can be increased when combined with Etanercept.
DB00005 DB00246 Ziprasidone The metabolism of Ziprasidone can be increased when combined with Etanercept.
DB00005 DB00439 Cerivastatin The metabolism of Cerivastatin can be increased when combined with Etanercept.
DB00005 DB00499 Flutamide The metabolism of Flutamide can be increased when combined with Etanercept.
DB00005 DB00528 Lercanidipine The metabolism of Lercanidipine can be increased when combined with Etanercept.
DB00005 DB00571 Propranolol The metabolism of Propranolol can be increased when combined with Etanercept.
DB00005 DB00588 Fluticasone propionate The metabolism of Fluticasone propionate can be increased when combined with Etanercept.
DB00005 DB00608 Chloroquine The metabolism of Chloroquine can be increased when combined with Etanercept.
DB00005 DB00688 Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be increased when combined with Etanercept.
DB00005 DB00717 Norethisterone The metabolism of Norethisterone can be increased when combined with Etanercept.
DB00005 DB00738 Pentamidine The metabolism of Pentamidine can be increased when combined with Etanercept.
DB00005 DB00741 Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Etanercept.
DB00005 DB00762 Irinotecan The metabolism of Irinotecan can be increased when combined with Etanercept.
DB00005 DB00822 Disulfiram The metabolism of Disulfiram can be increased when combined with Etanercept.
DB00005 DB00834 Mifepristone The metabolism of Mifepristone can be increased when combined with Etanercept.
DB00005 DB00938 Salmeterol The metabolism of Salmeterol can be increased when combined with Etanercept.
DB00005 DB00962 Zaleplon The metabolism of Zaleplon can be increased when combined with Etanercept.
DB00005 DB00976 Telithromycin The metabolism of Telithromycin can be increased when combined with Etanercept.
DB00005 DB01054 Nitrendipine The metabolism of Nitrendipine can be increased when combined with Etanercept.
DB00005 DB01058 Praziquantel The metabolism of Praziquantel can be increased when combined with Etanercept.
DB00005 DB01062 Oxybutynin The metabolism of Oxybutynin can be increased when combined with Etanercept.
DB00005 DB01076 Atorvastatin The metabolism of Atorvastatin can be increased when combined with Etanercept.
DB00005 DB01103 Quinacrine The metabolism of Quinacrine can be increased when combined with Etanercept.
DB00005 DB01115 Nifedipine The metabolism of Nifedipine can be increased when combined with Etanercept.
DB00005 DB01126 Dutasteride The metabolism of Dutasteride can be increased when combined with Etanercept.
DB00005 DB01166 Cilostazol The metabolism of Cilostazol can be increased when combined with Etanercept.
DB00005 DB01184 Domperidone The metabolism of Domperidone can be increased when combined with Etanercept.
DB00005 DB01211 Clarithromycin The metabolism of Clarithromycin can be increased when combined with Etanercept.
DB00005 DB01216 Finasteride The metabolism of Finasteride can be increased when combined with Etanercept.
DB00005 DB01218 Halofantrine The metabolism of Halofantrine can be increased when combined with Etanercept.
DB00005 DB05521 Telaprevir The metabolism of Telaprevir can be increased when combined with Etanercept.
DB00005 DB05773 Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be increased when combined with Etanercept.
DB00005 DB06267 Udenafil The metabolism of Udenafil can be increased when combined with Etanercept.
DB00005 DB06335 Saxagliptin The metabolism of Saxagliptin can be increased when combined with Etanercept.
DB00005 DB06403 Ambrisentan The metabolism of Ambrisentan can be increased when combined with Etanercept.
DB00005 DB06419 Cethromycin The metabolism of Cethromycin can be increased when combined with Etanercept.
DB00005 DB06772 Cabazitaxel The metabolism of Cabazitaxel can be increased when combined with Etanercept.
DB00005 DB06789 Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be increased when combined with Etanercept.
DB00005 DB08820 Ivacaftor The metabolism of Ivacaftor can be increased when combined with Etanercept.
DB00005 DB08873 Boceprevir The metabolism of Boceprevir can be increased when combined with Etanercept.
DB00005 DB08883 Perampanel The metabolism of Perampanel can be increased when combined with Etanercept.
DB00005 DB08906 Fluticasone furoate The metabolism of Fluticasone furoate can be increased when combined with Etanercept.
DB00005 DB09065 Cobicistat The metabolism of Cobicistat can be increased when combined with Etanercept.
DB00005 DB09074 Olaparib The metabolism of Olaparib can be increased when combined with Etanercept.
DB00005 DB09102 Daclatasvir The metabolism of Daclatasvir can be increased when combined with Etanercept.
DB00005 DB09231 Benidipine The metabolism of Benidipine can be increased when combined with Etanercept.
DB00005 DB09297 Paritaprevir The metabolism of Paritaprevir can be increased when combined with Etanercept.
DB00005 DB11574 Elbasvir The metabolism of Elbasvir can be increased when combined with Etanercept.
DB00005 DB11712 Tezacaftor The metabolism of Tezacaftor can be increased when combined with Etanercept.
DB00005 DB11737 Icotinib The metabolism of Icotinib can be increased when combined with Etanercept.
DB00005 DB12301 Doravirine The metabolism of Doravirine can be increased when combined with Etanercept.
DB00005 DB13867 Fluticasone The metabolism of Fluticasone can be increased when combined with Etanercept.
DB00005 DB14538 Hydrocortisone aceponate The metabolism of Hydrocortisone aceponate can be increased when combined with Etanercept.
DB00005 DB14539 Hydrocortisone acetate The metabolism of Hydrocortisone acetate can be increased when combined with Etanercept.
DB00005 DB14541 Hydrocortisone cypionate The metabolism of Hydrocortisone cypionate can be increased when combined with Etanercept.
DB00005 DB14542 Hydrocortisone phosphate The metabolism of Hydrocortisone phosphate can be increased when combined with Etanercept.
DB00005 DB00396 Progesterone The metabolism of Progesterone can be increased when combined with Etanercept.
DB00005 DB04856 Dexloxiglumide The metabolism of Dexloxiglumide can be increased when combined with Etanercept.
DB00005 DB04957 Azimilide The metabolism of Azimilide can be increased when combined with Etanercept.
DB00005 DB00250 Dapsone The metabolism of Dapsone can be increased when combined with Etanercept.
DB00005 DB00317 Gefitinib The metabolism of Gefitinib can be increased when combined with Etanercept.
DB00005 DB00367 Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Etanercept.
DB00005 DB00497 Oxycodone The metabolism of Oxycodone can be increased when combined with Etanercept.
DB00005 DB00620 Triamcinolone The metabolism of Triamcinolone can be increased when combined with Etanercept.
DB00005 DB00624 Testosterone The metabolism of Testosterone can be increased when combined with Etanercept.
DB00005 DB00656 Trazodone The metabolism of Trazodone can be increased when combined with Etanercept.
DB00005 DB00734 Risperidone The metabolism of Risperidone can be increased when combined with Etanercept.
DB00005 DB01114 Chlorpheniramine The metabolism of Chlorpheniramine can be increased when combined with Etanercept.
DB00005 DB01238 Aripiprazole The metabolism of Aripiprazole can be increased when combined with Etanercept.
DB00005 DB01267 Paliperidone The metabolism of Paliperidone can be increased when combined with Etanercept.
DB00005 DB04946 Iloperidone The metabolism of Iloperidone can be increased when combined with Etanercept.
DB00005 DB11915 Valbenazine The metabolism of Valbenazine can be increased when combined with Etanercept.
DB00005 DB12161 Deutetrabenazine The metabolism of Deutetrabenazine can be increased when combined with Etanercept.
DB00005 DB14185 Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Etanercept.
DB00005 DB01234 Dexamethasone The metabolism of Dexamethasone can be increased when combined with Etanercept.
DB00005 DB09237 Levamlodipine The metabolism of Levamlodipine can be increased when combined with Etanercept.
DB00005 DB11951 Lemborexant The metabolism of Lemborexant can be increased when combined with Etanercept.
DB00005 DB00557 Hydroxyzine The metabolism of Hydroxyzine can be increased when combined with Etanercept.
DB00005 DB00203 Sildenafil The metabolism of Sildenafil can be increased when combined with Etanercept.
DB00005 DB00227 Lovastatin The metabolism of Lovastatin can be increased when combined with Etanercept.
DB00005 DB00490 Buspirone The metabolism of Buspirone can be increased when combined with Etanercept.
DB00005 DB00641 Simvastatin The metabolism of Simvastatin can be increased when combined with Etanercept.
DB00005 DB00673 Aprepitant The metabolism of Aprepitant can be increased when combined with Etanercept.
DB00005 DB00820 Tadalafil The metabolism of Tadalafil can be increased when combined with Etanercept.
DB00005 DB00862 Vardenafil The metabolism of Vardenafil can be increased when combined with Etanercept.
DB00005 DB01190 Clindamycin The metabolism of Clindamycin can be increased when combined with Etanercept.
DB00005 DB00503 Ritonavir The metabolism of Ritonavir can be increased when combined with Etanercept.
DB00005 DB00224 Indinavir The metabolism of Indinavir can be increased when combined with Etanercept.
DB00005 DB00401 Nisoldipine The metabolism of Nisoldipine can be increased when combined with Etanercept.
DB00005 DB00637 Astemizole The metabolism of Astemizole can be increased when combined with Etanercept.
DB00005 DB00683 Midazolam The metabolism of Midazolam can be increased when combined with Etanercept.
DB00005 DB00700 Eplerenone The metabolism of Eplerenone can be increased when combined with Etanercept.
DB00005 DB00802 Alfentanil The metabolism of Alfentanil can be increased when combined with Etanercept.
DB00005 DB00813 Fentanyl The metabolism of Fentanyl can be increased when combined with Etanercept.
DB00005 DB00897 Triazolam The metabolism of Triazolam can be increased when combined with Etanercept.
DB00005 DB01023 Felodipine The metabolism of Felodipine can be increased when combined with Etanercept.
DB00005 DB01227 Levacetylmethadol The metabolism of Levacetylmethadol can be increased when combined with Etanercept.
DB00005 DB01232 Saquinavir The metabolism of Saquinavir can be increased when combined with Etanercept.
DB00005 DB06228 Rivaroxaban The metabolism of Rivaroxaban can be increased when combined with Etanercept.
DB00005 DB05804 Prasterone sulfate The metabolism of Prasterone sulfate can be increased when combined with Etanercept.
DB00005 DB00091 Cyclosporine Etanercept may increase the immunosuppressive activities of Cyclosporine.
DB00005 DB05676 Apremilast The therapeutic efficacy of Apremilast can be decreased when used in combination with Etanercept.
DB00005 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Etanercept.
DB00005 DB01601 Lopinavir The serum concentration of Etanercept can be increased when it is combined with Lopinavir.
DB00005 DB12530 Inebilizumab The risk or severity of infection can be increased when Etanercept is combined with Inebilizumab.
DB00006 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Bivalirudin.
DB00006 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bivalirudin.
DB00006 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Bivalirudin is combined with Deferasirox.
DB00006 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Ursodeoxycholic acid.
DB00006 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Glycochenodeoxycholic Acid.
DB00006 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Cholic Acid.
DB00006 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Glycocholic acid.
DB00006 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Deoxycholic acid.
DB00006 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Taurocholic acid.
DB00006 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Obeticholic acid.
DB00006 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Chenodeoxycholic acid.
DB00006 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Taurochenodeoxycholic acid.
DB00006 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Tauroursodeoxycholic acid.
DB00006 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Bamet-UD2.
DB00006 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Dehydrocholic acid.
DB00006 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Hyodeoxycholic Acid.
DB00006 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Bivalirudin.
DB00006 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Bivalirudin.
DB00006 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Obinutuzumab.
DB00006 DB06228 Rivaroxaban Bivalirudin may increase the anticoagulant activities of Rivaroxaban.
DB00006 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Sugammadex.
DB00006 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Bivalirudin.
DB00006 DB00013 Urokinase Urokinase may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Bivalirudin.
DB00006 DB09030 Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Bivalirudin.
DB00006 DB01381 Ginkgo biloba The therapeutic efficacy of Bivalirudin can be increased when used in combination with Ginkgo biloba.
DB00006 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Bivalirudin.
DB00006 DB00468 Quinine The therapeutic efficacy of Bivalirudin can be increased when used in combination with Quinine.
DB00006 DB00908 Quinidine The therapeutic efficacy of Bivalirudin can be increased when used in combination with Quinidine.
DB00006 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Bivalirudin.
DB00006 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Bivalirudin.
DB00006 DB00806 Pentoxifylline The therapeutic efficacy of Bivalirudin can be increased when used in combination with Pentoxifylline.
DB00006 DB00686 Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00583 Levocarnitine The therapeutic efficacy of Bivalirudin can be increased when used in combination with Levocarnitine.
DB00006 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB04573 Estriol Estriol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB11674 Equol Equol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Bivalirudin.
DB00006 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Bivalirudin.
DB00006 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Bivalirudin.
DB00006 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Bivalirudin.
DB00006 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Bivalirudin.
DB00006 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Bivalirudin.
DB00006 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Bivalirudin.
DB00006 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Bivalirudin.
DB00006 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Bivalirudin.
DB00006 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Bivalirudin.
DB00006 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Bivalirudin.
DB00006 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Bivalirudin.
DB00006 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Bivalirudin.
DB00006 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Bivalirudin.
DB00006 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Bivalirudin.
DB00006 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Bivalirudin.
DB00006 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Bivalirudin.
DB00006 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Bivalirudin.
DB00006 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Bivalirudin.
DB00006 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Bivalirudin.
DB00006 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Bivalirudin.
DB00006 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Bivalirudin.
DB00006 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Bivalirudin.
DB00006 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Bivalirudin.
DB00006 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Bivalirudin.
DB00006 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Bivalirudin.
DB00006 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Bivalirudin.
DB00006 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Bivalirudin.
DB00006 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Bivalirudin.
DB00006 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Bivalirudin.
DB00006 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Bivalirudin.
DB00006 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Bivalirudin.
DB00006 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Bivalirudin.
DB00006 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Bivalirudin.
DB00006 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Bivalirudin.
DB00006 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Bivalirudin.
DB00006 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Bivalirudin.
DB00006 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Bivalirudin.
DB00006 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Bivalirudin.
DB00006 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Bivalirudin.
DB00006 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Bivalirudin.
DB00006 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Bivalirudin.
DB00006 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Bivalirudin.
DB00006 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Bivalirudin.
DB00006 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Bivalirudin.
DB00006 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Bivalirudin.
DB00006 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Bivalirudin.
DB00006 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Bivalirudin.
DB00006 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Bivalirudin.
DB00006 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Bivalirudin.
DB00006 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Bivalirudin.
DB00006 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Bivalirudin.
DB00006 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Bivalirudin.
DB00006 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Bivalirudin.
DB00006 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Bivalirudin.
DB00006 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Bivalirudin.
DB00006 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Bivalirudin.
DB00006 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Bivalirudin.
DB00006 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Bivalirudin.
DB00006 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Bivalirudin.
DB00006 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Bivalirudin.
DB00006 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Bivalirudin.
DB00006 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Bivalirudin.
DB00006 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Bivalirudin.
DB00006 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Bivalirudin.
DB00006 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Bivalirudin.
DB00006 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Bivalirudin.
DB00006 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Bivalirudin.
DB00006 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Bivalirudin.
DB00006 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Bivalirudin.
DB00006 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Bivalirudin.
DB00006 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Bivalirudin.
DB00006 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Bivalirudin.
DB00006 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Bivalirudin.
DB00006 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Bivalirudin.
DB00006 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Bivalirudin.
DB00006 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Bivalirudin.
DB00006 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Bivalirudin.
DB00006 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Bivalirudin.
DB00006 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Bivalirudin.
DB00006 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Bivalirudin.
DB00006 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Bivalirudin.
DB00006 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Bivalirudin.
DB00006 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Bivalirudin.
DB00006 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Bivalirudin.
DB00006 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Bivalirudin.
DB00006 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Bivalirudin.
DB00006 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Bivalirudin.
DB00006 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Bivalirudin.
DB00006 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Bivalirudin.
DB00006 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Bivalirudin.
DB00006 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Bivalirudin.
DB00006 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Bivalirudin.
DB00006 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Bivalirudin.
DB00006 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Bivalirudin.
DB00006 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Bivalirudin.
DB00006 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Bivalirudin.
DB00006 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Bivalirudin.
DB00006 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Bivalirudin.
DB00006 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Bivalirudin.
DB00006 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Bivalirudin.
DB00006 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Bivalirudin.
DB00006 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Bivalirudin.
DB00006 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Bivalirudin.
DB00006 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Bivalirudin.
DB00006 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Bivalirudin is combined with Omacetaxine mepesuccinate.
DB00006 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Tositumomab.
DB00006 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase clostridium histolyticum.
DB00006 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Bivalirudin.
DB00006 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Bivalirudin.
DB00006 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Bivalirudin.
DB00006 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Bivalirudin.
DB00006 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Bivalirudin.
DB00006 DB00834 Mifepristone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Mifepristone.
DB00006 DB04066 p-Coumaric acid The therapeutic efficacy of Bivalirudin can be decreased when used in combination with p-Coumaric acid.
DB00006 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00006 DB05830 Trestolone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Trestolone.
DB00006 DB06266 Lonidamine The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Lonidamine.
DB00006 DB08867 Ulipristal The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ulipristal.
DB00006 DB09401 Isosorbide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Isosorbide.
DB00006 DB11507 Cloprostenol The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cloprostenol.
DB00006 DB12025 Triptolide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Triptolide.
DB00006 DB13044 Gossypol The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gossypol.
DB00006 DB13310 Ormeloxifene The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ormeloxifene.
DB00006 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Bivalirudin.
DB00006 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bivalirudin.
DB00006 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Bivalirudin.
DB00006 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Bivalirudin.
DB00006 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Bivalirudin.
DB00006 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Bivalirudin.
DB00006 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Bivalirudin.
DB00006 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Bivalirudin.
DB00006 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Bivalirudin.
DB00006 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Bivalirudin.
DB00006 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Bivalirudin.
DB00006 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Bivalirudin.
DB00006 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Bivalirudin.
DB00006 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Bivalirudin.
DB00006 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Bivalirudin.
DB00006 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Bivalirudin.
DB00006 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Bivalirudin.
DB00006 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Bivalirudin.
DB00006 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bivalirudin.
DB00006 DB01166 Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Bivalirudin.
DB00006 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Bivalirudin.
DB00006 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Bivalirudin.
DB00006 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Bivalirudin.
DB00006 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Bivalirudin.
DB00006 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Bivalirudin.
DB00006 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Bivalirudin.
DB00006 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Bivalirudin.
DB00006 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Bivalirudin.
DB00006 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Bivalirudin.
DB00006 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Bivalirudin.
DB00006 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Bivalirudin.
DB00006 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Bivalirudin.
DB00006 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Bivalirudin.
DB00006 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Bivalirudin.
DB00006 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Bivalirudin.
DB00006 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Bivalirudin.
DB00006 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bivalirudin.
DB00006 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Bivalirudin.
DB00006 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Bivalirudin.
DB00006 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Bivalirudin.
DB00006 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Bivalirudin.
DB00006 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Bivalirudin.
DB00006 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Bivalirudin.
DB00006 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Bivalirudin.
DB00006 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Bivalirudin.
DB00006 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Bivalirudin.
DB00006 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Bivalirudin.
DB00006 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Bivalirudin.
DB00006 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Bivalirudin.
DB00006 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Bivalirudin.
DB00006 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Bivalirudin.
DB00006 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Bivalirudin.
DB00006 DB00374 Treprostinil The risk or severity of bleeding can be increased when Treprostinil is combined with Bivalirudin.
DB00006 DB03404 Hemin Hemin may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Bivalirudin.
DB00006 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Bivalirudin.
DB00006 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Bivalirudin.
DB00006 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Bivalirudin is combined with Azficel-T.
DB00006 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Bivalirudin can be increased when used in combination with Omega-3-carboxylic acids.
DB00006 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Bivalirudin.
DB00006 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Bivalirudin.
DB00006 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Bivalirudin.
DB00006 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Bivalirudin.
DB00006 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Bivalirudin.
DB00006 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Bivalirudin.
DB00006 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Bivalirudin.
DB00006 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Bivalirudin.
DB00006 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Bivalirudin.
DB00006 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Bivalirudin.
DB00006 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Bivalirudin.
DB00006 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Bivalirudin.
DB00006 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Bivalirudin.
DB00006 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Bivalirudin.
DB00006 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Bivalirudin.
DB00006 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Bivalirudin.
DB00006 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Bivalirudin.
DB00006 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Bivalirudin.
DB00006 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Bivalirudin.
DB00006 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Bivalirudin.
DB00006 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Bivalirudin.
DB00006 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Bivalirudin.
DB00006 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Bivalirudin.
DB00006 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Bivalirudin.
DB00006 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Bivalirudin.
DB00006 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Bivalirudin.
DB00006 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Bivalirudin.
DB00006 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Bivalirudin.
DB00006 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Bivalirudin.
DB00006 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Bivalirudin.
DB00006 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Bivalirudin.
DB00006 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Bivalirudin.
DB00006 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Bivalirudin.
DB00006 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Bivalirudin.
DB00006 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Bivalirudin.
DB00006 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Bivalirudin.
DB00006 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Bivalirudin.
DB00006 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Bivalirudin.
DB00006 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Bivalirudin.
DB00006 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Bivalirudin.
DB00006 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Bivalirudin.
DB00006 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Bivalirudin.
DB00006 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Bivalirudin.
DB00006 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Bivalirudin.
DB00006 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Bivalirudin.
DB00006 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Bivalirudin.
DB00006 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Bivalirudin.
DB00006 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Bivalirudin.
DB00006 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Bivalirudin.
DB00006 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Bivalirudin.
DB00006 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Bivalirudin.
DB00006 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Bivalirudin.
DB00006 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Bivalirudin.
DB00006 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Bivalirudin.
DB00006 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Bivalirudin.
DB00006 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Bivalirudin.
DB00006 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Bivalirudin.
DB00006 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Bivalirudin.
DB00006 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Bivalirudin.
DB00006 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Bivalirudin.
DB00006 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Bivalirudin.
DB00006 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Bivalirudin.
DB00006 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Bivalirudin.
DB00006 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Bivalirudin.
DB00006 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Bivalirudin.
DB00006 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Bivalirudin.
DB00006 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Bivalirudin.
DB00006 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Bivalirudin.
DB00006 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Bivalirudin.
DB00006 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Bivalirudin.
DB00006 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Bivalirudin.
DB00006 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Bivalirudin.
DB00006 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Bivalirudin.
DB00006 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Bivalirudin.
DB00006 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Bivalirudin.
DB00006 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Bivalirudin.
DB00006 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Bivalirudin.
DB00006 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Bivalirudin.
DB00006 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Bivalirudin.
DB00006 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Bivalirudin.
DB00006 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Bivalirudin.
DB00006 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Bivalirudin.
DB00006 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Bivalirudin.
DB00006 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Bivalirudin is combined with Dicoumarol.
DB00006 DB00278 Argatroban The risk or severity of bleeding can be increased when Bivalirudin is combined with Argatroban.
DB00006 DB00407 Ardeparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Ardeparin.
DB00006 DB00498 Phenindione The risk or severity of bleeding can be increased when Bivalirudin is combined with Phenindione.
DB00006 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Bivalirudin is combined with Fondaparinux.
DB00006 DB00682 Warfarin The risk or severity of bleeding can be increased when Bivalirudin is combined with Warfarin.
DB00006 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Bivalirudin is combined with Phenprocoumon.
DB00006 DB00974 Edetic acid The risk or severity of bleeding can be increased when Bivalirudin is combined with Edetic acid.
DB00006 DB01109 Heparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Heparin.
DB00006 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Enoxaparin.
DB00006 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Bivalirudin is combined with Acenocoumarol.
DB00006 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Bivalirudin is combined with Ximelagatran.
DB00006 DB05099 Ancrod The risk or severity of bleeding can be increased when Bivalirudin is combined with Ancrod.
DB00006 DB06271 Sulodexide The risk or severity of bleeding can be increased when Bivalirudin is combined with Sulodexide.
DB00006 DB06406 Idraparinux The risk or severity of bleeding can be increased when Bivalirudin is combined with Idraparinux.
DB00006 DB06635 Otamixaban The risk or severity of bleeding can be increased when Bivalirudin is combined with Otamixaban.
DB00006 DB06754 Danaparoid The risk or severity of bleeding can be increased when Bivalirudin is combined with Danaparoid.
DB00006 DB06779 Dalteparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Dalteparin.
DB00006 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Bivalirudin is combined with Ferulic acid.
DB00006 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Bivalirudin is combined with Ethyl biscoumacetate.
DB00006 DB08813 Nadroparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Nadroparin.
DB00006 DB09255 Dextran The risk or severity of bleeding can be increased when Bivalirudin is combined with Dextran.
DB00006 DB09259 Reviparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Reviparin.
DB00006 DB09261 Certoparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Certoparin.
DB00006 DB11095 Desirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Desirudin.
DB00006 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Bivalirudin is combined with Protocatechualdehyde.
DB00006 DB11312 Protein C The risk or severity of bleeding can be increased when Bivalirudin is combined with Protein C.
DB00006 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Bivalirudin is combined with Antithrombin III human.
DB00006 DB11984 Letaxaban The risk or severity of bleeding can be increased when Bivalirudin is combined with Letaxaban.
DB00006 DB12289 Darexaban The risk or severity of bleeding can be increased when Bivalirudin is combined with Darexaban.
DB00006 DB12598 Nafamostat The risk or severity of bleeding can be increased when Bivalirudin is combined with Nafamostat.
DB00006 DB12831 Gabexate The risk or severity of bleeding can be increased when Bivalirudin is combined with Gabexate.
DB00006 DB13124 Troxerutin The risk or severity of bleeding can be increased when Bivalirudin is combined with Troxerutin.
DB00006 DB13136 Fluindione The risk or severity of bleeding can be increased when Bivalirudin is combined with Fluindione.
DB00006 DB13149 Protein S human The risk or severity of bleeding can be increased when Bivalirudin is combined with Protein S human.
DB00006 DB13616 Melagatran The risk or severity of bleeding can be increased when Bivalirudin is combined with Melagatran.
DB00006 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Bivalirudin is combined with Potassium citrate.
DB00006 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Bivalirudin is combined with Sodium citrate.
DB00006 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Tenecteplase.
DB00006 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Bivalirudin is combined with Drotrecogin alfa.
DB00006 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Tinzaparin.
DB00006 DB13199 Brinase The risk or severity of bleeding can be increased when Bivalirudin is combined with Brinase.
DB00006 DB13646 Saruplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Saruplase.
DB00006 DB00086 Streptokinase The risk or severity of bleeding can be increased when Bivalirudin is combined with Streptokinase.
DB00006 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Desmoteplase.
DB00006 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Bivalirudin is combined with Fibrinolysin.
DB00006 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Bivalirudin is combined with Astaxanthin.
DB00006 DB08994 Ditazole The risk or severity of bleeding can be increased when Bivalirudin is combined with Ditazole.
DB00006 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Bemiparin.
DB00006 DB09260 Parnaparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Parnaparin.
DB00006 DB13275 Clorindione The risk or severity of bleeding can be increased when Bivalirudin is combined with Clorindione.
DB00006 DB13347 Diphenadione The risk or severity of bleeding can be increased when Bivalirudin is combined with Diphenadione.
DB00006 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Bivalirudin is combined with Tioclomarol.
DB00006 DB00001 Lepirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Lepirudin.
DB00006 DB00009 Alteplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Alteplase.
DB00006 DB00015 Reteplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Reteplase.
DB00006 DB00029 Anistreplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Anistreplase.
DB00006 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Bivalirudin is combined with Tocopherylquinone.
DB00006 DB06679 Amediplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Amediplase.
DB00006 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Bivalirudin is combined with 4-hydroxycoumarin.
DB00006 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Bivalirudin is combined with (R)-warfarin.
DB00006 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Bivalirudin is combined with (S)-Warfarin.
DB00006 DB12364 Betrixaban The risk or severity of bleeding can be increased when Bivalirudin is combined with Betrixaban.
DB00006 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Bivalirudin is combined with Edetate calcium disodium anhydrous.
DB00006 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Bivalirudin is combined with Zinc citrate.
DB00006 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Bivalirudin is combined with Antithrombin Alfa.
DB00006 DB04665 Coumarin The risk or severity of bleeding can be increased when Bivalirudin is combined with Coumarin.
DB00006 DB14726 Dabigatran The risk or severity of bleeding can be increased when Bivalirudin is combined with Dabigatran.
DB00006 DB06294 Semuloparin The risk or severity of bleeding can be increased when Bivalirudin is combined with Semuloparin.
DB00006 DB12726 Monteplase The risk or severity of bleeding can be increased when Bivalirudin is combined with Monteplase.
DB00006 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Bivalirudin is combined with Sildenafil.
DB00006 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Bivalirudin is combined with Peginterferon alfa-2a.
DB00006 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-n1.
DB00006 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-n3.
DB00006 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Bivalirudin is combined with Peginterferon alfa-2b.
DB00006 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon gamma-1b.
DB00006 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-2a, Recombinant.
DB00006 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Bivalirudin is combined with Aldesleukin.
DB00006 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemtuzumab ozogamicin.
DB00006 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon beta-1b.
DB00006 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfacon-1.
DB00006 DB00073 Rituximab The risk or severity of bleeding can be increased when Bivalirudin is combined with Rituximab.
DB00006 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.
DB00006 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Bivalirudin is combined with Alemtuzumab.
DB00006 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-2b.
DB00006 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Bivalirudin is combined with Phenylalanine.
DB00006 DB00188 Bortezomib The risk or severity of bleeding can be increased when Bivalirudin is combined with Bortezomib.
DB00006 DB00242 Cladribine The risk or severity of bleeding can be increased when Bivalirudin is combined with Cladribine.
DB00006 DB00262 Carmustine The risk or severity of bleeding can be increased when Bivalirudin is combined with Carmustine.
DB00006 DB00276 Amsacrine The risk or severity of bleeding can be increased when Bivalirudin is combined with Amsacrine.
DB00006 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Bivalirudin is combined with Chlorambucil.
DB00006 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Bivalirudin is combined with Raltitrexed.
DB00006 DB00305 Mitomycin The risk or severity of bleeding can be increased when Bivalirudin is combined with Mitomycin.
DB00006 DB00307 Bexarotene The risk or severity of bleeding can be increased when Bivalirudin is combined with Bexarotene.
DB00006 DB00309 Vindesine The risk or severity of bleeding can be increased when Bivalirudin is combined with Vindesine.
DB00006 DB00322 Floxuridine The risk or severity of bleeding can be increased when Bivalirudin is combined with Floxuridine.
DB00006 DB00352 Tioguanine The risk or severity of bleeding can be increased when Bivalirudin is combined with Tioguanine.
DB00006 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Bivalirudin is combined with Vinorelbine.
DB00006 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Bivalirudin is combined with Dexrazoxane.
DB00006 DB00398 Sorafenib The risk or severity of bleeding can be increased when Bivalirudin is combined with Sorafenib.
DB00006 DB00428 Streptozocin The risk or severity of bleeding can be increased when Bivalirudin is combined with Streptozocin.
DB00006 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Gemcitabine.
DB00006 DB00444 Teniposide The risk or severity of bleeding can be increased when Bivalirudin is combined with Teniposide.
DB00006 DB00445 Epirubicin The risk or severity of bleeding can be increased when Bivalirudin is combined with Epirubicin.
DB00006 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Bivalirudin is combined with Chloramphenicol.
DB00006 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Bivalirudin is combined with Lenalidomide.
DB00006 DB00488 Altretamine The risk or severity of bleeding can be increased when Bivalirudin is combined with Altretamine.
DB00006 DB00495 Zidovudine The risk or severity of bleeding can be increased when Bivalirudin is combined with Zidovudine.
DB00006 DB00515 Cisplatin The risk or severity of bleeding can be increased when Bivalirudin is combined with Cisplatin.
DB00006 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Bivalirudin is combined with Oxaliplatin.
DB00006 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Bivalirudin is combined with Cyclophosphamide.
DB00006 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Bivalirudin is combined with Fluorouracil.
DB00006 DB00552 Pentostatin The risk or severity of bleeding can be increased when Bivalirudin is combined with Pentostatin.
DB00006 DB00563 Methotrexate The risk or severity of bleeding can be increased when Bivalirudin is combined with Methotrexate.
DB00006 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Bivalirudin is combined with Carbamazepine.
DB00006 DB00570 Vinblastine The risk or severity of bleeding can be increased when Bivalirudin is combined with Vinblastine.
DB00006 DB00619 Imatinib The risk or severity of bleeding can be increased when Bivalirudin is combined with Imatinib.
DB00006 DB00631 Clofarabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Clofarabine.
DB00006 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Bivalirudin is combined with Pemetrexed.
DB00006 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Bivalirudin is combined with Daunorubicin.
DB00006 DB00762 Irinotecan The risk or severity of bleeding can be increased when Bivalirudin is combined with Irinotecan.
DB00006 DB00773 Etoposide The risk or severity of bleeding can be increased when Bivalirudin is combined with Etoposide.
DB00006 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Bivalirudin is combined with Dacarbazine.
DB00006 DB00853 Temozolomide The risk or severity of bleeding can be increased when Bivalirudin is combined with Temozolomide.
DB00006 DB00859 Penicillamine The risk or severity of bleeding can be increased when Bivalirudin is combined with Penicillamine.
DB00006 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Bivalirudin is combined with Tacrolimus.
DB00006 DB00877 Sirolimus The risk or severity of bleeding can be increased when Bivalirudin is combined with Sirolimus.
DB00006 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Bivalirudin is combined with Mechlorethamine.
DB00006 DB00928 Azacitidine The risk or severity of bleeding can be increased when Bivalirudin is combined with Azacitidine.
DB00006 DB00958 Carboplatin The risk or severity of bleeding can be increased when Bivalirudin is combined with Carboplatin.
DB00006 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Bivalirudin is combined with Dactinomycin.
DB00006 DB00987 Cytarabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Cytarabine.
DB00006 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Bivalirudin is combined with Doxorubicin.
DB00006 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Bivalirudin is combined with Hydroxyurea.
DB00006 DB01008 Busulfan The risk or severity of bleeding can be increased when Bivalirudin is combined with Busulfan.
DB00006 DB01030 Topotecan The risk or severity of bleeding can be increased when Bivalirudin is combined with Topotecan.
DB00006 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Bivalirudin is combined with Mercaptopurine.
DB00006 DB01041 Thalidomide The risk or severity of bleeding can be increased when Bivalirudin is combined with Thalidomide.
DB00006 DB01042 Melphalan The risk or severity of bleeding can be increased when Bivalirudin is combined with Melphalan.
DB00006 DB01073 Fludarabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Fludarabine.
DB00006 DB01099 Flucytosine The risk or severity of bleeding can be increased when Bivalirudin is combined with Flucytosine.
DB00006 DB01101 Capecitabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Capecitabine.
DB00006 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Bivalirudin is combined with Arsenic trioxide.
DB00006 DB01177 Idarubicin The risk or severity of bleeding can be increased when Bivalirudin is combined with Idarubicin.
DB00006 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Bivalirudin is combined with Mitoxantrone.
DB00006 DB01206 Lomustine The risk or severity of bleeding can be increased when Bivalirudin is combined with Lomustine.
DB00006 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Bivalirudin is combined with Paclitaxel.
DB00006 DB01248 Docetaxel The risk or severity of bleeding can be increased when Bivalirudin is combined with Docetaxel.
DB00006 DB01262 Decitabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Decitabine.
DB00006 DB01280 Nelarabine The risk or severity of bleeding can be increased when Bivalirudin is combined with Nelarabine.
DB00006 DB01590 Everolimus The risk or severity of bleeding can be increased when Bivalirudin is combined with Everolimus.
DB00006 DB02546 Vorinostat The risk or severity of bleeding can be increased when Bivalirudin is combined with Vorinostat.
DB00006 DB04572 Thiotepa The risk or severity of bleeding can be increased when Bivalirudin is combined with Thiotepa.
DB00006 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Bivalirudin is combined with Ixabepilone.
DB00006 DB04868 Nilotinib The risk or severity of bleeding can be increased when Bivalirudin is combined with Nilotinib.
DB00006 DB05015 Belinostat The risk or severity of bleeding can be increased when Bivalirudin is combined with Belinostat.
DB00006 DB05109 Trabectedin The risk or severity of bleeding can be increased when Bivalirudin is combined with Trabectedin.
DB00006 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa.
DB00006 DB05472 omega interferon The risk or severity of bleeding can be increased when Bivalirudin is combined with omega interferon.
DB00006 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Bivalirudin is combined with Trastuzumab emtansine.
DB00006 DB06287 Temsirolimus The risk or severity of bleeding can be increased when Bivalirudin is combined with Temsirolimus.
DB00006 DB06616 Bosutinib The risk or severity of bleeding can be increased when Bivalirudin is combined with Bosutinib.
DB00006 DB06769 Bendamustine The risk or severity of bleeding can be increased when Bivalirudin is combined with Bendamustine.
DB00006 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Bivalirudin is combined with Cabazitaxel.
DB00006 DB08871 Eribulin The risk or severity of bleeding can be increased when Bivalirudin is combined with Eribulin.
DB00006 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Bivalirudin is combined with Ruxolitinib.
DB00006 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Bivalirudin is combined with Carfilzomib.
DB00006 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Bivalirudin is combined with Tofacitinib.
DB00006 DB08901 Ponatinib The risk or severity of bleeding can be increased when Bivalirudin is combined with Ponatinib.
DB00006 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Bivalirudin is combined with Pomalidomide.
DB00006 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Bivalirudin is combined with Tedizolid phosphate.
DB00006 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Bivalirudin is combined with Blinatumomab.
DB00006 DB09073 Palbociclib The risk or severity of bleeding can be increased when Bivalirudin is combined with Palbociclib.
DB00006 DB09074 Olaparib The risk or severity of bleeding can be increased when Bivalirudin is combined with Olaparib.
DB00006 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Bivalirudin is combined with Dinutuximab.
DB00006 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Bivalirudin is combined with Peginterferon beta-1a.
DB00006 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Bivalirudin is combined with Cepeginterferon alfa-2B.
DB00006 DB00229 Cefotiam The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefotiam.
DB00006 DB00267 Cefmenoxime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefmenoxime.
DB00006 DB00274 Cefmetazole The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefmetazole.
DB00006 DB00430 Cefpiramide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefpiramide.
DB00006 DB00438 Ceftazidime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftazidime.
DB00006 DB00447 Loracarbef The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Loracarbef.
DB00006 DB00456 Cefalotin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefalotin.
DB00006 DB00493 Cefotaxime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefotaxime.
DB00006 DB00535 Cefdinir The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefdinir.
DB00006 DB00567 Cephalexin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cephalexin.
DB00006 DB00671 Cefixime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefixime.
DB00006 DB00689 Cephaloglycin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cephaloglycin.
DB00006 DB00833 Cefaclor The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefaclor.
DB00006 DB00923 Ceforanide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceforanide.
DB00006 DB01066 Cefditoren The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefditoren.
DB00006 DB01112 Cefuroxime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefuroxime.
DB00006 DB01139 Cefapirin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefapirin.
DB00006 DB01140 Cefadroxil The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefadroxil.
DB00006 DB01150 Cefprozil The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefprozil.
DB00006 DB01212 Ceftriaxone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftriaxone.
DB00006 DB01326 Cefamandole The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefamandole.
DB00006 DB01327 Cefazolin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefazolin.
DB00006 DB01328 Cefonicid The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefonicid.
DB00006 DB01329 Cefoperazone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefoperazone.
DB00006 DB01330 Cefotetan The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefotetan.
DB00006 DB01331 Cefoxitin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefoxitin.
DB00006 DB01332 Ceftizoxime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftizoxime.
DB00006 DB01333 Cefradine The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefradine.
DB00006 DB01413 Cefepime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefepime.
DB00006 DB01414 Cefacetrile The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefacetrile.
DB00006 DB01415 Ceftibuten The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftibuten.
DB00006 DB01416 Cefpodoxime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefpodoxime.
DB00006 DB04570 Latamoxef The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Latamoxef.
DB00006 DB04918 Ceftobiprole The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftobiprole.
DB00006 DB06590 Ceftaroline fosamil The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftaroline fosamil.
DB00006 DB09008 Cefaloridine The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefaloridine.
DB00006 DB09050 Ceftolozane The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftolozane.
DB00006 DB09062 Cefminox The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefminox.
DB00006 DB11367 Cefroxadine The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefroxadine.
DB00006 DB11935 Flomoxef The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Flomoxef.
DB00006 DB13266 Cefatrizine The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefatrizine.
DB00006 DB13461 Cefcapene The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefcapene.
DB00006 DB13470 Cefodizime The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefodizime.
DB00006 DB13499 Cefsulodin The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefsulodin.
DB00006 DB13504 Cefetamet The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefetamet.
DB00006 DB13638 Cefbuperazone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefbuperazone.
DB00006 DB13667 Cefozopran The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefozopran.
DB00006 DB13682 Cefpirome The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefpirome.
DB00006 DB13778 Cefazedone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefazedone.
DB00006 DB13821 Ceftezole The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Ceftezole.
DB00006 DB14725 Cefamandole nafate The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cefamandole nafate.
DB00006 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Bivalirudin.
DB00006 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Bivalirudin.
DB00006 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Bivalirudin.
DB00006 DB00945 Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Bivalirudin.
DB00006 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Bivalirudin.
DB00006 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Bivalirudin.
DB00006 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Bivalirudin.
DB00006 DB00620 Triamcinolone The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Triamcinolone.
DB00006 DB09079 Nintedanib The risk or severity of bleeding can be increased when Bivalirudin is combined with Nintedanib.
DB00006 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Bivalirudin.
DB00006 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Bivalirudin.
DB00006 DB00232 Methyclothiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Methyclothiazide.
DB00006 DB00436 Bendroflumethiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Bendroflumethiazide.
DB00006 DB00562 Benzthiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Benzthiazide.
DB00006 DB00606 Cyclothiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cyclothiazide.
DB00006 DB00774 Hydroflumethiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Hydroflumethiazide.
DB00006 DB00880 Chlorothiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Chlorothiazide.
DB00006 DB00999 Hydrochlorothiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Hydrochlorothiazide.
DB00006 DB01021 Trichlormethiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Trichlormethiazide.
DB00006 DB01324 Polythiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Polythiazide.
DB00006 DB13430 Mebutizide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Mebutizide.
DB00006 DB13532 Cyclopenthiazide The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Cyclopenthiazide.
DB00007 DB09066 Corifollitropin alfa The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Leuprolide.
DB00007 DB09083 Ivabradine Ivabradine may increase the QTc-prolonging activities of Leuprolide.
DB00007 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Leuprolide is combined with Peginesatide.
DB00007 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Leuprolide.
DB00007 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Leuprolide.
DB00007 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide.
DB00007 DB09277 Choline C 11 Leuprolide may decrease effectiveness of Choline C 11 as a diagnostic agent.
DB00007 DB00089 Capromab pendetide Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
DB00007 DB00030 Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide.
DB00007 DB00046 Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Leuprolide.
DB00007 DB00047 Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Leuprolide.
DB00007 DB00071 Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.
DB00007 DB00197 Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB00222 Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.
DB00007 DB00284 Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.
DB00007 DB00359 Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Leuprolide.
DB00007 DB00412 Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB00414 Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.
DB00007 DB00491 Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.
DB00007 DB00672 Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.
DB00007 DB00731 Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.
DB00007 DB00839 Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.
DB00007 DB00912 Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.
DB00007 DB00914 Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.
DB00007 DB01016 Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.
DB00007 DB01067 Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.
DB00007 DB01120 Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.
DB00007 DB01124 Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.
DB00007 DB01132 Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB01251 Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.
DB00007 DB01252 Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Leuprolide.
DB00007 DB01261 Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.
DB00007 DB01276 Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.
DB00007 DB01277 Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Leuprolide.
DB00007 DB01278 Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.
DB00007 DB01289 Glisoxepide The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Leuprolide.
DB00007 DB01306 Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Leuprolide.
DB00007 DB01307 Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Leuprolide.
DB00007 DB01309 Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Leuprolide.
DB00007 DB01382 Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Leuprolide.
DB00007 DB01700 AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Leuprolide.
DB00007 DB04830 Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Leuprolide.
DB00007 DB04876 Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.
DB00007 DB04878 Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Leuprolide.
DB00007 DB05115 NN344 The therapeutic efficacy of NN344 can be decreased when used in combination with Leuprolide.
DB00007 DB05819 NBI-6024 The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Leuprolide.
DB00007 DB06011 AMG-222 The therapeutic efficacy of AMG-222 can be decreased when used in combination with Leuprolide.
DB00007 DB06127 Bisegliptin The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Leuprolide.
DB00007 DB06203 Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.
DB00007 DB06292 Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB06335 Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.
DB00007 DB06655 Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.
DB00007 DB08382 Gosogliptin The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Leuprolide.
DB00007 DB08882 Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.
DB00007 DB08907 Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB08962 Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.
DB00007 DB09022 Benfluorex The therapeutic efficacy of Benfluorex can be decreased when used in combination with Leuprolide.
DB00007 DB09038 Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB09043 Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide.
DB00007 DB09045 Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.
DB00007 DB09198 Lobeglitazone The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB09199 Netoglitazone The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB09200 Rivoglitazone The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB09201 Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB09265 Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Leuprolide.
DB00007 DB09456 Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Leuprolide.
DB00007 DB09564 Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Leuprolide.
DB00007 DB11567 Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Leuprolide.
DB00007 DB11568 Insulin tregopil The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Leuprolide.
DB00007 DB11698 Ipragliflozin The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB11723 Dutogliptin The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Leuprolide.
DB00007 DB11780 Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Leuprolide.
DB00007 DB11824 Tofogliflozin The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB11827 Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB11898 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Leuprolide.
DB00007 DB11950 Teneligliptin The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Leuprolide.
DB00007 DB11992 Omarigliptin The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Leuprolide.
DB00007 DB12268 Carmegliptin The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Leuprolide.
DB00007 DB12412 Gemigliptin The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Leuprolide.
DB00007 DB12417 Anagliptin The therapeutic efficacy of Anagliptin can be decreased when used in combination with Leuprolide.
DB00007 DB12625 Evogliptin The therapeutic efficacy of Evogliptin can be decreased when used in combination with Leuprolide.
DB00007 DB12713 Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Leuprolide.
DB00007 DB12781 Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Leuprolide.
DB00007 DB12935 Remogliflozin etabonate The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Leuprolide.
DB00007 DB13406 Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Leuprolide.
DB00007 DB13446 Guar gum The therapeutic efficacy of Guar gum can be decreased when used in combination with Leuprolide.
DB00007 DB13675 Metahexamide The therapeutic efficacy of Metahexamide can be decreased when used in combination with Leuprolide.
DB00007 DB13928 Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Leuprolide.
DB00007 DB14027 Taspoglutide The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Leuprolide.
DB00007 DB14035 Englitazone The therapeutic efficacy of Englitazone can be decreased when used in combination with Leuprolide.
DB00007 DB15171 Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Leuprolide.
DB00007 DB15217 Gastric inhibitory polypeptide The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Leuprolide.
DB00007 DB01200 Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide.
DB00007 DB00215 Citalopram The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Citalopram.
DB00007 DB00261 Anagrelide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.
DB00007 DB00280 Disopyramide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide.
DB00007 DB00283 Clemastine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clemastine.
DB00007 DB00308 Ibutilide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ibutilide.
DB00007 DB00313 Valproic acid The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid.
DB00007 DB00365 Grepafloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Grepafloxacin.
DB00007 DB00468 Quinine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinine.
DB00007 DB00489 Sotalol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sotalol.
DB00007 DB00530 Erlotinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erlotinib.
DB00007 DB00539 Toremifene The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Toremifene.
DB00007 DB00619 Imatinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imatinib.
DB00007 DB00679 Thioridazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Thioridazine.
DB00007 DB00685 Trovafloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Trovafloxacin.
DB00007 DB00834 Mifepristone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mifepristone.
DB00007 DB00875 Flupentixol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flupentixol.
DB00007 DB00907 Cocaine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cocaine.
DB00007 DB01035 Procainamide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Procainamide.
DB00007 DB01169 Arsenic trioxide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.
DB00007 DB01175 Escitalopram The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Escitalopram.
DB00007 DB01184 Domperidone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Domperidone.
DB00007 DB01208 Sparfloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sparfloxacin.
DB00007 DB01218 Halofantrine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Halofantrine.
DB00007 DB01244 Bepridil The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bepridil.
DB00007 DB01267 Paliperidone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone.
DB00007 DB01356 Lithium cation The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lithium cation.
DB00007 DB01405 Temafloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Temafloxacin.
DB00007 DB01624 Zuclopenthixol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Zuclopenthixol.
DB00007 DB04844 Tetrabenazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tetrabenazine.
DB00007 DB04868 Nilotinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilotinib.
DB00007 DB04946 Iloperidone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Iloperidone.
DB00007 DB05294 Vandetanib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vandetanib.
DB00007 DB06176 Romidepsin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin.
DB00007 DB06216 Asenapine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.
DB00007 DB06697 Artemether The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.
DB00007 DB06708 Lumefantrine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lumefantrine.
DB00007 DB08881 Vemurafenib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vemurafenib.
DB00007 DB11730 Ribociclib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ribociclib.
DB00007 DB11978 Glasdegib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib.
DB00007 DB12161 Deutetrabenazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Deutetrabenazine.
DB00007 DB13074 Macimorelin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Macimorelin.
DB00007 DB13725 Terodiline The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terodiline.
DB00007 DB00204 Dofetilide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dofetilide.
DB00007 DB00342 Terfenadine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terfenadine.
DB00007 DB00604 Cisapride The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cisapride.
DB00007 DB00637 Astemizole The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Astemizole.
DB00007 DB00908 Quinidine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinidine.
DB00007 DB01100 Pimozide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pimozide.
DB00007 DB01118 Amiodarone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.
DB00007 DB04855 Dronedarone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dronedarone.
DB00007 DB09039 Eliglustat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Eliglustat.
DB00007 DB00014 Goserelin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin.
DB00007 DB00195 Betaxolol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Betaxolol.
DB00007 DB00199 Erythromycin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erythromycin.
DB00007 DB00207 Azithromycin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Azithromycin.
DB00007 DB00218 Moxifloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin.
DB00007 DB00243 Ranolazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ranolazine.
DB00007 DB00263 Sulfisoxazole The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sulfisoxazole.
DB00007 DB00333 Methadone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Methadone.
DB00007 DB00343 Diltiazem The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Diltiazem.
DB00007 DB00363 Clozapine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clozapine.
DB00007 DB00391 Sulpiride The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sulpiride.
DB00007 DB00393 Nimodipine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nimodipine.
DB00007 DB00420 Promazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Promazine.
DB00007 DB00433 Prochlorperazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prochlorperazine.
DB00007 DB00450 Droperidol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Droperidol.
DB00007 DB00477 Chlorpromazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpromazine.
DB00007 DB00526 Oxaliplatin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin.
DB00007 DB00537 Ciprofloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ciprofloxacin.
DB00007 DB00544 Fluorouracil The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluorouracil.
DB00007 DB00556 Perflutren The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Perflutren.
DB00007 DB00568 Cinnarizine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinnarizine.
DB00007 DB00571 Propranolol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propranolol.
DB00007 DB00572 Atropine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Atropine.
DB00007 DB00608 Chloroquine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chloroquine.
DB00007 DB00640 Adenosine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Adenosine.
DB00007 DB00738 Pentamidine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pentamidine.
DB00007 DB00743 Gadobenic acid The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gadobenic acid.
DB00007 DB00748 Carbinoxamine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Carbinoxamine.
DB00007 DB00757 Dolasetron The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dolasetron.
DB00007 DB00778 Roxithromycin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Roxithromycin.
DB00007 DB00779 Nalidixic acid The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nalidixic acid.
DB00007 DB00827 Cinoxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinoxacin.
DB00007 DB00889 Granisetron The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Granisetron.
DB00007 DB00904 Ondansetron The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ondansetron.
DB00007 DB00922 Levosimendan The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levosimendan.
DB00007 DB00933 Mesoridazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mesoridazine.
DB00007 DB00967 Desloratadine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Desloratadine.
DB00007 DB00978 Lomefloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lomefloxacin.
DB00007 DB00985 Dimenhydrinate The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dimenhydrinate.
DB00007 DB01087 Primaquine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Primaquine.
DB00007 DB01113 Papaverine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Papaverine.
DB00007 DB01114 Chlorpheniramine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpheniramine.
DB00007 DB01115 Nifedipine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nifedipine.
DB00007 DB01137 Levofloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levofloxacin.
DB00007 DB01155 Gemifloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gemifloxacin.
DB00007 DB01165 Ofloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ofloxacin.
DB00007 DB01182 Propafenone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propafenone.
DB00007 DB01193 Acebutolol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Acebutolol.
DB00007 DB01195 Flecainide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flecainide.
DB00007 DB01580 Oxprenolol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxprenolol.
DB00007 DB01599 Probucol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Probucol.
DB00007 DB01615 Aceprometazine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Aceprometazine.
DB00007 DB02638 Terlipressin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terlipressin.
DB00007 DB04825 Prenylamine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prenylamine.
DB00007 DB04842 Fluspirilene The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluspirilene.
DB00007 DB04948 Lofexidine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lofexidine.
DB00007 DB04957 Azimilide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Azimilide.
DB00007 DB05223 Pracinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pracinostat.
DB00007 DB05488 Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Technetium Tc-99m ciprofloxacin.
DB00007 DB06160 Garenoxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Garenoxacin.
DB00007 DB06200 Tedisamil The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tedisamil.
DB00007 DB06334 Tucidinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tucidinostat.
DB00007 DB06402 Telavancin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telavancin.
DB00007 DB06589 Pazopanib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pazopanib.
DB00007 DB06600 Nemonoxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nemonoxacin.
DB00007 DB06603 Panobinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Panobinostat.
DB00007 DB06712 Nilvadipine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilvadipine.
DB00007 DB08799 Antazoline The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Antazoline.
DB00007 DB08865 Crizotinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Crizotinib.
DB00007 DB08903 Bedaquiline The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bedaquiline.
DB00007 DB08980 Fendiline The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fendiline.
DB00007 DB08992 Eperisone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Eperisone.
DB00007 DB09016 Butriptyline The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Butriptyline.
DB00007 DB09063 Ceritinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ceritinib.
DB00007 DB09078 Lenvatinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lenvatinib.
DB00007 DB09224 Melperone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Melperone.
DB00007 DB09231 Benidipine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Benidipine.
DB00007 DB09555 Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine maleate.
DB00007 DB11640 Amifampridine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amifampridine.
DB00007 DB11830 Mocetinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mocetinostat.
DB00007 DB11841 Entinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entinostat.
DB00007 DB12141 Gilteritinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gilteritinib.
DB00007 DB12174 CUDC-101 The risk or severity of QTc prolongation can be increased when Leuprolide is combined with CUDC-101.
DB00007 DB12286 Simendan The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Simendan.
DB00007 DB12376 Ricolinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ricolinostat.
DB00007 DB12523 Mizolastine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mizolastine.
DB00007 DB12565 Abexinostat The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Abexinostat.
DB00007 DB12877 Oxatomide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxatomide.
DB00007 DB13261 Sitafloxacin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sitafloxacin.
DB00007 DB13273 Sultopride The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sultopride.
DB00007 DB13500 Otilonium The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Otilonium.
DB00007 DB13546 Nizofenone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nizofenone.
DB00007 DB13652 Bunaftine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bunaftine.
DB00007 DB13653 Lorcainide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lorcainide.
DB00007 DB13679 Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine.
DB00007 DB13791 Penfluridol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Penfluridol.
DB00007 DB14063 Dexverapamil The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexverapamil.
DB00007 DB14568 Ivosidenib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ivosidenib.
DB00007 DB00625 Efavirenz The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Efavirenz.
DB00007 DB00836 Loperamide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Loperamide.
DB00007 DB00976 Telithromycin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telithromycin.
DB00007 DB01211 Clarithromycin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clarithromycin.
DB00007 DB01224 Quetiapine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quetiapine.
DB00007 DB01227 Levacetylmethadol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levacetylmethadol.
DB00007 DB01232 Saquinavir The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Saquinavir.
DB00007 DB01388 Mibefradil The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mibefradil.
DB00007 DB00321 Amitriptyline The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amitriptyline.
DB00007 DB00458 Imipramine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine.
DB00007 DB01242 Clomipramine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clomipramine.
DB00007 DB11718 Encorafenib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib.
DB00007 DB00104 Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.
DB00007 DB00107 Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.
DB00007 DB00187 Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Leuprolide.
DB00007 DB00188 Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Leuprolide.
DB00007 DB00196 Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Leuprolide.
DB00007 DB00230 Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Leuprolide.
DB00007 DB00245 Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Leuprolide.
DB00007 DB00270 Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Leuprolide.
DB00007 DB00285 Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Leuprolide.
DB00007 DB00289 Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Leuprolide.
DB00007 DB00334 Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Leuprolide.
DB00007 DB00341 Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Leuprolide.
DB00007 DB00344 Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Leuprolide.
DB00007 DB00346 Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Leuprolide.
DB00007 DB00347 Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Leuprolide.
DB00007 DB00354 Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Leuprolide.
DB00007 DB00358 Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Leuprolide.
DB00007 DB00366 Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Leuprolide.
DB00007 DB00370 Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Leuprolide.
DB00007 DB00373 Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Leuprolide.
DB00007 DB00374 Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Leuprolide.
DB00007 DB00398 Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Leuprolide.
DB00007 DB00405 Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide.
DB00007 DB00424 Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Leuprolide.
DB00007 DB00427 Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Leuprolide.
DB00007 DB00434 Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Leuprolide.
DB00007 DB00467 Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Leuprolide.
DB00007 DB00487 Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Leuprolide.
DB00007 DB00529 Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Leuprolide.
DB00007 DB00543 Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Leuprolide.
DB00007 DB00555 Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Leuprolide.
DB00007 DB00613 Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Leuprolide.
DB00007 DB00622 Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Leuprolide.
DB00007 DB00674 Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Leuprolide.
DB00007 DB00675 Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Leuprolide.
DB00007 DB00678 Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Leuprolide.
DB00007 DB00680 Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Leuprolide.
DB00007 DB00691 Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Leuprolide.
DB00007 DB00697 Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Leuprolide.
DB00007 DB00710 Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Leuprolide.
DB00007 DB00714 Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Leuprolide.
DB00007 DB00719 Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Leuprolide.
DB00007 DB00734 Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Leuprolide.
DB00007 DB00753 Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Leuprolide.
DB00007 DB00808 Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Leuprolide.
DB00007 DB00817 Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Leuprolide.
DB00007 DB00818 Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Leuprolide.
DB00007 DB00822 Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Leuprolide.
DB00007 DB00825 Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Leuprolide.
DB00007 DB00835 Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Leuprolide.
DB00007 DB00871 Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Leuprolide.
DB00007 DB00909 Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Leuprolide.
DB00007 DB00915 Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Leuprolide.
DB00007 DB00916 Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Leuprolide.
DB00007 DB00920 Ketotifen The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Leuprolide.
DB00007 DB00927 Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide.
DB00007 DB00934 Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Leuprolide.
DB00007 DB00938 Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Leuprolide.
DB00007 DB00949 Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Leuprolide.
DB00007 DB00983 Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Leuprolide.
DB00007 DB00999 Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Leuprolide.
DB00007 DB01001 Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Leuprolide.
DB00007 DB01015 Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Leuprolide.
DB00007 DB01036 Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Leuprolide.
DB00007 DB01044 Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Leuprolide.
DB00007 DB01054 Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Leuprolide.
DB00007 DB01059 Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Leuprolide.
DB00007 DB01069 Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Leuprolide.
DB00007 DB01071 Mequitazine The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Leuprolide.
DB00007 DB01074 Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Leuprolide.
DB00007 DB01075 Diphenhydramine The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Leuprolide.
DB00007 DB01106 Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Leuprolide.
DB00007 DB01158 Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Leuprolide.
DB00007 DB01166 Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Leuprolide.
DB00007 DB01173 Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Leuprolide.
DB00007 DB01176 Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Leuprolide.
DB00007 DB01189 Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Leuprolide.
DB00007 DB01228 Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Leuprolide.
DB00007 DB01233 Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Leuprolide.
DB00007 DB01236 Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Leuprolide.
DB00007 DB01238 Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide.
DB00007 DB01239 Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Leuprolide.
DB00007 DB01246 Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Leuprolide.
DB00007 DB01259 Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Leuprolide.
DB00007 DB01268 Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Leuprolide.
DB00007 DB01274 Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Leuprolide.
DB00007 DB01403 Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Leuprolide.
DB00007 DB01426 Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Leuprolide.
DB00007 DB01591 Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Leuprolide.
DB00007 DB01611 Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Leuprolide.
DB00007 DB01620 Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Leuprolide.
DB00007 DB01623 Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Leuprolide.
DB00007 DB02546 Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Leuprolide.
DB00007 DB04576 Fleroxacin The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Leuprolide.
DB00007 DB04695 Farnesyl thiopyrophosphate The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Leuprolide.
DB00007 DB04846 Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Leuprolide.
DB00007 DB04953 Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Leuprolide.
DB00007 DB05039 Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Leuprolide.
DB00007 DB05246 Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Leuprolide.
DB00007 DB05465 Tandutinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Leuprolide.
DB00007 DB06217 Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Leuprolide.
DB00007 DB06282 Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Leuprolide.
DB00007 DB06288 Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Leuprolide.
DB00007 DB06468 Cariporide The risk or severity of QTc prolongation can be increased when Cariporide is combined with Leuprolide.
DB00007 DB06663 Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Leuprolide.
DB00007 DB06691 Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Leuprolide.
DB00007 DB06699 Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Leuprolide.
DB00007 DB06719 Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Leuprolide.
DB00007 DB06788 Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Leuprolide.
DB00007 DB06825 Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide.
DB00007 DB07780 Farnesyl diphosphate The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Leuprolide.
DB00007 DB07841 Geranylgeranyl diphosphate The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Leuprolide.
DB00007 DB08808 Bupranolol The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Leuprolide.
DB00007 DB08871 Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Leuprolide.
DB00007 DB08893 Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Leuprolide.
DB00007 DB08912 Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide.
DB00007 DB08936 Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Leuprolide.
DB00007 DB08952 Indenolol The risk or severity of QTc prolongation can be increased when Indenolol is combined with Leuprolide.
DB00007 DB08972 Flumequine The risk or severity of QTc prolongation can be increased when Flumequine is combined with Leuprolide.
DB00007 DB09080 Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Leuprolide.
DB00007 DB09082 Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Leuprolide.
DB00007 DB09089 Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Leuprolide.
DB00007 DB09090 Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Leuprolide.
DB00007 DB09167 Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Leuprolide.
DB00007 DB09229 Aranidipine The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Leuprolide.
DB00007 DB09235 Efonidipine The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Leuprolide.
DB00007 DB09236 Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Leuprolide.
DB00007 DB09239 Niguldipine The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Leuprolide.
DB00007 DB09488 Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Leuprolide.
DB00007 DB11390 Coumaphos The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Leuprolide.
DB00007 DB11397 Dichlorvos The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Leuprolide.
DB00007 DB11408 Famphur The risk or severity of QTc prolongation can be increased when Famphur is combined with Leuprolide.
DB00007 DB11412 Fenthion The risk or severity of QTc prolongation can be increased when Fenthion is combined with Leuprolide.
DB00007 DB11443 Orbifloxacin The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Leuprolide.
DB00007 DB11448 Phosmet The risk or severity of QTc prolongation can be increased when Phosmet is combined with Leuprolide.
DB00007 DB11491 Sarafloxacin The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Leuprolide.
DB00007 DB11511 Difloxacin The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Leuprolide.
DB00007 DB11591 Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Leuprolide.
DB00007 DB11614 Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Leuprolide.
DB00007 DB11770 Talinolol The risk or severity of QTc prolongation can be increased when Talinolol is combined with Leuprolide.
DB00007 DB11774 Pazufloxacin The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Leuprolide.
DB00007 DB11785 Anisodamine The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Leuprolide.
DB00007 DB11891 CUDC-907 The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Leuprolide.
DB00007 DB11892 Prulifloxacin The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Leuprolide.
DB00007 DB11943 Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Leuprolide.
DB00007 DB12093 Tetrahydropalmatine The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Leuprolide.
DB00007 DB12231 Temefos The risk or severity of QTc prolongation can be increased when Temefos is combined with Leuprolide.
DB00007 DB12245 Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Leuprolide.
DB00007 DB12645 Givinostat The risk or severity of QTc prolongation can be increased when Givinostat is combined with Leuprolide.
DB00007 DB12712 Pilsicainide The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Leuprolide.
DB00007 DB12766 Cicletanine The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Leuprolide.
DB00007 DB12923 Gallopamil The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Leuprolide.
DB00007 DB13358 Cibenzoline The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Leuprolide.
DB00007 DB13488 Bencyclane The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Leuprolide.
DB00007 DB13555 Prajmaline The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Leuprolide.
DB00007 DB13627 Oxolinic acid The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Leuprolide.
DB00007 DB13651 Lorajmine The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Leuprolide.
DB00007 DB13691 Acetyldigoxin The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Leuprolide.
DB00007 DB13744 Piromidic acid The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Leuprolide.
DB00007 DB13766 Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Leuprolide.
DB00007 DB13772 Rufloxacin The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Leuprolide.
DB00007 DB13823 Pipemidic acid The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Leuprolide.
DB00007 DB14185 Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Leuprolide.
DB00007 DB14713 Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Leuprolide.
DB00007 DB00220 Nelfinavir The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nelfinavir.
DB00007 DB00726 Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Leuprolide.
DB00007 DB00540 Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Leuprolide.
DB00007 DB00582 Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Leuprolide.
DB00007 DB00593 Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Leuprolide.
DB00007 DB00862 Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Leuprolide.
DB00007 DB00864 Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Leuprolide.
DB00007 DB01023 Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Leuprolide.
DB00007 DB01026 Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Leuprolide.
DB00007 DB01072 Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Leuprolide.
DB00007 DB01167 Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Leuprolide.
DB00007 DB01254 Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Leuprolide.
DB00007 DB01263 Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Leuprolide.
DB00007 DB01396 Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Leuprolide.
DB00007 DB08815 Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Leuprolide.
DB00007 DB08864 Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Leuprolide.
DB00007 DB11742 Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Leuprolide.
DB00007 DB01142 Doxepin The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Doxepin.
DB00007 DB01151 Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Leuprolide.
DB00007 DB00503 Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Leuprolide.
DB00007 DB00845 Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Leuprolide.
DB00007 DB11637 Delamanid Leuprolide may increase the QTc-prolonging activities of Delamanid.
DB00007 DB00159 Icosapent Icosapent may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00229 Cefotiam Cefotiam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00244 Mesalazine Mesalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00267 Cefmenoxime Cefmenoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00274 Cefmetazole Cefmetazole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00282 Pamidronic acid Pamidronic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00300 Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00328 Indomethacin Indomethacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00369 Cidofovir Cidofovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00384 Triamterene Triamterene may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00430 Cefpiramide Cefpiramide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00438 Ceftazidime Ceftazidime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00447 Loracarbef Loracarbef may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00456 Cefalotin Cefalotin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00461 Nabumetone Nabumetone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00465 Ketorolac Ketorolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00469 Tenoxicam Tenoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00482 Celecoxib Celecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00493 Cefotaxime Cefotaxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00500 Tolmetin Tolmetin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00533 Rofecoxib Rofecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00554 Piroxicam Piroxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00563 Methotrexate Methotrexate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00567 Cephalexin Cephalexin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00573 Fenoprofen Fenoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00577 Valaciclovir Valaciclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00580 Valdecoxib Valdecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00586 Diclofenac Diclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00605 Sulindac Sulindac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00626 Bacitracin Bacitracin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00681 Amphotericin B Amphotericin B may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00689 Cephaloglycin Cephaloglycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00712 Flurbiprofen Flurbiprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00718 Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00742 Mannitol Mannitol may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00749 Etodolac Etodolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00784 Mefenamic acid Mefenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00787 Acyclovir Acyclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00788 Naproxen Naproxen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00795 Sulfasalazine Sulfasalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00812 Phenylbutazone Phenylbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00814 Meloxicam Meloxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00821 Carprofen Carprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00833 Cefaclor Cefaclor may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00861 Diflunisal Diflunisal may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00903 Etacrynic acid Etacrynic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00923 Ceforanide Ceforanide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00936 Salicylic acid Salicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00939 Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00945 Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00958 Carboplatin Carboplatin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00991 Oxaprozin Oxaprozin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01009 Ketoprofen Ketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01014 Balsalazide Balsalazide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01050 Ibuprofen Ibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01066 Cefditoren Cefditoren may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01111 Colistimethate Colistimethate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01112 Cefuroxime Cefuroxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01139 Cefapirin Cefapirin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01140 Cefadroxil Cefadroxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01150 Cefprozil Cefprozil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01212 Ceftriaxone Ceftriaxone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01250 Olsalazine Olsalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01283 Lumiracoxib Lumiracoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01326 Cefamandole Cefamandole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01327 Cefazolin Cefazolin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01328 Cefonicid Cefonicid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01329 Cefoperazone Cefoperazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01330 Cefotetan Cefotetan may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01331 Cefoxitin Cefoxitin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01332 Ceftizoxime Ceftizoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01333 Cefradine Cefradine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01397 Magnesium salicylate Magnesium salicylate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01399 Salsalate Salsalate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01401 Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01413 Cefepime Cefepime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01414 Cefacetrile Cefacetrile may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01415 Ceftibuten Ceftibuten may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01416 Cefpodoxime Cefpodoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01419 Antrafenine Antrafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01424 Aminophenazone Aminophenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01435 Antipyrine Antipyrine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01600 Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01628 Etoricoxib Etoricoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB02247 Hydrolyzed Cephalothin Hydrolyzed Cephalothin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB03450 Cephalothin Group Cephalothin Group may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB03585 Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04552 Niflumic acid Niflumic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04570 Latamoxef Latamoxef may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04743 Nimesulide Nimesulide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04812 Benoxaprofen Benoxaprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04817 Metamizole Metamizole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04828 Zomepirac Zomepirac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04918 Ceftobiprole Ceftobiprole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB05095 Cimicoxib Cimicoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB06590 Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB06725 Lornoxicam Lornoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB06736 Aceclofenac Aceclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB06737 Zaltoprofen Zaltoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB07402 Azapropazone Azapropazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB07477 Felbinac Felbinac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08439 Parecoxib Parecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08797 Salicylamide Salicylamide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08940 Kebuzone Kebuzone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08942 Isoxicam Isoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08951 Indoprofen Indoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08955 Ibuproxam Ibuproxam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08976 Floctafenine Floctafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08981 Fenbufen Fenbufen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08984 Etofenamate Etofenamate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08991 Epirizole Epirizole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09008 Cefaloridine Cefaloridine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09062 Cefminox Cefminox may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09084 Benzydamine Benzydamine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09212 Loxoprofen Loxoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09213 Dexibuprofen Dexibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09214 Dexketoprofen Dexketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09215 Droxicam Droxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09216 Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09217 Firocoxib Firocoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09218 Clonixin Clonixin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09285 Morniflumate Morniflumate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09288 Propacetamol Propacetamol may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09295 Talniflumate Talniflumate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB09299 Tenofovir alafenamide Tenofovir alafenamide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11367 Cefroxadine Cefroxadine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11455 Robenacoxib Robenacoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11466 Tepoxalin Tepoxalin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11518 Flunixin Flunixin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11935 Flomoxef Flomoxef may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB12151 Brincidofovir Brincidofovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB12445 Nitroaspirin Nitroaspirin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB12545 Indobufen Indobufen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13001 Tinoridine Tinoridine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13167 Alclofenac Alclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13217 Fentiazac Fentiazac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13232 Suxibuzone Suxibuzone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13266 Cefatrizine Cefatrizine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13286 Bumadizone Bumadizone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13314 Alminoprofen Alminoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13317 Flunoxaprofen Flunoxaprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13364 Feprazone Feprazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13371 Difenpiramide Difenpiramide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13407 Nifenazone Nifenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13432 Lonazolac Lonazolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13461 Cefcapene Cefcapene may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13470 Cefodizime Cefodizime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13481 Tenidap Tenidap may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13499 Cefsulodin Cefsulodin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13501 Bendazac Bendazac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13504 Cefetamet Cefetamet may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13514 Pranoprofen Pranoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13524 Propyphenazone Propyphenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13527 Proglumetacin Proglumetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13538 Guacetisal Guacetisal may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13544 Ethenzamide Ethenzamide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13612 Carbaspirin calcium Carbaspirin calcium may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13629 Mofebutazone Mofebutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13638 Cefbuperazone Cefbuperazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13649 Proquazone Proquazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13657 Benorilate Benorilate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13667 Cefozopran Cefozopran may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13682 Cefpirome Cefpirome may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13722 Pirprofen Pirprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13778 Cefazedone Cefazedone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13783 Acemetacin Acemetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13821 Ceftezole Ceftezole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13860 Imidazole salicylate Imidazole salicylate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13868 Adefovir Adefovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB14059 SC-236 SC-236 may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB14060 NS-398 NS-398 may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB14126 Tenofovir Tenofovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01438 Phenazopyridine Phenazopyridine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00091 Cyclosporine Cyclosporine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB15066 Givosiran Givosiran may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01601 Lopinavir Lopinavir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB14507 Lithium citrate Lithium citrate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00017 Salmon calcitonin Leuprolide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00007 DB00035 Desmopressin Leuprolide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00007 DB00041 Aldesleukin Leuprolide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00007 DB00081 Tositumomab Leuprolide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
DB00007 DB00115 Cyanocobalamin Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
DB00007 DB00158 Folic acid Leuprolide may decrease the excretion rate of Folic acid which could result in a higher serum level.
DB00007 DB00165 Pyridoxine Leuprolide may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
DB00007 DB00176 Fluvoxamine Leuprolide may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
DB00007 DB00182 Amphetamine Leuprolide may decrease the excretion rate of Amphetamine which could result in a higher serum level.
DB00007 DB00185 Cevimeline Leuprolide may decrease the excretion rate of Cevimeline which could result in a higher serum level.
DB00007 DB00186 Lorazepam Leuprolide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00007 DB00190 Carbidopa Leuprolide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00007 DB00193 Tramadol Leuprolide may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00007 DB00198 Oseltamivir Leuprolide may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00007 DB00200 Hydroxocobalamin Leuprolide may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00007 DB00206 Reserpine Leuprolide may decrease the excretion rate of Reserpine which could result in a higher serum level.
DB00007 DB00208 Ticlopidine Leuprolide may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
DB00007 DB00213 Pantoprazole Leuprolide may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00007 DB00225 Gadodiamide Leuprolide may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00007 DB00231 Temazepam Leuprolide may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00007 DB00235 Milrinone Leuprolide may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00007 DB00237 Butabarbital Leuprolide may decrease the excretion rate of Butabarbital which could result in a higher serum level.
DB00007 DB00254 Doxycycline Leuprolide may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00007 DB00262 Carmustine Leuprolide may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00007 DB00264 Metoprolol Leuprolide may decrease the excretion rate of Metoprolol which could result in a higher serum level.
DB00007 DB00271 Diatrizoate Leuprolide may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00007 DB00273 Topiramate Leuprolide may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00007 DB00279 Liothyronine Leuprolide may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00007 DB00286 Conjugated estrogens Leuprolide may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00007 DB00290 Bleomycin Leuprolide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00007 DB00292 Etomidate Leuprolide may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00007 DB00294 Etonogestrel Leuprolide may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00007 DB00296 Ropivacaine Leuprolide may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00007 DB00303 Ertapenem Leuprolide may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00007 DB00316 Acetaminophen Leuprolide may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
DB00007 DB00319 Piperacillin Leuprolide may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00007 DB00322 Floxuridine Leuprolide may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00007 DB00323 Tolcapone Leuprolide may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00007 DB00325 Nitroprusside Leuprolide may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00007 DB00327 Hydromorphone Leuprolide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
DB00007 DB00330 Ethambutol Leuprolide may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00007 DB00339 Pyrazinamide Leuprolide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00007 DB00349 Clobazam Leuprolide may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00007 DB00351 Megestrol acetate Leuprolide may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00007 DB00355 Aztreonam Leuprolide may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00007 DB00356 Chlorzoxazone Leuprolide may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
DB00007 DB00364 Sucralfate Leuprolide may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00007 DB00372 Thiethylperazine Leuprolide may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00007 DB00377 Palonosetron Leuprolide may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00007 DB00380 Dexrazoxane Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00007 DB00402 Eszopiclone Leuprolide may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
DB00007 DB00413 Pramipexole Leuprolide may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00007 DB00415 Ampicillin Leuprolide may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00007 DB00418 Secobarbital Leuprolide may decrease the excretion rate of Secobarbital which could result in a higher serum level.
DB00007 DB00422 Methylphenidate Leuprolide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00007 DB00432 Trifluridine Leuprolide may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00007 DB00435 Nitric Oxide Leuprolide may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00007 DB00437 Allopurinol Leuprolide may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00007 DB00441 Gemcitabine Leuprolide may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00007 DB00476 Duloxetine Leuprolide may decrease the excretion rate of Duloxetine which could result in a higher serum level.
DB00007 DB00480 Lenalidomide Leuprolide may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00007 DB00492 Fosinopril Leuprolide may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00007 DB00499 Flutamide Leuprolide may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00007 DB00535 Cefdinir Leuprolide may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00007 DB00548 Azelaic acid Leuprolide may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00007 DB00553 Methoxsalen Leuprolide may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00007 DB00558 Zanamivir Leuprolide may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00007 DB00569 Fondaparinux Leuprolide may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00007 DB00583 Levocarnitine Leuprolide may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00007 DB00591 Fluocinolone acetonide Leuprolide may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
DB00007 DB00597 Gadoteridol Leuprolide may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00007 DB00598 Labetalol Leuprolide may decrease the excretion rate of Labetalol which could result in a higher serum level.
DB00007 DB00603 Medroxyprogesterone acetate Leuprolide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00007 DB00612 Bisoprolol Leuprolide may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00007 DB00624 Testosterone Leuprolide may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00007 DB00628 Clorazepic acid Leuprolide may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00007 DB00631 Clofarabine Leuprolide may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00007 DB00633 Dexmedetomidine Leuprolide may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00007 DB00635 Prednisone Leuprolide may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00007 DB00651 Dyphylline Leuprolide may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00007 DB00657 Mecamylamine Leuprolide may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
DB00007 DB00660 Metaxalone Leuprolide may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00007 DB00665 Nilutamide Leuprolide may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00007 DB00669 Sumatriptan Leuprolide may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00007 DB00690 Flurazepam Leuprolide may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00007 DB00692 Phentolamine Leuprolide may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00007 DB00698 Nitrofurantoin Leuprolide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00007 DB00706 Tamsulosin Leuprolide may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00007 DB00713 Oxacillin Leuprolide may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00007 DB00716 Nedocromil Leuprolide may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00007 DB00722 Lisinopril Leuprolide may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00007 DB00730 Thiabendazole Leuprolide may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00007 DB00733 Pralidoxime Leuprolide may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00007 DB00759 Tetracycline Leuprolide may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00007 DB00760 Meropenem Leuprolide may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00007 DB00761 Potassium chloride Leuprolide may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00007 DB00775 Tirofiban Leuprolide may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00007 DB00780 Phenelzine Leuprolide may decrease the excretion rate of Phenelzine which could result in a higher serum level.
DB00007 DB00782 Propantheline Leuprolide may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00007 DB00783 Estradiol Leuprolide may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00007 DB00789 Gadopentetic acid Leuprolide may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00007 DB00790 Perindopril Leuprolide may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB00007 DB00800 Fenoldopam Leuprolide may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00007 DB00804 Dicyclomine Leuprolide may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00007 DB00806 Pentoxifylline Leuprolide may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00007 DB00811 Ribavirin Leuprolide may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00007 DB00828 Fosfomycin Leuprolide may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00007 DB00829 Diazepam Leuprolide may decrease the excretion rate of Diazepam which could result in a higher serum level.
DB00007 DB00841 Dobutamine Leuprolide may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00007 DB00842 Oxazepam Leuprolide may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00007 DB00851 Dacarbazine Leuprolide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00007 DB00853 Temozolomide Leuprolide may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00007 DB00894 Testolactone Leuprolide may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00007 DB00900 Didanosine Leuprolide may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00007 DB00911 Tinidazole Leuprolide may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00007 DB00918 Almotriptan Leuprolide may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00007 DB00928 Azacitidine Leuprolide may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00007 DB00953 Rizatriptan Leuprolide may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00007 DB00960 Pindolol Leuprolide may decrease the excretion rate of Pindolol which could result in a higher serum level.
DB00007 DB00961 Mepivacaine Leuprolide may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00007 DB00962 Zaleplon Leuprolide may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00007 DB00980 Ramelteon Leuprolide may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00007 DB00988 Dopamine Leuprolide may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00007 DB00993 Azathioprine Leuprolide may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00007 DB00995 Auranofin Leuprolide may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB00007 DB01002 Levobupivacaine Leuprolide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB00007 DB01010 Edrophonium Leuprolide may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB00007 DB01011 Metyrapone Leuprolide may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB00007 DB01018 Guanfacine Leuprolide may decrease the excretion rate of Guanfacine which could result in a higher serum level.
DB00007 DB01020 Isosorbide mononitrate Leuprolide may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB00007 DB01022 Phylloquinone Leuprolide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB00007 DB01024 Mycophenolic acid Leuprolide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB00007 DB01030 Topotecan Leuprolide may decrease the excretion rate of Topotecan which could result in a higher serum level.
DB00007 DB01032 Probenecid Leuprolide may decrease the excretion rate of Probenecid which could result in a higher serum level.
DB00007 DB01043 Memantine Leuprolide may decrease the excretion rate of Memantine which could result in a higher serum level.
DB00007 DB01046 Lubiprostone Leuprolide may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB00007 DB01048 Abacavir Leuprolide may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB00007 DB01060 Amoxicillin Leuprolide may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB00007 DB01068 Clonazepam Leuprolide may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB00007 DB01093 Dimethyl sulfoxide Leuprolide may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB00007 DB01099 Flucytosine Leuprolide may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB00007 DB01101 Capecitabine Leuprolide may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB00007 DB01105 Sibutramine Leuprolide may decrease the excretion rate of Sibutramine which could result in a higher serum level.
DB00007 DB01129 Rabeprazole Leuprolide may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
DB00007 DB01133 Tiludronic acid Leuprolide may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB00007 DB01135 Doxacurium Leuprolide may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB00007 DB01148 Flavoxate Leuprolide may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB00007 DB01156 Bupropion Leuprolide may decrease the excretion rate of Bupropion which could result in a higher serum level.
DB00007 DB01157 Trimetrexate Leuprolide may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB00007 DB01170 Guanethidine Leuprolide may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB00007 DB01181 Ifosfamide Leuprolide may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
DB00007 DB01203 Nadolol Leuprolide may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB00007 DB01205 Flumazenil Leuprolide may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB00007 DB01213 Fomepizole Leuprolide may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB00007 DB01215 Estazolam Leuprolide may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB00007 DB01221 Ketamine Leuprolide may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB00007 DB01240 Epoprostenol Leuprolide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB00007 DB01249 Iodixanol Leuprolide may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB00007 DB01273 Varenicline Leuprolide may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB00007 DB01275 Hydralazine Leuprolide may decrease the excretion rate of Hydralazine which could result in a higher serum level.
DB00007 DB01359 Penbutolol Leuprolide may decrease the excretion rate of Penbutolol which could result in a higher serum level.
DB00007 DB01367 Rasagiline Leuprolide may decrease the excretion rate of Rasagiline which could result in a higher serum level.
DB00007 DB01409 Tiotropium Leuprolide may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB00007 DB01420 Testosterone propionate Leuprolide may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB00007 DB01427 Amrinone Leuprolide may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB00007 DB01428 Oxybenzone Leuprolide may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB00007 DB01431 Allylestrenol Leuprolide may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB00007 DB01550 Fenproporex Leuprolide may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB00007 DB01558 Bromazepam Leuprolide may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB00007 DB01563 Chloral hydrate Leuprolide may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB00007 DB01577 Metamfetamine Leuprolide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
DB00007 DB01587 Ketazolam Leuprolide may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB00007 DB01610 Valganciclovir Leuprolide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB00007 DB01638 Sorbitol Leuprolide may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB00007 DB01656 Roflumilast Leuprolide may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB00007 DB01685 Topiroxostat Leuprolide may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB00007 DB04574 Estrone sulfate Leuprolide may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB00007 DB04871 Lorcaserin Leuprolide may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB00007 DB04895 Pegaptanib Leuprolide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB00007 DB04896 Milnacipran Leuprolide may decrease the excretion rate of Milnacipran which could result in a higher serum level.
DB00007 DB04920 Clevidipine Leuprolide may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB00007 DB05018 Migalastat Leuprolide may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB00007 DB05541 Brivaracetam Leuprolide may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB00007 DB06154 Pentaerythritol tetranitrate Leuprolide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB00007 DB06186 Ipilimumab Leuprolide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB00007 DB06196 Icatibant Leuprolide may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB00007 DB06209 Prasugrel Leuprolide may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB00007 DB06211 Doripenem Leuprolide may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB00007 DB06230 Nalmefene Leuprolide may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB00007 DB06262 Droxidopa Leuprolide may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB00007 DB06480 Prucalopride Leuprolide may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB00007 DB06623 Flupirtine Leuprolide may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB00007 DB06637 Dalfampridine Leuprolide may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB00007 DB06695 Dabigatran etexilate Leuprolide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB00007 DB06700 Desvenlafaxine Leuprolide may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
DB00007 DB06702 Fesoterodine Leuprolide may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB00007 DB06705 Gadofosveset trisodium Leuprolide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB00007 DB06710 Methyltestosterone Leuprolide may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB00007 DB06767 Ammonium chloride Leuprolide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB00007 DB06782 Dimercaprol Leuprolide may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB00007 DB06796 Mangafodipir Leuprolide may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB00007 DB06800 Methylnaltrexone Leuprolide may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB00007 DB06809 Plerixafor Leuprolide may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB00007 DB06813 Pralatrexate Leuprolide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB00007 DB06823 Tiopronin Leuprolide may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB00007 DB06824 Triethylenetetramine Leuprolide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB00007 DB08824 Ioflupane I-123 Leuprolide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB00007 DB08826 Deferiprone Leuprolide may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB00007 DB08840 N-methylnicotinamide Leuprolide may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB00007 DB08872 Gabapentin enacarbil Leuprolide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB00007 DB08877 Ruxolitinib Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DB00007 DB08897 Aclidinium Leuprolide may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB00007 DB08900 Teduglutide Leuprolide may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB00007 DB08905 Formestane Leuprolide may decrease the excretion rate of Formestane which could result in a higher serum level.
DB00007 DB08909 Glycerol phenylbutyrate Leuprolide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB00007 DB08910 Pomalidomide Leuprolide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
DB00007 DB08911 Trametinib Leuprolide may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB00007 DB08918 Levomilnacipran Leuprolide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
DB00007 DB08932 Macitentan Leuprolide may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB00007 DB08934 Sofosbuvir Leuprolide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB00007 DB08964 Gemeprost Leuprolide may decrease the excretion rate of Gemeprost which could result in a higher serum level.
DB00007 DB09027 Ledipasvir Leuprolide may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB00007 DB09050 Ceftolozane Leuprolide may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB00007 DB09068 Vortioxetine Leuprolide may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB00007 DB09071 Tasimelteon Leuprolide may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
DB00007 DB09075 Edoxaban Leuprolide may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB00007 DB09081 Idebenone Leuprolide may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB00007 DB09091 Tixocortol Leuprolide may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB00007 DB09103 Ancestim Leuprolide may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB00007 DB09104 Magnesium hydroxide Leuprolide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB00007 DB09106 Hydroxyethyl Starch Leuprolide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB00007 DB09111 Pentastarch Leuprolide may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB00007 DB09121 Aurothioglucose Leuprolide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB00007 DB09123 Dienogest Leuprolide may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB00007 DB09129 Chromic chloride Leuprolide may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB00007 DB09132 Gadoteric acid Leuprolide may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB00007 DB09133 Iothalamic acid Leuprolide may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB00007 DB09134 Ioversol Leuprolide may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB00007 DB09135 Ioxilan Leuprolide may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB00007 DB09136 Isosulfan blue Leuprolide may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB00007 DB09137 Technetium Tc-99m mebrofenin Leuprolide may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB00007 DB09139 Technetium Tc-99m oxidronate Leuprolide may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB00007 DB09148 Florbetaben (18F) Leuprolide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB00007 DB09149 Florbetapir (18F) Leuprolide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB00007 DB09156 Iopromide Leuprolide may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB00007 DB09163 Technetium Tc-99m exametazime Leuprolide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB00007 DB09165 Technetium Tc-99m pyrophosphate Leuprolide may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB00007 DB09185 Viloxazine Leuprolide may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB00007 DB09194 Etoperidone Leuprolide may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB00007 DB09195 Lorpiprazole Leuprolide may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB00007 DB09204 Arotinolol Leuprolide may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB00007 DB09205 Moxisylyte Leuprolide may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB00007 DB09209 Pholcodine Leuprolide may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB00007 DB09210 Piracetam Leuprolide may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB00007 DB09219 Bisoxatin Leuprolide may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB00007 DB09220 Nicorandil Leuprolide may decrease the excretion rate of Nicorandil which could result in a higher serum level.
DB00007 DB09223 Blonanserin Leuprolide may decrease the excretion rate of Blonanserin which could result in a higher serum level.
DB00007 DB09241 Methylene blue Leuprolide may decrease the excretion rate of Methylene blue which could result in a higher serum level.
DB00007 DB09244 Pirlindole Leuprolide may decrease the excretion rate of Pirlindole which could result in a higher serum level.
DB00007 DB09245 Toloxatone Leuprolide may decrease the excretion rate of Toloxatone which could result in a higher serum level.
DB00007 DB09255 Dextran Leuprolide may decrease the excretion rate of Dextran which could result in a higher serum level.
DB00007 DB09256 Tegafur Leuprolide may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB00007 DB09257 Gimeracil Leuprolide may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB00007 DB09262 Imidafenacin Leuprolide may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB00007 DB09264 Idarucizumab Leuprolide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB00007 DB09268 Picosulfuric acid Leuprolide may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB00007 DB09276 Sodium aurothiomalate Leuprolide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB00007 DB09281 Magnesium trisilicate Leuprolide may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB00007 DB09292 Sacubitril Leuprolide may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB00007 DB09301 Chondroitin sulfate Leuprolide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB00007 DB09317 Synthetic Conjugated Estrogens, A Leuprolide may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB00007 DB09318 Synthetic Conjugated Estrogens, B Leuprolide may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB00007 DB09320 Procaine benzylpenicillin Leuprolide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB00007 DB09324 Sulbactam Leuprolide may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB00007 DB09325 Sodium fluoride Leuprolide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB00007 DB09329 Antihemophilic Factor (Recombinant), PEGylated Leuprolide may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB00007 DB09344 Invert sugar Leuprolide may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB00007 DB09357 Dexpanthenol Leuprolide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB00007 DB09394 Phosphoric acid Leuprolide may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB00007 DB09395 Sodium acetate Leuprolide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB00007 DB09407 Magnesium chloride Leuprolide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB00007 DB09418 Potassium perchlorate Leuprolide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB00007 DB09472 Sodium sulfate Leuprolide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB00007 DB09477 Enalaprilat Leuprolide may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB00007 DB09481 Magnesium carbonate Leuprolide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB00007 DB09496 Octinoxate Leuprolide may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB00007 DB09502 Fludeoxyglucose (18F) Leuprolide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB00007 DB09546 Iobenguane sulfate I-123 Leuprolide may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB00007 DB09570 Ixazomib Leuprolide may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB00007 DB11077 Polyethylene glycol 400 Leuprolide may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB00007 DB11090 Potassium nitrate Leuprolide may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB00007 DB11098 Potassium bicarbonate Leuprolide may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB00007 DB11102 N-acetyltyrosine Leuprolide may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB00007 DB11114 Eucalyptus oil Leuprolide may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB00007 DB11127 Selenious acid Leuprolide may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB00007 DB11130 Opium Leuprolide may decrease the excretion rate of Opium which could result in a higher serum level.
DB00007 DB11135 Selenium Leuprolide may decrease the excretion rate of Selenium which could result in a higher serum level.
DB00007 DB11136 Chromium Leuprolide may decrease the excretion rate of Chromium which could result in a higher serum level.
DB00007 DB11145 Oxyquinoline Leuprolide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB00007 DB11156 Pyrantel Leuprolide may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB00007 DB11164 Bicisate Leuprolide may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB00007 DB11251 Tocopherol Leuprolide may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB00007 DB11278 DL-Methylephedrine Leuprolide may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB00007 DB11328 Tetradecyl hydrogen sulfate (ester) Leuprolide may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB00007 DB11338 Clove oil Leuprolide may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB00007 DB11358 Evening primrose oil Leuprolide may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB00007 DB11364 Pidotimod Leuprolide may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB00007 DB11560 Lesinurad Leuprolide may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB00007 DB11577 Indigotindisulfonic acid Leuprolide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB00007 DB11587 Etafedrine Leuprolide may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB00007 DB11598 Antithrombin III human Leuprolide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB00007 DB11691 Naldemedine Leuprolide may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB00007 DB11699 Tropisetron Leuprolide may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB00007 DB11817 Baricitinib Leuprolide may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB00007 DB11915 Valbenazine Leuprolide may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB00007 DB11989 Benznidazole Leuprolide may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB00007 DB12007 Isoflavone Leuprolide may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB00007 DB12107 Vaborbactam Leuprolide may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB00007 DB12278 Propiverine Leuprolide may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB00007 DB12783 Benserazide Leuprolide may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB00007 DB13025 Tiapride Leuprolide may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB00007 DB13139 Levosalbutamol Leuprolide may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB00007 DB13156 Inosine pranobex Leuprolide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB00007 DB13178 Inositol Leuprolide may decrease the excretion rate of Inositol which could result in a higher serum level.
DB00007 DB13185 Oxabolone cipionate Leuprolide may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB00007 DB13191 Phosphocreatine Leuprolide may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB00007 DB13269 Dichlorobenzyl alcohol Leuprolide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB00007 DB13595 Almasilate Leuprolide may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB00007 DB13884 Albutrepenonacog alfa Leuprolide may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB00007 DB13909 Bismuth subgallate Leuprolide may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB00007 DB13943 Testosterone cypionate Leuprolide may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB00007 DB13944 Testosterone enanthate Leuprolide may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB00007 DB13946 Testosterone undecanoate Leuprolide may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
DB00007 DB13952 Estradiol acetate Leuprolide may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB00007 DB13954 Estradiol cypionate Leuprolide may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB00007 DB13955 Estradiol dienanthate Leuprolide may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB00007 DB13956 Estradiol valerate Leuprolide may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB00007 DB13967 Patent Blue Leuprolide may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB00007 DB14006 Choline salicylate Leuprolide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB00007 DB14007 Pentetic acid Leuprolide may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB00007 DB14498 Potassium acetate Leuprolide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB00007 DB14499 Potassium sulfate Leuprolide may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB00007 DB14526 Chromic citrate Leuprolide may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB00007 DB14527 Chromic nitrate Leuprolide may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB00007 DB14528 Chromium gluconate Leuprolide may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB00007 DB14529 Chromium nicotinate Leuprolide may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB00007 DB14530 Chromous sulfate Leuprolide may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB00007 DB14754 Solriamfetol Leuprolide may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
DB00007 DB06815 Pyrithione Leuprolide may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB00007 DB11121 Chloroxylenol Leuprolide may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB00007 DB11085 Resorcinol Leuprolide may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB00007 DB00312 Pentobarbital Leuprolide may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
DB00007 DB00401 Nisoldipine Leuprolide may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00007 DB00404 Alprazolam Leuprolide may decrease the excretion rate of Alprazolam which could result in a higher serum level.
DB00007 DB00490 Buspirone Leuprolide may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00007 DB00661 Verapamil Leuprolide may decrease the excretion rate of Verapamil which could result in a higher serum level.
DB00007 DB00683 Midazolam Leuprolide may decrease the excretion rate of Midazolam which could result in a higher serum level.
DB00007 DB00763 Methimazole Leuprolide may decrease the excretion rate of Methimazole which could result in a higher serum level.
DB00007 DB00820 Tadalafil Leuprolide may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00007 DB01149 Nefazodone Leuprolide may decrease the excretion rate of Nefazodone which could result in a higher serum level.
DB00007 DB01183 Naloxone Leuprolide may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB00007 DB01222 Budesonide Leuprolide may decrease the excretion rate of Budesonide which could result in a higher serum level.
DB00007 DB05676 Apremilast Leuprolide may decrease the excretion rate of Apremilast which could result in a higher serum level.
DB00007 DB06228 Rivaroxaban Leuprolide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB00007 DB08899 Enzalutamide Leuprolide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB00007 DB08904 Certolizumab pegol Leuprolide may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
DB00007 DB09118 Stiripentol Leuprolide may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB00007 DB11901 Apalutamide Leuprolide may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB00007 DB15593 Golodirsen Leuprolide may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00007 DB00318 Codeine Leuprolide may decrease the excretion rate of Codeine which could result in a higher serum level.
DB00007 DB00454 Meperidine Leuprolide may decrease the excretion rate of Meperidine which could result in a higher serum level.
DB00007 DB00813 Fentanyl Leuprolide may decrease the excretion rate of Fentanyl which could result in a higher serum level.
DB00007 DB00879 Emtricitabine Leuprolide may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB00007 DB08996 Dimetacrine Leuprolide may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
DB00007 DB14506 Lithium hydroxide Leuprolide may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB00007 DB00452 Framycetin Framycetin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00479 Amikacin Amikacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00684 Tobramycin Tobramycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00798 Gentamicin Gentamicin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00955 Netilmicin Netilmicin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00994 Neomycin Neomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01082 Streptomycin Streptomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01172 Kanamycin Kanamycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB01421 Paromomycin Paromomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB03615 Ribostamycin Ribostamycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04263 Geneticin Geneticin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04626 Apramycin Apramycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04729 Gentamicin C1a Gentamicin C1a may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB04808 Neamine Neamine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB06696 Arbekacin Arbekacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB08437 Puromycin Puromycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11512 Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB11520 Hygromycin B Hygromycin B may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB12604 Sisomicin Sisomicin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13270 Dibekacin Dibekacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13274 Micronomicin Micronomicin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13540 Isepamicin Isepamicin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB13673 Bekanamycin Bekanamycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
DB00007 DB00552 Pentostatin Leuprolide may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB00007 DB13145 Nedaplatin Leuprolide may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00007 DB00314 Capreomycin Leuprolide may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00007 DB00390 Digoxin Leuprolide may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00007 DB00512 Vancomycin Leuprolide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00007 DB00515 Cisplatin Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00007 DB00642 Pemetrexed Leuprolide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB00007 DB00982 Isotretinoin Leuprolide may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB00007 DB12615 Plazomicin Leuprolide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00007 DB14509 Lithium carbonate Leuprolide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB00007 DB00564 Carbamazepine Leuprolide may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
DB00007 DB00682 Warfarin Leuprolide may decrease the excretion rate of Warfarin which could result in a higher serum level.
DB00007 DB00524 Metolazone Leuprolide may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00695 Furosemide Leuprolide may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB09338 Mersalyl Leuprolide may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00214 Torasemide Torasemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00232 Methyclothiazide Methyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00310 Chlorthalidone Chlorthalidone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00311 Ethoxzolamide Ethoxzolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00421 Spironolactone Spironolactone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00436 Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00562 Benzthiazide Benzthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00594 Amiloride Amiloride may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00606 Cyclothiazide Cyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00774 Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00880 Chlorothiazide Chlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01021 Trichlormethiazide Trichlormethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01119 Diazoxide Diazoxide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01144 Diclofenamide Diclofenamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01324 Polythiazide Polythiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01325 Quinethazone Quinethazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01412 Theobromine Theobromine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB02925 Piretanide Piretanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB04831 Tienilic acid Tienilic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB05034 Ularitide Ularitide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB08961 Azosemide Azosemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB09015 Canrenoic acid Canrenoic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB09125 Potassium citrate Potassium citrate may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB09401 Isosorbide Isosorbide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB12221 Canrenone Canrenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB12670 Rolofylline Rolofylline may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB12704 Spiradoline Spiradoline may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13284 Meticrane Meticrane may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13316 Ibopamine Ibopamine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13405 Mefruside Mefruside may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13430 Mebutizide Mebutizide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13532 Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13617 Clorexolone Clorexolone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13663 Clofenamide Clofenamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13708 Fenquizone Fenquizone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13792 Clopamide Clopamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13801 Muzolimine Muzolimine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13803 Xipamide Xipamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB13989 Epitizide Epitizide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB14018 Bromotheophylline Bromotheophylline may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB14500 Potassium Potassium may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00703 Methazolamide Methazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00700 Eplerenone Eplerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00819 Acetazolamide Acetazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00872 Conivaptan Conivaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB01395 Drospirenone Drospirenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB06212 Tolvaptan Tolvaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB06370 Indisulam Indisulam may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
DB00007 DB00052 Somatotropin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Somatotropin.
DB00007 DB00080 Daptomycin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin.
DB00007 DB00175 Pravastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pravastatin.
DB00007 DB00181 Baclofen The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Baclofen.
DB00007 DB00242 Cladribine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cladribine.
DB00007 DB00382 Tacrine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrine.
DB00007 DB00389 Carbimazole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Carbimazole.
DB00007 DB00439 Cerivastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cerivastatin.
DB00007 DB00443 Betamethasone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Betamethasone.
DB00007 DB00471 Montelukast The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Montelukast.
DB00007 DB00495 Zidovudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Zidovudine.
DB00007 DB00501 Cimetidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cimetidine.
DB00007 DB00528 Lercanidipine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lercanidipine.
DB00007 DB00541 Vincristine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Vincristine.
DB00007 DB00550 Propylthiouracil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propylthiouracil.
DB00007 DB00584 Enalapril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Enalapril.
DB00007 DB00585 Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nizatidine.
DB00007 DB00602 Ivermectin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ivermectin.
DB00007 DB00620 Triamcinolone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triamcinolone.
DB00007 DB00627 Niacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Niacin.
DB00007 DB00630 Alendronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid.
DB00007 DB00636 Clofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Clofibrate.
DB00007 DB00649 Stavudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Stavudine.
DB00007 DB00666 Nafarelin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nafarelin.
DB00007 DB00688 Mycophenolate mofetil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mycophenolate mofetil.
DB00007 DB00704 Naltrexone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Naltrexone.
DB00007 DB00709 Lamivudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lamivudine.
DB00007 DB00857 Terbinafine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Terbinafine.
DB00007 DB00859 Penicillamine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Penicillamine.
DB00007 DB00863 Ranitidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ranitidine.
DB00007 DB00876 Eprosartan The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Eprosartan.
DB00007 DB00884 Risedronic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Risedronic acid.
DB00007 DB00887 Bumetanide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Bumetanide.
DB00007 DB00898 Ethanol The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ethanol.
DB00007 DB00968 Methyldopa The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methyldopa.
DB00007 DB00987 Cytarabine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine.
DB00007 DB01004 Ganciclovir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ganciclovir.
DB00007 DB01006 Letrozole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Letrozole.
DB00007 DB01017 Minocycline The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Minocycline.
DB00007 DB01039 Fenofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibrate.
DB00007 DB01076 Atorvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Atorvastatin.
DB00007 DB01088 Iloprost The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Iloprost.
DB00007 DB01095 Fluvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fluvastatin.
DB00007 DB01097 Leflunomide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Leflunomide.
DB00007 DB01098 Rosuvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Rosuvastatin.
DB00007 DB01168 Procarbazine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Procarbazine.
DB00007 DB01197 Captopril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Captopril.
DB00007 DB01241 Gemfibrozil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Gemfibrozil.
DB00007 DB01248 Docetaxel The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Docetaxel.
DB00007 DB01393 Bezafibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Bezafibrate.
DB00007 DB02703 Fusidic acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fusidic acid.
DB00007 DB05109 Trabectedin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trabectedin.
DB00007 DB06693 Mevastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mevastatin.
DB00007 DB06817 Raltegravir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Raltegravir.
DB00007 DB08860 Pitavastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pitavastatin.
DB00007 DB08983 Etofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Etofibrate.
DB00007 DB09055 Acipimox The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Acipimox.
DB00007 DB09064 Ciprofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ciprofibrate.
DB00007 DB09270 Ubidecarenone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ubidecarenone.
DB00007 DB12554 Mebeverine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mebeverine.
DB00007 DB13293 Ipecac The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ipecac.
DB00007 DB13393 Emetine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Emetine.
DB00007 DB13433 Simfibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Simfibrate.
DB00007 DB13460 Ronifibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ronifibrate.
DB00007 DB13780 Aluminium clofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Aluminium clofibrate.
DB00007 DB13849 Clofibride The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Clofibride.
DB00007 DB13873 Fenofibric acid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibric acid.
DB00007 DB00951 Isoniazid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isoniazid.
DB00007 DB00897 Triazolam The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triazolam.
DB00007 DB01394 Colchicine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Colchicine.
DB00007 DB00065 Infliximab The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab.
DB00007 DB00203 Sildenafil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Sildenafil.
DB00007 DB00224 Indinavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Indinavir.
DB00007 DB00227 Lovastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lovastatin.
DB00007 DB00252 Phenytoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Phenytoin.
DB00007 DB00641 Simvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Simvastatin.
DB00007 DB01229 Paclitaxel The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Paclitaxel.
DB00007 DB01234 Dexamethasone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Dexamethasone.
DB00007 DB09289 Tianeptine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tianeptine.
DB00007 DB00440 Trimethoprim The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trimethoprim.
DB00007 DB00331 Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.
DB00007 DB00656 Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Leuprolide.
DB00007 DB11986 Entrectinib The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib.
DB00007 DB11642 Pitolisant Leuprolide may increase the QTc-prolonging activities of Pitolisant.
DB00007 DB12825 Lefamulin Lefamulin may increase the QTc-prolonging activities of Leuprolide.
DB00007 DB00557 Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Leuprolide.
DB00007 DB00246 Ziprasidone The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ziprasidone.
DB00007 DB00502 Haloperidol The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol.
DB00007 DB00472 Fluoxetine The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluoxetine.
DB00008 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2a.
DB00008 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2a.
DB00008 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-n1.
DB00008 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-n3.
DB00008 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon alfa-2b.
DB00008 DB00026 Anakinra The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Anakinra.
DB00008 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon gamma-1b.
DB00008 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2a, Recombinant.
DB00008 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Adalimumab.
DB00008 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemtuzumab ozogamicin.
DB00008 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pegaspargase.
DB00008 DB00065 Infliximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Infliximab.
DB00008 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon beta-1b.
DB00008 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfacon-1.
DB00008 DB00073 Rituximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rituximab.
DB00008 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Basiliximab.
DB00008 DB00075 Muromonab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Muromonab.
DB00008 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibritumomab tiuxetan.
DB00008 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tositumomab.
DB00008 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alemtuzumab.
DB00008 DB00092 Alefacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Alefacept.
DB00008 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Efalizumab.
DB00008 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit).
DB00008 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2b.
DB00008 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daclizumab.
DB00008 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bevacizumab.
DB00008 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Phenylalanine.
DB00008 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Flunisolide.
DB00008 DB00188 Bortezomib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bortezomib.
DB00008 DB00242 Cladribine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cladribine.
DB00008 DB00262 Carmustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carmustine.
DB00008 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Amsacrine.
DB00008 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleomycin.
DB00008 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Chlorambucil.
DB00008 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Raltitrexed.
DB00008 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitomycin.
DB00008 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bexarotene.
DB00008 DB00309 Vindesine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vindesine.
DB00008 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Floxuridine.
DB00008 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Indomethacin.
DB00008 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tioguanine.
DB00008 DB00361 Vinorelbine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinorelbine.
DB00008 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexrazoxane.
DB00008 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Beclomethasone dipropionate.
DB00008 DB00398 Sorafenib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sorafenib.
DB00008 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Streptozocin.
DB00008 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trifluridine.
DB00008 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gemcitabine.
DB00008 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Betamethasone.
DB00008 DB00444 Teniposide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teniposide.
DB00008 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Epirubicin.
DB00008 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Chloramphenicol.
DB00008 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Lenalidomide.
DB00008 DB00488 Altretamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Altretamine.
DB00008 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cisplatin.
DB00008 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Oxaliplatin.
DB00008 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cyclophosphamide.
DB00008 DB00541 Vincristine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vincristine.
DB00008 DB00544 Fluorouracil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluorouracil.
DB00008 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Propylthiouracil.
DB00008 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pentostatin.
DB00008 DB00563 Methotrexate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methotrexate.
DB00008 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carbamazepine.
DB00008 DB00570 Vinblastine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vinblastine.
DB00008 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluticasone propionate.
DB00008 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocinolone acetonide.
DB00008 DB00601 Linezolid The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Linezolid.
DB00008 DB00619 Imatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Imatinib.
DB00008 DB00620 Triamcinolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Triamcinolone.
DB00008 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clofarabine.
DB00008 DB00635 Prednisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisone.
DB00008 DB00642 Pemetrexed The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pemetrexed.
DB00008 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fludrocortisone.
DB00008 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mycophenolate mofetil.
DB00008 DB00694 Daunorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin.
DB00008 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tretinoin.
DB00008 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Irinotecan.
DB00008 DB00763 Methimazole The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methimazole.
DB00008 DB00764 Mometasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mometasone.
DB00008 DB00773 Etoposide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Etoposide.
DB00008 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sulfasalazine.
DB00008 DB00851 Dacarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dacarbazine.
DB00008 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Temozolomide.
DB00008 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Penicillamine.
DB00008 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisolone.
DB00008 DB00877 Sirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sirolimus.
DB00008 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mechlorethamine.
DB00008 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Azacitidine.
DB00008 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carboplatin.
DB00008 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methylprednisolone.
DB00008 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dactinomycin.
DB00008 DB00987 Cytarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine.
DB00008 DB00993 Azathioprine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Azathioprine.
DB00008 DB00997 Doxorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Doxorubicin.
DB00008 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxyurea.
DB00008 DB01008 Busulfan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Busulfan.
DB00008 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mycophenolic acid.
DB00008 DB01030 Topotecan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Topotecan.
DB00008 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mercaptopurine.
DB00008 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thalidomide.
DB00008 DB01042 Melphalan The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Melphalan.
DB00008 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fludarabine.
DB00008 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Flucytosine.
DB00008 DB01101 Capecitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Capecitabine.
DB00008 DB01108 Trilostane The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trilostane.
DB00008 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Procarbazine.
DB00008 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Arsenic trioxide.
DB00008 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idarubicin.
DB00008 DB01181 Ifosfamide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ifosfamide.
DB00008 DB01196 Estramustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Estramustine.
DB00008 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mitoxantrone.
DB00008 DB01206 Lomustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Lomustine.
DB00008 DB01222 Budesonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Budesonide.
DB00008 DB01229 Paclitaxel The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Paclitaxel.
DB00008 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexamethasone.
DB00008 DB01248 Docetaxel The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Docetaxel.
DB00008 DB01254 Dasatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dasatinib.
DB00008 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eculizumab.
DB00008 DB01262 Decitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Decitabine.
DB00008 DB01268 Sunitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sunitinib.
DB00008 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Nelarabine.
DB00008 DB01281 Abatacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Abatacept.
DB00008 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Corticotropin.
DB00008 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cortisone acetate.
DB00008 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Paramethasone.
DB00008 DB01394 Colchicine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Colchicine.
DB00008 DB01410 Ciclesonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ciclesonide.
DB00008 DB01423 Stepronin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Stepronin.
DB00008 DB01590 Everolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Everolimus.
DB00008 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydroxychloroquine.
DB00008 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Castanospermine.
DB00008 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vorinostat.
DB00008 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with 2-Methoxyethanol.
DB00008 DB03523 Brequinar The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brequinar.
DB00008 DB04572 Thiotepa The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Thiotepa.
DB00008 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldosterone.
DB00008 DB04845 Ixabepilone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixabepilone.
DB00008 DB04868 Nilotinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Nilotinib.
DB00008 DB04951 Pirfenidone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pirfenidone.
DB00008 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Afelimomab.
DB00008 DB05015 Belinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belinostat.
DB00008 DB05109 Trabectedin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trabectedin.
DB00008 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa.
DB00008 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Glatiramer.
DB00008 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gallium nitrate.
DB00008 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Briakinumab.
DB00008 DB05472 omega interferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with omega interferon.
DB00008 DB05676 Apremilast The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Apremilast.
DB00008 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trastuzumab emtansine.
DB00008 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Canakinumab.
DB00008 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tocilizumab.
DB00008 DB06287 Temsirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Temsirolimus.
DB00008 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rilonacept.
DB00008 DB06589 Pazopanib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pazopanib.
DB00008 DB06603 Panobinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Panobinostat.
DB00008 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mepolizumab.
DB00008 DB06616 Bosutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bosutinib.
DB00008 DB06662 Abetimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Abetimus.
DB00008 DB06674 Golimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Golimumab.
DB00008 DB06681 Belatacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belatacept.
DB00008 DB06769 Bendamustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bendamustine.
DB00008 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cabazitaxel.
DB00008 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pralatrexate.
DB00008 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Wortmannin.
DB00008 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brentuximab vedotin.
DB00008 DB08871 Eribulin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eribulin.
DB00008 DB08877 Ruxolitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ruxolitinib.
DB00008 DB08879 Belimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belimumab.
DB00008 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Teriflunomide.
DB00008 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Carfilzomib.
DB00008 DB08901 Ponatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ponatinib.
DB00008 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Certolizumab pegol.
DB00008 DB08906 Fluticasone furoate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluticasone furoate.
DB00008 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dimethyl fumarate.
DB00008 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pomalidomide.
DB00008 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Obinutuzumab.
DB00008 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluprednidene.
DB00008 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocortolone.
DB00008 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Secukinumab.
DB00008 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vedolizumab.
DB00008 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siltuximab.
DB00008 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Blinatumomab.
DB00008 DB09053 Ibrutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ibrutinib.
DB00008 DB09054 Idelalisib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idelalisib.
DB00008 DB09073 Palbociclib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Palbociclib.
DB00008 DB09074 Olaparib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Olaparib.
DB00008 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dinutuximab.
DB00008 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vilanterol.
DB00008 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tixocortol.
DB00008 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon beta-1a.
DB00008 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antilymphocyte immunoglobulin (horse).
DB00008 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluprednisolone.
DB00008 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Meprednisone.
DB00008 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tepoxalin.
DB00008 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dexamethasone isonicotinate.
DB00008 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Melengestrol.
DB00008 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixekizumab.
DB00008 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ravulizumab.
DB00008 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pirarubicin.
DB00008 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Voclosporin.
DB00008 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peficitinib.
DB00008 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clobetasol.
DB00008 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sarilumab.
DB00008 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Brodalumab.
DB00008 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sirukumab.
DB00008 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Baricitinib.
DB00008 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Guselkumab.
DB00008 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Deflazacort.
DB00008 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ocrelizumab.
DB00008 DB12025 Triptolide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Triptolide.
DB00008 DB12371 Siponimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Siponimod.
DB00008 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ozanimod.
DB00008 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mizoribine.
DB00008 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Gusperimus.
DB00008 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cepeginterferon alfa-2B.
DB00008 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Trofosfamide.
DB00008 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Doxifluridine.
DB00008 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Deoxyspergualin.
DB00008 DB12996 Acteoside The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Acteoside.
DB00008 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cortivazol.
DB00008 DB13014 Hypericin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hypericin.
DB00008 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00008 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednylidene.
DB00008 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocortin.
DB00008 DB13241 Begelomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Begelomab.
DB00008 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluperolone.
DB00008 DB13664 Formocortal The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Formocortal.
DB00008 DB13728 Halometasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Halometasone.
DB00008 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cloprednol.
DB00008 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluclorolone.
DB00008 DB13867 Fluticasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluticasone.
DB00008 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Tetrandrine.
DB00008 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Monomethyl fumarate.
DB00008 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mometasone furoate.
DB00008 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydrocortisone aceponate.
DB00008 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydrocortisone acetate.
DB00008 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hydrocortisone succinate.
DB00008 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Emapalumab.
DB00008 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Risankizumab.
DB00008 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Rozanolixizumab.
DB00008 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleselumab.
DB00008 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Natalizumab.
DB00008 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Peginterferon alfa-2a.
DB00008 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Peginterferon alfa-2a.
DB00008 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.
DB00008 DB00363 Clozapine The risk or severity of neutropenia can be increased when Peginterferon alfa-2a is combined with Clozapine.
DB00008 DB00333 Methadone The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.
DB00008 DB01265 Telbivudine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine.
DB00008 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.
DB00008 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Peginterferon alfa-2a is combined with Peginesatide.
DB00008 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Peginterferon alfa-2a is combined with Methoxy polyethylene glycol-epoetin beta.
DB00008 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Peginterferon alfa-2a.
DB00008 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Peginterferon alfa-2a.
DB00008 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Peginterferon alfa-2a.
DB00008 DB04817 Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2a.
DB00008 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Leflunomide.
DB00008 DB08895 Tofacitinib Peginterferon alfa-2a may increase the immunosuppressive activities of Tofacitinib.
DB00008 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2a.
DB00008 DB00019 Pegfilgrastim The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB00061 Pegademase The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB00082 Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB01839 Propylene glycol The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB03394 Heptaethylene glycol The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB04895 Pegaptanib The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05202 Egaptivon pegol The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05321 PEG-uricase The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05860 Peginterferon alfacon-1 The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06022 GlycoPEG-GCSF The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06293 Pegnivacogin The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06325 Pegpleranib The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06611 Pegsunercept The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06811 Polidocanol The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB09208 Pegloticase The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB09287 Polyethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11077 Polyethylene glycol 400 The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11567 Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11661 Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11707 Olaptesed Pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB12258 Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB12578 Lexaptepid Pegol The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB12839 Pegvaliase The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB12842 Pegamotecan The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14712 Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB08868 Fingolimod Peginterferon alfa-2a may increase the immunosuppressive activities of Fingolimod.
DB00008 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2a.
DB00008 DB00201 Caffeine The metabolism of Caffeine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00651 Dyphylline The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01412 Theobromine The metabolism of Theobromine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01482 Fenethylline The metabolism of Fenethylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01667 8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01978 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB02134 Xanthine The metabolism of Xanthine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB02245 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB02377 Guanine The metabolism of Guanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB02568 Peldesine The metabolism of Peldesine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06479 Propentofylline The metabolism of Propentofylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06575 Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB07954 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB08844 Uric acid The metabolism of Uric acid can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09273 Doxofylline The metabolism of Doxofylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12406 Lisofylline The metabolism of Lisofylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12531 Lobucavir The metabolism of Lobucavir can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12926 Cafedrine The metabolism of Cafedrine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12927 Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13203 Bamifylline The metabolism of Bamifylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13449 Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13573 Acefylline The metabolism of Acefylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13592 Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13634 Pentifylline The metabolism of Pentifylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13812 Bufylline The metabolism of Bufylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB14029 Furafylline The metabolism of Furafylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB15122 PCS-499 The metabolism of PCS-499 can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00390 Digoxin Digoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB00511 Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB01078 Deslanoside Deslanoside may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB01092 Ouabain Ouabain may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB01396 Digitoxin Digitoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB12843 Oleandrin Oleandrin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13240 Cymarin Cymarin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13307 Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13401 Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13467 Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13537 Gitoformate Gitoformate may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13691 Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB13756 Peruvoside Peruvoside may decrease the cardiotoxic activities of Peginterferon alfa-2a.
DB00008 DB01217 Anastrozole The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Anastrozole.
DB00008 DB06013 Aldoxorubicin The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Aldoxorubicin.
DB00008 DB06171 Paclitaxel trevatide The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Paclitaxel trevatide.
DB00008 DB13809 Paclitaxel poliglumex The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Paclitaxel poliglumex.
DB00008 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Peginterferon alfa-2a.
DB00008 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2a.
DB00008 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Peginterferon alfa-2a.
DB00008 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Peginterferon alfa-2a.
DB00008 DB00945 Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2a.
DB00008 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2a.
DB00008 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Peginterferon alfa-2a.
DB00008 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2a.
DB00008 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Peginterferon alfa-2a.
DB00008 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Peginterferon alfa-2a.
DB00008 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Peginterferon alfa-2a.
DB00008 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Peginterferon alfa-2a.
DB00008 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Peginterferon alfa-2a.
DB00008 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2a.
DB00008 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Peginterferon alfa-2a.
DB00008 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Peginterferon alfa-2a.
DB00008 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Peginterferon alfa-2a.
DB00008 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2a.
DB00008 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Peginterferon alfa-2a.
DB00008 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Peginterferon alfa-2a.
DB00008 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Peginterferon alfa-2a.
DB00008 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Peginterferon alfa-2a.
DB00008 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2a.
DB00008 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon alfa-2a.
DB00008 DB09030 Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Peginterferon alfa-2a.
DB00008 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Peginterferon alfa-2a.
DB00008 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Peginterferon alfa-2a.
DB00008 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Peginterferon alfa-2a.
DB00008 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Peginterferon alfa-2a.
DB00008 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Peginterferon alfa-2a.
DB00008 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Peginterferon alfa-2a.
DB00008 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Peginterferon alfa-2a.
DB00008 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Peginterferon alfa-2a.
DB00008 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Peginterferon alfa-2a.
DB00008 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Peginterferon alfa-2a.
DB00008 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Peginterferon alfa-2a.
DB00008 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Peginterferon alfa-2a.
DB00008 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Peginterferon alfa-2a.
DB00008 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Peginterferon alfa-2a.
DB00008 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Peginterferon alfa-2a.
DB00008 DB13200 Lipegfilgrastim Peginterferon alfa-2a may increase the myelosuppressive activities of Lipegfilgrastim.
DB00008 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Peginterferon alfa-2a is combined with Varicella Zoster Vaccine (Live/attenuated).
DB00008 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Peginterferon alfa-2a.
DB00008 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Peginterferon alfa-2a.
DB00008 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Peginterferon alfa-2a.
DB00008 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Peginterferon alfa-2a.
DB00008 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Peginterferon alfa-2a.
DB00008 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Peginterferon alfa-2a.
DB00008 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Peginterferon alfa-2a.
DB00008 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Peginterferon alfa-2a.
DB00008 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Peginterferon alfa-2a.
DB00008 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Peginterferon alfa-2a.
DB00008 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Peginterferon alfa-2a.
DB00008 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00184 Nicotine The metabolism of Nicotine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00195 Betaxolol The metabolism of Betaxolol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00261 Anagrelide The metabolism of Anagrelide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00280 Disopyramide The metabolism of Disopyramide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00281 Lidocaine The metabolism of Lidocaine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00296 Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00316 Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00334 Olanzapine The metabolism of Olanzapine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00370 Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00379 Mexiletine The metabolism of Mexiletine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00382 Tacrine The metabolism of Tacrine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00384 Triamterene The metabolism of Triamterene can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00420 Promazine The metabolism of Promazine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00425 Zolpidem The metabolism of Zolpidem can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00442 Entecavir The metabolism of Entecavir can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00461 Nabumetone The metabolism of Nabumetone can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00468 Quinine The metabolism of Quinine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00472 Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00476 Duloxetine The metabolism of Duloxetine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00499 Flutamide The metabolism of Flutamide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00502 Haloperidol The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00518 Albendazole The metabolism of Albendazole can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00533 Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00568 Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00571 Propranolol The metabolism of Propranolol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00586 Diclofenac The metabolism of Diclofenac can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00629 Guanabenz The metabolism of Guanabenz can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00661 Verapamil The metabolism of Verapamil can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00715 Paroxetine The metabolism of Paroxetine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00730 Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00740 Riluzole The metabolism of Riluzole can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00744 Zileuton The metabolism of Zileuton can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00758 Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00783 Estradiol The metabolism of Estradiol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00787 Acyclovir The metabolism of Acyclovir can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00788 Naproxen The metabolism of Naproxen can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00850 Perphenazine The metabolism of Perphenazine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00857 Terbinafine The metabolism of Terbinafine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00863 Ranitidine The metabolism of Ranitidine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00898 Ethanol The metabolism of Ethanol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00934 Maprotiline The metabolism of Maprotiline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00969 Alosetron The metabolism of Alosetron can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00980 Ramelteon The metabolism of Ramelteon can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00998 Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01012 Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01037 Selegiline The metabolism of Selegiline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01056 Tocainide The metabolism of Tocainide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01058 Praziquantel The metabolism of Praziquantel can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01065 Melatonin The metabolism of Melatonin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01087 Primaquine The metabolism of Primaquine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01094 Hesperetin The metabolism of Hesperetin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01115 Nifedipine The metabolism of Nifedipine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01136 Carvedilol The metabolism of Carvedilol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01166 Cilostazol The metabolism of Cilostazol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01182 Propafenone The metabolism of Propafenone can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01184 Domperidone The metabolism of Domperidone can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01367 Rasagiline The metabolism of Rasagiline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01405 Temafloxacin The metabolism of Temafloxacin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01424 Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01435 Antipyrine The metabolism of Antipyrine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01558 Bromazepam The metabolism of Bromazepam can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01623 Thiothixene The metabolism of Thiothixene can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01628 Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01645 Genistein The metabolism of Genistein can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB02709 Resveratrol The metabolism of Resveratrol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB03783 Phenacetin The metabolism of Phenacetin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04841 Flunarizine The metabolism of Flunarizine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04871 Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04948 Lofexidine The metabolism of Lofexidine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06148 Mianserin The metabolism of Mianserin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06210 Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06216 Asenapine The metabolism of Asenapine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06235 Vadimezan The metabolism of Vadimezan can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06594 Agomelatine The metabolism of Agomelatine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06626 Axitinib The metabolism of Axitinib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB06774 Capsaicin The metabolism of Capsaicin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB08883 Perampanel The metabolism of Perampanel can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09071 Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09118 Stiripentol The metabolism of Stiripentol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09225 Zotepine The metabolism of Zotepine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09288 Propacetamol The metabolism of Propacetamol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09290 Ramosetron The metabolism of Ramosetron can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB11967 Binimetinib The metabolism of Binimetinib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12245 Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12332 Rucaparib The metabolism of Rucaparib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB12945 Dihydralazine The metabolism of Dihydralazine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB11757 Istradefylline The metabolism of Istradefylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00972 Azelastine The metabolism of Azelastine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00625 Efavirenz The metabolism of Efavirenz can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01233 Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB04889 Bicifadine The metabolism of Bicifadine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB05708 GTS-21 The metabolism of GTS-21 can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01195 Flecainide The metabolism of Flecainide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00321 Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00458 Imipramine The metabolism of Imipramine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01142 Doxepin The metabolism of Doxepin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00532 Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00540 Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00575 Clonidine The metabolism of Clonidine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01151 Desipramine The metabolism of Desipramine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01242 Clomipramine The metabolism of Clomipramine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB11689 Selumetinib The metabolism of Selumetinib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00675 Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00277 Theophylline The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00682 Warfarin The metabolism of Warfarin can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00697 Tizanidine The metabolism of Tizanidine can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01100 Pimozide The metabolism of Pimozide can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01223 Aminophylline The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00530 Erlotinib The metabolism of Erlotinib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB09256 Tegafur The metabolism of Tegafur can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB13874 Enasidenib The metabolism of Enasidenib can be decreased when combined with Peginterferon alfa-2a.
DB00008 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.
DB00008 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Peginterferon alfa-2a.
DB00008 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Peginterferon alfa-2a.
DB00008 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Peginterferon alfa-2a.
DB00008 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2a.
DB00008 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Peginterferon alfa-2a.
DB00008 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Peginterferon alfa-2a.
DB00008 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2a.
DB00008 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2a.
DB00008 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Peginterferon alfa-2a.
DB00008 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Peginterferon alfa-2a.
DB00008 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Peginterferon alfa-2a.
DB00008 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Peginterferon alfa-2a.
DB00008 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Peginterferon alfa-2a.
DB00008 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Peginterferon alfa-2a.
DB00008 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Peginterferon alfa-2a.
DB00008 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Peginterferon alfa-2a.
DB00008 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Peginterferon alfa-2a.
DB00008 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Peginterferon alfa-2a.
DB00008 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Peginterferon alfa-2a.
DB00008 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Peginterferon alfa-2a.
DB00008 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Peginterferon alfa-2a.
DB00008 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Peginterferon alfa-2a.
DB00008 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Peginterferon alfa-2a.
DB00008 DB06228 Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Peginterferon alfa-2a.
DB00008 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Peginterferon alfa-2a.
DB00008 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Peginterferon alfa-2a.
DB00008 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Peginterferon alfa-2a.
DB00008 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Peginterferon alfa-2a.
DB00008 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Peginterferon alfa-2a.
DB00008 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Peginterferon alfa-2a.
DB00008 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Peginterferon alfa-2a.
DB00008 DB06695 Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Peginterferon alfa-2a.
DB00008 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Peginterferon alfa-2a.
DB00008 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Peginterferon alfa-2a.
DB00008 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Peginterferon alfa-2a.
DB00008 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Peginterferon alfa-2a.
DB00008 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Peginterferon alfa-2a.
DB00008 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Peginterferon alfa-2a.
DB00008 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Peginterferon alfa-2a.
DB00008 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Peginterferon alfa-2a.
DB00008 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Peginterferon alfa-2a.
DB00008 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Peginterferon alfa-2a.
DB00008 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Peginterferon alfa-2a.
DB00008 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Peginterferon alfa-2a.
DB00008 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Peginterferon alfa-2a.
DB00008 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Peginterferon alfa-2a.
DB00008 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Peginterferon alfa-2a.
DB00008 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Peginterferon alfa-2a.
DB00008 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Peginterferon alfa-2a.
DB00008 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Peginterferon alfa-2a.
DB00008 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Peginterferon alfa-2a.
DB00008 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Peginterferon alfa-2a.
DB00008 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Peginterferon alfa-2a.
DB00008 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Peginterferon alfa-2a.
DB00008 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Peginterferon alfa-2a.
DB00008 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Peginterferon alfa-2a.
DB00008 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Peginterferon alfa-2a.
DB00008 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Peginterferon alfa-2a.
DB00008 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Peginterferon alfa-2a.
DB00008 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Peginterferon alfa-2a.
DB00008 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Peginterferon alfa-2a.
DB00008 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Peginterferon alfa-2a.
DB00008 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Peginterferon alfa-2a.
DB00008 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Peginterferon alfa-2a.
DB00008 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Peginterferon alfa-2a.
DB00008 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Peginterferon alfa-2a.
DB00008 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Peginterferon alfa-2a.
DB00008 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Peginterferon alfa-2a.
DB00008 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Peginterferon alfa-2a.
DB00008 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon alfa-2a.
DB00008 DB00232 Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2a.
DB00008 DB00436 Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Peginterferon alfa-2a.
DB00008 DB00562 Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Peginterferon alfa-2a.
DB00008 DB00606 Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Peginterferon alfa-2a.
DB00008 DB00774 Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Peginterferon alfa-2a.
DB00008 DB00880 Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Peginterferon alfa-2a.
DB00008 DB00999 Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Peginterferon alfa-2a.
DB00008 DB01021 Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Peginterferon alfa-2a.
DB00008 DB01324 Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Peginterferon alfa-2a.
DB00008 DB13430 Mebutizide The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Peginterferon alfa-2a.
DB00008 DB13532 Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Peginterferon alfa-2a.
DB00008 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Peginterferon alfa-2a is combined with Tedizolid phosphate.
DB00008 DB00091 Cyclosporine Peginterferon alfa-2a may increase the immunosuppressive activities of Cyclosporine.
DB00008 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ropinirole.
DB00008 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2a.
DB00008 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Peginterferon alfa-2a.
DB00008 DB12978 Pexidartinib Peginterferon alfa-2a may increase the hepatotoxic activities of Pexidartinib.
DB00008 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Peginterferon alfa-2a.
DB00008 DB01601 Lopinavir The serum concentration of Peginterferon alfa-2a can be increased when it is combined with Lopinavir.
DB00008 DB12530 Inebilizumab The risk or severity of infection can be increased when Peginterferon alfa-2a is combined with Inebilizumab.
DB00009 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Alteplase.
DB00009 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Alteplase.
DB00009 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Alteplase.
DB00009 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Alteplase is combined with Deferasirox.
DB00009 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Ursodeoxycholic acid.
DB00009 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Glycochenodeoxycholic Acid.
DB00009 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Cholic Acid.
DB00009 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Glycocholic acid.
DB00009 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Deoxycholic acid.
DB00009 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Taurocholic acid.
DB00009 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Obeticholic acid.
DB00009 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Chenodeoxycholic acid.
DB00009 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Taurochenodeoxycholic acid.
DB00009 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Tauroursodeoxycholic acid.
DB00009 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Bamet-UD2.
DB00009 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Dehydrocholic acid.
DB00009 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Hyodeoxycholic Acid.
DB00009 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Alteplase.
DB00009 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Alteplase.
DB00009 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Obinutuzumab.
DB00009 DB06228 Rivaroxaban Alteplase may increase the anticoagulant activities of Rivaroxaban.
DB00009 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Sugammadex.
DB00009 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Alteplase.
DB00009 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Alteplase.
DB00009 DB00013 Urokinase Urokinase may increase the anticoagulant activities of Alteplase.
DB00009 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Alteplase.
DB00009 DB09030 Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Alteplase.
DB00009 DB06692 Aprotinin The therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin.
DB00009 DB00727 Nitroglycerin The serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin.
DB00009 DB01381 Ginkgo biloba The therapeutic efficacy of Alteplase can be increased when used in combination with Ginkgo biloba.
DB00009 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Alteplase.
DB00009 DB00468 Quinine The therapeutic efficacy of Alteplase can be increased when used in combination with Quinine.
DB00009 DB00908 Quinidine The therapeutic efficacy of Alteplase can be increased when used in combination with Quinidine.
DB00009 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Alteplase.
DB00009 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Alteplase.
DB00009 DB00806 Pentoxifylline The therapeutic efficacy of Alteplase can be increased when used in combination with Pentoxifylline.
DB00009 DB00686 Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Alteplase.
DB00009 DB00583 Levocarnitine The therapeutic efficacy of Alteplase can be increased when used in combination with Levocarnitine.
DB00009 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Alteplase.
DB00009 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Alteplase.
DB00009 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Alteplase.
DB00009 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Alteplase.
DB00009 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Alteplase.
DB00009 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Alteplase.
DB00009 DB04573 Estriol Estriol may decrease the anticoagulant activities of Alteplase.
DB00009 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Alteplase.
DB00009 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Alteplase.
DB00009 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Alteplase.
DB00009 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Alteplase.
DB00009 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Alteplase.
DB00009 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Alteplase.
DB00009 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Alteplase.
DB00009 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Alteplase.
DB00009 DB11674 Equol Equol may decrease the anticoagulant activities of Alteplase.
DB00009 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Alteplase.
DB00009 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Alteplase.
DB00009 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Alteplase.
DB00009 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Alteplase.
DB00009 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Alteplase.
DB00009 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Alteplase.
DB00009 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Alteplase.
DB00009 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Alteplase.
DB00009 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Alteplase.
DB00009 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Alteplase.
DB00009 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Alteplase.
DB00009 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Alteplase.
DB00009 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Alteplase.
DB00009 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Alteplase.
DB00009 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Alteplase.
DB00009 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Alteplase.
DB00009 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Alteplase.
DB00009 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Alteplase.
DB00009 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Alteplase.
DB00009 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Alteplase.
DB00009 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Alteplase.
DB00009 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Alteplase.
DB00009 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Alteplase.
DB00009 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Alteplase.
DB00009 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Alteplase.
DB00009 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Alteplase.
DB00009 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Alteplase.
DB00009 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Alteplase.
DB00009 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Alteplase.
DB00009 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Alteplase.
DB00009 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Alteplase.
DB00009 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Alteplase.
DB00009 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Alteplase.
DB00009 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Alteplase.
DB00009 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Alteplase.
DB00009 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Alteplase.
DB00009 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Alteplase.
DB00009 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Alteplase.
DB00009 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Alteplase.
DB00009 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Alteplase.
DB00009 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Alteplase.
DB00009 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Alteplase.
DB00009 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Alteplase.
DB00009 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Alteplase.
DB00009 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Alteplase.
DB00009 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Alteplase.
DB00009 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Alteplase.
DB00009 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Alteplase.
DB00009 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Alteplase.
DB00009 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Alteplase.
DB00009 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Alteplase.
DB00009 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Alteplase.
DB00009 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Alteplase.
DB00009 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Alteplase.
DB00009 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Alteplase.
DB00009 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Alteplase.
DB00009 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Alteplase.
DB00009 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Alteplase.
DB00009 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Alteplase.
DB00009 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Alteplase.
DB00009 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Alteplase.
DB00009 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Alteplase.
DB00009 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Alteplase.
DB00009 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Alteplase.
DB00009 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Alteplase.
DB00009 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Alteplase.
DB00009 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Alteplase.
DB00009 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Alteplase.
DB00009 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Alteplase.
DB00009 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Alteplase.
DB00009 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Alteplase.
DB00009 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Alteplase.
DB00009 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Alteplase.
DB00009 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Alteplase.
DB00009 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Alteplase.
DB00009 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Alteplase.
DB00009 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Alteplase.
DB00009 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Alteplase.
DB00009 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Alteplase.
DB00009 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Alteplase.
DB00009 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Alteplase.
DB00009 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Alteplase.
DB00009 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Alteplase.
DB00009 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Alteplase.
DB00009 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Alteplase.
DB00009 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Alteplase.
DB00009 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Alteplase.
DB00009 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Alteplase.
DB00009 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Alteplase.
DB00009 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Alteplase.
DB00009 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Alteplase.
DB00009 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Alteplase.
DB00009 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Alteplase.
DB00009 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Alteplase.
DB00009 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Alteplase.
DB00009 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Alteplase.
DB00009 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Alteplase.
DB00009 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Alteplase.
DB00009 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Alteplase.
DB00009 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Alteplase.
DB00009 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Alteplase.
DB00009 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Alteplase.
DB00009 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Alteplase.
DB00009 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Alteplase.
DB00009 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Alteplase.
DB00009 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Alteplase.
DB00009 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Alteplase.
DB00009 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Alteplase.
DB00009 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Alteplase.
DB00009 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Alteplase.
DB00009 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Alteplase.
DB00009 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Alteplase.
DB00009 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Alteplase.
DB00009 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Alteplase is combined with Omacetaxine mepesuccinate.
DB00009 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Alteplase.
DB00009 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Tositumomab.
DB00009 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Alteplase.
DB00009 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Alteplase is combined with Collagenase clostridium histolyticum.
DB00009 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Alteplase.
DB00009 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Alteplase.
DB00009 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Alteplase.
DB00009 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Alteplase.
DB00009 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Alteplase.
DB00009 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Alteplase.
DB00009 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Alteplase.
DB00009 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Alteplase.
DB00009 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Alteplase.
DB00009 DB00834 Mifepristone The therapeutic efficacy of Alteplase can be decreased when used in combination with Mifepristone.
DB00009 DB04066 p-Coumaric acid The therapeutic efficacy of Alteplase can be decreased when used in combination with p-Coumaric acid.
DB00009 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Alteplase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00009 DB05830 Trestolone The therapeutic efficacy of Alteplase can be decreased when used in combination with Trestolone.
DB00009 DB06266 Lonidamine The therapeutic efficacy of Alteplase can be decreased when used in combination with Lonidamine.
DB00009 DB08867 Ulipristal The therapeutic efficacy of Alteplase can be decreased when used in combination with Ulipristal.
DB00009 DB09401 Isosorbide The therapeutic efficacy of Alteplase can be decreased when used in combination with Isosorbide.
DB00009 DB11507 Cloprostenol The therapeutic efficacy of Alteplase can be decreased when used in combination with Cloprostenol.
DB00009 DB12025 Triptolide The therapeutic efficacy of Alteplase can be decreased when used in combination with Triptolide.
DB00009 DB13044 Gossypol The therapeutic efficacy of Alteplase can be decreased when used in combination with Gossypol.
DB00009 DB13310 Ormeloxifene The therapeutic efficacy of Alteplase can be decreased when used in combination with Ormeloxifene.
DB00009 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Alteplase.
DB00009 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Alteplase.
DB00009 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Alteplase.
DB00009 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Alteplase.
DB00009 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Alteplase.
DB00009 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Alteplase.
DB00009 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Alteplase.
DB00009 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Alteplase.
DB00009 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Alteplase.
DB00009 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Alteplase.
DB00009 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Alteplase.
DB00009 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Alteplase.
DB00009 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Alteplase.
DB00009 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Alteplase.
DB00009 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Alteplase.
DB00009 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Alteplase.
DB00009 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Alteplase.
DB00009 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Alteplase.
DB00009 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Alteplase.
DB00009 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Alteplase.
DB00009 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Alteplase.
DB00009 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Alteplase.
DB00009 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Alteplase.
DB00009 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Alteplase.
DB00009 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Alteplase.
DB00009 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Alteplase.
DB00009 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Alteplase.
DB00009 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Alteplase.
DB00009 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Alteplase.
DB00009 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Alteplase.
DB00009 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Alteplase.
DB00009 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Alteplase.
DB00009 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Alteplase.
DB00009 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Alteplase.
DB00009 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Alteplase.
DB00009 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Alteplase.
DB00009 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Alteplase.
DB00009 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Alteplase.
DB00009 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Alteplase.
DB00009 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Alteplase.
DB00009 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Alteplase.
DB00009 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Alteplase.
DB00009 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Alteplase.
DB00009 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Alteplase.
DB00009 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Alteplase.
DB00009 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Alteplase.
DB00009 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Alteplase.
DB00009 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Alteplase.
DB00009 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alteplase.
DB00009 DB01166 Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Alteplase.
DB00009 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Alteplase.
DB00009 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Alteplase.
DB00009 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Alteplase.
DB00009 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Alteplase.
DB00009 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Alteplase.
DB00009 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Alteplase.
DB00009 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Alteplase.
DB00009 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Alteplase.
DB00009 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Alteplase.
DB00009 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Alteplase.
DB00009 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Alteplase.
DB00009 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Alteplase.
DB00009 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Alteplase.
DB00009 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Alteplase.
DB00009 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Alteplase.
DB00009 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Alteplase.
DB00009 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alteplase.
DB00009 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Alteplase.
DB00009 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Alteplase.
DB00009 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Alteplase.
DB00009 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Alteplase.
DB00009 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Alteplase.
DB00009 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Alteplase.
DB00009 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Alteplase.
DB00009 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Alteplase.
DB00009 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Alteplase.
DB00009 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Alteplase.
DB00009 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Alteplase.
DB00009 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Alteplase.
DB00009 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Alteplase.
DB00009 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Alteplase.
DB00009 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Alteplase.
DB00009 DB00374 Treprostinil The risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.
DB00009 DB03404 Hemin Hemin may increase the anticoagulant activities of Alteplase.
DB00009 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Alteplase.
DB00009 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Alteplase.
DB00009 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Alteplase.
DB00009 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Alteplase.
DB00009 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Alteplase.
DB00009 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Alteplase.
DB00009 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Alteplase.
DB00009 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Alteplase.
DB00009 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Alteplase.
DB00009 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Alteplase.
DB00009 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Alteplase.
DB00009 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Alteplase.
DB00009 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Alteplase.
DB00009 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Alteplase.
DB00009 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Alteplase.
DB00009 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Alteplase.
DB00009 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Alteplase is combined with Azficel-T.
DB00009 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Alteplase can be increased when used in combination with Omega-3-carboxylic acids.
DB00009 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Alteplase.
DB00009 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Alteplase.
DB00009 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Alteplase.
DB00009 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Alteplase.
DB00009 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Alteplase.
DB00009 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Alteplase.
DB00009 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Alteplase.
DB00009 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Alteplase.
DB00009 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Alteplase.
DB00009 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Alteplase.
DB00009 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Alteplase.
DB00009 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Alteplase.
DB00009 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Alteplase.
DB00009 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Alteplase.
DB00009 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Alteplase.
DB00009 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Alteplase.
DB00009 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Alteplase.
DB00009 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Alteplase.
DB00009 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Alteplase.
DB00009 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Alteplase.
DB00009 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Alteplase.
DB00009 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Alteplase.
DB00009 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Alteplase.
DB00009 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Alteplase.
DB00009 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Alteplase.
DB00009 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Alteplase.
DB00009 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Alteplase.
DB00009 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Alteplase.
DB00009 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Alteplase.
DB00009 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Alteplase.
DB00009 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Alteplase.
DB00009 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Alteplase.
DB00009 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Alteplase.
DB00009 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Alteplase.
DB00009 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Alteplase.
DB00009 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Alteplase.
DB00009 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Alteplase.
DB00009 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Alteplase.
DB00009 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Alteplase.
DB00009 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Alteplase.
DB00009 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Alteplase.
DB00009 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Alteplase.
DB00009 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Alteplase.
DB00009 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Alteplase.
DB00009 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Alteplase.
DB00009 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Alteplase.
DB00009 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Alteplase.
DB00009 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Alteplase.
DB00009 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Alteplase.
DB00009 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Alteplase.
DB00009 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Alteplase.
DB00009 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Alteplase.
DB00009 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Alteplase.
DB00009 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Alteplase.
DB00009 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Alteplase.
DB00009 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Alteplase.
DB00009 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Alteplase.
DB00009 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Alteplase.
DB00009 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Alteplase.
DB00009 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Alteplase.
DB00009 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Alteplase.
DB00009 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Alteplase.
DB00009 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Alteplase.
DB00009 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Alteplase.
DB00009 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Alteplase.
DB00009 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Alteplase.
DB00009 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Alteplase.
DB00009 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Alteplase.
DB00009 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Alteplase.
DB00009 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Alteplase.
DB00009 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Alteplase.
DB00009 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Alteplase.
DB00009 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Alteplase.
DB00009 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Alteplase.
DB00009 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Alteplase.
DB00009 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Alteplase.
DB00009 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Alteplase.
DB00009 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Alteplase.
DB00009 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Alteplase.
DB00009 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Alteplase.
DB00009 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Alteplase.
DB00009 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Alteplase.
DB00009 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Alteplase.
DB00009 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Alteplase.
DB00009 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Alteplase.
DB00009 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Alteplase.
DB00009 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Alteplase.
DB00009 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Alteplase.
DB00009 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Alteplase.
DB00009 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Alteplase.
DB00009 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Alteplase.
DB00009 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Alteplase.
DB00009 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Alteplase.
DB00009 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Alteplase.
DB00009 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Alteplase.
DB00009 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Alteplase.
DB00009 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Alteplase.
DB00009 DB00682 Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Alteplase.
DB00009 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Alteplase.
DB00009 DB00974 Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Alteplase.
DB00009 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Alteplase.
DB00009 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Alteplase.
DB00009 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Alteplase.
DB00009 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Alteplase.
DB00009 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Alteplase.
DB00009 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Alteplase.
DB00009 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Alteplase.
DB00009 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Alteplase.
DB00009 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Alteplase.
DB00009 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Alteplase.
DB00009 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Alteplase.
DB00009 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Alteplase.
DB00009 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Alteplase.
DB00009 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Alteplase.
DB00009 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Alteplase.
DB00009 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Alteplase.
DB00009 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Alteplase.
DB00009 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Alteplase.
DB00009 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Alteplase.
DB00009 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Alteplase.
DB00009 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Alteplase.
DB00009 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Alteplase.
DB00009 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Alteplase.
DB00009 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Alteplase.
DB00009 DB13124 Troxerutin The risk or severity of bleeding can be increased when Troxerutin is combined with Alteplase.
DB00009 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Alteplase.
DB00009 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Alteplase.
DB00009 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Alteplase.
DB00009 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Alteplase.
DB00009 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Alteplase.
DB00009 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Alteplase.
DB00009 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Alteplase.
DB00009 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Alteplase.
DB00009 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Alteplase.
DB00009 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Alteplase.
DB00009 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Alteplase.
DB00009 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Alteplase.
DB00009 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Alteplase.
DB00009 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Alteplase.
DB00009 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Alteplase.
DB00009 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Alteplase.
DB00009 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Alteplase.
DB00009 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Alteplase.
DB00009 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Alteplase.
DB00009 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Alteplase.
DB00009 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Alteplase.
DB00009 DB00015 Reteplase The risk or severity of bleeding can be increased when Alteplase is combined with Reteplase.
DB00009 DB00029 Anistreplase The risk or severity of bleeding can be increased when Alteplase is combined with Anistreplase.
DB00009 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Alteplase is combined with Tocopherylquinone.
DB00009 DB06679 Amediplase The risk or severity of bleeding can be increased when Alteplase is combined with Amediplase.
DB00009 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Alteplase is combined with 4-hydroxycoumarin.
DB00009 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Alteplase is combined with (R)-warfarin.
DB00009 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Alteplase is combined with (S)-Warfarin.
DB00009 DB12364 Betrixaban The risk or severity of bleeding can be increased when Alteplase is combined with Betrixaban.
DB00009 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Alteplase is combined with Edetate calcium disodium anhydrous.
DB00009 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Alteplase is combined with Zinc citrate.
DB00009 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Alteplase is combined with Antithrombin Alfa.
DB00009 DB04665 Coumarin The risk or severity of bleeding can be increased when Alteplase is combined with Coumarin.
DB00009 DB14726 Dabigatran The risk or severity of bleeding can be increased when Alteplase is combined with Dabigatran.
DB00009 DB06294 Semuloparin The risk or severity of bleeding can be increased when Alteplase is combined with Semuloparin.
DB00009 DB12726 Monteplase The risk or severity of bleeding can be increased when Alteplase is combined with Monteplase.
DB00009 DB00177 Valsartan The risk or severity of angioedema can be increased when Alteplase is combined with Valsartan.
DB00009 DB00178 Ramipril The risk or severity of angioedema can be increased when Alteplase is combined with Ramipril.
DB00009 DB00230 Pregabalin The risk or severity of angioedema can be increased when Alteplase is combined with Pregabalin.
DB00009 DB00492 Fosinopril The risk or severity of angioedema can be increased when Alteplase is combined with Fosinopril.
DB00009 DB00519 Trandolapril The risk or severity of angioedema can be increased when Alteplase is combined with Trandolapril.
DB00009 DB00542 Benazepril The risk or severity of angioedema can be increased when Alteplase is combined with Benazepril.
DB00009 DB00584 Enalapril The risk or severity of angioedema can be increased when Alteplase is combined with Enalapril.
DB00009 DB00678 Losartan The risk or severity of angioedema can be increased when Alteplase is combined with Losartan.
DB00009 DB00691 Moexipril The risk or severity of angioedema can be increased when Alteplase is combined with Moexipril.
DB00009 DB00722 Lisinopril The risk or severity of angioedema can be increased when Alteplase is combined with Lisinopril.
DB00009 DB00790 Perindopril The risk or severity of angioedema can be increased when Alteplase is combined with Perindopril.
DB00009 DB00876 Eprosartan The risk or severity of angioedema can be increased when Alteplase is combined with Eprosartan.
DB00009 DB00877 Sirolimus The risk or severity of angioedema can be increased when Alteplase is combined with Sirolimus.
DB00009 DB00881 Quinapril The risk or severity of angioedema can be increased when Alteplase is combined with Quinapril.
DB00009 DB00886 Omapatrilat The risk or severity of angioedema can be increased when Alteplase is combined with Omapatrilat.
DB00009 DB00966 Telmisartan The risk or severity of angioedema can be increased when Alteplase is combined with Telmisartan.
DB00009 DB01050 Ibuprofen The risk or severity of angioedema can be increased when Alteplase is combined with Ibuprofen.
DB00009 DB01180 Rescinnamine The risk or severity of angioedema can be increased when Alteplase is combined with Rescinnamine.
DB00009 DB01197 Captopril The risk or severity of angioedema can be increased when Alteplase is combined with Captopril.
DB00009 DB01261 Sitagliptin The risk or severity of angioedema can be increased when Alteplase is combined with Sitagliptin.
DB00009 DB01340 Cilazapril The risk or severity of angioedema can be increased when Alteplase is combined with Cilazapril.
DB00009 DB01342 Forasartan The risk or severity of angioedema can be increased when Alteplase is combined with Forasartan.
DB00009 DB01347 Saprisartan The risk or severity of angioedema can be increased when Alteplase is combined with Saprisartan.
DB00009 DB01348 Spirapril The risk or severity of angioedema can be increased when Alteplase is combined with Spirapril.
DB00009 DB04876 Vildagliptin The risk or severity of angioedema can be increased when Alteplase is combined with Vildagliptin.
DB00009 DB06011 AMG-222 The risk or severity of angioedema can be increased when Alteplase is combined with AMG-222.
DB00009 DB06127 Bisegliptin The risk or severity of angioedema can be increased when Alteplase is combined with Bisegliptin.
DB00009 DB06196 Icatibant The risk or severity of angioedema can be increased when Alteplase is combined with Icatibant.
DB00009 DB06203 Alogliptin The risk or severity of angioedema can be increased when Alteplase is combined with Alogliptin.
DB00009 DB06245 Lanoteplase The risk or severity of angioedema can be increased when Alteplase is combined with Lanoteplase.
DB00009 DB06287 Temsirolimus The risk or severity of angioedema can be increased when Alteplase is combined with Temsirolimus.
DB00009 DB06335 Saxagliptin The risk or severity of angioedema can be increased when Alteplase is combined with Saxagliptin.
DB00009 DB08382 Gosogliptin The risk or severity of angioedema can be increased when Alteplase is combined with Gosogliptin.
DB00009 DB08822 Azilsartan medoxomil The risk or severity of angioedema can be increased when Alteplase is combined with Azilsartan medoxomil.
DB00009 DB08836 Temocapril The risk or severity of angioedema can be increased when Alteplase is combined with Temocapril.
DB00009 DB08882 Linagliptin The risk or severity of angioedema can be increased when Alteplase is combined with Linagliptin.
DB00009 DB09292 Sacubitril The risk or severity of angioedema can be increased when Alteplase is combined with Sacubitril.
DB00009 DB09477 Enalaprilat The risk or severity of angioedema can be increased when Alteplase is combined with Enalaprilat.
DB00009 DB11723 Dutogliptin The risk or severity of angioedema can be increased when Alteplase is combined with Dutogliptin.
DB00009 DB11783 Imidapril The risk or severity of angioedema can be increased when Alteplase is combined with Imidapril.
DB00009 DB11950 Teneligliptin The risk or severity of angioedema can be increased when Alteplase is combined with Teneligliptin.
DB00009 DB11992 Omarigliptin The risk or severity of angioedema can be increased when Alteplase is combined with Omarigliptin.
DB00009 DB12268 Carmegliptin The risk or severity of angioedema can be increased when Alteplase is combined with Carmegliptin.
DB00009 DB12412 Gemigliptin The risk or severity of angioedema can be increased when Alteplase is combined with Gemigliptin.
DB00009 DB12417 Anagliptin The risk or severity of angioedema can be increased when Alteplase is combined with Anagliptin.
DB00009 DB12625 Evogliptin The risk or severity of angioedema can be increased when Alteplase is combined with Evogliptin.
DB00009 DB13166 Zofenopril The risk or severity of angioedema can be increased when Alteplase is combined with Zofenopril.
DB00009 DB13312 Delapril The risk or severity of angioedema can be increased when Alteplase is combined with Delapril.
DB00009 DB14125 Benazeprilat The risk or severity of angioedema can be increased when Alteplase is combined with Benazeprilat.
DB00009 DB14207 Fosinoprilat The risk or severity of angioedema can be increased when Alteplase is combined with Fosinoprilat.
DB00009 DB14208 Ramiprilat The risk or severity of angioedema can be increased when Alteplase is combined with Ramiprilat.
DB00009 DB14209 Trandolaprilat The risk or severity of angioedema can be increased when Alteplase is combined with Trandolaprilat.
DB00009 DB14210 Moexiprilat The risk or severity of angioedema can be increased when Alteplase is combined with Moexiprilat.
DB00009 DB14213 Perindoprilat The risk or severity of angioedema can be increased when Alteplase is combined with Perindoprilat.
DB00009 DB14217 Quinaprilat The risk or severity of angioedema can be increased when Alteplase is combined with Quinaprilat.
DB00009 DB14231 Quinoline Yellow WS The risk or severity of angioedema can be increased when Alteplase is combined with Quinoline Yellow WS.
DB00009 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Alteplase is combined with Sildenafil.
DB00009 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Alteplase is combined with Peginterferon alfa-2a.
DB00009 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-n1.
DB00009 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-n3.
DB00009 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Alteplase is combined with Peginterferon alfa-2b.
DB00009 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Alteplase is combined with Interferon gamma-1b.
DB00009 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-2a, Recombinant.
DB00009 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Alteplase is combined with Aldesleukin.
DB00009 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Alteplase is combined with Gemtuzumab ozogamicin.
DB00009 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Alteplase is combined with Interferon beta-1b.
DB00009 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfacon-1.
DB00009 DB00073 Rituximab The risk or severity of bleeding can be increased when Alteplase is combined with Rituximab.
DB00009 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Alteplase is combined with Ibritumomab tiuxetan.
DB00009 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Alteplase is combined with Alemtuzumab.
DB00009 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-2b.
DB00009 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Alteplase is combined with Phenylalanine.
DB00009 DB00188 Bortezomib The risk or severity of bleeding can be increased when Alteplase is combined with Bortezomib.
DB00009 DB00242 Cladribine The risk or severity of bleeding can be increased when Alteplase is combined with Cladribine.
DB00009 DB00262 Carmustine The risk or severity of bleeding can be increased when Alteplase is combined with Carmustine.
DB00009 DB00276 Amsacrine The risk or severity of bleeding can be increased when Alteplase is combined with Amsacrine.
DB00009 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Alteplase is combined with Chlorambucil.
DB00009 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Alteplase is combined with Raltitrexed.
DB00009 DB00305 Mitomycin The risk or severity of bleeding can be increased when Alteplase is combined with Mitomycin.
DB00009 DB00307 Bexarotene The risk or severity of bleeding can be increased when Alteplase is combined with Bexarotene.
DB00009 DB00309 Vindesine The risk or severity of bleeding can be increased when Alteplase is combined with Vindesine.
DB00009 DB00322 Floxuridine The risk or severity of bleeding can be increased when Alteplase is combined with Floxuridine.
DB00009 DB00352 Tioguanine The risk or severity of bleeding can be increased when Alteplase is combined with Tioguanine.
DB00009 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Alteplase is combined with Vinorelbine.
DB00009 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Alteplase is combined with Dexrazoxane.
DB00009 DB00398 Sorafenib The risk or severity of bleeding can be increased when Alteplase is combined with Sorafenib.
DB00009 DB00428 Streptozocin The risk or severity of bleeding can be increased when Alteplase is combined with Streptozocin.
DB00009 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Alteplase is combined with Gemcitabine.
DB00009 DB00444 Teniposide The risk or severity of bleeding can be increased when Alteplase is combined with Teniposide.
DB00009 DB00445 Epirubicin The risk or severity of bleeding can be increased when Alteplase is combined with Epirubicin.
DB00009 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Alteplase is combined with Chloramphenicol.
DB00009 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Alteplase is combined with Lenalidomide.
DB00009 DB00488 Altretamine The risk or severity of bleeding can be increased when Alteplase is combined with Altretamine.
DB00009 DB00495 Zidovudine The risk or severity of bleeding can be increased when Alteplase is combined with Zidovudine.
DB00009 DB00515 Cisplatin The risk or severity of bleeding can be increased when Alteplase is combined with Cisplatin.
DB00009 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Alteplase is combined with Oxaliplatin.
DB00009 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Alteplase is combined with Cyclophosphamide.
DB00009 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Alteplase is combined with Fluorouracil.
DB00009 DB00552 Pentostatin The risk or severity of bleeding can be increased when Alteplase is combined with Pentostatin.
DB00009 DB00563 Methotrexate The risk or severity of bleeding can be increased when Alteplase is combined with Methotrexate.
DB00009 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Alteplase is combined with Carbamazepine.
DB00009 DB00570 Vinblastine The risk or severity of bleeding can be increased when Alteplase is combined with Vinblastine.
DB00009 DB00619 Imatinib The risk or severity of bleeding can be increased when Alteplase is combined with Imatinib.
DB00009 DB00631 Clofarabine The risk or severity of bleeding can be increased when Alteplase is combined with Clofarabine.
DB00009 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Alteplase is combined with Pemetrexed.
DB00009 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Alteplase is combined with Daunorubicin.
DB00009 DB00762 Irinotecan The risk or severity of bleeding can be increased when Alteplase is combined with Irinotecan.
DB00009 DB00773 Etoposide The risk or severity of bleeding can be increased when Alteplase is combined with Etoposide.
DB00009 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Alteplase is combined with Dacarbazine.
DB00009 DB00853 Temozolomide The risk or severity of bleeding can be increased when Alteplase is combined with Temozolomide.
DB00009 DB00859 Penicillamine The risk or severity of bleeding can be increased when Alteplase is combined with Penicillamine.
DB00009 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Alteplase is combined with Tacrolimus.
DB00009 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Alteplase is combined with Mechlorethamine.
DB00009 DB00928 Azacitidine The risk or severity of bleeding can be increased when Alteplase is combined with Azacitidine.
DB00009 DB00958 Carboplatin The risk or severity of bleeding can be increased when Alteplase is combined with Carboplatin.
DB00009 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Alteplase is combined with Dactinomycin.
DB00009 DB00987 Cytarabine The risk or severity of bleeding can be increased when Alteplase is combined with Cytarabine.
DB00009 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Alteplase is combined with Doxorubicin.
DB00009 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Alteplase is combined with Hydroxyurea.
DB00009 DB01008 Busulfan The risk or severity of bleeding can be increased when Alteplase is combined with Busulfan.
DB00009 DB01030 Topotecan The risk or severity of bleeding can be increased when Alteplase is combined with Topotecan.
DB00009 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Alteplase is combined with Mercaptopurine.
DB00009 DB01041 Thalidomide The risk or severity of bleeding can be increased when Alteplase is combined with Thalidomide.
DB00009 DB01042 Melphalan The risk or severity of bleeding can be increased when Alteplase is combined with Melphalan.
DB00009 DB01073 Fludarabine The risk or severity of bleeding can be increased when Alteplase is combined with Fludarabine.
DB00009 DB01099 Flucytosine The risk or severity of bleeding can be increased when Alteplase is combined with Flucytosine.
DB00009 DB01101 Capecitabine The risk or severity of bleeding can be increased when Alteplase is combined with Capecitabine.
DB00009 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Alteplase is combined with Arsenic trioxide.
DB00009 DB01177 Idarubicin The risk or severity of bleeding can be increased when Alteplase is combined with Idarubicin.
DB00009 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Alteplase is combined with Mitoxantrone.
DB00009 DB01206 Lomustine The risk or severity of bleeding can be increased when Alteplase is combined with Lomustine.
DB00009 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Alteplase is combined with Paclitaxel.
DB00009 DB01248 Docetaxel The risk or severity of bleeding can be increased when Alteplase is combined with Docetaxel.
DB00009 DB01262 Decitabine The risk or severity of bleeding can be increased when Alteplase is combined with Decitabine.
DB00009 DB01280 Nelarabine The risk or severity of bleeding can be increased when Alteplase is combined with Nelarabine.
DB00009 DB01590 Everolimus The risk or severity of bleeding can be increased when Alteplase is combined with Everolimus.
DB00009 DB02546 Vorinostat The risk or severity of bleeding can be increased when Alteplase is combined with Vorinostat.
DB00009 DB04572 Thiotepa The risk or severity of bleeding can be increased when Alteplase is combined with Thiotepa.
DB00009 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Alteplase is combined with Ixabepilone.
DB00009 DB04868 Nilotinib The risk or severity of bleeding can be increased when Alteplase is combined with Nilotinib.
DB00009 DB05015 Belinostat The risk or severity of bleeding can be increased when Alteplase is combined with Belinostat.
DB00009 DB05109 Trabectedin The risk or severity of bleeding can be increased when Alteplase is combined with Trabectedin.
DB00009 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa.
DB00009 DB05472 omega interferon The risk or severity of bleeding can be increased when Alteplase is combined with omega interferon.
DB00009 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Alteplase is combined with Trastuzumab emtansine.
DB00009 DB06616 Bosutinib The risk or severity of bleeding can be increased when Alteplase is combined with Bosutinib.
DB00009 DB06769 Bendamustine The risk or severity of bleeding can be increased when Alteplase is combined with Bendamustine.
DB00009 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Alteplase is combined with Cabazitaxel.
DB00009 DB08871 Eribulin The risk or severity of bleeding can be increased when Alteplase is combined with Eribulin.
DB00009 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Alteplase is combined with Ruxolitinib.
DB00009 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Alteplase is combined with Carfilzomib.
DB00009 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Alteplase is combined with Tofacitinib.
DB00009 DB08901 Ponatinib The risk or severity of bleeding can be increased when Alteplase is combined with Ponatinib.
DB00009 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Alteplase is combined with Pomalidomide.
DB00009 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Alteplase is combined with Tedizolid phosphate.
DB00009 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Alteplase is combined with Blinatumomab.
DB00009 DB09073 Palbociclib The risk or severity of bleeding can be increased when Alteplase is combined with Palbociclib.
DB00009 DB09074 Olaparib The risk or severity of bleeding can be increased when Alteplase is combined with Olaparib.
DB00009 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Alteplase is combined with Dinutuximab.
DB00009 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Alteplase is combined with Peginterferon beta-1a.
DB00009 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Alteplase is combined with Cepeginterferon alfa-2B.
DB00009 DB00229 Cefotiam The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefotiam.
DB00009 DB00267 Cefmenoxime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefmenoxime.
DB00009 DB00274 Cefmetazole The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefmetazole.
DB00009 DB00430 Cefpiramide The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefpiramide.
DB00009 DB00438 Ceftazidime The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftazidime.
DB00009 DB00447 Loracarbef The therapeutic efficacy of Alteplase can be decreased when used in combination with Loracarbef.
DB00009 DB00456 Cefalotin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefalotin.
DB00009 DB00493 Cefotaxime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefotaxime.
DB00009 DB00535 Cefdinir The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefdinir.
DB00009 DB00567 Cephalexin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cephalexin.
DB00009 DB00671 Cefixime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefixime.
DB00009 DB00689 Cephaloglycin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cephaloglycin.
DB00009 DB00833 Cefaclor The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefaclor.
DB00009 DB00923 Ceforanide The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceforanide.
DB00009 DB01066 Cefditoren The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefditoren.
DB00009 DB01112 Cefuroxime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefuroxime.
DB00009 DB01139 Cefapirin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefapirin.
DB00009 DB01140 Cefadroxil The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefadroxil.
DB00009 DB01150 Cefprozil The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefprozil.
DB00009 DB01212 Ceftriaxone The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftriaxone.
DB00009 DB01326 Cefamandole The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole.
DB00009 DB01327 Cefazolin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefazolin.
DB00009 DB01328 Cefonicid The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefonicid.
DB00009 DB01329 Cefoperazone The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefoperazone.
DB00009 DB01330 Cefotetan The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefotetan.
DB00009 DB01331 Cefoxitin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefoxitin.
DB00009 DB01332 Ceftizoxime The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftizoxime.
DB00009 DB01333 Cefradine The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefradine.
DB00009 DB01413 Cefepime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefepime.
DB00009 DB01414 Cefacetrile The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefacetrile.
DB00009 DB01415 Ceftibuten The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftibuten.
DB00009 DB01416 Cefpodoxime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefpodoxime.
DB00009 DB04570 Latamoxef The therapeutic efficacy of Alteplase can be decreased when used in combination with Latamoxef.
DB00009 DB04918 Ceftobiprole The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftobiprole.
DB00009 DB06590 Ceftaroline fosamil The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftaroline fosamil.
DB00009 DB09008 Cefaloridine The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefaloridine.
DB00009 DB09050 Ceftolozane The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftolozane.
DB00009 DB09062 Cefminox The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefminox.
DB00009 DB11367 Cefroxadine The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefroxadine.
DB00009 DB11935 Flomoxef The therapeutic efficacy of Alteplase can be decreased when used in combination with Flomoxef.
DB00009 DB13266 Cefatrizine The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefatrizine.
DB00009 DB13461 Cefcapene The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefcapene.
DB00009 DB13470 Cefodizime The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefodizime.
DB00009 DB13499 Cefsulodin The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefsulodin.
DB00009 DB13504 Cefetamet The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefetamet.
DB00009 DB13638 Cefbuperazone The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefbuperazone.
DB00009 DB13667 Cefozopran The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefozopran.
DB00009 DB13682 Cefpirome The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefpirome.
DB00009 DB13778 Cefazedone The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefazedone.
DB00009 DB13821 Ceftezole The therapeutic efficacy of Alteplase can be decreased when used in combination with Ceftezole.
DB00009 DB14725 Cefamandole nafate The therapeutic efficacy of Alteplase can be decreased when used in combination with Cefamandole nafate.
DB00009 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Alteplase.
DB00009 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Alteplase.
DB00009 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Alteplase.
DB00009 DB00945 Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Alteplase.
DB00009 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Alteplase.
DB00009 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Alteplase.
DB00009 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Alteplase.
DB00009 DB00620 Triamcinolone The therapeutic efficacy of Alteplase can be decreased when used in combination with Triamcinolone.
DB00009 DB09079 Nintedanib The risk or severity of bleeding can be increased when Alteplase is combined with Nintedanib.
DB00009 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Alteplase.
DB00009 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Alteplase.
DB00009 DB00232 Methyclothiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Methyclothiazide.
DB00009 DB00436 Bendroflumethiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Bendroflumethiazide.
DB00009 DB00562 Benzthiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Benzthiazide.
DB00009 DB00606 Cyclothiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Cyclothiazide.
DB00009 DB00774 Hydroflumethiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Hydroflumethiazide.
DB00009 DB00880 Chlorothiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Chlorothiazide.
DB00009 DB00999 Hydrochlorothiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Hydrochlorothiazide.
DB00009 DB01021 Trichlormethiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Trichlormethiazide.
DB00009 DB01324 Polythiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Polythiazide.
DB00009 DB13430 Mebutizide The therapeutic efficacy of Alteplase can be decreased when used in combination with Mebutizide.
DB00009 DB13532 Cyclopenthiazide The therapeutic efficacy of Alteplase can be decreased when used in combination with Cyclopenthiazide.
DB00011 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-n1.
DB00011 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n1.
DB00011 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-n1.
DB00011 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-n3.
DB00011 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peginterferon alfa-2b.
DB00011 DB00026 Anakinra The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Anakinra.
DB00011 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon gamma-1b.
DB00011 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2a, Recombinant.
DB00011 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Aldesleukin.
DB00011 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Adalimumab.
DB00011 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemtuzumab ozogamicin.
DB00011 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pegaspargase.
DB00011 DB00065 Infliximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Infliximab.
DB00011 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon beta-1b.
DB00011 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfacon-1.
DB00011 DB00073 Rituximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rituximab.
DB00011 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Basiliximab.
DB00011 DB00075 Muromonab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Muromonab.
DB00011 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibritumomab tiuxetan.
DB00011 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tositumomab.
DB00011 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alemtuzumab.
DB00011 DB00092 Alefacept The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Alefacept.
DB00011 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Efalizumab.
DB00011 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antithymocyte immunoglobulin (rabbit).
DB00011 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2b.
DB00011 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab.
DB00011 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bevacizumab.
DB00011 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Phenylalanine.
DB00011 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Flunisolide.
DB00011 DB00188 Bortezomib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bortezomib.
DB00011 DB00242 Cladribine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cladribine.
DB00011 DB00262 Carmustine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carmustine.
DB00011 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Amsacrine.
DB00011 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bleomycin.
DB00011 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Chlorambucil.
DB00011 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Raltitrexed.
DB00011 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mitomycin.
DB00011 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bexarotene.
DB00011 DB00309 Vindesine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vindesine.
DB00011 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Floxuridine.
DB00011 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Indomethacin.
DB00011 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tioguanine.
DB00011 DB00361 Vinorelbine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vinorelbine.
DB00011 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexrazoxane.
DB00011 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Beclomethasone dipropionate.
DB00011 DB00398 Sorafenib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sorafenib.
DB00011 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Streptozocin.
DB00011 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trifluridine.
DB00011 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gemcitabine.
DB00011 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Betamethasone.
DB00011 DB00444 Teniposide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Teniposide.
DB00011 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Epirubicin.
DB00011 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Chloramphenicol.
DB00011 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Lenalidomide.
DB00011 DB00488 Altretamine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Altretamine.
DB00011 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.
DB00011 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cisplatin.
DB00011 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Oxaliplatin.
DB00011 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cyclophosphamide.
DB00011 DB00541 Vincristine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vincristine.
DB00011 DB00544 Fluorouracil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluorouracil.
DB00011 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Propylthiouracil.
DB00011 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pentostatin.
DB00011 DB00563 Methotrexate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methotrexate.
DB00011 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carbamazepine.
DB00011 DB00570 Vinblastine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vinblastine.
DB00011 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluticasone propionate.
DB00011 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocinolone acetonide.
DB00011 DB00601 Linezolid The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Linezolid.
DB00011 DB00619 Imatinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Imatinib.
DB00011 DB00620 Triamcinolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Triamcinolone.
DB00011 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Clofarabine.
DB00011 DB00635 Prednisone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednisone.
DB00011 DB00642 Pemetrexed The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pemetrexed.
DB00011 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fludrocortisone.
DB00011 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mycophenolate mofetil.
DB00011 DB00694 Daunorubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin.
DB00011 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tretinoin.
DB00011 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Irinotecan.
DB00011 DB00763 Methimazole The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methimazole.
DB00011 DB00764 Mometasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mometasone.
DB00011 DB00773 Etoposide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Etoposide.
DB00011 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sulfasalazine.
DB00011 DB00851 Dacarbazine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dacarbazine.
DB00011 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Temozolomide.
DB00011 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Penicillamine.
DB00011 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednisolone.
DB00011 DB00877 Sirolimus The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sirolimus.
DB00011 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mechlorethamine.
DB00011 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Azacitidine.
DB00011 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carboplatin.
DB00011 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methylprednisolone.
DB00011 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dactinomycin.
DB00011 DB00987 Cytarabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cytarabine.
DB00011 DB00993 Azathioprine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Azathioprine.
DB00011 DB00997 Doxorubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Doxorubicin.
DB00011 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydroxyurea.
DB00011 DB01008 Busulfan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Busulfan.
DB00011 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mycophenolic acid.
DB00011 DB01030 Topotecan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Topotecan.
DB00011 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mercaptopurine.
DB00011 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Thalidomide.
DB00011 DB01042 Melphalan The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Melphalan.
DB00011 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fludarabine.
DB00011 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Flucytosine.
DB00011 DB01101 Capecitabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Capecitabine.
DB00011 DB01108 Trilostane The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trilostane.
DB00011 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Procarbazine.
DB00011 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Arsenic trioxide.
DB00011 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Idarubicin.
DB00011 DB01181 Ifosfamide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ifosfamide.
DB00011 DB01196 Estramustine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Estramustine.
DB00011 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mitoxantrone.
DB00011 DB01206 Lomustine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Lomustine.
DB00011 DB01222 Budesonide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Budesonide.
DB00011 DB01229 Paclitaxel The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Paclitaxel.
DB00011 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexamethasone.
DB00011 DB01248 Docetaxel The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Docetaxel.
DB00011 DB01254 Dasatinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dasatinib.
DB00011 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Eculizumab.
DB00011 DB01262 Decitabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Decitabine.
DB00011 DB01268 Sunitinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sunitinib.
DB00011 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Nelarabine.
DB00011 DB01281 Abatacept The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Abatacept.
DB00011 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Corticotropin.
DB00011 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cortisone acetate.
DB00011 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Paramethasone.
DB00011 DB01394 Colchicine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Colchicine.
DB00011 DB01410 Ciclesonide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ciclesonide.
DB00011 DB01423 Stepronin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Stepronin.
DB00011 DB01590 Everolimus The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Everolimus.
DB00011 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydroxychloroquine.
DB00011 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Castanospermine.
DB00011 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vorinostat.
DB00011 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with 2-Methoxyethanol.
DB00011 DB03523 Brequinar The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Brequinar.
DB00011 DB04572 Thiotepa The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Thiotepa.
DB00011 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Aldosterone.
DB00011 DB04845 Ixabepilone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ixabepilone.
DB00011 DB04868 Nilotinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Nilotinib.
DB00011 DB04951 Pirfenidone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pirfenidone.
DB00011 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Afelimomab.
DB00011 DB05015 Belinostat The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Belinostat.
DB00011 DB05109 Trabectedin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trabectedin.
DB00011 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa.
DB00011 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Glatiramer.
DB00011 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gallium nitrate.
DB00011 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Briakinumab.
DB00011 DB05472 omega interferon The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with omega interferon.
DB00011 DB05676 Apremilast The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Apremilast.
DB00011 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trastuzumab emtansine.
DB00011 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Canakinumab.
DB00011 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tocilizumab.
DB00011 DB06287 Temsirolimus The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Temsirolimus.
DB00011 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rilonacept.
DB00011 DB06589 Pazopanib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pazopanib.
DB00011 DB06603 Panobinostat The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Panobinostat.
DB00011 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mepolizumab.
DB00011 DB06616 Bosutinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bosutinib.
DB00011 DB06662 Abetimus The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Abetimus.
DB00011 DB06674 Golimumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Golimumab.
DB00011 DB06681 Belatacept The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Belatacept.
DB00011 DB06769 Bendamustine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bendamustine.
DB00011 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cabazitaxel.
DB00011 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pralatrexate.
DB00011 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Wortmannin.
DB00011 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Brentuximab vedotin.
DB00011 DB08871 Eribulin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Eribulin.
DB00011 DB08877 Ruxolitinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ruxolitinib.
DB00011 DB08879 Belimumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Belimumab.
DB00011 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Teriflunomide.
DB00011 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Carfilzomib.
DB00011 DB08901 Ponatinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ponatinib.
DB00011 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Certolizumab pegol.
DB00011 DB08906 Fluticasone furoate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluticasone furoate.
DB00011 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dimethyl fumarate.
DB00011 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pomalidomide.
DB00011 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Obinutuzumab.
DB00011 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluprednidene.
DB00011 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocortolone.
DB00011 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Secukinumab.
DB00011 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vedolizumab.
DB00011 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Siltuximab.
DB00011 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Blinatumomab.
DB00011 DB09053 Ibrutinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ibrutinib.
DB00011 DB09054 Idelalisib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Idelalisib.
DB00011 DB09073 Palbociclib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Palbociclib.
DB00011 DB09074 Olaparib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Olaparib.
DB00011 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dinutuximab.
DB00011 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vilanterol.
DB00011 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tixocortol.
DB00011 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peginterferon beta-1a.
DB00011 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antilymphocyte immunoglobulin (horse).
DB00011 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluprednisolone.
DB00011 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Meprednisone.
DB00011 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tepoxalin.
DB00011 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dexamethasone isonicotinate.
DB00011 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Melengestrol.
DB00011 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ixekizumab.
DB00011 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ravulizumab.
DB00011 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pirarubicin.
DB00011 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Voclosporin.
DB00011 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peficitinib.
DB00011 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Clobetasol.
DB00011 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sarilumab.
DB00011 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Brodalumab.
DB00011 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sirukumab.
DB00011 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Baricitinib.
DB00011 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Guselkumab.
DB00011 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Deflazacort.
DB00011 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ocrelizumab.
DB00011 DB12025 Triptolide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Triptolide.
DB00011 DB12371 Siponimod The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Siponimod.
DB00011 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ozanimod.
DB00011 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mizoribine.
DB00011 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Gusperimus.
DB00011 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cepeginterferon alfa-2B.
DB00011 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Trofosfamide.
DB00011 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Doxifluridine.
DB00011 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Deoxyspergualin.
DB00011 DB12996 Acteoside The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Acteoside.
DB00011 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cortivazol.
DB00011 DB13014 Hypericin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hypericin.
DB00011 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00011 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednylidene.
DB00011 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocortin.
DB00011 DB13241 Begelomab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Begelomab.
DB00011 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluperolone.
DB00011 DB13664 Formocortal The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Formocortal.
DB00011 DB13728 Halometasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Halometasone.
DB00011 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cloprednol.
DB00011 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluclorolone.
DB00011 DB13867 Fluticasone The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluticasone.
DB00011 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Tetrandrine.
DB00011 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Monomethyl fumarate.
DB00011 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mometasone furoate.
DB00011 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydrocortisone aceponate.
DB00011 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydrocortisone acetate.
DB00011 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hydrocortisone succinate.
DB00011 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Emapalumab.
DB00011 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Risankizumab.
DB00011 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Rozanolixizumab.
DB00011 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bleselumab.
DB00011 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Natalizumab.
DB00011 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-n1.
DB00011 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Interferon alfa-n1.
DB00011 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB00363 Clozapine The risk or severity of neutropenia can be increased when Interferon alfa-n1 is combined with Clozapine.
DB00011 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-n1.
DB00011 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-n1.
DB00011 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Leflunomide.
DB00011 DB08895 Tofacitinib Interferon alfa-n1 may increase the immunosuppressive activities of Tofacitinib.
DB00011 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Interferon alfa-n1.
DB00011 DB08868 Fingolimod Interferon alfa-n1 may increase the immunosuppressive activities of Fingolimod.
DB00011 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Interferon alfa-n1.
DB00011 DB00201 Caffeine The metabolism of Caffeine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00651 Dyphylline The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB01412 Theobromine The metabolism of Theobromine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01482 Fenethylline The metabolism of Fenethylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB01667 8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01978 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB02134 Xanthine The metabolism of Xanthine can be decreased when combined with Interferon alfa-n1.
DB00011 DB02245 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB02377 Guanine The metabolism of Guanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB02568 Peldesine The metabolism of Peldesine can be decreased when combined with Interferon alfa-n1.
DB00011 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-n1.
DB00011 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB06479 Propentofylline The metabolism of Propentofylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB06575 Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Interferon alfa-n1.
DB00011 DB07954 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfa-n1.
DB00011 DB08844 Uric acid The metabolism of Uric acid can be decreased when combined with Interferon alfa-n1.
DB00011 DB09273 Doxofylline The metabolism of Doxofylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfa-n1.
DB00011 DB12406 Lisofylline The metabolism of Lisofylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB12531 Lobucavir The metabolism of Lobucavir can be decreased when combined with Interferon alfa-n1.
DB00011 DB12926 Cafedrine The metabolism of Cafedrine can be decreased when combined with Interferon alfa-n1.
DB00011 DB12927 Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Interferon alfa-n1.
DB00011 DB13203 Bamifylline The metabolism of Bamifylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB13449 Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB13573 Acefylline The metabolism of Acefylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB13592 Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB13634 Pentifylline The metabolism of Pentifylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB13812 Bufylline The metabolism of Bufylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB14029 Furafylline The metabolism of Furafylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB15122 PCS-499 The metabolism of PCS-499 can be decreased when combined with Interferon alfa-n1.
DB00011 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfa-n1.
DB00011 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n1.
DB00011 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfa-n1.
DB00011 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfa-n1.
DB00011 DB00945 Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-n1.
DB00011 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-n1.
DB00011 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfa-n1.
DB00011 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-n1.
DB00011 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfa-n1.
DB00011 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfa-n1.
DB00011 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-n1.
DB00011 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfa-n1.
DB00011 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfa-n1.
DB00011 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-n1.
DB00011 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfa-n1.
DB00011 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfa-n1.
DB00011 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfa-n1.
DB00011 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-n1.
DB00011 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfa-n1.
DB00011 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfa-n1.
DB00011 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfa-n1.
DB00011 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfa-n1.
DB00011 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-n1.
DB00011 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-n1.
DB00011 DB09030 Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfa-n1.
DB00011 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfa-n1.
DB00011 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfa-n1.
DB00011 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfa-n1.
DB00011 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfa-n1.
DB00011 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfa-n1.
DB00011 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfa-n1.
DB00011 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfa-n1.
DB00011 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfa-n1.
DB00011 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfa-n1.
DB00011 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfa-n1.
DB00011 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfa-n1.
DB00011 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfa-n1.
DB00011 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfa-n1.
DB00011 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfa-n1.
DB00011 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfa-n1.
DB00011 DB13200 Lipegfilgrastim Interferon alfa-n1 may increase the myelosuppressive activities of Lipegfilgrastim.
DB00011 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Interferon alfa-n1 is combined with Varicella Zoster Vaccine (Live/attenuated).
DB00011 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-n1.
DB00011 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfa-n1.
DB00011 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-n1.
DB00011 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfa-n1.
DB00011 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfa-n1.
DB00011 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfa-n1.
DB00011 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfa-n1.
DB00011 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfa-n1.
DB00011 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfa-n1.
DB00011 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfa-n1.
DB00011 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfa-n1.
DB00011 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00184 Nicotine The metabolism of Nicotine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00195 Betaxolol The metabolism of Betaxolol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00261 Anagrelide The metabolism of Anagrelide can be decreased when combined with Interferon alfa-n1.
DB00011 DB00280 Disopyramide The metabolism of Disopyramide can be decreased when combined with Interferon alfa-n1.
DB00011 DB00281 Lidocaine The metabolism of Lidocaine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfa-n1.
DB00011 DB00296 Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00316 Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-n1.
DB00011 DB00334 Olanzapine The metabolism of Olanzapine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfa-n1.
DB00011 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Interferon alfa-n1.
DB00011 DB00370 Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00379 Mexiletine The metabolism of Mexiletine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00382 Tacrine The metabolism of Tacrine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00384 Triamterene The metabolism of Triamterene can be decreased when combined with Interferon alfa-n1.
DB00011 DB00420 Promazine The metabolism of Promazine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00425 Zolpidem The metabolism of Zolpidem can be decreased when combined with Interferon alfa-n1.
DB00011 DB00442 Entecavir The metabolism of Entecavir can be decreased when combined with Interferon alfa-n1.
DB00011 DB00461 Nabumetone The metabolism of Nabumetone can be decreased when combined with Interferon alfa-n1.
DB00011 DB00468 Quinine The metabolism of Quinine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00472 Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00476 Duloxetine The metabolism of Duloxetine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00499 Flutamide The metabolism of Flutamide can be decreased when combined with Interferon alfa-n1.
DB00011 DB00502 Haloperidol The metabolism of Haloperidol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00518 Albendazole The metabolism of Albendazole can be decreased when combined with Interferon alfa-n1.
DB00011 DB00533 Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Interferon alfa-n1.
DB00011 DB00568 Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00571 Propranolol The metabolism of Propranolol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00586 Diclofenac The metabolism of Diclofenac can be decreased when combined with Interferon alfa-n1.
DB00011 DB00629 Guanabenz The metabolism of Guanabenz can be decreased when combined with Interferon alfa-n1.
DB00011 DB00661 Verapamil The metabolism of Verapamil can be decreased when combined with Interferon alfa-n1.
DB00011 DB00715 Paroxetine The metabolism of Paroxetine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00730 Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Interferon alfa-n1.
DB00011 DB00740 Riluzole The metabolism of Riluzole can be decreased when combined with Interferon alfa-n1.
DB00011 DB00744 Zileuton The metabolism of Zileuton can be decreased when combined with Interferon alfa-n1.
DB00011 DB00758 Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Interferon alfa-n1.
DB00011 DB00783 Estradiol The metabolism of Estradiol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00787 Acyclovir The metabolism of Acyclovir can be decreased when combined with Interferon alfa-n1.
DB00011 DB00788 Naproxen The metabolism of Naproxen can be decreased when combined with Interferon alfa-n1.
DB00011 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00850 Perphenazine The metabolism of Perphenazine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00857 Terbinafine The metabolism of Terbinafine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00863 Ranitidine The metabolism of Ranitidine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00898 Ethanol The metabolism of Ethanol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00934 Maprotiline The metabolism of Maprotiline can be decreased when combined with Interferon alfa-n1.
DB00011 DB00969 Alosetron The metabolism of Alosetron can be decreased when combined with Interferon alfa-n1.
DB00011 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Interferon alfa-n1.
DB00011 DB00980 Ramelteon The metabolism of Ramelteon can be decreased when combined with Interferon alfa-n1.
DB00011 DB00998 Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Interferon alfa-n1.
DB00011 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01012 Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Interferon alfa-n1.
DB00011 DB01037 Selegiline The metabolism of Selegiline can be decreased when combined with Interferon alfa-n1.
DB00011 DB01056 Tocainide The metabolism of Tocainide can be decreased when combined with Interferon alfa-n1.
DB00011 DB01058 Praziquantel The metabolism of Praziquantel can be decreased when combined with Interferon alfa-n1.
DB00011 DB01065 Melatonin The metabolism of Melatonin can be decreased when combined with Interferon alfa-n1.
DB00011 DB01087 Primaquine The metabolism of Primaquine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01094 Hesperetin The metabolism of Hesperetin can be decreased when combined with Interferon alfa-n1.
DB00011 DB01115 Nifedipine The metabolism of Nifedipine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01136 Carvedilol The metabolism of Carvedilol can be decreased when combined with Interferon alfa-n1.
DB00011 DB01166 Cilostazol The metabolism of Cilostazol can be decreased when combined with Interferon alfa-n1.
DB00011 DB01182 Propafenone The metabolism of Propafenone can be decreased when combined with Interferon alfa-n1.
DB00011 DB01184 Domperidone The metabolism of Domperidone can be decreased when combined with Interferon alfa-n1.
DB00011 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01367 Rasagiline The metabolism of Rasagiline can be decreased when combined with Interferon alfa-n1.
DB00011 DB01405 Temafloxacin The metabolism of Temafloxacin can be decreased when combined with Interferon alfa-n1.
DB00011 DB01424 Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Interferon alfa-n1.
DB00011 DB01435 Antipyrine The metabolism of Antipyrine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01558 Bromazepam The metabolism of Bromazepam can be decreased when combined with Interferon alfa-n1.
DB00011 DB01623 Thiothixene The metabolism of Thiothixene can be decreased when combined with Interferon alfa-n1.
DB00011 DB01628 Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Interferon alfa-n1.
DB00011 DB01645 Genistein The metabolism of Genistein can be decreased when combined with Interferon alfa-n1.
DB00011 DB02709 Resveratrol The metabolism of Resveratrol can be decreased when combined with Interferon alfa-n1.
DB00011 DB03783 Phenacetin The metabolism of Phenacetin can be decreased when combined with Interferon alfa-n1.
DB00011 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Interferon alfa-n1.
DB00011 DB04841 Flunarizine The metabolism of Flunarizine can be decreased when combined with Interferon alfa-n1.
DB00011 DB04871 Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Interferon alfa-n1.
DB00011 DB04948 Lofexidine The metabolism of Lofexidine can be decreased when combined with Interferon alfa-n1.
DB00011 DB06148 Mianserin The metabolism of Mianserin can be decreased when combined with Interferon alfa-n1.
DB00011 DB06210 Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-n1.
DB00011 DB06216 Asenapine The metabolism of Asenapine can be decreased when combined with Interferon alfa-n1.
DB00011 DB06235 Vadimezan The metabolism of Vadimezan can be decreased when combined with Interferon alfa-n1.
DB00011 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-n1.
DB00011 DB06594 Agomelatine The metabolism of Agomelatine can be decreased when combined with Interferon alfa-n1.
DB00011 DB06626 Axitinib The metabolism of Axitinib can be decreased when combined with Interferon alfa-n1.
DB00011 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfa-n1.
DB00011 DB06774 Capsaicin The metabolism of Capsaicin can be decreased when combined with Interferon alfa-n1.
DB00011 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be decreased when combined with Interferon alfa-n1.
DB00011 DB08883 Perampanel The metabolism of Perampanel can be decreased when combined with Interferon alfa-n1.
DB00011 DB09071 Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Interferon alfa-n1.
DB00011 DB09118 Stiripentol The metabolism of Stiripentol can be decreased when combined with Interferon alfa-n1.
DB00011 DB09225 Zotepine The metabolism of Zotepine can be decreased when combined with Interferon alfa-n1.
DB00011 DB09288 Propacetamol The metabolism of Propacetamol can be decreased when combined with Interferon alfa-n1.
DB00011 DB09290 Ramosetron The metabolism of Ramosetron can be decreased when combined with Interferon alfa-n1.
DB00011 DB11967 Binimetinib The metabolism of Binimetinib can be decreased when combined with Interferon alfa-n1.
DB00011 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Interferon alfa-n1.
DB00011 DB12245 Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Interferon alfa-n1.
DB00011 DB12332 Rucaparib The metabolism of Rucaparib can be decreased when combined with Interferon alfa-n1.
DB00011 DB12945 Dihydralazine The metabolism of Dihydralazine can be decreased when combined with Interferon alfa-n1.
DB00011 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Interferon alfa-n1.
DB00011 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfa-n1.
DB00011 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfa-n1.
DB00011 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfa-n1.
DB00011 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Interferon alfa-n1.
DB00011 DB11757 Istradefylline The metabolism of Istradefylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB00972 Azelastine The metabolism of Azelastine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00625 Efavirenz The metabolism of Efavirenz can be decreased when combined with Interferon alfa-n1.
DB00011 DB01233 Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-n1.
DB00011 DB04889 Bicifadine The metabolism of Bicifadine can be decreased when combined with Interferon alfa-n1.
DB00011 DB05708 GTS-21 The metabolism of GTS-21 can be decreased when combined with Interferon alfa-n1.
DB00011 DB01195 Flecainide The metabolism of Flecainide can be decreased when combined with Interferon alfa-n1.
DB00011 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00321 Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-n1.
DB00011 DB00458 Imipramine The metabolism of Imipramine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01142 Doxepin The metabolism of Doxepin can be decreased when combined with Interferon alfa-n1.
DB00011 DB00532 Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Interferon alfa-n1.
DB00011 DB00540 Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Interferon alfa-n1.
DB00011 DB00575 Clonidine The metabolism of Clonidine can be decreased when combined with Interferon alfa-n1.
DB00011 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01151 Desipramine The metabolism of Desipramine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01242 Clomipramine The metabolism of Clomipramine can be decreased when combined with Interferon alfa-n1.
DB00011 DB11689 Selumetinib The metabolism of Selumetinib can be decreased when combined with Interferon alfa-n1.
DB00011 DB00277 Theophylline The metabolism of Theophylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB00682 Warfarin The metabolism of Warfarin can be decreased when combined with Interferon alfa-n1.
DB00011 DB00697 Tizanidine The metabolism of Tizanidine can be decreased when combined with Interferon alfa-n1.
DB00011 DB01100 Pimozide The metabolism of Pimozide can be decreased when combined with Interferon alfa-n1.
DB00011 DB01223 Aminophylline The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1.
DB00011 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-n1.
DB00011 DB00530 Erlotinib The metabolism of Erlotinib can be decreased when combined with Interferon alfa-n1.
DB00011 DB09256 Tegafur The metabolism of Tegafur can be decreased when combined with Interferon alfa-n1.
DB00011 DB13874 Enasidenib The metabolism of Enasidenib can be decreased when combined with Interferon alfa-n1.
DB00011 DB00675 Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Interferon alfa-n1.
DB00011 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.
DB00011 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-n1.
DB00011 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-n1.
DB00011 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-n1.
DB00011 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n1.
DB00011 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-n1.
DB00011 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-n1.
DB00011 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n1.
DB00011 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n1.
DB00011 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfa-n1.
DB00011 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfa-n1.
DB00011 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfa-n1.
DB00011 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfa-n1.
DB00011 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfa-n1.
DB00011 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfa-n1.
DB00011 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfa-n1.
DB00011 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfa-n1.
DB00011 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfa-n1.
DB00011 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfa-n1.
DB00011 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfa-n1.
DB00011 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfa-n1.
DB00011 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfa-n1.
DB00011 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfa-n1.
DB00011 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfa-n1.
DB00011 DB06228 Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfa-n1.
DB00011 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfa-n1.
DB00011 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfa-n1.
DB00011 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfa-n1.
DB00011 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfa-n1.
DB00011 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfa-n1.
DB00011 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfa-n1.
DB00011 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfa-n1.
DB00011 DB06695 Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-n1.
DB00011 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfa-n1.
DB00011 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfa-n1.
DB00011 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfa-n1.
DB00011 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfa-n1.
DB00011 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfa-n1.
DB00011 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfa-n1.
DB00011 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfa-n1.
DB00011 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfa-n1.
DB00011 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfa-n1.
DB00011 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-n1.
DB00011 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfa-n1.
DB00011 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfa-n1.
DB00011 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfa-n1.
DB00011 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfa-n1.
DB00011 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfa-n1.
DB00011 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfa-n1.
DB00011 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfa-n1.
DB00011 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-n1.
DB00011 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfa-n1.
DB00011 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-n1.
DB00011 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfa-n1.
DB00011 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfa-n1.
DB00011 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfa-n1.
DB00011 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfa-n1.
DB00011 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfa-n1.
DB00011 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfa-n1.
DB00011 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfa-n1.
DB00011 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfa-n1.
DB00011 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfa-n1.
DB00011 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfa-n1.
DB00011 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfa-n1.
DB00011 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfa-n1.
DB00011 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfa-n1.
DB00011 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfa-n1.
DB00011 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfa-n1.
DB00011 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfa-n1.
DB00011 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfa-n1.
DB00011 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-n1.
DB00011 DB00232 Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-n1.
DB00011 DB00436 Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-n1.
DB00011 DB00562 Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfa-n1.
DB00011 DB00606 Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfa-n1.
DB00011 DB00774 Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfa-n1.
DB00011 DB00880 Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfa-n1.
DB00011 DB00999 Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfa-n1.
DB00011 DB01021 Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfa-n1.
DB00011 DB01324 Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfa-n1.
DB00011 DB13430 Mebutizide The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfa-n1.
DB00011 DB13532 Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfa-n1.
DB00011 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Interferon alfa-n1 is combined with Tedizolid phosphate.
DB00011 DB00091 Cyclosporine Interferon alfa-n1 may increase the immunosuppressive activities of Cyclosporine.
DB00011 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ropinirole.
DB00011 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n1.
DB00011 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfa-n1.
DB00011 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Interferon alfa-n1.
DB00011 DB01601 Lopinavir The serum concentration of Interferon alfa-n1 can be increased when it is combined with Lopinavir.
DB00011 DB12530 Inebilizumab The risk or severity of infection can be increased when Interferon alfa-n1 is combined with Inebilizumab.
DB00012 DB00480 Lenalidomide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lenalidomide.
DB00012 DB01041 Thalidomide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Thalidomide.
DB00012 DB08910 Pomalidomide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pomalidomide.
DB00012 DB00002 Cetuximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cetuximab.
DB00012 DB00004 Denileukin diftitox The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Denileukin diftitox.
DB00012 DB00007 Leuprolide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Leuprolide.
DB00012 DB00008 Peginterferon alfa-2a The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Peginterferon alfa-2a.
DB00012 DB00014 Goserelin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Goserelin.
DB00012 DB00023 Asparaginase Escherichia coli The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Asparaginase Escherichia coli.
DB00012 DB00041 Aldesleukin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aldesleukin.
DB00012 DB00056 Gemtuzumab ozogamicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemtuzumab ozogamicin.
DB00012 DB00059 Pegaspargase The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pegaspargase.
DB00012 DB00072 Trastuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab.
DB00012 DB00073 Rituximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rituximab.
DB00012 DB00081 Tositumomab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tositumomab.
DB00012 DB00087 Alemtuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alemtuzumab.
DB00012 DB00104 Octreotide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Octreotide.
DB00012 DB00105 Interferon alfa-2b The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Interferon alfa-2b.
DB00012 DB00112 Bevacizumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bevacizumab.
DB00012 DB00179 Masoprocol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Masoprocol.
DB00012 DB00188 Bortezomib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bortezomib.
DB00012 DB00236 Pipobroman The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pipobroman.
DB00012 DB00242 Cladribine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cladribine.
DB00012 DB00248 Cabergoline The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabergoline.
DB00012 DB00261 Anagrelide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anagrelide.
DB00012 DB00262 Carmustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carmustine.
DB00012 DB00269 Chlorotrianisene The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Chlorotrianisene.
DB00012 DB00276 Amsacrine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Amsacrine.
DB00012 DB00282 Pamidronic acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pamidronic acid.
DB00012 DB00290 Bleomycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bleomycin.
DB00012 DB00291 Chlorambucil The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Chlorambucil.
DB00012 DB00293 Raltitrexed The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Raltitrexed.
DB00012 DB00305 Mitomycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitomycin.
DB00012 DB00307 Bexarotene The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bexarotene.
DB00012 DB00313 Valproic acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valproic acid.
DB00012 DB00317 Gefitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gefitinib.
DB00012 DB00322 Floxuridine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Floxuridine.
DB00012 DB00351 Megestrol acetate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Megestrol acetate.
DB00012 DB00352 Tioguanine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tioguanine.
DB00012 DB00357 Aminoglutethimide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aminoglutethimide.
DB00012 DB00385 Valrubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valrubicin.
DB00012 DB00398 Sorafenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sorafenib.
DB00012 DB00428 Streptozocin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Streptozocin.
DB00012 DB00432 Trifluridine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trifluridine.
DB00012 DB00441 Gemcitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gemcitabine.
DB00012 DB00444 Teniposide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Teniposide.
DB00012 DB00445 Epirubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epirubicin.
DB00012 DB00488 Altretamine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Altretamine.
DB00012 DB00499 Flutamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Flutamide.
DB00012 DB00515 Cisplatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cisplatin.
DB00012 DB00523 Alitretinoin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alitretinoin.
DB00012 DB00526 Oxaliplatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oxaliplatin.
DB00012 DB00530 Erlotinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Erlotinib.
DB00012 DB00539 Toremifene The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Toremifene.
DB00012 DB00544 Fluorouracil The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fluorouracil.
DB00012 DB00552 Pentostatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pentostatin.
DB00012 DB00563 Methotrexate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methotrexate.
DB00012 DB00603 Medroxyprogesterone acetate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Medroxyprogesterone acetate.
DB00012 DB00619 Imatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Imatinib.
DB00012 DB00631 Clofarabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Clofarabine.
DB00012 DB00635 Prednisone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednisone.
DB00012 DB00642 Pemetrexed The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pemetrexed.
DB00012 DB00648 Mitotane The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitotane.
DB00012 DB00665 Nilutamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nilutamide.
DB00012 DB00675 Tamoxifen The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tamoxifen.
DB00012 DB00694 Daunorubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daunorubicin.
DB00012 DB00707 Porfimer sodium The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Porfimer sodium.
DB00012 DB00755 Tretinoin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretinoin.
DB00012 DB00762 Irinotecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Irinotecan.
DB00012 DB00773 Etoposide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etoposide.
DB00012 DB00791 Uracil mustard The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Uracil mustard.
DB00012 DB00851 Dacarbazine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacarbazine.
DB00012 DB00853 Temozolomide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temozolomide.
DB00012 DB00855 Aminolevulinic acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aminolevulinic acid.
DB00012 DB00860 Prednisolone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednisolone.
DB00012 DB00888 Mechlorethamine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mechlorethamine.
DB00012 DB00894 Testolactone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Testolactone.
DB00012 DB00928 Azacitidine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Azacitidine.
DB00012 DB00947 Fulvestrant The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fulvestrant.
DB00012 DB00958 Carboplatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboplatin.
DB00012 DB00959 Methylprednisolone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylprednisolone.
DB00012 DB00970 Dactinomycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dactinomycin.
DB00012 DB00987 Cytarabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cytarabine.
DB00012 DB00990 Exemestane The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exemestane.
DB00012 DB00997 Doxorubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Doxorubicin.
DB00012 DB01005 Hydroxyurea The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hydroxyurea.
DB00012 DB01006 Letrozole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Letrozole.
DB00012 DB01008 Busulfan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Busulfan.
DB00012 DB01030 Topotecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Topotecan.
DB00012 DB01033 Mercaptopurine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mercaptopurine.
DB00012 DB01042 Melphalan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Melphalan.
DB00012 DB01073 Fludarabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fludarabine.
DB00012 DB01101 Capecitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Capecitabine.
DB00012 DB01108 Trilostane The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trilostane.
DB00012 DB01128 Bicalutamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bicalutamide.
DB00012 DB01157 Trimetrexate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trimetrexate.
DB00012 DB01168 Procarbazine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Procarbazine.
DB00012 DB01169 Arsenic trioxide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Arsenic trioxide.
DB00012 DB01177 Idarubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idarubicin.
DB00012 DB01181 Ifosfamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ifosfamide.
DB00012 DB01196 Estramustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Estramustine.
DB00012 DB01204 Mitoxantrone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitoxantrone.
DB00012 DB01206 Lomustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lomustine.
DB00012 DB01217 Anastrozole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anastrozole.
DB00012 DB01229 Paclitaxel The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel.
DB00012 DB01234 Dexamethasone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dexamethasone.
DB00012 DB01248 Docetaxel The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Docetaxel.
DB00012 DB01254 Dasatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dasatinib.
DB00012 DB01259 Lapatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lapatinib.
DB00012 DB01262 Decitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Decitabine.
DB00012 DB01268 Sunitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sunitinib.
DB00012 DB01269 Panitumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Panitumumab.
DB00012 DB01280 Nelarabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nelarabine.
DB00012 DB01590 Everolimus The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Everolimus.
DB00012 DB01645 Genistein The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Genistein.
DB00012 DB01667 8-azaguanine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 8-azaguanine.
DB00012 DB01873 Epothilone D The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epothilone D.
DB00012 DB01933 7-Hydroxystaurosporine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 7-Hydroxystaurosporine.
DB00012 DB02109 Hadacidin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hadacidin.
DB00012 DB02342 2-Methoxyestradiol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-Methoxyestradiol.
DB00012 DB02424 Geldanamycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Geldanamycin.
DB00012 DB02546 Vorinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vorinostat.
DB00012 DB02640 Fumagillin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fumagillin.
DB00012 DB03010 Patupilone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Patupilone.
DB00012 DB03172 Tubercidin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tubercidin.
DB00012 DB03459 Sparfosic acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sparfosic acid.
DB00012 DB03496 Alvocidib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alvocidib.
DB00012 DB03509 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
DB00012 DB03523 Brequinar The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brequinar.
DB00012 DB03695 Piritrexim The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Piritrexim.
DB00012 DB03825 Rhodamine 6G The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rhodamine 6G.
DB00012 DB03880 Batimastat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Batimastat.
DB00012 DB03946 3,4-Dihydroxybenzoic Acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 3,4-Dihydroxybenzoic Acid.
DB00012 DB04106 Fotemustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fotemustine.
DB00012 DB04222 Sparsomycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sparsomycin.
DB00012 DB04253 Tretazicar The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretazicar.
DB00012 DB04258 Seocalcitol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Seocalcitol.
DB00012 DB04331 Monastrol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Monastrol.
DB00012 DB04440 Nebularine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nebularine.
DB00012 DB04468 Afimoxifene The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Afimoxifene.
DB00012 DB04572 Thiotepa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Thiotepa.
DB00012 DB04576 Fleroxacin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fleroxacin.
DB00012 DB04655 Metoprine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Metoprine.
DB00012 DB04690 Camptothecin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Camptothecin.
DB00012 DB04786 Suramin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Suramin.
DB00012 DB04827 Urethane The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Urethane.
DB00012 DB04839 Cyproterone acetate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cyproterone acetate.
DB00012 DB04845 Ixabepilone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ixabepilone.
DB00012 DB04849 Cediranib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cediranib.
DB00012 DB04858 Tirapazamine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tirapazamine.
DB00012 DB04865 Omacetaxine mepesuccinate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Omacetaxine mepesuccinate.
DB00012 DB04866 Halofuginone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Halofuginone.
DB00012 DB04868 Nilotinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nilotinib.
DB00012 DB04894 Vapreotide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vapreotide.
DB00012 DB04900 Thymalfasin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Thymalfasin.
DB00012 DB04901 Galiximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Galiximab.
DB00012 DB04907 Sitimagene ceradenovec The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sitimagene ceradenovec.
DB00012 DB04950 Ranpirnase The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ranpirnase.
DB00012 DB04951 Pirfenidone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pirfenidone.
DB00012 DB04958 Epratuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epratuzumab.
DB00012 DB04960 Tipifarnib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tipifarnib.
DB00012 DB04961 Troxacitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Troxacitabine.
DB00012 DB04964 Oregovomab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oregovomab.
DB00012 DB04975 Banoxantrone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Banoxantrone.
DB00012 DB04977 Plitidepsin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plitidepsin.
DB00012 DB04996 Satraplatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Satraplatin.
DB00012 DB05015 Belinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belinostat.
DB00012 DB05022 Amonafide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Amonafide.
DB00012 DB05076 Fenretinide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fenretinide.
DB00012 DB05088 Tetrathiomolybdate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tetrathiomolybdate.
DB00012 DB05097 Labetuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Labetuzumab.
DB00012 DB05109 Trabectedin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trabectedin.
DB00012 DB05129 Elsamitrucin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Elsamitrucin.
DB00012 DB05136 Bavituximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bavituximab.
DB00012 DB05223 Pracinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pracinostat.
DB00012 DB05239 Cobimetinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cobimetinib.
DB00012 DB05260 Gallium nitrate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gallium nitrate.
DB00012 DB05265 Ecabet The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ecabet.
DB00012 DB05294 Vandetanib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vandetanib.
DB00012 DB05374 Rindopepimut The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rindopepimut.
DB00012 DB05424 Canertinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Canertinib.
DB00012 DB05428 Motexafin gadolinium The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Motexafin gadolinium.
DB00012 DB05482 7-ethyl-10-hydroxycamptothecin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 7-ethyl-10-hydroxycamptothecin.
DB00012 DB05524 Pelitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pelitinib.
DB00012 DB05540 Alanosine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alanosine.
DB00012 DB05578 Ramucirumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ramucirumab.
DB00012 DB05595 Farletuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Farletuzumab.
DB00012 DB05656 Veltuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Veltuzumab.
DB00012 DB05668 Palifosfamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Palifosfamide.
DB00012 DB05697 AP 12009 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AP 12009.
DB00012 DB05773 Trastuzumab emtansine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trastuzumab emtansine.
DB00012 DB05779 Oglufanide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oglufanide.
DB00012 DB05786 Irofulven The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Irofulven.
DB00012 DB05812 Abiraterone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Abiraterone.
DB00012 DB05889 Inotuzumab ozogamicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Inotuzumab ozogamicin.
DB00012 DB05903 KOS-1584 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KOS-1584.
DB00012 DB05916 CT-011 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CT-011.
DB00012 DB05974 Transcrocetinate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Transcrocetinate.
DB00012 DB05996 Glembatumumab vedotin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glembatumumab vedotin.
DB00012 DB06013 Aldoxorubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aldoxorubicin.
DB00012 DB06021 AV-412 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AV-412.
DB00012 DB06040 Filanesib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Filanesib.
DB00012 DB06043 Olaratumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olaratumab.
DB00012 DB06159 Rubitecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rubitecan.
DB00012 DB06160 Garenoxacin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Garenoxacin.
DB00012 DB06163 Plevitrexed The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plevitrexed.
DB00012 DB06171 Paclitaxel trevatide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel trevatide.
DB00012 DB06176 Romidepsin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Romidepsin.
DB00012 DB06181 IMO-2055 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with IMO-2055.
DB00012 DB06186 Ipilimumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ipilimumab.
DB00012 DB06192 Nimotuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nimotuzumab.
DB00012 DB06193 Pixantrone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pixantrone.
DB00012 DB06195 Seliciclib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Seliciclib.
DB00012 DB06199 Atrasentan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Atrasentan.
DB00012 DB06233 Ridaforolimus The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ridaforolimus.
DB00012 DB06235 Vadimezan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vadimezan.
DB00012 DB06246 Exisulind The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exisulind.
DB00012 DB06263 Amrubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Amrubicin.
DB00012 DB06266 Lonidamine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lonidamine.
DB00012 DB06272 Maxacalcitol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Maxacalcitol.
DB00012 DB06287 Temsirolimus The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temsirolimus.
DB00012 DB06317 Elotuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Elotuzumab.
DB00012 DB06334 Tucidinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tucidinostat.
DB00012 DB06365 Sapacitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sapacitabine.
DB00012 DB06366 Pertuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pertuzumab.
DB00012 DB06370 Indisulam The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Indisulam.
DB00012 DB06420 Annamycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Annamycin.
DB00012 DB06423 Endostatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Endostatin.
DB00012 DB06433 Tezacitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tezacitabine.
DB00012 DB06436 Semaxanib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Semaxanib.
DB00012 DB06445 Diethylnorspermine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Diethylnorspermine.
DB00012 DB06461 Squalamine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Squalamine.
DB00012 DB06478 Porfiromycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Porfiromycin.
DB00012 DB06517 MLN576 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with MLN576.
DB00012 DB06589 Pazopanib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pazopanib.
DB00012 DB06595 Midostaurin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Midostaurin.
DB00012 DB06603 Panobinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Panobinostat.
DB00012 DB06607 Catumaxomab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Catumaxomab.
DB00012 DB06616 Bosutinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bosutinib.
DB00012 DB06626 Axitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Axitinib.
DB00012 DB06647 Volociximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Volociximab.
DB00012 DB06650 Ofatumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ofatumumab.
DB00012 DB06699 Degarelix The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Degarelix.
DB00012 DB06710 Methyltestosterone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methyltestosterone.
DB00012 DB06719 Buserelin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Buserelin.
DB00012 DB06748 Ginsenoside C The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ginsenoside C.
DB00012 DB06769 Bendamustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bendamustine.
DB00012 DB06772 Cabazitaxel The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabazitaxel.
DB00012 DB06789 Hydroxyprogesterone caproate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hydroxyprogesterone caproate.
DB00012 DB06791 Lanreotide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lanreotide.
DB00012 DB06810 Plicamycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plicamycin.
DB00012 DB06813 Pralatrexate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralatrexate.
DB00012 DB06825 Triptorelin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triptorelin.
DB00012 DB07232 Veliparib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Veliparib.
DB00012 DB07931 Hexestrol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hexestrol.
DB00012 DB08313 Nocodazole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nocodazole.
DB00012 DB08437 Puromycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Puromycin.
DB00012 DB08486 Efaproxiral The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Efaproxiral.
DB00012 DB08633 TNP-470 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with TNP-470.
DB00012 DB08828 Vismodegib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vismodegib.
DB00012 DB08865 Crizotinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Crizotinib.
DB00012 DB08870 Brentuximab vedotin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brentuximab vedotin.
DB00012 DB08871 Eribulin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Eribulin.
DB00012 DB08875 Cabozantinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cabozantinib.
DB00012 DB08877 Ruxolitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ruxolitinib.
DB00012 DB08881 Vemurafenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vemurafenib.
DB00012 DB08886 Asparaginase Erwinia chrysanthemi The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Asparaginase Erwinia chrysanthemi.
DB00012 DB08889 Carfilzomib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carfilzomib.
DB00012 DB08896 Regorafenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Regorafenib.
DB00012 DB08899 Enzalutamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enzalutamide.
DB00012 DB08901 Ponatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ponatinib.
DB00012 DB08905 Formestane The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Formestane.
DB00012 DB08911 Trametinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trametinib.
DB00012 DB08912 Dabrafenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dabrafenib.
DB00012 DB08913 Radium Ra 223 dichloride The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Radium Ra 223 dichloride.
DB00012 DB08916 Afatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Afatinib.
DB00012 DB08935 Obinutuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Obinutuzumab.
DB00012 DB08972 Flumequine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Flumequine.
DB00012 DB09010 Carmofur The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carmofur.
DB00012 DB09031 Miltefosine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Miltefosine.
DB00012 DB09035 Nivolumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nivolumab.
DB00012 DB09036 Siltuximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Siltuximab.
DB00012 DB09037 Pembrolizumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pembrolizumab.
DB00012 DB09052 Blinatumomab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Blinatumomab.
DB00012 DB09053 Ibrutinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ibrutinib.
DB00012 DB09054 Idelalisib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Idelalisib.
DB00012 DB09063 Ceritinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ceritinib.
DB00012 DB09073 Palbociclib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Palbociclib.
DB00012 DB09074 Olaparib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olaparib.
DB00012 DB09077 Dinutuximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dinutuximab.
DB00012 DB09078 Lenvatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lenvatinib.
DB00012 DB09079 Nintedanib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nintedanib.
DB00012 DB09123 Dienogest The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dienogest.
DB00012 DB09143 Sonidegib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sonidegib.
DB00012 DB09239 Niguldipine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Niguldipine.
DB00012 DB09256 Tegafur The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tegafur.
DB00012 DB09274 Artesunate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Artesunate.
DB00012 DB09298 Silibinin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Silibinin.
DB00012 DB09330 Osimertinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Osimertinib.
DB00012 DB09331 Daratumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daratumumab.
DB00012 DB09559 Necitumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Necitumumab.
DB00012 DB09570 Ixazomib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ixazomib.
DB00012 DB11363 Alectinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alectinib.
DB00012 DB11366 Roquinimex The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Roquinimex.
DB00012 DB11526 Masitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Masitinib.
DB00012 DB11581 Venetoclax The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Venetoclax.
DB00012 DB11595 Atezolizumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Atezolizumab.
DB00012 DB11616 Pirarubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pirarubicin.
DB00012 DB11617 Aclarubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aclarubicin.
DB00012 DB11618 Zorubicin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Zorubicin.
DB00012 DB11630 Temoporfin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Temoporfin.
DB00012 DB11646 Conatumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Conatumumab.
DB00012 DB11651 Dactolisib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dactolisib.
DB00012 DB11662 Rabusertib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rabusertib.
DB00012 DB11669 Ortataxel The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ortataxel.
DB00012 DB11678 Treosulfan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Treosulfan.
DB00012 DB11688 2-chloroethyl-3-sarcosinamide-1-nitrosourea The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.
DB00012 DB11694 Ilorasertib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ilorasertib.
DB00012 DB11714 Durvalumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Durvalumab.
DB00012 DB11716 Misonidazole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Misonidazole.
DB00012 DB11717 Epacadostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epacadostat.
DB00012 DB11718 Encorafenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Encorafenib.
DB00012 DB11727 Endostar The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Endostar.
DB00012 DB11730 Ribociclib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ribociclib.
DB00012 DB11737 Icotinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Icotinib.
DB00012 DB11752 Bryostatin 1 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bryostatin 1.
DB00012 DB11760 Talazoparib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talazoparib.
DB00012 DB11771 Tremelimumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tremelimumab.
DB00012 DB11793 Niraparib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Niraparib.
DB00012 DB11795 GSK-2636771 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with GSK-2636771.
DB00012 DB11800 Tivozanib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tivozanib.
DB00012 DB11805 Saracatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Saracatinib.
DB00012 DB11812 Talaporfin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talaporfin.
DB00012 DB11828 Neratinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Neratinib.
DB00012 DB11830 Mocetinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mocetinostat.
DB00012 DB11832 Crenolanib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Crenolanib.
DB00012 DB11841 Entinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entinostat.
DB00012 DB11880 Acridine Carboxamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Acridine Carboxamide.
DB00012 DB11886 Infigratinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Infigratinib.
DB00012 DB11891 CUDC-907 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CUDC-907.
DB00012 DB11894 Efatutazone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Efatutazone.
DB00012 DB11901 Apalutamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Apalutamide.
DB00012 DB11907 Rociletinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rociletinib.
DB00012 DB11918 Guadecitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Guadecitabine.
DB00012 DB11919 6-O-benzylguanine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 6-O-benzylguanine.
DB00012 DB11945 Avelumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Avelumab.
DB00012 DB11960 Carboxyamidotriazole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboxyamidotriazole.
DB00012 DB11963 Dacomitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacomitinib.
DB00012 DB11967 Binimetinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Binimetinib.
DB00012 DB11972 Rilotumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rilotumumab.
DB00012 DB11973 Tesevatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tesevatinib.
DB00012 DB11978 Glasdegib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glasdegib.
DB00012 DB11986 Entrectinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Entrectinib.
DB00012 DB11999 Vosaroxin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vosaroxin.
DB00012 DB12001 Abemaciclib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Abemaciclib.
DB00012 DB12015 Alpelisib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alpelisib.
DB00012 DB12025 Triptolide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triptolide.
DB00012 DB12028 Broxuridine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Broxuridine.
DB00012 DB12036 Naquotinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Naquotinib.
DB00012 DB12056 Trebananib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trebananib.
DB00012 DB12081 Anecortave The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anecortave.
DB00012 DB12082 Vesnarinone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vesnarinone.
DB00012 DB12083 Mafosfamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mafosfamide.
DB00012 DB12085 LCL-161 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with LCL-161.
DB00012 DB12089 Lorvotuzumab mertansine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lorvotuzumab mertansine.
DB00012 DB12108 Taselisib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Taselisib.
DB00012 DB12124 Namitecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Namitecan.
DB00012 DB12130 Lorlatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lorlatinib.
DB00012 DB12141 Gilteritinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gilteritinib.
DB00012 DB12142 Duligotuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Duligotuzumab.
DB00012 DB12146 Rigosertib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rigosertib.
DB00012 DB12147 Erdafitinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Erdafitinib.
DB00012 DB12156 Cordycepin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cordycepin.
DB00012 DB12174 CUDC-101 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CUDC-101.
DB00012 DB12182 Binetrakin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Binetrakin.
DB00012 DB12185 Exatecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Exatecan.
DB00012 DB12202 Zalutumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Zalutumumab.
DB00012 DB12222 Lurtotecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lurtotecan.
DB00012 DB12232 KRN-7000 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KRN-7000.
DB00012 DB12257 Platinum The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Platinum.
DB00012 DB12259 CG-200745 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with CG-200745.
DB00012 DB12266 Epofolate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Epofolate.
DB00012 DB12267 Brigatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brigatinib.
DB00012 DB12279 OBP-801 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with OBP-801.
DB00012 DB12332 Rucaparib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rucaparib.
DB00012 DB12340 Navitoclax The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Navitoclax.
DB00012 DB12352 Bizelesin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bizelesin.
DB00012 DB12376 Ricolinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ricolinostat.
DB00012 DB12379 Indirubin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Indirubin.
DB00012 DB12381 Merestinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Merestinib.
DB00012 DB12382 R-306465 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with R-306465.
DB00012 DB12385 10-hydroxycamptothecin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 10-hydroxycamptothecin.
DB00012 DB12391 Sagopilone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sagopilone.
DB00012 DB12422 Sulforaphane The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sulforaphane.
DB00012 DB12459 Belotecan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belotecan.
DB00012 DB12473 Taurolidine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Taurolidine.
DB00012 DB12480 Betulinic Acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Betulinic Acid.
DB00012 DB12483 Copanlisib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Copanlisib.
DB00012 DB12498 Mogamulizumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mogamulizumab.
DB00012 DB12515 9-aminocamptothecin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with 9-aminocamptothecin.
DB00012 DB12525 Molgramostim The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Molgramostim.
DB00012 DB12539 Oltipraz The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oltipraz.
DB00012 DB12549 Pyrazoloacridine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pyrazoloacridine.
DB00012 DB12565 Abexinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Abexinostat.
DB00012 DB12577 Fosbretabulin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fosbretabulin.
DB00012 DB12589 Dacetuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacetuzumab.
DB00012 DB12593 Apaziquone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Apaziquone.
DB00012 DB12596 Combretastatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Combretastatin.
DB00012 DB12617 Mizoribine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mizoribine.
DB00012 DB12637 Onapristone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Onapristone.
DB00012 DB12638 PU-H71 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with PU-H71.
DB00012 DB12645 Givinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Givinostat.
DB00012 DB12671 Beloranib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Beloranib.
DB00012 DB12677 Soblidotin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Soblidotin.
DB00012 DB12681 Salirasib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Salirasib.
DB00012 DB12688 Moxetumomab Pasudotox The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Moxetumomab Pasudotox.
DB00012 DB12692 Gusperimus The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Gusperimus.
DB00012 DB12695 Phenethyl Isothiocyanate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Phenethyl Isothiocyanate.
DB00012 DB12697 Methylselenocysteine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylselenocysteine.
DB00012 DB12701 Intetumumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Intetumumab.
DB00012 DB12730 Dolastatin 10 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dolastatin 10.
DB00012 DB12736 Etanidazole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etanidazole.
DB00012 DB12769 Lometrexol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lometrexol.
DB00012 DB12797 Ecromeximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ecromeximab.
DB00012 DB12832 Prednimustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednimustine.
DB00012 DB12870 Buthionine Sulfoximine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Buthionine Sulfoximine.
DB00012 DB12873 Dianhydrogalactitol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dianhydrogalactitol.
DB00012 DB12881 Indole-3-carbinol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Indole-3-carbinol.
DB00012 DB12901 Fiacitabine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fiacitabine.
DB00012 DB12902 Trofosfamide The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Trofosfamide.
DB00012 DB12912 Nolatrexed The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nolatrexed.
DB00012 DB12916 Mitolactol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitolactol.
DB00012 DB12920 Pinometostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pinometostat.
DB00012 DB12947 Doxifluridine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Doxifluridine.
DB00012 DB12948 Didox The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Didox.
DB00012 DB12967 Mitoguazone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitoguazone.
DB00012 DB12978 Pexidartinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pexidartinib.
DB00012 DB12987 Penclomedine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Penclomedine.
DB00012 DB12991 Deoxyspergualin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Deoxyspergualin.
DB00012 DB12996 Acteoside The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Acteoside.
DB00012 DB13005 Rebastinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rebastinib.
DB00012 DB13014 Hypericin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Hypericin.
DB00012 DB13046 Tocladesine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tocladesine.
DB00012 DB13066 Liarozole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Liarozole.
DB00012 DB13069 Nimustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nimustine.
DB00012 DB13104 X-396 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with X-396.
DB00012 DB13128 Sizofiran The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sizofiran.
DB00012 DB13145 Nedaplatin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nedaplatin.
DB00012 DB13164 Olmutinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olmutinib.
DB00012 DB13182 Daidzein The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daidzein.
DB00012 DB13243 Tiazofurine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tiazofurine.
DB00012 DB13304 Triaziquone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Triaziquone.
DB00012 DB13318 Demecolcine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Demecolcine.
DB00012 DB13334 Mannosulfan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mannosulfan.
DB00012 DB13339 Etoglucid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etoglucid.
DB00012 DB13375 Edrecolomab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Edrecolomab.
DB00012 DB13480 Lentinan The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lentinan.
DB00012 DB13543 Mitobronitol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mitobronitol.
DB00012 DB13627 Oxolinic acid The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oxolinic acid.
DB00012 DB13647 Semustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Semustine.
DB00012 DB13677 Carboquone The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Carboquone.
DB00012 DB13767 Vorozole The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Vorozole.
DB00012 DB13809 Paclitaxel poliglumex The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Paclitaxel poliglumex.
DB00012 DB13811 Oblimersen The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Oblimersen.
DB00012 DB13832 Ranimustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ranimustine.
DB00012 DB13874 Enasidenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enasidenib.
DB00012 DB13877 Iniparib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Iniparib.
DB00012 DB13896 Talimogene laherparepvec The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Talimogene laherparepvec.
DB00012 DB13912 Coumermycin A1 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Coumermycin A1.
DB00012 DB13916 Toyocamycin The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Toyocamycin.
DB00012 DB14031 Tretamine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretamine.
DB00012 DB14066 Tetrandrine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tetrandrine.
DB00012 DB14067 Dofequidar The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dofequidar.
DB00012 DB14068 Dexniguldipine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dexniguldipine.
DB00012 DB14568 Ivosidenib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ivosidenib.
DB00012 DB14644 Methylprednisolone hemisuccinate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylprednisolone hemisuccinate.
DB00012 DB14646 Prednisone acetate The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Prednisone acetate.
DB00012 DB14680 Combretastatin A4 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Combretastatin A4.
DB00012 DB14707 Cemiplimab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cemiplimab.
DB00012 DB14723 Larotrectinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Larotrectinib.
DB00012 DB14731 Tagraxofusp The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tagraxofusp.
DB00012 DB14765 Rivoceranib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Rivoceranib.
DB00012 DB14792 AZD-5991 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with AZD-5991.
DB00012 DB14844 ONC-201 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with ONC-201.
DB00012 DB14860 Ensartinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ensartinib.
DB00012 DB14865 Human interleukin-2 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Human interleukin-2.
DB00012 DB14877 Lintuzumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lintuzumab.
DB00012 DB14947 Bermekimab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bermekimab.
DB00012 DB14951 Etirinotecan pegol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etirinotecan pegol.
DB00012 DB15035 Zanubrutinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Zanubrutinib.
DB00012 DB15057 NUC-1031 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with NUC-1031.
DB00012 DB15157 Voruciclib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Voruciclib.
DB00012 DB15215 KRN-5500 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with KRN-5500.
DB00012 DB15289 Perillyl alcohol The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Perillyl alcohol.
DB00012 DB15321 Tefinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tefinostat.
DB00012 DB15334 Biochanin A The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Biochanin A.
DB00012 DB15351 Dihematoporphyrin ether The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dihematoporphyrin ether.
DB00012 DB15366 SOR-C13 The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with SOR-C13.
DB00012 DB15383 Pidilizumab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pidilizumab.
DB00012 DB15419 Nanatinostat The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nanatinostat.
DB00012 DB15466 Tallimustine The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tallimustine.
DB00012 DB12062 Volasertib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Volasertib.
DB00012 DB14811 Isatuximab The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Isatuximab.
DB00012 DB15102 Pemigatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pemigatinib.
DB00012 DB11791 Capmatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Capmatinib.
DB00012 DB15685 Selpercatinib The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Selpercatinib.
DB00012 DB00531 Cyclophosphamide The risk or severity of pulmonary toxicity can be increased when Darbepoetin alfa is combined with Cyclophosphamide.
DB00012 DB00984 Nandrolone phenpropionate The therapeutic efficacy of Darbepoetin alfa can be increased when used in combination with Nandrolone phenpropionate.
DB00012 DB08804 Nandrolone decanoate The therapeutic efficacy of Darbepoetin alfa can be increased when used in combination with Nandrolone decanoate.
DB00012 DB13169 Nandrolone The therapeutic efficacy of Darbepoetin alfa can be increased when used in combination with Nandrolone.
DB00012 DB00309 Vindesine The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vindesine.
DB00012 DB00361 Vinorelbine The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vinorelbine.
DB00012 DB00541 Vincristine The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vincristine.
DB00012 DB00570 Vinblastine The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vinblastine.
DB00012 DB05168 Vintafolide The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vintafolide.
DB00012 DB11641 Vinflunine The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vinflunine.
DB00012 DB13374 Vincamine The risk or severity of peripheral neuropathy can be increased when Darbepoetin alfa is combined with Vincamine.
DB00013 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Urokinase.
DB00013 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Urokinase.
DB00013 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Urokinase.
DB00013 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Urokinase is combined with Deferasirox.
DB00013 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Ursodeoxycholic acid.
DB00013 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Glycochenodeoxycholic Acid.
DB00013 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Cholic Acid.
DB00013 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Glycocholic acid.
DB00013 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Deoxycholic acid.
DB00013 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Taurocholic acid.
DB00013 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Obeticholic acid.
DB00013 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Chenodeoxycholic acid.
DB00013 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Taurochenodeoxycholic acid.
DB00013 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Tauroursodeoxycholic acid.
DB00013 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Bamet-UD2.
DB00013 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Dehydrocholic acid.
DB00013 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Hyodeoxycholic Acid.
DB00013 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Urokinase.
DB00013 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Urokinase.
DB00013 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Obinutuzumab.
DB00013 DB06228 Rivaroxaban Urokinase may increase the anticoagulant activities of Rivaroxaban.
DB00013 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Sugammadex.
DB00013 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Urokinase.
DB00013 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Urokinase.
DB00013 DB00001 Lepirudin Urokinase may increase the anticoagulant activities of Lepirudin.
DB00013 DB00006 Bivalirudin Urokinase may increase the anticoagulant activities of Bivalirudin.
DB00013 DB00009 Alteplase Urokinase may increase the anticoagulant activities of Alteplase.
DB00013 DB00015 Reteplase Urokinase may increase the anticoagulant activities of Reteplase.
DB00013 DB00029 Anistreplase Urokinase may increase the anticoagulant activities of Anistreplase.
DB00013 DB00031 Tenecteplase Urokinase may increase the anticoagulant activities of Tenecteplase.
DB00013 DB00054 Abciximab Urokinase may increase the anticoagulant activities of Abciximab.
DB00013 DB00055 Drotrecogin alfa Urokinase may increase the anticoagulant activities of Drotrecogin alfa.
DB00013 DB00086 Streptokinase Urokinase may increase the anticoagulant activities of Streptokinase.
DB00013 DB00266 Dicoumarol Urokinase may increase the anticoagulant activities of Dicoumarol.
DB00013 DB00278 Argatroban Urokinase may increase the anticoagulant activities of Argatroban.
DB00013 DB00407 Ardeparin Urokinase may increase the anticoagulant activities of Ardeparin.
DB00013 DB00498 Phenindione Urokinase may increase the anticoagulant activities of Phenindione.
DB00013 DB00569 Fondaparinux Urokinase may increase the anticoagulant activities of Fondaparinux.
DB00013 DB00682 Warfarin Urokinase may increase the anticoagulant activities of Warfarin.
DB00013 DB00686 Pentosan polysulfate Urokinase may increase the anticoagulant activities of Pentosan polysulfate.
DB00013 DB00945 Acetylsalicylic acid Urokinase may increase the anticoagulant activities of Acetylsalicylic acid.
DB00013 DB00946 Phenprocoumon Urokinase may increase the anticoagulant activities of Phenprocoumon.
DB00013 DB00975 Dipyridamole Urokinase may increase the anticoagulant activities of Dipyridamole.
DB00013 DB01088 Iloprost Urokinase may increase the anticoagulant activities of Iloprost.
DB00013 DB01109 Heparin Urokinase may increase the anticoagulant activities of Heparin.
DB00013 DB01225 Enoxaparin Urokinase may increase the anticoagulant activities of Enoxaparin.
DB00013 DB01240 Epoprostenol Urokinase may increase the anticoagulant activities of Epoprostenol.
DB00013 DB01418 Acenocoumarol Urokinase may increase the anticoagulant activities of Acenocoumarol.
DB00013 DB03410 4-hydroxycoumarin Urokinase may increase the anticoagulant activities of 4-hydroxycoumarin.
DB00013 DB04665 Coumarin Urokinase may increase the anticoagulant activities of Coumarin.
DB00013 DB04898 Ximelagatran Urokinase may increase the anticoagulant activities of Ximelagatran.
DB00013 DB04925 Desmoteplase Urokinase may increase the anticoagulant activities of Desmoteplase.
DB00013 DB04932 Defibrotide Urokinase may increase the anticoagulant activities of Defibrotide.
DB00013 DB05099 Ancrod Urokinase may increase the anticoagulant activities of Ancrod.
DB00013 DB05229 Beraprost Urokinase may increase the anticoagulant activities of Beraprost.
DB00013 DB05254 Fibrinolysin Urokinase may increase the anticoagulant activities of Fibrinolysin.
DB00013 DB06209 Prasugrel Urokinase may increase the anticoagulant activities of Prasugrel.
DB00013 DB06271 Sulodexide Urokinase may increase the anticoagulant activities of Sulodexide.
DB00013 DB06294 Semuloparin Urokinase may increase the anticoagulant activities of Semuloparin.
DB00013 DB06406 Idraparinux Urokinase may increase the anticoagulant activities of Idraparinux.
DB00013 DB06441 Cangrelor Urokinase may increase the anticoagulant activities of Cangrelor.
DB00013 DB06543 Astaxanthin Urokinase may increase the anticoagulant activities of Astaxanthin.
DB00013 DB06635 Otamixaban Urokinase may increase the anticoagulant activities of Otamixaban.
DB00013 DB06679 Amediplase Urokinase may increase the anticoagulant activities of Amediplase.
DB00013 DB06754 Danaparoid Urokinase may increase the anticoagulant activities of Danaparoid.
DB00013 DB06779 Dalteparin Urokinase may increase the anticoagulant activities of Dalteparin.
DB00013 DB06822 Tinzaparin Urokinase may increase the anticoagulant activities of Tinzaparin.
DB00013 DB07767 Ferulic acid Urokinase may increase the anticoagulant activities of Ferulic acid.
DB00013 DB08496 (R)-warfarin Urokinase may increase the anticoagulant activities of (R)-warfarin.
DB00013 DB08794 Ethyl biscoumacetate Urokinase may increase the anticoagulant activities of Ethyl biscoumacetate.
DB00013 DB08813 Nadroparin Urokinase may increase the anticoagulant activities of Nadroparin.
DB00013 DB08814 Triflusal Urokinase may increase the anticoagulant activities of Triflusal.
DB00013 DB08816 Ticagrelor Urokinase may increase the anticoagulant activities of Ticagrelor.
DB00013 DB08994 Ditazole Urokinase may increase the anticoagulant activities of Ditazole.
DB00013 DB09030 Vorapaxar Urokinase may increase the anticoagulant activities of Vorapaxar.
DB00013 DB09125 Potassium citrate Urokinase may increase the anticoagulant activities of Potassium citrate.
DB00013 DB09154 Sodium citrate Urokinase may increase the anticoagulant activities of Sodium citrate.
DB00013 DB09255 Dextran Urokinase may increase the anticoagulant activities of Dextran.
DB00013 DB09258 Bemiparin Urokinase may increase the anticoagulant activities of Bemiparin.
DB00013 DB09259 Reviparin Urokinase may increase the anticoagulant activities of Reviparin.
DB00013 DB09260 Parnaparin Urokinase may increase the anticoagulant activities of Parnaparin.
DB00013 DB09261 Certoparin Urokinase may increase the anticoagulant activities of Certoparin.
DB00013 DB11095 Desirudin Urokinase may increase the anticoagulant activities of Desirudin.
DB00013 DB11154 Zinc citrate Urokinase may increase the anticoagulant activities of Zinc citrate.
DB00013 DB11166 Antithrombin Alfa Urokinase may increase the anticoagulant activities of Antithrombin Alfa.
DB00013 DB11312 Protein C Urokinase may increase the anticoagulant activities of Protein C.
DB00013 DB11598 Antithrombin III human Urokinase may increase the anticoagulant activities of Antithrombin III human.
DB00013 DB11984 Letaxaban Urokinase may increase the anticoagulant activities of Letaxaban.
DB00013 DB12289 Darexaban Urokinase may increase the anticoagulant activities of Darexaban.
DB00013 DB12364 Betrixaban Urokinase may increase the anticoagulant activities of Betrixaban.
DB00013 DB12598 Nafamostat Urokinase may increase the anticoagulant activities of Nafamostat.
DB00013 DB12726 Monteplase Urokinase may increase the anticoagulant activities of Monteplase.
DB00013 DB12831 Gabexate Urokinase may increase the anticoagulant activities of Gabexate.
DB00013 DB13136 Fluindione Urokinase may increase the anticoagulant activities of Fluindione.
DB00013 DB13149 Protein S human Urokinase may increase the anticoagulant activities of Protein S human.
DB00013 DB13199 Brinase Urokinase may increase the anticoagulant activities of Brinase.
DB00013 DB13275 Clorindione Urokinase may increase the anticoagulant activities of Clorindione.
DB00013 DB13347 Diphenadione Urokinase may increase the anticoagulant activities of Diphenadione.
DB00013 DB13451 Tioclomarol Urokinase may increase the anticoagulant activities of Tioclomarol.
DB00013 DB13616 Melagatran Urokinase may increase the anticoagulant activities of Melagatran.
DB00013 DB13646 Saruplase Urokinase may increase the anticoagulant activities of Saruplase.
DB00013 DB14055 (S)-Warfarin Urokinase may increase the anticoagulant activities of (S)-Warfarin.
DB00013 DB14094 Tocopherylquinone Urokinase may increase the anticoagulant activities of Tocopherylquinone.
DB00013 DB14598 Edetate calcium disodium anhydrous Urokinase may increase the anticoagulant activities of Edetate calcium disodium anhydrous.
DB00013 DB14726 Dabigatran Urokinase may increase the anticoagulant activities of Dabigatran.
DB00013 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Urokinase.
DB00013 DB06692 Aprotinin The therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin.
DB00013 DB00063 Eptifibatide Eptifibatide may increase the anticoagulant activities of Urokinase.
DB00013 DB00208 Ticlopidine Ticlopidine may increase the anticoagulant activities of Urokinase.
DB00013 DB00758 Clopidogrel Clopidogrel may increase the anticoagulant activities of Urokinase.
DB00013 DB00775 Tirofiban Tirofiban may increase the anticoagulant activities of Urokinase.
DB00013 DB00806 Pentoxifylline Pentoxifylline may increase the anticoagulant activities of Urokinase.
DB00013 DB01138 Sulfinpyrazone Sulfinpyrazone may increase the anticoagulant activities of Urokinase.
DB00013 DB01166 Cilostazol Cilostazol may increase the anticoagulant activities of Urokinase.
DB00013 DB01207 Ridogrel Ridogrel may increase the anticoagulant activities of Urokinase.
DB00013 DB01236 Sevoflurane Sevoflurane may increase the anticoagulant activities of Urokinase.
DB00013 DB02709 Resveratrol Resveratrol may increase the anticoagulant activities of Urokinase.
DB00013 DB04743 Nimesulide Nimesulide may increase the anticoagulant activities of Urokinase.
DB00013 DB04905 Tesmilifene Tesmilifene may increase the anticoagulant activities of Urokinase.
DB00013 DB05266 Ibudilast Ibudilast may increase the anticoagulant activities of Urokinase.
DB00013 DB05767 Andrographolide Andrographolide may increase the anticoagulant activities of Urokinase.
DB00013 DB06081 Caplacizumab Caplacizumab may increase the anticoagulant activities of Urokinase.
DB00013 DB07615 Tranilast Tranilast may increase the anticoagulant activities of Urokinase.
DB00013 DB08887 Icosapent ethyl Icosapent ethyl may increase the anticoagulant activities of Urokinase.
DB00013 DB09283 Trapidil Trapidil may increase the anticoagulant activities of Urokinase.
DB00013 DB12092 Naftopidil Naftopidil may increase the anticoagulant activities of Urokinase.
DB00013 DB12163 Sarpogrelate Sarpogrelate may increase the anticoagulant activities of Urokinase.
DB00013 DB12321 Ifetroban Ifetroban may increase the anticoagulant activities of Urokinase.
DB00013 DB12445 Nitroaspirin Nitroaspirin may increase the anticoagulant activities of Urokinase.
DB00013 DB12465 Ketanserin Ketanserin may increase the anticoagulant activities of Urokinase.
DB00013 DB12545 Indobufen Indobufen may increase the anticoagulant activities of Urokinase.
DB00013 DB12749 Butylphthalide Butylphthalide may increase the anticoagulant activities of Urokinase.
DB00013 DB12771 Hydroxytyrosol Hydroxytyrosol may increase the anticoagulant activities of Urokinase.
DB00013 DB13036 Ramatroban Ramatroban may increase the anticoagulant activities of Urokinase.
DB00013 DB13327 Picotamide Picotamide may increase the anticoagulant activities of Urokinase.
DB00013 DB13367 Cloricromen Cloricromen may increase the anticoagulant activities of Urokinase.
DB00013 DB13400 Linsidomine Linsidomine may increase the anticoagulant activities of Urokinase.
DB00013 DB13510 Buflomedil Buflomedil may increase the anticoagulant activities of Urokinase.
DB00013 DB13929 Relcovaptan Relcovaptan may increase the anticoagulant activities of Urokinase.
DB00013 DB00261 Anagrelide Anagrelide may increase the anticoagulant activities of Urokinase.
DB00013 DB01381 Ginkgo biloba The therapeutic efficacy of Urokinase can be increased when used in combination with Ginkgo biloba.
DB00013 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Urokinase.
DB00013 DB00468 Quinine The therapeutic efficacy of Urokinase can be increased when used in combination with Quinine.
DB00013 DB00908 Quinidine The therapeutic efficacy of Urokinase can be increased when used in combination with Quinidine.
DB00013 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Urokinase.
DB00013 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Urokinase.
DB00013 DB00583 Levocarnitine The therapeutic efficacy of Urokinase can be increased when used in combination with Levocarnitine.
DB00013 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Urokinase.
DB00013 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Urokinase.
DB00013 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Urokinase.
DB00013 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Urokinase.
DB00013 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Urokinase.
DB00013 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Urokinase.
DB00013 DB04573 Estriol Estriol may decrease the anticoagulant activities of Urokinase.
DB00013 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Urokinase.
DB00013 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Urokinase.
DB00013 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Urokinase.
DB00013 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Urokinase.
DB00013 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Urokinase.
DB00013 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Urokinase.
DB00013 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Urokinase.
DB00013 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Urokinase.
DB00013 DB11674 Equol Equol may decrease the anticoagulant activities of Urokinase.
DB00013 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Urokinase.
DB00013 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Urokinase.
DB00013 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Urokinase.
DB00013 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Urokinase.
DB00013 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Urokinase.
DB00013 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Urokinase.
DB00013 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Urokinase.
DB00013 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Urokinase.
DB00013 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Urokinase.
DB00013 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Urokinase.
DB00013 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Urokinase.
DB00013 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Urokinase.
DB00013 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Urokinase.
DB00013 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Urokinase.
DB00013 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Urokinase.
DB00013 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Urokinase.
DB00013 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Urokinase.
DB00013 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Urokinase.
DB00013 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Urokinase.
DB00013 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Urokinase.
DB00013 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Urokinase.
DB00013 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Urokinase.
DB00013 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Urokinase.
DB00013 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Urokinase.
DB00013 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Urokinase.
DB00013 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Urokinase.
DB00013 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Urokinase.
DB00013 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Urokinase.
DB00013 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Urokinase.
DB00013 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Urokinase.
DB00013 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Urokinase.
DB00013 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Urokinase.
DB00013 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Urokinase.
DB00013 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Urokinase.
DB00013 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Urokinase.
DB00013 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Urokinase.
DB00013 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Urokinase.
DB00013 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Urokinase.
DB00013 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Urokinase.
DB00013 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Urokinase.
DB00013 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Urokinase.
DB00013 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Urokinase.
DB00013 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Urokinase.
DB00013 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Urokinase.
DB00013 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Urokinase.
DB00013 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Urokinase.
DB00013 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Urokinase.
DB00013 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Urokinase.
DB00013 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Urokinase.
DB00013 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Urokinase.
DB00013 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Urokinase.
DB00013 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Urokinase.
DB00013 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Urokinase.
DB00013 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Urokinase.
DB00013 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Urokinase.
DB00013 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Urokinase.
DB00013 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Urokinase.
DB00013 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Urokinase.
DB00013 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Urokinase.
DB00013 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Urokinase.
DB00013 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Urokinase.
DB00013 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Urokinase.
DB00013 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Urokinase.
DB00013 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Urokinase.
DB00013 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Urokinase.
DB00013 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Urokinase.
DB00013 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Urokinase.
DB00013 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Urokinase.
DB00013 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Urokinase.
DB00013 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Urokinase.
DB00013 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Urokinase.
DB00013 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Urokinase.
DB00013 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Urokinase.
DB00013 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Urokinase.
DB00013 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Urokinase.
DB00013 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Urokinase.
DB00013 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Urokinase.
DB00013 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Urokinase.
DB00013 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Urokinase.
DB00013 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Urokinase.
DB00013 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Urokinase.
DB00013 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Urokinase.
DB00013 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Urokinase.
DB00013 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Urokinase.
DB00013 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Urokinase.
DB00013 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Urokinase.
DB00013 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Urokinase.
DB00013 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Urokinase.
DB00013 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Urokinase.
DB00013 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Urokinase.
DB00013 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Urokinase.
DB00013 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Urokinase.
DB00013 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Urokinase.
DB00013 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Urokinase.
DB00013 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Urokinase.
DB00013 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Urokinase.
DB00013 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Urokinase.
DB00013 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Urokinase.
DB00013 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Urokinase.
DB00013 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Urokinase.
DB00013 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Urokinase.
DB00013 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Urokinase.
DB00013 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Urokinase.
DB00013 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Urokinase.
DB00013 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Urokinase.
DB00013 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Urokinase.
DB00013 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Urokinase.
DB00013 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Urokinase.
DB00013 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Urokinase.
DB00013 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Urokinase.
DB00013 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Urokinase.
DB00013 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Urokinase.
DB00013 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Urokinase.
DB00013 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Urokinase is combined with Omacetaxine mepesuccinate.
DB00013 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Urokinase.
DB00013 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Tositumomab.
DB00013 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Urokinase.
DB00013 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Urokinase is combined with Collagenase clostridium histolyticum.
DB00013 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Urokinase.
DB00013 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Urokinase.
DB00013 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Urokinase.
DB00013 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Urokinase.
DB00013 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Urokinase.
DB00013 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Urokinase.
DB00013 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Urokinase.
DB00013 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Urokinase.
DB00013 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Urokinase.
DB00013 DB00834 Mifepristone The therapeutic efficacy of Urokinase can be decreased when used in combination with Mifepristone.
DB00013 DB04066 p-Coumaric acid The therapeutic efficacy of Urokinase can be decreased when used in combination with p-Coumaric acid.
DB00013 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Urokinase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00013 DB05830 Trestolone The therapeutic efficacy of Urokinase can be decreased when used in combination with Trestolone.
DB00013 DB06266 Lonidamine The therapeutic efficacy of Urokinase can be decreased when used in combination with Lonidamine.
DB00013 DB08867 Ulipristal The therapeutic efficacy of Urokinase can be decreased when used in combination with Ulipristal.
DB00013 DB09401 Isosorbide The therapeutic efficacy of Urokinase can be decreased when used in combination with Isosorbide.
DB00013 DB11507 Cloprostenol The therapeutic efficacy of Urokinase can be decreased when used in combination with Cloprostenol.
DB00013 DB12025 Triptolide The therapeutic efficacy of Urokinase can be decreased when used in combination with Triptolide.
DB00013 DB13044 Gossypol The therapeutic efficacy of Urokinase can be decreased when used in combination with Gossypol.
DB00013 DB13310 Ormeloxifene The therapeutic efficacy of Urokinase can be decreased when used in combination with Ormeloxifene.
DB00013 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Urokinase.
DB00013 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Urokinase.
DB00013 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Urokinase.
DB00013 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Urokinase.
DB00013 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Urokinase.
DB00013 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Urokinase.
DB00013 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Urokinase.
DB00013 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Urokinase.
DB00013 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Urokinase.
DB00013 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Urokinase.
DB00013 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Urokinase.
DB00013 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Urokinase.
DB00013 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Urokinase.
DB00013 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Urokinase.
DB00013 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Urokinase.
DB00013 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Urokinase.
DB00013 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Urokinase.
DB00013 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Urokinase.
DB00013 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Urokinase.
DB00013 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Urokinase.
DB00013 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Urokinase.
DB00013 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Urokinase.
DB00013 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Urokinase.
DB00013 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Urokinase.
DB00013 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Urokinase.
DB00013 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Urokinase.
DB00013 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Urokinase.
DB00013 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Urokinase.
DB00013 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Urokinase.
DB00013 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Urokinase.
DB00013 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Urokinase.
DB00013 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Urokinase.
DB00013 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Urokinase.
DB00013 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Urokinase.
DB00013 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Urokinase.
DB00013 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Urokinase.
DB00013 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Urokinase.
DB00013 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Urokinase.
DB00013 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Urokinase.
DB00013 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Urokinase.
DB00013 DB00374 Treprostinil The risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.
DB00013 DB03404 Hemin Hemin may increase the anticoagulant activities of Urokinase.
DB00013 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Urokinase.
DB00013 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Urokinase.
DB00013 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Urokinase.
DB00013 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Urokinase.
DB00013 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Urokinase.
DB00013 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Urokinase.
DB00013 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Urokinase.
DB00013 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Urokinase.
DB00013 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Urokinase.
DB00013 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Urokinase.
DB00013 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Urokinase.
DB00013 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Urokinase.
DB00013 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Urokinase.
DB00013 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Urokinase.
DB00013 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Urokinase.
DB00013 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Urokinase.
DB00013 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Urokinase is combined with Azficel-T.
DB00013 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Urokinase can be increased when used in combination with Omega-3-carboxylic acids.
DB00013 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Urokinase.
DB00013 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Urokinase.
DB00013 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Urokinase.
DB00013 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Urokinase.
DB00013 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Urokinase.
DB00013 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Urokinase.
DB00013 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Urokinase.
DB00013 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Urokinase.
DB00013 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Urokinase.
DB00013 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Urokinase.
DB00013 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Urokinase.
DB00013 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Urokinase.
DB00013 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Urokinase.
DB00013 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Urokinase.
DB00013 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Urokinase.
DB00013 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Urokinase.
DB00013 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Urokinase.
DB00013 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Urokinase.
DB00013 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Urokinase.
DB00013 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Urokinase.
DB00013 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Urokinase.
DB00013 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Urokinase.
DB00013 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Urokinase.
DB00013 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Urokinase.
DB00013 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Urokinase.
DB00013 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Urokinase.
DB00013 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Urokinase.
DB00013 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Urokinase.
DB00013 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Urokinase.
DB00013 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Urokinase.
DB00013 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Urokinase.
DB00013 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Urokinase.
DB00013 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Urokinase.
DB00013 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Urokinase.
DB00013 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Urokinase.
DB00013 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Urokinase.
DB00013 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Urokinase.
DB00013 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Urokinase.
DB00013 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Urokinase.
DB00013 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Urokinase.
DB00013 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Urokinase.
DB00013 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Urokinase.
DB00013 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Urokinase.
DB00013 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Urokinase.
DB00013 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Urokinase.
DB00013 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Urokinase.
DB00013 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Urokinase.
DB00013 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Urokinase.
DB00013 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Urokinase.
DB00013 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Urokinase.
DB00013 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Urokinase.
DB00013 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Urokinase.
DB00013 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Urokinase.
DB00013 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Urokinase.
DB00013 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Urokinase.
DB00013 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Urokinase.
DB00013 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Urokinase.
DB00013 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Urokinase.
DB00013 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Urokinase.
DB00013 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Urokinase.
DB00013 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Urokinase.
DB00013 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Urokinase.
DB00013 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Urokinase.
DB00013 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Urokinase.
DB00013 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Urokinase.
DB00013 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Urokinase.
DB00013 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Urokinase.
DB00013 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Urokinase.
DB00013 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Urokinase.
DB00013 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Urokinase.
DB00013 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Urokinase.
DB00013 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Urokinase.
DB00013 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Urokinase.
DB00013 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Urokinase.
DB00013 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Urokinase.
DB00013 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Urokinase.
DB00013 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Urokinase.
DB00013 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Urokinase.
DB00013 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Urokinase.
DB00013 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Urokinase.
DB00013 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Urokinase.
DB00013 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Urokinase.
DB00013 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Urokinase.
DB00013 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Urokinase.
DB00013 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Urokinase.
DB00013 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Urokinase.
DB00013 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Urokinase.
DB00013 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Urokinase.
DB00013 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Urokinase.
DB00013 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Urokinase.
DB00013 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Urokinase.
DB00013 DB00974 Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Urokinase.
DB00013 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Urokinase.
DB00013 DB13124 Troxerutin The risk or severity of bleeding can be increased when Troxerutin is combined with Urokinase.
DB00013 DB00177 Valsartan The risk or severity of angioedema can be increased when Urokinase is combined with Valsartan.
DB00013 DB00178 Ramipril The risk or severity of angioedema can be increased when Urokinase is combined with Ramipril.
DB00013 DB00230 Pregabalin The risk or severity of angioedema can be increased when Urokinase is combined with Pregabalin.
DB00013 DB00492 Fosinopril The risk or severity of angioedema can be increased when Urokinase is combined with Fosinopril.
DB00013 DB00519 Trandolapril The risk or severity of angioedema can be increased when Urokinase is combined with Trandolapril.
DB00013 DB00542 Benazepril The risk or severity of angioedema can be increased when Urokinase is combined with Benazepril.
DB00013 DB00584 Enalapril The risk or severity of angioedema can be increased when Urokinase is combined with Enalapril.
DB00013 DB00678 Losartan The risk or severity of angioedema can be increased when Urokinase is combined with Losartan.
DB00013 DB00691 Moexipril The risk or severity of angioedema can be increased when Urokinase is combined with Moexipril.
DB00013 DB00722 Lisinopril The risk or severity of angioedema can be increased when Urokinase is combined with Lisinopril.
DB00013 DB00790 Perindopril The risk or severity of angioedema can be increased when Urokinase is combined with Perindopril.
DB00013 DB00876 Eprosartan The risk or severity of angioedema can be increased when Urokinase is combined with Eprosartan.
DB00013 DB00877 Sirolimus The risk or severity of angioedema can be increased when Urokinase is combined with Sirolimus.
DB00013 DB00881 Quinapril The risk or severity of angioedema can be increased when Urokinase is combined with Quinapril.
DB00013 DB00886 Omapatrilat The risk or severity of angioedema can be increased when Urokinase is combined with Omapatrilat.
DB00013 DB00966 Telmisartan The risk or severity of angioedema can be increased when Urokinase is combined with Telmisartan.
DB00013 DB01050 Ibuprofen The risk or severity of angioedema can be increased when Urokinase is combined with Ibuprofen.
DB00013 DB01180 Rescinnamine The risk or severity of angioedema can be increased when Urokinase is combined with Rescinnamine.
DB00013 DB01197 Captopril The risk or severity of angioedema can be increased when Urokinase is combined with Captopril.
DB00013 DB01261 Sitagliptin The risk or severity of angioedema can be increased when Urokinase is combined with Sitagliptin.
DB00013 DB01340 Cilazapril The risk or severity of angioedema can be increased when Urokinase is combined with Cilazapril.
DB00013 DB01342 Forasartan The risk or severity of angioedema can be increased when Urokinase is combined with Forasartan.
DB00013 DB01347 Saprisartan The risk or severity of angioedema can be increased when Urokinase is combined with Saprisartan.
DB00013 DB01348 Spirapril The risk or severity of angioedema can be increased when Urokinase is combined with Spirapril.
DB00013 DB04876 Vildagliptin The risk or severity of angioedema can be increased when Urokinase is combined with Vildagliptin.
DB00013 DB06011 AMG-222 The risk or severity of angioedema can be increased when Urokinase is combined with AMG-222.
DB00013 DB06127 Bisegliptin The risk or severity of angioedema can be increased when Urokinase is combined with Bisegliptin.
DB00013 DB06196 Icatibant The risk or severity of angioedema can be increased when Urokinase is combined with Icatibant.
DB00013 DB06203 Alogliptin The risk or severity of angioedema can be increased when Urokinase is combined with Alogliptin.
DB00013 DB06245 Lanoteplase The risk or severity of angioedema can be increased when Urokinase is combined with Lanoteplase.
DB00013 DB06287 Temsirolimus The risk or severity of angioedema can be increased when Urokinase is combined with Temsirolimus.
DB00013 DB06335 Saxagliptin The risk or severity of angioedema can be increased when Urokinase is combined with Saxagliptin.
DB00013 DB08382 Gosogliptin The risk or severity of angioedema can be increased when Urokinase is combined with Gosogliptin.
DB00013 DB08822 Azilsartan medoxomil The risk or severity of angioedema can be increased when Urokinase is combined with Azilsartan medoxomil.
DB00013 DB08836 Temocapril The risk or severity of angioedema can be increased when Urokinase is combined with Temocapril.
DB00013 DB08882 Linagliptin The risk or severity of angioedema can be increased when Urokinase is combined with Linagliptin.
DB00013 DB09292 Sacubitril The risk or severity of angioedema can be increased when Urokinase is combined with Sacubitril.
DB00013 DB09477 Enalaprilat The risk or severity of angioedema can be increased when Urokinase is combined with Enalaprilat.
DB00013 DB11723 Dutogliptin The risk or severity of angioedema can be increased when Urokinase is combined with Dutogliptin.
DB00013 DB11783 Imidapril The risk or severity of angioedema can be increased when Urokinase is combined with Imidapril.
DB00013 DB11950 Teneligliptin The risk or severity of angioedema can be increased when Urokinase is combined with Teneligliptin.
DB00013 DB11992 Omarigliptin The risk or severity of angioedema can be increased when Urokinase is combined with Omarigliptin.
DB00013 DB12268 Carmegliptin The risk or severity of angioedema can be increased when Urokinase is combined with Carmegliptin.
DB00013 DB12412 Gemigliptin The risk or severity of angioedema can be increased when Urokinase is combined with Gemigliptin.
DB00013 DB12417 Anagliptin The risk or severity of angioedema can be increased when Urokinase is combined with Anagliptin.
DB00013 DB12625 Evogliptin The risk or severity of angioedema can be increased when Urokinase is combined with Evogliptin.
DB00013 DB13166 Zofenopril The risk or severity of angioedema can be increased when Urokinase is combined with Zofenopril.
DB00013 DB13312 Delapril The risk or severity of angioedema can be increased when Urokinase is combined with Delapril.
DB00013 DB14125 Benazeprilat The risk or severity of angioedema can be increased when Urokinase is combined with Benazeprilat.
DB00013 DB14207 Fosinoprilat The risk or severity of angioedema can be increased when Urokinase is combined with Fosinoprilat.
DB00013 DB14208 Ramiprilat The risk or severity of angioedema can be increased when Urokinase is combined with Ramiprilat.
DB00013 DB14209 Trandolaprilat The risk or severity of angioedema can be increased when Urokinase is combined with Trandolaprilat.
DB00013 DB14210 Moexiprilat The risk or severity of angioedema can be increased when Urokinase is combined with Moexiprilat.
DB00013 DB14213 Perindoprilat The risk or severity of angioedema can be increased when Urokinase is combined with Perindoprilat.
DB00013 DB14217 Quinaprilat The risk or severity of angioedema can be increased when Urokinase is combined with Quinaprilat.
DB00013 DB14231 Quinoline Yellow WS The risk or severity of angioedema can be increased when Urokinase is combined with Quinoline Yellow WS.
DB00013 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Urokinase is combined with Sildenafil.
DB00013 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Urokinase is combined with Peginterferon alfa-2a.
DB00013 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-n1.
DB00013 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-n3.
DB00013 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Urokinase is combined with Peginterferon alfa-2b.
DB00013 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Urokinase is combined with Interferon gamma-1b.
DB00013 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-2a, Recombinant.
DB00013 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Urokinase is combined with Aldesleukin.
DB00013 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Urokinase is combined with Gemtuzumab ozogamicin.
DB00013 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Urokinase is combined with Interferon beta-1b.
DB00013 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfacon-1.
DB00013 DB00073 Rituximab The risk or severity of bleeding can be increased when Urokinase is combined with Rituximab.
DB00013 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Urokinase is combined with Ibritumomab tiuxetan.
DB00013 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Urokinase is combined with Alemtuzumab.
DB00013 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-2b.
DB00013 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Urokinase is combined with Phenylalanine.
DB00013 DB00188 Bortezomib The risk or severity of bleeding can be increased when Urokinase is combined with Bortezomib.
DB00013 DB00242 Cladribine The risk or severity of bleeding can be increased when Urokinase is combined with Cladribine.
DB00013 DB00262 Carmustine The risk or severity of bleeding can be increased when Urokinase is combined with Carmustine.
DB00013 DB00276 Amsacrine The risk or severity of bleeding can be increased when Urokinase is combined with Amsacrine.
DB00013 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Urokinase is combined with Chlorambucil.
DB00013 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Urokinase is combined with Raltitrexed.
DB00013 DB00305 Mitomycin The risk or severity of bleeding can be increased when Urokinase is combined with Mitomycin.
DB00013 DB00307 Bexarotene The risk or severity of bleeding can be increased when Urokinase is combined with Bexarotene.
DB00013 DB00309 Vindesine The risk or severity of bleeding can be increased when Urokinase is combined with Vindesine.
DB00013 DB00322 Floxuridine The risk or severity of bleeding can be increased when Urokinase is combined with Floxuridine.
DB00013 DB00352 Tioguanine The risk or severity of bleeding can be increased when Urokinase is combined with Tioguanine.
DB00013 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Urokinase is combined with Vinorelbine.
DB00013 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Urokinase is combined with Dexrazoxane.
DB00013 DB00398 Sorafenib The risk or severity of bleeding can be increased when Urokinase is combined with Sorafenib.
DB00013 DB00428 Streptozocin The risk or severity of bleeding can be increased when Urokinase is combined with Streptozocin.
DB00013 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Urokinase is combined with Gemcitabine.
DB00013 DB00444 Teniposide The risk or severity of bleeding can be increased when Urokinase is combined with Teniposide.
DB00013 DB00445 Epirubicin The risk or severity of bleeding can be increased when Urokinase is combined with Epirubicin.
DB00013 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Urokinase is combined with Chloramphenicol.
DB00013 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Urokinase is combined with Lenalidomide.
DB00013 DB00488 Altretamine The risk or severity of bleeding can be increased when Urokinase is combined with Altretamine.
DB00013 DB00495 Zidovudine The risk or severity of bleeding can be increased when Urokinase is combined with Zidovudine.
DB00013 DB00515 Cisplatin The risk or severity of bleeding can be increased when Urokinase is combined with Cisplatin.
DB00013 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Urokinase is combined with Oxaliplatin.
DB00013 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Urokinase is combined with Cyclophosphamide.
DB00013 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Urokinase is combined with Fluorouracil.
DB00013 DB00552 Pentostatin The risk or severity of bleeding can be increased when Urokinase is combined with Pentostatin.
DB00013 DB00563 Methotrexate The risk or severity of bleeding can be increased when Urokinase is combined with Methotrexate.
DB00013 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Urokinase is combined with Carbamazepine.
DB00013 DB00570 Vinblastine The risk or severity of bleeding can be increased when Urokinase is combined with Vinblastine.
DB00013 DB00619 Imatinib The risk or severity of bleeding can be increased when Urokinase is combined with Imatinib.
DB00013 DB00631 Clofarabine The risk or severity of bleeding can be increased when Urokinase is combined with Clofarabine.
DB00013 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Urokinase is combined with Pemetrexed.
DB00013 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Urokinase is combined with Daunorubicin.
DB00013 DB00762 Irinotecan The risk or severity of bleeding can be increased when Urokinase is combined with Irinotecan.
DB00013 DB00773 Etoposide The risk or severity of bleeding can be increased when Urokinase is combined with Etoposide.
DB00013 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Urokinase is combined with Dacarbazine.
DB00013 DB00853 Temozolomide The risk or severity of bleeding can be increased when Urokinase is combined with Temozolomide.
DB00013 DB00859 Penicillamine The risk or severity of bleeding can be increased when Urokinase is combined with Penicillamine.
DB00013 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Urokinase is combined with Tacrolimus.
DB00013 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Urokinase is combined with Mechlorethamine.
DB00013 DB00928 Azacitidine The risk or severity of bleeding can be increased when Urokinase is combined with Azacitidine.
DB00013 DB00958 Carboplatin The risk or severity of bleeding can be increased when Urokinase is combined with Carboplatin.
DB00013 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Urokinase is combined with Dactinomycin.
DB00013 DB00987 Cytarabine The risk or severity of bleeding can be increased when Urokinase is combined with Cytarabine.
DB00013 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Urokinase is combined with Doxorubicin.
DB00013 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Urokinase is combined with Hydroxyurea.
DB00013 DB01008 Busulfan The risk or severity of bleeding can be increased when Urokinase is combined with Busulfan.
DB00013 DB01030 Topotecan The risk or severity of bleeding can be increased when Urokinase is combined with Topotecan.
DB00013 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Urokinase is combined with Mercaptopurine.
DB00013 DB01041 Thalidomide The risk or severity of bleeding can be increased when Urokinase is combined with Thalidomide.
DB00013 DB01042 Melphalan The risk or severity of bleeding can be increased when Urokinase is combined with Melphalan.
DB00013 DB01073 Fludarabine The risk or severity of bleeding can be increased when Urokinase is combined with Fludarabine.
DB00013 DB01099 Flucytosine The risk or severity of bleeding can be increased when Urokinase is combined with Flucytosine.
DB00013 DB01101 Capecitabine The risk or severity of bleeding can be increased when Urokinase is combined with Capecitabine.
DB00013 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Urokinase is combined with Arsenic trioxide.
DB00013 DB01177 Idarubicin The risk or severity of bleeding can be increased when Urokinase is combined with Idarubicin.
DB00013 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Urokinase is combined with Mitoxantrone.
DB00013 DB01206 Lomustine The risk or severity of bleeding can be increased when Urokinase is combined with Lomustine.
DB00013 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Urokinase is combined with Paclitaxel.
DB00013 DB01248 Docetaxel The risk or severity of bleeding can be increased when Urokinase is combined with Docetaxel.
DB00013 DB01262 Decitabine The risk or severity of bleeding can be increased when Urokinase is combined with Decitabine.
DB00013 DB01280 Nelarabine The risk or severity of bleeding can be increased when Urokinase is combined with Nelarabine.
DB00013 DB01590 Everolimus The risk or severity of bleeding can be increased when Urokinase is combined with Everolimus.
DB00013 DB02546 Vorinostat The risk or severity of bleeding can be increased when Urokinase is combined with Vorinostat.
DB00013 DB04572 Thiotepa The risk or severity of bleeding can be increased when Urokinase is combined with Thiotepa.
DB00013 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Urokinase is combined with Ixabepilone.
DB00013 DB04868 Nilotinib The risk or severity of bleeding can be increased when Urokinase is combined with Nilotinib.
DB00013 DB05015 Belinostat The risk or severity of bleeding can be increased when Urokinase is combined with Belinostat.
DB00013 DB05109 Trabectedin The risk or severity of bleeding can be increased when Urokinase is combined with Trabectedin.
DB00013 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa.
DB00013 DB05472 omega interferon The risk or severity of bleeding can be increased when Urokinase is combined with omega interferon.
DB00013 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Urokinase is combined with Trastuzumab emtansine.
DB00013 DB06616 Bosutinib The risk or severity of bleeding can be increased when Urokinase is combined with Bosutinib.
DB00013 DB06769 Bendamustine The risk or severity of bleeding can be increased when Urokinase is combined with Bendamustine.
DB00013 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Urokinase is combined with Cabazitaxel.
DB00013 DB08871 Eribulin The risk or severity of bleeding can be increased when Urokinase is combined with Eribulin.
DB00013 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Urokinase is combined with Ruxolitinib.
DB00013 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Urokinase is combined with Carfilzomib.
DB00013 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Urokinase is combined with Tofacitinib.
DB00013 DB08901 Ponatinib The risk or severity of bleeding can be increased when Urokinase is combined with Ponatinib.
DB00013 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Urokinase is combined with Pomalidomide.
DB00013 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Urokinase is combined with Tedizolid phosphate.
DB00013 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Urokinase is combined with Blinatumomab.
DB00013 DB09073 Palbociclib The risk or severity of bleeding can be increased when Urokinase is combined with Palbociclib.
DB00013 DB09074 Olaparib The risk or severity of bleeding can be increased when Urokinase is combined with Olaparib.
DB00013 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Urokinase is combined with Dinutuximab.
DB00013 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Urokinase is combined with Peginterferon beta-1a.
DB00013 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Urokinase is combined with Cepeginterferon alfa-2B.
DB00013 DB00229 Cefotiam The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefotiam.
DB00013 DB00267 Cefmenoxime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefmenoxime.
DB00013 DB00274 Cefmetazole The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefmetazole.
DB00013 DB00430 Cefpiramide The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefpiramide.
DB00013 DB00438 Ceftazidime The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftazidime.
DB00013 DB00447 Loracarbef The therapeutic efficacy of Urokinase can be decreased when used in combination with Loracarbef.
DB00013 DB00456 Cefalotin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefalotin.
DB00013 DB00493 Cefotaxime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefotaxime.
DB00013 DB00535 Cefdinir The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefdinir.
DB00013 DB00567 Cephalexin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cephalexin.
DB00013 DB00671 Cefixime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefixime.
DB00013 DB00689 Cephaloglycin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cephaloglycin.
DB00013 DB00833 Cefaclor The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefaclor.
DB00013 DB00923 Ceforanide The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceforanide.
DB00013 DB01066 Cefditoren The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefditoren.
DB00013 DB01112 Cefuroxime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefuroxime.
DB00013 DB01139 Cefapirin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefapirin.
DB00013 DB01140 Cefadroxil The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefadroxil.
DB00013 DB01150 Cefprozil The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefprozil.
DB00013 DB01212 Ceftriaxone The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftriaxone.
DB00013 DB01326 Cefamandole The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefamandole.
DB00013 DB01327 Cefazolin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefazolin.
DB00013 DB01328 Cefonicid The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefonicid.
DB00013 DB01329 Cefoperazone The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefoperazone.
DB00013 DB01330 Cefotetan The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefotetan.
DB00013 DB01331 Cefoxitin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefoxitin.
DB00013 DB01332 Ceftizoxime The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftizoxime.
DB00013 DB01333 Cefradine The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefradine.
DB00013 DB01413 Cefepime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefepime.
DB00013 DB01414 Cefacetrile The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefacetrile.
DB00013 DB01415 Ceftibuten The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftibuten.
DB00013 DB01416 Cefpodoxime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefpodoxime.
DB00013 DB04570 Latamoxef The therapeutic efficacy of Urokinase can be decreased when used in combination with Latamoxef.
DB00013 DB04918 Ceftobiprole The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftobiprole.
DB00013 DB06590 Ceftaroline fosamil The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftaroline fosamil.
DB00013 DB09008 Cefaloridine The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefaloridine.
DB00013 DB09050 Ceftolozane The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftolozane.
DB00013 DB09062 Cefminox The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefminox.
DB00013 DB11367 Cefroxadine The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefroxadine.
DB00013 DB11935 Flomoxef The therapeutic efficacy of Urokinase can be decreased when used in combination with Flomoxef.
DB00013 DB13266 Cefatrizine The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefatrizine.
DB00013 DB13461 Cefcapene The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefcapene.
DB00013 DB13470 Cefodizime The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefodizime.
DB00013 DB13499 Cefsulodin The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefsulodin.
DB00013 DB13504 Cefetamet The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefetamet.
DB00013 DB13638 Cefbuperazone The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefbuperazone.
DB00013 DB13667 Cefozopran The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefozopran.
DB00013 DB13682 Cefpirome The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefpirome.
DB00013 DB13778 Cefazedone The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefazedone.
DB00013 DB13821 Ceftezole The therapeutic efficacy of Urokinase can be decreased when used in combination with Ceftezole.
DB00013 DB14725 Cefamandole nafate The therapeutic efficacy of Urokinase can be decreased when used in combination with Cefamandole nafate.
DB00013 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Urokinase.
DB00013 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Urokinase.
DB00013 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Urokinase.
DB00013 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Urokinase.
DB00013 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Urokinase.
DB00013 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Urokinase.
DB00013 DB00620 Triamcinolone The therapeutic efficacy of Urokinase can be decreased when used in combination with Triamcinolone.
DB00013 DB09079 Nintedanib The risk or severity of bleeding can be increased when Urokinase is combined with Nintedanib.
DB00013 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Urokinase.
DB00013 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Urokinase.
DB00013 DB00232 Methyclothiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Methyclothiazide.
DB00013 DB00436 Bendroflumethiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Bendroflumethiazide.
DB00013 DB00562 Benzthiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Benzthiazide.
DB00013 DB00606 Cyclothiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Cyclothiazide.
DB00013 DB00774 Hydroflumethiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Hydroflumethiazide.
DB00013 DB00880 Chlorothiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Chlorothiazide.
DB00013 DB00999 Hydrochlorothiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Hydrochlorothiazide.
DB00013 DB01021 Trichlormethiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Trichlormethiazide.
DB00013 DB01324 Polythiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Polythiazide.
DB00013 DB13430 Mebutizide The therapeutic efficacy of Urokinase can be decreased when used in combination with Mebutizide.
DB00013 DB13532 Cyclopenthiazide The therapeutic efficacy of Urokinase can be decreased when used in combination with Cyclopenthiazide.
DB00014 DB09066 Corifollitropin alfa The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Goserelin.
DB00014 DB09083 Ivabradine Ivabradine may increase the QTc-prolonging activities of Goserelin.
DB00014 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Goserelin is combined with Peginesatide.
DB00014 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Goserelin.
DB00014 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Goserelin.
DB00014 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin.
DB00014 DB09277 Choline C 11 Goserelin may decrease effectiveness of Choline C 11 as a diagnostic agent.
DB00014 DB00089 Capromab pendetide Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
DB00014 DB00030 Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin.
DB00014 DB00046 Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Goserelin.
DB00014 DB00047 Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Goserelin.
DB00014 DB00071 Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin.
DB00014 DB00197 Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin.
DB00014 DB00222 Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.
DB00014 DB00284 Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin.
DB00014 DB00359 Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Goserelin.
DB00014 DB00412 Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.
DB00014 DB00414 Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.
DB00014 DB00491 Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.
DB00014 DB00672 Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.
DB00014 DB00731 Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin.
DB00014 DB00839 Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.
DB00014 DB00912 Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.
DB00014 DB00914 Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin.
DB00014 DB01016 Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.
DB00014 DB01067 Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.
DB00014 DB01120 Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.
DB00014 DB01124 Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.
DB00014 DB01132 Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.
DB00014 DB01200 Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Goserelin.
DB00014 DB01251 Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.
DB00014 DB01252 Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Goserelin.
DB00014 DB01261 Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.
DB00014 DB01276 Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin.
DB00014 DB01277 Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Goserelin.
DB00014 DB01278 Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin.
DB00014 DB01289 Glisoxepide The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Goserelin.
DB00014 DB01306 Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Goserelin.
DB00014 DB01307 Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Goserelin.
DB00014 DB01309 Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Goserelin.
DB00014 DB01382 Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Goserelin.
DB00014 DB01700 AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Goserelin.
DB00014 DB04830 Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Goserelin.
DB00014 DB04876 Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.
DB00014 DB04878 Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Goserelin.
DB00014 DB05115 NN344 The therapeutic efficacy of NN344 can be decreased when used in combination with Goserelin.
DB00014 DB05819 NBI-6024 The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Goserelin.
DB00014 DB06011 AMG-222 The therapeutic efficacy of AMG-222 can be decreased when used in combination with Goserelin.
DB00014 DB06127 Bisegliptin The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Goserelin.
DB00014 DB06203 Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.
DB00014 DB06292 Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin.
DB00014 DB06335 Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.
DB00014 DB06655 Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin.
DB00014 DB08382 Gosogliptin The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Goserelin.
DB00014 DB08882 Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.
DB00014 DB08907 Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
DB00014 DB08962 Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Goserelin.
DB00014 DB09022 Benfluorex The therapeutic efficacy of Benfluorex can be decreased when used in combination with Goserelin.
DB00014 DB09038 Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.
DB00014 DB09043 Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Goserelin.
DB00014 DB09045 Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.
DB00014 DB09198 Lobeglitazone The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Goserelin.
DB00014 DB09199 Netoglitazone The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Goserelin.
DB00014 DB09200 Rivoglitazone The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Goserelin.
DB00014 DB09201 Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.
DB00014 DB09265 Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Goserelin.
DB00014 DB09456 Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Goserelin.
DB00014 DB09564 Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Goserelin.
DB00014 DB11567 Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Goserelin.
DB00014 DB11568 Insulin tregopil The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Goserelin.
DB00014 DB11698 Ipragliflozin The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Goserelin.
DB00014 DB11723 Dutogliptin The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Goserelin.
DB00014 DB11780 Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Goserelin.
DB00014 DB11824 Tofogliflozin The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Goserelin.
DB00014 DB11827 Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Goserelin.
DB00014 DB11898 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Goserelin.
DB00014 DB11950 Teneligliptin The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Goserelin.
DB00014 DB11992 Omarigliptin The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Goserelin.
DB00014 DB12268 Carmegliptin The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Goserelin.
DB00014 DB12412 Gemigliptin The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Goserelin.
DB00014 DB12417 Anagliptin The therapeutic efficacy of Anagliptin can be decreased when used in combination with Goserelin.
DB00014 DB12625 Evogliptin The therapeutic efficacy of Evogliptin can be decreased when used in combination with Goserelin.
DB00014 DB12713 Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Goserelin.
DB00014 DB12781 Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Goserelin.
DB00014 DB12935 Remogliflozin etabonate The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Goserelin.
DB00014 DB13406 Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Goserelin.
DB00014 DB13446 Guar gum The therapeutic efficacy of Guar gum can be decreased when used in combination with Goserelin.
DB00014 DB13675 Metahexamide The therapeutic efficacy of Metahexamide can be decreased when used in combination with Goserelin.
DB00014 DB13928 Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Goserelin.
DB00014 DB14027 Taspoglutide The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Goserelin.
DB00014 DB14035 Englitazone The therapeutic efficacy of Englitazone can be decreased when used in combination with Goserelin.
DB00014 DB15171 Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Goserelin.
DB00014 DB15217 Gastric inhibitory polypeptide The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Goserelin.
DB00014 DB00204 Dofetilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dofetilide.
DB00014 DB00215 Citalopram The risk or severity of QTc prolongation can be increased when Goserelin is combined with Citalopram.
DB00014 DB00261 Anagrelide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Anagrelide.
DB00014 DB00280 Disopyramide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Disopyramide.
DB00014 DB00283 Clemastine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clemastine.
DB00014 DB00308 Ibutilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ibutilide.
DB00014 DB00313 Valproic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid.
DB00014 DB00342 Terfenadine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terfenadine.
DB00014 DB00365 Grepafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Grepafloxacin.
DB00014 DB00468 Quinine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinine.
DB00014 DB00489 Sotalol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sotalol.
DB00014 DB00530 Erlotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib.
DB00014 DB00539 Toremifene The risk or severity of QTc prolongation can be increased when Goserelin is combined with Toremifene.
DB00014 DB00604 Cisapride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cisapride.
DB00014 DB00619 Imatinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imatinib.
DB00014 DB00637 Astemizole The risk or severity of QTc prolongation can be increased when Goserelin is combined with Astemizole.
DB00014 DB00679 Thioridazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Thioridazine.
DB00014 DB00685 Trovafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Trovafloxacin.
DB00014 DB00834 Mifepristone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mifepristone.
DB00014 DB00875 Flupentixol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flupentixol.
DB00014 DB00907 Cocaine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cocaine.
DB00014 DB00908 Quinidine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinidine.
DB00014 DB01035 Procainamide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Procainamide.
DB00014 DB01100 Pimozide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pimozide.
DB00014 DB01118 Amiodarone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amiodarone.
DB00014 DB01169 Arsenic trioxide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Arsenic trioxide.
DB00014 DB01175 Escitalopram The risk or severity of QTc prolongation can be increased when Goserelin is combined with Escitalopram.
DB00014 DB01184 Domperidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Domperidone.
DB00014 DB01208 Sparfloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sparfloxacin.
DB00014 DB01218 Halofantrine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Halofantrine.
DB00014 DB01244 Bepridil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bepridil.
DB00014 DB01267 Paliperidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Paliperidone.
DB00014 DB01356 Lithium cation The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lithium cation.
DB00014 DB01405 Temafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Temafloxacin.
DB00014 DB01624 Zuclopenthixol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Zuclopenthixol.
DB00014 DB04844 Tetrabenazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tetrabenazine.
DB00014 DB04855 Dronedarone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dronedarone.
DB00014 DB04868 Nilotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilotinib.
DB00014 DB04946 Iloperidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Iloperidone.
DB00014 DB05294 Vandetanib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vandetanib.
DB00014 DB06176 Romidepsin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin.
DB00014 DB06216 Asenapine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Asenapine.
DB00014 DB06697 Artemether The risk or severity of QTc prolongation can be increased when Goserelin is combined with Artemether.
DB00014 DB06708 Lumefantrine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lumefantrine.
DB00014 DB08881 Vemurafenib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vemurafenib.
DB00014 DB09039 Eliglustat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Eliglustat.
DB00014 DB11730 Ribociclib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ribociclib.
DB00014 DB11978 Glasdegib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib.
DB00014 DB12161 Deutetrabenazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Deutetrabenazine.
DB00014 DB13074 Macimorelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Macimorelin.
DB00014 DB13725 Terodiline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terodiline.
DB00014 DB00007 Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin.
DB00014 DB00195 Betaxolol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Betaxolol.
DB00014 DB00199 Erythromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erythromycin.
DB00014 DB00207 Azithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Azithromycin.
DB00014 DB00218 Moxifloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin.
DB00014 DB00243 Ranolazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ranolazine.
DB00014 DB00263 Sulfisoxazole The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sulfisoxazole.
DB00014 DB00333 Methadone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Methadone.
DB00014 DB00343 Diltiazem The risk or severity of QTc prolongation can be increased when Goserelin is combined with Diltiazem.
DB00014 DB00363 Clozapine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clozapine.
DB00014 DB00391 Sulpiride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sulpiride.
DB00014 DB00393 Nimodipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nimodipine.
DB00014 DB00420 Promazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Promazine.
DB00014 DB00433 Prochlorperazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prochlorperazine.
DB00014 DB00450 Droperidol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Droperidol.
DB00014 DB00477 Chlorpromazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpromazine.
DB00014 DB00526 Oxaliplatin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin.
DB00014 DB00537 Ciprofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ciprofloxacin.
DB00014 DB00544 Fluorouracil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluorouracil.
DB00014 DB00556 Perflutren The risk or severity of QTc prolongation can be increased when Goserelin is combined with Perflutren.
DB00014 DB00568 Cinnarizine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinnarizine.
DB00014 DB00571 Propranolol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Propranolol.
DB00014 DB00572 Atropine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Atropine.
DB00014 DB00608 Chloroquine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chloroquine.
DB00014 DB00625 Efavirenz The risk or severity of QTc prolongation can be increased when Goserelin is combined with Efavirenz.
DB00014 DB00640 Adenosine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Adenosine.
DB00014 DB00738 Pentamidine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pentamidine.
DB00014 DB00743 Gadobenic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gadobenic acid.
DB00014 DB00748 Carbinoxamine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Carbinoxamine.
DB00014 DB00757 Dolasetron The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dolasetron.
DB00014 DB00778 Roxithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Roxithromycin.
DB00014 DB00779 Nalidixic acid The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nalidixic acid.
DB00014 DB00827 Cinoxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinoxacin.
DB00014 DB00836 Loperamide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Loperamide.
DB00014 DB00889 Granisetron The risk or severity of QTc prolongation can be increased when Goserelin is combined with Granisetron.
DB00014 DB00904 Ondansetron The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ondansetron.
DB00014 DB00922 Levosimendan The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levosimendan.
DB00014 DB00933 Mesoridazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mesoridazine.
DB00014 DB00967 Desloratadine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Desloratadine.
DB00014 DB00976 Telithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telithromycin.
DB00014 DB00978 Lomefloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lomefloxacin.
DB00014 DB00985 Dimenhydrinate The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dimenhydrinate.
DB00014 DB01087 Primaquine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Primaquine.
DB00014 DB01113 Papaverine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Papaverine.
DB00014 DB01114 Chlorpheniramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpheniramine.
DB00014 DB01115 Nifedipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nifedipine.
DB00014 DB01137 Levofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levofloxacin.
DB00014 DB01155 Gemifloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gemifloxacin.
DB00014 DB01165 Ofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ofloxacin.
DB00014 DB01182 Propafenone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Propafenone.
DB00014 DB01193 Acebutolol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Acebutolol.
DB00014 DB01195 Flecainide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flecainide.
DB00014 DB01211 Clarithromycin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clarithromycin.
DB00014 DB01227 Levacetylmethadol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levacetylmethadol.
DB00014 DB01232 Saquinavir The risk or severity of QTc prolongation can be increased when Goserelin is combined with Saquinavir.
DB00014 DB01388 Mibefradil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mibefradil.
DB00014 DB01580 Oxprenolol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxprenolol.
DB00014 DB01599 Probucol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Probucol.
DB00014 DB01615 Aceprometazine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Aceprometazine.
DB00014 DB02638 Terlipressin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terlipressin.
DB00014 DB04825 Prenylamine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prenylamine.
DB00014 DB04842 Fluspirilene The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluspirilene.
DB00014 DB04948 Lofexidine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lofexidine.
DB00014 DB04957 Azimilide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Azimilide.
DB00014 DB05223 Pracinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pracinostat.
DB00014 DB05488 Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Technetium Tc-99m ciprofloxacin.
DB00014 DB06160 Garenoxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Garenoxacin.
DB00014 DB06200 Tedisamil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tedisamil.
DB00014 DB06334 Tucidinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tucidinostat.
DB00014 DB06402 Telavancin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telavancin.
DB00014 DB06589 Pazopanib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pazopanib.
DB00014 DB06600 Nemonoxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nemonoxacin.
DB00014 DB06603 Panobinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Panobinostat.
DB00014 DB06712 Nilvadipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilvadipine.
DB00014 DB08799 Antazoline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Antazoline.
DB00014 DB08865 Crizotinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Crizotinib.
DB00014 DB08903 Bedaquiline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bedaquiline.
DB00014 DB08980 Fendiline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fendiline.
DB00014 DB08992 Eperisone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Eperisone.
DB00014 DB09016 Butriptyline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Butriptyline.
DB00014 DB09063 Ceritinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ceritinib.
DB00014 DB09078 Lenvatinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lenvatinib.
DB00014 DB09224 Melperone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Melperone.
DB00014 DB09231 Benidipine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Benidipine.
DB00014 DB09555 Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine maleate.
DB00014 DB11640 Amifampridine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amifampridine.
DB00014 DB11830 Mocetinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mocetinostat.
DB00014 DB11841 Entinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entinostat.
DB00014 DB12141 Gilteritinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gilteritinib.
DB00014 DB12174 CUDC-101 The risk or severity of QTc prolongation can be increased when Goserelin is combined with CUDC-101.
DB00014 DB12286 Simendan The risk or severity of QTc prolongation can be increased when Goserelin is combined with Simendan.
DB00014 DB12376 Ricolinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ricolinostat.
DB00014 DB12523 Mizolastine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mizolastine.
DB00014 DB12565 Abexinostat The risk or severity of QTc prolongation can be increased when Goserelin is combined with Abexinostat.
DB00014 DB12877 Oxatomide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxatomide.
DB00014 DB13261 Sitafloxacin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sitafloxacin.
DB00014 DB13273 Sultopride The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sultopride.
DB00014 DB13500 Otilonium The risk or severity of QTc prolongation can be increased when Goserelin is combined with Otilonium.
DB00014 DB13546 Nizofenone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nizofenone.
DB00014 DB13652 Bunaftine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bunaftine.
DB00014 DB13653 Lorcainide The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lorcainide.
DB00014 DB13679 Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine.
DB00014 DB13791 Penfluridol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Penfluridol.
DB00014 DB14063 Dexverapamil The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexverapamil.
DB00014 DB14568 Ivosidenib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ivosidenib.
DB00014 DB01224 Quetiapine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quetiapine.
DB00014 DB00321 Amitriptyline The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amitriptyline.
DB00014 DB00458 Imipramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imipramine.
DB00014 DB01242 Clomipramine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clomipramine.
DB00014 DB11718 Encorafenib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Encorafenib.
DB00014 DB00104 Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin.
DB00014 DB00107 Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin.
DB00014 DB00187 Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Goserelin.
DB00014 DB00188 Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Goserelin.
DB00014 DB00196 Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Goserelin.
DB00014 DB00220 Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Goserelin.
DB00014 DB00230 Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Goserelin.
DB00014 DB00245 Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Goserelin.
DB00014 DB00270 Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Goserelin.
DB00014 DB00285 Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Goserelin.
DB00014 DB00289 Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Goserelin.
DB00014 DB00334 Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Goserelin.
DB00014 DB00341 Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Goserelin.
DB00014 DB00344 Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Goserelin.
DB00014 DB00346 Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Goserelin.
DB00014 DB00347 Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Goserelin.
DB00014 DB00354 Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Goserelin.
DB00014 DB00358 Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Goserelin.
DB00014 DB00366 Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Goserelin.
DB00014 DB00370 Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Goserelin.
DB00014 DB00373 Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Goserelin.
DB00014 DB00374 Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Goserelin.
DB00014 DB00398 Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Goserelin.
DB00014 DB00405 Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin.
DB00014 DB00424 Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Goserelin.
DB00014 DB00427 Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Goserelin.
DB00014 DB00434 Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Goserelin.
DB00014 DB00467 Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Goserelin.
DB00014 DB00487 Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Goserelin.
DB00014 DB00503 Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Goserelin.
DB00014 DB00529 Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Goserelin.
DB00014 DB00540 Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Goserelin.
DB00014 DB00543 Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Goserelin.
DB00014 DB00555 Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Goserelin.
DB00014 DB00582 Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Goserelin.
DB00014 DB00593 Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Goserelin.
DB00014 DB00613 Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Goserelin.
DB00014 DB00622 Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Goserelin.
DB00014 DB00674 Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Goserelin.
DB00014 DB00675 Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Goserelin.
DB00014 DB00678 Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Goserelin.
DB00014 DB00680 Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Goserelin.
DB00014 DB00691 Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Goserelin.
DB00014 DB00697 Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Goserelin.
DB00014 DB00710 Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin.
DB00014 DB00714 Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Goserelin.
DB00014 DB00719 Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Goserelin.
DB00014 DB00726 Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Goserelin.
DB00014 DB00734 Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Goserelin.
DB00014 DB00753 Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Goserelin.
DB00014 DB00808 Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Goserelin.
DB00014 DB00817 Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Goserelin.
DB00014 DB00818 Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Goserelin.
DB00014 DB00822 Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Goserelin.
DB00014 DB00825 Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Goserelin.
DB00014 DB00835 Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Goserelin.
DB00014 DB00862 Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Goserelin.
DB00014 DB00871 Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Goserelin.
DB00014 DB00909 Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Goserelin.
DB00014 DB00915 Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Goserelin.
DB00014 DB00916 Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Goserelin.
DB00014 DB00920 Ketotifen The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Goserelin.
DB00014 DB00927 Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin.
DB00014 DB00934 Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Goserelin.
DB00014 DB00938 Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Goserelin.
DB00014 DB00949 Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Goserelin.
DB00014 DB00983 Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Goserelin.
DB00014 DB00999 Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Goserelin.
DB00014 DB01001 Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Goserelin.
DB00014 DB01015 Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Goserelin.
DB00014 DB01023 Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Goserelin.
DB00014 DB01026 Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Goserelin.
DB00014 DB01036 Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Goserelin.
DB00014 DB01044 Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Goserelin.
DB00014 DB01054 Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Goserelin.
DB00014 DB01059 Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Goserelin.
DB00014 DB01069 Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Goserelin.
DB00014 DB01071 Mequitazine The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Goserelin.
DB00014 DB01072 Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Goserelin.
DB00014 DB01074 Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Goserelin.
DB00014 DB01075 Diphenhydramine The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Goserelin.
DB00014 DB01106 Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Goserelin.
DB00014 DB01158 Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Goserelin.
DB00014 DB01166 Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Goserelin.
DB00014 DB01167 Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Goserelin.
DB00014 DB01173 Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Goserelin.
DB00014 DB01176 Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Goserelin.
DB00014 DB01189 Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Goserelin.
DB00014 DB01228 Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Goserelin.
DB00014 DB01233 Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Goserelin.
DB00014 DB01236 Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Goserelin.
DB00014 DB01238 Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin.
DB00014 DB01239 Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Goserelin.
DB00014 DB01246 Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Goserelin.
DB00014 DB01254 Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Goserelin.
DB00014 DB01259 Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Goserelin.
DB00014 DB01263 Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Goserelin.
DB00014 DB01268 Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Goserelin.
DB00014 DB01274 Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Goserelin.
DB00014 DB01396 Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Goserelin.
DB00014 DB01403 Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Goserelin.
DB00014 DB01426 Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Goserelin.
DB00014 DB01591 Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Goserelin.
DB00014 DB01611 Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Goserelin.
DB00014 DB01620 Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Goserelin.
DB00014 DB01623 Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Goserelin.
DB00014 DB02546 Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Goserelin.
DB00014 DB04576 Fleroxacin The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Goserelin.
DB00014 DB04695 Farnesyl thiopyrophosphate The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Goserelin.
DB00014 DB04846 Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Goserelin.
DB00014 DB04953 Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Goserelin.
DB00014 DB05039 Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Goserelin.
DB00014 DB05246 Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Goserelin.
DB00014 DB05465 Tandutinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Goserelin.
DB00014 DB06217 Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Goserelin.
DB00014 DB06282 Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Goserelin.
DB00014 DB06288 Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Goserelin.
DB00014 DB06468 Cariporide The risk or severity of QTc prolongation can be increased when Cariporide is combined with Goserelin.
DB00014 DB06663 Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Goserelin.
DB00014 DB06691 Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Goserelin.
DB00014 DB06699 Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Goserelin.
DB00014 DB06719 Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Goserelin.
DB00014 DB06788 Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Goserelin.
DB00014 DB06825 Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin.
DB00014 DB07780 Farnesyl diphosphate The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Goserelin.
DB00014 DB07841 Geranylgeranyl diphosphate The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Goserelin.
DB00014 DB08808 Bupranolol The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Goserelin.
DB00014 DB08815 Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Goserelin.
DB00014 DB08864 Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Goserelin.
DB00014 DB08871 Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Goserelin.
DB00014 DB08893 Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Goserelin.
DB00014 DB08912 Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin.
DB00014 DB08936 Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Goserelin.
DB00014 DB08952 Indenolol The risk or severity of QTc prolongation can be increased when Indenolol is combined with Goserelin.
DB00014 DB08972 Flumequine The risk or severity of QTc prolongation can be increased when Flumequine is combined with Goserelin.
DB00014 DB09080 Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Goserelin.
DB00014 DB09082 Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Goserelin.
DB00014 DB09089 Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Goserelin.
DB00014 DB09090 Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Goserelin.
DB00014 DB09167 Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Goserelin.
DB00014 DB09229 Aranidipine The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Goserelin.
DB00014 DB09235 Efonidipine The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Goserelin.
DB00014 DB09236 Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Goserelin.
DB00014 DB09239 Niguldipine The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Goserelin.
DB00014 DB09488 Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Goserelin.
DB00014 DB11390 Coumaphos The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Goserelin.
DB00014 DB11397 Dichlorvos The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Goserelin.
DB00014 DB11408 Famphur The risk or severity of QTc prolongation can be increased when Famphur is combined with Goserelin.
DB00014 DB11412 Fenthion The risk or severity of QTc prolongation can be increased when Fenthion is combined with Goserelin.
DB00014 DB11443 Orbifloxacin The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Goserelin.
DB00014 DB11448 Phosmet The risk or severity of QTc prolongation can be increased when Phosmet is combined with Goserelin.
DB00014 DB11491 Sarafloxacin The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Goserelin.
DB00014 DB11511 Difloxacin The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Goserelin.
DB00014 DB11591 Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Goserelin.
DB00014 DB11614 Rupatadine The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Goserelin.
DB00014 DB11742 Ebastine The risk or severity of QTc prolongation can be increased when Ebastine is combined with Goserelin.
DB00014 DB11770 Talinolol The risk or severity of QTc prolongation can be increased when Talinolol is combined with Goserelin.
DB00014 DB11774 Pazufloxacin The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Goserelin.
DB00014 DB11785 Anisodamine The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Goserelin.
DB00014 DB11891 CUDC-907 The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Goserelin.
DB00014 DB11892 Prulifloxacin The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Goserelin.
DB00014 DB11943 Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Goserelin.
DB00014 DB12093 Tetrahydropalmatine The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Goserelin.
DB00014 DB12231 Temefos The risk or severity of QTc prolongation can be increased when Temefos is combined with Goserelin.
DB00014 DB12245 Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Goserelin.
DB00014 DB12645 Givinostat The risk or severity of QTc prolongation can be increased when Givinostat is combined with Goserelin.
DB00014 DB12712 Pilsicainide The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Goserelin.
DB00014 DB12766 Cicletanine The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Goserelin.
DB00014 DB12923 Gallopamil The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Goserelin.
DB00014 DB13358 Cibenzoline The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Goserelin.
DB00014 DB13488 Bencyclane The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Goserelin.
DB00014 DB13555 Prajmaline The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Goserelin.
DB00014 DB13627 Oxolinic acid The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Goserelin.
DB00014 DB13651 Lorajmine The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Goserelin.
DB00014 DB13691 Acetyldigoxin The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Goserelin.
DB00014 DB13744 Piromidic acid The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Goserelin.
DB00014 DB13766 Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Goserelin.
DB00014 DB13772 Rufloxacin The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Goserelin.
DB00014 DB13823 Pipemidic acid The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Goserelin.
DB00014 DB14185 Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Goserelin.
DB00014 DB14713 Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Goserelin.
DB00014 DB01142 Doxepin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Doxepin.
DB00014 DB01151 Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Goserelin.
DB00014 DB00845 Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Goserelin.
DB00014 DB11637 Delamanid Goserelin may increase the QTc-prolonging activities of Delamanid.
DB00014 DB00091 Cyclosporine Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00159 Icosapent Icosapent may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00229 Cefotiam Cefotiam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00244 Mesalazine Mesalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00267 Cefmenoxime Cefmenoxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00274 Cefmetazole Cefmetazole may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00282 Pamidronic acid Pamidronic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00300 Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00328 Indomethacin Indomethacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00369 Cidofovir Cidofovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00384 Triamterene Triamterene may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00430 Cefpiramide Cefpiramide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00438 Ceftazidime Ceftazidime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00447 Loracarbef Loracarbef may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00456 Cefalotin Cefalotin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00461 Nabumetone Nabumetone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00465 Ketorolac Ketorolac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00469 Tenoxicam Tenoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00482 Celecoxib Celecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00493 Cefotaxime Cefotaxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00500 Tolmetin Tolmetin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00533 Rofecoxib Rofecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00554 Piroxicam Piroxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00563 Methotrexate Methotrexate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00567 Cephalexin Cephalexin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00573 Fenoprofen Fenoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00577 Valaciclovir Valaciclovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00580 Valdecoxib Valdecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00586 Diclofenac Diclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00605 Sulindac Sulindac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00626 Bacitracin Bacitracin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00681 Amphotericin B Amphotericin B may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00689 Cephaloglycin Cephaloglycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00712 Flurbiprofen Flurbiprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00718 Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00742 Mannitol Mannitol may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00749 Etodolac Etodolac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00784 Mefenamic acid Mefenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00787 Acyclovir Acyclovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00788 Naproxen Naproxen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00795 Sulfasalazine Sulfasalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00812 Phenylbutazone Phenylbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00814 Meloxicam Meloxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00821 Carprofen Carprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00833 Cefaclor Cefaclor may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00861 Diflunisal Diflunisal may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00864 Tacrolimus Tacrolimus may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00903 Etacrynic acid Etacrynic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00923 Ceforanide Ceforanide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00936 Salicylic acid Salicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00939 Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00945 Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00958 Carboplatin Carboplatin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00991 Oxaprozin Oxaprozin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01009 Ketoprofen Ketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01014 Balsalazide Balsalazide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01050 Ibuprofen Ibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01066 Cefditoren Cefditoren may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01111 Colistimethate Colistimethate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01112 Cefuroxime Cefuroxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01139 Cefapirin Cefapirin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01140 Cefadroxil Cefadroxil may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01150 Cefprozil Cefprozil may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01212 Ceftriaxone Ceftriaxone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01250 Olsalazine Olsalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01283 Lumiracoxib Lumiracoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01326 Cefamandole Cefamandole may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01327 Cefazolin Cefazolin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01328 Cefonicid Cefonicid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01329 Cefoperazone Cefoperazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01330 Cefotetan Cefotetan may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01331 Cefoxitin Cefoxitin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01332 Ceftizoxime Ceftizoxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01333 Cefradine Cefradine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01397 Magnesium salicylate Magnesium salicylate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01399 Salsalate Salsalate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01401 Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01413 Cefepime Cefepime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01414 Cefacetrile Cefacetrile may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01415 Ceftibuten Ceftibuten may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01416 Cefpodoxime Cefpodoxime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01419 Antrafenine Antrafenine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01424 Aminophenazone Aminophenazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01435 Antipyrine Antipyrine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01600 Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01628 Etoricoxib Etoricoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB02247 Hydrolyzed Cephalothin Hydrolyzed Cephalothin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB03450 Cephalothin Group Cephalothin Group may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB03585 Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04552 Niflumic acid Niflumic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04570 Latamoxef Latamoxef may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04743 Nimesulide Nimesulide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04812 Benoxaprofen Benoxaprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04817 Metamizole Metamizole may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04828 Zomepirac Zomepirac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04918 Ceftobiprole Ceftobiprole may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB05095 Cimicoxib Cimicoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB06590 Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB06725 Lornoxicam Lornoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB06736 Aceclofenac Aceclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB06737 Zaltoprofen Zaltoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB07402 Azapropazone Azapropazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB07477 Felbinac Felbinac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08439 Parecoxib Parecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08797 Salicylamide Salicylamide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08940 Kebuzone Kebuzone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08942 Isoxicam Isoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08951 Indoprofen Indoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08955 Ibuproxam Ibuproxam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08976 Floctafenine Floctafenine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08981 Fenbufen Fenbufen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08984 Etofenamate Etofenamate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08991 Epirizole Epirizole may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09008 Cefaloridine Cefaloridine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09062 Cefminox Cefminox may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09084 Benzydamine Benzydamine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09212 Loxoprofen Loxoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09213 Dexibuprofen Dexibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09214 Dexketoprofen Dexketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09215 Droxicam Droxicam may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09216 Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09217 Firocoxib Firocoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09218 Clonixin Clonixin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09285 Morniflumate Morniflumate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09288 Propacetamol Propacetamol may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09295 Talniflumate Talniflumate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB09299 Tenofovir alafenamide Tenofovir alafenamide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11367 Cefroxadine Cefroxadine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11455 Robenacoxib Robenacoxib may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11466 Tepoxalin Tepoxalin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11518 Flunixin Flunixin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11935 Flomoxef Flomoxef may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB12151 Brincidofovir Brincidofovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB12445 Nitroaspirin Nitroaspirin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB12545 Indobufen Indobufen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13001 Tinoridine Tinoridine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13167 Alclofenac Alclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13217 Fentiazac Fentiazac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13232 Suxibuzone Suxibuzone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13266 Cefatrizine Cefatrizine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13286 Bumadizone Bumadizone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13314 Alminoprofen Alminoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13317 Flunoxaprofen Flunoxaprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13364 Feprazone Feprazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13371 Difenpiramide Difenpiramide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13407 Nifenazone Nifenazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13432 Lonazolac Lonazolac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13461 Cefcapene Cefcapene may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13470 Cefodizime Cefodizime may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13481 Tenidap Tenidap may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13499 Cefsulodin Cefsulodin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13501 Bendazac Bendazac may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13504 Cefetamet Cefetamet may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13514 Pranoprofen Pranoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13524 Propyphenazone Propyphenazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13527 Proglumetacin Proglumetacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13538 Guacetisal Guacetisal may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13544 Ethenzamide Ethenzamide may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13612 Carbaspirin calcium Carbaspirin calcium may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13629 Mofebutazone Mofebutazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13638 Cefbuperazone Cefbuperazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13649 Proquazone Proquazone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13657 Benorilate Benorilate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13667 Cefozopran Cefozopran may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13682 Cefpirome Cefpirome may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13722 Pirprofen Pirprofen may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13778 Cefazedone Cefazedone may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13783 Acemetacin Acemetacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13821 Ceftezole Ceftezole may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13860 Imidazole salicylate Imidazole salicylate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13868 Adefovir Adefovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB14059 SC-236 SC-236 may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB14060 NS-398 NS-398 may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB14126 Tenofovir Tenofovir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01438 Phenazopyridine Phenazopyridine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB15066 Givosiran Givosiran may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01601 Lopinavir Lopinavir may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB14507 Lithium citrate Lithium citrate may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00017 Salmon calcitonin Goserelin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00014 DB00035 Desmopressin Goserelin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00014 DB00041 Aldesleukin Goserelin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00014 DB00080 Daptomycin Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
DB00014 DB00081 Tositumomab Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
DB00014 DB00115 Cyanocobalamin Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
DB00014 DB00158 Folic acid Goserelin may decrease the excretion rate of Folic acid which could result in a higher serum level.
DB00014 DB00165 Pyridoxine Goserelin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
DB00014 DB00176 Fluvoxamine Goserelin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
DB00014 DB00181 Baclofen Goserelin may decrease the excretion rate of Baclofen which could result in a higher serum level.
DB00014 DB00182 Amphetamine Goserelin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
DB00014 DB00185 Cevimeline Goserelin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
DB00014 DB00186 Lorazepam Goserelin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00014 DB00190 Carbidopa Goserelin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00014 DB00193 Tramadol Goserelin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00014 DB00198 Oseltamivir Goserelin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00014 DB00200 Hydroxocobalamin Goserelin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00014 DB00206 Reserpine Goserelin may decrease the excretion rate of Reserpine which could result in a higher serum level.
DB00014 DB00208 Ticlopidine Goserelin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
DB00014 DB00213 Pantoprazole Goserelin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00014 DB00225 Gadodiamide Goserelin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00014 DB00231 Temazepam Goserelin may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00014 DB00235 Milrinone Goserelin may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00014 DB00237 Butabarbital Goserelin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
DB00014 DB00254 Doxycycline Goserelin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00014 DB00262 Carmustine Goserelin may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00014 DB00264 Metoprolol Goserelin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
DB00014 DB00271 Diatrizoate Goserelin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00014 DB00273 Topiramate Goserelin may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00014 DB00279 Liothyronine Goserelin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00014 DB00286 Conjugated estrogens Goserelin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00014 DB00290 Bleomycin Goserelin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00014 DB00292 Etomidate Goserelin may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00014 DB00294 Etonogestrel Goserelin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00014 DB00296 Ropivacaine Goserelin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00014 DB00303 Ertapenem Goserelin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00014 DB00312 Pentobarbital Goserelin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
DB00014 DB00316 Acetaminophen Goserelin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
DB00014 DB00319 Piperacillin Goserelin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00014 DB00322 Floxuridine Goserelin may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00014 DB00323 Tolcapone Goserelin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00014 DB00325 Nitroprusside Goserelin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00014 DB00327 Hydromorphone Goserelin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
DB00014 DB00330 Ethambutol Goserelin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00014 DB00339 Pyrazinamide Goserelin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00014 DB00349 Clobazam Goserelin may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00014 DB00351 Megestrol acetate Goserelin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00014 DB00355 Aztreonam Goserelin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00014 DB00356 Chlorzoxazone Goserelin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
DB00014 DB00364 Sucralfate Goserelin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00014 DB00372 Thiethylperazine Goserelin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00014 DB00377 Palonosetron Goserelin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00014 DB00380 Dexrazoxane Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00014 DB00401 Nisoldipine Goserelin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00014 DB00402 Eszopiclone Goserelin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
DB00014 DB00404 Alprazolam Goserelin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
DB00014 DB00413 Pramipexole Goserelin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00014 DB00415 Ampicillin Goserelin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00014 DB00418 Secobarbital Goserelin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
DB00014 DB00422 Methylphenidate Goserelin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00014 DB00432 Trifluridine Goserelin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00014 DB00435 Nitric Oxide Goserelin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00014 DB00437 Allopurinol Goserelin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00014 DB00441 Gemcitabine Goserelin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00014 DB00476 Duloxetine Goserelin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
DB00014 DB00480 Lenalidomide Goserelin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00014 DB00490 Buspirone Goserelin may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00014 DB00492 Fosinopril Goserelin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00014 DB00499 Flutamide Goserelin may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00014 DB00501 Cimetidine Goserelin may decrease the excretion rate of Cimetidine which could result in a higher serum level.
DB00014 DB00535 Cefdinir Goserelin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00014 DB00548 Azelaic acid Goserelin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00014 DB00553 Methoxsalen Goserelin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00014 DB00558 Zanamivir Goserelin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00014 DB00569 Fondaparinux Goserelin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00014 DB00583 Levocarnitine Goserelin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00014 DB00591 Fluocinolone acetonide Goserelin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
DB00014 DB00597 Gadoteridol Goserelin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00014 DB00598 Labetalol Goserelin may decrease the excretion rate of Labetalol which could result in a higher serum level.
DB00014 DB00603 Medroxyprogesterone acetate Goserelin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00014 DB00612 Bisoprolol Goserelin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00014 DB00624 Testosterone Goserelin may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00014 DB00628 Clorazepic acid Goserelin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00014 DB00631 Clofarabine Goserelin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00014 DB00633 Dexmedetomidine Goserelin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00014 DB00635 Prednisone Goserelin may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00014 DB00651 Dyphylline Goserelin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00014 DB00657 Mecamylamine Goserelin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
DB00014 DB00660 Metaxalone Goserelin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00014 DB00665 Nilutamide Goserelin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00014 DB00669 Sumatriptan Goserelin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00014 DB00683 Midazolam Goserelin may decrease the excretion rate of Midazolam which could result in a higher serum level.
DB00014 DB00688 Mycophenolate mofetil Goserelin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00014 DB00690 Flurazepam Goserelin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00014 DB00692 Phentolamine Goserelin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00014 DB00698 Nitrofurantoin Goserelin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00014 DB00706 Tamsulosin Goserelin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00014 DB00709 Lamivudine Goserelin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00014 DB00713 Oxacillin Goserelin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00014 DB00716 Nedocromil Goserelin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00014 DB00722 Lisinopril Goserelin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00014 DB00730 Thiabendazole Goserelin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00014 DB00733 Pralidoxime Goserelin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00014 DB00759 Tetracycline Goserelin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00014 DB00760 Meropenem Goserelin may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00014 DB00761 Potassium chloride Goserelin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00014 DB00763 Methimazole Goserelin may decrease the excretion rate of Methimazole which could result in a higher serum level.
DB00014 DB00775 Tirofiban Goserelin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00014 DB00780 Phenelzine Goserelin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
DB00014 DB00782 Propantheline Goserelin may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00014 DB00783 Estradiol Goserelin may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00014 DB00789 Gadopentetic acid Goserelin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00014 DB00790 Perindopril Goserelin may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB00014 DB00800 Fenoldopam Goserelin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00014 DB00804 Dicyclomine Goserelin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00014 DB00806 Pentoxifylline Goserelin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00014 DB00811 Ribavirin Goserelin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00014 DB00820 Tadalafil Goserelin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00014 DB00828 Fosfomycin Goserelin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00014 DB00829 Diazepam Goserelin may decrease the excretion rate of Diazepam which could result in a higher serum level.
DB00014 DB00841 Dobutamine Goserelin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00014 DB00842 Oxazepam Goserelin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00014 DB00851 Dacarbazine Goserelin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00014 DB00853 Temozolomide Goserelin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00014 DB00863 Ranitidine Goserelin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
DB00014 DB00894 Testolactone Goserelin may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00014 DB00897 Triazolam Goserelin may decrease the excretion rate of Triazolam which could result in a higher serum level.
DB00014 DB00900 Didanosine Goserelin may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00014 DB00911 Tinidazole Goserelin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00014 DB00918 Almotriptan Goserelin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00014 DB00928 Azacitidine Goserelin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00014 DB00951 Isoniazid Goserelin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
DB00014 DB00953 Rizatriptan Goserelin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00014 DB00960 Pindolol Goserelin may decrease the excretion rate of Pindolol which could result in a higher serum level.
DB00014 DB00961 Mepivacaine Goserelin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00014 DB00962 Zaleplon Goserelin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00014 DB00968 Methyldopa Goserelin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
DB00014 DB00980 Ramelteon Goserelin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00014 DB00988 Dopamine Goserelin may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00014 DB00993 Azathioprine Goserelin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00014 DB00995 Auranofin Goserelin may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB00014 DB01002 Levobupivacaine Goserelin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB00014 DB01004 Ganciclovir Goserelin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB00014 DB01010 Edrophonium Goserelin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB00014 DB01011 Metyrapone Goserelin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB00014 DB01018 Guanfacine Goserelin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
DB00014 DB01020 Isosorbide mononitrate Goserelin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB00014 DB01022 Phylloquinone Goserelin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB00014 DB01024 Mycophenolic acid Goserelin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB00014 DB01030 Topotecan Goserelin may decrease the excretion rate of Topotecan which could result in a higher serum level.
DB00014 DB01032 Probenecid Goserelin may decrease the excretion rate of Probenecid which could result in a higher serum level.
DB00014 DB01039 Fenofibrate Goserelin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
DB00014 DB01043 Memantine Goserelin may decrease the excretion rate of Memantine which could result in a higher serum level.
DB00014 DB01046 Lubiprostone Goserelin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB00014 DB01048 Abacavir Goserelin may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB00014 DB01060 Amoxicillin Goserelin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB00014 DB01068 Clonazepam Goserelin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB00014 DB01093 Dimethyl sulfoxide Goserelin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB00014 DB01099 Flucytosine Goserelin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB00014 DB01101 Capecitabine Goserelin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB00014 DB01105 Sibutramine Goserelin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
DB00014 DB01129 Rabeprazole Goserelin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
DB00014 DB01133 Tiludronic acid Goserelin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB00014 DB01135 Doxacurium Goserelin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB00014 DB01148 Flavoxate Goserelin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB00014 DB01149 Nefazodone Goserelin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
DB00014 DB01156 Bupropion Goserelin may decrease the excretion rate of Bupropion which could result in a higher serum level.
DB00014 DB01157 Trimetrexate Goserelin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB00014 DB01170 Guanethidine Goserelin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB00014 DB01181 Ifosfamide Goserelin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
DB00014 DB01183 Naloxone Goserelin may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB00014 DB01203 Nadolol Goserelin may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB00014 DB01205 Flumazenil Goserelin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB00014 DB01213 Fomepizole Goserelin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB00014 DB01215 Estazolam Goserelin may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB00014 DB01221 Ketamine Goserelin may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB00014 DB01222 Budesonide Goserelin may decrease the excretion rate of Budesonide which could result in a higher serum level.
DB00014 DB01240 Epoprostenol Goserelin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB00014 DB01241 Gemfibrozil Goserelin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB00014 DB01249 Iodixanol Goserelin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB00014 DB01273 Varenicline Goserelin may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB00014 DB01275 Hydralazine Goserelin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
DB00014 DB01359 Penbutolol Goserelin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
DB00014 DB01367 Rasagiline Goserelin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
DB00014 DB01394 Colchicine Goserelin may decrease the excretion rate of Colchicine which could result in a higher serum level.
DB00014 DB01409 Tiotropium Goserelin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB00014 DB01420 Testosterone propionate Goserelin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB00014 DB01427 Amrinone Goserelin may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB00014 DB01428 Oxybenzone Goserelin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB00014 DB01431 Allylestrenol Goserelin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB00014 DB01550 Fenproporex Goserelin may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB00014 DB01558 Bromazepam Goserelin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB00014 DB01563 Chloral hydrate Goserelin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB00014 DB01577 Metamfetamine Goserelin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
DB00014 DB01587 Ketazolam Goserelin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB00014 DB01610 Valganciclovir Goserelin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB00014 DB01638 Sorbitol Goserelin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB00014 DB01656 Roflumilast Goserelin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB00014 DB01685 Topiroxostat Goserelin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB00014 DB04574 Estrone sulfate Goserelin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB00014 DB04871 Lorcaserin Goserelin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB00014 DB04895 Pegaptanib Goserelin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB00014 DB04896 Milnacipran Goserelin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
DB00014 DB04920 Clevidipine Goserelin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB00014 DB05018 Migalastat Goserelin may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB00014 DB05541 Brivaracetam Goserelin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB00014 DB05676 Apremilast Goserelin may decrease the excretion rate of Apremilast which could result in a higher serum level.
DB00014 DB06154 Pentaerythritol tetranitrate Goserelin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB00014 DB06186 Ipilimumab Goserelin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB00014 DB06196 Icatibant Goserelin may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB00014 DB06209 Prasugrel Goserelin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB00014 DB06211 Doripenem Goserelin may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB00014 DB06228 Rivaroxaban Goserelin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB00014 DB06230 Nalmefene Goserelin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB00014 DB06262 Droxidopa Goserelin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB00014 DB06480 Prucalopride Goserelin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB00014 DB06623 Flupirtine Goserelin may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB00014 DB06637 Dalfampridine Goserelin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB00014 DB06695 Dabigatran etexilate Goserelin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB00014 DB06700 Desvenlafaxine Goserelin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
DB00014 DB06702 Fesoterodine Goserelin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB00014 DB06705 Gadofosveset trisodium Goserelin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB00014 DB06710 Methyltestosterone Goserelin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB00014 DB06767 Ammonium chloride Goserelin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB00014 DB06782 Dimercaprol Goserelin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB00014 DB06796 Mangafodipir Goserelin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB00014 DB06800 Methylnaltrexone Goserelin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB00014 DB06809 Plerixafor Goserelin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB00014 DB06813 Pralatrexate Goserelin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB00014 DB06823 Tiopronin Goserelin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB00014 DB06824 Triethylenetetramine Goserelin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB00014 DB08824 Ioflupane I-123 Goserelin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB00014 DB08826 Deferiprone Goserelin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB00014 DB08840 N-methylnicotinamide Goserelin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB00014 DB08872 Gabapentin enacarbil Goserelin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB00014 DB08877 Ruxolitinib Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DB00014 DB08897 Aclidinium Goserelin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB00014 DB08899 Enzalutamide Goserelin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB00014 DB08900 Teduglutide Goserelin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB00014 DB08904 Certolizumab pegol Goserelin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
DB00014 DB08905 Formestane Goserelin may decrease the excretion rate of Formestane which could result in a higher serum level.
DB00014 DB08909 Glycerol phenylbutyrate Goserelin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB00014 DB08910 Pomalidomide Goserelin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
DB00014 DB08911 Trametinib Goserelin may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB00014 DB08918 Levomilnacipran Goserelin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
DB00014 DB08932 Macitentan Goserelin may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB00014 DB08934 Sofosbuvir Goserelin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB00014 DB08964 Gemeprost Goserelin may decrease the excretion rate of Gemeprost which could result in a higher serum level.
DB00014 DB09027 Ledipasvir Goserelin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB00014 DB09050 Ceftolozane Goserelin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB00014 DB09068 Vortioxetine Goserelin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB00014 DB09071 Tasimelteon Goserelin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
DB00014 DB09075 Edoxaban Goserelin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB00014 DB09081 Idebenone Goserelin may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB00014 DB09091 Tixocortol Goserelin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB00014 DB09103 Ancestim Goserelin may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB00014 DB09104 Magnesium hydroxide Goserelin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB00014 DB09106 Hydroxyethyl Starch Goserelin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB00014 DB09111 Pentastarch Goserelin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB00014 DB09118 Stiripentol Goserelin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB00014 DB09121 Aurothioglucose Goserelin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB00014 DB09123 Dienogest Goserelin may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB00014 DB09129 Chromic chloride Goserelin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB00014 DB09132 Gadoteric acid Goserelin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB00014 DB09133 Iothalamic acid Goserelin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB00014 DB09134 Ioversol Goserelin may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB00014 DB09135 Ioxilan Goserelin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB00014 DB09136 Isosulfan blue Goserelin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB00014 DB09137 Technetium Tc-99m mebrofenin Goserelin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB00014 DB09139 Technetium Tc-99m oxidronate Goserelin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB00014 DB09148 Florbetaben (18F) Goserelin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB00014 DB09149 Florbetapir (18F) Goserelin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB00014 DB09156 Iopromide Goserelin may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB00014 DB09163 Technetium Tc-99m exametazime Goserelin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB00014 DB09165 Technetium Tc-99m pyrophosphate Goserelin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB00014 DB09185 Viloxazine Goserelin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB00014 DB09194 Etoperidone Goserelin may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB00014 DB09195 Lorpiprazole Goserelin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB00014 DB09204 Arotinolol Goserelin may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB00014 DB09205 Moxisylyte Goserelin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB00014 DB09209 Pholcodine Goserelin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB00014 DB09210 Piracetam Goserelin may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB00014 DB09219 Bisoxatin Goserelin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB00014 DB09220 Nicorandil Goserelin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
DB00014 DB09223 Blonanserin Goserelin may decrease the excretion rate of Blonanserin which could result in a higher serum level.
DB00014 DB09241 Methylene blue Goserelin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
DB00014 DB09244 Pirlindole Goserelin may decrease the excretion rate of Pirlindole which could result in a higher serum level.
DB00014 DB09245 Toloxatone Goserelin may decrease the excretion rate of Toloxatone which could result in a higher serum level.
DB00014 DB09255 Dextran Goserelin may decrease the excretion rate of Dextran which could result in a higher serum level.
DB00014 DB09256 Tegafur Goserelin may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB00014 DB09257 Gimeracil Goserelin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB00014 DB09262 Imidafenacin Goserelin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB00014 DB09264 Idarucizumab Goserelin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB00014 DB09268 Picosulfuric acid Goserelin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB00014 DB09276 Sodium aurothiomalate Goserelin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB00014 DB09281 Magnesium trisilicate Goserelin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB00014 DB09292 Sacubitril Goserelin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB00014 DB09301 Chondroitin sulfate Goserelin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB00014 DB09317 Synthetic Conjugated Estrogens, A Goserelin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB00014 DB09318 Synthetic Conjugated Estrogens, B Goserelin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB00014 DB09320 Procaine benzylpenicillin Goserelin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB00014 DB09324 Sulbactam Goserelin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB00014 DB09325 Sodium fluoride Goserelin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB00014 DB09329 Antihemophilic Factor (Recombinant), PEGylated Goserelin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB00014 DB09344 Invert sugar Goserelin may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB00014 DB09357 Dexpanthenol Goserelin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB00014 DB09394 Phosphoric acid Goserelin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB00014 DB09395 Sodium acetate Goserelin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB00014 DB09407 Magnesium chloride Goserelin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB00014 DB09418 Potassium perchlorate Goserelin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB00014 DB09472 Sodium sulfate Goserelin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB00014 DB09477 Enalaprilat Goserelin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB00014 DB09481 Magnesium carbonate Goserelin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB00014 DB09496 Octinoxate Goserelin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB00014 DB09502 Fludeoxyglucose (18F) Goserelin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB00014 DB09546 Iobenguane sulfate I-123 Goserelin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB00014 DB09570 Ixazomib Goserelin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB00014 DB11077 Polyethylene glycol 400 Goserelin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB00014 DB11090 Potassium nitrate Goserelin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB00014 DB11098 Potassium bicarbonate Goserelin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB00014 DB11102 N-acetyltyrosine Goserelin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB00014 DB11114 Eucalyptus oil Goserelin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB00014 DB11127 Selenious acid Goserelin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB00014 DB11130 Opium Goserelin may decrease the excretion rate of Opium which could result in a higher serum level.
DB00014 DB11135 Selenium Goserelin may decrease the excretion rate of Selenium which could result in a higher serum level.
DB00014 DB11136 Chromium Goserelin may decrease the excretion rate of Chromium which could result in a higher serum level.
DB00014 DB11145 Oxyquinoline Goserelin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB00014 DB11156 Pyrantel Goserelin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB00014 DB11164 Bicisate Goserelin may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB00014 DB11251 Tocopherol Goserelin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB00014 DB11278 DL-Methylephedrine Goserelin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB00014 DB11328 Tetradecyl hydrogen sulfate (ester) Goserelin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB00014 DB11338 Clove oil Goserelin may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB00014 DB11358 Evening primrose oil Goserelin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB00014 DB11364 Pidotimod Goserelin may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB00014 DB11560 Lesinurad Goserelin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB00014 DB11577 Indigotindisulfonic acid Goserelin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB00014 DB11587 Etafedrine Goserelin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB00014 DB11598 Antithrombin III human Goserelin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB00014 DB11691 Naldemedine Goserelin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB00014 DB11699 Tropisetron Goserelin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB00014 DB11817 Baricitinib Goserelin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB00014 DB11901 Apalutamide Goserelin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB00014 DB11915 Valbenazine Goserelin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB00014 DB11989 Benznidazole Goserelin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB00014 DB12007 Isoflavone Goserelin may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB00014 DB12107 Vaborbactam Goserelin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB00014 DB12278 Propiverine Goserelin may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB00014 DB12783 Benserazide Goserelin may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB00014 DB13025 Tiapride Goserelin may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB00014 DB13139 Levosalbutamol Goserelin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB00014 DB13156 Inosine pranobex Goserelin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB00014 DB13178 Inositol Goserelin may decrease the excretion rate of Inositol which could result in a higher serum level.
DB00014 DB13185 Oxabolone cipionate Goserelin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB00014 DB13191 Phosphocreatine Goserelin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB00014 DB13269 Dichlorobenzyl alcohol Goserelin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB00014 DB13293 Ipecac Goserelin may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB00014 DB13595 Almasilate Goserelin may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB00014 DB13873 Fenofibric acid Goserelin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB00014 DB13884 Albutrepenonacog alfa Goserelin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB00014 DB13909 Bismuth subgallate Goserelin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB00014 DB13943 Testosterone cypionate Goserelin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB00014 DB13944 Testosterone enanthate Goserelin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB00014 DB13946 Testosterone undecanoate Goserelin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
DB00014 DB13952 Estradiol acetate Goserelin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB00014 DB13954 Estradiol cypionate Goserelin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB00014 DB13955 Estradiol dienanthate Goserelin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB00014 DB13956 Estradiol valerate Goserelin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB00014 DB13967 Patent Blue Goserelin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB00014 DB14006 Choline salicylate Goserelin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB00014 DB14007 Pentetic acid Goserelin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB00014 DB14498 Potassium acetate Goserelin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB00014 DB14499 Potassium sulfate Goserelin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB00014 DB14526 Chromic citrate Goserelin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB00014 DB14527 Chromic nitrate Goserelin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB00014 DB14528 Chromium gluconate Goserelin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB00014 DB14529 Chromium nicotinate Goserelin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB00014 DB14530 Chromous sulfate Goserelin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB00014 DB14754 Solriamfetol Goserelin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
DB00014 DB06815 Pyrithione Goserelin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB00014 DB11121 Chloroxylenol Goserelin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB00014 DB11085 Resorcinol Goserelin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB00014 DB00661 Verapamil Goserelin may decrease the excretion rate of Verapamil which could result in a higher serum level.
DB00014 DB15593 Golodirsen Goserelin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00014 DB00440 Trimethoprim Goserelin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00014 DB00318 Codeine Goserelin may decrease the excretion rate of Codeine which could result in a higher serum level.
DB00014 DB00454 Meperidine Goserelin may decrease the excretion rate of Meperidine which could result in a higher serum level.
DB00014 DB00813 Fentanyl Goserelin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
DB00014 DB00879 Emtricitabine Goserelin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB00014 DB08996 Dimetacrine Goserelin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
DB00014 DB14506 Lithium hydroxide Goserelin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB00014 DB00452 Framycetin Framycetin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00479 Amikacin Amikacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00684 Tobramycin Tobramycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00798 Gentamicin Gentamicin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00955 Netilmicin Netilmicin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00994 Neomycin Neomycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01082 Streptomycin Streptomycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01172 Kanamycin Kanamycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB01421 Paromomycin Paromomycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB03615 Ribostamycin Ribostamycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04263 Geneticin Geneticin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04626 Apramycin Apramycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04729 Gentamicin C1a Gentamicin C1a may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB04808 Neamine Neamine may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB06696 Arbekacin Arbekacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB08437 Puromycin Puromycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11512 Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB11520 Hygromycin B Hygromycin B may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB12604 Sisomicin Sisomicin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13270 Dibekacin Dibekacin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13274 Micronomicin Micronomicin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13540 Isepamicin Isepamicin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB13673 Bekanamycin Bekanamycin may decrease the excretion rate of Goserelin which could result in a higher serum level.
DB00014 DB00552 Pentostatin Goserelin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB00014 DB13145 Nedaplatin Goserelin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00014 DB00314 Capreomycin Goserelin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00014 DB00390 Digoxin Goserelin may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00014 DB00512 Vancomycin Goserelin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00014 DB00515 Cisplatin Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00014 DB00564 Carbamazepine Goserelin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
DB00014 DB00642 Pemetrexed Goserelin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB00014 DB00682 Warfarin Goserelin may decrease the excretion rate of Warfarin which could result in a higher serum level.
DB00014 DB00982 Isotretinoin Goserelin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB00014 DB12615 Plazomicin Goserelin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00014 DB14509 Lithium carbonate Goserelin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB00014 DB00524 Metolazone Goserelin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00695 Furosemide Goserelin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00887 Bumetanide Goserelin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB09338 Mersalyl Goserelin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00214 Torasemide Torasemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00232 Methyclothiazide Methyclothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00310 Chlorthalidone Chlorthalidone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00311 Ethoxzolamide Ethoxzolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00421 Spironolactone Spironolactone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00436 Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00562 Benzthiazide Benzthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00594 Amiloride Amiloride may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00606 Cyclothiazide Cyclothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00700 Eplerenone Eplerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00703 Methazolamide Methazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00774 Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00819 Acetazolamide Acetazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00872 Conivaptan Conivaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00880 Chlorothiazide Chlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01021 Trichlormethiazide Trichlormethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01119 Diazoxide Diazoxide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01144 Diclofenamide Diclofenamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01324 Polythiazide Polythiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01325 Quinethazone Quinethazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01395 Drospirenone Drospirenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB01412 Theobromine Theobromine may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB02925 Piretanide Piretanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB04831 Tienilic acid Tienilic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB05034 Ularitide Ularitide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB06212 Tolvaptan Tolvaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB06370 Indisulam Indisulam may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB08961 Azosemide Azosemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB09015 Canrenoic acid Canrenoic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB09125 Potassium citrate Potassium citrate may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB09401 Isosorbide Isosorbide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB12221 Canrenone Canrenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB12670 Rolofylline Rolofylline may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB12704 Spiradoline Spiradoline may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13284 Meticrane Meticrane may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13316 Ibopamine Ibopamine may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13405 Mefruside Mefruside may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13430 Mebutizide Mebutizide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13532 Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13617 Clorexolone Clorexolone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13663 Clofenamide Clofenamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13708 Fenquizone Fenquizone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13792 Clopamide Clopamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13801 Muzolimine Muzolimine may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13803 Xipamide Xipamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB13989 Epitizide Epitizide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB14018 Bromotheophylline Bromotheophylline may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB14500 Potassium Potassium may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy.
DB00014 DB00331 Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.
DB00014 DB00656 Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Goserelin.
DB00014 DB11986 Entrectinib The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib.
DB00014 DB11642 Pitolisant Goserelin may increase the QTc-prolonging activities of Pitolisant.
DB00014 DB12825 Lefamulin Lefamulin may increase the QTc-prolonging activities of Goserelin.
DB00014 DB00557 Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Goserelin.
DB00014 DB00246 Ziprasidone The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ziprasidone.
DB00014 DB00502 Haloperidol The risk or severity of QTc prolongation can be increased when Goserelin is combined with Haloperidol.
DB00014 DB00472 Fluoxetine The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluoxetine.
DB00015 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Reteplase.
DB00015 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Reteplase.
DB00015 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reteplase.
DB00015 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Reteplase is combined with Deferasirox.
DB00015 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Ursodeoxycholic acid.
DB00015 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycochenodeoxycholic Acid.
DB00015 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Cholic Acid.
DB00015 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycocholic acid.
DB00015 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Deoxycholic acid.
DB00015 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurocholic acid.
DB00015 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Obeticholic acid.
DB00015 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Chenodeoxycholic acid.
DB00015 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurochenodeoxycholic acid.
DB00015 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Tauroursodeoxycholic acid.
DB00015 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Bamet-UD2.
DB00015 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Dehydrocholic acid.
DB00015 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Hyodeoxycholic Acid.
DB00015 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Reteplase.
DB00015 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reteplase.
DB00015 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Obinutuzumab.
DB00015 DB06228 Rivaroxaban Reteplase may increase the anticoagulant activities of Rivaroxaban.
DB00015 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Sugammadex.
DB00015 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Reteplase.
DB00015 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reteplase.
DB00015 DB00013 Urokinase Urokinase may increase the anticoagulant activities of Reteplase.
DB00015 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Reteplase.
DB00015 DB09030 Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Reteplase.
DB00015 DB06692 Aprotinin The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.
DB00015 DB01381 Ginkgo biloba The therapeutic efficacy of Reteplase can be increased when used in combination with Ginkgo biloba.
DB00015 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Reteplase.
DB00015 DB00468 Quinine The therapeutic efficacy of Reteplase can be increased when used in combination with Quinine.
DB00015 DB00908 Quinidine The therapeutic efficacy of Reteplase can be increased when used in combination with Quinidine.
DB00015 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Reteplase.
DB00015 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Reteplase.
DB00015 DB00806 Pentoxifylline The therapeutic efficacy of Reteplase can be increased when used in combination with Pentoxifylline.
DB00015 DB00686 Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Reteplase.
DB00015 DB00583 Levocarnitine The therapeutic efficacy of Reteplase can be increased when used in combination with Levocarnitine.
DB00015 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Reteplase.
DB00015 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Reteplase.
DB00015 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Reteplase.
DB00015 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Reteplase.
DB00015 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Reteplase.
DB00015 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Reteplase.
DB00015 DB04573 Estriol Estriol may decrease the anticoagulant activities of Reteplase.
DB00015 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Reteplase.
DB00015 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Reteplase.
DB00015 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Reteplase.
DB00015 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Reteplase.
DB00015 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reteplase.
DB00015 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Reteplase.
DB00015 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Reteplase.
DB00015 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Reteplase.
DB00015 DB11674 Equol Equol may decrease the anticoagulant activities of Reteplase.
DB00015 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Reteplase.
DB00015 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Reteplase.
DB00015 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Reteplase.
DB00015 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Reteplase.
DB00015 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Reteplase.
DB00015 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Reteplase.
DB00015 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Reteplase.
DB00015 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Reteplase.
DB00015 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Reteplase.
DB00015 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Reteplase.
DB00015 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reteplase.
DB00015 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reteplase.
DB00015 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Reteplase.
DB00015 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Reteplase.
DB00015 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Reteplase.
DB00015 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Reteplase.
DB00015 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Reteplase.
DB00015 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Reteplase.
DB00015 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Reteplase.
DB00015 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Reteplase.
DB00015 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Reteplase.
DB00015 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Reteplase.
DB00015 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reteplase.
DB00015 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Reteplase.
DB00015 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Reteplase.
DB00015 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Reteplase.
DB00015 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reteplase.
DB00015 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Reteplase.
DB00015 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Reteplase.
DB00015 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reteplase.
DB00015 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Reteplase.
DB00015 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Reteplase.
DB00015 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Reteplase.
DB00015 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Reteplase.
DB00015 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Reteplase.
DB00015 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Reteplase.
DB00015 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Reteplase.
DB00015 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Reteplase.
DB00015 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Reteplase.
DB00015 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Reteplase.
DB00015 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Reteplase.
DB00015 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Reteplase.
DB00015 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Reteplase.
DB00015 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Reteplase.
DB00015 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Reteplase.
DB00015 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Reteplase.
DB00015 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Reteplase.
DB00015 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Reteplase.
DB00015 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Reteplase.
DB00015 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Reteplase.
DB00015 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Reteplase.
DB00015 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Reteplase.
DB00015 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Reteplase.
DB00015 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Reteplase.
DB00015 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Reteplase.
DB00015 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Reteplase.
DB00015 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Reteplase.
DB00015 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Reteplase.
DB00015 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Reteplase.
DB00015 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Reteplase.
DB00015 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Reteplase.
DB00015 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Reteplase.
DB00015 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Reteplase.
DB00015 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Reteplase.
DB00015 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Reteplase.
DB00015 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Reteplase.
DB00015 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Reteplase.
DB00015 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Reteplase.
DB00015 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Reteplase.
DB00015 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Reteplase.
DB00015 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Reteplase.
DB00015 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Reteplase.
DB00015 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Reteplase.
DB00015 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Reteplase.
DB00015 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Reteplase.
DB00015 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Reteplase.
DB00015 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Reteplase.
DB00015 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Reteplase.
DB00015 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Reteplase.
DB00015 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Reteplase.
DB00015 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Reteplase.
DB00015 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Reteplase.
DB00015 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Reteplase.
DB00015 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Reteplase.
DB00015 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Reteplase.
DB00015 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Reteplase.
DB00015 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Reteplase.
DB00015 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Reteplase.
DB00015 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Reteplase.
DB00015 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Reteplase.
DB00015 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Reteplase.
DB00015 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Reteplase.
DB00015 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Reteplase.
DB00015 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Reteplase.
DB00015 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Reteplase.
DB00015 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Reteplase.
DB00015 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Reteplase.
DB00015 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Reteplase.
DB00015 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Reteplase.
DB00015 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Reteplase.
DB00015 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Reteplase.
DB00015 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Reteplase.
DB00015 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Reteplase.
DB00015 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Reteplase.
DB00015 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Reteplase.
DB00015 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Reteplase.
DB00015 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Reteplase.
DB00015 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Reteplase.
DB00015 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Reteplase.
DB00015 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Reteplase.
DB00015 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Reteplase.
DB00015 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Reteplase.
DB00015 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Reteplase.
DB00015 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Reteplase is combined with Omacetaxine mepesuccinate.
DB00015 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Reteplase.
DB00015 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Tositumomab.
DB00015 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase.
DB00015 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Reteplase is combined with Collagenase clostridium histolyticum.
DB00015 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Reteplase.
DB00015 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Reteplase.
DB00015 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Reteplase.
DB00015 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Reteplase.
DB00015 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Reteplase.
DB00015 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Reteplase.
DB00015 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Reteplase.
DB00015 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Reteplase.
DB00015 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Reteplase.
DB00015 DB00834 Mifepristone The therapeutic efficacy of Reteplase can be decreased when used in combination with Mifepristone.
DB00015 DB04066 p-Coumaric acid The therapeutic efficacy of Reteplase can be decreased when used in combination with p-Coumaric acid.
DB00015 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Reteplase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00015 DB05830 Trestolone The therapeutic efficacy of Reteplase can be decreased when used in combination with Trestolone.
DB00015 DB06266 Lonidamine The therapeutic efficacy of Reteplase can be decreased when used in combination with Lonidamine.
DB00015 DB08867 Ulipristal The therapeutic efficacy of Reteplase can be decreased when used in combination with Ulipristal.
DB00015 DB09401 Isosorbide The therapeutic efficacy of Reteplase can be decreased when used in combination with Isosorbide.
DB00015 DB11507 Cloprostenol The therapeutic efficacy of Reteplase can be decreased when used in combination with Cloprostenol.
DB00015 DB12025 Triptolide The therapeutic efficacy of Reteplase can be decreased when used in combination with Triptolide.
DB00015 DB13044 Gossypol The therapeutic efficacy of Reteplase can be decreased when used in combination with Gossypol.
DB00015 DB13310 Ormeloxifene The therapeutic efficacy of Reteplase can be decreased when used in combination with Ormeloxifene.
DB00015 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Reteplase.
DB00015 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Reteplase.
DB00015 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Reteplase.
DB00015 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Reteplase.
DB00015 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Reteplase.
DB00015 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Reteplase.
DB00015 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Reteplase.
DB00015 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Reteplase.
DB00015 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Reteplase.
DB00015 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Reteplase.
DB00015 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Reteplase.
DB00015 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Reteplase.
DB00015 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Reteplase.
DB00015 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Reteplase.
DB00015 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Reteplase.
DB00015 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Reteplase.
DB00015 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Reteplase.
DB00015 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Reteplase.
DB00015 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Reteplase.
DB00015 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Reteplase.
DB00015 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Reteplase.
DB00015 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Reteplase.
DB00015 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Reteplase.
DB00015 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Reteplase.
DB00015 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Reteplase.
DB00015 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Reteplase.
DB00015 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Reteplase.
DB00015 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Reteplase.
DB00015 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Reteplase.
DB00015 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Reteplase.
DB00015 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Reteplase.
DB00015 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reteplase.
DB00015 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Reteplase.
DB00015 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Reteplase.
DB00015 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Reteplase.
DB00015 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Reteplase.
DB00015 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Reteplase.
DB00015 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Reteplase.
DB00015 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Reteplase.
DB00015 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Reteplase.
DB00015 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Reteplase.
DB00015 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Reteplase.
DB00015 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Reteplase.
DB00015 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Reteplase.
DB00015 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Reteplase.
DB00015 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Reteplase.
DB00015 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Reteplase.
DB00015 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Reteplase.
DB00015 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Reteplase.
DB00015 DB01166 Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Reteplase.
DB00015 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Reteplase.
DB00015 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Reteplase.
DB00015 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Reteplase.
DB00015 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Reteplase.
DB00015 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Reteplase.
DB00015 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Reteplase.
DB00015 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Reteplase.
DB00015 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Reteplase.
DB00015 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Reteplase.
DB00015 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Reteplase.
DB00015 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Reteplase.
DB00015 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Reteplase.
DB00015 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Reteplase.
DB00015 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Reteplase.
DB00015 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Reteplase.
DB00015 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Reteplase.
DB00015 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Reteplase.
DB00015 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Reteplase.
DB00015 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Reteplase.
DB00015 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Reteplase.
DB00015 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Reteplase.
DB00015 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Reteplase.
DB00015 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Reteplase.
DB00015 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Reteplase.
DB00015 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Reteplase.
DB00015 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Reteplase.
DB00015 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Reteplase.
DB00015 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Reteplase.
DB00015 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Reteplase.
DB00015 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Reteplase.
DB00015 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Reteplase.
DB00015 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Reteplase.
DB00015 DB00374 Treprostinil The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.
DB00015 DB03404 Hemin Hemin may increase the anticoagulant activities of Reteplase.
DB00015 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Reteplase.
DB00015 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Reteplase.
DB00015 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Reteplase.
DB00015 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Reteplase.
DB00015 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Reteplase.
DB00015 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Reteplase.
DB00015 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Reteplase.
DB00015 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Reteplase.
DB00015 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Reteplase.
DB00015 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Reteplase.
DB00015 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Reteplase.
DB00015 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Reteplase.
DB00015 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Reteplase.
DB00015 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Reteplase.
DB00015 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Reteplase.
DB00015 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Reteplase.
DB00015 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Reteplase is combined with Azficel-T.
DB00015 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Reteplase can be increased when used in combination with Omega-3-carboxylic acids.
DB00015 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Reteplase.
DB00015 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Reteplase.
DB00015 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Reteplase.
DB00015 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Reteplase.
DB00015 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Reteplase.
DB00015 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Reteplase.
DB00015 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Reteplase.
DB00015 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Reteplase.
DB00015 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reteplase.
DB00015 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reteplase.
DB00015 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Reteplase.
DB00015 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Reteplase.
DB00015 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Reteplase.
DB00015 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Reteplase.
DB00015 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Reteplase.
DB00015 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Reteplase.
DB00015 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Reteplase.
DB00015 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Reteplase.
DB00015 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Reteplase.
DB00015 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Reteplase.
DB00015 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Reteplase.
DB00015 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Reteplase.
DB00015 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Reteplase.
DB00015 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Reteplase.
DB00015 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Reteplase.
DB00015 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Reteplase.
DB00015 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Reteplase.
DB00015 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Reteplase.
DB00015 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Reteplase.
DB00015 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Reteplase.
DB00015 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Reteplase.
DB00015 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Reteplase.
DB00015 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Reteplase.
DB00015 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Reteplase.
DB00015 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Reteplase.
DB00015 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Reteplase.
DB00015 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Reteplase.
DB00015 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Reteplase.
DB00015 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Reteplase.
DB00015 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Reteplase.
DB00015 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Reteplase.
DB00015 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Reteplase.
DB00015 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Reteplase.
DB00015 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Reteplase.
DB00015 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Reteplase.
DB00015 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Reteplase.
DB00015 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Reteplase.
DB00015 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Reteplase.
DB00015 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Reteplase.
DB00015 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Reteplase.
DB00015 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Reteplase.
DB00015 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Reteplase.
DB00015 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Reteplase.
DB00015 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Reteplase.
DB00015 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Reteplase.
DB00015 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Reteplase.
DB00015 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Reteplase.
DB00015 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Reteplase.
DB00015 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Reteplase.
DB00015 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Reteplase.
DB00015 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Reteplase.
DB00015 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Reteplase.
DB00015 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Reteplase.
DB00015 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Reteplase.
DB00015 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Reteplase.
DB00015 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Reteplase.
DB00015 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Reteplase.
DB00015 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Reteplase.
DB00015 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Reteplase.
DB00015 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Reteplase.
DB00015 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Reteplase.
DB00015 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Reteplase.
DB00015 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Reteplase.
DB00015 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Reteplase.
DB00015 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Reteplase.
DB00015 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Reteplase.
DB00015 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Reteplase.
DB00015 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Reteplase.
DB00015 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Reteplase.
DB00015 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Reteplase.
DB00015 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Reteplase.
DB00015 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Reteplase.
DB00015 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Reteplase.
DB00015 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Reteplase.
DB00015 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Reteplase.
DB00015 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Reteplase.
DB00015 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Reteplase.
DB00015 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Reteplase.
DB00015 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Reteplase.
DB00015 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Reteplase.
DB00015 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Reteplase.
DB00015 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Reteplase.
DB00015 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Reteplase.
DB00015 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Reteplase.
DB00015 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Reteplase.
DB00015 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Reteplase.
DB00015 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Reteplase.
DB00015 DB00682 Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Reteplase.
DB00015 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Reteplase.
DB00015 DB00974 Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Reteplase.
DB00015 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Reteplase.
DB00015 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Reteplase.
DB00015 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Reteplase.
DB00015 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Reteplase.
DB00015 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Reteplase.
DB00015 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Reteplase.
DB00015 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Reteplase.
DB00015 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Reteplase.
DB00015 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Reteplase.
DB00015 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Reteplase.
DB00015 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Reteplase.
DB00015 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Reteplase.
DB00015 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Reteplase.
DB00015 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Reteplase.
DB00015 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Reteplase.
DB00015 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Reteplase.
DB00015 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Reteplase.
DB00015 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Reteplase.
DB00015 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Reteplase.
DB00015 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Reteplase.
DB00015 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Reteplase.
DB00015 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Reteplase.
DB00015 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Reteplase.
DB00015 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Reteplase.
DB00015 DB13124 Troxerutin The risk or severity of bleeding can be increased when Troxerutin is combined with Reteplase.
DB00015 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Reteplase.
DB00015 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Reteplase.
DB00015 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Reteplase.
DB00015 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Reteplase.
DB00015 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Reteplase.
DB00015 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Reteplase.
DB00015 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Reteplase.
DB00015 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Reteplase.
DB00015 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Reteplase.
DB00015 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Reteplase.
DB00015 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Reteplase.
DB00015 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Reteplase.
DB00015 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Reteplase.
DB00015 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Reteplase.
DB00015 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Reteplase.
DB00015 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Reteplase.
DB00015 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Reteplase.
DB00015 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Reteplase.
DB00015 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Reteplase.
DB00015 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Reteplase.
DB00015 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.
DB00015 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Reteplase.
DB00015 DB00029 Anistreplase The risk or severity of bleeding can be increased when Reteplase is combined with Anistreplase.
DB00015 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Reteplase is combined with Tocopherylquinone.
DB00015 DB06679 Amediplase The risk or severity of bleeding can be increased when Reteplase is combined with Amediplase.
DB00015 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Reteplase is combined with 4-hydroxycoumarin.
DB00015 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Reteplase is combined with (R)-warfarin.
DB00015 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Reteplase is combined with (S)-Warfarin.
DB00015 DB12364 Betrixaban The risk or severity of bleeding can be increased when Reteplase is combined with Betrixaban.
DB00015 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Reteplase is combined with Edetate calcium disodium anhydrous.
DB00015 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Reteplase is combined with Zinc citrate.
DB00015 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Reteplase is combined with Antithrombin Alfa.
DB00015 DB04665 Coumarin The risk or severity of bleeding can be increased when Reteplase is combined with Coumarin.
DB00015 DB14726 Dabigatran The risk or severity of bleeding can be increased when Reteplase is combined with Dabigatran.
DB00015 DB06294 Semuloparin The risk or severity of bleeding can be increased when Reteplase is combined with Semuloparin.
DB00015 DB12726 Monteplase The risk or severity of bleeding can be increased when Reteplase is combined with Monteplase.
DB00015 DB00177 Valsartan The risk or severity of angioedema can be increased when Reteplase is combined with Valsartan.
DB00015 DB00178 Ramipril The risk or severity of angioedema can be increased when Reteplase is combined with Ramipril.
DB00015 DB00230 Pregabalin The risk or severity of angioedema can be increased when Reteplase is combined with Pregabalin.
DB00015 DB00492 Fosinopril The risk or severity of angioedema can be increased when Reteplase is combined with Fosinopril.
DB00015 DB00519 Trandolapril The risk or severity of angioedema can be increased when Reteplase is combined with Trandolapril.
DB00015 DB00542 Benazepril The risk or severity of angioedema can be increased when Reteplase is combined with Benazepril.
DB00015 DB00584 Enalapril The risk or severity of angioedema can be increased when Reteplase is combined with Enalapril.
DB00015 DB00678 Losartan The risk or severity of angioedema can be increased when Reteplase is combined with Losartan.
DB00015 DB00691 Moexipril The risk or severity of angioedema can be increased when Reteplase is combined with Moexipril.
DB00015 DB00722 Lisinopril The risk or severity of angioedema can be increased when Reteplase is combined with Lisinopril.
DB00015 DB00790 Perindopril The risk or severity of angioedema can be increased when Reteplase is combined with Perindopril.
DB00015 DB00876 Eprosartan The risk or severity of angioedema can be increased when Reteplase is combined with Eprosartan.
DB00015 DB00877 Sirolimus The risk or severity of angioedema can be increased when Reteplase is combined with Sirolimus.
DB00015 DB00881 Quinapril The risk or severity of angioedema can be increased when Reteplase is combined with Quinapril.
DB00015 DB00886 Omapatrilat The risk or severity of angioedema can be increased when Reteplase is combined with Omapatrilat.
DB00015 DB00966 Telmisartan The risk or severity of angioedema can be increased when Reteplase is combined with Telmisartan.
DB00015 DB01050 Ibuprofen The risk or severity of angioedema can be increased when Reteplase is combined with Ibuprofen.
DB00015 DB01180 Rescinnamine The risk or severity of angioedema can be increased when Reteplase is combined with Rescinnamine.
DB00015 DB01197 Captopril The risk or severity of angioedema can be increased when Reteplase is combined with Captopril.
DB00015 DB01261 Sitagliptin The risk or severity of angioedema can be increased when Reteplase is combined with Sitagliptin.
DB00015 DB01340 Cilazapril The risk or severity of angioedema can be increased when Reteplase is combined with Cilazapril.
DB00015 DB01342 Forasartan The risk or severity of angioedema can be increased when Reteplase is combined with Forasartan.
DB00015 DB01347 Saprisartan The risk or severity of angioedema can be increased when Reteplase is combined with Saprisartan.
DB00015 DB01348 Spirapril The risk or severity of angioedema can be increased when Reteplase is combined with Spirapril.
DB00015 DB04876 Vildagliptin The risk or severity of angioedema can be increased when Reteplase is combined with Vildagliptin.
DB00015 DB06011 AMG-222 The risk or severity of angioedema can be increased when Reteplase is combined with AMG-222.
DB00015 DB06127 Bisegliptin The risk or severity of angioedema can be increased when Reteplase is combined with Bisegliptin.
DB00015 DB06196 Icatibant The risk or severity of angioedema can be increased when Reteplase is combined with Icatibant.
DB00015 DB06203 Alogliptin The risk or severity of angioedema can be increased when Reteplase is combined with Alogliptin.
DB00015 DB06245 Lanoteplase The risk or severity of angioedema can be increased when Reteplase is combined with Lanoteplase.
DB00015 DB06287 Temsirolimus The risk or severity of angioedema can be increased when Reteplase is combined with Temsirolimus.
DB00015 DB06335 Saxagliptin The risk or severity of angioedema can be increased when Reteplase is combined with Saxagliptin.
DB00015 DB08382 Gosogliptin The risk or severity of angioedema can be increased when Reteplase is combined with Gosogliptin.
DB00015 DB08822 Azilsartan medoxomil The risk or severity of angioedema can be increased when Reteplase is combined with Azilsartan medoxomil.
DB00015 DB08836 Temocapril The risk or severity of angioedema can be increased when Reteplase is combined with Temocapril.
DB00015 DB08882 Linagliptin The risk or severity of angioedema can be increased when Reteplase is combined with Linagliptin.
DB00015 DB09292 Sacubitril The risk or severity of angioedema can be increased when Reteplase is combined with Sacubitril.
DB00015 DB09477 Enalaprilat The risk or severity of angioedema can be increased when Reteplase is combined with Enalaprilat.
DB00015 DB11723 Dutogliptin The risk or severity of angioedema can be increased when Reteplase is combined with Dutogliptin.
DB00015 DB11783 Imidapril The risk or severity of angioedema can be increased when Reteplase is combined with Imidapril.
DB00015 DB11950 Teneligliptin The risk or severity of angioedema can be increased when Reteplase is combined with Teneligliptin.
DB00015 DB11992 Omarigliptin The risk or severity of angioedema can be increased when Reteplase is combined with Omarigliptin.
DB00015 DB12268 Carmegliptin The risk or severity of angioedema can be increased when Reteplase is combined with Carmegliptin.
DB00015 DB12412 Gemigliptin The risk or severity of angioedema can be increased when Reteplase is combined with Gemigliptin.
DB00015 DB12417 Anagliptin The risk or severity of angioedema can be increased when Reteplase is combined with Anagliptin.
DB00015 DB12625 Evogliptin The risk or severity of angioedema can be increased when Reteplase is combined with Evogliptin.
DB00015 DB13166 Zofenopril The risk or severity of angioedema can be increased when Reteplase is combined with Zofenopril.
DB00015 DB13312 Delapril The risk or severity of angioedema can be increased when Reteplase is combined with Delapril.
DB00015 DB14125 Benazeprilat The risk or severity of angioedema can be increased when Reteplase is combined with Benazeprilat.
DB00015 DB14207 Fosinoprilat The risk or severity of angioedema can be increased when Reteplase is combined with Fosinoprilat.
DB00015 DB14208 Ramiprilat The risk or severity of angioedema can be increased when Reteplase is combined with Ramiprilat.
DB00015 DB14209 Trandolaprilat The risk or severity of angioedema can be increased when Reteplase is combined with Trandolaprilat.
DB00015 DB14210 Moexiprilat The risk or severity of angioedema can be increased when Reteplase is combined with Moexiprilat.
DB00015 DB14213 Perindoprilat The risk or severity of angioedema can be increased when Reteplase is combined with Perindoprilat.
DB00015 DB14217 Quinaprilat The risk or severity of angioedema can be increased when Reteplase is combined with Quinaprilat.
DB00015 DB14231 Quinoline Yellow WS The risk or severity of angioedema can be increased when Reteplase is combined with Quinoline Yellow WS.
DB00015 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Reteplase is combined with Sildenafil.
DB00015 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2a.
DB00015 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n1.
DB00015 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n3.
DB00015 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2b.
DB00015 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Reteplase is combined with Interferon gamma-1b.
DB00015 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2a, Recombinant.
DB00015 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Reteplase is combined with Aldesleukin.
DB00015 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Reteplase is combined with Gemtuzumab ozogamicin.
DB00015 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Reteplase is combined with Interferon beta-1b.
DB00015 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfacon-1.
DB00015 DB00073 Rituximab The risk or severity of bleeding can be increased when Reteplase is combined with Rituximab.
DB00015 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Reteplase is combined with Ibritumomab tiuxetan.
DB00015 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Reteplase is combined with Alemtuzumab.
DB00015 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2b.
DB00015 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Reteplase is combined with Phenylalanine.
DB00015 DB00188 Bortezomib The risk or severity of bleeding can be increased when Reteplase is combined with Bortezomib.
DB00015 DB00242 Cladribine The risk or severity of bleeding can be increased when Reteplase is combined with Cladribine.
DB00015 DB00262 Carmustine The risk or severity of bleeding can be increased when Reteplase is combined with Carmustine.
DB00015 DB00276 Amsacrine The risk or severity of bleeding can be increased when Reteplase is combined with Amsacrine.
DB00015 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Reteplase is combined with Chlorambucil.
DB00015 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Reteplase is combined with Raltitrexed.
DB00015 DB00305 Mitomycin The risk or severity of bleeding can be increased when Reteplase is combined with Mitomycin.
DB00015 DB00307 Bexarotene The risk or severity of bleeding can be increased when Reteplase is combined with Bexarotene.
DB00015 DB00309 Vindesine The risk or severity of bleeding can be increased when Reteplase is combined with Vindesine.
DB00015 DB00322 Floxuridine The risk or severity of bleeding can be increased when Reteplase is combined with Floxuridine.
DB00015 DB00352 Tioguanine The risk or severity of bleeding can be increased when Reteplase is combined with Tioguanine.
DB00015 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Reteplase is combined with Vinorelbine.
DB00015 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Reteplase is combined with Dexrazoxane.
DB00015 DB00398 Sorafenib The risk or severity of bleeding can be increased when Reteplase is combined with Sorafenib.
DB00015 DB00428 Streptozocin The risk or severity of bleeding can be increased when Reteplase is combined with Streptozocin.
DB00015 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Reteplase is combined with Gemcitabine.
DB00015 DB00444 Teniposide The risk or severity of bleeding can be increased when Reteplase is combined with Teniposide.
DB00015 DB00445 Epirubicin The risk or severity of bleeding can be increased when Reteplase is combined with Epirubicin.
DB00015 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Reteplase is combined with Chloramphenicol.
DB00015 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Reteplase is combined with Lenalidomide.
DB00015 DB00488 Altretamine The risk or severity of bleeding can be increased when Reteplase is combined with Altretamine.
DB00015 DB00495 Zidovudine The risk or severity of bleeding can be increased when Reteplase is combined with Zidovudine.
DB00015 DB00515 Cisplatin The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin.
DB00015 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Reteplase is combined with Oxaliplatin.
DB00015 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Reteplase is combined with Cyclophosphamide.
DB00015 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Reteplase is combined with Fluorouracil.
DB00015 DB00552 Pentostatin The risk or severity of bleeding can be increased when Reteplase is combined with Pentostatin.
DB00015 DB00563 Methotrexate The risk or severity of bleeding can be increased when Reteplase is combined with Methotrexate.
DB00015 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Reteplase is combined with Carbamazepine.
DB00015 DB00570 Vinblastine The risk or severity of bleeding can be increased when Reteplase is combined with Vinblastine.
DB00015 DB00619 Imatinib The risk or severity of bleeding can be increased when Reteplase is combined with Imatinib.
DB00015 DB00631 Clofarabine The risk or severity of bleeding can be increased when Reteplase is combined with Clofarabine.
DB00015 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Reteplase is combined with Pemetrexed.
DB00015 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin.
DB00015 DB00762 Irinotecan The risk or severity of bleeding can be increased when Reteplase is combined with Irinotecan.
DB00015 DB00773 Etoposide The risk or severity of bleeding can be increased when Reteplase is combined with Etoposide.
DB00015 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Reteplase is combined with Dacarbazine.
DB00015 DB00853 Temozolomide The risk or severity of bleeding can be increased when Reteplase is combined with Temozolomide.
DB00015 DB00859 Penicillamine The risk or severity of bleeding can be increased when Reteplase is combined with Penicillamine.
DB00015 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Reteplase is combined with Tacrolimus.
DB00015 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Reteplase is combined with Mechlorethamine.
DB00015 DB00928 Azacitidine The risk or severity of bleeding can be increased when Reteplase is combined with Azacitidine.
DB00015 DB00958 Carboplatin The risk or severity of bleeding can be increased when Reteplase is combined with Carboplatin.
DB00015 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Reteplase is combined with Dactinomycin.
DB00015 DB00987 Cytarabine The risk or severity of bleeding can be increased when Reteplase is combined with Cytarabine.
DB00015 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Reteplase is combined with Doxorubicin.
DB00015 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Reteplase is combined with Hydroxyurea.
DB00015 DB01008 Busulfan The risk or severity of bleeding can be increased when Reteplase is combined with Busulfan.
DB00015 DB01030 Topotecan The risk or severity of bleeding can be increased when Reteplase is combined with Topotecan.
DB00015 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Reteplase is combined with Mercaptopurine.
DB00015 DB01041 Thalidomide The risk or severity of bleeding can be increased when Reteplase is combined with Thalidomide.
DB00015 DB01042 Melphalan The risk or severity of bleeding can be increased when Reteplase is combined with Melphalan.
DB00015 DB01073 Fludarabine The risk or severity of bleeding can be increased when Reteplase is combined with Fludarabine.
DB00015 DB01099 Flucytosine The risk or severity of bleeding can be increased when Reteplase is combined with Flucytosine.
DB00015 DB01101 Capecitabine The risk or severity of bleeding can be increased when Reteplase is combined with Capecitabine.
DB00015 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Reteplase is combined with Arsenic trioxide.
DB00015 DB01177 Idarubicin The risk or severity of bleeding can be increased when Reteplase is combined with Idarubicin.
DB00015 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Reteplase is combined with Mitoxantrone.
DB00015 DB01206 Lomustine The risk or severity of bleeding can be increased when Reteplase is combined with Lomustine.
DB00015 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Reteplase is combined with Paclitaxel.
DB00015 DB01248 Docetaxel The risk or severity of bleeding can be increased when Reteplase is combined with Docetaxel.
DB00015 DB01262 Decitabine The risk or severity of bleeding can be increased when Reteplase is combined with Decitabine.
DB00015 DB01280 Nelarabine The risk or severity of bleeding can be increased when Reteplase is combined with Nelarabine.
DB00015 DB01590 Everolimus The risk or severity of bleeding can be increased when Reteplase is combined with Everolimus.
DB00015 DB02546 Vorinostat The risk or severity of bleeding can be increased when Reteplase is combined with Vorinostat.
DB00015 DB04572 Thiotepa The risk or severity of bleeding can be increased when Reteplase is combined with Thiotepa.
DB00015 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Reteplase is combined with Ixabepilone.
DB00015 DB04868 Nilotinib The risk or severity of bleeding can be increased when Reteplase is combined with Nilotinib.
DB00015 DB05015 Belinostat The risk or severity of bleeding can be increased when Reteplase is combined with Belinostat.
DB00015 DB05109 Trabectedin The risk or severity of bleeding can be increased when Reteplase is combined with Trabectedin.
DB00015 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa.
DB00015 DB05472 omega interferon The risk or severity of bleeding can be increased when Reteplase is combined with omega interferon.
DB00015 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Reteplase is combined with Trastuzumab emtansine.
DB00015 DB06616 Bosutinib The risk or severity of bleeding can be increased when Reteplase is combined with Bosutinib.
DB00015 DB06769 Bendamustine The risk or severity of bleeding can be increased when Reteplase is combined with Bendamustine.
DB00015 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Reteplase is combined with Cabazitaxel.
DB00015 DB08871 Eribulin The risk or severity of bleeding can be increased when Reteplase is combined with Eribulin.
DB00015 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Reteplase is combined with Ruxolitinib.
DB00015 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Reteplase is combined with Carfilzomib.
DB00015 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Reteplase is combined with Tofacitinib.
DB00015 DB08901 Ponatinib The risk or severity of bleeding can be increased when Reteplase is combined with Ponatinib.
DB00015 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Reteplase is combined with Pomalidomide.
DB00015 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Reteplase is combined with Tedizolid phosphate.
DB00015 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Reteplase is combined with Blinatumomab.
DB00015 DB09073 Palbociclib The risk or severity of bleeding can be increased when Reteplase is combined with Palbociclib.
DB00015 DB09074 Olaparib The risk or severity of bleeding can be increased when Reteplase is combined with Olaparib.
DB00015 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Reteplase is combined with Dinutuximab.
DB00015 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon beta-1a.
DB00015 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Reteplase is combined with Cepeginterferon alfa-2B.
DB00015 DB00229 Cefotiam The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotiam.
DB00015 DB00267 Cefmenoxime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefmenoxime.
DB00015 DB00274 Cefmetazole The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefmetazole.
DB00015 DB00430 Cefpiramide The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpiramide.
DB00015 DB00438 Ceftazidime The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftazidime.
DB00015 DB00447 Loracarbef The therapeutic efficacy of Reteplase can be decreased when used in combination with Loracarbef.
DB00015 DB00456 Cefalotin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefalotin.
DB00015 DB00493 Cefotaxime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotaxime.
DB00015 DB00535 Cefdinir The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefdinir.
DB00015 DB00567 Cephalexin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cephalexin.
DB00015 DB00671 Cefixime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefixime.
DB00015 DB00689 Cephaloglycin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cephaloglycin.
DB00015 DB00833 Cefaclor The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefaclor.
DB00015 DB00923 Ceforanide The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceforanide.
DB00015 DB01066 Cefditoren The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefditoren.
DB00015 DB01112 Cefuroxime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefuroxime.
DB00015 DB01139 Cefapirin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefapirin.
DB00015 DB01140 Cefadroxil The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefadroxil.
DB00015 DB01150 Cefprozil The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefprozil.
DB00015 DB01212 Ceftriaxone The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftriaxone.
DB00015 DB01326 Cefamandole The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole.
DB00015 DB01327 Cefazolin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefazolin.
DB00015 DB01328 Cefonicid The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefonicid.
DB00015 DB01329 Cefoperazone The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefoperazone.
DB00015 DB01330 Cefotetan The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefotetan.
DB00015 DB01331 Cefoxitin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefoxitin.
DB00015 DB01332 Ceftizoxime The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftizoxime.
DB00015 DB01333 Cefradine The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefradine.
DB00015 DB01413 Cefepime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefepime.
DB00015 DB01414 Cefacetrile The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefacetrile.
DB00015 DB01415 Ceftibuten The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftibuten.
DB00015 DB01416 Cefpodoxime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpodoxime.
DB00015 DB04570 Latamoxef The therapeutic efficacy of Reteplase can be decreased when used in combination with Latamoxef.
DB00015 DB04918 Ceftobiprole The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftobiprole.
DB00015 DB06590 Ceftaroline fosamil The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftaroline fosamil.
DB00015 DB09008 Cefaloridine The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefaloridine.
DB00015 DB09050 Ceftolozane The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftolozane.
DB00015 DB09062 Cefminox The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefminox.
DB00015 DB11367 Cefroxadine The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefroxadine.
DB00015 DB11935 Flomoxef The therapeutic efficacy of Reteplase can be decreased when used in combination with Flomoxef.
DB00015 DB13266 Cefatrizine The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefatrizine.
DB00015 DB13461 Cefcapene The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefcapene.
DB00015 DB13470 Cefodizime The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefodizime.
DB00015 DB13499 Cefsulodin The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefsulodin.
DB00015 DB13504 Cefetamet The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefetamet.
DB00015 DB13638 Cefbuperazone The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefbuperazone.
DB00015 DB13667 Cefozopran The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefozopran.
DB00015 DB13682 Cefpirome The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefpirome.
DB00015 DB13778 Cefazedone The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefazedone.
DB00015 DB13821 Ceftezole The therapeutic efficacy of Reteplase can be decreased when used in combination with Ceftezole.
DB00015 DB14725 Cefamandole nafate The therapeutic efficacy of Reteplase can be decreased when used in combination with Cefamandole nafate.
DB00015 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Reteplase.
DB00015 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Reteplase.
DB00015 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reteplase.
DB00015 DB00945 Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Reteplase.
DB00015 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Reteplase.
DB00015 DB00727 Nitroglycerin The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.
DB00015 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Reteplase.
DB00015 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Reteplase.
DB00015 DB00620 Triamcinolone The therapeutic efficacy of Reteplase can be decreased when used in combination with Triamcinolone.
DB00015 DB09079 Nintedanib The risk or severity of bleeding can be increased when Reteplase is combined with Nintedanib.
DB00015 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Reteplase.
DB00015 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Reteplase.
DB00015 DB00232 Methyclothiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Methyclothiazide.
DB00015 DB00436 Bendroflumethiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Bendroflumethiazide.
DB00015 DB00562 Benzthiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Benzthiazide.
DB00015 DB00606 Cyclothiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Cyclothiazide.
DB00015 DB00774 Hydroflumethiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Hydroflumethiazide.
DB00015 DB00880 Chlorothiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Chlorothiazide.
DB00015 DB00999 Hydrochlorothiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Hydrochlorothiazide.
DB00015 DB01021 Trichlormethiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Trichlormethiazide.
DB00015 DB01324 Polythiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Polythiazide.
DB00015 DB13430 Mebutizide The therapeutic efficacy of Reteplase can be decreased when used in combination with Mebutizide.
DB00015 DB13532 Cyclopenthiazide The therapeutic efficacy of Reteplase can be decreased when used in combination with Cyclopenthiazide.
DB00016 DB00480 Lenalidomide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lenalidomide.
DB00016 DB01041 Thalidomide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Thalidomide.
DB00016 DB08910 Pomalidomide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pomalidomide.
DB00016 DB00002 Cetuximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cetuximab.
DB00016 DB00004 Denileukin diftitox The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Denileukin diftitox.
DB00016 DB00007 Leuprolide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Leuprolide.
DB00016 DB00008 Peginterferon alfa-2a The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Peginterferon alfa-2a.
DB00016 DB00014 Goserelin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Goserelin.
DB00016 DB00023 Asparaginase Escherichia coli The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Asparaginase Escherichia coli.
DB00016 DB00041 Aldesleukin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aldesleukin.
DB00016 DB00056 Gemtuzumab ozogamicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemtuzumab ozogamicin.
DB00016 DB00059 Pegaspargase The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pegaspargase.
DB00016 DB00072 Trastuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trastuzumab.
DB00016 DB00073 Rituximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rituximab.
DB00016 DB00081 Tositumomab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tositumomab.
DB00016 DB00087 Alemtuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alemtuzumab.
DB00016 DB00104 Octreotide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Octreotide.
DB00016 DB00105 Interferon alfa-2b The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Interferon alfa-2b.
DB00016 DB00112 Bevacizumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bevacizumab.
DB00016 DB00179 Masoprocol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Masoprocol.
DB00016 DB00188 Bortezomib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bortezomib.
DB00016 DB00236 Pipobroman The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pipobroman.
DB00016 DB00242 Cladribine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cladribine.
DB00016 DB00248 Cabergoline The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cabergoline.
DB00016 DB00261 Anagrelide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Anagrelide.
DB00016 DB00262 Carmustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carmustine.
DB00016 DB00269 Chlorotrianisene The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Chlorotrianisene.
DB00016 DB00276 Amsacrine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Amsacrine.
DB00016 DB00282 Pamidronic acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pamidronic acid.
DB00016 DB00290 Bleomycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bleomycin.
DB00016 DB00291 Chlorambucil The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Chlorambucil.
DB00016 DB00293 Raltitrexed The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Raltitrexed.
DB00016 DB00305 Mitomycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mitomycin.
DB00016 DB00307 Bexarotene The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bexarotene.
DB00016 DB00313 Valproic acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Valproic acid.
DB00016 DB00317 Gefitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gefitinib.
DB00016 DB00322 Floxuridine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Floxuridine.
DB00016 DB00351 Megestrol acetate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Megestrol acetate.
DB00016 DB00352 Tioguanine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tioguanine.
DB00016 DB00357 Aminoglutethimide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aminoglutethimide.
DB00016 DB00385 Valrubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Valrubicin.
DB00016 DB00398 Sorafenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sorafenib.
DB00016 DB00428 Streptozocin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Streptozocin.
DB00016 DB00432 Trifluridine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trifluridine.
DB00016 DB00441 Gemcitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gemcitabine.
DB00016 DB00444 Teniposide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Teniposide.
DB00016 DB00445 Epirubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Epirubicin.
DB00016 DB00488 Altretamine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Altretamine.
DB00016 DB00499 Flutamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Flutamide.
DB00016 DB00515 Cisplatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cisplatin.
DB00016 DB00523 Alitretinoin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alitretinoin.
DB00016 DB00526 Oxaliplatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oxaliplatin.
DB00016 DB00530 Erlotinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Erlotinib.
DB00016 DB00539 Toremifene The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Toremifene.
DB00016 DB00544 Fluorouracil The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fluorouracil.
DB00016 DB00552 Pentostatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pentostatin.
DB00016 DB00563 Methotrexate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Methotrexate.
DB00016 DB00603 Medroxyprogesterone acetate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Medroxyprogesterone acetate.
DB00016 DB00619 Imatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Imatinib.
DB00016 DB00631 Clofarabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Clofarabine.
DB00016 DB00635 Prednisone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Prednisone.
DB00016 DB00642 Pemetrexed The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pemetrexed.
DB00016 DB00648 Mitotane The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mitotane.
DB00016 DB00665 Nilutamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nilutamide.
DB00016 DB00675 Tamoxifen The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tamoxifen.
DB00016 DB00694 Daunorubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Daunorubicin.
DB00016 DB00707 Porfimer sodium The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Porfimer sodium.
DB00016 DB00755 Tretinoin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tretinoin.
DB00016 DB00762 Irinotecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Irinotecan.
DB00016 DB00773 Etoposide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etoposide.
DB00016 DB00791 Uracil mustard The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Uracil mustard.
DB00016 DB00851 Dacarbazine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dacarbazine.
DB00016 DB00853 Temozolomide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Temozolomide.
DB00016 DB00855 Aminolevulinic acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aminolevulinic acid.
DB00016 DB00860 Prednisolone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Prednisolone.
DB00016 DB00888 Mechlorethamine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mechlorethamine.
DB00016 DB00894 Testolactone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Testolactone.
DB00016 DB00928 Azacitidine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Azacitidine.
DB00016 DB00947 Fulvestrant The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fulvestrant.
DB00016 DB00958 Carboplatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carboplatin.
DB00016 DB00959 Methylprednisolone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Methylprednisolone.
DB00016 DB00970 Dactinomycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dactinomycin.
DB00016 DB00987 Cytarabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cytarabine.
DB00016 DB00990 Exemestane The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Exemestane.
DB00016 DB00997 Doxorubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Doxorubicin.
DB00016 DB01005 Hydroxyurea The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Hydroxyurea.
DB00016 DB01006 Letrozole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Letrozole.
DB00016 DB01008 Busulfan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Busulfan.
DB00016 DB01030 Topotecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Topotecan.
DB00016 DB01033 Mercaptopurine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mercaptopurine.
DB00016 DB01042 Melphalan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Melphalan.
DB00016 DB01073 Fludarabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fludarabine.
DB00016 DB01101 Capecitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Capecitabine.
DB00016 DB01108 Trilostane The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trilostane.
DB00016 DB01128 Bicalutamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bicalutamide.
DB00016 DB01157 Trimetrexate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trimetrexate.
DB00016 DB01168 Procarbazine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Procarbazine.
DB00016 DB01169 Arsenic trioxide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Arsenic trioxide.
DB00016 DB01177 Idarubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Idarubicin.
DB00016 DB01181 Ifosfamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ifosfamide.
DB00016 DB01196 Estramustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Estramustine.
DB00016 DB01204 Mitoxantrone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mitoxantrone.
DB00016 DB01206 Lomustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lomustine.
DB00016 DB01217 Anastrozole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Anastrozole.
DB00016 DB01229 Paclitaxel The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Paclitaxel.
DB00016 DB01234 Dexamethasone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dexamethasone.
DB00016 DB01248 Docetaxel The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Docetaxel.
DB00016 DB01254 Dasatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dasatinib.
DB00016 DB01259 Lapatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lapatinib.
DB00016 DB01262 Decitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Decitabine.
DB00016 DB01268 Sunitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sunitinib.
DB00016 DB01269 Panitumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Panitumumab.
DB00016 DB01280 Nelarabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nelarabine.
DB00016 DB01590 Everolimus The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Everolimus.
DB00016 DB01645 Genistein The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Genistein.
DB00016 DB01667 8-azaguanine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 8-azaguanine.
DB00016 DB01873 Epothilone D The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Epothilone D.
DB00016 DB01933 7-Hydroxystaurosporine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 7-Hydroxystaurosporine.
DB00016 DB02109 Hadacidin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Hadacidin.
DB00016 DB02342 2-Methoxyestradiol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 2-Methoxyestradiol.
DB00016 DB02424 Geldanamycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Geldanamycin.
DB00016 DB02546 Vorinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vorinostat.
DB00016 DB02640 Fumagillin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fumagillin.
DB00016 DB03010 Patupilone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Patupilone.
DB00016 DB03172 Tubercidin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tubercidin.
DB00016 DB03459 Sparfosic acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sparfosic acid.
DB00016 DB03496 Alvocidib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alvocidib.
DB00016 DB03509 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
DB00016 DB03523 Brequinar The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brequinar.
DB00016 DB03695 Piritrexim The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Piritrexim.
DB00016 DB03825 Rhodamine 6G The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rhodamine 6G.
DB00016 DB03880 Batimastat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Batimastat.
DB00016 DB03946 3,4-Dihydroxybenzoic Acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 3,4-Dihydroxybenzoic Acid.
DB00016 DB04106 Fotemustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fotemustine.
DB00016 DB04222 Sparsomycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sparsomycin.
DB00016 DB04253 Tretazicar The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tretazicar.
DB00016 DB04258 Seocalcitol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Seocalcitol.
DB00016 DB04331 Monastrol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Monastrol.
DB00016 DB04440 Nebularine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nebularine.
DB00016 DB04468 Afimoxifene The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Afimoxifene.
DB00016 DB04572 Thiotepa The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Thiotepa.
DB00016 DB04576 Fleroxacin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fleroxacin.
DB00016 DB04655 Metoprine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Metoprine.
DB00016 DB04690 Camptothecin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Camptothecin.
DB00016 DB04786 Suramin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Suramin.
DB00016 DB04827 Urethane The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Urethane.
DB00016 DB04839 Cyproterone acetate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cyproterone acetate.
DB00016 DB04845 Ixabepilone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ixabepilone.
DB00016 DB04849 Cediranib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cediranib.
DB00016 DB04858 Tirapazamine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tirapazamine.
DB00016 DB04865 Omacetaxine mepesuccinate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Omacetaxine mepesuccinate.
DB00016 DB04866 Halofuginone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Halofuginone.
DB00016 DB04868 Nilotinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nilotinib.
DB00016 DB04894 Vapreotide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vapreotide.
DB00016 DB04900 Thymalfasin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Thymalfasin.
DB00016 DB04901 Galiximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Galiximab.
DB00016 DB04907 Sitimagene ceradenovec The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sitimagene ceradenovec.
DB00016 DB04950 Ranpirnase The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ranpirnase.
DB00016 DB04951 Pirfenidone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pirfenidone.
DB00016 DB04958 Epratuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Epratuzumab.
DB00016 DB04960 Tipifarnib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tipifarnib.
DB00016 DB04961 Troxacitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Troxacitabine.
DB00016 DB04964 Oregovomab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oregovomab.
DB00016 DB04975 Banoxantrone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Banoxantrone.
DB00016 DB04977 Plitidepsin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Plitidepsin.
DB00016 DB04996 Satraplatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Satraplatin.
DB00016 DB05015 Belinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Belinostat.
DB00016 DB05022 Amonafide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Amonafide.
DB00016 DB05076 Fenretinide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fenretinide.
DB00016 DB05088 Tetrathiomolybdate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tetrathiomolybdate.
DB00016 DB05097 Labetuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Labetuzumab.
DB00016 DB05109 Trabectedin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trabectedin.
DB00016 DB05129 Elsamitrucin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Elsamitrucin.
DB00016 DB05136 Bavituximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bavituximab.
DB00016 DB05223 Pracinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pracinostat.
DB00016 DB05239 Cobimetinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cobimetinib.
DB00016 DB05260 Gallium nitrate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gallium nitrate.
DB00016 DB05265 Ecabet The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ecabet.
DB00016 DB05294 Vandetanib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vandetanib.
DB00016 DB05374 Rindopepimut The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rindopepimut.
DB00016 DB05424 Canertinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Canertinib.
DB00016 DB05428 Motexafin gadolinium The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Motexafin gadolinium.
DB00016 DB05482 7-ethyl-10-hydroxycamptothecin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 7-ethyl-10-hydroxycamptothecin.
DB00016 DB05524 Pelitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pelitinib.
DB00016 DB05540 Alanosine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alanosine.
DB00016 DB05578 Ramucirumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ramucirumab.
DB00016 DB05595 Farletuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Farletuzumab.
DB00016 DB05656 Veltuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Veltuzumab.
DB00016 DB05668 Palifosfamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Palifosfamide.
DB00016 DB05697 AP 12009 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with AP 12009.
DB00016 DB05773 Trastuzumab emtansine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trastuzumab emtansine.
DB00016 DB05779 Oglufanide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oglufanide.
DB00016 DB05786 Irofulven The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Irofulven.
DB00016 DB05812 Abiraterone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Abiraterone.
DB00016 DB05889 Inotuzumab ozogamicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Inotuzumab ozogamicin.
DB00016 DB05903 KOS-1584 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with KOS-1584.
DB00016 DB05916 CT-011 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with CT-011.
DB00016 DB05974 Transcrocetinate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Transcrocetinate.
DB00016 DB05996 Glembatumumab vedotin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Glembatumumab vedotin.
DB00016 DB06013 Aldoxorubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aldoxorubicin.
DB00016 DB06021 AV-412 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with AV-412.
DB00016 DB06040 Filanesib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Filanesib.
DB00016 DB06043 Olaratumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Olaratumab.
DB00016 DB06159 Rubitecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rubitecan.
DB00016 DB06160 Garenoxacin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Garenoxacin.
DB00016 DB06163 Plevitrexed The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Plevitrexed.
DB00016 DB06171 Paclitaxel trevatide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Paclitaxel trevatide.
DB00016 DB06176 Romidepsin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Romidepsin.
DB00016 DB06181 IMO-2055 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with IMO-2055.
DB00016 DB06186 Ipilimumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ipilimumab.
DB00016 DB06192 Nimotuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nimotuzumab.
DB00016 DB06193 Pixantrone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pixantrone.
DB00016 DB06195 Seliciclib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Seliciclib.
DB00016 DB06199 Atrasentan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Atrasentan.
DB00016 DB06233 Ridaforolimus The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ridaforolimus.
DB00016 DB06235 Vadimezan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vadimezan.
DB00016 DB06246 Exisulind The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Exisulind.
DB00016 DB06263 Amrubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Amrubicin.
DB00016 DB06266 Lonidamine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lonidamine.
DB00016 DB06272 Maxacalcitol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Maxacalcitol.
DB00016 DB06287 Temsirolimus The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Temsirolimus.
DB00016 DB06317 Elotuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Elotuzumab.
DB00016 DB06334 Tucidinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tucidinostat.
DB00016 DB06365 Sapacitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sapacitabine.
DB00016 DB06366 Pertuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pertuzumab.
DB00016 DB06370 Indisulam The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Indisulam.
DB00016 DB06420 Annamycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Annamycin.
DB00016 DB06423 Endostatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Endostatin.
DB00016 DB06433 Tezacitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tezacitabine.
DB00016 DB06436 Semaxanib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Semaxanib.
DB00016 DB06445 Diethylnorspermine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Diethylnorspermine.
DB00016 DB06461 Squalamine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Squalamine.
DB00016 DB06478 Porfiromycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Porfiromycin.
DB00016 DB06517 MLN576 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with MLN576.
DB00016 DB06589 Pazopanib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pazopanib.
DB00016 DB06595 Midostaurin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Midostaurin.
DB00016 DB06603 Panobinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Panobinostat.
DB00016 DB06607 Catumaxomab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Catumaxomab.
DB00016 DB06616 Bosutinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bosutinib.
DB00016 DB06626 Axitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Axitinib.
DB00016 DB06647 Volociximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Volociximab.
DB00016 DB06650 Ofatumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ofatumumab.
DB00016 DB06699 Degarelix The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Degarelix.
DB00016 DB06710 Methyltestosterone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Methyltestosterone.
DB00016 DB06719 Buserelin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Buserelin.
DB00016 DB06748 Ginsenoside C The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ginsenoside C.
DB00016 DB06769 Bendamustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bendamustine.
DB00016 DB06772 Cabazitaxel The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cabazitaxel.
DB00016 DB06789 Hydroxyprogesterone caproate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Hydroxyprogesterone caproate.
DB00016 DB06791 Lanreotide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lanreotide.
DB00016 DB06810 Plicamycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Plicamycin.
DB00016 DB06813 Pralatrexate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pralatrexate.
DB00016 DB06825 Triptorelin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Triptorelin.
DB00016 DB07232 Veliparib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Veliparib.
DB00016 DB07931 Hexestrol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Hexestrol.
DB00016 DB08313 Nocodazole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nocodazole.
DB00016 DB08437 Puromycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Puromycin.
DB00016 DB08486 Efaproxiral The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Efaproxiral.
DB00016 DB08633 TNP-470 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with TNP-470.
DB00016 DB08828 Vismodegib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vismodegib.
DB00016 DB08865 Crizotinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Crizotinib.
DB00016 DB08870 Brentuximab vedotin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brentuximab vedotin.
DB00016 DB08871 Eribulin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Eribulin.
DB00016 DB08875 Cabozantinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cabozantinib.
DB00016 DB08877 Ruxolitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ruxolitinib.
DB00016 DB08881 Vemurafenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vemurafenib.
DB00016 DB08886 Asparaginase Erwinia chrysanthemi The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Asparaginase Erwinia chrysanthemi.
DB00016 DB08889 Carfilzomib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carfilzomib.
DB00016 DB08896 Regorafenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Regorafenib.
DB00016 DB08899 Enzalutamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Enzalutamide.
DB00016 DB08901 Ponatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ponatinib.
DB00016 DB08905 Formestane The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Formestane.
DB00016 DB08911 Trametinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trametinib.
DB00016 DB08912 Dabrafenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dabrafenib.
DB00016 DB08913 Radium Ra 223 dichloride The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Radium Ra 223 dichloride.
DB00016 DB08916 Afatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Afatinib.
DB00016 DB08935 Obinutuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Obinutuzumab.
DB00016 DB08972 Flumequine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Flumequine.
DB00016 DB09010 Carmofur The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carmofur.
DB00016 DB09031 Miltefosine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Miltefosine.
DB00016 DB09035 Nivolumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nivolumab.
DB00016 DB09036 Siltuximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Siltuximab.
DB00016 DB09037 Pembrolizumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pembrolizumab.
DB00016 DB09052 Blinatumomab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Blinatumomab.
DB00016 DB09053 Ibrutinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ibrutinib.
DB00016 DB09054 Idelalisib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Idelalisib.
DB00016 DB09063 Ceritinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ceritinib.
DB00016 DB09073 Palbociclib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Palbociclib.
DB00016 DB09074 Olaparib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Olaparib.
DB00016 DB09077 Dinutuximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dinutuximab.
DB00016 DB09078 Lenvatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lenvatinib.
DB00016 DB09079 Nintedanib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nintedanib.
DB00016 DB09123 Dienogest The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dienogest.
DB00016 DB09143 Sonidegib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sonidegib.
DB00016 DB09239 Niguldipine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Niguldipine.
DB00016 DB09256 Tegafur The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tegafur.
DB00016 DB09274 Artesunate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Artesunate.
DB00016 DB09298 Silibinin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Silibinin.
DB00016 DB09330 Osimertinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Osimertinib.
DB00016 DB09331 Daratumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Daratumumab.
DB00016 DB09559 Necitumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Necitumumab.
DB00016 DB09570 Ixazomib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ixazomib.
DB00016 DB11363 Alectinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alectinib.
DB00016 DB11366 Roquinimex The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Roquinimex.
DB00016 DB11526 Masitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Masitinib.
DB00016 DB11581 Venetoclax The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Venetoclax.
DB00016 DB11595 Atezolizumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Atezolizumab.
DB00016 DB11616 Pirarubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pirarubicin.
DB00016 DB11617 Aclarubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aclarubicin.
DB00016 DB11618 Zorubicin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Zorubicin.
DB00016 DB11630 Temoporfin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Temoporfin.
DB00016 DB11646 Conatumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Conatumumab.
DB00016 DB11651 Dactolisib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dactolisib.
DB00016 DB11662 Rabusertib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rabusertib.
DB00016 DB11669 Ortataxel The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ortataxel.
DB00016 DB11678 Treosulfan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Treosulfan.
DB00016 DB11688 2-chloroethyl-3-sarcosinamide-1-nitrosourea The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.
DB00016 DB11694 Ilorasertib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ilorasertib.
DB00016 DB11714 Durvalumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Durvalumab.
DB00016 DB11716 Misonidazole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Misonidazole.
DB00016 DB11717 Epacadostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Epacadostat.
DB00016 DB11718 Encorafenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Encorafenib.
DB00016 DB11727 Endostar The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Endostar.
DB00016 DB11730 Ribociclib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ribociclib.
DB00016 DB11737 Icotinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Icotinib.
DB00016 DB11752 Bryostatin 1 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bryostatin 1.
DB00016 DB11760 Talazoparib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Talazoparib.
DB00016 DB11771 Tremelimumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tremelimumab.
DB00016 DB11793 Niraparib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Niraparib.
DB00016 DB11795 GSK-2636771 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with GSK-2636771.
DB00016 DB11800 Tivozanib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tivozanib.
DB00016 DB11805 Saracatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Saracatinib.
DB00016 DB11812 Talaporfin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Talaporfin.
DB00016 DB11828 Neratinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Neratinib.
DB00016 DB11830 Mocetinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mocetinostat.
DB00016 DB11832 Crenolanib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Crenolanib.
DB00016 DB11841 Entinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Entinostat.
DB00016 DB11880 Acridine Carboxamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Acridine Carboxamide.
DB00016 DB11886 Infigratinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Infigratinib.
DB00016 DB11891 CUDC-907 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with CUDC-907.
DB00016 DB11894 Efatutazone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Efatutazone.
DB00016 DB11901 Apalutamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Apalutamide.
DB00016 DB11907 Rociletinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rociletinib.
DB00016 DB11918 Guadecitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Guadecitabine.
DB00016 DB11919 6-O-benzylguanine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 6-O-benzylguanine.
DB00016 DB11945 Avelumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Avelumab.
DB00016 DB11960 Carboxyamidotriazole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carboxyamidotriazole.
DB00016 DB11963 Dacomitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dacomitinib.
DB00016 DB11967 Binimetinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Binimetinib.
DB00016 DB11972 Rilotumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rilotumumab.
DB00016 DB11973 Tesevatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tesevatinib.
DB00016 DB11978 Glasdegib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Glasdegib.
DB00016 DB11986 Entrectinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Entrectinib.
DB00016 DB11999 Vosaroxin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vosaroxin.
DB00016 DB12001 Abemaciclib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Abemaciclib.
DB00016 DB12015 Alpelisib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Alpelisib.
DB00016 DB12025 Triptolide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Triptolide.
DB00016 DB12028 Broxuridine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Broxuridine.
DB00016 DB12036 Naquotinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Naquotinib.
DB00016 DB12056 Trebananib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trebananib.
DB00016 DB12081 Anecortave The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Anecortave.
DB00016 DB12082 Vesnarinone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vesnarinone.
DB00016 DB12083 Mafosfamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mafosfamide.
DB00016 DB12085 LCL-161 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with LCL-161.
DB00016 DB12089 Lorvotuzumab mertansine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lorvotuzumab mertansine.
DB00016 DB12108 Taselisib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Taselisib.
DB00016 DB12124 Namitecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Namitecan.
DB00016 DB12130 Lorlatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lorlatinib.
DB00016 DB12141 Gilteritinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gilteritinib.
DB00016 DB12142 Duligotuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Duligotuzumab.
DB00016 DB12146 Rigosertib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rigosertib.
DB00016 DB12147 Erdafitinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Erdafitinib.
DB00016 DB12156 Cordycepin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cordycepin.
DB00016 DB12174 CUDC-101 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with CUDC-101.
DB00016 DB12182 Binetrakin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Binetrakin.
DB00016 DB12185 Exatecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Exatecan.
DB00016 DB12202 Zalutumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Zalutumumab.
DB00016 DB12222 Lurtotecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lurtotecan.
DB00016 DB12232 KRN-7000 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with KRN-7000.
DB00016 DB12257 Platinum The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Platinum.
DB00016 DB12259 CG-200745 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with CG-200745.
DB00016 DB12266 Epofolate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Epofolate.
DB00016 DB12267 Brigatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brigatinib.
DB00016 DB12279 OBP-801 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with OBP-801.
DB00016 DB12332 Rucaparib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rucaparib.
DB00016 DB12340 Navitoclax The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Navitoclax.
DB00016 DB12352 Bizelesin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bizelesin.
DB00016 DB12376 Ricolinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ricolinostat.
DB00016 DB12379 Indirubin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Indirubin.
DB00016 DB12381 Merestinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Merestinib.
DB00016 DB12382 R-306465 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with R-306465.
DB00016 DB12385 10-hydroxycamptothecin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 10-hydroxycamptothecin.
DB00016 DB12391 Sagopilone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sagopilone.
DB00016 DB12422 Sulforaphane The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sulforaphane.
DB00016 DB12459 Belotecan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Belotecan.
DB00016 DB12473 Taurolidine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Taurolidine.
DB00016 DB12480 Betulinic Acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Betulinic Acid.
DB00016 DB12483 Copanlisib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Copanlisib.
DB00016 DB12498 Mogamulizumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mogamulizumab.
DB00016 DB12515 9-aminocamptothecin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with 9-aminocamptothecin.
DB00016 DB12525 Molgramostim The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Molgramostim.
DB00016 DB12539 Oltipraz The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oltipraz.
DB00016 DB12549 Pyrazoloacridine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pyrazoloacridine.
DB00016 DB12565 Abexinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Abexinostat.
DB00016 DB12577 Fosbretabulin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fosbretabulin.
DB00016 DB12589 Dacetuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dacetuzumab.
DB00016 DB12593 Apaziquone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Apaziquone.
DB00016 DB12596 Combretastatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Combretastatin.
DB00016 DB12617 Mizoribine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mizoribine.
DB00016 DB12637 Onapristone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Onapristone.
DB00016 DB12638 PU-H71 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with PU-H71.
DB00016 DB12645 Givinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Givinostat.
DB00016 DB12671 Beloranib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Beloranib.
DB00016 DB12677 Soblidotin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Soblidotin.
DB00016 DB12681 Salirasib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Salirasib.
DB00016 DB12688 Moxetumomab Pasudotox The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Moxetumomab Pasudotox.
DB00016 DB12692 Gusperimus The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Gusperimus.
DB00016 DB12695 Phenethyl Isothiocyanate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Phenethyl Isothiocyanate.
DB00016 DB12697 Methylselenocysteine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Methylselenocysteine.
DB00016 DB12701 Intetumumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Intetumumab.
DB00016 DB12730 Dolastatin 10 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dolastatin 10.
DB00016 DB12736 Etanidazole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etanidazole.
DB00016 DB12769 Lometrexol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lometrexol.
DB00016 DB12797 Ecromeximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ecromeximab.
DB00016 DB12832 Prednimustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Prednimustine.
DB00016 DB12870 Buthionine Sulfoximine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Buthionine Sulfoximine.
DB00016 DB12873 Dianhydrogalactitol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dianhydrogalactitol.
DB00016 DB12881 Indole-3-carbinol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Indole-3-carbinol.
DB00016 DB12901 Fiacitabine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fiacitabine.
DB00016 DB12902 Trofosfamide The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Trofosfamide.
DB00016 DB12912 Nolatrexed The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nolatrexed.
DB00016 DB12916 Mitolactol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mitolactol.
DB00016 DB12920 Pinometostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pinometostat.
DB00016 DB12947 Doxifluridine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Doxifluridine.
DB00016 DB12948 Didox The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Didox.
DB00016 DB12967 Mitoguazone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mitoguazone.
DB00016 DB12978 Pexidartinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pexidartinib.
DB00016 DB12987 Penclomedine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Penclomedine.
DB00016 DB12991 Deoxyspergualin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Deoxyspergualin.
DB00016 DB12996 Acteoside The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Acteoside.
DB00016 DB13005 Rebastinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rebastinib.
DB00016 DB13014 Hypericin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Hypericin.
DB00016 DB13046 Tocladesine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tocladesine.
DB00016 DB13066 Liarozole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Liarozole.
DB00016 DB13069 Nimustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nimustine.
DB00016 DB13104 X-396 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with X-396.
DB00016 DB13128 Sizofiran The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sizofiran.
DB00016 DB13145 Nedaplatin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nedaplatin.
DB00016 DB13164 Olmutinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Olmutinib.
DB00016 DB13182 Daidzein The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Daidzein.
DB00016 DB13243 Tiazofurine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tiazofurine.
DB00016 DB13304 Triaziquone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Triaziquone.
DB00016 DB13318 Demecolcine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Demecolcine.
DB00016 DB13334 Mannosulfan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mannosulfan.
DB00016 DB13339 Etoglucid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etoglucid.
DB00016 DB13375 Edrecolomab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Edrecolomab.
DB00016 DB13480 Lentinan The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lentinan.
DB00016 DB13543 Mitobronitol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mitobronitol.
DB00016 DB13627 Oxolinic acid The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oxolinic acid.
DB00016 DB13647 Semustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Semustine.
DB00016 DB13677 Carboquone The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Carboquone.
DB00016 DB13767 Vorozole The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Vorozole.
DB00016 DB13809 Paclitaxel poliglumex The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Paclitaxel poliglumex.
DB00016 DB13811 Oblimersen The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oblimersen.
DB00016 DB13832 Ranimustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ranimustine.
DB00016 DB13874 Enasidenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Enasidenib.
DB00016 DB13877 Iniparib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Iniparib.
DB00016 DB13896 Talimogene laherparepvec The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Talimogene laherparepvec.
DB00016 DB13912 Coumermycin A1 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Coumermycin A1.
DB00016 DB13916 Toyocamycin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Toyocamycin.
DB00016 DB14031 Tretamine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tretamine.
DB00016 DB14066 Tetrandrine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tetrandrine.
DB00016 DB14067 Dofequidar The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dofequidar.
DB00016 DB14068 Dexniguldipine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dexniguldipine.
DB00016 DB14568 Ivosidenib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ivosidenib.
DB00016 DB14644 Methylprednisolone hemisuccinate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Methylprednisolone hemisuccinate.
DB00016 DB14646 Prednisone acetate The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Prednisone acetate.
DB00016 DB14680 Combretastatin A4 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Combretastatin A4.
DB00016 DB14707 Cemiplimab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cemiplimab.
DB00016 DB14723 Larotrectinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Larotrectinib.
DB00016 DB14731 Tagraxofusp The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tagraxofusp.
DB00016 DB14765 Rivoceranib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Rivoceranib.
DB00016 DB14792 AZD-5991 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with AZD-5991.
DB00016 DB14844 ONC-201 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with ONC-201.
DB00016 DB14860 Ensartinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ensartinib.
DB00016 DB14865 Human interleukin-2 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Human interleukin-2.
DB00016 DB14877 Lintuzumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lintuzumab.
DB00016 DB14947 Bermekimab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bermekimab.
DB00016 DB14951 Etirinotecan pegol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etirinotecan pegol.
DB00016 DB15035 Zanubrutinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Zanubrutinib.
DB00016 DB15057 NUC-1031 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with NUC-1031.
DB00016 DB15157 Voruciclib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Voruciclib.
DB00016 DB15215 KRN-5500 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with KRN-5500.
DB00016 DB15289 Perillyl alcohol The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Perillyl alcohol.
DB00016 DB15321 Tefinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tefinostat.
DB00016 DB15334 Biochanin A The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Biochanin A.
DB00016 DB15351 Dihematoporphyrin ether The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dihematoporphyrin ether.
DB00016 DB15366 SOR-C13 The risk or severity of Thrombosis can be increased when Erythropoietin is combined with SOR-C13.
DB00016 DB15383 Pidilizumab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pidilizumab.
DB00016 DB15419 Nanatinostat The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nanatinostat.
DB00016 DB15466 Tallimustine The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tallimustine.
DB00016 DB12062 Volasertib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Volasertib.
DB00016 DB14811 Isatuximab The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Isatuximab.
DB00016 DB15102 Pemigatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pemigatinib.
DB00016 DB11791 Capmatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Capmatinib.
DB00016 DB15685 Selpercatinib The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Selpercatinib.
DB00016 DB00531 Cyclophosphamide The risk or severity of pulmonary toxicity can be increased when Erythropoietin is combined with Cyclophosphamide.
DB00016 DB00984 Nandrolone phenpropionate The therapeutic efficacy of Erythropoietin can be increased when used in combination with Nandrolone phenpropionate.
DB00016 DB08804 Nandrolone decanoate The therapeutic efficacy of Erythropoietin can be increased when used in combination with Nandrolone decanoate.
DB00016 DB13169 Nandrolone The therapeutic efficacy of Erythropoietin can be increased when used in combination with Nandrolone.
DB00016 DB00178 Ramipril The serum concentration of Erythropoietin can be decreased when it is combined with Ramipril.
DB00016 DB00492 Fosinopril The serum concentration of Erythropoietin can be decreased when it is combined with Fosinopril.
DB00016 DB00519 Trandolapril The serum concentration of Erythropoietin can be decreased when it is combined with Trandolapril.
DB00016 DB00542 Benazepril The serum concentration of Erythropoietin can be decreased when it is combined with Benazepril.
DB00016 DB00584 Enalapril The serum concentration of Erythropoietin can be decreased when it is combined with Enalapril.
DB00016 DB00691 Moexipril The serum concentration of Erythropoietin can be decreased when it is combined with Moexipril.
DB00016 DB00722 Lisinopril The serum concentration of Erythropoietin can be decreased when it is combined with Lisinopril.
DB00016 DB00790 Perindopril The serum concentration of Erythropoietin can be decreased when it is combined with Perindopril.
DB00016 DB00881 Quinapril The serum concentration of Erythropoietin can be decreased when it is combined with Quinapril.
DB00016 DB00886 Omapatrilat The serum concentration of Erythropoietin can be decreased when it is combined with Omapatrilat.
DB00016 DB01180 Rescinnamine The serum concentration of Erythropoietin can be decreased when it is combined with Rescinnamine.
DB00016 DB01197 Captopril The serum concentration of Erythropoietin can be decreased when it is combined with Captopril.
DB00016 DB01340 Cilazapril The serum concentration of Erythropoietin can be decreased when it is combined with Cilazapril.
DB00016 DB01348 Spirapril The serum concentration of Erythropoietin can be decreased when it is combined with Spirapril.
DB00016 DB08836 Temocapril The serum concentration of Erythropoietin can be decreased when it is combined with Temocapril.
DB00016 DB09477 Enalaprilat The serum concentration of Erythropoietin can be decreased when it is combined with Enalaprilat.
DB00016 DB11783 Imidapril The serum concentration of Erythropoietin can be decreased when it is combined with Imidapril.
DB00016 DB13166 Zofenopril The serum concentration of Erythropoietin can be decreased when it is combined with Zofenopril.
DB00016 DB13312 Delapril The serum concentration of Erythropoietin can be decreased when it is combined with Delapril.
DB00016 DB14125 Benazeprilat The serum concentration of Erythropoietin can be decreased when it is combined with Benazeprilat.
DB00016 DB14207 Fosinoprilat The serum concentration of Erythropoietin can be decreased when it is combined with Fosinoprilat.
DB00016 DB14208 Ramiprilat The serum concentration of Erythropoietin can be decreased when it is combined with Ramiprilat.
DB00016 DB14209 Trandolaprilat The serum concentration of Erythropoietin can be decreased when it is combined with Trandolaprilat.
DB00016 DB14210 Moexiprilat The serum concentration of Erythropoietin can be decreased when it is combined with Moexiprilat.
DB00016 DB14213 Perindoprilat The serum concentration of Erythropoietin can be decreased when it is combined with Perindoprilat.
DB00016 DB14217 Quinaprilat The serum concentration of Erythropoietin can be decreased when it is combined with Quinaprilat.
DB00016 DB14231 Quinoline Yellow WS The serum concentration of Erythropoietin can be decreased when it is combined with Quinoline Yellow WS.
DB00016 DB15565 Cilazaprilat The serum concentration of Erythropoietin can be decreased when it is combined with Cilazaprilat.
DB00016 DB00309 Vindesine The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vindesine.
DB00016 DB00361 Vinorelbine The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vinorelbine.
DB00016 DB00541 Vincristine The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vincristine.
DB00016 DB00570 Vinblastine The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vinblastine.
DB00016 DB05168 Vintafolide The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vintafolide.
DB00016 DB11641 Vinflunine The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vinflunine.
DB00016 DB13374 Vincamine The risk or severity of peripheral neuropathy can be increased when Erythropoietin is combined with Vincamine.
DB00017 DB00215 Citalopram The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Citalopram.
DB00017 DB00472 Fluoxetine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fluoxetine.
DB00017 DB00656 Trazodone The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Trazodone.
DB00017 DB01104 Sertraline The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Sertraline.
DB00017 DB01175 Escitalopram The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Escitalopram.
DB00017 DB04832 Zimelidine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Zimelidine.
DB00017 DB04884 Dapoxetine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Dapoxetine.
DB00017 DB06731 Seproxetine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Seproxetine.
DB00017 DB08953 Indalpine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Indalpine.
DB00017 DB12693 Ritanserin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ritanserin.
DB00017 DB13233 Alaproclate The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Alaproclate.
DB00017 DB00715 Paroxetine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Paroxetine.
DB00017 DB00399 Zoledronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Zoledronic acid.
DB00017 DB00630 Alendronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Alendronic acid.
DB00017 DB00710 Ibandronate The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Ibandronate.
DB00017 DB00720 Clodronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Clodronic acid.
DB00017 DB00884 Risedronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Risedronic acid.
DB00017 DB01077 Etidronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Etidronic acid.
DB00017 DB06255 Incadronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Incadronic acid.
DB00017 DB00282 Pamidronic acid The risk or severity of hypocalcemia can be increased when Pamidronic acid is combined with Salmon calcitonin.
DB00017 DB01133 Tiludronic acid The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Tiludronic acid.
DB00017 DB01356 Lithium cation Salmon calcitonin may increase the excretion rate of Lithium cation which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB14507 Lithium citrate Salmon calcitonin may increase the excretion rate of Lithium citrate which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB14509 Lithium carbonate Salmon calcitonin may increase the excretion rate of Lithium carbonate which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB14506 Lithium hydroxide Salmon calcitonin may increase the excretion rate of Lithium hydroxide which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00091 Cyclosporine Cyclosporine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00159 Icosapent Icosapent may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00229 Cefotiam Cefotiam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00244 Mesalazine Mesalazine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00267 Cefmenoxime Cefmenoxime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00274 Cefmetazole Cefmetazole may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00300 Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00328 Indomethacin Indomethacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00369 Cidofovir Cidofovir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00384 Triamterene Triamterene may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00430 Cefpiramide Cefpiramide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00438 Ceftazidime Ceftazidime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00447 Loracarbef Loracarbef may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00456 Cefalotin Cefalotin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00461 Nabumetone Nabumetone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00465 Ketorolac Ketorolac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00469 Tenoxicam Tenoxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00482 Celecoxib Celecoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00493 Cefotaxime Cefotaxime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00500 Tolmetin Tolmetin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00529 Foscarnet Foscarnet may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00533 Rofecoxib Rofecoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00554 Piroxicam Piroxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00563 Methotrexate Methotrexate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00567 Cephalexin Cephalexin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00573 Fenoprofen Fenoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00577 Valaciclovir Valaciclovir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00580 Valdecoxib Valdecoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00586 Diclofenac Diclofenac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00605 Sulindac Sulindac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00626 Bacitracin Bacitracin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00681 Amphotericin B Amphotericin B may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00689 Cephaloglycin Cephaloglycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00712 Flurbiprofen Flurbiprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00718 Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00738 Pentamidine Pentamidine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00742 Mannitol Mannitol may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00749 Etodolac Etodolac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00784 Mefenamic acid Mefenamic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00787 Acyclovir Acyclovir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00788 Naproxen Naproxen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00795 Sulfasalazine Sulfasalazine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00812 Phenylbutazone Phenylbutazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00814 Meloxicam Meloxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00821 Carprofen Carprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00833 Cefaclor Cefaclor may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00861 Diflunisal Diflunisal may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00864 Tacrolimus Tacrolimus may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00903 Etacrynic acid Etacrynic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00923 Ceforanide Ceforanide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00936 Salicylic acid Salicylic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00939 Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00945 Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00958 Carboplatin Carboplatin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00991 Oxaprozin Oxaprozin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00999 Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01009 Ketoprofen Ketoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01014 Balsalazide Balsalazide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01050 Ibuprofen Ibuprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01066 Cefditoren Cefditoren may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01072 Atazanavir Atazanavir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01111 Colistimethate Colistimethate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01112 Cefuroxime Cefuroxime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01139 Cefapirin Cefapirin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01140 Cefadroxil Cefadroxil may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01150 Cefprozil Cefprozil may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01212 Ceftriaxone Ceftriaxone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01250 Olsalazine Olsalazine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01283 Lumiracoxib Lumiracoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01326 Cefamandole Cefamandole may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01327 Cefazolin Cefazolin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01328 Cefonicid Cefonicid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01329 Cefoperazone Cefoperazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01330 Cefotetan Cefotetan may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01331 Cefoxitin Cefoxitin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01332 Ceftizoxime Ceftizoxime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01333 Cefradine Cefradine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01397 Magnesium salicylate Magnesium salicylate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01399 Salsalate Salsalate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01401 Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01413 Cefepime Cefepime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01414 Cefacetrile Cefacetrile may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01415 Ceftibuten Ceftibuten may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01416 Cefpodoxime Cefpodoxime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01419 Antrafenine Antrafenine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01424 Aminophenazone Aminophenazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01435 Antipyrine Antipyrine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01600 Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01601 Lopinavir Lopinavir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01628 Etoricoxib Etoricoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB02247 Hydrolyzed Cephalothin Hydrolyzed Cephalothin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB03450 Cephalothin Group Cephalothin Group may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB03585 Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04552 Niflumic acid Niflumic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04570 Latamoxef Latamoxef may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04743 Nimesulide Nimesulide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04812 Benoxaprofen Benoxaprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04817 Metamizole Metamizole may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04828 Zomepirac Zomepirac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04918 Ceftobiprole Ceftobiprole may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB05095 Cimicoxib Cimicoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB06590 Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB06725 Lornoxicam Lornoxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB06736 Aceclofenac Aceclofenac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB06737 Zaltoprofen Zaltoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB07402 Azapropazone Azapropazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB07477 Felbinac Felbinac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08439 Parecoxib Parecoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08797 Salicylamide Salicylamide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08940 Kebuzone Kebuzone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08942 Isoxicam Isoxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08951 Indoprofen Indoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08955 Ibuproxam Ibuproxam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08976 Floctafenine Floctafenine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08981 Fenbufen Fenbufen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08984 Etofenamate Etofenamate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08991 Epirizole Epirizole may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09008 Cefaloridine Cefaloridine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09062 Cefminox Cefminox may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09084 Benzydamine Benzydamine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09212 Loxoprofen Loxoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09213 Dexibuprofen Dexibuprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09214 Dexketoprofen Dexketoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09215 Droxicam Droxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09216 Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09217 Firocoxib Firocoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09218 Clonixin Clonixin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09285 Morniflumate Morniflumate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09288 Propacetamol Propacetamol may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09295 Talniflumate Talniflumate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB09299 Tenofovir alafenamide Tenofovir alafenamide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11367 Cefroxadine Cefroxadine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11455 Robenacoxib Robenacoxib may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11466 Tepoxalin Tepoxalin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11518 Flunixin Flunixin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11935 Flomoxef Flomoxef may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB12151 Brincidofovir Brincidofovir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB12445 Nitroaspirin Nitroaspirin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB12545 Indobufen Indobufen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13001 Tinoridine Tinoridine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13167 Alclofenac Alclofenac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13217 Fentiazac Fentiazac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13232 Suxibuzone Suxibuzone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13266 Cefatrizine Cefatrizine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13286 Bumadizone Bumadizone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13314 Alminoprofen Alminoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13317 Flunoxaprofen Flunoxaprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13364 Feprazone Feprazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13371 Difenpiramide Difenpiramide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13407 Nifenazone Nifenazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13432 Lonazolac Lonazolac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13461 Cefcapene Cefcapene may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13470 Cefodizime Cefodizime may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13481 Tenidap Tenidap may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13499 Cefsulodin Cefsulodin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13501 Bendazac Bendazac may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13504 Cefetamet Cefetamet may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13514 Pranoprofen Pranoprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13524 Propyphenazone Propyphenazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13527 Proglumetacin Proglumetacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13538 Guacetisal Guacetisal may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13544 Ethenzamide Ethenzamide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13612 Carbaspirin calcium Carbaspirin calcium may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13629 Mofebutazone Mofebutazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13638 Cefbuperazone Cefbuperazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13649 Proquazone Proquazone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13657 Benorilate Benorilate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13667 Cefozopran Cefozopran may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13682 Cefpirome Cefpirome may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13722 Pirprofen Pirprofen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13778 Cefazedone Cefazedone may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13783 Acemetacin Acemetacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13821 Ceftezole Ceftezole may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13860 Imidazole salicylate Imidazole salicylate may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13868 Adefovir Adefovir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB14059 SC-236 SC-236 may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB14060 NS-398 NS-398 may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB14126 Tenofovir Tenofovir may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB14713 Inotersen Inotersen may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01438 Phenazopyridine Phenazopyridine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB15066 Givosiran Givosiran may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00007 Leuprolide Leuprolide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00014 Goserelin Goserelin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00035 Desmopressin Salmon calcitonin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00017 DB00080 Daptomycin Salmon calcitonin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
DB00017 DB00081 Tositumomab Salmon calcitonin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
DB00017 DB00115 Cyanocobalamin Salmon calcitonin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
DB00017 DB00158 Folic acid Salmon calcitonin may decrease the excretion rate of Folic acid which could result in a higher serum level.
DB00017 DB00165 Pyridoxine Salmon calcitonin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
DB00017 DB00176 Fluvoxamine Salmon calcitonin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
DB00017 DB00181 Baclofen Salmon calcitonin may decrease the excretion rate of Baclofen which could result in a higher serum level.
DB00017 DB00185 Cevimeline Salmon calcitonin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
DB00017 DB00186 Lorazepam Salmon calcitonin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00017 DB00190 Carbidopa Salmon calcitonin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00017 DB00193 Tramadol Salmon calcitonin may decrease the excretion rate of Tramadol which could result in a higher serum level.
DB00017 DB00196 Fluconazole Salmon calcitonin may decrease the excretion rate of Fluconazole which could result in a higher serum level.
DB00017 DB00198 Oseltamivir Salmon calcitonin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00017 DB00200 Hydroxocobalamin Salmon calcitonin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00017 DB00206 Reserpine Salmon calcitonin may decrease the excretion rate of Reserpine which could result in a higher serum level.
DB00017 DB00208 Ticlopidine Salmon calcitonin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
DB00017 DB00213 Pantoprazole Salmon calcitonin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00017 DB00225 Gadodiamide Salmon calcitonin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00017 DB00230 Pregabalin Salmon calcitonin may decrease the excretion rate of Pregabalin which could result in a higher serum level.
DB00017 DB00231 Temazepam Salmon calcitonin may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00017 DB00235 Milrinone Salmon calcitonin may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00017 DB00237 Butabarbital Salmon calcitonin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
DB00017 DB00243 Ranolazine Salmon calcitonin may decrease the excretion rate of Ranolazine which could result in a higher serum level.
DB00017 DB00245 Benzatropine Salmon calcitonin may decrease the excretion rate of Benzatropine which could result in a higher serum level.
DB00017 DB00254 Doxycycline Salmon calcitonin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00017 DB00262 Carmustine Salmon calcitonin may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00017 DB00264 Metoprolol Salmon calcitonin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
DB00017 DB00270 Isradipine Salmon calcitonin may decrease the excretion rate of Isradipine which could result in a higher serum level.
DB00017 DB00271 Diatrizoate Salmon calcitonin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00017 DB00273 Topiramate Salmon calcitonin may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00017 DB00279 Liothyronine Salmon calcitonin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00017 DB00280 Disopyramide Salmon calcitonin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
DB00017 DB00284 Acarbose Salmon calcitonin may decrease the excretion rate of Acarbose which could result in a higher serum level.
DB00017 DB00285 Venlafaxine Salmon calcitonin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
DB00017 DB00286 Conjugated estrogens Salmon calcitonin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00017 DB00289 Atomoxetine Salmon calcitonin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
DB00017 DB00290 Bleomycin Salmon calcitonin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00017 DB00292 Etomidate Salmon calcitonin may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00017 DB00294 Etonogestrel Salmon calcitonin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00017 DB00296 Ropivacaine Salmon calcitonin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00017 DB00303 Ertapenem Salmon calcitonin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00017 DB00308 Ibutilide Salmon calcitonin may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00017 DB00312 Pentobarbital Salmon calcitonin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
DB00017 DB00316 Acetaminophen Salmon calcitonin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
DB00017 DB00319 Piperacillin Salmon calcitonin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00017 DB00322 Floxuridine Salmon calcitonin may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00017 DB00323 Tolcapone Salmon calcitonin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00017 DB00325 Nitroprusside Salmon calcitonin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00017 DB00327 Hydromorphone Salmon calcitonin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
DB00017 DB00330 Ethambutol Salmon calcitonin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00017 DB00331 Metformin Salmon calcitonin may decrease the excretion rate of Metformin which could result in a higher serum level.
DB00017 DB00333 Methadone Salmon calcitonin may decrease the excretion rate of Methadone which could result in a higher serum level.
DB00017 DB00339 Pyrazinamide Salmon calcitonin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00017 DB00341 Cetirizine Salmon calcitonin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
DB00017 DB00349 Clobazam Salmon calcitonin may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00017 DB00351 Megestrol acetate Salmon calcitonin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00017 DB00355 Aztreonam Salmon calcitonin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00017 DB00356 Chlorzoxazone Salmon calcitonin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
DB00017 DB00359 Sulfadiazine Salmon calcitonin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
DB00017 DB00363 Clozapine Salmon calcitonin may decrease the excretion rate of Clozapine which could result in a higher serum level.
DB00017 DB00364 Sucralfate Salmon calcitonin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00017 DB00372 Thiethylperazine Salmon calcitonin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00017 DB00373 Timolol Salmon calcitonin may decrease the excretion rate of Timolol which could result in a higher serum level.
DB00017 DB00377 Palonosetron Salmon calcitonin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00017 DB00380 Dexrazoxane Salmon calcitonin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00017 DB00401 Nisoldipine Salmon calcitonin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00017 DB00402 Eszopiclone Salmon calcitonin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
DB00017 DB00404 Alprazolam Salmon calcitonin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
DB00017 DB00412 Rosiglitazone Salmon calcitonin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
DB00017 DB00413 Pramipexole Salmon calcitonin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00017 DB00415 Ampicillin Salmon calcitonin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00017 DB00418 Secobarbital Salmon calcitonin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
DB00017 DB00422 Methylphenidate Salmon calcitonin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00017 DB00432 Trifluridine Salmon calcitonin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00017 DB00435 Nitric Oxide Salmon calcitonin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00017 DB00437 Allopurinol Salmon calcitonin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00017 DB00440 Trimethoprim Salmon calcitonin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00017 DB00441 Gemcitabine Salmon calcitonin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00017 DB00476 Duloxetine Salmon calcitonin may decrease the excretion rate of Duloxetine which could result in a higher serum level.
DB00017 DB00477 Chlorpromazine Salmon calcitonin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.
DB00017 DB00480 Lenalidomide Salmon calcitonin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00017 DB00490 Buspirone Salmon calcitonin may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00017 DB00492 Fosinopril Salmon calcitonin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00017 DB00499 Flutamide Salmon calcitonin may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00017 DB00501 Cimetidine Salmon calcitonin may decrease the excretion rate of Cimetidine which could result in a higher serum level.
DB00017 DB00502 Haloperidol Salmon calcitonin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
DB00017 DB00535 Cefdinir Salmon calcitonin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00017 DB00537 Ciprofloxacin Salmon calcitonin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
DB00017 DB00548 Azelaic acid Salmon calcitonin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00017 DB00553 Methoxsalen Salmon calcitonin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00017 DB00555 Lamotrigine Salmon calcitonin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
DB00017 DB00558 Zanamivir Salmon calcitonin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00017 DB00569 Fondaparinux Salmon calcitonin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00017 DB00571 Propranolol Salmon calcitonin may decrease the excretion rate of Propranolol which could result in a higher serum level.
DB00017 DB00583 Levocarnitine Salmon calcitonin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00017 DB00591 Fluocinolone acetonide Salmon calcitonin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
DB00017 DB00597 Gadoteridol Salmon calcitonin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00017 DB00603 Medroxyprogesterone acetate Salmon calcitonin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00017 DB00608 Chloroquine Salmon calcitonin may decrease the excretion rate of Chloroquine which could result in a higher serum level.
DB00017 DB00612 Bisoprolol Salmon calcitonin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00017 DB00624 Testosterone Salmon calcitonin may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00017 DB00628 Clorazepic acid Salmon calcitonin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00017 DB00631 Clofarabine Salmon calcitonin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00017 DB00633 Dexmedetomidine Salmon calcitonin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00017 DB00635 Prednisone Salmon calcitonin may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00017 DB00651 Dyphylline Salmon calcitonin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00017 DB00657 Mecamylamine Salmon calcitonin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
DB00017 DB00660 Metaxalone Salmon calcitonin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00017 DB00661 Verapamil Salmon calcitonin may decrease the excretion rate of Verapamil which could result in a higher serum level.
DB00017 DB00665 Nilutamide Salmon calcitonin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00017 DB00669 Sumatriptan Salmon calcitonin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00017 DB00683 Midazolam Salmon calcitonin may decrease the excretion rate of Midazolam which could result in a higher serum level.
DB00017 DB00688 Mycophenolate mofetil Salmon calcitonin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00017 DB00690 Flurazepam Salmon calcitonin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00017 DB00692 Phentolamine Salmon calcitonin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00017 DB00698 Nitrofurantoin Salmon calcitonin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00017 DB00706 Tamsulosin Salmon calcitonin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00017 DB00709 Lamivudine Salmon calcitonin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00017 DB00713 Oxacillin Salmon calcitonin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00017 DB00716 Nedocromil Salmon calcitonin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00017 DB00722 Lisinopril Salmon calcitonin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00017 DB00730 Thiabendazole Salmon calcitonin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00017 DB00731 Nateglinide Salmon calcitonin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
DB00017 DB00733 Pralidoxime Salmon calcitonin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00017 DB00743 Gadobenic acid Salmon calcitonin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00017 DB00759 Tetracycline Salmon calcitonin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00017 DB00760 Meropenem Salmon calcitonin may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00017 DB00761 Potassium chloride Salmon calcitonin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00017 DB00763 Methimazole Salmon calcitonin may decrease the excretion rate of Methimazole which could result in a higher serum level.
DB00017 DB00775 Tirofiban Salmon calcitonin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00017 DB00780 Phenelzine Salmon calcitonin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
DB00017 DB00782 Propantheline Salmon calcitonin may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00017 DB00783 Estradiol Salmon calcitonin may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00017 DB00789 Gadopentetic acid Salmon calcitonin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00017 DB00790 Perindopril Salmon calcitonin may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB00017 DB00800 Fenoldopam Salmon calcitonin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00017 DB00804 Dicyclomine Salmon calcitonin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00017 DB00806 Pentoxifylline Salmon calcitonin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00017 DB00811 Ribavirin Salmon calcitonin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00017 DB00820 Tadalafil Salmon calcitonin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00017 DB00828 Fosfomycin Salmon calcitonin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00017 DB00842 Oxazepam Salmon calcitonin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00017 DB00851 Dacarbazine Salmon calcitonin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00017 DB00853 Temozolomide Salmon calcitonin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00017 DB00863 Ranitidine Salmon calcitonin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
DB00017 DB00894 Testolactone Salmon calcitonin may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00017 DB00897 Triazolam Salmon calcitonin may decrease the excretion rate of Triazolam which could result in a higher serum level.
DB00017 DB00900 Didanosine Salmon calcitonin may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00017 DB00911 Tinidazole Salmon calcitonin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00017 DB00915 Amantadine Salmon calcitonin may decrease the excretion rate of Amantadine which could result in a higher serum level.
DB00017 DB00918 Almotriptan Salmon calcitonin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00017 DB00928 Azacitidine Salmon calcitonin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00017 DB00934 Maprotiline Salmon calcitonin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
DB00017 DB00951 Isoniazid Salmon calcitonin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
DB00017 DB00953 Rizatriptan Salmon calcitonin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00017 DB00960 Pindolol Salmon calcitonin may decrease the excretion rate of Pindolol which could result in a higher serum level.
DB00017 DB00961 Mepivacaine Salmon calcitonin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00017 DB00962 Zaleplon Salmon calcitonin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00017 DB00968 Methyldopa Salmon calcitonin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
DB00017 DB00980 Ramelteon Salmon calcitonin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00017 DB00993 Azathioprine Salmon calcitonin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00017 DB00995 Auranofin Salmon calcitonin may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB00017 DB01001 Salbutamol Salmon calcitonin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB00017 DB01002 Levobupivacaine Salmon calcitonin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB00017 DB01004 Ganciclovir Salmon calcitonin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB00017 DB01010 Edrophonium Salmon calcitonin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB00017 DB01011 Metyrapone Salmon calcitonin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB00017 DB01015 Sulfamethoxazole Salmon calcitonin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.
DB00017 DB01018 Guanfacine Salmon calcitonin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
DB00017 DB01020 Isosorbide mononitrate Salmon calcitonin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB00017 DB01022 Phylloquinone Salmon calcitonin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB00017 DB01024 Mycophenolic acid Salmon calcitonin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB00017 DB01030 Topotecan Salmon calcitonin may decrease the excretion rate of Topotecan which could result in a higher serum level.
DB00017 DB01032 Probenecid Salmon calcitonin may decrease the excretion rate of Probenecid which could result in a higher serum level.
DB00017 DB01036 Tolterodine Salmon calcitonin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
DB00017 DB01039 Fenofibrate Salmon calcitonin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
DB00017 DB01043 Memantine Salmon calcitonin may decrease the excretion rate of Memantine which could result in a higher serum level.
DB00017 DB01046 Lubiprostone Salmon calcitonin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB00017 DB01048 Abacavir Salmon calcitonin may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB00017 DB01060 Amoxicillin Salmon calcitonin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB00017 DB01068 Clonazepam Salmon calcitonin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB00017 DB01069 Promethazine Salmon calcitonin may decrease the excretion rate of Promethazine which could result in a higher serum level.
DB00017 DB01093 Dimethyl sulfoxide Salmon calcitonin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB00017 DB01099 Flucytosine Salmon calcitonin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB00017 DB01101 Capecitabine Salmon calcitonin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB00017 DB01105 Sibutramine Salmon calcitonin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
DB00017 DB01115 Nifedipine Salmon calcitonin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
DB00017 DB01129 Rabeprazole Salmon calcitonin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
DB00017 DB01135 Doxacurium Salmon calcitonin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB00017 DB01137 Levofloxacin Salmon calcitonin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB00017 DB01148 Flavoxate Salmon calcitonin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB00017 DB01149 Nefazodone Salmon calcitonin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
DB00017 DB01156 Bupropion Salmon calcitonin may decrease the excretion rate of Bupropion which could result in a higher serum level.
DB00017 DB01157 Trimetrexate Salmon calcitonin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB00017 DB01166 Cilostazol Salmon calcitonin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
DB00017 DB01169 Arsenic trioxide Salmon calcitonin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
DB00017 DB01170 Guanethidine Salmon calcitonin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB00017 DB01181 Ifosfamide Salmon calcitonin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
DB00017 DB01183 Naloxone Salmon calcitonin may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB00017 DB01203 Nadolol Salmon calcitonin may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB00017 DB01205 Flumazenil Salmon calcitonin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB00017 DB01213 Fomepizole Salmon calcitonin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB00017 DB01215 Estazolam Salmon calcitonin may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB00017 DB01221 Ketamine Salmon calcitonin may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB00017 DB01222 Budesonide Salmon calcitonin may decrease the excretion rate of Budesonide which could result in a higher serum level.
DB00017 DB01224 Quetiapine Salmon calcitonin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
DB00017 DB01240 Epoprostenol Salmon calcitonin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB00017 DB01241 Gemfibrozil Salmon calcitonin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB00017 DB01249 Iodixanol Salmon calcitonin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB00017 DB01261 Sitagliptin Salmon calcitonin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
DB00017 DB01267 Paliperidone Salmon calcitonin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
DB00017 DB01273 Varenicline Salmon calcitonin may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB00017 DB01274 Arformoterol Salmon calcitonin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB00017 DB01275 Hydralazine Salmon calcitonin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
DB00017 DB01359 Penbutolol Salmon calcitonin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
DB00017 DB01367 Rasagiline Salmon calcitonin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
DB00017 DB01394 Colchicine Salmon calcitonin may decrease the excretion rate of Colchicine which could result in a higher serum level.
DB00017 DB01409 Tiotropium Salmon calcitonin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB00017 DB01420 Testosterone propionate Salmon calcitonin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB00017 DB01427 Amrinone Salmon calcitonin may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB00017 DB01428 Oxybenzone Salmon calcitonin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB00017 DB01431 Allylestrenol Salmon calcitonin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB00017 DB01550 Fenproporex Salmon calcitonin may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB00017 DB01558 Bromazepam Salmon calcitonin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB00017 DB01563 Chloral hydrate Salmon calcitonin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB00017 DB01587 Ketazolam Salmon calcitonin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB00017 DB01610 Valganciclovir Salmon calcitonin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB00017 DB01638 Sorbitol Salmon calcitonin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB00017 DB01656 Roflumilast Salmon calcitonin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB00017 DB01685 Topiroxostat Salmon calcitonin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB00017 DB04574 Estrone sulfate Salmon calcitonin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB00017 DB04871 Lorcaserin Salmon calcitonin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB00017 DB04895 Pegaptanib Salmon calcitonin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB00017 DB04896 Milnacipran Salmon calcitonin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
DB00017 DB04920 Clevidipine Salmon calcitonin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB00017 DB04948 Lofexidine Salmon calcitonin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
DB00017 DB04953 Ezogabine Salmon calcitonin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
DB00017 DB05018 Migalastat Salmon calcitonin may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB00017 DB05541 Brivaracetam Salmon calcitonin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB00017 DB05676 Apremilast Salmon calcitonin may decrease the excretion rate of Apremilast which could result in a higher serum level.
DB00017 DB06154 Pentaerythritol tetranitrate Salmon calcitonin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB00017 DB06186 Ipilimumab Salmon calcitonin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB00017 DB06196 Icatibant Salmon calcitonin may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB00017 DB06203 Alogliptin Salmon calcitonin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
DB00017 DB06209 Prasugrel Salmon calcitonin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB00017 DB06211 Doripenem Salmon calcitonin may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB00017 DB06228 Rivaroxaban Salmon calcitonin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB00017 DB06230 Nalmefene Salmon calcitonin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB00017 DB06262 Droxidopa Salmon calcitonin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB00017 DB06282 Levocetirizine Salmon calcitonin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
DB00017 DB06335 Saxagliptin Salmon calcitonin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
DB00017 DB06402 Telavancin Salmon calcitonin may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB00017 DB06480 Prucalopride Salmon calcitonin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB00017 DB06623 Flupirtine Salmon calcitonin may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB00017 DB06637 Dalfampridine Salmon calcitonin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB00017 DB06695 Dabigatran etexilate Salmon calcitonin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB00017 DB06700 Desvenlafaxine Salmon calcitonin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
DB00017 DB06702 Fesoterodine Salmon calcitonin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB00017 DB06705 Gadofosveset trisodium Salmon calcitonin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB00017 DB06710 Methyltestosterone Salmon calcitonin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB00017 DB06767 Ammonium chloride Salmon calcitonin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB00017 DB06782 Dimercaprol Salmon calcitonin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB00017 DB06796 Mangafodipir Salmon calcitonin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB00017 DB06800 Methylnaltrexone Salmon calcitonin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB00017 DB06809 Plerixafor Salmon calcitonin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB00017 DB06813 Pralatrexate Salmon calcitonin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB00017 DB06823 Tiopronin Salmon calcitonin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB00017 DB06824 Triethylenetetramine Salmon calcitonin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB00017 DB08824 Ioflupane I-123 Salmon calcitonin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB00017 DB08826 Deferiprone Salmon calcitonin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB00017 DB08840 N-methylnicotinamide Salmon calcitonin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB00017 DB08872 Gabapentin enacarbil Salmon calcitonin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB00017 DB08893 Mirabegron Salmon calcitonin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
DB00017 DB08894 Peginesatide Salmon calcitonin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
DB00017 DB08897 Aclidinium Salmon calcitonin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB00017 DB08899 Enzalutamide Salmon calcitonin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB00017 DB08900 Teduglutide Salmon calcitonin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB00017 DB08904 Certolizumab pegol Salmon calcitonin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
DB00017 DB08905 Formestane Salmon calcitonin may decrease the excretion rate of Formestane which could result in a higher serum level.
DB00017 DB08909 Glycerol phenylbutyrate Salmon calcitonin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB00017 DB08910 Pomalidomide Salmon calcitonin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
DB00017 DB08911 Trametinib Salmon calcitonin may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB00017 DB08918 Levomilnacipran Salmon calcitonin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
DB00017 DB08932 Macitentan Salmon calcitonin may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB00017 DB08934 Sofosbuvir Salmon calcitonin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB00017 DB08964 Gemeprost Salmon calcitonin may decrease the excretion rate of Gemeprost which could result in a higher serum level.
DB00017 DB09027 Ledipasvir Salmon calcitonin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB00017 DB09050 Ceftolozane Salmon calcitonin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB00017 DB09066 Corifollitropin alfa Salmon calcitonin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB00017 DB09068 Vortioxetine Salmon calcitonin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB00017 DB09071 Tasimelteon Salmon calcitonin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
DB00017 DB09075 Edoxaban Salmon calcitonin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB00017 DB09081 Idebenone Salmon calcitonin may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB00017 DB09082 Vilanterol Salmon calcitonin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
DB00017 DB09089 Trimebutine Salmon calcitonin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
DB00017 DB09091 Tixocortol Salmon calcitonin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB00017 DB09103 Ancestim Salmon calcitonin may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB00017 DB09104 Magnesium hydroxide Salmon calcitonin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB00017 DB09106 Hydroxyethyl Starch Salmon calcitonin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB00017 DB09111 Pentastarch Salmon calcitonin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB00017 DB09118 Stiripentol Salmon calcitonin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB00017 DB09121 Aurothioglucose Salmon calcitonin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB00017 DB09123 Dienogest Salmon calcitonin may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB00017 DB09129 Chromic chloride Salmon calcitonin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB00017 DB09132 Gadoteric acid Salmon calcitonin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB00017 DB09133 Iothalamic acid Salmon calcitonin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB00017 DB09134 Ioversol Salmon calcitonin may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB00017 DB09135 Ioxilan Salmon calcitonin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB00017 DB09136 Isosulfan blue Salmon calcitonin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB00017 DB09137 Technetium Tc-99m mebrofenin Salmon calcitonin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB00017 DB09139 Technetium Tc-99m oxidronate Salmon calcitonin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB00017 DB09148 Florbetaben (18F) Salmon calcitonin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB00017 DB09149 Florbetapir (18F) Salmon calcitonin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB00017 DB09156 Iopromide Salmon calcitonin may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB00017 DB09163 Technetium Tc-99m exametazime Salmon calcitonin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB00017 DB09165 Technetium Tc-99m pyrophosphate Salmon calcitonin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB00017 DB09185 Viloxazine Salmon calcitonin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB00017 DB09194 Etoperidone Salmon calcitonin may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB00017 DB09195 Lorpiprazole Salmon calcitonin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB00017 DB09204 Arotinolol Salmon calcitonin may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB00017 DB09205 Moxisylyte Salmon calcitonin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB00017 DB09209 Pholcodine Salmon calcitonin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB00017 DB09210 Piracetam Salmon calcitonin may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB00017 DB09219 Bisoxatin Salmon calcitonin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB00017 DB09220 Nicorandil Salmon calcitonin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
DB00017 DB09223 Blonanserin Salmon calcitonin may decrease the excretion rate of Blonanserin which could result in a higher serum level.
DB00017 DB09224 Melperone Salmon calcitonin may decrease the excretion rate of Melperone which could result in a higher serum level.
DB00017 DB09241 Methylene blue Salmon calcitonin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
DB00017 DB09244 Pirlindole Salmon calcitonin may decrease the excretion rate of Pirlindole which could result in a higher serum level.
DB00017 DB09245 Toloxatone Salmon calcitonin may decrease the excretion rate of Toloxatone which could result in a higher serum level.
DB00017 DB09255 Dextran Salmon calcitonin may decrease the excretion rate of Dextran which could result in a higher serum level.
DB00017 DB09256 Tegafur Salmon calcitonin may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB00017 DB09257 Gimeracil Salmon calcitonin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB00017 DB09262 Imidafenacin Salmon calcitonin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB00017 DB09264 Idarucizumab Salmon calcitonin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB00017 DB09265 Lixisenatide Salmon calcitonin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
DB00017 DB09268 Picosulfuric acid Salmon calcitonin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB00017 DB09276 Sodium aurothiomalate Salmon calcitonin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB00017 DB09277 Choline C 11 Salmon calcitonin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB00017 DB09281 Magnesium trisilicate Salmon calcitonin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB00017 DB09292 Sacubitril Salmon calcitonin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB00017 DB09301 Chondroitin sulfate Salmon calcitonin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB00017 DB09317 Synthetic Conjugated Estrogens, A Salmon calcitonin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB00017 DB09318 Synthetic Conjugated Estrogens, B Salmon calcitonin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB00017 DB09320 Procaine benzylpenicillin Salmon calcitonin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB00017 DB09324 Sulbactam Salmon calcitonin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB00017 DB09325 Sodium fluoride Salmon calcitonin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB00017 DB09329 Antihemophilic Factor (Recombinant), PEGylated Salmon calcitonin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB00017 DB09344 Invert sugar Salmon calcitonin may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB00017 DB09357 Dexpanthenol Salmon calcitonin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB00017 DB09394 Phosphoric acid Salmon calcitonin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB00017 DB09395 Sodium acetate Salmon calcitonin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB00017 DB09407 Magnesium chloride Salmon calcitonin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB00017 DB09418 Potassium perchlorate Salmon calcitonin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB00017 DB09472 Sodium sulfate Salmon calcitonin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB00017 DB09477 Enalaprilat Salmon calcitonin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB00017 DB09481 Magnesium carbonate Salmon calcitonin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB00017 DB09488 Acrivastine Salmon calcitonin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB00017 DB09496 Octinoxate Salmon calcitonin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB00017 DB09502 Fludeoxyglucose (18F) Salmon calcitonin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB00017 DB09546 Iobenguane sulfate I-123 Salmon calcitonin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB00017 DB09570 Ixazomib Salmon calcitonin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB00017 DB11077 Polyethylene glycol 400 Salmon calcitonin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB00017 DB11090 Potassium nitrate Salmon calcitonin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB00017 DB11098 Potassium bicarbonate Salmon calcitonin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB00017 DB11102 N-acetyltyrosine Salmon calcitonin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB00017 DB11114 Eucalyptus oil Salmon calcitonin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB00017 DB11127 Selenious acid Salmon calcitonin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB00017 DB11130 Opium Salmon calcitonin may decrease the excretion rate of Opium which could result in a higher serum level.
DB00017 DB11135 Selenium Salmon calcitonin may decrease the excretion rate of Selenium which could result in a higher serum level.
DB00017 DB11136 Chromium Salmon calcitonin may decrease the excretion rate of Chromium which could result in a higher serum level.
DB00017 DB11145 Oxyquinoline Salmon calcitonin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB00017 DB11156 Pyrantel Salmon calcitonin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB00017 DB11164 Bicisate Salmon calcitonin may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB00017 DB11251 Tocopherol Salmon calcitonin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB00017 DB11278 DL-Methylephedrine Salmon calcitonin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB00017 DB11328 Tetradecyl hydrogen sulfate (ester) Salmon calcitonin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB00017 DB11338 Clove oil Salmon calcitonin may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB00017 DB11358 Evening primrose oil Salmon calcitonin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB00017 DB11364 Pidotimod Salmon calcitonin may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB00017 DB11560 Lesinurad Salmon calcitonin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB00017 DB11577 Indigotindisulfonic acid Salmon calcitonin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB00017 DB11587 Etafedrine Salmon calcitonin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB00017 DB11598 Antithrombin III human Salmon calcitonin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB00017 DB11642 Pitolisant Salmon calcitonin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
DB00017 DB11691 Naldemedine Salmon calcitonin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB00017 DB11699 Tropisetron Salmon calcitonin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB00017 DB11817 Baricitinib Salmon calcitonin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB00017 DB11901 Apalutamide Salmon calcitonin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB00017 DB11915 Valbenazine Salmon calcitonin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB00017 DB11943 Delafloxacin Salmon calcitonin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
DB00017 DB11989 Benznidazole Salmon calcitonin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB00017 DB12007 Isoflavone Salmon calcitonin may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB00017 DB12107 Vaborbactam Salmon calcitonin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB00017 DB12161 Deutetrabenazine Salmon calcitonin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
DB00017 DB12278 Propiverine Salmon calcitonin may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB00017 DB12783 Benserazide Salmon calcitonin may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB00017 DB13025 Tiapride Salmon calcitonin may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB00017 DB13139 Levosalbutamol Salmon calcitonin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB00017 DB13156 Inosine pranobex Salmon calcitonin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB00017 DB13178 Inositol Salmon calcitonin may decrease the excretion rate of Inositol which could result in a higher serum level.
DB00017 DB13185 Oxabolone cipionate Salmon calcitonin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB00017 DB13191 Phosphocreatine Salmon calcitonin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB00017 DB13269 Dichlorobenzyl alcohol Salmon calcitonin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB00017 DB13293 Ipecac Salmon calcitonin may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB00017 DB13595 Almasilate Salmon calcitonin may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB00017 DB13873 Fenofibric acid Salmon calcitonin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB00017 DB13884 Albutrepenonacog alfa Salmon calcitonin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB00017 DB13909 Bismuth subgallate Salmon calcitonin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB00017 DB13943 Testosterone cypionate Salmon calcitonin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB00017 DB13944 Testosterone enanthate Salmon calcitonin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB00017 DB13946 Testosterone undecanoate Salmon calcitonin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
DB00017 DB13952 Estradiol acetate Salmon calcitonin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB00017 DB13954 Estradiol cypionate Salmon calcitonin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB00017 DB13955 Estradiol dienanthate Salmon calcitonin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB00017 DB13956 Estradiol valerate Salmon calcitonin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB00017 DB13967 Patent Blue Salmon calcitonin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB00017 DB14006 Choline salicylate Salmon calcitonin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB00017 DB14007 Pentetic acid Salmon calcitonin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB00017 DB14498 Potassium acetate Salmon calcitonin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB00017 DB14499 Potassium sulfate Salmon calcitonin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB00017 DB14526 Chromic citrate Salmon calcitonin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB00017 DB14527 Chromic nitrate Salmon calcitonin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB00017 DB14528 Chromium gluconate Salmon calcitonin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB00017 DB14529 Chromium nicotinate Salmon calcitonin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB00017 DB14530 Chromous sulfate Salmon calcitonin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB00017 DB14754 Solriamfetol Salmon calcitonin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
DB00017 DB06815 Pyrithione Salmon calcitonin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB00017 DB11121 Chloroxylenol Salmon calcitonin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB00017 DB15593 Golodirsen Salmon calcitonin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00017 DB00318 Codeine Salmon calcitonin may decrease the excretion rate of Codeine which could result in a higher serum level.
DB00017 DB00454 Meperidine Salmon calcitonin may decrease the excretion rate of Meperidine which could result in a higher serum level.
DB00017 DB00813 Fentanyl Salmon calcitonin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
DB00017 DB00879 Emtricitabine Salmon calcitonin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB00017 DB00452 Framycetin Framycetin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00479 Amikacin Amikacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00684 Tobramycin Tobramycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00798 Gentamicin Gentamicin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00955 Netilmicin Netilmicin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00994 Neomycin Neomycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01082 Streptomycin Streptomycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01172 Kanamycin Kanamycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB01421 Paromomycin Paromomycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB03615 Ribostamycin Ribostamycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04263 Geneticin Geneticin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04626 Apramycin Apramycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04729 Gentamicin C1a Gentamicin C1a may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB04808 Neamine Neamine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB06696 Arbekacin Arbekacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB08437 Puromycin Puromycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11512 Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB11520 Hygromycin B Hygromycin B may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB12604 Sisomicin Sisomicin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13270 Dibekacin Dibekacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13274 Micronomicin Micronomicin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13540 Isepamicin Isepamicin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB13673 Bekanamycin Bekanamycin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
DB00017 DB00552 Pentostatin Salmon calcitonin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB00017 DB13145 Nedaplatin Salmon calcitonin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00017 DB00314 Capreomycin Salmon calcitonin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00017 DB00390 Digoxin Salmon calcitonin may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00017 DB00512 Vancomycin Salmon calcitonin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00017 DB00515 Cisplatin Salmon calcitonin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00017 DB00564 Carbamazepine Salmon calcitonin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
DB00017 DB00642 Pemetrexed Salmon calcitonin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB00017 DB00682 Warfarin Salmon calcitonin may decrease the excretion rate of Warfarin which could result in a higher serum level.
DB00017 DB00908 Quinidine Salmon calcitonin may decrease the excretion rate of Quinidine which could result in a higher serum level.
DB00017 DB00982 Isotretinoin Salmon calcitonin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB00017 DB01035 Procainamide Salmon calcitonin may decrease the excretion rate of Procainamide which could result in a higher serum level.
DB00017 DB12615 Plazomicin Salmon calcitonin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00017 DB00524 Metolazone Salmon calcitonin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00695 Furosemide Salmon calcitonin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00808 Indapamide Salmon calcitonin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00887 Bumetanide Salmon calcitonin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00909 Zonisamide Salmon calcitonin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB08907 Canagliflozin Salmon calcitonin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB09338 Mersalyl Salmon calcitonin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00214 Torasemide Torasemide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00232 Methyclothiazide Methyclothiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00310 Chlorthalidone Chlorthalidone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00311 Ethoxzolamide Ethoxzolamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00421 Spironolactone Spironolactone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00436 Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00562 Benzthiazide Benzthiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00594 Amiloride Amiloride may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00606 Cyclothiazide Cyclothiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00700 Eplerenone Eplerenone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00703 Methazolamide Methazolamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00774 Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00819 Acetazolamide Acetazolamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00872 Conivaptan Conivaptan may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00880 Chlorothiazide Chlorothiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01021 Trichlormethiazide Trichlormethiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01119 Diazoxide Diazoxide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01144 Diclofenamide Diclofenamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01324 Polythiazide Polythiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01325 Quinethazone Quinethazone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01395 Drospirenone Drospirenone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB01412 Theobromine Theobromine may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB02925 Piretanide Piretanide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB04831 Tienilic acid Tienilic acid may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB05034 Ularitide Ularitide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB06212 Tolvaptan Tolvaptan may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB06292 Dapagliflozin Dapagliflozin may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB06370 Indisulam Indisulam may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB08961 Azosemide Azosemide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB09015 Canrenoic acid Canrenoic acid may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB09125 Potassium citrate Potassium citrate may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB09235 Efonidipine Efonidipine may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB09401 Isosorbide Isosorbide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB11827 Ertugliflozin Ertugliflozin may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB12221 Canrenone Canrenone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB12670 Rolofylline Rolofylline may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB12704 Spiradoline Spiradoline may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB12766 Cicletanine Cicletanine may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13284 Meticrane Meticrane may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13316 Ibopamine Ibopamine may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13405 Mefruside Mefruside may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13430 Mebutizide Mebutizide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13532 Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13617 Clorexolone Clorexolone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13663 Clofenamide Clofenamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13708 Fenquizone Fenquizone may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13792 Clopamide Clopamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13801 Muzolimine Muzolimine may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13803 Xipamide Xipamide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB13989 Epitizide Epitizide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB14018 Bromotheophylline Bromotheophylline may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB14500 Potassium Potassium may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.
DB00017 DB00191 Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Salmon calcitonin.
DB00017 DB00211 Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Salmon calcitonin.
DB00017 DB00368 Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Salmon calcitonin.
DB00017 DB00388 Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Salmon calcitonin.
DB00017 DB00397 Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Salmon calcitonin.
DB00017 DB00610 Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Salmon calcitonin.
DB00017 DB00668 Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Salmon calcitonin.
DB00017 DB00723 Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Salmon calcitonin.
DB00017 DB00816 Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Salmon calcitonin.
DB00017 DB00830 Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Salmon calcitonin.
DB00017 DB00852 Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Salmon calcitonin.
DB00017 DB00865 Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Salmon calcitonin.
DB00017 DB00867 Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Salmon calcitonin.
DB00017 DB00935 Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Salmon calcitonin.
DB00017 DB00937 Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Salmon calcitonin.
DB00017 DB01064 Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Salmon calcitonin.
DB00017 DB01255 Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Salmon calcitonin.
DB00017 DB01288 Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Salmon calcitonin.
DB00017 DB01364 Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Salmon calcitonin.
DB00017 DB01365 Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Salmon calcitonin.
DB00017 DB01366 Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Salmon calcitonin.
DB00017 DB01407 Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Salmon calcitonin.
DB00017 DB01442 MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Salmon calcitonin.
DB00017 DB01454 Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Salmon calcitonin.
DB00017 DB01467 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Salmon calcitonin.
DB00017 DB01484 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Salmon calcitonin.
DB00017 DB01509 Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Salmon calcitonin.
DB00017 DB01556 Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Salmon calcitonin.
DB00017 DB01566 Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Salmon calcitonin.
DB00017 DB01576 Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Salmon calcitonin.
DB00017 DB06152 Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Salmon calcitonin.
DB00017 DB06764 Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Salmon calcitonin.
DB00017 DB08841 Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Salmon calcitonin.
DB00017 DB08941 Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Salmon calcitonin.
DB00017 DB08985 Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Salmon calcitonin.
DB00017 DB09203 Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Salmon calcitonin.
DB00017 DB09480 Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Salmon calcitonin.
DB00017 DB11124 Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Salmon calcitonin.
DB00017 DB12080 Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Salmon calcitonin.
DB00017 DB13064 Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Salmon calcitonin.
DB00017 DB13108 Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Salmon calcitonin.
DB00017 DB13341 Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Salmon calcitonin.
DB00017 DB13624 Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Salmon calcitonin.
DB00017 DB13692 Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Salmon calcitonin.
DB00017 DB13703 Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Salmon calcitonin.
DB00017 DB13777 Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Salmon calcitonin.
DB00017 DB13852 Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Salmon calcitonin.
DB00017 DB13940 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Salmon calcitonin.
DB00017 DB00182 Amphetamine The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Amphetamine.
DB00017 DB00598 Labetalol The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Labetalol.
DB00017 DB00841 Dobutamine The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Dobutamine.
DB00017 DB00871 Terbutaline The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Terbutaline.
DB00017 DB00988 Dopamine The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Dopamine.
DB00017 DB01577 Metamfetamine The risk or severity of adverse effects can be increased when Salmon calcitonin is combined with Metamfetamine.
DB00017 DB01193 Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Salmon calcitonin.
DB00017 DB04846 Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Salmon calcitonin.
DB00017 DB12752 Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Salmon calcitonin.
DB00017 DB13757 Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Salmon calcitonin.
DB00017 DB00317 Gefitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Gefitinib.
DB00017 DB00530 Erlotinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Erlotinib.
DB00017 DB00619 Imatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Imatinib.
DB00017 DB01254 Dasatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Dasatinib.
DB00017 DB01259 Lapatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Lapatinib.
DB00017 DB01268 Sunitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Sunitinib.
DB00017 DB01645 Genistein The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Genistein.
DB00017 DB02058 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
DB00017 DB02424 Geldanamycin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Geldanamycin.
DB00017 DB02567 PD173955 The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with PD173955.
DB00017 DB03758 Radicicol The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Radicicol.
DB00017 DB04849 Cediranib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Cediranib.
DB00017 DB04868 Nilotinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Nilotinib.
DB00017 DB04879 Vatalanib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Vatalanib.
DB00017 DB05294 Vandetanib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Vandetanib.
DB00017 DB05424 Canertinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Canertinib.
DB00017 DB05465 Tandutinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Tandutinib.
DB00017 DB05575 Motesanib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Motesanib.
DB00017 DB05928 Dovitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Dovitinib.
DB00017 DB06302 Glesatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Glesatinib.
DB00017 DB06469 Lestaurtinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Lestaurtinib.
DB00017 DB06589 Pazopanib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Pazopanib.
DB00017 DB06595 Midostaurin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Midostaurin.
DB00017 DB06616 Bosutinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Bosutinib.
DB00017 DB06626 Axitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Axitinib.
DB00017 DB08399 Piceatannol The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Piceatannol.
DB00017 DB08865 Crizotinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Crizotinib.
DB00017 DB08875 Cabozantinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Cabozantinib.
DB00017 DB08881 Vemurafenib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Vemurafenib.
DB00017 DB08896 Regorafenib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Regorafenib.
DB00017 DB08901 Ponatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ponatinib.
DB00017 DB08916 Afatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Afatinib.
DB00017 DB09053 Ibrutinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ibrutinib.
DB00017 DB09063 Ceritinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ceritinib.
DB00017 DB09078 Lenvatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Lenvatinib.
DB00017 DB09079 Nintedanib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Nintedanib.
DB00017 DB09330 Osimertinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Osimertinib.
DB00017 DB11363 Alectinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Alectinib.
DB00017 DB11689 Selumetinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Selumetinib.
DB00017 DB11697 Pacritinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Pacritinib.
DB00017 DB11703 Acalabrutinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Acalabrutinib.
DB00017 DB11737 Icotinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Icotinib.
DB00017 DB11805 Saracatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Saracatinib.
DB00017 DB11828 Neratinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Neratinib.
DB00017 DB11832 Crenolanib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Crenolanib.
DB00017 DB11904 Flumatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Flumatinib.
DB00017 DB11963 Dacomitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Dacomitinib.
DB00017 DB11973 Tesevatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Tesevatinib.
DB00017 DB11986 Entrectinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Entrectinib.
DB00017 DB12010 Fostamatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fostamatinib.
DB00017 DB12048 Savolitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Savolitinib.
DB00017 DB12141 Gilteritinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Gilteritinib.
DB00017 DB12147 Erdafitinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Erdafitinib.
DB00017 DB12267 Brigatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Brigatinib.
DB00017 DB12307 Foretinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Foretinib.
DB00017 DB12323 Radotinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Radotinib.
DB00017 DB14723 Larotrectinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Larotrectinib.
DB00017 DB00398 Sorafenib The therapeutic efficacy of Sorafenib can be decreased when used in combination with Salmon calcitonin.
DB00017 DB08877 Ruxolitinib The therapeutic efficacy of Ruxolitinib can be decreased when used in combination with Salmon calcitonin.
DB00017 DB12978 Pexidartinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Pexidartinib.
DB00017 DB12500 Fedratinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fedratinib.
DB00017 DB11652 Tucatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Tucatinib.
DB00017 DB11791 Capmatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Capmatinib.
DB00017 DB15685 Selpercatinib The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Selpercatinib.
DB00017 DB05258 Interferon alfa The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Interferon alfa.
DB00017 DB00041 Aldesleukin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Aldesleukin.
DB00017 DB00227 Lovastatin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Lovastatin.
DB00017 DB00609 Ethionamide The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ethionamide.
DB00017 DB00850 Perphenazine The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Perphenazine.
DB00017 DB14651 Perphenazine enanthate The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Perphenazine enanthate.
DB00017 DB00829 Diazepam The therapeutic efficacy of Diazepam can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01233 Metoclopramide The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB00233 Aminosalicylic acid The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Aminosalicylic acid.
DB00017 DB11085 Resorcinol The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Resorcinol.
DB00017 DB00672 Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB00839 Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01067 Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01124 Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB00222 Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Salmon calcitonin.
DB00017 DB00414 Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01016 Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01120 Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01251 Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01289 Glisoxepide The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB08962 Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Salmon calcitonin.
DB00017 DB13406 Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB13675 Metahexamide The therapeutic efficacy of Metahexamide can be decreased when used in combination with Salmon calcitonin.
DB00017 DB01151 Desipramine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Desipramine.
DB00017 DB01242 Clomipramine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Clomipramine.
DB00017 DB08996 Dimetacrine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Dimetacrine.
DB00017 DB00540 Nortriptyline The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Nortriptyline.
DB00017 DB00321 Amitriptyline The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Amitriptyline.
DB00017 DB00344 Protriptyline The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Protriptyline.
DB00017 DB00458 Imipramine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Imipramine.
DB00017 DB00543 Amoxapine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Amoxapine.
DB00017 DB00726 Trimipramine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Trimipramine.
DB00017 DB01142 Doxepin The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Doxepin.
DB00017 DB04836 Amineptine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Amineptine.
DB00017 DB09016 Butriptyline The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Butriptyline.
DB00017 DB09167 Dosulepin The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Dosulepin.
DB00017 DB09289 Tianeptine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Tianeptine.
DB00017 DB09307 Oxaprotiline The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Oxaprotiline.
DB00017 DB12930 Opipramol The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Opipramol.
DB00017 DB13114 Amitriptylinoxide The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Amitriptylinoxide.
DB00017 DB13225 Dibenzepin The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Dibenzepin.
DB00017 DB13246 Quinupramine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Quinupramine.
DB00017 DB13384 Melitracen The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Melitracen.
DB00017 DB13411 Lofepramine The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Lofepramine.
DB00017 DB13496 Iprindole The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Iprindole.
DB00017 DB13782 Imipramine oxide The risk or severity of Cardiac Arrhythmia can be increased when Salmon calcitonin is combined with Imipramine oxide.
DB00018 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-n3.
DB00018 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-n3.
DB00018 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-n3.
DB00018 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-n3.
DB00018 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Peginterferon alfa-2b.
DB00018 DB00026 Anakinra The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Anakinra.
DB00018 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon gamma-1b.
DB00018 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2a, Recombinant.
DB00018 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Adalimumab.
DB00018 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemtuzumab ozogamicin.
DB00018 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pegaspargase.
DB00018 DB00065 Infliximab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Infliximab.
DB00018 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon beta-1b.
DB00018 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfacon-1.
DB00018 DB00073 Rituximab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rituximab.
DB00018 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Basiliximab.
DB00018 DB00075 Muromonab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Muromonab.
DB00018 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibritumomab tiuxetan.
DB00018 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tositumomab.
DB00018 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alemtuzumab.
DB00018 DB00092 Alefacept The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Alefacept.
DB00018 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Efalizumab.
DB00018 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antithymocyte immunoglobulin (rabbit).
DB00018 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2b.
DB00018 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daclizumab.
DB00018 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bevacizumab.
DB00018 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Phenylalanine.
DB00018 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Flunisolide.
DB00018 DB00188 Bortezomib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bortezomib.
DB00018 DB00242 Cladribine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cladribine.
DB00018 DB00262 Carmustine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carmustine.
DB00018 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Amsacrine.
DB00018 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bleomycin.
DB00018 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Chlorambucil.
DB00018 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Raltitrexed.
DB00018 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mitomycin.
DB00018 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bexarotene.
DB00018 DB00309 Vindesine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vindesine.
DB00018 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Floxuridine.
DB00018 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Indomethacin.
DB00018 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tioguanine.
DB00018 DB00361 Vinorelbine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vinorelbine.
DB00018 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dexrazoxane.
DB00018 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Beclomethasone dipropionate.
DB00018 DB00398 Sorafenib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sorafenib.
DB00018 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Streptozocin.
DB00018 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trifluridine.
DB00018 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gemcitabine.
DB00018 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Betamethasone.
DB00018 DB00444 Teniposide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Teniposide.
DB00018 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Epirubicin.
DB00018 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Chloramphenicol.
DB00018 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Lenalidomide.
DB00018 DB00488 Altretamine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Altretamine.
DB00018 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Zidovudine.
DB00018 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cisplatin.
DB00018 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Oxaliplatin.
DB00018 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cyclophosphamide.
DB00018 DB00541 Vincristine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vincristine.
DB00018 DB00544 Fluorouracil The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluorouracil.
DB00018 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Propylthiouracil.
DB00018 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pentostatin.
DB00018 DB00563 Methotrexate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Methotrexate.
DB00018 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carbamazepine.
DB00018 DB00570 Vinblastine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vinblastine.
DB00018 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluticasone propionate.
DB00018 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocinolone acetonide.
DB00018 DB00601 Linezolid The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Linezolid.
DB00018 DB00619 Imatinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Imatinib.
DB00018 DB00620 Triamcinolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Triamcinolone.
DB00018 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clofarabine.
DB00018 DB00635 Prednisone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Prednisone.
DB00018 DB00642 Pemetrexed The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pemetrexed.
DB00018 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fludrocortisone.
DB00018 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mycophenolate mofetil.
DB00018 DB00694 Daunorubicin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daunorubicin.
DB00018 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tretinoin.
DB00018 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Irinotecan.
DB00018 DB00763 Methimazole The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Methimazole.
DB00018 DB00764 Mometasone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mometasone.
DB00018 DB00773 Etoposide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Etoposide.
DB00018 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sulfasalazine.
DB00018 DB00851 Dacarbazine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dacarbazine.
DB00018 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Temozolomide.
DB00018 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Penicillamine.
DB00018 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Prednisolone.
DB00018 DB00877 Sirolimus The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sirolimus.
DB00018 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mechlorethamine.
DB00018 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Azacitidine.
DB00018 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carboplatin.
DB00018 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Methylprednisolone.
DB00018 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dactinomycin.
DB00018 DB00987 Cytarabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cytarabine.
DB00018 DB00993 Azathioprine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Azathioprine.
DB00018 DB00997 Doxorubicin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Doxorubicin.
DB00018 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hydroxyurea.
DB00018 DB01008 Busulfan The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Busulfan.
DB00018 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mycophenolic acid.
DB00018 DB01030 Topotecan The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Topotecan.
DB00018 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mercaptopurine.
DB00018 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Thalidomide.
DB00018 DB01042 Melphalan The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Melphalan.
DB00018 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fludarabine.
DB00018 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Flucytosine.
DB00018 DB01101 Capecitabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Capecitabine.
DB00018 DB01108 Trilostane The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trilostane.
DB00018 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Procarbazine.
DB00018 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Arsenic trioxide.
DB00018 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Idarubicin.
DB00018 DB01181 Ifosfamide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ifosfamide.
DB00018 DB01196 Estramustine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Estramustine.
DB00018 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mitoxantrone.
DB00018 DB01206 Lomustine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Lomustine.
DB00018 DB01222 Budesonide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Budesonide.
DB00018 DB01229 Paclitaxel The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Paclitaxel.
DB00018 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dexamethasone.
DB00018 DB01248 Docetaxel The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Docetaxel.
DB00018 DB01254 Dasatinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dasatinib.
DB00018 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Eculizumab.
DB00018 DB01262 Decitabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Decitabine.
DB00018 DB01268 Sunitinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sunitinib.
DB00018 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Nelarabine.
DB00018 DB01281 Abatacept The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Abatacept.
DB00018 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Corticotropin.
DB00018 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cortisone acetate.
DB00018 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Paramethasone.
DB00018 DB01394 Colchicine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Colchicine.
DB00018 DB01410 Ciclesonide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ciclesonide.
DB00018 DB01423 Stepronin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Stepronin.
DB00018 DB01590 Everolimus The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Everolimus.
DB00018 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hydroxychloroquine.
DB00018 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Castanospermine.
DB00018 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vorinostat.
DB00018 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with 2-Methoxyethanol.
DB00018 DB03523 Brequinar The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Brequinar.
DB00018 DB04572 Thiotepa The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Thiotepa.
DB00018 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldosterone.
DB00018 DB04845 Ixabepilone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ixabepilone.
DB00018 DB04868 Nilotinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Nilotinib.
DB00018 DB04951 Pirfenidone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pirfenidone.
DB00018 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Afelimomab.
DB00018 DB05015 Belinostat The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Belinostat.
DB00018 DB05109 Trabectedin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trabectedin.
DB00018 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa.
DB00018 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Glatiramer.
DB00018 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gallium nitrate.
DB00018 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Briakinumab.
DB00018 DB05472 omega interferon The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with omega interferon.
DB00018 DB05676 Apremilast The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Apremilast.
DB00018 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trastuzumab emtansine.
DB00018 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Canakinumab.
DB00018 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tocilizumab.
DB00018 DB06287 Temsirolimus The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Temsirolimus.
DB00018 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rilonacept.
DB00018 DB06589 Pazopanib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pazopanib.
DB00018 DB06603 Panobinostat The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Panobinostat.
DB00018 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mepolizumab.
DB00018 DB06616 Bosutinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bosutinib.
DB00018 DB06662 Abetimus The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Abetimus.
DB00018 DB06674 Golimumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Golimumab.
DB00018 DB06681 Belatacept The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Belatacept.
DB00018 DB06769 Bendamustine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bendamustine.
DB00018 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cabazitaxel.
DB00018 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pralatrexate.
DB00018 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Wortmannin.
DB00018 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Brentuximab vedotin.
DB00018 DB08871 Eribulin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Eribulin.
DB00018 DB08877 Ruxolitinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ruxolitinib.
DB00018 DB08879 Belimumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Belimumab.
DB00018 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Teriflunomide.
DB00018 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Carfilzomib.
DB00018 DB08901 Ponatinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ponatinib.
DB00018 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Certolizumab pegol.
DB00018 DB08906 Fluticasone furoate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluticasone furoate.
DB00018 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dimethyl fumarate.
DB00018 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pomalidomide.
DB00018 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Obinutuzumab.
DB00018 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluprednidene.
DB00018 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocortolone.
DB00018 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Secukinumab.
DB00018 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vedolizumab.
DB00018 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Siltuximab.
DB00018 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Blinatumomab.
DB00018 DB09053 Ibrutinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ibrutinib.
DB00018 DB09054 Idelalisib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Idelalisib.
DB00018 DB09073 Palbociclib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Palbociclib.
DB00018 DB09074 Olaparib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Olaparib.
DB00018 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dinutuximab.
DB00018 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vilanterol.
DB00018 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tixocortol.
DB00018 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Peginterferon beta-1a.
DB00018 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antilymphocyte immunoglobulin (horse).
DB00018 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluprednisolone.
DB00018 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Meprednisone.
DB00018 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tepoxalin.
DB00018 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dexamethasone isonicotinate.
DB00018 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Melengestrol.
DB00018 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ixekizumab.
DB00018 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ravulizumab.
DB00018 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pirarubicin.
DB00018 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Voclosporin.
DB00018 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Peficitinib.
DB00018 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clobetasol.
DB00018 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sarilumab.
DB00018 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Brodalumab.
DB00018 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sirukumab.
DB00018 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Baricitinib.
DB00018 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Guselkumab.
DB00018 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Deflazacort.
DB00018 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ocrelizumab.
DB00018 DB12025 Triptolide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Triptolide.
DB00018 DB12371 Siponimod The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Siponimod.
DB00018 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ozanimod.
DB00018 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mizoribine.
DB00018 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Gusperimus.
DB00018 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cepeginterferon alfa-2B.
DB00018 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Trofosfamide.
DB00018 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Doxifluridine.
DB00018 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Deoxyspergualin.
DB00018 DB12996 Acteoside The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Acteoside.
DB00018 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cortivazol.
DB00018 DB13014 Hypericin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hypericin.
DB00018 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00018 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Prednylidene.
DB00018 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocortin.
DB00018 DB13241 Begelomab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Begelomab.
DB00018 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluperolone.
DB00018 DB13664 Formocortal The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Formocortal.
DB00018 DB13728 Halometasone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Halometasone.
DB00018 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cloprednol.
DB00018 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluclorolone.
DB00018 DB13867 Fluticasone The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluticasone.
DB00018 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Tetrandrine.
DB00018 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Monomethyl fumarate.
DB00018 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mometasone furoate.
DB00018 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hydrocortisone aceponate.
DB00018 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hydrocortisone acetate.
DB00018 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hydrocortisone succinate.
DB00018 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Emapalumab.
DB00018 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Risankizumab.
DB00018 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Rozanolixizumab.
DB00018 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bleselumab.
DB00018 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Natalizumab.
DB00018 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-n3.
DB00018 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Interferon alfa-n3.
DB00018 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.
DB00018 DB00363 Clozapine The risk or severity of neutropenia can be increased when Interferon alfa-n3 is combined with Clozapine.
DB00018 DB00333 Methadone The serum concentration of Methadone can be increased when it is combined with Interferon alfa-n3.
DB00018 DB00811 Ribavirin The risk or severity of anemia can be increased when Interferon alfa-n3 is combined with Ribavirin.
DB00018 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-n3.
DB00018 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-n3.
DB00018 DB01265 Telbivudine The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Telbivudine.
DB00018 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Leflunomide.
DB00018 DB08895 Tofacitinib Interferon alfa-n3 may increase the immunosuppressive activities of Tofacitinib.
DB00018 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Interferon alfa-n3.
DB00018 DB08868 Fingolimod Interferon alfa-n3 may increase the immunosuppressive activities of Fingolimod.
DB00018 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Interferon alfa-n3.
DB00018 DB00201 Caffeine The metabolism of Caffeine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00651 Dyphylline The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB01412 Theobromine The metabolism of Theobromine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01482 Fenethylline The metabolism of Fenethylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB01667 8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01978 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB02134 Xanthine The metabolism of Xanthine can be decreased when combined with Interferon alfa-n3.
DB00018 DB02245 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB02377 Guanine The metabolism of Guanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB02568 Peldesine The metabolism of Peldesine can be decreased when combined with Interferon alfa-n3.
DB00018 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-n3.
DB00018 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB06479 Propentofylline The metabolism of Propentofylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB06575 Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Interferon alfa-n3.
DB00018 DB07954 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfa-n3.
DB00018 DB08844 Uric acid The metabolism of Uric acid can be decreased when combined with Interferon alfa-n3.
DB00018 DB09273 Doxofylline The metabolism of Doxofylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfa-n3.
DB00018 DB12406 Lisofylline The metabolism of Lisofylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB12531 Lobucavir The metabolism of Lobucavir can be decreased when combined with Interferon alfa-n3.
DB00018 DB12926 Cafedrine The metabolism of Cafedrine can be decreased when combined with Interferon alfa-n3.
DB00018 DB12927 Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Interferon alfa-n3.
DB00018 DB13203 Bamifylline The metabolism of Bamifylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB13449 Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB13573 Acefylline The metabolism of Acefylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB13592 Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB13634 Pentifylline The metabolism of Pentifylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB13812 Bufylline The metabolism of Bufylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB14029 Furafylline The metabolism of Furafylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB15122 PCS-499 The metabolism of PCS-499 can be decreased when combined with Interferon alfa-n3.
DB00018 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfa-n3.
DB00018 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-n3.
DB00018 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfa-n3.
DB00018 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfa-n3.
DB00018 DB00945 Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-n3.
DB00018 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-n3.
DB00018 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfa-n3.
DB00018 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-n3.
DB00018 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfa-n3.
DB00018 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfa-n3.
DB00018 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-n3.
DB00018 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfa-n3.
DB00018 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfa-n3.
DB00018 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-n3.
DB00018 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfa-n3.
DB00018 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfa-n3.
DB00018 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfa-n3.
DB00018 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-n3.
DB00018 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfa-n3.
DB00018 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfa-n3.
DB00018 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfa-n3.
DB00018 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfa-n3.
DB00018 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-n3.
DB00018 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-n3.
DB00018 DB09030 Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfa-n3.
DB00018 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfa-n3.
DB00018 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfa-n3.
DB00018 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfa-n3.
DB00018 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfa-n3.
DB00018 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfa-n3.
DB00018 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfa-n3.
DB00018 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfa-n3.
DB00018 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfa-n3.
DB00018 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfa-n3.
DB00018 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfa-n3.
DB00018 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfa-n3.
DB00018 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfa-n3.
DB00018 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfa-n3.
DB00018 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfa-n3.
DB00018 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfa-n3.
DB00018 DB13200 Lipegfilgrastim Interferon alfa-n3 may increase the myelosuppressive activities of Lipegfilgrastim.
DB00018 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-n3.
DB00018 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon alfa-n3.
DB00018 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfa-n3.
DB00018 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-n3.
DB00018 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfa-n3.
DB00018 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfa-n3.
DB00018 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfa-n3.
DB00018 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfa-n3.
DB00018 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfa-n3.
DB00018 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfa-n3.
DB00018 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfa-n3.
DB00018 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfa-n3.
DB00018 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00184 Nicotine The metabolism of Nicotine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00195 Betaxolol The metabolism of Betaxolol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00261 Anagrelide The metabolism of Anagrelide can be decreased when combined with Interferon alfa-n3.
DB00018 DB00280 Disopyramide The metabolism of Disopyramide can be decreased when combined with Interferon alfa-n3.
DB00018 DB00281 Lidocaine The metabolism of Lidocaine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfa-n3.
DB00018 DB00296 Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00316 Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-n3.
DB00018 DB00334 Olanzapine The metabolism of Olanzapine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfa-n3.
DB00018 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Interferon alfa-n3.
DB00018 DB00370 Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00379 Mexiletine The metabolism of Mexiletine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00382 Tacrine The metabolism of Tacrine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00384 Triamterene The metabolism of Triamterene can be decreased when combined with Interferon alfa-n3.
DB00018 DB00420 Promazine The metabolism of Promazine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00425 Zolpidem The metabolism of Zolpidem can be decreased when combined with Interferon alfa-n3.
DB00018 DB00442 Entecavir The metabolism of Entecavir can be decreased when combined with Interferon alfa-n3.
DB00018 DB00461 Nabumetone The metabolism of Nabumetone can be decreased when combined with Interferon alfa-n3.
DB00018 DB00468 Quinine The metabolism of Quinine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00472 Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00476 Duloxetine The metabolism of Duloxetine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00499 Flutamide The metabolism of Flutamide can be decreased when combined with Interferon alfa-n3.
DB00018 DB00502 Haloperidol The metabolism of Haloperidol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00518 Albendazole The metabolism of Albendazole can be decreased when combined with Interferon alfa-n3.
DB00018 DB00533 Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Interferon alfa-n3.
DB00018 DB00568 Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00571 Propranolol The metabolism of Propranolol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00586 Diclofenac The metabolism of Diclofenac can be decreased when combined with Interferon alfa-n3.
DB00018 DB00629 Guanabenz The metabolism of Guanabenz can be decreased when combined with Interferon alfa-n3.
DB00018 DB00661 Verapamil The metabolism of Verapamil can be decreased when combined with Interferon alfa-n3.
DB00018 DB00715 Paroxetine The metabolism of Paroxetine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00730 Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Interferon alfa-n3.
DB00018 DB00740 Riluzole The metabolism of Riluzole can be decreased when combined with Interferon alfa-n3.
DB00018 DB00744 Zileuton The metabolism of Zileuton can be decreased when combined with Interferon alfa-n3.
DB00018 DB00758 Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Interferon alfa-n3.
DB00018 DB00783 Estradiol The metabolism of Estradiol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00787 Acyclovir The metabolism of Acyclovir can be decreased when combined with Interferon alfa-n3.
DB00018 DB00788 Naproxen The metabolism of Naproxen can be decreased when combined with Interferon alfa-n3.
DB00018 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00850 Perphenazine The metabolism of Perphenazine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00857 Terbinafine The metabolism of Terbinafine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00863 Ranitidine The metabolism of Ranitidine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00898 Ethanol The metabolism of Ethanol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00934 Maprotiline The metabolism of Maprotiline can be decreased when combined with Interferon alfa-n3.
DB00018 DB00969 Alosetron The metabolism of Alosetron can be decreased when combined with Interferon alfa-n3.
DB00018 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Interferon alfa-n3.
DB00018 DB00980 Ramelteon The metabolism of Ramelteon can be decreased when combined with Interferon alfa-n3.
DB00018 DB00998 Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Interferon alfa-n3.
DB00018 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01012 Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Interferon alfa-n3.
DB00018 DB01037 Selegiline The metabolism of Selegiline can be decreased when combined with Interferon alfa-n3.
DB00018 DB01056 Tocainide The metabolism of Tocainide can be decreased when combined with Interferon alfa-n3.
DB00018 DB01058 Praziquantel The metabolism of Praziquantel can be decreased when combined with Interferon alfa-n3.
DB00018 DB01065 Melatonin The metabolism of Melatonin can be decreased when combined with Interferon alfa-n3.
DB00018 DB01087 Primaquine The metabolism of Primaquine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01094 Hesperetin The metabolism of Hesperetin can be decreased when combined with Interferon alfa-n3.
DB00018 DB01115 Nifedipine The metabolism of Nifedipine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01136 Carvedilol The metabolism of Carvedilol can be decreased when combined with Interferon alfa-n3.
DB00018 DB01166 Cilostazol The metabolism of Cilostazol can be decreased when combined with Interferon alfa-n3.
DB00018 DB01182 Propafenone The metabolism of Propafenone can be decreased when combined with Interferon alfa-n3.
DB00018 DB01184 Domperidone The metabolism of Domperidone can be decreased when combined with Interferon alfa-n3.
DB00018 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01367 Rasagiline The metabolism of Rasagiline can be decreased when combined with Interferon alfa-n3.
DB00018 DB01405 Temafloxacin The metabolism of Temafloxacin can be decreased when combined with Interferon alfa-n3.
DB00018 DB01424 Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Interferon alfa-n3.
DB00018 DB01435 Antipyrine The metabolism of Antipyrine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01558 Bromazepam The metabolism of Bromazepam can be decreased when combined with Interferon alfa-n3.
DB00018 DB01623 Thiothixene The metabolism of Thiothixene can be decreased when combined with Interferon alfa-n3.
DB00018 DB01628 Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Interferon alfa-n3.
DB00018 DB01645 Genistein The metabolism of Genistein can be decreased when combined with Interferon alfa-n3.
DB00018 DB02709 Resveratrol The metabolism of Resveratrol can be decreased when combined with Interferon alfa-n3.
DB00018 DB03783 Phenacetin The metabolism of Phenacetin can be decreased when combined with Interferon alfa-n3.
DB00018 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Interferon alfa-n3.
DB00018 DB04841 Flunarizine The metabolism of Flunarizine can be decreased when combined with Interferon alfa-n3.
DB00018 DB04871 Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Interferon alfa-n3.
DB00018 DB04948 Lofexidine The metabolism of Lofexidine can be decreased when combined with Interferon alfa-n3.
DB00018 DB06148 Mianserin The metabolism of Mianserin can be decreased when combined with Interferon alfa-n3.
DB00018 DB06210 Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-n3.
DB00018 DB06216 Asenapine The metabolism of Asenapine can be decreased when combined with Interferon alfa-n3.
DB00018 DB06235 Vadimezan The metabolism of Vadimezan can be decreased when combined with Interferon alfa-n3.
DB00018 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-n3.
DB00018 DB06594 Agomelatine The metabolism of Agomelatine can be decreased when combined with Interferon alfa-n3.
DB00018 DB06626 Axitinib The metabolism of Axitinib can be decreased when combined with Interferon alfa-n3.
DB00018 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfa-n3.
DB00018 DB06774 Capsaicin The metabolism of Capsaicin can be decreased when combined with Interferon alfa-n3.
DB00018 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be decreased when combined with Interferon alfa-n3.
DB00018 DB08883 Perampanel The metabolism of Perampanel can be decreased when combined with Interferon alfa-n3.
DB00018 DB09071 Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Interferon alfa-n3.
DB00018 DB09118 Stiripentol The metabolism of Stiripentol can be decreased when combined with Interferon alfa-n3.
DB00018 DB09225 Zotepine The metabolism of Zotepine can be decreased when combined with Interferon alfa-n3.
DB00018 DB09288 Propacetamol The metabolism of Propacetamol can be decreased when combined with Interferon alfa-n3.
DB00018 DB09290 Ramosetron The metabolism of Ramosetron can be decreased when combined with Interferon alfa-n3.
DB00018 DB11967 Binimetinib The metabolism of Binimetinib can be decreased when combined with Interferon alfa-n3.
DB00018 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Interferon alfa-n3.
DB00018 DB12245 Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Interferon alfa-n3.
DB00018 DB12332 Rucaparib The metabolism of Rucaparib can be decreased when combined with Interferon alfa-n3.
DB00018 DB12945 Dihydralazine The metabolism of Dihydralazine can be decreased when combined with Interferon alfa-n3.
DB00018 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Interferon alfa-n3.
DB00018 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfa-n3.
DB00018 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfa-n3.
DB00018 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfa-n3.
DB00018 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Interferon alfa-n3.
DB00018 DB11757 Istradefylline The metabolism of Istradefylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB00972 Azelastine The metabolism of Azelastine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00625 Efavirenz The metabolism of Efavirenz can be decreased when combined with Interferon alfa-n3.
DB00018 DB01233 Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-n3.
DB00018 DB04889 Bicifadine The metabolism of Bicifadine can be decreased when combined with Interferon alfa-n3.
DB00018 DB05708 GTS-21 The metabolism of GTS-21 can be decreased when combined with Interferon alfa-n3.
DB00018 DB01195 Flecainide The metabolism of Flecainide can be decreased when combined with Interferon alfa-n3.
DB00018 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00321 Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-n3.
DB00018 DB00458 Imipramine The metabolism of Imipramine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01142 Doxepin The metabolism of Doxepin can be decreased when combined with Interferon alfa-n3.
DB00018 DB00532 Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Interferon alfa-n3.
DB00018 DB00540 Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Interferon alfa-n3.
DB00018 DB00575 Clonidine The metabolism of Clonidine can be decreased when combined with Interferon alfa-n3.
DB00018 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01151 Desipramine The metabolism of Desipramine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01242 Clomipramine The metabolism of Clomipramine can be decreased when combined with Interferon alfa-n3.
DB00018 DB11689 Selumetinib The metabolism of Selumetinib can be decreased when combined with Interferon alfa-n3.
DB00018 DB00277 Theophylline The metabolism of Theophylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB00682 Warfarin The metabolism of Warfarin can be decreased when combined with Interferon alfa-n3.
DB00018 DB00697 Tizanidine The metabolism of Tizanidine can be decreased when combined with Interferon alfa-n3.
DB00018 DB01100 Pimozide The metabolism of Pimozide can be decreased when combined with Interferon alfa-n3.
DB00018 DB01223 Aminophylline The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n3.
DB00018 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-n3.
DB00018 DB00530 Erlotinib The metabolism of Erlotinib can be decreased when combined with Interferon alfa-n3.
DB00018 DB09256 Tegafur The metabolism of Tegafur can be decreased when combined with Interferon alfa-n3.
DB00018 DB13874 Enasidenib The metabolism of Enasidenib can be decreased when combined with Interferon alfa-n3.
DB00018 DB00675 Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Interferon alfa-n3.
DB00018 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3.
DB00018 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-n3.
DB00018 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-n3.
DB00018 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-n3.
DB00018 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-n3.
DB00018 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-n3.
DB00018 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-n3.
DB00018 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-n3.
DB00018 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-n3.
DB00018 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfa-n3.
DB00018 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfa-n3.
DB00018 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfa-n3.
DB00018 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfa-n3.
DB00018 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfa-n3.
DB00018 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfa-n3.
DB00018 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfa-n3.
DB00018 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfa-n3.
DB00018 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfa-n3.
DB00018 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfa-n3.
DB00018 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfa-n3.
DB00018 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfa-n3.
DB00018 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfa-n3.
DB00018 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfa-n3.
DB00018 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfa-n3.
DB00018 DB06228 Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfa-n3.
DB00018 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfa-n3.
DB00018 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfa-n3.
DB00018 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfa-n3.
DB00018 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfa-n3.
DB00018 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfa-n3.
DB00018 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfa-n3.
DB00018 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfa-n3.
DB00018 DB06695 Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-n3.
DB00018 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfa-n3.
DB00018 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfa-n3.
DB00018 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfa-n3.
DB00018 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfa-n3.
DB00018 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfa-n3.
DB00018 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfa-n3.
DB00018 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfa-n3.
DB00018 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfa-n3.
DB00018 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfa-n3.
DB00018 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-n3.
DB00018 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfa-n3.
DB00018 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfa-n3.
DB00018 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfa-n3.
DB00018 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfa-n3.
DB00018 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfa-n3.
DB00018 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfa-n3.
DB00018 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfa-n3.
DB00018 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-n3.
DB00018 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfa-n3.
DB00018 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-n3.
DB00018 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfa-n3.
DB00018 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfa-n3.
DB00018 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfa-n3.
DB00018 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfa-n3.
DB00018 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfa-n3.
DB00018 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfa-n3.
DB00018 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfa-n3.
DB00018 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfa-n3.
DB00018 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfa-n3.
DB00018 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfa-n3.
DB00018 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfa-n3.
DB00018 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfa-n3.
DB00018 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfa-n3.
DB00018 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfa-n3.
DB00018 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfa-n3.
DB00018 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfa-n3.
DB00018 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfa-n3.
DB00018 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-n3.
DB00018 DB00232 Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-n3.
DB00018 DB00436 Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-n3.
DB00018 DB00562 Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfa-n3.
DB00018 DB00606 Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfa-n3.
DB00018 DB00774 Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfa-n3.
DB00018 DB00880 Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfa-n3.
DB00018 DB00999 Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfa-n3.
DB00018 DB01021 Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfa-n3.
DB00018 DB01324 Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfa-n3.
DB00018 DB13430 Mebutizide The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfa-n3.
DB00018 DB13532 Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfa-n3.
DB00018 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Interferon alfa-n3 is combined with Tedizolid phosphate.
DB00018 DB00091 Cyclosporine Interferon alfa-n3 may increase the immunosuppressive activities of Cyclosporine.
DB00018 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ropinirole.
DB00018 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-n3.
DB00018 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfa-n3.
DB00018 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Interferon alfa-n3.
DB00018 DB01601 Lopinavir The serum concentration of Interferon alfa-n3 can be increased when it is combined with Lopinavir.
DB00018 DB12530 Inebilizumab The risk or severity of infection can be increased when Interferon alfa-n3 is combined with Inebilizumab.
DB00019 DB00531 Cyclophosphamide The risk or severity of pulmonary toxicity can be increased when Pegfilgrastim is combined with Cyclophosphamide.
DB00019 DB01030 Topotecan The risk or severity of neutropenia can be increased when Pegfilgrastim is combined with Topotecan.
DB00019 DB00008 Peginterferon alfa-2a The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Peginterferon alfa-2a.
DB00019 DB00022 Peginterferon alfa-2b The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.
DB00019 DB00059 Pegaspargase The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegfilgrastim.
DB00019 DB00061 Pegademase The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.
DB00019 DB00082 Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegfilgrastim.
DB00019 DB01839 Propylene glycol The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB03394 Heptaethylene glycol The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB04895 Pegaptanib The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegfilgrastim.
DB00019 DB05202 Egaptivon pegol The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB05321 PEG-uricase The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.
DB00019 DB05860 Peginterferon alfacon-1 The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegfilgrastim.
DB00019 DB06022 GlycoPEG-GCSF The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegfilgrastim.
DB00019 DB06293 Pegnivacogin The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegfilgrastim.
DB00019 DB06325 Pegpleranib The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegfilgrastim.
DB00019 DB06611 Pegsunercept The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegfilgrastim.
DB00019 DB06811 Polidocanol The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB08894 Peginesatide The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegfilgrastim.
DB00019 DB08904 Certolizumab pegol The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB09107 Methoxy polyethylene glycol-epoetin beta The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegfilgrastim.
DB00019 DB09122 Peginterferon beta-1a The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegfilgrastim.
DB00019 DB09208 Pegloticase The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegfilgrastim.
DB00019 DB09287 Polyethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Pegfilgrastim.
DB00019 DB11077 Polyethylene glycol 400 The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Pegfilgrastim.
DB00019 DB11567 Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegfilgrastim.
DB00019 DB11661 Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegfilgrastim.
DB00019 DB11707 Olaptesed Pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB12258 Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB12578 Lexaptepid Pegol The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB12814 Cepeginterferon alfa-2B The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegfilgrastim.
DB00019 DB12839 Pegvaliase The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegfilgrastim.
DB00019 DB12842 Pegamotecan The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegfilgrastim.
DB00019 DB13200 Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegfilgrastim.
DB00019 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegfilgrastim.
DB00019 DB14712 Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegfilgrastim.
DB00019 DB00309 Vindesine The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vindesine.
DB00019 DB00361 Vinorelbine The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinorelbine.
DB00019 DB00541 Vincristine The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincristine.
DB00019 DB00570 Vinblastine The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinblastine.
DB00019 DB05168 Vintafolide The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vintafolide.
DB00019 DB11641 Vinflunine The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vinflunine.
DB00019 DB13374 Vincamine The risk or severity of peripheral neuropathy can be increased when Pegfilgrastim is combined with Vincamine.
DB00020 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin.
DB00020 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.
DB00020 DB00309 Vindesine The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vindesine.
DB00020 DB00361 Vinorelbine The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vinorelbine.
DB00020 DB00541 Vincristine The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vincristine.
DB00020 DB00570 Vinblastine The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vinblastine.
DB00020 DB05168 Vintafolide The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vintafolide.
DB00020 DB11641 Vinflunine The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vinflunine.
DB00020 DB13374 Vincamine The risk or severity of peripheral neuropathy can be increased when Sargramostim is combined with Vincamine.
DB00022 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Peginterferon alfa-2b.
DB00022 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Peginterferon alfa-2b.
DB00022 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Peginterferon alfa-2b.
DB00022 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Peginterferon alfa-2b.
DB00022 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Peginterferon alfa-2b.
DB00022 DB00026 Anakinra The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Anakinra.
DB00022 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon gamma-1b.
DB00022 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2a, Recombinant.
DB00022 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Adalimumab.
DB00022 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemtuzumab ozogamicin.
DB00022 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pegaspargase.
DB00022 DB00065 Infliximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Infliximab.
DB00022 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon beta-1b.
DB00022 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfacon-1.
DB00022 DB00073 Rituximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rituximab.
DB00022 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Basiliximab.
DB00022 DB00075 Muromonab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Muromonab.
DB00022 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibritumomab tiuxetan.
DB00022 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tositumomab.
DB00022 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alemtuzumab.
DB00022 DB00092 Alefacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Alefacept.
DB00022 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Efalizumab.
DB00022 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antithymocyte immunoglobulin (rabbit).
DB00022 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2b.
DB00022 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab.
DB00022 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bevacizumab.
DB00022 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Phenylalanine.
DB00022 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Flunisolide.
DB00022 DB00242 Cladribine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cladribine.
DB00022 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Amsacrine.
DB00022 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bleomycin.
DB00022 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Chlorambucil.
DB00022 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Raltitrexed.
DB00022 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitomycin.
DB00022 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bexarotene.
DB00022 DB00309 Vindesine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vindesine.
DB00022 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Floxuridine.
DB00022 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Indomethacin.
DB00022 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tioguanine.
DB00022 DB00361 Vinorelbine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vinorelbine.
DB00022 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexrazoxane.
DB00022 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Beclomethasone dipropionate.
DB00022 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Streptozocin.
DB00022 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trifluridine.
DB00022 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gemcitabine.
DB00022 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Betamethasone.
DB00022 DB00444 Teniposide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teniposide.
DB00022 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Epirubicin.
DB00022 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Chloramphenicol.
DB00022 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Lenalidomide.
DB00022 DB00488 Altretamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Altretamine.
DB00022 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cisplatin.
DB00022 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Oxaliplatin.
DB00022 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cyclophosphamide.
DB00022 DB00541 Vincristine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vincristine.
DB00022 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Propylthiouracil.
DB00022 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pentostatin.
DB00022 DB00563 Methotrexate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methotrexate.
DB00022 DB00570 Vinblastine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vinblastine.
DB00022 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluticasone propionate.
DB00022 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocinolone acetonide.
DB00022 DB00601 Linezolid The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Linezolid.
DB00022 DB00620 Triamcinolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Triamcinolone.
DB00022 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clofarabine.
DB00022 DB00635 Prednisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednisone.
DB00022 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fludrocortisone.
DB00022 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mycophenolate mofetil.
DB00022 DB00694 Daunorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin.
DB00022 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tretinoin.
DB00022 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Irinotecan.
DB00022 DB00763 Methimazole The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methimazole.
DB00022 DB00764 Mometasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mometasone.
DB00022 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sulfasalazine.
DB00022 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Temozolomide.
DB00022 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Penicillamine.
DB00022 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednisolone.
DB00022 DB00877 Sirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sirolimus.
DB00022 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mechlorethamine.
DB00022 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Azacitidine.
DB00022 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carboplatin.
DB00022 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methylprednisolone.
DB00022 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dactinomycin.
DB00022 DB00987 Cytarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cytarabine.
DB00022 DB00997 Doxorubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Doxorubicin.
DB00022 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydroxyurea.
DB00022 DB01008 Busulfan The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Busulfan.
DB00022 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mycophenolic acid.
DB00022 DB01030 Topotecan The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Topotecan.
DB00022 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mercaptopurine.
DB00022 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Thalidomide.
DB00022 DB01042 Melphalan The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Melphalan.
DB00022 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fludarabine.
DB00022 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Flucytosine.
DB00022 DB01108 Trilostane The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trilostane.
DB00022 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Procarbazine.
DB00022 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Arsenic trioxide.
DB00022 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idarubicin.
DB00022 DB01181 Ifosfamide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ifosfamide.
DB00022 DB01196 Estramustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Estramustine.
DB00022 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mitoxantrone.
DB00022 DB01206 Lomustine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Lomustine.
DB00022 DB01222 Budesonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Budesonide.
DB00022 DB01229 Paclitaxel The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Paclitaxel.
DB00022 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexamethasone.
DB00022 DB01248 Docetaxel The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Docetaxel.
DB00022 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Eculizumab.
DB00022 DB01262 Decitabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Decitabine.
DB00022 DB01268 Sunitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sunitinib.
DB00022 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Nelarabine.
DB00022 DB01281 Abatacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Abatacept.
DB00022 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Corticotropin.
DB00022 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cortisone acetate.
DB00022 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Paramethasone.
DB00022 DB01394 Colchicine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Colchicine.
DB00022 DB01410 Ciclesonide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ciclesonide.
DB00022 DB01423 Stepronin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Stepronin.
DB00022 DB01590 Everolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Everolimus.
DB00022 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydroxychloroquine.
DB00022 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Castanospermine.
DB00022 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vorinostat.
DB00022 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with 2-Methoxyethanol.
DB00022 DB03523 Brequinar The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brequinar.
DB00022 DB04572 Thiotepa The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Thiotepa.
DB00022 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldosterone.
DB00022 DB04845 Ixabepilone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ixabepilone.
DB00022 DB04868 Nilotinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Nilotinib.
DB00022 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Afelimomab.
DB00022 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa.
DB00022 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Glatiramer.
DB00022 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gallium nitrate.
DB00022 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Briakinumab.
DB00022 DB05472 omega interferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with omega interferon.
DB00022 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trastuzumab emtansine.
DB00022 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Canakinumab.
DB00022 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tocilizumab.
DB00022 DB06287 Temsirolimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Temsirolimus.
DB00022 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rilonacept.
DB00022 DB06603 Panobinostat The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Panobinostat.
DB00022 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mepolizumab.
DB00022 DB06616 Bosutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bosutinib.
DB00022 DB06662 Abetimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Abetimus.
DB00022 DB06674 Golimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Golimumab.
DB00022 DB06681 Belatacept The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belatacept.
DB00022 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cabazitaxel.
DB00022 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pralatrexate.
DB00022 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Wortmannin.
DB00022 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brentuximab vedotin.
DB00022 DB08871 Eribulin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Eribulin.
DB00022 DB08877 Ruxolitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ruxolitinib.
DB00022 DB08879 Belimumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belimumab.
DB00022 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Teriflunomide.
DB00022 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Carfilzomib.
DB00022 DB08901 Ponatinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ponatinib.
DB00022 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Certolizumab pegol.
DB00022 DB08906 Fluticasone furoate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluticasone furoate.
DB00022 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dimethyl fumarate.
DB00022 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Obinutuzumab.
DB00022 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluprednidene.
DB00022 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocortolone.
DB00022 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Secukinumab.
DB00022 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vedolizumab.
DB00022 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Siltuximab.
DB00022 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Blinatumomab.
DB00022 DB09053 Ibrutinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ibrutinib.
DB00022 DB09054 Idelalisib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idelalisib.
DB00022 DB09073 Palbociclib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Palbociclib.
DB00022 DB09074 Olaparib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Olaparib.
DB00022 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dinutuximab.
DB00022 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vilanterol.
DB00022 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tixocortol.
DB00022 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Peginterferon beta-1a.
DB00022 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antilymphocyte immunoglobulin (horse).
DB00022 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluprednisolone.
DB00022 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Meprednisone.
DB00022 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tepoxalin.
DB00022 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dexamethasone isonicotinate.
DB00022 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Melengestrol.
DB00022 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ixekizumab.
DB00022 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ravulizumab.
DB00022 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pirarubicin.
DB00022 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Voclosporin.
DB00022 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Peficitinib.
DB00022 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clobetasol.
DB00022 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sarilumab.
DB00022 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Brodalumab.
DB00022 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sirukumab.
DB00022 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Baricitinib.
DB00022 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Guselkumab.
DB00022 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Deflazacort.
DB00022 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ocrelizumab.
DB00022 DB12025 Triptolide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Triptolide.
DB00022 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ozanimod.
DB00022 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mizoribine.
DB00022 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Gusperimus.
DB00022 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cepeginterferon alfa-2B.
DB00022 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Trofosfamide.
DB00022 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Doxifluridine.
DB00022 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Deoxyspergualin.
DB00022 DB12996 Acteoside The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Acteoside.
DB00022 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cortivazol.
DB00022 DB13014 Hypericin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hypericin.
DB00022 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00022 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednylidene.
DB00022 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocortin.
DB00022 DB13241 Begelomab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Begelomab.
DB00022 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluperolone.
DB00022 DB13664 Formocortal The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Formocortal.
DB00022 DB13728 Halometasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Halometasone.
DB00022 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cloprednol.
DB00022 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluclorolone.
DB00022 DB13867 Fluticasone The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluticasone.
DB00022 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Tetrandrine.
DB00022 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Monomethyl fumarate.
DB00022 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mometasone furoate.
DB00022 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydrocortisone aceponate.
DB00022 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydrocortisone acetate.
DB00022 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hydrocortisone succinate.
DB00022 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Emapalumab.
DB00022 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Risankizumab.
DB00022 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Rozanolixizumab.
DB00022 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bleselumab.
DB00022 DB12371 Siponimod The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Siponimod.
DB00022 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Natalizumab.
DB00022 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Peginterferon alfa-2b.
DB00022 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Peginterferon alfa-2b.
DB00022 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.
DB00022 DB00363 Clozapine The risk or severity of neutropenia can be increased when Peginterferon alfa-2b is combined with Clozapine.
DB00022 DB00333 Methadone The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.
DB00022 DB00472 Fluoxetine The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.
DB00022 DB01265 Telbivudine The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.
DB00022 DB00675 Tamoxifen The serum concentration of Tamoxifen can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00972 Azelastine The serum concentration of Azelastine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00176 Fluvoxamine The serum concentration of Fluvoxamine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00184 Nicotine The serum concentration of Nicotine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00188 Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00195 Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00201 Caffeine The serum concentration of Caffeine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00261 Anagrelide The serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00262 Carmustine The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00277 Theophylline The serum concentration of Theophylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00280 Disopyramide The serum concentration of Disopyramide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00281 Lidocaine The serum concentration of Lidocaine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00286 Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00296 Ropivacaine The serum concentration of Ropivacaine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00316 Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00334 Olanzapine The serum concentration of Olanzapine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00356 Chlorzoxazone The serum concentration of Chlorzoxazone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00365 Grepafloxacin The serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00370 Mirtazapine The serum concentration of Mirtazapine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00379 Mexiletine The serum concentration of Mexiletine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00382 Tacrine The serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00384 Triamterene The serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00398 Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00420 Promazine The serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00425 Zolpidem The serum concentration of Zolpidem can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00442 Entecavir The serum concentration of Entecavir can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00458 Imipramine The serum concentration of Imipramine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00461 Nabumetone The serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00468 Quinine The serum concentration of Quinine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00476 Duloxetine The serum concentration of Duloxetine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00477 Chlorpromazine The serum concentration of Chlorpromazine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00499 Flutamide The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00518 Albendazole The serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00530 Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00532 Mephenytoin The serum concentration of Mephenytoin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00533 Rofecoxib The serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00540 Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00544 Fluorouracil The serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00564 Carbamazepine The serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00568 Cinnarizine The serum concentration of Cinnarizine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00571 Propranolol The serum concentration of Propranolol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00575 Clonidine The serum concentration of Clonidine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00586 Diclofenac The serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00619 Imatinib The serum concentration of Imatinib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00629 Guanabenz The serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00642 Pemetrexed The serum concentration of Pemetrexed can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00661 Verapamil The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00682 Warfarin The serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00697 Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00715 Paroxetine The serum concentration of Paroxetine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00730 Thiabendazole The serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00740 Riluzole The serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00744 Zileuton The serum concentration of Zileuton can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00758 Clopidogrel The serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00773 Etoposide The serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00783 Estradiol The serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00787 Acyclovir The serum concentration of Acyclovir can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00788 Naproxen The serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00806 Pentoxifylline The serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00831 Trifluoperazine The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00850 Perphenazine The serum concentration of Perphenazine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00851 Dacarbazine The serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00857 Terbinafine The serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00863 Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00898 Ethanol The serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00924 Cyclobenzaprine The serum concentration of Cyclobenzaprine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00934 Maprotiline The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00969 Alosetron The serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00978 Lomefloxacin The serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00980 Ramelteon The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00993 Azathioprine The serum concentration of Azathioprine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00998 Frovatriptan The serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01002 Levobupivacaine The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01012 Cinacalcet The serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01037 Selegiline The serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01056 Tocainide The serum concentration of Tocainide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01058 Praziquantel The serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01065 Melatonin The serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01087 Primaquine The serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01094 Hesperetin The serum concentration of Hesperetin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01100 Pimozide The serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01115 Nifedipine The serum concentration of Nifedipine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01136 Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01142 Doxepin The serum concentration of Doxepin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01151 Desipramine The serum concentration of Desipramine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01166 Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01182 Propafenone The serum concentration of Propafenone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01184 Domperidone The serum concentration of Domperidone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01191 Dexfenfluramine The serum concentration of Dexfenfluramine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01223 Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01242 Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01254 Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01303 Oxtriphylline The serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01367 Rasagiline The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01405 Temafloxacin The serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01412 Theobromine The serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01418 Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01424 Aminophenazone The serum concentration of Aminophenazone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01435 Antipyrine The serum concentration of Antipyrine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01482 Fenethylline The serum concentration of Fenethylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01558 Bromazepam The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01623 Thiothixene The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01628 Etoricoxib The serum concentration of Etoricoxib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01645 Genistein The serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01667 8-azaguanine The serum concentration of 8-azaguanine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB02134 Xanthine The serum concentration of Xanthine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB02489 9-Methylguanine The serum concentration of 9-Methylguanine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB02568 Peldesine The serum concentration of Peldesine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB02709 Resveratrol The serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB03783 Phenacetin The serum concentration of Phenacetin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04076 Hypoxanthine The serum concentration of Hypoxanthine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04356 9-Deazaguanine The serum concentration of 9-Deazaguanine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04574 Estrone sulfate The serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04841 Flunarizine The serum concentration of Flunarizine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04871 Lorcaserin The serum concentration of Lorcaserin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04948 Lofexidine The serum concentration of Lofexidine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04951 Pirfenidone The serum concentration of Pirfenidone can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB05676 Apremilast The serum concentration of Apremilast can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06148 Mianserin The serum concentration of Mianserin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06210 Eltrombopag The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06216 Asenapine The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06235 Vadimezan The serum concentration of Vadimezan can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06292 Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06479 Propentofylline The serum concentration of Propentofylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06589 Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06594 Agomelatine The serum concentration of Agomelatine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06626 Axitinib The serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06769 Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06770 Benzyl alcohol The serum concentration of Benzyl alcohol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB06774 Capsaicin The serum concentration of Capsaicin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB08496 (R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB08883 Perampanel The serum concentration of Perampanel can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB08910 Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09071 Tasimelteon The serum concentration of Tasimelteon can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09118 Stiripentol The serum concentration of Stiripentol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09225 Zotepine The serum concentration of Zotepine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09256 Tegafur The serum concentration of Tegafur can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09273 Doxofylline The serum concentration of Doxofylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09288 Propacetamol The serum concentration of Propacetamol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB09290 Ramosetron The serum concentration of Ramosetron can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB11919 6-O-benzylguanine The serum concentration of 6-O-benzylguanine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB11967 Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12026 Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12245 Triclabendazole The serum concentration of Triclabendazole can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12332 Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12406 Lisofylline The serum concentration of Lisofylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12531 Lobucavir The serum concentration of Lobucavir can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12926 Cafedrine The serum concentration of Cafedrine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12927 Theodrenaline The serum concentration of Theodrenaline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12945 Dihydralazine The serum concentration of Dihydralazine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13203 Bamifylline The serum concentration of Bamifylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13449 Proxyphylline The serum concentration of Proxyphylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13573 Acefylline The serum concentration of Acefylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13592 Etamiphylline The serum concentration of Etamiphylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13634 Pentifylline The serum concentration of Pentifylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13812 Bufylline The serum concentration of Bufylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13874 Enasidenib The serum concentration of Enasidenib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13952 Estradiol acetate The serum concentration of Estradiol acetate can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13953 Estradiol benzoate The serum concentration of Estradiol benzoate can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13954 Estradiol cypionate The serum concentration of Estradiol cypionate can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13955 Estradiol dienanthate The serum concentration of Estradiol dienanthate can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB13956 Estradiol valerate The serum concentration of Estradiol valerate can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB14018 Bromotheophylline The serum concentration of Bromotheophylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB14132 8-chlorotheophylline The serum concentration of 8-chlorotheophylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01195 Flecainide The serum concentration of Flecainide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB01233 Metoclopramide The serum concentration of Metoclopramide can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB11757 Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00625 Efavirenz The serum concentration of Efavirenz can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB04889 Bicifadine The serum concentration of Bicifadine can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB05708 GTS-21 The serum concentration of GTS-21 can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00977 Ethinylestradiol The serum concentration of Ethinylestradiol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB11689 Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00289 Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Peginterferon alfa-2b.
DB00022 DB04817 Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2b.
DB00022 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Leflunomide.
DB00022 DB08895 Tofacitinib Peginterferon alfa-2b may increase the immunosuppressive activities of Tofacitinib.
DB00022 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Peginterferon alfa-2b.
DB00022 DB00019 Pegfilgrastim The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegfilgrastim.
DB00022 DB00061 Pegademase The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB00082 Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB01839 Propylene glycol The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB03394 Heptaethylene glycol The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB04895 Pegaptanib The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05202 Egaptivon pegol The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05321 PEG-uricase The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05860 Peginterferon alfacon-1 The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06022 GlycoPEG-GCSF The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06293 Pegnivacogin The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06325 Pegpleranib The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06611 Pegsunercept The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06811 Polidocanol The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB08894 Peginesatide The therapeutic efficacy of Peginesatide can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB09107 Methoxy polyethylene glycol-epoetin beta The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB09208 Pegloticase The therapeutic efficacy of Pegloticase can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB09287 Polyethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11077 Polyethylene glycol 400 The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11567 Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11661 Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11707 Olaptesed Pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB12258 Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB12578 Lexaptepid Pegol The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB12839 Pegvaliase The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB12842 Pegamotecan The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14712 Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB08868 Fingolimod Peginterferon alfa-2b may increase the immunosuppressive activities of Fingolimod.
DB00022 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Peginterferon alfa-2b.
DB00022 DB00651 Dyphylline The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01978 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB02245 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB02377 Guanine The metabolism of Guanine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06575 Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB07954 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08844 Uric acid The metabolism of Uric acid can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB14029 Furafylline The metabolism of Furafylline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB15122 PCS-499 The metabolism of PCS-499 can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Peginterferon alfa-2b.
DB00022 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Peginterferon alfa-2b.
DB00022 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Peginterferon alfa-2b.
DB00022 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Peginterferon alfa-2b.
DB00022 DB00945 Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Peginterferon alfa-2b.
DB00022 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Peginterferon alfa-2b.
DB00022 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Peginterferon alfa-2b.
DB00022 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2b.
DB00022 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Peginterferon alfa-2b.
DB00022 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Peginterferon alfa-2b.
DB00022 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Peginterferon alfa-2b.
DB00022 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Peginterferon alfa-2b.
DB00022 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Peginterferon alfa-2b.
DB00022 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Peginterferon alfa-2b.
DB00022 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Peginterferon alfa-2b.
DB00022 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Peginterferon alfa-2b.
DB00022 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Peginterferon alfa-2b.
DB00022 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2b.
DB00022 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Peginterferon alfa-2b.
DB00022 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Peginterferon alfa-2b.
DB00022 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Peginterferon alfa-2b.
DB00022 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Peginterferon alfa-2b.
DB00022 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Peginterferon alfa-2b.
DB00022 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon alfa-2b.
DB00022 DB09030 Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Peginterferon alfa-2b.
DB00022 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Peginterferon alfa-2b.
DB00022 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Peginterferon alfa-2b.
DB00022 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Peginterferon alfa-2b.
DB00022 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Peginterferon alfa-2b.
DB00022 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Peginterferon alfa-2b.
DB00022 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Peginterferon alfa-2b.
DB00022 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Peginterferon alfa-2b.
DB00022 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Peginterferon alfa-2b.
DB00022 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Peginterferon alfa-2b.
DB00022 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Peginterferon alfa-2b.
DB00022 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Peginterferon alfa-2b.
DB00022 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Peginterferon alfa-2b.
DB00022 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Peginterferon alfa-2b.
DB00022 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Peginterferon alfa-2b.
DB00022 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Peginterferon alfa-2b.
DB00022 DB13200 Lipegfilgrastim Peginterferon alfa-2b may increase the myelosuppressive activities of Lipegfilgrastim.
DB00022 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Peginterferon alfa-2b is combined with Varicella Zoster Vaccine (Live/attenuated).
DB00022 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Peginterferon alfa-2b.
DB00022 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Peginterferon alfa-2b.
DB00022 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Peginterferon alfa-2b.
DB00022 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Peginterferon alfa-2b.
DB00022 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Peginterferon alfa-2b.
DB00022 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Peginterferon alfa-2b.
DB00022 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Peginterferon alfa-2b.
DB00022 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Peginterferon alfa-2b.
DB00022 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Peginterferon alfa-2b.
DB00022 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Peginterferon alfa-2b.
DB00022 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Peginterferon alfa-2b.
DB00022 DB01238 Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB14185 Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB00757 Dolasetron The metabolism of Dolasetron can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00182 Amphetamine The metabolism of Amphetamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00185 Cevimeline The metabolism of Cevimeline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00187 Esmolol The metabolism of Esmolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00215 Citalopram The metabolism of Citalopram can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00243 Ranolazine The metabolism of Ranolazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00245 Benzatropine The metabolism of Benzatropine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00264 Metoprolol The metabolism of Metoprolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00297 Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00317 Gefitinib The metabolism of Gefitinib can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00318 Codeine The metabolism of Codeine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00335 Atenolol The metabolism of Atenolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00342 Terfenadine The metabolism of Terfenadine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00377 Palonosetron The metabolism of Palonosetron can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00409 Remoxipride The metabolism of Remoxipride can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00433 Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00490 Buspirone The metabolism of Buspirone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00496 Darifenacin The metabolism of Darifenacin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00497 Oxycodone The metabolism of Oxycodone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00503 Ritonavir The metabolism of Ritonavir can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00589 Lisuride The metabolism of Lisuride can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00592 Piperazine The metabolism of Piperazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00608 Chloroquine The metabolism of Chloroquine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00637 Astemizole The metabolism of Astemizole can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00641 Simvastatin The metabolism of Simvastatin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00647 Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00656 Trazodone The metabolism of Trazodone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00674 Galantamine The metabolism of Galantamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00679 Thioridazine The metabolism of Thioridazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00699 Nicergoline The metabolism of Nicergoline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00705 Delavirdine The metabolism of Delavirdine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00706 Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00734 Risperidone The metabolism of Risperidone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00737 Meclizine The metabolism of Meclizine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00738 Pentamidine The metabolism of Pentamidine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00805 Minaprine The metabolism of Minaprine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00836 Loperamide The metabolism of Loperamide can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00866 Alprenolol The metabolism of Alprenolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00914 Phenformin The metabolism of Phenformin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00918 Almotriptan The metabolism of Almotriptan can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00932 Tipranavir The metabolism of Tipranavir can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00933 Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00956 Hydrocodone The metabolism of Hydrocodone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00960 Pindolol The metabolism of Pindolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01069 Promethazine The metabolism of Promethazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01071 Mequitazine The metabolism of Mequitazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01074 Perhexiline The metabolism of Perhexiline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01079 Tegaserod The metabolism of Tegaserod can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01114 Chlorpheniramine The metabolism of Chlorpheniramine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01149 Nefazodone The metabolism of Nefazodone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01175 Escitalopram The metabolism of Escitalopram can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01192 Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01193 Acebutolol The metabolism of Acebutolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01203 Nadolol The metabolism of Nadolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01224 Quetiapine The metabolism of Quetiapine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01228 Encainide The metabolism of Encainide can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01244 Bepridil The metabolism of Bepridil can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01255 Lisdexamfetamine The metabolism of Lisdexamfetamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01267 Paliperidone The metabolism of Paliperidone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01295 Bevantolol The metabolism of Bevantolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01297 Practolol The metabolism of Practolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01359 Penbutolol The metabolism of Penbutolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01392 Yohimbine The metabolism of Yohimbine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01403 Methotrimeprazine The metabolism of Methotrimeprazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01409 Tiotropium The metabolism of Tiotropium can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01429 Aprindine The metabolism of Aprindine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01454 Midomafetamine The metabolism of Midomafetamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01466 Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01472 4-Methoxyamphetamine The metabolism of 4-Methoxyamphetamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01551 Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01576 Dextroamphetamine The metabolism of Dextroamphetamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01577 Metamfetamine The metabolism of Metamfetamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01580 Oxprenolol The metabolism of Oxprenolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01591 Solifenacin The metabolism of Solifenacin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01621 Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01624 Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB02703 Fusidic acid The metabolism of Fusidic acid can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04829 Lysergic acid diethylamide The metabolism of Lysergic acid diethylamide can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04840 Debrisoquine The metabolism of Debrisoquine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04844 Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04846 Celiprolol The metabolism of Celiprolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04861 Nebivolol The metabolism of Nebivolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04884 Dapoxetine The metabolism of Dapoxetine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04920 Clevidipine The metabolism of Clevidipine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB04946 Iloperidone The metabolism of Iloperidone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB05271 Rotigotine The metabolism of Rotigotine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06016 Cariprazine The metabolism of Cariprazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06144 Sertindole The metabolism of Sertindole can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06203 Alogliptin The metabolism of Alogliptin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06217 Vernakalant The metabolism of Vernakalant can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06506 Repinotan The metabolism of Repinotan can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06608 Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06678 Esmirtazapine The metabolism of Esmirtazapine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06684 Vilazodone The metabolism of Vilazodone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06702 Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06726 Bufuralol The metabolism of Bufuralol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06727 Sparteine The metabolism of Sparteine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB06735 Enclomiphene The metabolism of Enclomiphene can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08807 Bopindolol The metabolism of Bopindolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08808 Bupranolol The metabolism of Bupranolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08893 Mirabegron The metabolism of Mirabegron can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08918 Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08922 Perospirone The metabolism of Perospirone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB08952 Indenolol The metabolism of Indenolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09013 Befunolol The metabolism of Befunolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09039 Eliglustat The metabolism of Eliglustat can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09076 Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09128 Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09183 Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09195 Lorpiprazole The metabolism of Lorpiprazole can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09204 Arotinolol The metabolism of Arotinolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09351 Levobetaxolol The metabolism of Levobetaxolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09555 Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11130 Opium The metabolism of Opium can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11770 Talinolol The metabolism of Talinolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11785 Anisodamine The metabolism of Anisodamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11855 Revefenacin The metabolism of Revefenacin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11915 Valbenazine The metabolism of Valbenazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11979 Elagolix The metabolism of Elagolix can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB12070 Letermovir The metabolism of Letermovir can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB12161 Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB12212 Landiolol The metabolism of Landiolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB12752 Bucindolol The metabolism of Bucindolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13293 Ipecac The metabolism of Ipecac can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13443 Esatenolol The metabolism of Esatenolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13508 Cloranolol The metabolism of Cloranolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13530 Mepindolol The metabolism of Mepindolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13679 Dexchlorpheniramine The metabolism of Dexchlorpheniramine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13757 Epanolol The metabolism of Epanolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB13775 Tertatolol The metabolism of Tertatolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09173 Butyrfentanyl The metabolism of Butyrfentanyl can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00598 Labetalol The metabolism of Labetalol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB14010 5-methoxy-N,N-dimethyltryptamine The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11642 Pitolisant The metabolism of Pitolisant can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00344 Protriptyline The metabolism of Protriptyline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00454 Meperidine The metabolism of Meperidine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00543 Amoxapine The metabolism of Amoxapine can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB12930 Opipramol The metabolism of Opipramol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB05109 Trabectedin The metabolism of Trabectedin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11963 Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00489 Sotalol The metabolism of Sotalol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01035 Procainamide The metabolism of Procainamide can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB09167 Dosulepin The metabolism of Dosulepin can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB11718 Encorafenib The metabolism of Encorafenib can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB01118 Amiodarone The metabolism of Amiodarone can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.
DB00022 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Peginterferon alfa-2b.
DB00022 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Peginterferon alfa-2b.
DB00022 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Peginterferon alfa-2b.
DB00022 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Peginterferon alfa-2b.
DB00022 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Peginterferon alfa-2b.
DB00022 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Peginterferon alfa-2b.
DB00022 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Peginterferon alfa-2b.
DB00022 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Peginterferon alfa-2b.
DB00022 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Peginterferon alfa-2b.
DB00022 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Peginterferon alfa-2b.
DB00022 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Peginterferon alfa-2b.
DB00022 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Peginterferon alfa-2b.
DB00022 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Peginterferon alfa-2b.
DB00022 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Peginterferon alfa-2b.
DB00022 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Peginterferon alfa-2b.
DB00022 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Peginterferon alfa-2b.
DB00022 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Peginterferon alfa-2b.
DB00022 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Peginterferon alfa-2b.
DB00022 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Peginterferon alfa-2b.
DB00022 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Peginterferon alfa-2b.
DB00022 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Peginterferon alfa-2b.
DB00022 DB06228 Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Peginterferon alfa-2b.
DB00022 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Peginterferon alfa-2b.
DB00022 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Peginterferon alfa-2b.
DB00022 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Peginterferon alfa-2b.
DB00022 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Peginterferon alfa-2b.
DB00022 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Peginterferon alfa-2b.
DB00022 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Peginterferon alfa-2b.
DB00022 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Peginterferon alfa-2b.
DB00022 DB06695 Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Peginterferon alfa-2b.
DB00022 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Peginterferon alfa-2b.
DB00022 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Peginterferon alfa-2b.
DB00022 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Peginterferon alfa-2b.
DB00022 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Peginterferon alfa-2b.
DB00022 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Peginterferon alfa-2b.
DB00022 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Peginterferon alfa-2b.
DB00022 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Peginterferon alfa-2b.
DB00022 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Peginterferon alfa-2b.
DB00022 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Peginterferon alfa-2b.
DB00022 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Peginterferon alfa-2b.
DB00022 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Peginterferon alfa-2b.
DB00022 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Peginterferon alfa-2b.
DB00022 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Peginterferon alfa-2b.
DB00022 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Peginterferon alfa-2b.
DB00022 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Peginterferon alfa-2b.
DB00022 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Peginterferon alfa-2b.
DB00022 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Peginterferon alfa-2b.
DB00022 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Peginterferon alfa-2b.
DB00022 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Peginterferon alfa-2b.
DB00022 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Peginterferon alfa-2b.
DB00022 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Peginterferon alfa-2b.
DB00022 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Peginterferon alfa-2b.
DB00022 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Peginterferon alfa-2b.
DB00022 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Peginterferon alfa-2b.
DB00022 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Peginterferon alfa-2b.
DB00022 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Peginterferon alfa-2b.
DB00022 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Peginterferon alfa-2b.
DB00022 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Peginterferon alfa-2b.
DB00022 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Peginterferon alfa-2b.
DB00022 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Peginterferon alfa-2b.
DB00022 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Peginterferon alfa-2b.
DB00022 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Peginterferon alfa-2b.
DB00022 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Peginterferon alfa-2b.
DB00022 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Peginterferon alfa-2b.
DB00022 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Peginterferon alfa-2b.
DB00022 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Peginterferon alfa-2b.
DB00022 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Peginterferon alfa-2b.
DB00022 DB00177 Valsartan The metabolism of Valsartan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00197 Troglitazone The metabolism of Troglitazone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00203 Sildenafil The metabolism of Sildenafil can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00214 Torasemide The metabolism of Torasemide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00216 Eletriptan The metabolism of Eletriptan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00222 Glimepiride The metabolism of Glimepiride can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00238 Nevirapine The metabolism of Nevirapine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00250 Dapsone The metabolism of Dapsone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00285 Venlafaxine The metabolism of Venlafaxine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00304 Desogestrel The metabolism of Desogestrel can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00327 Hydromorphone The metabolism of Hydromorphone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00338 Omeprazole The metabolism of Omeprazole can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00343 Diltiazem The metabolism of Diltiazem can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00347 Trimethadione The metabolism of Trimethadione can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00374 Treprostinil The metabolism of Treprostinil can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00396 Progesterone The metabolism of Progesterone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00404 Alprazolam The metabolism of Alprazolam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00412 Rosiglitazone The metabolism of Rosiglitazone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00414 Acetohexamide The metabolism of Acetohexamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00440 Trimethoprim The metabolism of Trimethoprim can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00448 Lansoprazole The metabolism of Lansoprazole can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00469 Tenoxicam The metabolism of Tenoxicam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00470 Dronabinol The metabolism of Dronabinol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00471 Montelukast The metabolism of Montelukast can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00482 Celecoxib The metabolism of Celecoxib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00514 Dextromethorphan The metabolism of Dextromethorphan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00549 Zafirlukast The metabolism of Zafirlukast can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00554 Piroxicam The metabolism of Piroxicam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00559 Bosentan The metabolism of Bosentan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00580 Valdecoxib The metabolism of Valdecoxib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00582 Voriconazole The metabolism of Voriconazole can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00590 Doxazosin The metabolism of Doxazosin can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00617 Paramethadione The metabolism of Paramethadione can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00624 Testosterone The metabolism of Testosterone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00672 Chlorpropamide The metabolism of Chlorpropamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00678 Losartan The metabolism of Losartan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00701 Amprenavir The metabolism of Amprenavir can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00712 Flurbiprofen The metabolism of Flurbiprofen can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00731 Nateglinide The metabolism of Nateglinide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00749 Etodolac The metabolism of Etodolac can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00784 Mefenamic acid The metabolism of Mefenamic acid can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00794 Primidone The metabolism of Primidone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00796 Candesartan cilexetil The metabolism of Candesartan cilexetil can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00812 Phenylbutazone The metabolism of Phenylbutazone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00814 Meloxicam The metabolism of Meloxicam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00818 Propofol The metabolism of Propofol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00829 Diazepam The metabolism of Diazepam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00839 Tolazamide The metabolism of Tolazamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00843 Donepezil The metabolism of Donepezil can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00904 Ondansetron The metabolism of Ondansetron can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00921 Buprenorphine The metabolism of Buprenorphine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00936 Salicylic acid The metabolism of Salicylic acid can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00983 Formoterol The metabolism of Formoterol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01016 Glyburide The metabolism of Glyburide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01028 Methoxyflurane The metabolism of Methoxyflurane can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01029 Irbesartan The metabolism of Irbesartan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01036 Tolterodine The metabolism of Tolterodine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01050 Ibuprofen The metabolism of Ibuprofen can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01067 Glipizide The metabolism of Glipizide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01072 Atazanavir The metabolism of Atazanavir can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01075 Diphenhydramine The metabolism of Diphenhydramine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01095 Fluvastatin The metabolism of Fluvastatin can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01098 Rosuvastatin The metabolism of Rosuvastatin can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01104 Sertraline The metabolism of Sertraline can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01120 Gliclazide The metabolism of Gliclazide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01124 Tolbutamide The metabolism of Tolbutamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01131 Proguanil The metabolism of Proguanil can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01154 Thiamylal The metabolism of Thiamylal can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01156 Bupropion The metabolism of Bupropion can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01159 Halothane The metabolism of Halothane can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01171 Moclobemide The metabolism of Moclobemide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01174 Phenobarbital The metabolism of Phenobarbital can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01198 Zopiclone The metabolism of Zopiclone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01221 Ketamine The metabolism of Ketamine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01251 Gliquidone The metabolism of Gliquidone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01274 Arformoterol The metabolism of Arformoterol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01283 Lumiracoxib The metabolism of Lumiracoxib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01289 Glisoxepide The metabolism of Glisoxepide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01355 Hexobarbital The metabolism of Hexobarbital can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01357 Mestranol The metabolism of Mestranol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01544 Flunitrazepam The metabolism of Flunitrazepam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01589 Quazepam The metabolism of Quazepam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB03756 Doconexent The metabolism of Doconexent can be increased when combined with Peginterferon alfa-2b.
DB00022 DB04557 Arachidonic Acid The metabolism of Arachidonic Acid can be increased when combined with Peginterferon alfa-2b.
DB00022 DB04725 Licofelone The metabolism of Licofelone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB04938 Ospemifene The metabolism of Ospemifene can be increased when combined with Peginterferon alfa-2b.
DB00022 DB05541 Brivaracetam The metabolism of Brivaracetam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06204 Tapentadol The metabolism of Tapentadol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06218 Lacosamide The metabolism of Lacosamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06268 Sitaxentan The metabolism of Sitaxentan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06370 Indisulam The metabolism of Indisulam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06414 Etravirine The metabolism of Etravirine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06652 Vicriviroc The metabolism of Vicriviroc can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06697 Artemether The metabolism of Artemether can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06725 Lornoxicam The metabolism of Lornoxicam can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06737 Zaltoprofen The metabolism of Zaltoprofen can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06738 Ketobemidone The metabolism of Ketobemidone can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06739 Seratrodast The metabolism of Seratrodast can be increased when combined with Peginterferon alfa-2b.
DB00022 DB06803 Niclosamide The metabolism of Niclosamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB08439 Parecoxib The metabolism of Parecoxib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB08828 Vismodegib The metabolism of Vismodegib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB08860 Pitavastatin The metabolism of Pitavastatin can be increased when combined with Peginterferon alfa-2b.
DB00022 DB08875 Cabozantinib The metabolism of Cabozantinib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB08899 Enzalutamide The metabolism of Enzalutamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB08962 Glibornuride The metabolism of Glibornuride can be increased when combined with Peginterferon alfa-2b.
DB00022 DB09048 Netupitant The metabolism of Netupitant can be increased when combined with Peginterferon alfa-2b.
DB00022 DB09061 Cannabidiol The metabolism of Cannabidiol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB09068 Vortioxetine The metabolism of Vortioxetine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB09080 Olodaterol The metabolism of Olodaterol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB11560 Lesinurad The metabolism of Lesinurad can be increased when combined with Peginterferon alfa-2b.
DB00022 DB11586 Asunaprevir The metabolism of Asunaprevir can be increased when combined with Peginterferon alfa-2b.
DB00022 DB11614 Rupatadine The metabolism of Rupatadine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB11823 Esketamine The metabolism of Esketamine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB12474 Lynestrenol The metabolism of Lynestrenol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13406 Carbutamide The metabolism of Carbutamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13675 Metahexamide The metabolism of Metahexamide can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13919 Candesartan The metabolism of Candesartan can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13941 Piperaquine The metabolism of Piperaquine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13943 Testosterone cypionate The metabolism of Testosterone cypionate can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13944 Testosterone enanthate The metabolism of Testosterone enanthate can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13946 Testosterone undecanoate The metabolism of Testosterone undecanoate can be increased when combined with Peginterferon alfa-2b.
DB00022 DB14009 Medical Cannabis The metabolism of Medical Cannabis can be increased when combined with Peginterferon alfa-2b.
DB00022 DB14011 Nabiximols The metabolism of Nabiximols can be increased when combined with Peginterferon alfa-2b.
DB00022 DB09213 Dexibuprofen The metabolism of Dexibuprofen can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00465 Ketorolac The metabolism of Ketorolac can be increased when combined with Peginterferon alfa-2b.
DB00022 DB14975 Voxelotor The metabolism of Voxelotor can be increased when combined with Peginterferon alfa-2b.
DB00022 DB15233 Avapritinib The metabolism of Avapritinib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00726 Trimipramine The metabolism of Trimipramine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01101 Capecitabine The metabolism of Capecitabine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB05015 Belinostat The metabolism of Belinostat can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00252 Phenytoin The metabolism of Phenytoin can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00266 Dicoumarol The metabolism of Dicoumarol can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00313 Valproic acid The metabolism of Valproic acid can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00908 Quinidine The metabolism of Quinidine can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00946 Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Peginterferon alfa-2b.
DB00022 DB01320 Fosphenytoin The metabolism of Fosphenytoin can be increased when combined with Peginterferon alfa-2b.
DB00022 DB13136 Fluindione The metabolism of Fluindione can be increased when combined with Peginterferon alfa-2b.
DB00022 DB12147 Erdafitinib The metabolism of Erdafitinib can be increased when combined with Peginterferon alfa-2b.
DB00022 DB00232 Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Peginterferon alfa-2b.
DB00022 DB00436 Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Peginterferon alfa-2b.
DB00022 DB00562 Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Peginterferon alfa-2b.
DB00022 DB00606 Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Peginterferon alfa-2b.
DB00022 DB00774 Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Peginterferon alfa-2b.
DB00022 DB00880 Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Peginterferon alfa-2b.
DB00022 DB00999 Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Peginterferon alfa-2b.
DB00022 DB01021 Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Peginterferon alfa-2b.
DB00022 DB01324 Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Peginterferon alfa-2b.
DB00022 DB13430 Mebutizide The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Peginterferon alfa-2b.
DB00022 DB13532 Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Peginterferon alfa-2b.
DB00022 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Peginterferon alfa-2b is combined with Tedizolid phosphate.
DB00022 DB00091 Cyclosporine Peginterferon alfa-2b may increase the immunosuppressive activities of Cyclosporine.
DB00022 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ropinirole.
DB00022 DB00321 Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Peginterferon alfa-2b.
DB00022 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Peginterferon alfa-2b.
DB00022 DB00373 Timolol The metabolism of Timolol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB00193 Tramadol The metabolism of Tramadol can be decreased when combined with Peginterferon alfa-2b.
DB00022 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Peginterferon alfa-2b.
DB00022 DB01601 Lopinavir The serum concentration of Peginterferon alfa-2b can be increased when it is combined with Lopinavir.
DB00022 DB00502 Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b.
DB00022 DB12530 Inebilizumab The risk or severity of infection can be increased when Peginterferon alfa-2b is combined with Inebilizumab.
DB00023 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Asparaginase Escherichia coli.
DB00023 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Asparaginase Escherichia coli.
DB00023 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Asparaginase Escherichia coli.
DB00023 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asparaginase Escherichia coli.
DB00023 DB01234 Dexamethasone The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Escherichia coli.
DB00023 DB00563 Methotrexate The therapeutic efficacy of Methotrexate can be decreased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00619 Imatinib The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Imatinib.
DB00023 DB00252 Phenytoin The therapeutic efficacy of Phenytoin can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00279 Liothyronine The therapeutic efficacy of Liothyronine can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00451 Levothyroxine The therapeutic efficacy of Levothyroxine can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00532 Mephenytoin The therapeutic efficacy of Mephenytoin can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00564 Carbamazepine The therapeutic efficacy of Carbamazepine can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00695 Furosemide The therapeutic efficacy of Furosemide can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00698 Nitrofurantoin The therapeutic efficacy of Nitrofurantoin can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00754 Ethotoin The therapeutic efficacy of Ethotoin can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB00939 Meclofenamic acid The therapeutic efficacy of Meclofenamic acid can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB01109 Heparin The therapeutic efficacy of Heparin can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB01219 Dantrolene The therapeutic efficacy of Dantrolene can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB01320 Fosphenytoin The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB01583 Liotrix The therapeutic efficacy of Liotrix can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB08899 Enzalutamide The therapeutic efficacy of Enzalutamide can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB08984 Etofenamate The therapeutic efficacy of Etofenamate can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB12425 Liothyronine I-131 The therapeutic efficacy of Liothyronine I-131 can be increased when used in combination with Asparaginase Escherichia coli.
DB00023 DB13396 Neocitrullamon The therapeutic efficacy of Neocitrullamon can be increased when used in combination with Asparaginase Escherichia coli.
DB00024 DB01344 Tolevamer Tolevamer can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00024 DB00255 Diethylstilbestrol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Diethylstilbestrol.
DB00024 DB00269 Chlorotrianisene The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Chlorotrianisene.
DB00024 DB00286 Conjugated estrogens The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Conjugated estrogens.
DB00024 DB00783 Estradiol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estradiol.
DB00024 DB00977 Ethinylestradiol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ethinylestradiol.
DB00024 DB01357 Mestranol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Mestranol.
DB00024 DB04573 Estriol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estriol.
DB00024 DB04574 Estrone sulfate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estrone sulfate.
DB00024 DB04575 Quinestrol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Quinestrol.
DB00024 DB07931 Hexestrol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Hexestrol.
DB00024 DB09070 Tibolone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tibolone.
DB00024 DB09317 Synthetic Conjugated Estrogens, A The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Synthetic Conjugated Estrogens, A.
DB00024 DB09318 Synthetic Conjugated Estrogens, B The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Synthetic Conjugated Estrogens, B.
DB00024 DB09369 Polyestradiol phosphate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Polyestradiol phosphate.
DB00024 DB09381 Esterified estrogens The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Esterified estrogens.
DB00024 DB11478 Zeranol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Zeranol.
DB00024 DB11674 Equol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Equol.
DB00024 DB12487 Promestriene The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Promestriene.
DB00024 DB13143 Methallenestril The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Methallenestril.
DB00024 DB13386 Epimestrol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Epimestrol.
DB00024 DB13418 Moxestrol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Moxestrol.
DB00024 DB13952 Estradiol acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estradiol acetate.
DB00024 DB13953 Estradiol benzoate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estradiol benzoate.
DB00024 DB13954 Estradiol cypionate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estradiol cypionate.
DB00024 DB13956 Estradiol valerate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Estradiol valerate.
DB00024 DB15334 Biochanin A The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Biochanin A.
DB00024 DB15335 Formononetin The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Formononetin.
DB00024 DB00176 Fluvoxamine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluvoxamine.
DB00024 DB00215 Citalopram The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Citalopram.
DB00024 DB00472 Fluoxetine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluoxetine.
DB00024 DB00476 Duloxetine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Duloxetine.
DB00024 DB00656 Trazodone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Trazodone.
DB00024 DB00715 Paroxetine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Paroxetine.
DB00024 DB01104 Sertraline The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sertraline.
DB00024 DB01105 Sibutramine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sibutramine.
DB00024 DB01149 Nefazodone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Nefazodone.
DB00024 DB01175 Escitalopram The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Escitalopram.
DB00024 DB04832 Zimelidine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Zimelidine.
DB00024 DB04884 Dapoxetine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dapoxetine.
DB00024 DB04896 Milnacipran The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Milnacipran.
DB00024 DB06700 Desvenlafaxine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Desvenlafaxine.
DB00024 DB06731 Seproxetine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Seproxetine.
DB00024 DB08918 Levomilnacipran The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Levomilnacipran.
DB00024 DB08953 Indalpine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Indalpine.
DB00024 DB12693 Ritanserin The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ritanserin.
DB00024 DB13233 Alaproclate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Alaproclate.
DB00024 DB00930 Colesevelam The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Colesevelam.
DB00024 DB00258 Calcium acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium acetate.
DB00024 DB00326 Calcium glucoheptonate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium glucoheptonate.
DB00024 DB01164 Calcium chloride The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium chloride.
DB00024 DB01373 Calcium The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium.
DB00024 DB06724 Calcium carbonate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium carbonate.
DB00024 DB11093 Calcium citrate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium citrate.
DB00024 DB11126 Calcium gluconate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium gluconate.
DB00024 DB11348 Calcium Phosphate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium Phosphate.
DB00024 DB13142 Calcium glubionate anhydrous The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium glubionate anhydrous.
DB00024 DB13231 Calcium lactate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium lactate.
DB00024 DB13365 Calcium lactate gluconate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium lactate gluconate.
DB00024 DB13590 Calcium pangamate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium pangamate.
DB00024 DB13800 Calcium levulinate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium levulinate.
DB00024 DB14577 Calcium cation The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium cation.
DB00024 DB14684 Calcium polycarbophil The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Calcium polycarbophil.
DB00024 DB06792 Lanthanum carbonate Lanthanum carbonate can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00024 DB09210 Piracetam The risk or severity of confusion, irritability, and sleep disorders can be increased when Thyrotropin alfa is combined with Piracetam.
DB00024 DB00331 Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Thyrotropin alfa.
DB00024 DB00067 Vasopressin Thyrotropin alfa may increase the vasoconstricting activities of Vasopressin.
DB00024 DB00093 Felypressin Thyrotropin alfa may increase the vasoconstricting activities of Felypressin.
DB00024 DB00247 Methysergide Thyrotropin alfa may increase the vasoconstricting activities of Methysergide.
DB00024 DB00320 Dihydroergotamine Thyrotropin alfa may increase the vasoconstricting activities of Dihydroergotamine.
DB00024 DB00669 Sumatriptan Thyrotropin alfa may increase the vasoconstricting activities of Sumatriptan.
DB00024 DB00696 Ergotamine Thyrotropin alfa may increase the vasoconstricting activities of Ergotamine.
DB00024 DB00907 Cocaine Thyrotropin alfa may increase the vasoconstricting activities of Cocaine.
DB00024 DB00952 Naratriptan Thyrotropin alfa may increase the vasoconstricting activities of Naratriptan.
DB00024 DB02234 S-Ethylisothiourea Thyrotropin alfa may increase the vasoconstricting activities of S-Ethylisothiourea.
DB00024 DB02638 Terlipressin Thyrotropin alfa may increase the vasoconstricting activities of Terlipressin.
DB00024 DB02860 Calyculin A Thyrotropin alfa may increase the vasoconstricting activities of Calyculin A.
DB00024 DB06694 Xylometazoline Thyrotropin alfa may increase the vasoconstricting activities of Xylometazoline.
DB00024 DB06707 Levonordefrin Thyrotropin alfa may increase the vasoconstricting activities of Levonordefrin.
DB00024 DB06711 Naphazoline Thyrotropin alfa may increase the vasoconstricting activities of Naphazoline.
DB00024 DB09202 Cirazoline Thyrotropin alfa may increase the vasoconstricting activities of Cirazoline.
DB00024 DB11842 Angiotensin II Thyrotropin alfa may increase the vasoconstricting activities of Angiotensin II.
DB00024 DB13251 Octopamine Thyrotropin alfa may increase the vasoconstricting activities of Octopamine.
DB00024 DB13394 Adrenalone Thyrotropin alfa may increase the vasoconstricting activities of Adrenalone.
DB00024 DB13464 Ornipressin Thyrotropin alfa may increase the vasoconstricting activities of Ornipressin.
DB00024 DB13517 Angiotensinamide Thyrotropin alfa may increase the vasoconstricting activities of Angiotensinamide.
DB00024 DB14642 Lypressin Thyrotropin alfa may increase the vasoconstricting activities of Lypressin.
DB00024 DB00233 Aminosalicylic acid The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Aminosalicylic acid.
DB00024 DB00244 Mesalazine The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Mesalazine.
DB00024 DB00795 Sulfasalazine The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Sulfasalazine.
DB00024 DB00861 Diflunisal The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Diflunisal.
DB00024 DB00936 Salicylic acid The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Salicylic acid.
DB00024 DB00945 Acetylsalicylic acid The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Acetylsalicylic acid.
DB00024 DB01014 Balsalazide The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Balsalazide.
DB00024 DB01250 Olsalazine The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Olsalazine.
DB00024 DB01294 Bismuth subsalicylate The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Bismuth subsalicylate.
DB00024 DB06251 Dersalazine The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Dersalazine.
DB00024 DB06807 Phenyl aminosalicylate The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Phenyl aminosalicylate.
DB00024 DB09543 Methyl salicylate The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Methyl salicylate.
DB00024 DB12445 Nitroaspirin The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Nitroaspirin.
DB00024 DB13509 Aloxiprin The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Aloxiprin.
DB00024 DB13538 Guacetisal The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Guacetisal.
DB00024 DB13612 Carbaspirin calcium The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Carbaspirin calcium.
DB00024 DB14006 Choline salicylate The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Choline salicylate.
DB00024 DB14026 Thiosalicylic acid The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Thiosalicylic acid.
DB00024 DB00187 Esmolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Esmolol.
DB00024 DB00195 Betaxolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Betaxolol.
DB00024 DB00264 Metoprolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Metoprolol.
DB00024 DB00335 Atenolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Atenolol.
DB00024 DB00373 Timolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Timolol.
DB00024 DB00489 Sotalol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sotalol.
DB00024 DB00571 Propranolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Propranolol.
DB00024 DB00598 Labetalol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Labetalol.
DB00024 DB00612 Bisoprolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bisoprolol.
DB00024 DB00866 Alprenolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Alprenolol.
DB00024 DB00960 Pindolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Pindolol.
DB00024 DB01136 Carvedilol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Carvedilol.
DB00024 DB01182 Propafenone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Propafenone.
DB00024 DB01193 Acebutolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Acebutolol.
DB00024 DB01203 Nadolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Nadolol.
DB00024 DB01295 Bevantolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bevantolol.
DB00024 DB01297 Practolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Practolol.
DB00024 DB01359 Penbutolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Penbutolol.
DB00024 DB01580 Oxprenolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Oxprenolol.
DB00024 DB03322 Dexpropranolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dexpropranolol.
DB00024 DB04846 Celiprolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Celiprolol.
DB00024 DB04861 Nebivolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Nebivolol.
DB00024 DB06726 Bufuralol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bufuralol.
DB00024 DB08807 Bopindolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bopindolol.
DB00024 DB08808 Bupranolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bupranolol.
DB00024 DB08952 Indenolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Indenolol.
DB00024 DB09013 Befunolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Befunolol.
DB00024 DB09204 Arotinolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Arotinolol.
DB00024 DB09351 Levobetaxolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Levobetaxolol.
DB00024 DB11770 Talinolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Talinolol.
DB00024 DB11785 Anisodamine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Anisodamine.
DB00024 DB12212 Landiolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Landiolol.
DB00024 DB12752 Bucindolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bucindolol.
DB00024 DB13443 Esatenolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Esatenolol.
DB00024 DB13508 Cloranolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cloranolol.
DB00024 DB13530 Mepindolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Mepindolol.
DB00024 DB13757 Epanolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Epanolol.
DB00024 DB13775 Tertatolol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tertatolol.
DB00024 DB00394 Beclomethasone dipropionate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Beclomethasone dipropionate.
DB00024 DB00443 Betamethasone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Betamethasone.
DB00024 DB00620 Triamcinolone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Triamcinolone.
DB00024 DB00635 Prednisone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Prednisone.
DB00024 DB00764 Mometasone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Mometasone.
DB00024 DB01380 Cortisone acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cortisone acetate.
DB00024 DB01384 Paramethasone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Paramethasone.
DB00024 DB01410 Ciclesonide The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ciclesonide.
DB00024 DB08906 Fluticasone furoate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluticasone furoate.
DB00024 DB08970 Fluprednidene The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluprednidene.
DB00024 DB08971 Fluocortolone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluocortolone.
DB00024 DB09383 Meprednisone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Meprednisone.
DB00024 DB11487 Dexamethasone isonicotinate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dexamethasone isonicotinate.
DB00024 DB11750 Clobetasol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Clobetasol.
DB00024 DB11921 Deflazacort The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Deflazacort.
DB00024 DB13003 Cortivazol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cortivazol.
DB00024 DB13208 Prednylidene The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Prednylidene.
DB00024 DB13728 Halometasone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Halometasone.
DB00024 DB13843 Cloprednol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cloprednol.
DB00024 DB13867 Fluticasone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluticasone.
DB00024 DB14512 Mometasone furoate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Mometasone furoate.
DB00024 DB14631 Prednisolone phosphate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Prednisolone phosphate.
DB00024 DB14633 Prednisolone hemisuccinate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Prednisolone hemisuccinate.
DB00024 DB14634 Fluprednidene acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluprednidene acetate.
DB00024 DB14644 Methylprednisolone hemisuccinate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Methylprednisolone hemisuccinate.
DB00024 DB14646 Prednisone acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Prednisone acetate.
DB00024 DB14652 Clocortolone acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Clocortolone acetate.
DB00024 DB14659 Melengestrol acetate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Melengestrol acetate.
DB00024 DB14669 Betamethasone phosphate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Betamethasone phosphate.
DB00024 DB14681 Cortisone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cortisone.
DB00024 DB01118 Amiodarone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Amiodarone.
DB00024 DB00182 Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Thyrotropin alfa.
DB00024 DB00191 Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Thyrotropin alfa.
DB00024 DB00211 Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Thyrotropin alfa.
DB00024 DB00368 Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Thyrotropin alfa.
DB00024 DB00388 Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Thyrotropin alfa.
DB00024 DB00397 Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Thyrotropin alfa.
DB00024 DB00610 Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Thyrotropin alfa.
DB00024 DB00668 Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Thyrotropin alfa.
DB00024 DB00723 Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Thyrotropin alfa.
DB00024 DB00816 Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Thyrotropin alfa.
DB00024 DB00830 Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Thyrotropin alfa.
DB00024 DB00841 Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Thyrotropin alfa.
DB00024 DB00852 Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Thyrotropin alfa.
DB00024 DB00865 Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Thyrotropin alfa.
DB00024 DB00867 Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Thyrotropin alfa.
DB00024 DB00871 Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Thyrotropin alfa.
DB00024 DB00935 Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Thyrotropin alfa.
DB00024 DB00937 Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Thyrotropin alfa.
DB00024 DB00988 Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Thyrotropin alfa.
DB00024 DB01064 Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Thyrotropin alfa.
DB00024 DB01255 Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Thyrotropin alfa.
DB00024 DB01288 Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Thyrotropin alfa.
DB00024 DB01364 Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Thyrotropin alfa.
DB00024 DB01365 Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Thyrotropin alfa.
DB00024 DB01366 Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Thyrotropin alfa.
DB00024 DB01407 Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Thyrotropin alfa.
DB00024 DB01442 MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Thyrotropin alfa.
DB00024 DB01454 Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Thyrotropin alfa.
DB00024 DB01467 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Thyrotropin alfa.
DB00024 DB01484 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Thyrotropin alfa.
DB00024 DB01509 Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Thyrotropin alfa.
DB00024 DB01556 Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Thyrotropin alfa.
DB00024 DB01566 Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Thyrotropin alfa.
DB00024 DB01576 Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Thyrotropin alfa.
DB00024 DB01577 Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Thyrotropin alfa.
DB00024 DB06152 Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Thyrotropin alfa.
DB00024 DB06764 Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Thyrotropin alfa.
DB00024 DB08841 Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Thyrotropin alfa.
DB00024 DB08941 Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Thyrotropin alfa.
DB00024 DB08985 Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Thyrotropin alfa.
DB00024 DB09203 Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Thyrotropin alfa.
DB00024 DB09480 Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Thyrotropin alfa.
DB00024 DB11124 Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Thyrotropin alfa.
DB00024 DB12080 Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Thyrotropin alfa.
DB00024 DB13064 Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Thyrotropin alfa.
DB00024 DB13108 Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Thyrotropin alfa.
DB00024 DB13341 Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Thyrotropin alfa.
DB00024 DB13624 Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Thyrotropin alfa.
DB00024 DB13692 Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Thyrotropin alfa.
DB00024 DB13703 Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Thyrotropin alfa.
DB00024 DB13777 Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Thyrotropin alfa.
DB00024 DB13852 Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Thyrotropin alfa.
DB00024 DB13940 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Thyrotropin alfa.
DB00024 DB00317 Gefitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Gefitinib.
DB00024 DB00398 Sorafenib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sorafenib.
DB00024 DB00530 Erlotinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Erlotinib.
DB00024 DB00619 Imatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Imatinib.
DB00024 DB01254 Dasatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dasatinib.
DB00024 DB01259 Lapatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Lapatinib.
DB00024 DB01268 Sunitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sunitinib.
DB00024 DB01645 Genistein The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Genistein.
DB00024 DB02058 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
DB00024 DB02424 Geldanamycin The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Geldanamycin.
DB00024 DB02567 PD173955 The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with PD173955.
DB00024 DB03758 Radicicol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Radicicol.
DB00024 DB04849 Cediranib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cediranib.
DB00024 DB04868 Nilotinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Nilotinib.
DB00024 DB04879 Vatalanib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Vatalanib.
DB00024 DB05294 Vandetanib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Vandetanib.
DB00024 DB05424 Canertinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Canertinib.
DB00024 DB05465 Tandutinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tandutinib.
DB00024 DB05575 Motesanib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Motesanib.
DB00024 DB05928 Dovitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dovitinib.
DB00024 DB06302 Glesatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Glesatinib.
DB00024 DB06469 Lestaurtinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Lestaurtinib.
DB00024 DB06589 Pazopanib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Pazopanib.
DB00024 DB06595 Midostaurin The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Midostaurin.
DB00024 DB06616 Bosutinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Bosutinib.
DB00024 DB06626 Axitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Axitinib.
DB00024 DB08399 Piceatannol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Piceatannol.
DB00024 DB08865 Crizotinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Crizotinib.
DB00024 DB08875 Cabozantinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Cabozantinib.
DB00024 DB08877 Ruxolitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ruxolitinib.
DB00024 DB08881 Vemurafenib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Vemurafenib.
DB00024 DB08896 Regorafenib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Regorafenib.
DB00024 DB08901 Ponatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ponatinib.
DB00024 DB08916 Afatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Afatinib.
DB00024 DB09053 Ibrutinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ibrutinib.
DB00024 DB09063 Ceritinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ceritinib.
DB00024 DB09078 Lenvatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Lenvatinib.
DB00024 DB09079 Nintedanib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Nintedanib.
DB00024 DB09330 Osimertinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Osimertinib.
DB00024 DB11363 Alectinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Alectinib.
DB00024 DB11689 Selumetinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Selumetinib.
DB00024 DB11697 Pacritinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Pacritinib.
DB00024 DB11703 Acalabrutinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Acalabrutinib.
DB00024 DB11737 Icotinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Icotinib.
DB00024 DB11805 Saracatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Saracatinib.
DB00024 DB11828 Neratinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Neratinib.
DB00024 DB11832 Crenolanib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Crenolanib.
DB00024 DB11904 Flumatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Flumatinib.
DB00024 DB11963 Dacomitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dacomitinib.
DB00024 DB11973 Tesevatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tesevatinib.
DB00024 DB11986 Entrectinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Entrectinib.
DB00024 DB12010 Fostamatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fostamatinib.
DB00024 DB12048 Savolitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Savolitinib.
DB00024 DB12141 Gilteritinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Gilteritinib.
DB00024 DB12147 Erdafitinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Erdafitinib.
DB00024 DB12267 Brigatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Brigatinib.
DB00024 DB12307 Foretinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Foretinib.
DB00024 DB12323 Radotinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Radotinib.
DB00024 DB14723 Larotrectinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Larotrectinib.
DB00024 DB12978 Pexidartinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Pexidartinib.
DB00024 DB12500 Fedratinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fedratinib.
DB00024 DB11652 Tucatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Tucatinib.
DB00024 DB11791 Capmatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Capmatinib.
DB00024 DB15685 Selpercatinib The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Selpercatinib.
DB00024 DB05258 Interferon alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Interferon alfa.
DB00024 DB00041 Aldesleukin The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Aldesleukin.
DB00024 DB00227 Lovastatin The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Lovastatin.
DB00024 DB00609 Ethionamide The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ethionamide.
DB00024 DB00829 Diazepam The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Diazepam.
DB00024 DB00850 Perphenazine The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Perphenazine.
DB00024 DB01233 Metoclopramide The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Metoclopramide.
DB00024 DB14651 Perphenazine enanthate The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Perphenazine enanthate.
DB00024 DB11085 Resorcinol The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Resorcinol.
DB00024 DB00201 Caffeine Thyrotropin alfa may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB00277 Theophylline Thyrotropin alfa may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB00651 Dyphylline Thyrotropin alfa may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB00806 Pentoxifylline Thyrotropin alfa may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01033 Mercaptopurine Thyrotropin alfa may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01223 Aminophylline Thyrotropin alfa may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01303 Oxtriphylline Thyrotropin alfa may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01412 Theobromine Thyrotropin alfa may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01482 Fenethylline Thyrotropin alfa may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01667 8-azaguanine Thyrotropin alfa may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01978 7,9-Dimethylguanine Thyrotropin alfa may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB02134 Xanthine Thyrotropin alfa may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB02245 7-Deazaguanine Thyrotropin alfa may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB02377 Guanine Thyrotropin alfa may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB02489 9-Methylguanine Thyrotropin alfa may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB02568 Peldesine Thyrotropin alfa may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB04076 Hypoxanthine Thyrotropin alfa may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB04356 9-Deazaguanine Thyrotropin alfa may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB06479 Propentofylline Thyrotropin alfa may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB06575 Valomaciclovir Thyrotropin alfa may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB07954 3-isobutyl-1-methyl-7H-xanthine Thyrotropin alfa may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB08844 Uric acid Thyrotropin alfa may increase the excretion rate of Uric acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB09273 Doxofylline Thyrotropin alfa may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB11919 6-O-benzylguanine Thyrotropin alfa may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB12406 Lisofylline Thyrotropin alfa may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB12531 Lobucavir Thyrotropin alfa may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB12926 Cafedrine Thyrotropin alfa may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB12927 Theodrenaline Thyrotropin alfa may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB13203 Bamifylline Thyrotropin alfa may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB13449 Proxyphylline Thyrotropin alfa may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB13573 Acefylline Thyrotropin alfa may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB13592 Etamiphylline Thyrotropin alfa may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB13634 Pentifylline Thyrotropin alfa may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB13812 Bufylline Thyrotropin alfa may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB14018 Bromotheophylline Thyrotropin alfa may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB14029 Furafylline Thyrotropin alfa may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB14132 8-chlorotheophylline Thyrotropin alfa may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB15122 PCS-499 Thyrotropin alfa may increase the excretion rate of PCS-499 which could result in a lower serum level and potentially a reduction in efficacy.
DB00024 DB01432 Cholestyramine Cholestyramine can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00024 DB00375 Colestipol Colestipol can cause a decrease in the absorption of Thyrotropin alfa resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00024 DB00658 Sevelamer The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sevelamer.
DB00024 DB00390 Digoxin The serum concentration of Digoxin can be decreased when it is combined with Thyrotropin alfa.
DB00024 DB13401 Metildigoxin The serum concentration of Metildigoxin can be decreased when it is combined with Thyrotropin alfa.
DB00024 DB13691 Acetyldigoxin The serum concentration of Acetyldigoxin can be decreased when it is combined with Thyrotropin alfa.
DB00024 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Dicoumarol.
DB00024 DB00498 Phenindione The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Phenindione.
DB00024 DB00682 Warfarin The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Warfarin.
DB00024 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Phenprocoumon.
DB00024 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Acenocoumarol.
DB00024 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with 4-hydroxycoumarin.
DB00024 DB04665 Coumarin The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Coumarin.
DB00024 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with (R)-warfarin.
DB00024 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Ethyl biscoumacetate.
DB00024 DB13136 Fluindione The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Fluindione.
DB00024 DB13275 Clorindione The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Clorindione.
DB00024 DB13347 Diphenadione The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Diphenadione.
DB00024 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with Tioclomarol.
DB00024 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Thyrotropin alfa is combined with (S)-Warfarin.
DB00024 DB00222 Glimepiride Thyrotropin alfa may decrease the hypoglycemic activities of Glimepiride.
DB00024 DB00414 Acetohexamide Thyrotropin alfa may decrease the hypoglycemic activities of Acetohexamide.
DB00024 DB00672 Chlorpropamide Thyrotropin alfa may decrease the hypoglycemic activities of Chlorpropamide.
DB00024 DB00839 Tolazamide Thyrotropin alfa may decrease the hypoglycemic activities of Tolazamide.
DB00024 DB01016 Glyburide Thyrotropin alfa may decrease the hypoglycemic activities of Glyburide.
DB00024 DB01067 Glipizide Thyrotropin alfa may decrease the hypoglycemic activities of Glipizide.
DB00024 DB01120 Gliclazide Thyrotropin alfa may decrease the hypoglycemic activities of Gliclazide.
DB00024 DB01124 Tolbutamide Thyrotropin alfa may decrease the hypoglycemic activities of Tolbutamide.
DB00024 DB01251 Gliquidone Thyrotropin alfa may decrease the hypoglycemic activities of Gliquidone.
DB00024 DB01289 Glisoxepide Thyrotropin alfa may decrease the hypoglycemic activities of Glisoxepide.
DB00024 DB08962 Glibornuride Thyrotropin alfa may decrease the hypoglycemic activities of Glibornuride.
DB00024 DB13406 Carbutamide Thyrotropin alfa may decrease the hypoglycemic activities of Carbutamide.
DB00024 DB13675 Metahexamide Thyrotropin alfa may decrease the hypoglycemic activities of Metahexamide.
DB00024 DB00030 Insulin human Thyrotropin alfa may decrease the hypoglycemic activities of Insulin human.
DB00024 DB00046 Insulin lispro Thyrotropin alfa may decrease the hypoglycemic activities of Insulin lispro.
DB00024 DB00047 Insulin glargine Thyrotropin alfa may decrease the hypoglycemic activities of Insulin glargine.
DB00024 DB00071 Insulin pork Thyrotropin alfa may decrease the hypoglycemic activities of Insulin pork.
DB00024 DB00197 Troglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Troglitazone.
DB00024 DB00263 Sulfisoxazole Thyrotropin alfa may decrease the hypoglycemic activities of Sulfisoxazole.
DB00024 DB00280 Disopyramide Thyrotropin alfa may decrease the hypoglycemic activities of Disopyramide.
DB00024 DB00284 Acarbose Thyrotropin alfa may decrease the hypoglycemic activities of Acarbose.
DB00024 DB00359 Sulfadiazine Thyrotropin alfa may decrease the hypoglycemic activities of Sulfadiazine.
DB00024 DB00412 Rosiglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Rosiglitazone.
DB00024 DB00468 Quinine Thyrotropin alfa may decrease the hypoglycemic activities of Quinine.
DB00024 DB00491 Miglitol Thyrotropin alfa may decrease the hypoglycemic activities of Miglitol.
DB00024 DB00731 Nateglinide Thyrotropin alfa may decrease the hypoglycemic activities of Nateglinide.
DB00024 DB00738 Pentamidine Thyrotropin alfa may decrease the hypoglycemic activities of Pentamidine.
DB00024 DB00834 Mifepristone Thyrotropin alfa may decrease the hypoglycemic activities of Mifepristone.
DB00024 DB00912 Repaglinide Thyrotropin alfa may decrease the hypoglycemic activities of Repaglinide.
DB00024 DB00914 Phenformin Thyrotropin alfa may decrease the hypoglycemic activities of Phenformin.
DB00024 DB01015 Sulfamethoxazole Thyrotropin alfa may decrease the hypoglycemic activities of Sulfamethoxazole.
DB00024 DB01132 Pioglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Pioglitazone.
DB00024 DB01200 Bromocriptine Thyrotropin alfa may decrease the hypoglycemic activities of Bromocriptine.
DB00024 DB01252 Mitiglinide Thyrotropin alfa may decrease the hypoglycemic activities of Mitiglinide.
DB00024 DB01261 Sitagliptin Thyrotropin alfa may decrease the hypoglycemic activities of Sitagliptin.
DB00024 DB01276 Exenatide Thyrotropin alfa may decrease the hypoglycemic activities of Exenatide.
DB00024 DB01277 Mecasermin Thyrotropin alfa may decrease the hypoglycemic activities of Mecasermin.
DB00024 DB01278 Pramlintide Thyrotropin alfa may decrease the hypoglycemic activities of Pramlintide.
DB00024 DB01306 Insulin aspart Thyrotropin alfa may decrease the hypoglycemic activities of Insulin aspart.
DB00024 DB01307 Insulin detemir Thyrotropin alfa may decrease the hypoglycemic activities of Insulin detemir.
DB00024 DB01309 Insulin glulisine Thyrotropin alfa may decrease the hypoglycemic activities of Insulin glulisine.
DB00024 DB01382 Glymidine Thyrotropin alfa may decrease the hypoglycemic activities of Glymidine.
DB00024 DB01700 AICA ribonucleotide Thyrotropin alfa may decrease the hypoglycemic activities of AICA ribonucleotide.
DB00024 DB04830 Buformin Thyrotropin alfa may decrease the hypoglycemic activities of Buformin.
DB00024 DB04876 Vildagliptin Thyrotropin alfa may decrease the hypoglycemic activities of Vildagliptin.
DB00024 DB04878 Voglibose Thyrotropin alfa may decrease the hypoglycemic activities of Voglibose.
DB00024 DB05115 NN344 Thyrotropin alfa may decrease the hypoglycemic activities of NN344.
DB00024 DB05819 NBI-6024 Thyrotropin alfa may decrease the hypoglycemic activities of NBI-6024.
DB00024 DB06011 AMG-222 Thyrotropin alfa may decrease the hypoglycemic activities of AMG-222.
DB00024 DB06127 Bisegliptin Thyrotropin alfa may decrease the hypoglycemic activities of Bisegliptin.
DB00024 DB06203 Alogliptin Thyrotropin alfa may decrease the hypoglycemic activities of Alogliptin.
DB00024 DB06292 Dapagliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Dapagliflozin.
DB00024 DB06335 Saxagliptin Thyrotropin alfa may decrease the hypoglycemic activities of Saxagliptin.
DB00024 DB06655 Liraglutide Thyrotropin alfa may decrease the hypoglycemic activities of Liraglutide.
DB00024 DB08382 Gosogliptin Thyrotropin alfa may decrease the hypoglycemic activities of Gosogliptin.
DB00024 DB08882 Linagliptin Thyrotropin alfa may decrease the hypoglycemic activities of Linagliptin.
DB00024 DB08907 Canagliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Canagliflozin.
DB00024 DB09022 Benfluorex Thyrotropin alfa may decrease the hypoglycemic activities of Benfluorex.
DB00024 DB09038 Empagliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Empagliflozin.
DB00024 DB09043 Albiglutide Thyrotropin alfa may decrease the hypoglycemic activities of Albiglutide.
DB00024 DB09045 Dulaglutide Thyrotropin alfa may decrease the hypoglycemic activities of Dulaglutide.
DB00024 DB09198 Lobeglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Lobeglitazone.
DB00024 DB09199 Netoglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Netoglitazone.
DB00024 DB09200 Rivoglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Rivoglitazone.
DB00024 DB09201 Ciglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Ciglitazone.
DB00024 DB09265 Lixisenatide Thyrotropin alfa may decrease the hypoglycemic activities of Lixisenatide.
DB00024 DB09456 Insulin beef Thyrotropin alfa may decrease the hypoglycemic activities of Insulin beef.
DB00024 DB09564 Insulin degludec Thyrotropin alfa may decrease the hypoglycemic activities of Insulin degludec.
DB00024 DB11567 Insulin peglispro Thyrotropin alfa may decrease the hypoglycemic activities of Insulin peglispro.
DB00024 DB11568 Insulin tregopil Thyrotropin alfa may decrease the hypoglycemic activities of Insulin tregopil.
DB00024 DB11698 Ipragliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Ipragliflozin.
DB00024 DB11723 Dutogliptin Thyrotropin alfa may decrease the hypoglycemic activities of Dutogliptin.
DB00024 DB11780 Allicin Thyrotropin alfa may decrease the hypoglycemic activities of Allicin.
DB00024 DB11824 Tofogliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Tofogliflozin.
DB00024 DB11827 Ertugliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Ertugliflozin.
DB00024 DB11898 2,4-thiazolidinedione Thyrotropin alfa may decrease the hypoglycemic activities of 2,4-thiazolidinedione.
DB00024 DB11950 Teneligliptin Thyrotropin alfa may decrease the hypoglycemic activities of Teneligliptin.
DB00024 DB11992 Omarigliptin Thyrotropin alfa may decrease the hypoglycemic activities of Omarigliptin.
DB00024 DB12268 Carmegliptin Thyrotropin alfa may decrease the hypoglycemic activities of Carmegliptin.
DB00024 DB12412 Gemigliptin Thyrotropin alfa may decrease the hypoglycemic activities of Gemigliptin.
DB00024 DB12417 Anagliptin Thyrotropin alfa may decrease the hypoglycemic activities of Anagliptin.
DB00024 DB12625 Evogliptin Thyrotropin alfa may decrease the hypoglycemic activities of Evogliptin.
DB00024 DB12713 Sotagliflozin Thyrotropin alfa may decrease the hypoglycemic activities of Sotagliflozin.
DB00024 DB12781 Balaglitazone Thyrotropin alfa may decrease the hypoglycemic activities of Balaglitazone.
DB00024 DB12935 Remogliflozin etabonate Thyrotropin alfa may decrease the hypoglycemic activities of Remogliflozin etabonate.
DB00024 DB13446 Guar gum Thyrotropin alfa may decrease the hypoglycemic activities of Guar gum.
DB00024 DB13928 Semaglutide Thyrotropin alfa may decrease the hypoglycemic activities of Semaglutide.
DB00024 DB14027 Taspoglutide Thyrotropin alfa may decrease the hypoglycemic activities of Taspoglutide.
DB00024 DB14035 Englitazone Thyrotropin alfa may decrease the hypoglycemic activities of Englitazone.
DB00024 DB15171 Tirzepatide Thyrotropin alfa may decrease the hypoglycemic activities of Tirzepatide.
DB00024 DB15217 Gastric inhibitory polypeptide Thyrotropin alfa may decrease the hypoglycemic activities of Gastric inhibitory polypeptide.
DB00024 DB00540 Nortriptyline The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Nortriptyline.
DB00024 DB00321 Amitriptyline The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Amitriptyline.
DB00024 DB00344 Protriptyline The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Protriptyline.
DB00024 DB00458 Imipramine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Imipramine.
DB00024 DB00543 Amoxapine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Amoxapine.
DB00024 DB00726 Trimipramine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Trimipramine.
DB00024 DB01142 Doxepin The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Doxepin.
DB00024 DB01151 Desipramine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Desipramine.
DB00024 DB01242 Clomipramine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Clomipramine.
DB00024 DB04836 Amineptine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Amineptine.
DB00024 DB08996 Dimetacrine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Dimetacrine.
DB00024 DB09016 Butriptyline The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Butriptyline.
DB00024 DB09167 Dosulepin The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Dosulepin.
DB00024 DB09289 Tianeptine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Tianeptine.
DB00024 DB09307 Oxaprotiline The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Oxaprotiline.
DB00024 DB12930 Opipramol The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Opipramol.
DB00024 DB13114 Amitriptylinoxide The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Amitriptylinoxide.
DB00024 DB13225 Dibenzepin The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Dibenzepin.
DB00024 DB13246 Quinupramine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Quinupramine.
DB00024 DB13384 Melitracen The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Melitracen.
DB00024 DB13411 Lofepramine The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Lofepramine.
DB00024 DB13496 Iprindole The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Iprindole.
DB00024 DB13782 Imipramine oxide The risk or severity of Cardiac Arrhythmia can be increased when Thyrotropin alfa is combined with Imipramine oxide.
DB00025 DB00513 Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Antihemophilic factor, human recombinant.
DB00025 DB00058 Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB00170 Menadione Menadione may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB00302 Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB06692 Aprotinin Aprotinin may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB11091 Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB13244 Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB13729 Camostat Camostat may increase the thrombogenic activities of Antihemophilic factor, human recombinant.
DB00025 DB12726 Monteplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Monteplase.
DB00025 DB00001 Lepirudin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.
DB00025 DB00006 Bivalirudin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Bivalirudin.
DB00025 DB00009 Alteplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Alteplase.
DB00025 DB00013 Urokinase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Urokinase.
DB00025 DB00015 Reteplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reteplase.
DB00025 DB00029 Anistreplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Anistreplase.
DB00025 DB00031 Tenecteplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tenecteplase.
DB00025 DB00054 Abciximab The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Abciximab.
DB00025 DB00055 Drotrecogin alfa The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Drotrecogin alfa.
DB00025 DB00086 Streptokinase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Streptokinase.
DB00025 DB00266 Dicoumarol The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dicoumarol.
DB00025 DB00278 Argatroban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Argatroban.
DB00025 DB00407 Ardeparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ardeparin.
DB00025 DB00498 Phenindione The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Phenindione.
DB00025 DB00569 Fondaparinux The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Fondaparinux.
DB00025 DB00682 Warfarin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Warfarin.
DB00025 DB00686 Pentosan polysulfate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Pentosan polysulfate.
DB00025 DB00945 Acetylsalicylic acid The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Acetylsalicylic acid.
DB00025 DB00946 Phenprocoumon The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Phenprocoumon.
DB00025 DB00975 Dipyridamole The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dipyridamole.
DB00025 DB01088 Iloprost The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Iloprost.
DB00025 DB01109 Heparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Heparin.
DB00025 DB01225 Enoxaparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Enoxaparin.
DB00025 DB01240 Epoprostenol The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Epoprostenol.
DB00025 DB01418 Acenocoumarol The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Acenocoumarol.
DB00025 DB03410 4-hydroxycoumarin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with 4-hydroxycoumarin.
DB00025 DB04665 Coumarin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Coumarin.
DB00025 DB04898 Ximelagatran The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ximelagatran.
DB00025 DB04925 Desmoteplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Desmoteplase.
DB00025 DB04932 Defibrotide The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Defibrotide.
DB00025 DB05099 Ancrod The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ancrod.
DB00025 DB05229 Beraprost The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Beraprost.
DB00025 DB05254 Fibrinolysin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Fibrinolysin.
DB00025 DB06209 Prasugrel The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Prasugrel.
DB00025 DB06228 Rivaroxaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Rivaroxaban.
DB00025 DB06271 Sulodexide The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Sulodexide.
DB00025 DB06406 Idraparinux The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Idraparinux.
DB00025 DB06441 Cangrelor The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Cangrelor.
DB00025 DB06543 Astaxanthin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Astaxanthin.
DB00025 DB06605 Apixaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Apixaban.
DB00025 DB06635 Otamixaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Otamixaban.
DB00025 DB06679 Amediplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Amediplase.
DB00025 DB06695 Dabigatran etexilate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dabigatran etexilate.
DB00025 DB06754 Danaparoid The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Danaparoid.
DB00025 DB06779 Dalteparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dalteparin.
DB00025 DB06822 Tinzaparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tinzaparin.
DB00025 DB07767 Ferulic acid The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ferulic acid.
DB00025 DB08496 (R)-warfarin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with (R)-warfarin.
DB00025 DB08794 Ethyl biscoumacetate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ethyl biscoumacetate.
DB00025 DB08813 Nadroparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Nadroparin.
DB00025 DB08814 Triflusal The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Triflusal.
DB00025 DB08816 Ticagrelor The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ticagrelor.
DB00025 DB08994 Ditazole The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Ditazole.
DB00025 DB09030 Vorapaxar The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Vorapaxar.
DB00025 DB09075 Edoxaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Edoxaban.
DB00025 DB09125 Potassium citrate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Potassium citrate.
DB00025 DB09154 Sodium citrate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Sodium citrate.
DB00025 DB09255 Dextran The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dextran.
DB00025 DB09258 Bemiparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Bemiparin.
DB00025 DB09259 Reviparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Reviparin.
DB00025 DB09260 Parnaparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Parnaparin.
DB00025 DB09261 Certoparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Certoparin.
DB00025 DB11095 Desirudin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Desirudin.
DB00025 DB11154 Zinc citrate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Zinc citrate.
DB00025 DB11166 Antithrombin Alfa The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Antithrombin Alfa.
DB00025 DB11312 Protein C The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Protein C.
DB00025 DB11598 Antithrombin III human The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Antithrombin III human.
DB00025 DB11984 Letaxaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Letaxaban.
DB00025 DB12289 Darexaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Darexaban.
DB00025 DB12364 Betrixaban The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Betrixaban.
DB00025 DB12598 Nafamostat The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Nafamostat.
DB00025 DB12831 Gabexate The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Gabexate.
DB00025 DB13136 Fluindione The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Fluindione.
DB00025 DB13149 Protein S human The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Protein S human.
DB00025 DB13199 Brinase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Brinase.
DB00025 DB13275 Clorindione The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Clorindione.
DB00025 DB13347 Diphenadione The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Diphenadione.
DB00025 DB13451 Tioclomarol The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tioclomarol.
DB00025 DB13616 Melagatran The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Melagatran.
DB00025 DB13646 Saruplase The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Saruplase.
DB00025 DB14055 (S)-Warfarin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with (S)-Warfarin.
DB00025 DB14094 Tocopherylquinone The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tocopherylquinone.
DB00025 DB14598 Edetate calcium disodium anhydrous The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Edetate calcium disodium anhydrous.
DB00025 DB14726 Dabigatran The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dabigatran.
DB00025 DB06294 Semuloparin The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Semuloparin.
DB00026 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.
DB00026 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.
DB00026 DB00065 Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.
DB00026 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.
DB00026 DB06674 Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.
DB00026 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anakinra.
DB00026 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.
DB00026 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Anakinra.
DB00026 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Anakinra.
DB00026 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Anakinra.
DB00026 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Anakinra.
DB00026 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon gamma-1b.
DB00026 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2a, Recombinant.
DB00026 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Anakinra is combined with Aldesleukin.
DB00026 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Anakinra is combined with Gemtuzumab ozogamicin.
DB00026 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Anakinra is combined with Pegaspargase.
DB00026 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon beta-1b.
DB00026 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfacon-1.
DB00026 DB00073 Rituximab The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.
DB00026 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Anakinra is combined with Basiliximab.
DB00026 DB00075 Muromonab The risk or severity of adverse effects can be increased when Anakinra is combined with Muromonab.
DB00026 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Anakinra is combined with Ibritumomab tiuxetan.
DB00026 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Anakinra is combined with Tositumomab.
DB00026 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Anakinra is combined with Alemtuzumab.
DB00026 DB00092 Alefacept The risk or severity of adverse effects can be increased when Anakinra is combined with Alefacept.
DB00026 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Efalizumab.
DB00026 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Anakinra is combined with Antithymocyte immunoglobulin (rabbit).
DB00026 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2b.
DB00026 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab.
DB00026 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Bevacizumab.
DB00026 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Anakinra is combined with Phenylalanine.
DB00026 DB00242 Cladribine The risk or severity of adverse effects can be increased when Anakinra is combined with Cladribine.
DB00026 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Anakinra is combined with Amsacrine.
DB00026 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Anakinra is combined with Bleomycin.
DB00026 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Anakinra is combined with Chlorambucil.
DB00026 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Anakinra is combined with Raltitrexed.
DB00026 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Anakinra is combined with Mitomycin.
DB00026 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Anakinra is combined with Floxuridine.
DB00026 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Anakinra is combined with Tioguanine.
DB00026 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Anakinra is combined with Dexrazoxane.
DB00026 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Anakinra is combined with Streptozocin.
DB00026 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Anakinra is combined with Trifluridine.
DB00026 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Anakinra is combined with Gemcitabine.
DB00026 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Anakinra is combined with Epirubicin.
DB00026 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Anakinra is combined with Chloramphenicol.
DB00026 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Anakinra is combined with Lenalidomide.
DB00026 DB00488 Altretamine The risk or severity of adverse effects can be increased when Anakinra is combined with Altretamine.
DB00026 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin.
DB00026 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Anakinra is combined with Oxaliplatin.
DB00026 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Anakinra is combined with Propylthiouracil.
DB00026 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Anakinra is combined with Pentostatin.
DB00026 DB00601 Linezolid The risk or severity of adverse effects can be increased when Anakinra is combined with Linezolid.
DB00026 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Anakinra is combined with Clofarabine.
DB00026 DB00763 Methimazole The risk or severity of adverse effects can be increased when Anakinra is combined with Methimazole.
DB00026 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Anakinra is combined with Sulfasalazine.
DB00026 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Anakinra is combined with Temozolomide.
DB00026 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Anakinra is combined with Penicillamine.
DB00026 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Anakinra is combined with Mechlorethamine.
DB00026 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Anakinra is combined with Azacitidine.
DB00026 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Anakinra is combined with Carboplatin.
DB00026 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Anakinra is combined with Dactinomycin.
DB00026 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Anakinra is combined with Hydroxyurea.
DB00026 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Anakinra is combined with Mycophenolic acid.
DB00026 DB01030 Topotecan The risk or severity of adverse effects can be increased when Anakinra is combined with Topotecan.
DB00026 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Anakinra is combined with Mercaptopurine.
DB00026 DB01042 Melphalan The risk or severity of adverse effects can be increased when Anakinra is combined with Melphalan.
DB00026 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Anakinra is combined with Fludarabine.
DB00026 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Anakinra is combined with Flucytosine.
DB00026 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Anakinra is combined with Procarbazine.
DB00026 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Anakinra is combined with Arsenic trioxide.
DB00026 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Anakinra is combined with Mitoxantrone.
DB00026 DB01206 Lomustine The risk or severity of adverse effects can be increased when Anakinra is combined with Lomustine.
DB00026 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Eculizumab.
DB00026 DB01262 Decitabine The risk or severity of adverse effects can be increased when Anakinra is combined with Decitabine.
DB00026 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Anakinra is combined with Nelarabine.
DB00026 DB01423 Stepronin The risk or severity of adverse effects can be increased when Anakinra is combined with Stepronin.
DB00026 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Anakinra is combined with Castanospermine.
DB00026 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Anakinra is combined with Vorinostat.
DB00026 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Anakinra is combined with 2-Methoxyethanol.
DB00026 DB03523 Brequinar The risk or severity of adverse effects can be increased when Anakinra is combined with Brequinar.
DB00026 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa.
DB00026 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Anakinra is combined with Glatiramer.
DB00026 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Anakinra is combined with Gallium nitrate.
DB00026 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Anakinra is combined with Briakinumab.
DB00026 DB05472 omega interferon The risk or severity of adverse effects can be increased when Anakinra is combined with omega interferon.
DB00026 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.
DB00026 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Anakinra is combined with Rilonacept.
DB00026 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Mepolizumab.
DB00026 DB06662 Abetimus The risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus.
DB00026 DB06681 Belatacept The risk or severity of adverse effects can be increased when Anakinra is combined with Belatacept.
DB00026 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Anakinra is combined with Pralatrexate.
DB00026 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Anakinra is combined with Wortmannin.
DB00026 DB08871 Eribulin The risk or severity of adverse effects can be increased when Anakinra is combined with Eribulin.
DB00026 DB08879 Belimumab The risk or severity of adverse effects can be increased when Anakinra is combined with Belimumab.
DB00026 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Anakinra is combined with Teriflunomide.
DB00026 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Anakinra is combined with Carfilzomib.
DB00026 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Anakinra is combined with Dimethyl fumarate.
DB00026 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Anakinra is combined with Obinutuzumab.
DB00026 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Anakinra is combined with Secukinumab.
DB00026 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Vedolizumab.
DB00026 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Anakinra is combined with Siltuximab.
DB00026 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Anakinra is combined with Blinatumomab.
DB00026 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Anakinra is combined with Dinutuximab.
DB00026 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Anakinra is combined with Tixocortol.
DB00026 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Anakinra is combined with Peginterferon beta-1a.
DB00026 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Anakinra is combined with Antilymphocyte immunoglobulin (horse).
DB00026 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Anakinra is combined with Tepoxalin.
DB00026 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Ixekizumab.
DB00026 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Ravulizumab.
DB00026 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Anakinra is combined with Pirarubicin.
DB00026 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Anakinra is combined with Voclosporin.
DB00026 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Anakinra is combined with Peficitinib.
DB00026 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Anakinra is combined with Sarilumab.
DB00026 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Anakinra is combined with Brodalumab.
DB00026 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Anakinra is combined with Sirukumab.
DB00026 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Anakinra is combined with Guselkumab.
DB00026 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Ocrelizumab.
DB00026 DB12025 Triptolide The risk or severity of adverse effects can be increased when Anakinra is combined with Triptolide.
DB00026 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Anakinra is combined with Ozanimod.
DB00026 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Anakinra is combined with Mizoribine.
DB00026 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Anakinra is combined with Gusperimus.
DB00026 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Anakinra is combined with Cepeginterferon alfa-2B.
DB00026 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Anakinra is combined with Trofosfamide.
DB00026 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Anakinra is combined with Doxifluridine.
DB00026 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Anakinra is combined with Deoxyspergualin.
DB00026 DB12996 Acteoside The risk or severity of adverse effects can be increased when Anakinra is combined with Acteoside.
DB00026 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Anakinra is combined with Cortivazol.
DB00026 DB13014 Hypericin The risk or severity of adverse effects can be increased when Anakinra is combined with Hypericin.
DB00026 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Anakinra is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00026 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortin.
DB00026 DB13241 Begelomab The risk or severity of adverse effects can be increased when Anakinra is combined with Begelomab.
DB00026 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Anakinra is combined with Fluperolone.
DB00026 DB13664 Formocortal The risk or severity of adverse effects can be increased when Anakinra is combined with Formocortal.
DB00026 DB13728 Halometasone The risk or severity of adverse effects can be increased when Anakinra is combined with Halometasone.
DB00026 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Anakinra is combined with Cloprednol.
DB00026 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Anakinra is combined with Fluclorolone.
DB00026 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Anakinra is combined with Monomethyl fumarate.
DB00026 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Anakinra is combined with Emapalumab.
DB00026 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Risankizumab.
DB00026 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Rozanolixizumab.
DB00026 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Anakinra is combined with Bleselumab.
DB00026 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Anakinra is combined with Flunisolide.
DB00026 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Anakinra is combined with Beclomethasone dipropionate.
DB00026 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Anakinra is combined with Betamethasone.
DB00026 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocinolone acetonide.
DB00026 DB00635 Prednisone The risk or severity of adverse effects can be increased when Anakinra is combined with Prednisone.
DB00026 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Anakinra is combined with Fludrocortisone.
DB00026 DB00764 Mometasone The risk or severity of adverse effects can be increased when Anakinra is combined with Mometasone.
DB00026 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Anakinra is combined with Prednisolone.
DB00026 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Anakinra is combined with Methylprednisolone.
DB00026 DB01196 Estramustine The risk or severity of adverse effects can be increased when Anakinra is combined with Estramustine.
DB00026 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Anakinra is combined with Corticotropin.
DB00026 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Anakinra is combined with Cortisone acetate.
DB00026 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Anakinra is combined with Paramethasone.
DB00026 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Anakinra is combined with Hydroxychloroquine.
DB00026 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Anakinra is combined with Aldosterone.
DB00026 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Anakinra is combined with Fluprednidene.
DB00026 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortolone.
DB00026 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Anakinra is combined with Vilanterol.
DB00026 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Anakinra is combined with Fluprednisolone.
DB00026 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Anakinra is combined with Meprednisone.
DB00026 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Anakinra is combined with Dexamethasone isonicotinate.
DB00026 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Anakinra is combined with Melengestrol.
DB00026 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Anakinra is combined with Clobetasol.
DB00026 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Anakinra is combined with Baricitinib.
DB00026 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Anakinra is combined with Deflazacort.
DB00026 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Anakinra is combined with Prednylidene.
DB00026 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Anakinra is combined with Tetrandrine.
DB00026 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Anakinra is combined with Mometasone furoate.
DB00026 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Anakinra is combined with Hydrocortisone succinate.
DB00026 DB01222 Budesonide The risk or severity of adverse effects can be increased when Anakinra is combined with Budesonide.
DB00026 DB01394 Colchicine The risk or severity of adverse effects can be increased when Anakinra is combined with Colchicine.
DB00026 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.
DB00026 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.
DB00026 DB01656 Roflumilast Anakinra may increase the immunosuppressive activities of Roflumilast.
DB00026 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.
DB00026 DB01281 Abatacept The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept.
DB00026 DB06168 Canakinumab Anakinra may increase the immunosuppressive activities of Canakinumab.
DB00026 DB08895 Tofacitinib The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.
DB00026 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Anakinra.
DB00026 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.
DB00026 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Anakinra.
DB00026 DB08868 Fingolimod Anakinra may increase the immunosuppressive activities of Fingolimod.
DB00026 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Anakinra.
DB00026 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Anakinra.
DB00026 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Anakinra.
DB00026 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Anakinra.
DB00026 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Anakinra.
DB00026 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Anakinra.
DB00026 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Anakinra.
DB00026 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Anakinra.
DB00026 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Anakinra.
DB00026 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Anakinra.
DB00026 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Anakinra.
DB00026 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.
DB00026 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Anakinra.
DB00026 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra.
DB00026 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Anakinra.
DB00026 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Anakinra.
DB00026 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anakinra.
DB00026 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Anakinra.
DB00026 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anakinra.
DB00026 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anakinra.
DB00026 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Anakinra.
DB00026 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Anakinra.
DB00026 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Anakinra.
DB00026 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Anakinra.
DB00026 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Anakinra.
DB00026 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Anakinra.
DB00026 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
DB00026 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Anakinra.
DB00026 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anakinra.
DB00026 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Anakinra.
DB00026 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Anakinra.
DB00026 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Anakinra.
DB00026 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Anakinra.
DB00026 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Anakinra.
DB00026 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Anakinra.
DB00026 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Anakinra.
DB00026 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Anakinra.
DB00026 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Anakinra.
DB00026 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Anakinra.
DB00026 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Anakinra.
DB00026 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Anakinra.
DB00026 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Anakinra.
DB00026 DB00201 Caffeine The metabolism of Caffeine can be increased when combined with Anakinra.
DB00026 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Anakinra.
DB00026 DB00195 Betaxolol The metabolism of Betaxolol can be increased when combined with Anakinra.
DB00026 DB00261 Anagrelide The metabolism of Anagrelide can be increased when combined with Anakinra.
DB00026 DB00262 Carmustine The metabolism of Carmustine can be increased when combined with Anakinra.
DB00026 DB00268 Ropinirole The metabolism of Ropinirole can be increased when combined with Anakinra.
DB00026 DB00280 Disopyramide The metabolism of Disopyramide can be increased when combined with Anakinra.
DB00026 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Anakinra.
DB00026 DB00296 Ropivacaine The metabolism of Ropivacaine can be increased when combined with Anakinra.
DB00026 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be increased when combined with Anakinra.
DB00026 DB00316 Acetaminophen The metabolism of Acetaminophen can be increased when combined with Anakinra.
DB00026 DB00334 Olanzapine The metabolism of Olanzapine can be increased when combined with Anakinra.
DB00026 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Anakinra.
DB00026 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be increased when combined with Anakinra.
DB00026 DB00370 Mirtazapine The metabolism of Mirtazapine can be increased when combined with Anakinra.
DB00026 DB00379 Mexiletine The metabolism of Mexiletine can be increased when combined with Anakinra.
DB00026 DB00382 Tacrine The metabolism of Tacrine can be increased when combined with Anakinra.
DB00026 DB00384 Triamterene The metabolism of Triamterene can be increased when combined with Anakinra.
DB00026 DB00442 Entecavir The metabolism of Entecavir can be increased when combined with Anakinra.
DB00026 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be increased when combined with Anakinra.
DB00026 DB00518 Albendazole The metabolism of Albendazole can be increased when combined with Anakinra.
DB00026 DB00544 Fluorouracil The metabolism of Fluorouracil can be increased when combined with Anakinra.
DB00026 DB00629 Guanabenz The metabolism of Guanabenz can be increased when combined with Anakinra.
DB00026 DB00642 Pemetrexed The metabolism of Pemetrexed can be increased when combined with Anakinra.
DB00026 DB00730 Thiabendazole The metabolism of Thiabendazole can be increased when combined with Anakinra.
DB00026 DB00740 Riluzole The metabolism of Riluzole can be increased when combined with Anakinra.
DB00026 DB00787 Acyclovir The metabolism of Acyclovir can be increased when combined with Anakinra.
DB00026 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be increased when combined with Anakinra.
DB00026 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Anakinra.
DB00026 DB00863 Ranitidine The metabolism of Ranitidine can be increased when combined with Anakinra.
DB00026 DB00898 Ethanol The metabolism of Ethanol can be increased when combined with Anakinra.
DB00026 DB00934 Maprotiline The metabolism of Maprotiline can be increased when combined with Anakinra.
DB00026 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be increased when combined with Anakinra.
DB00026 DB00993 Azathioprine The metabolism of Azathioprine can be increased when combined with Anakinra.
DB00026 DB00998 Frovatriptan The metabolism of Frovatriptan can be increased when combined with Anakinra.
DB00026 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Anakinra.
DB00026 DB01012 Cinacalcet The metabolism of Cinacalcet can be increased when combined with Anakinra.
DB00026 DB01056 Tocainide The metabolism of Tocainide can be increased when combined with Anakinra.
DB00026 DB01087 Primaquine The metabolism of Primaquine can be increased when combined with Anakinra.
DB00026 DB01094 Hesperetin The metabolism of Hesperetin can be increased when combined with Anakinra.
DB00026 DB01182 Propafenone The metabolism of Propafenone can be increased when combined with Anakinra.
DB00026 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Anakinra.
DB00026 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Anakinra.
DB00026 DB01367 Rasagiline The metabolism of Rasagiline can be increased when combined with Anakinra.
DB00026 DB01405 Temafloxacin The metabolism of Temafloxacin can be increased when combined with Anakinra.
DB00026 DB01412 Theobromine The metabolism of Theobromine can be increased when combined with Anakinra.
DB00026 DB01482 Fenethylline The metabolism of Fenethylline can be increased when combined with Anakinra.
DB00026 DB01558 Bromazepam The metabolism of Bromazepam can be increased when combined with Anakinra.
DB00026 DB01623 Thiothixene The metabolism of Thiothixene can be increased when combined with Anakinra.
DB00026 DB01645 Genistein The metabolism of Genistein can be increased when combined with Anakinra.
DB00026 DB01667 8-azaguanine The metabolism of 8-azaguanine can be increased when combined with Anakinra.
DB00026 DB02134 Xanthine The metabolism of Xanthine can be increased when combined with Anakinra.
DB00026 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be increased when combined with Anakinra.
DB00026 DB02568 Peldesine The metabolism of Peldesine can be increased when combined with Anakinra.
DB00026 DB02709 Resveratrol The metabolism of Resveratrol can be increased when combined with Anakinra.
DB00026 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be increased when combined with Anakinra.
DB00026 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be increased when combined with Anakinra.
DB00026 DB04871 Lorcaserin The metabolism of Lorcaserin can be increased when combined with Anakinra.
DB00026 DB04948 Lofexidine The metabolism of Lofexidine can be increased when combined with Anakinra.
DB00026 DB04951 Pirfenidone The metabolism of Pirfenidone can be increased when combined with Anakinra.
DB00026 DB06148 Mianserin The metabolism of Mianserin can be increased when combined with Anakinra.
DB00026 DB06210 Eltrombopag The metabolism of Eltrombopag can be increased when combined with Anakinra.
DB00026 DB06216 Asenapine The metabolism of Asenapine can be increased when combined with Anakinra.
DB00026 DB06235 Vadimezan The metabolism of Vadimezan can be increased when combined with Anakinra.
DB00026 DB06479 Propentofylline The metabolism of Propentofylline can be increased when combined with Anakinra.
DB00026 DB06594 Agomelatine The metabolism of Agomelatine can be increased when combined with Anakinra.
DB00026 DB06769 Bendamustine The metabolism of Bendamustine can be increased when combined with Anakinra.
DB00026 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be increased when combined with Anakinra.
DB00026 DB06774 Capsaicin The metabolism of Capsaicin can be increased when combined with Anakinra.
DB00026 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Anakinra.
DB00026 DB09071 Tasimelteon The metabolism of Tasimelteon can be increased when combined with Anakinra.
DB00026 DB09118 Stiripentol The metabolism of Stiripentol can be increased when combined with Anakinra.
DB00026 DB09225 Zotepine The metabolism of Zotepine can be increased when combined with Anakinra.
DB00026 DB09273 Doxofylline The metabolism of Doxofylline can be increased when combined with Anakinra.
DB00026 DB09290 Ramosetron The metabolism of Ramosetron can be increased when combined with Anakinra.
DB00026 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be increased when combined with Anakinra.
DB00026 DB11967 Binimetinib The metabolism of Binimetinib can be increased when combined with Anakinra.
DB00026 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be increased when combined with Anakinra.
DB00026 DB12245 Triclabendazole The metabolism of Triclabendazole can be increased when combined with Anakinra.
DB00026 DB12332 Rucaparib The metabolism of Rucaparib can be increased when combined with Anakinra.
DB00026 DB12406 Lisofylline The metabolism of Lisofylline can be increased when combined with Anakinra.
DB00026 DB12531 Lobucavir The metabolism of Lobucavir can be increased when combined with Anakinra.
DB00026 DB12926 Cafedrine The metabolism of Cafedrine can be increased when combined with Anakinra.
DB00026 DB12927 Theodrenaline The metabolism of Theodrenaline can be increased when combined with Anakinra.
DB00026 DB12945 Dihydralazine The metabolism of Dihydralazine can be increased when combined with Anakinra.
DB00026 DB13203 Bamifylline The metabolism of Bamifylline can be increased when combined with Anakinra.
DB00026 DB13449 Proxyphylline The metabolism of Proxyphylline can be increased when combined with Anakinra.
DB00026 DB13573 Acefylline The metabolism of Acefylline can be increased when combined with Anakinra.
DB00026 DB13592 Etamiphylline The metabolism of Etamiphylline can be increased when combined with Anakinra.
DB00026 DB13634 Pentifylline The metabolism of Pentifylline can be increased when combined with Anakinra.
DB00026 DB13812 Bufylline The metabolism of Bufylline can be increased when combined with Anakinra.
DB00026 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Anakinra.
DB00026 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be increased when combined with Anakinra.
DB00026 DB11757 Istradefylline The metabolism of Istradefylline can be increased when combined with Anakinra.
DB00026 DB04889 Bicifadine The metabolism of Bicifadine can be increased when combined with Anakinra.
DB00026 DB05708 GTS-21 The metabolism of GTS-21 can be increased when combined with Anakinra.
DB00026 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be increased when combined with Anakinra.
DB00026 DB00425 Zolpidem The metabolism of Zolpidem can be increased when combined with Anakinra.
DB00026 DB00458 Imipramine The metabolism of Imipramine can be increased when combined with Anakinra.
DB00026 DB00532 Mephenytoin The metabolism of Mephenytoin can be increased when combined with Anakinra.
DB00026 DB00540 Nortriptyline The metabolism of Nortriptyline can be increased when combined with Anakinra.
DB00026 DB00575 Clonidine The metabolism of Clonidine can be increased when combined with Anakinra.
DB00026 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Anakinra.
DB00026 DB01242 Clomipramine The metabolism of Clomipramine can be increased when combined with Anakinra.
DB00026 DB11689 Selumetinib The metabolism of Selumetinib can be increased when combined with Anakinra.
DB00026 DB00277 Theophylline The metabolism of Theophylline can be increased when combined with Anakinra.
DB00026 DB00564 Carbamazepine The metabolism of Carbamazepine can be increased when combined with Anakinra.
DB00026 DB00682 Warfarin The metabolism of Warfarin can be increased when combined with Anakinra.
DB00026 DB00697 Tizanidine The metabolism of Tizanidine can be increased when combined with Anakinra.
DB00026 DB01100 Pimozide The metabolism of Pimozide can be increased when combined with Anakinra.
DB00026 DB01223 Aminophylline The metabolism of Aminophylline can be increased when combined with Anakinra.
DB00026 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Anakinra.
DB00026 DB09256 Tegafur The metabolism of Tegafur can be increased when combined with Anakinra.
DB00026 DB00851 Dacarbazine The metabolism of Dacarbazine can be increased when combined with Anakinra.
DB00026 DB08910 Pomalidomide The metabolism of Pomalidomide can be increased when combined with Anakinra.
DB00026 DB00238 Nevirapine The metabolism of Nevirapine can be increased when combined with Anakinra.
DB00026 DB00471 Montelukast The metabolism of Montelukast can be increased when combined with Anakinra.
DB00026 DB00690 Flurazepam The metabolism of Flurazepam can be increased when combined with Anakinra.
DB00026 DB00916 Metronidazole The metabolism of Metronidazole can be increased when combined with Anakinra.
DB00026 DB00983 Formoterol The metabolism of Formoterol can be increased when combined with Anakinra.
DB00026 DB01006 Letrozole The metabolism of Letrozole can be increased when combined with Anakinra.
DB00026 DB01028 Methoxyflurane The metabolism of Methoxyflurane can be increased when combined with Anakinra.
DB00026 DB01159 Halothane The metabolism of Halothane can be increased when combined with Anakinra.
DB00026 DB01236 Sevoflurane The metabolism of Sevoflurane can be increased when combined with Anakinra.
DB00026 DB01274 Arformoterol The metabolism of Arformoterol can be increased when combined with Anakinra.
DB00026 DB01544 Flunitrazepam The metabolism of Flunitrazepam can be increased when combined with Anakinra.
DB00026 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be increased when combined with Anakinra.
DB00026 DB06470 Clomethiazole The metabolism of Clomethiazole can be increased when combined with Anakinra.
DB00026 DB09068 Vortioxetine The metabolism of Vortioxetine can be increased when combined with Anakinra.
DB00026 DB09327 Tegafur-uracil The metabolism of Tegafur-uracil can be increased when combined with Anakinra.
DB00026 DB11586 Asunaprevir The metabolism of Asunaprevir can be increased when combined with Anakinra.
DB00026 DB04977 Plitidepsin The metabolism of Plitidepsin can be increased when combined with Anakinra.
DB00026 DB06119 Cenobamate The metabolism of Cenobamate can be increased when combined with Anakinra.
DB00026 DB00193 Tramadol The metabolism of Tramadol can be increased when combined with Anakinra.
DB00026 DB00333 Methadone The metabolism of Methadone can be increased when combined with Anakinra.
DB00026 DB00349 Clobazam The metabolism of Clobazam can be increased when combined with Anakinra.
DB00026 DB00625 Efavirenz The metabolism of Efavirenz can be increased when combined with Anakinra.
DB00026 DB00753 Isoflurane The metabolism of Isoflurane can be increased when combined with Anakinra.
DB00026 DB00818 Propofol The metabolism of Propofol can be increased when combined with Anakinra.
DB00026 DB00835 Brompheniramine The metabolism of Brompheniramine can be increased when combined with Anakinra.
DB00026 DB00836 Loperamide The metabolism of Loperamide can be increased when combined with Anakinra.
DB00026 DB00849 Methylphenobarbital The metabolism of Methylphenobarbital can be increased when combined with Anakinra.
DB00026 DB00865 Benzphetamine The metabolism of Benzphetamine can be increased when combined with Anakinra.
DB00026 DB01069 Promethazine The metabolism of Promethazine can be increased when combined with Anakinra.
DB00026 DB01074 Perhexiline The metabolism of Perhexiline can be increased when combined with Anakinra.
DB00026 DB01221 Ketamine The metabolism of Ketamine can be increased when combined with Anakinra.
DB00026 DB01466 Ethylmorphine The metabolism of Ethylmorphine can be increased when combined with Anakinra.
DB00026 DB01559 Clotiazepam The metabolism of Clotiazepam can be increased when combined with Anakinra.
DB00026 DB04938 Ospemifene The metabolism of Ospemifene can be increased when combined with Anakinra.
DB00026 DB04975 Banoxantrone The metabolism of Banoxantrone can be increased when combined with Anakinra.
DB00026 DB05541 Brivaracetam The metabolism of Brivaracetam can be increased when combined with Anakinra.
DB00026 DB06176 Romidepsin The metabolism of Romidepsin can be increased when combined with Anakinra.
DB00026 DB06209 Prasugrel The metabolism of Prasugrel can be increased when combined with Anakinra.
DB00026 DB06697 Artemether The metabolism of Artemether can be increased when combined with Anakinra.
DB00026 DB06710 Methyltestosterone The metabolism of Methyltestosterone can be increased when combined with Anakinra.
DB00026 DB06738 Ketobemidone The metabolism of Ketobemidone can be increased when combined with Anakinra.
DB00026 DB06739 Seratrodast The metabolism of Seratrodast can be increased when combined with Anakinra.
DB00026 DB11613 Velpatasvir The metabolism of Velpatasvir can be increased when combined with Anakinra.
DB00026 DB13132 Artemisinin The metabolism of Artemisinin can be increased when combined with Anakinra.
DB00026 DB13943 Testosterone cypionate The metabolism of Testosterone cypionate can be increased when combined with Anakinra.
DB00026 DB13944 Testosterone enanthate The metabolism of Testosterone enanthate can be increased when combined with Anakinra.
DB00026 DB13946 Testosterone undecanoate The metabolism of Testosterone undecanoate can be increased when combined with Anakinra.
DB00026 DB01156 Bupropion The metabolism of Bupropion can be increased when combined with Anakinra.
DB00026 DB00956 Hydrocodone The metabolism of Hydrocodone can be increased when combined with Anakinra.
DB00026 DB14975 Voxelotor The metabolism of Voxelotor can be increased when combined with Anakinra.
DB00026 DB11837 Osilodrostat The metabolism of Osilodrostat can be increased when combined with Anakinra.
DB00026 DB13384 Melitracen The metabolism of Melitracen can be increased when combined with Anakinra.
DB00026 DB13411 Lofepramine The metabolism of Lofepramine can be increased when combined with Anakinra.
DB00026 DB00714 Apomorphine The metabolism of Apomorphine can be increased when combined with Anakinra.
DB00026 DB09167 Dosulepin The metabolism of Dosulepin can be increased when combined with Anakinra.
DB00026 DB00213 Pantoprazole The metabolism of Pantoprazole can be increased when combined with Anakinra.
DB00026 DB00215 Citalopram The metabolism of Citalopram can be increased when combined with Anakinra.
DB00026 DB00312 Pentobarbital The metabolism of Pentobarbital can be increased when combined with Anakinra.
DB00026 DB00338 Omeprazole The metabolism of Omeprazole can be increased when combined with Anakinra.
DB00026 DB00347 Trimethadione The metabolism of Trimethadione can be increased when combined with Anakinra.
DB00026 DB00395 Carisoprodol The metabolism of Carisoprodol can be increased when combined with Anakinra.
DB00026 DB00448 Lansoprazole The metabolism of Lansoprazole can be increased when combined with Anakinra.
DB00026 DB00474 Methohexital The metabolism of Methohexital can be increased when combined with Anakinra.
DB00026 DB00582 Voriconazole The metabolism of Voriconazole can be increased when combined with Anakinra.
DB00026 DB00679 Thioridazine The metabolism of Thioridazine can be increased when combined with Anakinra.
DB00026 DB00736 Esomeprazole The metabolism of Esomeprazole can be increased when combined with Anakinra.
DB00026 DB00794 Primidone The metabolism of Primidone can be increased when combined with Anakinra.
DB00026 DB00909 Zonisamide The metabolism of Zonisamide can be increased when combined with Anakinra.
DB00026 DB01129 Rabeprazole The metabolism of Rabeprazole can be increased when combined with Anakinra.
DB00026 DB01131 Proguanil The metabolism of Proguanil can be increased when combined with Anakinra.
DB00026 DB01175 Escitalopram The metabolism of Escitalopram can be increased when combined with Anakinra.
DB00026 DB01259 Lapatinib The metabolism of Lapatinib can be increased when combined with Anakinra.
DB00026 DB01323 St. John's Wort The metabolism of St. John's Wort can be increased when combined with Anakinra.
DB00026 DB01355 Hexobarbital The metabolism of Hexobarbital can be increased when combined with Anakinra.
DB00026 DB01483 Barbital The metabolism of Barbital can be increased when combined with Anakinra.
DB00026 DB05246 Methsuximide The metabolism of Methsuximide can be increased when combined with Anakinra.
DB00026 DB05351 Dexlansoprazole The metabolism of Dexlansoprazole can be increased when combined with Anakinra.
DB00026 DB06218 Lacosamide The metabolism of Lacosamide can be increased when combined with Anakinra.
DB00026 DB06414 Etravirine The metabolism of Etravirine can be increased when combined with Anakinra.
DB00026 DB06605 Apixaban The metabolism of Apixaban can be increased when combined with Anakinra.
DB00026 DB09166 Etizolam The metabolism of Etizolam can be increased when combined with Anakinra.
DB00026 DB12130 Lorlatinib The metabolism of Lorlatinib can be increased when combined with Anakinra.
DB00026 DB12474 Lynestrenol The metabolism of Lynestrenol can be increased when combined with Anakinra.
DB00026 DB13762 Dexrabeprazole The metabolism of Dexrabeprazole can be increased when combined with Anakinra.
DB00026 DB14055 (S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Anakinra.
DB00026 DB00715 Paroxetine The metabolism of Paroxetine can be increased when combined with Anakinra.
DB00026 DB12500 Fedratinib The metabolism of Fedratinib can be increased when combined with Anakinra.
DB00026 DB04861 Nebivolol The metabolism of Nebivolol can be increased when combined with Anakinra.
DB00026 DB06684 Vilazodone The metabolism of Vilazodone can be increased when combined with Anakinra.
DB00026 DB01104 Sertraline The metabolism of Sertraline can be increased when combined with Anakinra.
DB00026 DB11823 Esketamine The metabolism of Esketamine can be increased when combined with Anakinra.
DB00026 DB00252 Phenytoin The metabolism of Phenytoin can be increased when combined with Anakinra.
DB00026 DB00599 Thiopental The metabolism of Thiopental can be increased when combined with Anakinra.
DB00026 DB01174 Phenobarbital The metabolism of Phenobarbital can be increased when combined with Anakinra.
DB00026 DB01320 Fosphenytoin The metabolism of Fosphenytoin can be increased when combined with Anakinra.
DB00026 DB00613 Amodiaquine The metabolism of Amodiaquine can be increased when combined with Anakinra.
DB00026 DB00799 Tazarotene The metabolism of Tazarotene can be increased when combined with Anakinra.
DB00026 DB05229 Beraprost The metabolism of Beraprost can be increased when combined with Anakinra.
DB00026 DB06510 Muraglitazar The metabolism of Muraglitazar can be increased when combined with Anakinra.
DB00026 DB09296 Ombitasvir The metabolism of Ombitasvir can be increased when combined with Anakinra.
DB00026 DB01217 Anastrozole The metabolism of Anastrozole can be increased when combined with Anakinra.
DB00026 DB00255 Diethylstilbestrol The metabolism of Diethylstilbestrol can be increased when combined with Anakinra.
DB00026 DB00295 Morphine The metabolism of Morphine can be increased when combined with Anakinra.
DB00026 DB00359 Sulfadiazine The metabolism of Sulfadiazine can be increased when combined with Anakinra.
DB00026 DB00402 Eszopiclone The metabolism of Eszopiclone can be increased when combined with Anakinra.
DB00026 DB00622 Nicardipine The metabolism of Nicardipine can be increased when combined with Anakinra.
DB00026 DB00912 Repaglinide The metabolism of Repaglinide can be increased when combined with Anakinra.
DB00026 DB01261 Sitagliptin The metabolism of Sitagliptin can be increased when combined with Anakinra.
DB00026 DB06670 Odanacatib The metabolism of Odanacatib can be increased when combined with Anakinra.
DB00026 DB08502 Capravirine The metabolism of Capravirine can be increased when combined with Anakinra.
DB00026 DB08931 Riociguat The metabolism of Riociguat can be increased when combined with Anakinra.
DB00026 DB09198 Lobeglitazone The metabolism of Lobeglitazone can be increased when combined with Anakinra.
DB00026 DB09199 Netoglitazone The metabolism of Netoglitazone can be increased when combined with Anakinra.
DB00026 DB09200 Rivoglitazone The metabolism of Rivoglitazone can be increased when combined with Anakinra.
DB00026 DB09201 Ciglitazone The metabolism of Ciglitazone can be increased when combined with Anakinra.
DB00026 DB11362 Selexipag The metabolism of Selexipag can be increased when combined with Anakinra.
DB00026 DB11901 Apalutamide The metabolism of Apalutamide can be increased when combined with Anakinra.
DB00026 DB11978 Glasdegib The metabolism of Glasdegib can be increased when combined with Anakinra.
DB00026 DB12781 Balaglitazone The metabolism of Balaglitazone can be increased when combined with Anakinra.
DB00026 DB01132 Pioglitazone The metabolism of Pioglitazone can be increased when combined with Anakinra.
DB00026 DB11652 Tucatinib The metabolism of Tucatinib can be increased when combined with Anakinra.
DB00026 DB00946 Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Anakinra.
DB00026 DB01229 Paclitaxel The metabolism of Paclitaxel can be increased when combined with Anakinra.
DB00026 DB00177 Valsartan The metabolism of Valsartan can be increased when combined with Anakinra.
DB00026 DB00184 Nicotine The metabolism of Nicotine can be increased when combined with Anakinra.
DB00026 DB00197 Troglitazone The metabolism of Troglitazone can be increased when combined with Anakinra.
DB00026 DB00214 Torasemide The metabolism of Torasemide can be increased when combined with Anakinra.
DB00026 DB00222 Glimepiride The metabolism of Glimepiride can be increased when combined with Anakinra.
DB00026 DB00285 Venlafaxine The metabolism of Venlafaxine can be increased when combined with Anakinra.
DB00026 DB00304 Desogestrel The metabolism of Desogestrel can be increased when combined with Anakinra.
DB00026 DB00307 Bexarotene The metabolism of Bexarotene can be increased when combined with Anakinra.
DB00026 DB00327 Hydromorphone The metabolism of Hydromorphone can be increased when combined with Anakinra.
DB00026 DB00328 Indomethacin The metabolism of Indomethacin can be increased when combined with Anakinra.
DB00026 DB00343 Diltiazem The metabolism of Diltiazem can be increased when combined with Anakinra.
DB00026 DB00374 Treprostinil The metabolism of Treprostinil can be increased when combined with Anakinra.
DB00026 DB00412 Rosiglitazone The metabolism of Rosiglitazone can be increased when combined with Anakinra.
DB00026 DB00414 Acetohexamide The metabolism of Acetohexamide can be increased when combined with Anakinra.
DB00026 DB00420 Promazine The metabolism of Promazine can be increased when combined with Anakinra.
DB00026 DB00440 Trimethoprim The metabolism of Trimethoprim can be increased when combined with Anakinra.
DB00026 DB00461 Nabumetone The metabolism of Nabumetone can be increased when combined with Anakinra.
DB00026 DB00468 Quinine The metabolism of Quinine can be increased when combined with Anakinra.
DB00026 DB00469 Tenoxicam The metabolism of Tenoxicam can be increased when combined with Anakinra.
DB00026 DB00472 Fluoxetine The metabolism of Fluoxetine can be increased when combined with Anakinra.
DB00026 DB00476 Duloxetine The metabolism of Duloxetine can be increased when combined with Anakinra.
DB00026 DB00482 Celecoxib The metabolism of Celecoxib can be increased when combined with Anakinra.
DB00026 DB00495 Zidovudine The metabolism of Zidovudine can be increased when combined with Anakinra.
DB00026 DB00502 Haloperidol The metabolism of Haloperidol can be increased when combined with Anakinra.
DB00026 DB00531 Cyclophosphamide The metabolism of Cyclophosphamide can be increased when combined with Anakinra.
DB00026 DB00533 Rofecoxib The metabolism of Rofecoxib can be increased when combined with Anakinra.
DB00026 DB00549 Zafirlukast The metabolism of Zafirlukast can be increased when combined with Anakinra.
DB00026 DB00554 Piroxicam The metabolism of Piroxicam can be increased when combined with Anakinra.
DB00026 DB00559 Bosentan The metabolism of Bosentan can be increased when combined with Anakinra.
DB00026 DB00568 Cinnarizine The metabolism of Cinnarizine can be increased when combined with Anakinra.
DB00026 DB00580 Valdecoxib The metabolism of Valdecoxib can be increased when combined with Anakinra.
DB00026 DB00586 Diclofenac The metabolism of Diclofenac can be increased when combined with Anakinra.
DB00026 DB00617 Paramethadione The metabolism of Paramethadione can be increased when combined with Anakinra.
DB00026 DB00661 Verapamil The metabolism of Verapamil can be increased when combined with Anakinra.
DB00026 DB00672 Chlorpropamide The metabolism of Chlorpropamide can be increased when combined with Anakinra.
DB00026 DB00678 Losartan The metabolism of Losartan can be increased when combined with Anakinra.
DB00026 DB00701 Amprenavir The metabolism of Amprenavir can be increased when combined with Anakinra.
DB00026 DB00712 Flurbiprofen The metabolism of Flurbiprofen can be increased when combined with Anakinra.
DB00026 DB00731 Nateglinide The metabolism of Nateglinide can be increased when combined with Anakinra.
DB00026 DB00744 Zileuton The metabolism of Zileuton can be increased when combined with Anakinra.
DB00026 DB00749 Etodolac The metabolism of Etodolac can be increased when combined with Anakinra.
DB00026 DB00755 Tretinoin The metabolism of Tretinoin can be increased when combined with Anakinra.
DB00026 DB00758 Clopidogrel The metabolism of Clopidogrel can be increased when combined with Anakinra.
DB00026 DB00783 Estradiol The metabolism of Estradiol can be increased when combined with Anakinra.
DB00026 DB00784 Mefenamic acid The metabolism of Mefenamic acid can be increased when combined with Anakinra.
DB00026 DB00788 Naproxen The metabolism of Naproxen can be increased when combined with Anakinra.
DB00026 DB00796 Candesartan cilexetil The metabolism of Candesartan cilexetil can be increased when combined with Anakinra.
DB00026 DB00812 Phenylbutazone The metabolism of Phenylbutazone can be increased when combined with Anakinra.
DB00026 DB00814 Meloxicam The metabolism of Meloxicam can be increased when combined with Anakinra.
DB00026 DB00839 Tolazamide The metabolism of Tolazamide can be increased when combined with Anakinra.
DB00026 DB00843 Donepezil The metabolism of Donepezil can be increased when combined with Anakinra.
DB00026 DB00857 Terbinafine The metabolism of Terbinafine can be increased when combined with Anakinra.
DB00026 DB00904 Ondansetron The metabolism of Ondansetron can be increased when combined with Anakinra.
DB00026 DB00921 Buprenorphine The metabolism of Buprenorphine can be increased when combined with Anakinra.
DB00026 DB00936 Salicylic acid The metabolism of Salicylic acid can be increased when combined with Anakinra.
DB00026 DB00945 Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be increased when combined with Anakinra.
DB00026 DB00969 Alosetron The metabolism of Alosetron can be increased when combined with Anakinra.
DB00026 DB00972 Azelastine The metabolism of Azelastine can be increased when combined with Anakinra.
DB00026 DB00980 Ramelteon The metabolism of Ramelteon can be increased when combined with Anakinra.
DB00026 DB01016 Glyburide The metabolism of Glyburide can be increased when combined with Anakinra.
DB00026 DB01029 Irbesartan The metabolism of Irbesartan can be increased when combined with Anakinra.
DB00026 DB01036 Tolterodine The metabolism of Tolterodine can be increased when combined with Anakinra.
DB00026 DB01037 Selegiline The metabolism of Selegiline can be increased when combined with Anakinra.
DB00026 DB01041 Thalidomide The metabolism of Thalidomide can be increased when combined with Anakinra.
DB00026 DB01050 Ibuprofen The metabolism of Ibuprofen can be increased when combined with Anakinra.
DB00026 DB01065 Melatonin The metabolism of Melatonin can be increased when combined with Anakinra.
DB00026 DB01067 Glipizide The metabolism of Glipizide can be increased when combined with Anakinra.
DB00026 DB01072 Atazanavir The metabolism of Atazanavir can be increased when combined with Anakinra.
DB00026 DB01075 Diphenhydramine The metabolism of Diphenhydramine can be increased when combined with Anakinra.
DB00026 DB01095 Fluvastatin The metabolism of Fluvastatin can be increased when combined with Anakinra.
DB00026 DB01098 Rosuvastatin The metabolism of Rosuvastatin can be increased when combined with Anakinra.
DB00026 DB01120 Gliclazide The metabolism of Gliclazide can be increased when combined with Anakinra.
DB00026 DB01124 Tolbutamide The metabolism of Tolbutamide can be increased when combined with Anakinra.
DB00026 DB01136 Carvedilol The metabolism of Carvedilol can be increased when combined with Anakinra.
DB00026 DB01154 Thiamylal The metabolism of Thiamylal can be increased when combined with Anakinra.
DB00026 DB01171 Moclobemide The metabolism of Moclobemide can be increased when combined with Anakinra.
DB00026 DB01177 Idarubicin The metabolism of Idarubicin can be increased when combined with Anakinra.
DB00026 DB01198 Zopiclone The metabolism of Zopiclone can be increased when combined with Anakinra.
DB00026 DB01251 Gliquidone The metabolism of Gliquidone can be increased when combined with Anakinra.
DB00026 DB01283 Lumiracoxib The metabolism of Lumiracoxib can be increased when combined with Anakinra.
DB00026 DB01289 Glisoxepide The metabolism of Glisoxepide can be increased when combined with Anakinra.
DB00026 DB01357 Mestranol The metabolism of Mestranol can be increased when combined with Anakinra.
DB00026 DB01424 Aminophenazone The metabolism of Aminophenazone can be increased when combined with Anakinra.
DB00026 DB01435 Antipyrine The metabolism of Antipyrine can be increased when combined with Anakinra.
DB00026 DB01589 Quazepam The metabolism of Quazepam can be increased when combined with Anakinra.
DB00026 DB01628 Etoricoxib The metabolism of Etoricoxib can be increased when combined with Anakinra.
DB00026 DB03756 Doconexent The metabolism of Doconexent can be increased when combined with Anakinra.
DB00026 DB03783 Phenacetin The metabolism of Phenacetin can be increased when combined with Anakinra.
DB00026 DB04557 Arachidonic Acid The metabolism of Arachidonic Acid can be increased when combined with Anakinra.
DB00026 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Anakinra.
DB00026 DB04665 Coumarin The metabolism of Coumarin can be increased when combined with Anakinra.
DB00026 DB04725 Licofelone The metabolism of Licofelone can be increased when combined with Anakinra.
DB00026 DB04841 Flunarizine The metabolism of Flunarizine can be increased when combined with Anakinra.
DB00026 DB04898 Ximelagatran The metabolism of Ximelagatran can be increased when combined with Anakinra.
DB00026 DB06204 Tapentadol The metabolism of Tapentadol can be increased when combined with Anakinra.
DB00026 DB06268 Sitaxentan The metabolism of Sitaxentan can be increased when combined with Anakinra.
DB00026 DB06370 Indisulam The metabolism of Indisulam can be increased when combined with Anakinra.
DB00026 DB06652 Vicriviroc The metabolism of Vicriviroc can be increased when combined with Anakinra.
DB00026 DB06725 Lornoxicam The metabolism of Lornoxicam can be increased when combined with Anakinra.
DB00026 DB06737 Zaltoprofen The metabolism of Zaltoprofen can be increased when combined with Anakinra.
DB00026 DB06803 Niclosamide The metabolism of Niclosamide can be increased when combined with Anakinra.
DB00026 DB07615 Tranilast The metabolism of Tranilast can be increased when combined with Anakinra.
DB00026 DB08439 Parecoxib The metabolism of Parecoxib can be increased when combined with Anakinra.
DB00026 DB08828 Vismodegib The metabolism of Vismodegib can be increased when combined with Anakinra.
DB00026 DB08860 Pitavastatin The metabolism of Pitavastatin can be increased when combined with Anakinra.
DB00026 DB08875 Cabozantinib The metabolism of Cabozantinib can be increased when combined with Anakinra.
DB00026 DB08899 Enzalutamide The metabolism of Enzalutamide can be increased when combined with Anakinra.
DB00026 DB08962 Glibornuride The metabolism of Glibornuride can be increased when combined with Anakinra.
DB00026 DB09048 Netupitant The metabolism of Netupitant can be increased when combined with Anakinra.
DB00026 DB09061 Cannabidiol The metabolism of Cannabidiol can be increased when combined with Anakinra.
DB00026 DB09080 Olodaterol The metabolism of Olodaterol can be increased when combined with Anakinra.
DB00026 DB09288 Propacetamol The metabolism of Propacetamol can be increased when combined with Anakinra.
DB00026 DB11560 Lesinurad The metabolism of Lesinurad can be increased when combined with Anakinra.
DB00026 DB11614 Rupatadine The metabolism of Rupatadine can be increased when combined with Anakinra.
DB00026 DB13406 Carbutamide The metabolism of Carbutamide can be increased when combined with Anakinra.
DB00026 DB13675 Metahexamide The metabolism of Metahexamide can be increased when combined with Anakinra.
DB00026 DB13919 Candesartan The metabolism of Candesartan can be increased when combined with Anakinra.
DB00026 DB13941 Piperaquine The metabolism of Piperaquine can be increased when combined with Anakinra.
DB00026 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Anakinra.
DB00026 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Anakinra.
DB00026 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Anakinra.
DB00026 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Anakinra.
DB00026 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Anakinra.
DB00026 DB14009 Medical Cannabis The metabolism of Medical Cannabis can be increased when combined with Anakinra.
DB00026 DB14011 Nabiximols The metabolism of Nabiximols can be increased when combined with Anakinra.
DB00026 DB00829 Diazepam The metabolism of Diazepam can be increased when combined with Anakinra.
DB00026 DB00514 Dextromethorphan The metabolism of Dextromethorphan can be increased when combined with Anakinra.
DB00026 DB00470 Dronabinol The metabolism of Dronabinol can be increased when combined with Anakinra.
DB00026 DB09213 Dexibuprofen The metabolism of Dexibuprofen can be increased when combined with Anakinra.
DB00026 DB00465 Ketorolac The metabolism of Ketorolac can be increased when combined with Anakinra.
DB00026 DB15233 Avapritinib The metabolism of Avapritinib can be increased when combined with Anakinra.
DB00026 DB00321 Amitriptyline The metabolism of Amitriptyline can be increased when combined with Anakinra.
DB00026 DB01142 Doxepin The metabolism of Doxepin can be increased when combined with Anakinra.
DB00026 DB00216 Eletriptan The metabolism of Eletriptan can be increased when combined with Anakinra.
DB00026 DB00404 Alprazolam The metabolism of Alprazolam can be increased when combined with Anakinra.
DB00026 DB00726 Trimipramine The metabolism of Trimipramine can be increased when combined with Anakinra.
DB00026 DB01101 Capecitabine The metabolism of Capecitabine can be increased when combined with Anakinra.
DB00026 DB00266 Dicoumarol The metabolism of Dicoumarol can be increased when combined with Anakinra.
DB00026 DB00313 Valproic acid The metabolism of Valproic acid can be increased when combined with Anakinra.
DB00026 DB00908 Quinidine The metabolism of Quinidine can be increased when combined with Anakinra.
DB00026 DB13136 Fluindione The metabolism of Fluindione can be increased when combined with Anakinra.
DB00026 DB01224 Quetiapine The metabolism of Quetiapine can be increased when combined with Anakinra.
DB00026 DB00182 Amphetamine The metabolism of Amphetamine can be increased when combined with Anakinra.
DB00026 DB00187 Esmolol The metabolism of Esmolol can be increased when combined with Anakinra.
DB00026 DB00245 Benzatropine The metabolism of Benzatropine can be increased when combined with Anakinra.
DB00026 DB00289 Atomoxetine The metabolism of Atomoxetine can be increased when combined with Anakinra.
DB00026 DB00335 Atenolol The metabolism of Atenolol can be increased when combined with Anakinra.
DB00026 DB00373 Timolol The metabolism of Timolol can be increased when combined with Anakinra.
DB00026 DB00409 Remoxipride The metabolism of Remoxipride can be increased when combined with Anakinra.
DB00026 DB00592 Piperazine The metabolism of Piperazine can be increased when combined with Anakinra.
DB00026 DB00699 Nicergoline The metabolism of Nicergoline can be increased when combined with Anakinra.
DB00026 DB00737 Meclizine The metabolism of Meclizine can be increased when combined with Anakinra.
DB00026 DB00805 Minaprine The metabolism of Minaprine can be increased when combined with Anakinra.
DB00026 DB00866 Alprenolol The metabolism of Alprenolol can be increased when combined with Anakinra.
DB00026 DB00914 Phenformin The metabolism of Phenformin can be increased when combined with Anakinra.
DB00026 DB00933 Mesoridazine The metabolism of Mesoridazine can be increased when combined with Anakinra.
DB00026 DB00960 Pindolol The metabolism of Pindolol can be increased when combined with Anakinra.
DB00026 DB01071 Mequitazine The metabolism of Mequitazine can be increased when combined with Anakinra.
DB00026 DB01079 Tegaserod The metabolism of Tegaserod can be increased when combined with Anakinra.
DB00026 DB01193 Acebutolol The metabolism of Acebutolol can be increased when combined with Anakinra.
DB00026 DB01203 Nadolol The metabolism of Nadolol can be increased when combined with Anakinra.
DB00026 DB01228 Encainide The metabolism of Encainide can be increased when combined with Anakinra.
DB00026 DB01233 Metoclopramide The metabolism of Metoclopramide can be increased when combined with Anakinra.
DB00026 DB01255 Lisdexamfetamine The metabolism of Lisdexamfetamine can be increased when combined with Anakinra.
DB00026 DB01295 Bevantolol The metabolism of Bevantolol can be increased when combined with Anakinra.
DB00026 DB01297 Practolol The metabolism of Practolol can be increased when combined with Anakinra.
DB00026 DB01359 Penbutolol The metabolism of Penbutolol can be increased when combined with Anakinra.
DB00026 DB01403 Methotrimeprazine The metabolism of Methotrimeprazine can be increased when combined with Anakinra.
DB00026 DB01429 Aprindine The metabolism of Aprindine can be increased when combined with Anakinra.
DB00026 DB01454 Midomafetamine The metabolism of Midomafetamine can be increased when combined with Anakinra.
DB00026 DB01472 4-Methoxyamphetamine The metabolism of 4-Methoxyamphetamine can be increased when combined with Anakinra.
DB00026 DB01576 Dextroamphetamine The metabolism of Dextroamphetamine can be increased when combined with Anakinra.
DB00026 DB01577 Metamfetamine The metabolism of Metamfetamine can be increased when combined with Anakinra.
DB00026 DB01580 Oxprenolol The metabolism of Oxprenolol can be increased when combined with Anakinra.
DB00026 DB04840 Debrisoquine The metabolism of Debrisoquine can be increased when combined with Anakinra.
DB00026 DB04844 Tetrabenazine The metabolism of Tetrabenazine can be increased when combined with Anakinra.
DB00026 DB04846 Celiprolol The metabolism of Celiprolol can be increased when combined with Anakinra.
DB00026 DB06217 Vernakalant The metabolism of Vernakalant can be increased when combined with Anakinra.
DB00026 DB06506 Repinotan The metabolism of Repinotan can be increased when combined with Anakinra.
DB00026 DB06608 Tafenoquine The metabolism of Tafenoquine can be increased when combined with Anakinra.
DB00026 DB06678 Esmirtazapine The metabolism of Esmirtazapine can be increased when combined with Anakinra.
DB00026 DB06726 Bufuralol The metabolism of Bufuralol can be increased when combined with Anakinra.
DB00026 DB06727 Sparteine The metabolism of Sparteine can be increased when combined with Anakinra.
DB00026 DB06735 Enclomiphene The metabolism of Enclomiphene can be increased when combined with Anakinra.
DB00026 DB08807 Bopindolol The metabolism of Bopindolol can be increased when combined with Anakinra.
DB00026 DB08808 Bupranolol The metabolism of Bupranolol can be increased when combined with Anakinra.
DB00026 DB08952 Indenolol The metabolism of Indenolol can be increased when combined with Anakinra.
DB00026 DB09013 Befunolol The metabolism of Befunolol can be increased when combined with Anakinra.
DB00026 DB09076 Umeclidinium The metabolism of Umeclidinium can be increased when combined with Anakinra.
DB00026 DB09204 Arotinolol The metabolism of Arotinolol can be increased when combined with Anakinra.
DB00026 DB09351 Levobetaxolol The metabolism of Levobetaxolol can be increased when combined with Anakinra.
DB00026 DB11770 Talinolol The metabolism of Talinolol can be increased when combined with Anakinra.
DB00026 DB11785 Anisodamine The metabolism of Anisodamine can be increased when combined with Anakinra.
DB00026 DB11855 Revefenacin The metabolism of Revefenacin can be increased when combined with Anakinra.
DB00026 DB11979 Elagolix The metabolism of Elagolix can be increased when combined with Anakinra.
DB00026 DB12070 Letermovir The metabolism of Letermovir can be increased when combined with Anakinra.
DB00026 DB12212 Landiolol The metabolism of Landiolol can be increased when combined with Anakinra.
DB00026 DB12752 Bucindolol The metabolism of Bucindolol can be increased when combined with Anakinra.
DB00026 DB13443 Esatenolol The metabolism of Esatenolol can be increased when combined with Anakinra.
DB00026 DB13508 Cloranolol The metabolism of Cloranolol can be increased when combined with Anakinra.
DB00026 DB13530 Mepindolol The metabolism of Mepindolol can be increased when combined with Anakinra.
DB00026 DB13679 Dexchlorpheniramine The metabolism of Dexchlorpheniramine can be increased when combined with Anakinra.
DB00026 DB13757 Epanolol The metabolism of Epanolol can be increased when combined with Anakinra.
DB00026 DB13775 Tertatolol The metabolism of Tertatolol can be increased when combined with Anakinra.
DB00026 DB00850 Perphenazine The metabolism of Perphenazine can be increased when combined with Anakinra.
DB00026 DB09173 Butyrfentanyl The metabolism of Butyrfentanyl can be increased when combined with Anakinra.
DB00026 DB00281 Lidocaine The metabolism of Lidocaine can be increased when combined with Anakinra.
DB00026 DB00598 Labetalol The metabolism of Labetalol can be increased when combined with Anakinra.
DB00026 DB14010 5-methoxy-N,N-dimethyltryptamine The metabolism of 5-methoxy-N,N-dimethyltryptamine can be increased when combined with Anakinra.
DB00026 DB01410 Ciclesonide The metabolism of Ciclesonide can be increased when combined with Anakinra.
DB00026 DB00918 Almotriptan The metabolism of Almotriptan can be increased when combined with Anakinra.
DB00026 DB08918 Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Anakinra.
DB00026 DB08922 Perospirone The metabolism of Perospirone can be increased when combined with Anakinra.
DB00026 DB09183 Dasabuvir The metabolism of Dasabuvir can be increased when combined with Anakinra.
DB00026 DB00185 Cevimeline The metabolism of Cevimeline can be increased when combined with Anakinra.
DB00026 DB00243 Ranolazine The metabolism of Ranolazine can be increased when combined with Anakinra.
DB00026 DB00297 Bupivacaine The metabolism of Bupivacaine can be increased when combined with Anakinra.
DB00026 DB00318 Codeine The metabolism of Codeine can be increased when combined with Anakinra.
DB00026 DB00377 Palonosetron The metabolism of Palonosetron can be increased when combined with Anakinra.
DB00026 DB00589 Lisuride The metabolism of Lisuride can be increased when combined with Anakinra.
DB00026 DB00647 Dextropropoxyphene The metabolism of Dextropropoxyphene can be increased when combined with Anakinra.
DB00026 DB00674 Galantamine The metabolism of Galantamine can be increased when combined with Anakinra.
DB00026 DB00705 Delavirdine The metabolism of Delavirdine can be increased when combined with Anakinra.
DB00026 DB00706 Tamsulosin The metabolism of Tamsulosin can be increased when combined with Anakinra.
DB00026 DB00757 Dolasetron The metabolism of Dolasetron can be increased when combined with Anakinra.
DB00026 DB01149 Nefazodone The metabolism of Nefazodone can be increased when combined with Anakinra.
DB00026 DB01192 Oxymorphone The metabolism of Oxymorphone can be increased when combined with Anakinra.
DB00026 DB01244 Bepridil The metabolism of Bepridil can be increased when combined with Anakinra.
DB00026 DB01392 Yohimbine The metabolism of Yohimbine can be increased when combined with Anakinra.
DB00026 DB01409 Tiotropium The metabolism of Tiotropium can be increased when combined with Anakinra.
DB00026 DB01551 Dihydrocodeine The metabolism of Dihydrocodeine can be increased when combined with Anakinra.
DB00026 DB01591 Solifenacin The metabolism of Solifenacin can be increased when combined with Anakinra.
DB00026 DB01621 Pipotiazine The metabolism of Pipotiazine can be increased when combined with Anakinra.
DB00026 DB02703 Fusidic acid The metabolism of Fusidic acid can be increased when combined with Anakinra.
DB00026 DB04829 Lysergic acid diethylamide The metabolism of Lysergic acid diethylamide can be increased when combined with Anakinra.
DB00026 DB04884 Dapoxetine The metabolism of Dapoxetine can be increased when combined with Anakinra.
DB00026 DB04905 Tesmilifene The metabolism of Tesmilifene can be increased when combined with Anakinra.
DB00026 DB04920 Clevidipine The metabolism of Clevidipine can be increased when combined with Anakinra.
DB00026 DB05271 Rotigotine The metabolism of Rotigotine can be increased when combined with Anakinra.
DB00026 DB06016 Cariprazine The metabolism of Cariprazine can be increased when combined with Anakinra.
DB00026 DB06144 Sertindole The metabolism of Sertindole can be increased when combined with Anakinra.
DB00026 DB06203 Alogliptin The metabolism of Alogliptin can be increased when combined with Anakinra.
DB00026 DB06702 Fesoterodine The metabolism of Fesoterodine can be increased when combined with Anakinra.
DB00026 DB08893 Mirabegron The metabolism of Mirabegron can be increased when combined with Anakinra.
DB00026 DB09128 Brexpiprazole The metabolism of Brexpiprazole can be increased when combined with Anakinra.
DB00026 DB09195 Lorpiprazole The metabolism of Lorpiprazole can be increased when combined with Anakinra.
DB00026 DB09555 Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be increased when combined with Anakinra.
DB00026 DB11130 Opium The metabolism of Opium can be increased when combined with Anakinra.
DB00026 DB11642 Pitolisant The metabolism of Pitolisant can be increased when combined with Anakinra.
DB00026 DB13293 Ipecac The metabolism of Ipecac can be increased when combined with Anakinra.
DB00026 DB00344 Protriptyline The metabolism of Protriptyline can be increased when combined with Anakinra.
DB00026 DB00496 Darifenacin The metabolism of Darifenacin can be increased when combined with Anakinra.
DB00026 DB00543 Amoxapine The metabolism of Amoxapine can be increased when combined with Anakinra.
DB00026 DB00932 Tipranavir The metabolism of Tipranavir can be increased when combined with Anakinra.
DB00026 DB09039 Eliglustat The metabolism of Eliglustat can be increased when combined with Anakinra.
DB00026 DB12930 Opipramol The metabolism of Opipramol can be increased when combined with Anakinra.
DB00026 DB00489 Sotalol The metabolism of Sotalol can be increased when combined with Anakinra.
DB00026 DB01035 Procainamide The metabolism of Procainamide can be increased when combined with Anakinra.
DB00026 DB01195 Flecainide The metabolism of Flecainide can be increased when combined with Anakinra.
DB00026 DB00228 Enflurane The metabolism of Enflurane can be increased when combined with Anakinra.
DB00026 DB06712 Nilvadipine The metabolism of Nilvadipine can be increased when combined with Anakinra.
DB00026 DB06728 Aniline The metabolism of Aniline can be increased when combined with Anakinra.
DB00026 DB00949 Felbamate The metabolism of Felbamate can be increased when combined with Anakinra.
DB00026 DB00593 Ethosuximide The metabolism of Ethosuximide can be increased when combined with Anakinra.
DB00026 DB00186 Lorazepam The metabolism of Lorazepam can be increased when combined with Anakinra.
DB00026 DB00191 Phentermine The metabolism of Phentermine can be increased when combined with Anakinra.
DB00026 DB00207 Azithromycin The metabolism of Azithromycin can be increased when combined with Anakinra.
DB00026 DB00208 Ticlopidine The metabolism of Ticlopidine can be increased when combined with Anakinra.
DB00026 DB00264 Metoprolol The metabolism of Metoprolol can be increased when combined with Anakinra.
DB00026 DB00426 Famciclovir The metabolism of Famciclovir can be increased when combined with Anakinra.
DB00026 DB00433 Prochlorperazine The metabolism of Prochlorperazine can be increased when combined with Anakinra.
DB00026 DB00567 Cephalexin The metabolism of Cephalexin can be increased when combined with Anakinra.
DB00026 DB00590 Doxazosin The metabolism of Doxazosin can be increased when combined with Anakinra.
DB00026 DB01039 Fenofibrate The metabolism of Fenofibrate can be increased when combined with Anakinra.
DB00026 DB01395 Drospirenone The metabolism of Drospirenone can be increased when combined with Anakinra.
DB00026 DB01411 Pranlukast The metabolism of Pranlukast can be increased when combined with Anakinra.
DB00026 DB01431 Allylestrenol The metabolism of Allylestrenol can be increased when combined with Anakinra.
DB00026 DB01624 Zuclopenthixol The metabolism of Zuclopenthixol can be increased when combined with Anakinra.
DB00026 DB06201 Rufinamide The metabolism of Rufinamide can be increased when combined with Anakinra.
DB00026 DB06480 Prucalopride The metabolism of Prucalopride can be increased when combined with Anakinra.
DB00026 DB08882 Linagliptin The metabolism of Linagliptin can be increased when combined with Anakinra.
DB00026 DB09030 Vorapaxar The metabolism of Vorapaxar can be increased when combined with Anakinra.
DB00026 DB09034 Suvorexant The metabolism of Suvorexant can be increased when combined with Anakinra.
DB00026 DB09079 Nintedanib The metabolism of Nintedanib can be increased when combined with Anakinra.
DB00026 DB09299 Tenofovir alafenamide The metabolism of Tenofovir alafenamide can be increased when combined with Anakinra.
DB00026 DB09330 Osimertinib The metabolism of Osimertinib can be increased when combined with Anakinra.
DB00026 DB11094 Vitamin D The metabolism of Vitamin D can be increased when combined with Anakinra.
DB00026 DB11273 Dihydroergocornine The metabolism of Dihydroergocornine can be increased when combined with Anakinra.
DB00026 DB11730 Ribociclib The metabolism of Ribociclib can be increased when combined with Anakinra.
DB00026 DB11952 Duvelisib The metabolism of Duvelisib can be increased when combined with Anakinra.
DB00026 DB12141 Gilteritinib The metabolism of Gilteritinib can be increased when combined with Anakinra.
DB00026 DB12515 9-aminocamptothecin The metabolism of 9-aminocamptothecin can be increased when combined with Anakinra.
DB00026 DB12952 Methylprednisone The metabolism of Methylprednisone can be increased when combined with Anakinra.
DB00026 DB13345 Dihydroergocristine The metabolism of Dihydroergocristine can be increased when combined with Anakinra.
DB00026 DB13385 Dihydroergocryptine The metabolism of Dihydroergocryptine can be increased when combined with Anakinra.
DB00026 DB14126 Tenofovir The metabolism of Tenofovir can be increased when combined with Anakinra.
DB00026 DB15444 Elexacaftor The metabolism of Elexacaftor can be increased when combined with Anakinra.
DB00026 DB06717 Fosaprepitant The metabolism of Fosaprepitant can be increased when combined with Anakinra.
DB00026 DB12825 Lefamulin The metabolism of Lefamulin can be increased when combined with Anakinra.
DB00026 DB12887 Tazemetostat The metabolism of Tazemetostat can be increased when combined with Anakinra.
DB00026 DB00454 Meperidine The metabolism of Meperidine can be increased when combined with Anakinra.
DB00026 DB01151 Desipramine The metabolism of Desipramine can be increased when combined with Anakinra.
DB00026 DB12371 Siponimod The metabolism of Siponimod can be increased when combined with Anakinra.
DB00026 DB00247 Methysergide The metabolism of Methysergide can be increased when combined with Anakinra.
DB00026 DB08827 Lomitapide The metabolism of Lomitapide can be increased when combined with Anakinra.
DB00026 DB11742 Ebastine The metabolism of Ebastine can be increased when combined with Anakinra.
DB00026 DB05015 Belinostat The metabolism of Belinostat can be increased when combined with Anakinra.
DB00026 DB01118 Amiodarone The metabolism of Amiodarone can be increased when combined with Anakinra.
DB00026 DB00675 Tamoxifen The metabolism of Tamoxifen can be increased when combined with Anakinra.
DB00026 DB00204 Dofetilide The metabolism of Dofetilide can be increased when combined with Anakinra.
DB00026 DB00342 Terfenadine The metabolism of Terfenadine can be increased when combined with Anakinra.
DB00026 DB00451 Levothyroxine The metabolism of Levothyroxine can be increased when combined with Anakinra.
DB00026 DB00604 Cisapride The metabolism of Cisapride can be increased when combined with Anakinra.
DB00026 DB00877 Sirolimus The metabolism of Sirolimus can be increased when combined with Anakinra.
DB00026 DB01008 Busulfan The metabolism of Busulfan can be increased when combined with Anakinra.
DB00026 DB01254 Dasatinib The metabolism of Dasatinib can be increased when combined with Anakinra.
DB00026 DB01396 Digitoxin The metabolism of Digitoxin can be increased when combined with Anakinra.
DB00026 DB01590 Everolimus The metabolism of Everolimus can be increased when combined with Anakinra.
DB00026 DB03410 4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be increased when combined with Anakinra.
DB00026 DB04855 Dronedarone The metabolism of Dronedarone can be increased when combined with Anakinra.
DB00026 DB06287 Temsirolimus The metabolism of Temsirolimus can be increased when combined with Anakinra.
DB00026 DB09053 Ibrutinib The metabolism of Ibrutinib can be increased when combined with Anakinra.
DB00026 DB09289 Tianeptine The metabolism of Tianeptine can be increased when combined with Anakinra.
DB00026 DB11633 Isavuconazole The metabolism of Isavuconazole can be increased when combined with Anakinra.
DB00026 DB13275 Clorindione The metabolism of Clorindione can be increased when combined with Anakinra.
DB00026 DB00398 Sorafenib The metabolism of Sorafenib can be increased when combined with Anakinra.
DB00026 DB00444 Teniposide The metabolism of Teniposide can be increased when combined with Anakinra.
DB00026 DB00530 Erlotinib The metabolism of Erlotinib can be increased when combined with Anakinra.
DB00026 DB00541 Vincristine The metabolism of Vincristine can be increased when combined with Anakinra.
DB00026 DB00619 Imatinib The metabolism of Imatinib can be increased when combined with Anakinra.
DB00026 DB00773 Etoposide The metabolism of Etoposide can be increased when combined with Anakinra.
DB00026 DB01248 Docetaxel The metabolism of Docetaxel can be increased when combined with Anakinra.
DB00026 DB01268 Sunitinib The metabolism of Sunitinib can be increased when combined with Anakinra.
DB00026 DB06626 Axitinib The metabolism of Axitinib can be increased when combined with Anakinra.
DB00026 DB08865 Crizotinib The metabolism of Crizotinib can be increased when combined with Anakinra.
DB00026 DB08901 Ponatinib The metabolism of Ponatinib can be increased when combined with Anakinra.
DB00026 DB12483 Copanlisib The metabolism of Copanlisib can be increased when combined with Anakinra.
DB00026 DB00188 Bortezomib The metabolism of Bortezomib can be increased when combined with Anakinra.
DB00026 DB00363 Clozapine The metabolism of Clozapine can be increased when combined with Anakinra.
DB00026 DB01181 Ifosfamide The metabolism of Ifosfamide can be increased when combined with Anakinra.
DB00026 DB05109 Trabectedin The metabolism of Trabectedin can be increased when combined with Anakinra.
DB00026 DB12147 Erdafitinib The metabolism of Erdafitinib can be increased when combined with Anakinra.
DB00026 DB13874 Enasidenib The metabolism of Enasidenib can be increased when combined with Anakinra.
DB00026 DB06589 Pazopanib The metabolism of Pazopanib can be increased when combined with Anakinra.
DB00026 DB05239 Cobimetinib The metabolism of Cobimetinib can be increased when combined with Anakinra.
DB00026 DB09063 Ceritinib The metabolism of Ceritinib can be increased when combined with Anakinra.
DB00026 DB11963 Dacomitinib The metabolism of Dacomitinib can be increased when combined with Anakinra.
DB00026 DB12015 Alpelisib The metabolism of Alpelisib can be increased when combined with Anakinra.
DB00026 DB00309 Vindesine The metabolism of Vindesine can be increased when combined with Anakinra.
DB00026 DB00361 Vinorelbine The metabolism of Vinorelbine can be increased when combined with Anakinra.
DB00026 DB00570 Vinblastine The metabolism of Vinblastine can be increased when combined with Anakinra.
DB00026 DB00694 Daunorubicin The metabolism of Daunorubicin can be increased when combined with Anakinra.
DB00026 DB00987 Cytarabine The metabolism of Cytarabine can be increased when combined with Anakinra.
DB00026 DB00997 Doxorubicin The metabolism of Doxorubicin can be increased when combined with Anakinra.
DB00026 DB01108 Trilostane The metabolism of Trilostane can be increased when combined with Anakinra.
DB00026 DB04572 Thiotepa The metabolism of Thiotepa can be increased when combined with Anakinra.
DB00026 DB04845 Ixabepilone The metabolism of Ixabepilone can be increased when combined with Anakinra.
DB00026 DB04868 Nilotinib The metabolism of Nilotinib can be increased when combined with Anakinra.
DB00026 DB06603 Panobinostat The metabolism of Panobinostat can be increased when combined with Anakinra.
DB00026 DB06616 Bosutinib The metabolism of Bosutinib can be increased when combined with Anakinra.
DB00026 DB08870 Brentuximab vedotin The metabolism of Brentuximab vedotin can be increased when combined with Anakinra.
DB00026 DB08877 Ruxolitinib The metabolism of Ruxolitinib can be increased when combined with Anakinra.
DB00026 DB09073 Palbociclib The metabolism of Palbociclib can be increased when combined with Anakinra.
DB00026 DB08912 Dabrafenib The metabolism of Dabrafenib can be increased when combined with Anakinra.
DB00026 DB12267 Brigatinib The metabolism of Brigatinib can be increased when combined with Anakinra.
DB00026 DB11718 Encorafenib The metabolism of Encorafenib can be increased when combined with Anakinra.
DB00026 DB00563 Methotrexate The metabolism of Methotrexate can be increased when combined with Anakinra.
DB00026 DB05294 Vandetanib The metabolism of Vandetanib can be increased when combined with Anakinra.
DB00026 DB05812 Abiraterone The metabolism of Abiraterone can be increased when combined with Anakinra.
DB00026 DB08881 Vemurafenib The metabolism of Vemurafenib can be increased when combined with Anakinra.
DB00026 DB11363 Alectinib The metabolism of Alectinib can be increased when combined with Anakinra.
DB00026 DB11581 Venetoclax The metabolism of Venetoclax can be increased when combined with Anakinra.
DB00026 DB11641 Vinflunine The metabolism of Vinflunine can be increased when combined with Anakinra.
DB00026 DB11703 Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Anakinra.
DB00026 DB15035 Zanubrutinib The metabolism of Zanubrutinib can be increased when combined with Anakinra.
DB00026 DB00248 Cabergoline The metabolism of Cabergoline can be increased when combined with Anakinra.
DB00026 DB06595 Midostaurin The metabolism of Midostaurin can be increased when combined with Anakinra.
DB00026 DB09143 Sonidegib The metabolism of Sonidegib can be increased when combined with Anakinra.
DB00026 DB11828 Neratinib The metabolism of Neratinib can be increased when combined with Anakinra.
DB00026 DB11986 Entrectinib The metabolism of Entrectinib can be increased when combined with Anakinra.
DB00026 DB12978 Pexidartinib The metabolism of Pexidartinib can be increased when combined with Anakinra.
DB00026 DB14568 Ivosidenib The metabolism of Ivosidenib can be increased when combined with Anakinra.
DB00026 DB09054 Idelalisib The metabolism of Idelalisib can be increased when combined with Anakinra.
DB00026 DB09570 Ixazomib The metabolism of Ixazomib can be increased when combined with Anakinra.
DB00026 DB00199 Erythromycin The metabolism of Erythromycin can be increased when combined with Anakinra.
DB00026 DB00246 Ziprasidone The metabolism of Ziprasidone can be increased when combined with Anakinra.
DB00026 DB00439 Cerivastatin The metabolism of Cerivastatin can be increased when combined with Anakinra.
DB00026 DB00499 Flutamide The metabolism of Flutamide can be increased when combined with Anakinra.
DB00026 DB00528 Lercanidipine The metabolism of Lercanidipine can be increased when combined with Anakinra.
DB00026 DB00571 Propranolol The metabolism of Propranolol can be increased when combined with Anakinra.
DB00026 DB00588 Fluticasone propionate The metabolism of Fluticasone propionate can be increased when combined with Anakinra.
DB00026 DB00608 Chloroquine The metabolism of Chloroquine can be increased when combined with Anakinra.
DB00026 DB00688 Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be increased when combined with Anakinra.
DB00026 DB00717 Norethisterone The metabolism of Norethisterone can be increased when combined with Anakinra.
DB00026 DB00738 Pentamidine The metabolism of Pentamidine can be increased when combined with Anakinra.
DB00026 DB00741 Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Anakinra.
DB00026 DB00762 Irinotecan The metabolism of Irinotecan can be increased when combined with Anakinra.
DB00026 DB00822 Disulfiram The metabolism of Disulfiram can be increased when combined with Anakinra.
DB00026 DB00834 Mifepristone The metabolism of Mifepristone can be increased when combined with Anakinra.
DB00026 DB00938 Salmeterol The metabolism of Salmeterol can be increased when combined with Anakinra.
DB00026 DB00962 Zaleplon The metabolism of Zaleplon can be increased when combined with Anakinra.
DB00026 DB00976 Telithromycin The metabolism of Telithromycin can be increased when combined with Anakinra.
DB00026 DB01054 Nitrendipine The metabolism of Nitrendipine can be increased when combined with Anakinra.
DB00026 DB01058 Praziquantel The metabolism of Praziquantel can be increased when combined with Anakinra.
DB00026 DB01062 Oxybutynin The metabolism of Oxybutynin can be increased when combined with Anakinra.
DB00026 DB01076 Atorvastatin The metabolism of Atorvastatin can be increased when combined with Anakinra.
DB00026 DB01103 Quinacrine The metabolism of Quinacrine can be increased when combined with Anakinra.
DB00026 DB01115 Nifedipine The metabolism of Nifedipine can be increased when combined with Anakinra.
DB00026 DB01126 Dutasteride The metabolism of Dutasteride can be increased when combined with Anakinra.
DB00026 DB01166 Cilostazol The metabolism of Cilostazol can be increased when combined with Anakinra.
DB00026 DB01184 Domperidone The metabolism of Domperidone can be increased when combined with Anakinra.
DB00026 DB01211 Clarithromycin The metabolism of Clarithromycin can be increased when combined with Anakinra.
DB00026 DB01216 Finasteride The metabolism of Finasteride can be increased when combined with Anakinra.
DB00026 DB01218 Halofantrine The metabolism of Halofantrine can be increased when combined with Anakinra.
DB00026 DB05521 Telaprevir The metabolism of Telaprevir can be increased when combined with Anakinra.
DB00026 DB05773 Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be increased when combined with Anakinra.
DB00026 DB06267 Udenafil The metabolism of Udenafil can be increased when combined with Anakinra.
DB00026 DB06335 Saxagliptin The metabolism of Saxagliptin can be increased when combined with Anakinra.
DB00026 DB06403 Ambrisentan The metabolism of Ambrisentan can be increased when combined with Anakinra.
DB00026 DB06419 Cethromycin The metabolism of Cethromycin can be increased when combined with Anakinra.
DB00026 DB06772 Cabazitaxel The metabolism of Cabazitaxel can be increased when combined with Anakinra.
DB00026 DB06789 Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be increased when combined with Anakinra.
DB00026 DB08820 Ivacaftor The metabolism of Ivacaftor can be increased when combined with Anakinra.
DB00026 DB08873 Boceprevir The metabolism of Boceprevir can be increased when combined with Anakinra.
DB00026 DB08883 Perampanel The metabolism of Perampanel can be increased when combined with Anakinra.
DB00026 DB08906 Fluticasone furoate The metabolism of Fluticasone furoate can be increased when combined with Anakinra.
DB00026 DB09065 Cobicistat The metabolism of Cobicistat can be increased when combined with Anakinra.
DB00026 DB09074 Olaparib The metabolism of Olaparib can be increased when combined with Anakinra.
DB00026 DB09102 Daclatasvir The metabolism of Daclatasvir can be increased when combined with Anakinra.
DB00026 DB09231 Benidipine The metabolism of Benidipine can be increased when combined with Anakinra.
DB00026 DB09297 Paritaprevir The metabolism of Paritaprevir can be increased when combined with Anakinra.
DB00026 DB11574 Elbasvir The metabolism of Elbasvir can be increased when combined with Anakinra.
DB00026 DB11712 Tezacaftor The metabolism of Tezacaftor can be increased when combined with Anakinra.
DB00026 DB11737 Icotinib The metabolism of Icotinib can be increased when combined with Anakinra.
DB00026 DB12301 Doravirine The metabolism of Doravirine can be increased when combined with Anakinra.
DB00026 DB13867 Fluticasone The metabolism of Fluticasone can be increased when combined with Anakinra.
DB00026 DB14538 Hydrocortisone aceponate The metabolism of Hydrocortisone aceponate can be increased when combined with Anakinra.
DB00026 DB14539 Hydrocortisone acetate The metabolism of Hydrocortisone acetate can be increased when combined with Anakinra.
DB00026 DB14541 Hydrocortisone cypionate The metabolism of Hydrocortisone cypionate can be increased when combined with Anakinra.
DB00026 DB14542 Hydrocortisone phosphate The metabolism of Hydrocortisone phosphate can be increased when combined with Anakinra.
DB00026 DB00396 Progesterone The metabolism of Progesterone can be increased when combined with Anakinra.
DB00026 DB04856 Dexloxiglumide The metabolism of Dexloxiglumide can be increased when combined with Anakinra.
DB00026 DB04957 Azimilide The metabolism of Azimilide can be increased when combined with Anakinra.
DB00026 DB00250 Dapsone The metabolism of Dapsone can be increased when combined with Anakinra.
DB00026 DB00317 Gefitinib The metabolism of Gefitinib can be increased when combined with Anakinra.
DB00026 DB00367 Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Anakinra.
DB00026 DB00497 Oxycodone The metabolism of Oxycodone can be increased when combined with Anakinra.
DB00026 DB00620 Triamcinolone The metabolism of Triamcinolone can be increased when combined with Anakinra.
DB00026 DB00624 Testosterone The metabolism of Testosterone can be increased when combined with Anakinra.
DB00026 DB00656 Trazodone The metabolism of Trazodone can be increased when combined with Anakinra.
DB00026 DB00734 Risperidone The metabolism of Risperidone can be increased when combined with Anakinra.
DB00026 DB01114 Chlorpheniramine The metabolism of Chlorpheniramine can be increased when combined with Anakinra.
DB00026 DB01238 Aripiprazole The metabolism of Aripiprazole can be increased when combined with Anakinra.
DB00026 DB01267 Paliperidone The metabolism of Paliperidone can be increased when combined with Anakinra.
DB00026 DB04946 Iloperidone The metabolism of Iloperidone can be increased when combined with Anakinra.
DB00026 DB11915 Valbenazine The metabolism of Valbenazine can be increased when combined with Anakinra.
DB00026 DB12161 Deutetrabenazine The metabolism of Deutetrabenazine can be increased when combined with Anakinra.
DB00026 DB14185 Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Anakinra.
DB00026 DB01234 Dexamethasone The metabolism of Dexamethasone can be increased when combined with Anakinra.
DB00026 DB09237 Levamlodipine The metabolism of Levamlodipine can be increased when combined with Anakinra.
DB00026 DB11951 Lemborexant The metabolism of Lemborexant can be increased when combined with Anakinra.
DB00026 DB00557 Hydroxyzine The metabolism of Hydroxyzine can be increased when combined with Anakinra.
DB00026 DB00203 Sildenafil The metabolism of Sildenafil can be increased when combined with Anakinra.
DB00026 DB00227 Lovastatin The metabolism of Lovastatin can be increased when combined with Anakinra.
DB00026 DB00490 Buspirone The metabolism of Buspirone can be increased when combined with Anakinra.
DB00026 DB00641 Simvastatin The metabolism of Simvastatin can be increased when combined with Anakinra.
DB00026 DB00673 Aprepitant The metabolism of Aprepitant can be increased when combined with Anakinra.
DB00026 DB00820 Tadalafil The metabolism of Tadalafil can be increased when combined with Anakinra.
DB00026 DB00862 Vardenafil The metabolism of Vardenafil can be increased when combined with Anakinra.
DB00026 DB01190 Clindamycin The metabolism of Clindamycin can be increased when combined with Anakinra.
DB00026 DB00503 Ritonavir The metabolism of Ritonavir can be increased when combined with Anakinra.
DB00026 DB00224 Indinavir The metabolism of Indinavir can be increased when combined with Anakinra.
DB00026 DB00401 Nisoldipine The metabolism of Nisoldipine can be increased when combined with Anakinra.
DB00026 DB00637 Astemizole The metabolism of Astemizole can be increased when combined with Anakinra.
DB00026 DB00683 Midazolam The metabolism of Midazolam can be increased when combined with Anakinra.
DB00026 DB00700 Eplerenone The metabolism of Eplerenone can be increased when combined with Anakinra.
DB00026 DB00802 Alfentanil The metabolism of Alfentanil can be increased when combined with Anakinra.
DB00026 DB00813 Fentanyl The metabolism of Fentanyl can be increased when combined with Anakinra.
DB00026 DB00897 Triazolam The metabolism of Triazolam can be increased when combined with Anakinra.
DB00026 DB01023 Felodipine The metabolism of Felodipine can be increased when combined with Anakinra.
DB00026 DB01227 Levacetylmethadol The metabolism of Levacetylmethadol can be increased when combined with Anakinra.
DB00026 DB01232 Saquinavir The metabolism of Saquinavir can be increased when combined with Anakinra.
DB00026 DB06228 Rivaroxaban The metabolism of Rivaroxaban can be increased when combined with Anakinra.
DB00026 DB05804 Prasterone sulfate The metabolism of Prasterone sulfate can be increased when combined with Anakinra.
DB00026 DB00091 Cyclosporine Anakinra may increase the immunosuppressive activities of Cyclosporine.
DB00026 DB05676 Apremilast The therapeutic efficacy of Apremilast can be decreased when used in combination with Anakinra.
DB00026 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Anakinra.
DB00026 DB01601 Lopinavir The serum concentration of Anakinra can be increased when it is combined with Lopinavir.
DB00026 DB12530 Inebilizumab The risk or severity of infection can be increased when Anakinra is combined with Inebilizumab.
DB00027 DB12768 BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Gramicidin D.
DB00027 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Gramicidin D is combined with Dicoumarol.
DB00027 DB00498 Phenindione The risk or severity of bleeding can be increased when Gramicidin D is combined with Phenindione.
DB00027 DB00682 Warfarin The risk or severity of bleeding can be increased when Gramicidin D is combined with Warfarin.
DB00027 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Gramicidin D is combined with Phenprocoumon.
DB00027 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Gramicidin D is combined with Acenocoumarol.
DB00027 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Gramicidin D is combined with 4-hydroxycoumarin.
DB00027 DB04665 Coumarin The risk or severity of bleeding can be increased when Gramicidin D is combined with Coumarin.
DB00027 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Gramicidin D is combined with (R)-warfarin.
DB00027 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Gramicidin D is combined with Ethyl biscoumacetate.
DB00027 DB13136 Fluindione The risk or severity of bleeding can be increased when Gramicidin D is combined with Fluindione.
DB00027 DB13275 Clorindione The risk or severity of bleeding can be increased when Gramicidin D is combined with Clorindione.
DB00027 DB13347 Diphenadione The risk or severity of bleeding can be increased when Gramicidin D is combined with Diphenadione.
DB00027 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Gramicidin D is combined with Tioclomarol.
DB00027 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Gramicidin D is combined with (S)-Warfarin.
DB00027 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Gramicidin D.
DB00028 DB00255 Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00269 Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00286 Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00655 Estrone Estrone may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00783 Estradiol Estradiol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00890 Dienestrol Dienestrol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00977 Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB01357 Mestranol Mestranol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB04573 Estriol Estriol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB04574 Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB04575 Quinestrol Quinestrol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB07931 Hexestrol Hexestrol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB09070 Tibolone Tibolone may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB09369 Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB09381 Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB11478 Zeranol Zeranol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB11674 Equol Equol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB12487 Promestriene Promestriene may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13143 Methallenestril Methallenestril may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13386 Epimestrol Epimestrol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13418 Moxestrol Moxestrol may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13952 Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13953 Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13954 Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB13956 Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB15334 Biochanin A Biochanin A may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB15335 Formononetin Formononetin may increase the thrombogenic activities of Human immunoglobulin G.
DB00028 DB00002 Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Human immunoglobulin G.
DB00028 DB00043 Omalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Omalizumab.
DB00028 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adalimumab.
DB00028 DB00054 Abciximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abciximab.
DB00028 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gemtuzumab ozogamicin.
DB00028 DB00057 Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indium In-111 satumomab pendetide.
DB00028 DB00065 Infliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Infliximab.
DB00028 DB00072 Trastuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab.
DB00028 DB00073 Rituximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rituximab.
DB00028 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Basiliximab.
DB00028 DB00075 Muromonab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Muromonab.
DB00028 DB00076 Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine).
DB00028 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibritumomab tiuxetan.
DB00028 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tositumomab.
DB00028 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alemtuzumab.
DB00028 DB00089 Capromab pendetide The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Capromab pendetide.
DB00028 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efalizumab.
DB00028 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antithymocyte immunoglobulin (rabbit).
DB00028 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Natalizumab.
DB00028 DB00110 Palivizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab.
DB00028 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daclizumab.
DB00028 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab.
DB00028 DB00113 Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Technetium Tc-99m arcitumomab.
DB00028 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eculizumab.
DB00028 DB01269 Panitumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Panitumumab.
DB00028 DB01270 Ranibizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ranibizumab.
DB00028 DB04901 Galiximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galiximab.
DB00028 DB04949 Pexelizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pexelizumab.
DB00028 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Afelimomab.
DB00028 DB04958 Epratuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Epratuzumab.
DB00028 DB04962 Bectumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bectumomab.
DB00028 DB04964 Oregovomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Oregovomab.
DB00028 DB04988 IGN311 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IGN311.
DB00028 DB05006 Adecatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Adecatumumab.
DB00028 DB05097 Labetuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Labetuzumab.
DB00028 DB05101 Matuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Matuzumab.
DB00028 DB05111 Fontolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fontolizumab.
DB00028 DB05136 Bavituximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bavituximab.
DB00028 DB05139 CR002 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CR002.
DB00028 DB05209 Rozrolimupab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozrolimupab.
DB00028 DB05304 Girentuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Girentuximab.
DB00028 DB05336 Obiltoxaximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obiltoxaximab.
DB00028 DB05405 XTL-001 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with XTL-001.
DB00028 DB05437 NAV 1800 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with NAV 1800.
DB00028 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Briakinumab.
DB00028 DB05496 Otelixizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Otelixizumab.
DB00028 DB05545 AMG 108 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with AMG 108.
DB00028 DB05550 Iratumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Iratumumab.
DB00028 DB05555 Enokizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Enokizumab.
DB00028 DB05578 Ramucirumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ramucirumab.
DB00028 DB05595 Farletuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Farletuzumab.
DB00028 DB05656 Veltuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Veltuzumab.
DB00028 DB05679 Ustekinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ustekinumab.
DB00028 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab emtansine.
DB00028 DB05793 PRO-542 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with PRO-542.
DB00028 DB05797 TNX-901 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TNX-901.
DB00028 DB05889 Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inotuzumab ozogamicin.
DB00028 DB05892 RI 624 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with RI 624.
DB00028 DB05915 MYO-029 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with MYO-029.
DB00028 DB05916 CT-011 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with CT-011.
DB00028 DB05941 Leronlimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Leronlimab.
DB00028 DB05996 Glembatumumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Glembatumumab vedotin.
DB00028 DB06043 Olaratumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olaratumab.
DB00028 DB06049 IPH 2101 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IPH 2101.
DB00028 DB06050 TB-402 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TB-402.
DB00028 DB06081 Caplacizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Caplacizumab.
DB00028 DB06101 IMC-1C11 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IMC-1C11.
DB00028 DB06116 Eldelumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eldelumab.
DB00028 DB06162 Lumiliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumiliximab.
DB00028 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Canakinumab.
DB00028 DB06186 Ipilimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipilimumab.
DB00028 DB06192 Nimotuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nimotuzumab.
DB00028 DB06241 Clenoliximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Clenoliximab.
DB00028 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tocilizumab.
DB00028 DB06304 BIIB015 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with BIIB015.
DB00028 DB06305 Sonepcizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sonepcizumab.
DB00028 DB06310 Motavizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Motavizumab.
DB00028 DB06317 Elotuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Elotuzumab.
DB00028 DB06318 AVE9633 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with AVE9633.
DB00028 DB06322 Carotuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Carotuximab.
DB00028 DB06324 XmAb 2513 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with XmAb 2513.
DB00028 DB06342 Coltuximab ravtansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Coltuximab ravtansine.
DB00028 DB06343 Teprotumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teprotumumab.
DB00028 DB06360 Lucatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lucatumumab.
DB00028 DB06366 Pertuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pertuzumab.
DB00028 DB06371 Siplizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Siplizumab.
DB00028 DB06467 Apolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Apolizumab.
DB00028 DB06474 Sibrotuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sibrotuzumab.
DB00028 DB06550 Bivatuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bivatuzumab.
DB00028 DB06557 Lerdelimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lerdelimumab.
DB00028 DB06599 Lexatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lexatumumab.
DB00028 DB06602 Reslizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Reslizumab.
DB00028 DB06606 Teplizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Teplizumab.
DB00028 DB06607 Catumaxomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Catumaxomab.
DB00028 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mepolizumab.
DB00028 DB06643 Denosumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Denosumab.
DB00028 DB06647 Volociximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Volociximab.
DB00028 DB06650 Ofatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ofatumumab.
DB00028 DB06674 Golimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Golimumab.
DB00028 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brentuximab vedotin.
DB00028 DB08879 Belimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belimumab.
DB00028 DB08902 Raxibacumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Raxibacumab.
DB00028 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Certolizumab pegol.
DB00028 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Obinutuzumab.
DB00028 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Secukinumab.
DB00028 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vedolizumab.
DB00028 DB09035 Nivolumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nivolumab.
DB00028 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Siltuximab.
DB00028 DB09037 Pembrolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pembrolizumab.
DB00028 DB09045 Dulaglutide The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dulaglutide.
DB00028 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Blinatumomab.
DB00028 DB09057 Anthrax immune globulin human The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anthrax immune globulin human.
DB00028 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dinutuximab.
DB00028 DB09105 Asfotase alfa The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asfotase alfa.
DB00028 DB09264 Idarucizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Idarucizumab.
DB00028 DB09302 Alirocumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Alirocumab.
DB00028 DB09303 Evolocumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Evolocumab.
DB00028 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Antilymphocyte immunoglobulin (horse).
DB00028 DB09331 Daratumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daratumumab.
DB00028 DB09559 Necitumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Necitumumab.
DB00028 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ixekizumab.
DB00028 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ravulizumab.
DB00028 DB11595 Atezolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atezolizumab.
DB00028 DB11604 Tetanus Immune Globulin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tetanus Immune Globulin.
DB00028 DB11608 Eftrenonacog alfa The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eftrenonacog alfa.
DB00028 DB11621 Human Varicella-Zoster Immune Globulin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human Varicella-Zoster Immune Globulin.
DB00028 DB11646 Conatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Conatumumab.
DB00028 DB11657 Tabalumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tabalumab.
DB00028 DB11680 Ficlatuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ficlatuzumab.
DB00028 DB11685 Figitumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Figitumumab.
DB00028 DB11714 Durvalumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Durvalumab.
DB00028 DB11715 Bapineuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bapineuzumab.
DB00028 DB11731 Depatuxizumab mafodotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Depatuxizumab mafodotin.
DB00028 DB11746 Onartuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Onartuzumab.
DB00028 DB11756 Solanezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Solanezumab.
DB00028 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sarilumab.
DB00028 DB11771 Tremelimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tremelimumab.
DB00028 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brodalumab.
DB00028 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sirukumab.
DB00028 DB11826 Lampalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lampalizumab.
DB00028 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Guselkumab.
DB00028 DB11840 Dalotuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dalotuzumab.
DB00028 DB11849 Emibetuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emibetuzumab.
DB00028 DB11850 Ublituximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ublituximab.
DB00028 DB11856 Ligelizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ligelizumab.
DB00028 DB11857 Seribantumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Seribantumab.
DB00028 DB11862 Landogrozumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Landogrozumab.
DB00028 DB11866 Romosozumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Romosozumab.
DB00028 DB11884 Vadastuximab Talirine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vadastuximab Talirine.
DB00028 DB11914 Lebrikizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lebrikizumab.
DB00028 DB11930 Varlilumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Varlilumab.
DB00028 DB11945 Avelumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Avelumab.
DB00028 DB11959 Crenezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Crenezumab.
DB00028 DB11972 Rilotumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rilotumumab.
DB00028 DB11976 Anifrolumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anifrolumab.
DB00028 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ocrelizumab.
DB00028 DB12023 Benralizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Benralizumab.
DB00028 DB12034 Gantenerumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gantenerumab.
DB00028 DB12053 Visilizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Visilizumab.
DB00028 DB12077 Urelumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Urelumab.
DB00028 DB12089 Lorvotuzumab mertansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lorvotuzumab mertansine.
DB00028 DB12090 Patritumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Patritumab.
DB00028 DB12102 Fulranumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fulranumab.
DB00028 DB12104 Tarextumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tarextumab.
DB00028 DB12118 Sotatercept The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sotatercept.
DB00028 DB12119 Gevokizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gevokizumab.
DB00028 DB12142 Duligotuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Duligotuzumab.
DB00028 DB12152 Simtuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Simtuzumab.
DB00028 DB12157 Fasinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fasinumab.
DB00028 DB12159 Dupilumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dupilumab.
DB00028 DB12169 Tralokinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tralokinumab.
DB00028 DB12189 Etrolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Etrolizumab.
DB00028 DB12202 Zalutumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zalutumumab.
DB00028 DB12205 Ganitumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ganitumab.
DB00028 DB12213 Etaracizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Etaracizumab.
DB00028 DB12240 Polatuzumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Polatuzumab vedotin.
DB00028 DB12246 Inclacumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inclacumab.
DB00028 DB12250 Cixutumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cixutumumab.
DB00028 DB12261 Ascrinvacumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ascrinvacumab.
DB00028 DB12274 Aducanumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Aducanumab.
DB00028 DB12281 Luspatercept The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Luspatercept.
DB00028 DB12296 GS-5745 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with GS-5745.
DB00028 DB12317 Vanucizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vanucizumab.
DB00028 DB12331 Labetuzumab govitecan The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Labetuzumab govitecan.
DB00028 DB12335 Tanezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tanezumab.
DB00028 DB12342 Ensituximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ensituximab.
DB00028 DB12344 Fezakinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fezakinumab.
DB00028 DB12363 Dusigitumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dusigitumab.
DB00028 DB12396 Fresolimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fresolimumab.
DB00028 DB12413 Indusatumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indusatumab vedotin.
DB00028 DB12456 Bococizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bococizumab.
DB00028 DB12489 Mirvetuximab Soravtansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mirvetuximab Soravtansine.
DB00028 DB12498 Mogamulizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mogamulizumab.
DB00028 DB12520 Plozalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Plozalizumab.
DB00028 DB12530 Inebilizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inebilizumab.
DB00028 DB12534 Mavrilimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mavrilimumab.
DB00028 DB12560 Blosozumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Blosozumab.
DB00028 DB12584 Bimagrumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bimagrumab.
DB00028 DB12589 Dacetuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dacetuzumab.
DB00028 DB12609 Tovetumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tovetumab.
DB00028 DB12683 Lumretuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumretuzumab.
DB00028 DB12698 Ibalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ibalizumab.
DB00028 DB12701 Intetumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Intetumumab.
DB00028 DB12718 Carlumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Carlumab.
DB00028 DB12734 Demcizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Demcizumab.
DB00028 DB12773 Sifalimumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sifalimumab.
DB00028 DB12775 Abituzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abituzumab.
DB00028 DB12797 Ecromeximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ecromeximab.
DB00028 DB12807 Naptumomab Estafenatox The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Naptumomab Estafenatox.
DB00028 DB12815 Crotedumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Crotedumab.
DB00028 DB12820 Concizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Concizumab.
DB00028 DB12826 Depatuxizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Depatuxizumab.
DB00028 DB12844 Rontalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rontalizumab.
DB00028 DB12845 Amatuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Amatuximab.
DB00028 DB12849 Clazakizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Clazakizumab.
DB00028 DB12891 Ozanezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ozanezumab.
DB00028 DB12893 Sacituzumab govitecan The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sacituzumab govitecan.
DB00028 DB12917 Bimekizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bimekizumab.
DB00028 DB12943 Milatuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Milatuzumab.
DB00028 DB12976 Robatumumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Robatumumab.
DB00028 DB13017 Rovalpituzumab Tesirine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rovalpituzumab Tesirine.
DB00028 DB13037 Namilumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Namilumab.
DB00028 DB13045 Racotumomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Racotumomab.
DB00028 DB13073 Tregalizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tregalizumab.
DB00028 DB13127 Olokizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olokizumab.
DB00028 DB13140 Bezlotoxumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bezlotoxumab.
DB00028 DB13375 Edrecolomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Edrecolomab.
DB00028 DB13535 Nebacumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nebacumab.
DB00028 DB13886 Human cytomegalovirus immune globulin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human cytomegalovirus immune globulin.
DB00028 DB13923 Emicizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emicizumab.
DB00028 DB13976 Sulesomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sulesomab.
DB00028 DB13979 Besilesomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Besilesomab.
DB00028 DB14004 Tildrakizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tildrakizumab.
DB00028 DB14012 Burosumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Burosumab.
DB00028 DB14039 Erenumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Erenumab.
DB00028 DB14040 Eptinezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eptinezumab.
DB00028 DB14041 Fremanezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fremanezumab.
DB00028 DB14042 Galcanezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galcanezumab.
DB00028 DB14211 Fanolesomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fanolesomab.
DB00028 DB14580 Lecanemab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lecanemab.
DB00028 DB14597 Lanadelumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lanadelumab.
DB00028 DB14707 Cemiplimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cemiplimab.
DB00028 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emapalumab.
DB00028 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Risankizumab.
DB00028 DB14776 Camrelizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Camrelizumab.
DB00028 DB14778 Setrusumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Setrusumab.
DB00028 DB14784 Gancotamab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gancotamab.
DB00028 DB14809 Anetumab ravtansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Anetumab ravtansine.
DB00028 DB14811 Isatuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Isatuximab.
DB00028 DB14824 Icrucumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Icrucumab.
DB00028 DB14843 Codrituzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Codrituzumab.
DB00028 DB14864 Brolucizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Brolucizumab.
DB00028 DB14871 Xentuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Xentuzumab.
DB00028 DB14877 Lintuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lintuzumab.
DB00028 DB14891 Vobarilizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vobarilizumab.
DB00028 DB14897 Parsatuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Parsatuzumab.
DB00028 DB14905 Emactuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emactuzumab.
DB00028 DB14907 Bevacizumab zirconium Zr-89 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bevacizumab zirconium Zr-89.
DB00028 DB14908 Refanezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Refanezumab.
DB00028 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Rozanolixizumab.
DB00028 DB14947 Bermekimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bermekimab.
DB00028 DB14952 Pamrevlumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pamrevlumab.
DB00028 DB14959 Opicinumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Opicinumab.
DB00028 DB14962 Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Trastuzumab deruxtecan.
DB00028 DB14967 Margetuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Margetuximab.
DB00028 DB14988 Dalantercept The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dalantercept.
DB00028 DB14997 Pateclizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pateclizumab.
DB00028 DB15014 Gremubamab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gremubamab.
DB00028 DB15022 Apomab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Apomab.
DB00028 DB15044 Tafasitamab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tafasitamab.
DB00028 DB15045 Ipafricept The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipafricept.
DB00028 DB15076 Abrilumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abrilumab.
DB00028 DB15089 Frovocimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Frovocimab.
DB00028 DB15090 Tezepelumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tezepelumab.
DB00028 DB15101 Tigatuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tigatuzumab.
DB00028 DB15104 Telisotuzumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Telisotuzumab vedotin.
DB00028 DB15113 Utomilumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Utomilumab.
DB00028 DB15118 Zolbetuximab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zolbetuximab.
DB00028 DB15135 Ponezumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ponezumab.
DB00028 DB15160 Asunercept The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Asunercept.
DB00028 DB15172 Suvratoxumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Suvratoxumab.
DB00028 DB15225 Mitazalimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mitazalimab.
DB00028 DB15252 Nemolizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Nemolizumab.
DB00028 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bleselumab.
DB00028 DB15277 Gedivumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gedivumab.
DB00028 DB15336 Valanafusp alfa The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Valanafusp alfa.
DB00028 DB15349 Sofituzumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Sofituzumab vedotin.
DB00028 DB15354 Evinacumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Evinacumab.
DB00028 DB15363 Istiratumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Istiratumab.
DB00028 DB15383 Pidilizumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pidilizumab.
DB00028 DB15397 GMA-161 The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with GMA-161.
DB00028 DB15409 Ladiratuzumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ladiratuzumab vedotin.
DB00028 DB15415 Tomaralimab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tomaralimab.
DB00028 DB15428 Vesencumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vesencumab.
DB00028 DB15432 Pinatuzumab vedotin The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pinatuzumab vedotin.
DB00028 DB15441 Lulizumab pegol The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lulizumab pegol.
DB00028 DB15443 Lorukafusp alfa The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lorukafusp alfa.
DB00028 DB15453 Naratuximab emtansine The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Naratuximab emtansine.
DB00028 DB15559 Zenocutuzumab The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zenocutuzumab.
DB00028 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Human immunoglobulin G.
DB00029 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Anistreplase.
DB00029 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Anistreplase.
DB00029 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Anistreplase.
DB00029 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Anistreplase is combined with Deferasirox.
DB00029 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Ursodeoxycholic acid.
DB00029 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Glycochenodeoxycholic Acid.
DB00029 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Cholic Acid.
DB00029 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Glycocholic acid.
DB00029 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Deoxycholic acid.
DB00029 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Taurocholic acid.
DB00029 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Obeticholic acid.
DB00029 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Chenodeoxycholic acid.
DB00029 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Taurochenodeoxycholic acid.
DB00029 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Tauroursodeoxycholic acid.
DB00029 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Bamet-UD2.
DB00029 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Dehydrocholic acid.
DB00029 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Hyodeoxycholic Acid.
DB00029 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Anistreplase.
DB00029 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Anistreplase.
DB00029 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Obinutuzumab.
DB00029 DB06228 Rivaroxaban Anistreplase may increase the anticoagulant activities of Rivaroxaban.
DB00029 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Sugammadex.
DB00029 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Anistreplase.
DB00029 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Anistreplase.
DB00029 DB00013 Urokinase Urokinase may increase the anticoagulant activities of Anistreplase.
DB00029 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Anistreplase.
DB00029 DB09030 Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Anistreplase.
DB00029 DB06692 Aprotinin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Aprotinin.
DB00029 DB01381 Ginkgo biloba The therapeutic efficacy of Anistreplase can be increased when used in combination with Ginkgo biloba.
DB00029 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Anistreplase.
DB00029 DB00468 Quinine The therapeutic efficacy of Anistreplase can be increased when used in combination with Quinine.
DB00029 DB00908 Quinidine The therapeutic efficacy of Anistreplase can be increased when used in combination with Quinidine.
DB00029 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Anistreplase.
DB00029 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Anistreplase.
DB00029 DB00806 Pentoxifylline The therapeutic efficacy of Anistreplase can be increased when used in combination with Pentoxifylline.
DB00029 DB00686 Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Anistreplase.
DB00029 DB00583 Levocarnitine The therapeutic efficacy of Anistreplase can be increased when used in combination with Levocarnitine.
DB00029 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB04573 Estriol Estriol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Anistreplase.
DB00029 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB11674 Equol Equol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Anistreplase.
DB00029 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Anistreplase.
DB00029 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Anistreplase.
DB00029 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Anistreplase.
DB00029 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Anistreplase.
DB00029 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Anistreplase.
DB00029 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Anistreplase.
DB00029 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Anistreplase.
DB00029 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Anistreplase.
DB00029 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Anistreplase.
DB00029 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Anistreplase.
DB00029 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Anistreplase.
DB00029 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Anistreplase.
DB00029 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Anistreplase.
DB00029 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Anistreplase.
DB00029 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Anistreplase.
DB00029 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Anistreplase.
DB00029 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Anistreplase.
DB00029 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Anistreplase.
DB00029 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Anistreplase.
DB00029 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Anistreplase.
DB00029 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Anistreplase.
DB00029 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Anistreplase.
DB00029 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Anistreplase.
DB00029 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Anistreplase.
DB00029 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Anistreplase.
DB00029 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Anistreplase.
DB00029 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Anistreplase.
DB00029 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Anistreplase.
DB00029 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Anistreplase.
DB00029 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Anistreplase.
DB00029 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Anistreplase.
DB00029 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Anistreplase.
DB00029 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Anistreplase.
DB00029 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Anistreplase.
DB00029 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Anistreplase.
DB00029 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Anistreplase.
DB00029 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Anistreplase.
DB00029 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Anistreplase.
DB00029 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Anistreplase.
DB00029 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Anistreplase.
DB00029 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Anistreplase.
DB00029 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Anistreplase.
DB00029 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Anistreplase.
DB00029 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Anistreplase.
DB00029 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Anistreplase.
DB00029 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Anistreplase.
DB00029 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Anistreplase.
DB00029 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Anistreplase.
DB00029 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Anistreplase.
DB00029 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Anistreplase.
DB00029 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Anistreplase.
DB00029 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Anistreplase.
DB00029 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Anistreplase.
DB00029 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Anistreplase.
DB00029 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Anistreplase.
DB00029 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Anistreplase.
DB00029 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Anistreplase.
DB00029 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Anistreplase.
DB00029 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Anistreplase.
DB00029 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Anistreplase.
DB00029 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Anistreplase.
DB00029 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Anistreplase.
DB00029 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Anistreplase.
DB00029 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Anistreplase.
DB00029 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Anistreplase.
DB00029 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Anistreplase.
DB00029 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Anistreplase.
DB00029 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Anistreplase.
DB00029 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Anistreplase.
DB00029 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Anistreplase.
DB00029 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Anistreplase.
DB00029 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Anistreplase.
DB00029 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Anistreplase.
DB00029 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Anistreplase.
DB00029 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Anistreplase.
DB00029 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Anistreplase.
DB00029 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Anistreplase.
DB00029 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Anistreplase.
DB00029 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Anistreplase.
DB00029 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Anistreplase.
DB00029 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Anistreplase.
DB00029 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Anistreplase.
DB00029 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Anistreplase.
DB00029 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Anistreplase.
DB00029 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Anistreplase.
DB00029 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Anistreplase.
DB00029 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Anistreplase.
DB00029 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Anistreplase.
DB00029 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Anistreplase.
DB00029 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Anistreplase.
DB00029 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Anistreplase.
DB00029 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Anistreplase.
DB00029 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Anistreplase.
DB00029 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Anistreplase.
DB00029 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Anistreplase.
DB00029 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Anistreplase.
DB00029 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Anistreplase.
DB00029 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Anistreplase.
DB00029 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Anistreplase.
DB00029 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Anistreplase.
DB00029 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Anistreplase.
DB00029 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Anistreplase.
DB00029 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Anistreplase.
DB00029 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Anistreplase.
DB00029 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Anistreplase is combined with Omacetaxine mepesuccinate.
DB00029 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Anistreplase.
DB00029 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Tositumomab.
DB00029 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Anistreplase.
DB00029 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Anistreplase is combined with Collagenase clostridium histolyticum.
DB00029 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Anistreplase.
DB00029 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Anistreplase.
DB00029 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Anistreplase.
DB00029 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Anistreplase.
DB00029 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Anistreplase.
DB00029 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Anistreplase.
DB00029 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Anistreplase.
DB00029 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Anistreplase.
DB00029 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Anistreplase.
DB00029 DB00834 Mifepristone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Mifepristone.
DB00029 DB04066 p-Coumaric acid The therapeutic efficacy of Anistreplase can be decreased when used in combination with p-Coumaric acid.
DB00029 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Anistreplase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00029 DB05830 Trestolone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Trestolone.
DB00029 DB06266 Lonidamine The therapeutic efficacy of Anistreplase can be decreased when used in combination with Lonidamine.
DB00029 DB08867 Ulipristal The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ulipristal.
DB00029 DB09401 Isosorbide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Isosorbide.
DB00029 DB11507 Cloprostenol The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cloprostenol.
DB00029 DB12025 Triptolide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Triptolide.
DB00029 DB13044 Gossypol The therapeutic efficacy of Anistreplase can be decreased when used in combination with Gossypol.
DB00029 DB13310 Ormeloxifene The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ormeloxifene.
DB00029 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Anistreplase.
DB00029 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Anistreplase.
DB00029 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Anistreplase.
DB00029 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Anistreplase.
DB00029 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Anistreplase.
DB00029 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Anistreplase.
DB00029 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Anistreplase.
DB00029 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Anistreplase.
DB00029 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Anistreplase.
DB00029 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Anistreplase.
DB00029 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Anistreplase.
DB00029 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Anistreplase.
DB00029 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Anistreplase.
DB00029 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Anistreplase.
DB00029 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Anistreplase.
DB00029 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Anistreplase.
DB00029 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Anistreplase.
DB00029 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Anistreplase.
DB00029 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Anistreplase.
DB00029 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Anistreplase.
DB00029 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Anistreplase.
DB00029 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Anistreplase.
DB00029 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Anistreplase.
DB00029 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Anistreplase.
DB00029 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Anistreplase.
DB00029 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Anistreplase.
DB00029 DB01166 Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Anistreplase.
DB00029 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Anistreplase.
DB00029 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Anistreplase.
DB00029 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Anistreplase.
DB00029 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Anistreplase.
DB00029 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Anistreplase.
DB00029 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Anistreplase.
DB00029 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Anistreplase.
DB00029 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Anistreplase.
DB00029 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Anistreplase.
DB00029 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Anistreplase.
DB00029 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Anistreplase.
DB00029 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Anistreplase.
DB00029 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Anistreplase.
DB00029 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Anistreplase.
DB00029 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Anistreplase.
DB00029 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Anistreplase.
DB00029 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Anistreplase.
DB00029 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Anistreplase.
DB00029 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Anistreplase.
DB00029 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Anistreplase.
DB00029 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Anistreplase.
DB00029 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Anistreplase.
DB00029 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Anistreplase.
DB00029 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Anistreplase.
DB00029 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Anistreplase.
DB00029 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Anistreplase.
DB00029 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Anistreplase.
DB00029 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Anistreplase.
DB00029 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Anistreplase.
DB00029 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Anistreplase.
DB00029 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Anistreplase.
DB00029 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Anistreplase.
DB00029 DB00374 Treprostinil The risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.
DB00029 DB03404 Hemin Hemin may increase the anticoagulant activities of Anistreplase.
DB00029 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Anistreplase.
DB00029 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Anistreplase.
DB00029 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Anistreplase.
DB00029 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Anistreplase.
DB00029 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Anistreplase.
DB00029 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Anistreplase.
DB00029 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Anistreplase.
DB00029 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Anistreplase.
DB00029 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Anistreplase.
DB00029 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Anistreplase.
DB00029 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Anistreplase.
DB00029 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Anistreplase.
DB00029 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Anistreplase.
DB00029 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Anistreplase.
DB00029 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Anistreplase is combined with Azficel-T.
DB00029 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Anistreplase can be increased when used in combination with Omega-3-carboxylic acids.
DB00029 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Anistreplase.
DB00029 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Anistreplase.
DB00029 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Anistreplase.
DB00029 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Anistreplase.
DB00029 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Anistreplase.
DB00029 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Anistreplase.
DB00029 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Anistreplase.
DB00029 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Anistreplase.
DB00029 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Anistreplase.
DB00029 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Anistreplase.
DB00029 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Anistreplase.
DB00029 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Anistreplase.
DB00029 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Anistreplase.
DB00029 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Anistreplase.
DB00029 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Anistreplase.
DB00029 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Anistreplase.
DB00029 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Anistreplase.
DB00029 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Anistreplase.
DB00029 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Anistreplase.
DB00029 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Anistreplase.
DB00029 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Anistreplase.
DB00029 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Anistreplase.
DB00029 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Anistreplase.
DB00029 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Anistreplase.
DB00029 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Anistreplase.
DB00029 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Anistreplase.
DB00029 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Anistreplase.
DB00029 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Anistreplase.
DB00029 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Anistreplase.
DB00029 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Anistreplase.
DB00029 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Anistreplase.
DB00029 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Anistreplase.
DB00029 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Anistreplase.
DB00029 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Anistreplase.
DB00029 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Anistreplase.
DB00029 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Anistreplase.
DB00029 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Anistreplase.
DB00029 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Anistreplase.
DB00029 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Anistreplase.
DB00029 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Anistreplase.
DB00029 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Anistreplase.
DB00029 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Anistreplase.
DB00029 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Anistreplase.
DB00029 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Anistreplase.
DB00029 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Anistreplase.
DB00029 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Anistreplase.
DB00029 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Anistreplase.
DB00029 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Anistreplase.
DB00029 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Anistreplase.
DB00029 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Anistreplase.
DB00029 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Anistreplase.
DB00029 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Anistreplase.
DB00029 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Anistreplase.
DB00029 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Anistreplase.
DB00029 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Anistreplase.
DB00029 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Anistreplase.
DB00029 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Anistreplase.
DB00029 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Anistreplase.
DB00029 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Anistreplase.
DB00029 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Anistreplase.
DB00029 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Anistreplase.
DB00029 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Anistreplase.
DB00029 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Anistreplase.
DB00029 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Anistreplase.
DB00029 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Anistreplase.
DB00029 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Anistreplase.
DB00029 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Anistreplase.
DB00029 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Anistreplase.
DB00029 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Anistreplase.
DB00029 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Anistreplase.
DB00029 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Anistreplase.
DB00029 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Anistreplase.
DB00029 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Anistreplase.
DB00029 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Anistreplase.
DB00029 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Anistreplase.
DB00029 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Anistreplase.
DB00029 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Anistreplase.
DB00029 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Anistreplase.
DB00029 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Anistreplase.
DB00029 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Anistreplase.
DB00029 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Anistreplase.
DB00029 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Anistreplase.
DB00029 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Anistreplase.
DB00029 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Anistreplase.
DB00029 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Anistreplase.
DB00029 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Anistreplase.
DB00029 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Anistreplase.
DB00029 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Anistreplase.
DB00029 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Anistreplase.
DB00029 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Anistreplase.
DB00029 DB00682 Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Anistreplase.
DB00029 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Anistreplase.
DB00029 DB00974 Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Anistreplase.
DB00029 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Anistreplase.
DB00029 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Anistreplase.
DB00029 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Anistreplase.
DB00029 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Anistreplase.
DB00029 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Anistreplase.
DB00029 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Anistreplase.
DB00029 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Anistreplase.
DB00029 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Anistreplase.
DB00029 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Anistreplase.
DB00029 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Anistreplase.
DB00029 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Anistreplase.
DB00029 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Anistreplase.
DB00029 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Anistreplase.
DB00029 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Anistreplase.
DB00029 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Anistreplase.
DB00029 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Anistreplase.
DB00029 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Anistreplase.
DB00029 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Anistreplase.
DB00029 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Anistreplase.
DB00029 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Anistreplase.
DB00029 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Anistreplase.
DB00029 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Anistreplase.
DB00029 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Anistreplase.
DB00029 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Anistreplase.
DB00029 DB13124 Troxerutin The risk or severity of bleeding can be increased when Troxerutin is combined with Anistreplase.
DB00029 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Anistreplase.
DB00029 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Anistreplase.
DB00029 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Anistreplase.
DB00029 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Anistreplase.
DB00029 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Anistreplase.
DB00029 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Anistreplase.
DB00029 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Anistreplase.
DB00029 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Anistreplase.
DB00029 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Anistreplase.
DB00029 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Anistreplase.
DB00029 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Anistreplase.
DB00029 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Anistreplase.
DB00029 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Anistreplase.
DB00029 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Anistreplase.
DB00029 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Anistreplase.
DB00029 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Anistreplase.
DB00029 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Anistreplase.
DB00029 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Anistreplase.
DB00029 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Anistreplase.
DB00029 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Anistreplase.
DB00029 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Anistreplase.
DB00029 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Anistreplase.
DB00029 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Anistreplase.
DB00029 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Anistreplase is combined with Tocopherylquinone.
DB00029 DB06679 Amediplase The risk or severity of bleeding can be increased when Anistreplase is combined with Amediplase.
DB00029 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Anistreplase is combined with 4-hydroxycoumarin.
DB00029 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Anistreplase is combined with (R)-warfarin.
DB00029 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Anistreplase is combined with (S)-Warfarin.
DB00029 DB12364 Betrixaban The risk or severity of bleeding can be increased when Anistreplase is combined with Betrixaban.
DB00029 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Anistreplase is combined with Edetate calcium disodium anhydrous.
DB00029 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Anistreplase is combined with Zinc citrate.
DB00029 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Anistreplase is combined with Antithrombin Alfa.
DB00029 DB04665 Coumarin The risk or severity of bleeding can be increased when Anistreplase is combined with Coumarin.
DB00029 DB14726 Dabigatran The risk or severity of bleeding can be increased when Anistreplase is combined with Dabigatran.
DB00029 DB06294 Semuloparin The risk or severity of bleeding can be increased when Anistreplase is combined with Semuloparin.
DB00029 DB12726 Monteplase The risk or severity of bleeding can be increased when Anistreplase is combined with Monteplase.
DB00029 DB00177 Valsartan The risk or severity of angioedema can be increased when Anistreplase is combined with Valsartan.
DB00029 DB00178 Ramipril The risk or severity of angioedema can be increased when Anistreplase is combined with Ramipril.
DB00029 DB00230 Pregabalin The risk or severity of angioedema can be increased when Anistreplase is combined with Pregabalin.
DB00029 DB00492 Fosinopril The risk or severity of angioedema can be increased when Anistreplase is combined with Fosinopril.
DB00029 DB00519 Trandolapril The risk or severity of angioedema can be increased when Anistreplase is combined with Trandolapril.
DB00029 DB00542 Benazepril The risk or severity of angioedema can be increased when Anistreplase is combined with Benazepril.
DB00029 DB00584 Enalapril The risk or severity of angioedema can be increased when Anistreplase is combined with Enalapril.
DB00029 DB00678 Losartan The risk or severity of angioedema can be increased when Anistreplase is combined with Losartan.
DB00029 DB00691 Moexipril The risk or severity of angioedema can be increased when Anistreplase is combined with Moexipril.
DB00029 DB00722 Lisinopril The risk or severity of angioedema can be increased when Anistreplase is combined with Lisinopril.
DB00029 DB00790 Perindopril The risk or severity of angioedema can be increased when Anistreplase is combined with Perindopril.
DB00029 DB00876 Eprosartan The risk or severity of angioedema can be increased when Anistreplase is combined with Eprosartan.
DB00029 DB00877 Sirolimus The risk or severity of angioedema can be increased when Anistreplase is combined with Sirolimus.
DB00029 DB00881 Quinapril The risk or severity of angioedema can be increased when Anistreplase is combined with Quinapril.
DB00029 DB00886 Omapatrilat The risk or severity of angioedema can be increased when Anistreplase is combined with Omapatrilat.
DB00029 DB00966 Telmisartan The risk or severity of angioedema can be increased when Anistreplase is combined with Telmisartan.
DB00029 DB01050 Ibuprofen The risk or severity of angioedema can be increased when Anistreplase is combined with Ibuprofen.
DB00029 DB01180 Rescinnamine The risk or severity of angioedema can be increased when Anistreplase is combined with Rescinnamine.
DB00029 DB01197 Captopril The risk or severity of angioedema can be increased when Anistreplase is combined with Captopril.
DB00029 DB01261 Sitagliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Sitagliptin.
DB00029 DB01340 Cilazapril The risk or severity of angioedema can be increased when Anistreplase is combined with Cilazapril.
DB00029 DB01342 Forasartan The risk or severity of angioedema can be increased when Anistreplase is combined with Forasartan.
DB00029 DB01347 Saprisartan The risk or severity of angioedema can be increased when Anistreplase is combined with Saprisartan.
DB00029 DB01348 Spirapril The risk or severity of angioedema can be increased when Anistreplase is combined with Spirapril.
DB00029 DB04876 Vildagliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Vildagliptin.
DB00029 DB06011 AMG-222 The risk or severity of angioedema can be increased when Anistreplase is combined with AMG-222.
DB00029 DB06127 Bisegliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Bisegliptin.
DB00029 DB06196 Icatibant The risk or severity of angioedema can be increased when Anistreplase is combined with Icatibant.
DB00029 DB06203 Alogliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Alogliptin.
DB00029 DB06245 Lanoteplase The risk or severity of angioedema can be increased when Anistreplase is combined with Lanoteplase.
DB00029 DB06287 Temsirolimus The risk or severity of angioedema can be increased when Anistreplase is combined with Temsirolimus.
DB00029 DB06335 Saxagliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Saxagliptin.
DB00029 DB08382 Gosogliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Gosogliptin.
DB00029 DB08822 Azilsartan medoxomil The risk or severity of angioedema can be increased when Anistreplase is combined with Azilsartan medoxomil.
DB00029 DB08836 Temocapril The risk or severity of angioedema can be increased when Anistreplase is combined with Temocapril.
DB00029 DB08882 Linagliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Linagliptin.
DB00029 DB09292 Sacubitril The risk or severity of angioedema can be increased when Anistreplase is combined with Sacubitril.
DB00029 DB09477 Enalaprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Enalaprilat.
DB00029 DB11723 Dutogliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Dutogliptin.
DB00029 DB11783 Imidapril The risk or severity of angioedema can be increased when Anistreplase is combined with Imidapril.
DB00029 DB11950 Teneligliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Teneligliptin.
DB00029 DB11992 Omarigliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Omarigliptin.
DB00029 DB12268 Carmegliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Carmegliptin.
DB00029 DB12412 Gemigliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Gemigliptin.
DB00029 DB12417 Anagliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Anagliptin.
DB00029 DB12625 Evogliptin The risk or severity of angioedema can be increased when Anistreplase is combined with Evogliptin.
DB00029 DB13166 Zofenopril The risk or severity of angioedema can be increased when Anistreplase is combined with Zofenopril.
DB00029 DB13312 Delapril The risk or severity of angioedema can be increased when Anistreplase is combined with Delapril.
DB00029 DB14125 Benazeprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Benazeprilat.
DB00029 DB14207 Fosinoprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Fosinoprilat.
DB00029 DB14208 Ramiprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Ramiprilat.
DB00029 DB14209 Trandolaprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Trandolaprilat.
DB00029 DB14210 Moexiprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Moexiprilat.
DB00029 DB14213 Perindoprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Perindoprilat.
DB00029 DB14217 Quinaprilat The risk or severity of angioedema can be increased when Anistreplase is combined with Quinaprilat.
DB00029 DB14231 Quinoline Yellow WS The risk or severity of angioedema can be increased when Anistreplase is combined with Quinoline Yellow WS.
DB00029 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Anistreplase is combined with Sildenafil.
DB00029 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Anistreplase is combined with Peginterferon alfa-2a.
DB00029 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-n1.
DB00029 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-n3.
DB00029 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Anistreplase is combined with Peginterferon alfa-2b.
DB00029 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon gamma-1b.
DB00029 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-2a, Recombinant.
DB00029 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Anistreplase is combined with Aldesleukin.
DB00029 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Anistreplase is combined with Gemtuzumab ozogamicin.
DB00029 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon beta-1b.
DB00029 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfacon-1.
DB00029 DB00073 Rituximab The risk or severity of bleeding can be increased when Anistreplase is combined with Rituximab.
DB00029 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Anistreplase is combined with Ibritumomab tiuxetan.
DB00029 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Anistreplase is combined with Alemtuzumab.
DB00029 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-2b.
DB00029 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Anistreplase is combined with Phenylalanine.
DB00029 DB00188 Bortezomib The risk or severity of bleeding can be increased when Anistreplase is combined with Bortezomib.
DB00029 DB00242 Cladribine The risk or severity of bleeding can be increased when Anistreplase is combined with Cladribine.
DB00029 DB00262 Carmustine The risk or severity of bleeding can be increased when Anistreplase is combined with Carmustine.
DB00029 DB00276 Amsacrine The risk or severity of bleeding can be increased when Anistreplase is combined with Amsacrine.
DB00029 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Anistreplase is combined with Chlorambucil.
DB00029 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Anistreplase is combined with Raltitrexed.
DB00029 DB00305 Mitomycin The risk or severity of bleeding can be increased when Anistreplase is combined with Mitomycin.
DB00029 DB00307 Bexarotene The risk or severity of bleeding can be increased when Anistreplase is combined with Bexarotene.
DB00029 DB00309 Vindesine The risk or severity of bleeding can be increased when Anistreplase is combined with Vindesine.
DB00029 DB00322 Floxuridine The risk or severity of bleeding can be increased when Anistreplase is combined with Floxuridine.
DB00029 DB00352 Tioguanine The risk or severity of bleeding can be increased when Anistreplase is combined with Tioguanine.
DB00029 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Anistreplase is combined with Vinorelbine.
DB00029 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Anistreplase is combined with Dexrazoxane.
DB00029 DB00398 Sorafenib The risk or severity of bleeding can be increased when Anistreplase is combined with Sorafenib.
DB00029 DB00428 Streptozocin The risk or severity of bleeding can be increased when Anistreplase is combined with Streptozocin.
DB00029 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Anistreplase is combined with Gemcitabine.
DB00029 DB00444 Teniposide The risk or severity of bleeding can be increased when Anistreplase is combined with Teniposide.
DB00029 DB00445 Epirubicin The risk or severity of bleeding can be increased when Anistreplase is combined with Epirubicin.
DB00029 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Anistreplase is combined with Chloramphenicol.
DB00029 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Anistreplase is combined with Lenalidomide.
DB00029 DB00488 Altretamine The risk or severity of bleeding can be increased when Anistreplase is combined with Altretamine.
DB00029 DB00495 Zidovudine The risk or severity of bleeding can be increased when Anistreplase is combined with Zidovudine.
DB00029 DB00515 Cisplatin The risk or severity of bleeding can be increased when Anistreplase is combined with Cisplatin.
DB00029 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Anistreplase is combined with Oxaliplatin.
DB00029 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Anistreplase is combined with Cyclophosphamide.
DB00029 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Anistreplase is combined with Fluorouracil.
DB00029 DB00552 Pentostatin The risk or severity of bleeding can be increased when Anistreplase is combined with Pentostatin.
DB00029 DB00563 Methotrexate The risk or severity of bleeding can be increased when Anistreplase is combined with Methotrexate.
DB00029 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Anistreplase is combined with Carbamazepine.
DB00029 DB00570 Vinblastine The risk or severity of bleeding can be increased when Anistreplase is combined with Vinblastine.
DB00029 DB00619 Imatinib The risk or severity of bleeding can be increased when Anistreplase is combined with Imatinib.
DB00029 DB00631 Clofarabine The risk or severity of bleeding can be increased when Anistreplase is combined with Clofarabine.
DB00029 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Anistreplase is combined with Pemetrexed.
DB00029 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Anistreplase is combined with Daunorubicin.
DB00029 DB00762 Irinotecan The risk or severity of bleeding can be increased when Anistreplase is combined with Irinotecan.
DB00029 DB00773 Etoposide The risk or severity of bleeding can be increased when Anistreplase is combined with Etoposide.
DB00029 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Anistreplase is combined with Dacarbazine.
DB00029 DB00853 Temozolomide The risk or severity of bleeding can be increased when Anistreplase is combined with Temozolomide.
DB00029 DB00859 Penicillamine The risk or severity of bleeding can be increased when Anistreplase is combined with Penicillamine.
DB00029 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Anistreplase is combined with Tacrolimus.
DB00029 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Anistreplase is combined with Mechlorethamine.
DB00029 DB00928 Azacitidine The risk or severity of bleeding can be increased when Anistreplase is combined with Azacitidine.
DB00029 DB00958 Carboplatin The risk or severity of bleeding can be increased when Anistreplase is combined with Carboplatin.
DB00029 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Anistreplase is combined with Dactinomycin.
DB00029 DB00987 Cytarabine The risk or severity of bleeding can be increased when Anistreplase is combined with Cytarabine.
DB00029 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Anistreplase is combined with Doxorubicin.
DB00029 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Anistreplase is combined with Hydroxyurea.
DB00029 DB01008 Busulfan The risk or severity of bleeding can be increased when Anistreplase is combined with Busulfan.
DB00029 DB01030 Topotecan The risk or severity of bleeding can be increased when Anistreplase is combined with Topotecan.
DB00029 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Anistreplase is combined with Mercaptopurine.
DB00029 DB01041 Thalidomide The risk or severity of bleeding can be increased when Anistreplase is combined with Thalidomide.
DB00029 DB01042 Melphalan The risk or severity of bleeding can be increased when Anistreplase is combined with Melphalan.
DB00029 DB01073 Fludarabine The risk or severity of bleeding can be increased when Anistreplase is combined with Fludarabine.
DB00029 DB01099 Flucytosine The risk or severity of bleeding can be increased when Anistreplase is combined with Flucytosine.
DB00029 DB01101 Capecitabine The risk or severity of bleeding can be increased when Anistreplase is combined with Capecitabine.
DB00029 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Anistreplase is combined with Arsenic trioxide.
DB00029 DB01177 Idarubicin The risk or severity of bleeding can be increased when Anistreplase is combined with Idarubicin.
DB00029 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Anistreplase is combined with Mitoxantrone.
DB00029 DB01206 Lomustine The risk or severity of bleeding can be increased when Anistreplase is combined with Lomustine.
DB00029 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Anistreplase is combined with Paclitaxel.
DB00029 DB01248 Docetaxel The risk or severity of bleeding can be increased when Anistreplase is combined with Docetaxel.
DB00029 DB01262 Decitabine The risk or severity of bleeding can be increased when Anistreplase is combined with Decitabine.
DB00029 DB01280 Nelarabine The risk or severity of bleeding can be increased when Anistreplase is combined with Nelarabine.
DB00029 DB01590 Everolimus The risk or severity of bleeding can be increased when Anistreplase is combined with Everolimus.
DB00029 DB02546 Vorinostat The risk or severity of bleeding can be increased when Anistreplase is combined with Vorinostat.
DB00029 DB04572 Thiotepa The risk or severity of bleeding can be increased when Anistreplase is combined with Thiotepa.
DB00029 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Anistreplase is combined with Ixabepilone.
DB00029 DB04868 Nilotinib The risk or severity of bleeding can be increased when Anistreplase is combined with Nilotinib.
DB00029 DB05015 Belinostat The risk or severity of bleeding can be increased when Anistreplase is combined with Belinostat.
DB00029 DB05109 Trabectedin The risk or severity of bleeding can be increased when Anistreplase is combined with Trabectedin.
DB00029 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa.
DB00029 DB05472 omega interferon The risk or severity of bleeding can be increased when Anistreplase is combined with omega interferon.
DB00029 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Anistreplase is combined with Trastuzumab emtansine.
DB00029 DB06616 Bosutinib The risk or severity of bleeding can be increased when Anistreplase is combined with Bosutinib.
DB00029 DB06769 Bendamustine The risk or severity of bleeding can be increased when Anistreplase is combined with Bendamustine.
DB00029 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Anistreplase is combined with Cabazitaxel.
DB00029 DB08871 Eribulin The risk or severity of bleeding can be increased when Anistreplase is combined with Eribulin.
DB00029 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Anistreplase is combined with Ruxolitinib.
DB00029 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Anistreplase is combined with Carfilzomib.
DB00029 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Anistreplase is combined with Tofacitinib.
DB00029 DB08901 Ponatinib The risk or severity of bleeding can be increased when Anistreplase is combined with Ponatinib.
DB00029 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Anistreplase is combined with Pomalidomide.
DB00029 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Anistreplase is combined with Tedizolid phosphate.
DB00029 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Anistreplase is combined with Blinatumomab.
DB00029 DB09073 Palbociclib The risk or severity of bleeding can be increased when Anistreplase is combined with Palbociclib.
DB00029 DB09074 Olaparib The risk or severity of bleeding can be increased when Anistreplase is combined with Olaparib.
DB00029 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Anistreplase is combined with Dinutuximab.
DB00029 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Anistreplase is combined with Peginterferon beta-1a.
DB00029 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Anistreplase is combined with Cepeginterferon alfa-2B.
DB00029 DB00229 Cefotiam The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefotiam.
DB00029 DB00267 Cefmenoxime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefmenoxime.
DB00029 DB00274 Cefmetazole The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefmetazole.
DB00029 DB00430 Cefpiramide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefpiramide.
DB00029 DB00438 Ceftazidime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftazidime.
DB00029 DB00447 Loracarbef The therapeutic efficacy of Anistreplase can be decreased when used in combination with Loracarbef.
DB00029 DB00456 Cefalotin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefalotin.
DB00029 DB00493 Cefotaxime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefotaxime.
DB00029 DB00535 Cefdinir The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefdinir.
DB00029 DB00567 Cephalexin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cephalexin.
DB00029 DB00671 Cefixime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefixime.
DB00029 DB00689 Cephaloglycin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cephaloglycin.
DB00029 DB00833 Cefaclor The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefaclor.
DB00029 DB00923 Ceforanide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceforanide.
DB00029 DB01066 Cefditoren The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefditoren.
DB00029 DB01112 Cefuroxime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefuroxime.
DB00029 DB01139 Cefapirin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefapirin.
DB00029 DB01140 Cefadroxil The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefadroxil.
DB00029 DB01150 Cefprozil The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefprozil.
DB00029 DB01212 Ceftriaxone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftriaxone.
DB00029 DB01326 Cefamandole The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefamandole.
DB00029 DB01327 Cefazolin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefazolin.
DB00029 DB01328 Cefonicid The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefonicid.
DB00029 DB01329 Cefoperazone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefoperazone.
DB00029 DB01330 Cefotetan The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefotetan.
DB00029 DB01331 Cefoxitin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefoxitin.
DB00029 DB01332 Ceftizoxime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftizoxime.
DB00029 DB01333 Cefradine The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefradine.
DB00029 DB01413 Cefepime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefepime.
DB00029 DB01414 Cefacetrile The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefacetrile.
DB00029 DB01415 Ceftibuten The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftibuten.
DB00029 DB01416 Cefpodoxime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefpodoxime.
DB00029 DB04570 Latamoxef The therapeutic efficacy of Anistreplase can be decreased when used in combination with Latamoxef.
DB00029 DB04918 Ceftobiprole The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftobiprole.
DB00029 DB06590 Ceftaroline fosamil The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftaroline fosamil.
DB00029 DB09008 Cefaloridine The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefaloridine.
DB00029 DB09050 Ceftolozane The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftolozane.
DB00029 DB09062 Cefminox The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefminox.
DB00029 DB11367 Cefroxadine The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefroxadine.
DB00029 DB11935 Flomoxef The therapeutic efficacy of Anistreplase can be decreased when used in combination with Flomoxef.
DB00029 DB13266 Cefatrizine The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefatrizine.
DB00029 DB13461 Cefcapene The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefcapene.
DB00029 DB13470 Cefodizime The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefodizime.
DB00029 DB13499 Cefsulodin The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefsulodin.
DB00029 DB13504 Cefetamet The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefetamet.
DB00029 DB13638 Cefbuperazone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefbuperazone.
DB00029 DB13667 Cefozopran The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefozopran.
DB00029 DB13682 Cefpirome The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefpirome.
DB00029 DB13778 Cefazedone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefazedone.
DB00029 DB13821 Ceftezole The therapeutic efficacy of Anistreplase can be decreased when used in combination with Ceftezole.
DB00029 DB14725 Cefamandole nafate The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cefamandole nafate.
DB00029 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Anistreplase.
DB00029 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Anistreplase.
DB00029 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Anistreplase.
DB00029 DB00945 Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Anistreplase.
DB00029 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Anistreplase.
DB00029 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Anistreplase.
DB00029 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Anistreplase.
DB00029 DB00620 Triamcinolone The therapeutic efficacy of Anistreplase can be decreased when used in combination with Triamcinolone.
DB00029 DB09079 Nintedanib The risk or severity of bleeding can be increased when Anistreplase is combined with Nintedanib.
DB00029 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Anistreplase.
DB00029 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Anistreplase.
DB00029 DB00232 Methyclothiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Methyclothiazide.
DB00029 DB00436 Bendroflumethiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Bendroflumethiazide.
DB00029 DB00562 Benzthiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Benzthiazide.
DB00029 DB00606 Cyclothiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cyclothiazide.
DB00029 DB00774 Hydroflumethiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Hydroflumethiazide.
DB00029 DB00880 Chlorothiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Chlorothiazide.
DB00029 DB00999 Hydrochlorothiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Hydrochlorothiazide.
DB00029 DB01021 Trichlormethiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Trichlormethiazide.
DB00029 DB01324 Polythiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Polythiazide.
DB00029 DB13430 Mebutizide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Mebutizide.
DB00029 DB13532 Cyclopenthiazide The therapeutic efficacy of Anistreplase can be decreased when used in combination with Cyclopenthiazide.
DB00030 DB06655 Liraglutide Liraglutide may increase the hypoglycemic activities of Insulin human.
DB00030 DB09046 Metreleptin Metreleptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB00082 Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.
DB00030 DB01132 Pioglitazone The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin human.
DB00030 DB01278 Pramlintide Pramlintide may increase the hypoglycemic activities of Insulin human.
DB00030 DB00412 Rosiglitazone The risk or severity of congestive heart failure can be increased when Insulin human is combined with Rosiglitazone.
DB00030 DB00166 Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin human.
DB00030 DB00974 Edetic acid Edetic acid may increase the hypoglycemic activities of Insulin human.
DB00030 DB00187 Esmolol Esmolol may increase the hypoglycemic activities of Insulin human.
DB00030 DB00218 Moxifloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.
DB00030 DB00365 Grepafloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Grepafloxacin.
DB00030 DB00467 Enoxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Enoxacin.
DB00030 DB00487 Pefloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Pefloxacin.
DB00030 DB00537 Ciprofloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Ciprofloxacin.
DB00030 DB00685 Trovafloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Trovafloxacin.
DB00030 DB00779 Nalidixic acid The therapeutic efficacy of Insulin human can be increased when used in combination with Nalidixic acid.
DB00030 DB00817 Rosoxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Rosoxacin.
DB00030 DB00827 Cinoxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Cinoxacin.
DB00030 DB00978 Lomefloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Lomefloxacin.
DB00030 DB01044 Gatifloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Gatifloxacin.
DB00030 DB01059 Norfloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Norfloxacin.
DB00030 DB01137 Levofloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Levofloxacin.
DB00030 DB01155 Gemifloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Gemifloxacin.
DB00030 DB01165 Ofloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Ofloxacin.
DB00030 DB01208 Sparfloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Sparfloxacin.
DB00030 DB01405 Temafloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Temafloxacin.
DB00030 DB04576 Fleroxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Fleroxacin.
DB00030 DB05488 Technetium Tc-99m ciprofloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
DB00030 DB06160 Garenoxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Garenoxacin.
DB00030 DB06600 Nemonoxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Nemonoxacin.
DB00030 DB08972 Flumequine The therapeutic efficacy of Insulin human can be increased when used in combination with Flumequine.
DB00030 DB11404 Enrofloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Enrofloxacin.
DB00030 DB11443 Orbifloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Orbifloxacin.
DB00030 DB11491 Sarafloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Sarafloxacin.
DB00030 DB11511 Difloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Difloxacin.
DB00030 DB11774 Pazufloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Pazufloxacin.
DB00030 DB11892 Prulifloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Prulifloxacin.
DB00030 DB11943 Delafloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Delafloxacin.
DB00030 DB13261 Sitafloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Sitafloxacin.
DB00030 DB13627 Oxolinic acid The therapeutic efficacy of Insulin human can be increased when used in combination with Oxolinic acid.
DB00030 DB13772 Rufloxacin The therapeutic efficacy of Insulin human can be increased when used in combination with Rufloxacin.
DB00030 DB13823 Pipemidic acid The therapeutic efficacy of Insulin human can be increased when used in combination with Pipemidic acid.
DB00030 DB00232 Methyclothiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Methyclothiazide.
DB00030 DB00310 Chlorthalidone The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorthalidone.
DB00030 DB00436 Bendroflumethiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Bendroflumethiazide.
DB00030 DB00524 Metolazone The therapeutic efficacy of Insulin human can be decreased when used in combination with Metolazone.
DB00030 DB00562 Benzthiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Benzthiazide.
DB00030 DB00774 Hydroflumethiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydroflumethiazide.
DB00030 DB00808 Indapamide The therapeutic efficacy of Insulin human can be decreased when used in combination with Indapamide.
DB00030 DB00880 Chlorothiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorothiazide.
DB00030 DB00999 Hydrochlorothiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydrochlorothiazide.
DB00030 DB01021 Trichlormethiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Trichlormethiazide.
DB00030 DB01324 Polythiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Polythiazide.
DB00030 DB01325 Quinethazone The therapeutic efficacy of Insulin human can be decreased when used in combination with Quinethazone.
DB00030 DB13532 Cyclopenthiazide The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyclopenthiazide.
DB00030 DB13989 Epitizide The therapeutic efficacy of Insulin human can be decreased when used in combination with Epitizide.
DB00030 DB00344 Protriptyline Protriptyline may decrease the hypoglycemic activities of Insulin human.
DB00030 DB00543 Amoxapine Amoxapine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB00726 Trimipramine Trimipramine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB04836 Amineptine Amineptine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB08996 Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB09016 Butriptyline Butriptyline may decrease the hypoglycemic activities of Insulin human.
DB00030 DB09167 Dosulepin Dosulepin may decrease the hypoglycemic activities of Insulin human.
DB00030 DB09289 Tianeptine Tianeptine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB09307 Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of Insulin human.
DB00030 DB12930 Opipramol Opipramol may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13114 Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13225 Dibenzepin Dibenzepin may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13246 Quinupramine Quinupramine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13384 Melitracen Melitracen may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13411 Lofepramine Lofepramine may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13496 Iprindole Iprindole may decrease the hypoglycemic activities of Insulin human.
DB00030 DB13782 Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of Insulin human.
DB00030 DB06292 Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Insulin human.
DB00030 DB08907 Canagliflozin Canagliflozin may increase the hypoglycemic activities of Insulin human.
DB00030 DB00007 Leuprolide The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide.
DB00030 DB00014 Goserelin The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin.
DB00030 DB00104 Octreotide The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.
DB00030 DB00220 Nelfinavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Nelfinavir.
DB00030 DB00224 Indinavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Indinavir.
DB00030 DB00246 Ziprasidone The therapeutic efficacy of Insulin human can be decreased when used in combination with Ziprasidone.
DB00030 DB00294 Etonogestrel The therapeutic efficacy of Insulin human can be decreased when used in combination with Etonogestrel.
DB00030 DB00304 Desogestrel The therapeutic efficacy of Insulin human can be decreased when used in combination with Desogestrel.
DB00030 DB00334 Olanzapine The therapeutic efficacy of Insulin human can be decreased when used in combination with Olanzapine.
DB00030 DB00351 Megestrol acetate The therapeutic efficacy of Insulin human can be decreased when used in combination with Megestrol acetate.
DB00030 DB00363 Clozapine The therapeutic efficacy of Insulin human can be decreased when used in combination with Clozapine.
DB00030 DB00367 Levonorgestrel The therapeutic efficacy of Insulin human can be decreased when used in combination with Levonorgestrel.
DB00030 DB00396 Progesterone The therapeutic efficacy of Insulin human can be decreased when used in combination with Progesterone.
DB00030 DB00477 Chlorpromazine The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorpromazine.
DB00030 DB00502 Haloperidol The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol.
DB00030 DB00503 Ritonavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Ritonavir.
DB00030 DB00592 Piperazine The therapeutic efficacy of Insulin human can be decreased when used in combination with Piperazine.
DB00030 DB00603 Medroxyprogesterone acetate The therapeutic efficacy of Insulin human can be decreased when used in combination with Medroxyprogesterone acetate.
DB00030 DB00627 Niacin The therapeutic efficacy of Insulin human can be decreased when used in combination with Niacin.
DB00030 DB00668 Epinephrine The therapeutic efficacy of Insulin human can be decreased when used in combination with Epinephrine.
DB00030 DB00717 Norethisterone The therapeutic efficacy of Insulin human can be decreased when used in combination with Norethisterone.
DB00030 DB00734 Risperidone The therapeutic efficacy of Insulin human can be decreased when used in combination with Risperidone.
DB00030 DB00738 Pentamidine The therapeutic efficacy of Insulin human can be decreased when used in combination with Pentamidine.
DB00030 DB00823 Ethynodiol diacetate The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethynodiol diacetate.
DB00030 DB00852 Pseudoephedrine The therapeutic efficacy of Insulin human can be decreased when used in combination with Pseudoephedrine.
DB00030 DB00864 Tacrolimus The therapeutic efficacy of Insulin human can be decreased when used in combination with Tacrolimus.
DB00030 DB00877 Sirolimus The therapeutic efficacy of Insulin human can be decreased when used in combination with Sirolimus.
DB00030 DB00903 Etacrynic acid The therapeutic efficacy of Insulin human can be decreased when used in combination with Etacrynic acid.
DB00030 DB00932 Tipranavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Tipranavir.
DB00030 DB00957 Norgestimate The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestimate.
DB00030 DB00977 Ethinylestradiol The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethinylestradiol.
DB00030 DB01072 Atazanavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Atazanavir.
DB00030 DB01169 Arsenic trioxide The therapeutic efficacy of Insulin human can be decreased when used in combination with Arsenic trioxide.
DB00030 DB01224 Quetiapine The therapeutic efficacy of Insulin human can be decreased when used in combination with Quetiapine.
DB00030 DB01232 Saquinavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Saquinavir.
DB00030 DB01238 Aripiprazole The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole.
DB00030 DB01267 Paliperidone The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone.
DB00030 DB01319 Fosamprenavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Fosamprenavir.
DB00030 DB01323 St. John's Wort The therapeutic efficacy of Insulin human can be decreased when used in combination with St. John's Wort.
DB00030 DB01357 Mestranol The therapeutic efficacy of Insulin human can be decreased when used in combination with Mestranol.
DB00030 DB01363 Ephedra sinica root The therapeutic efficacy of Insulin human can be decreased when used in combination with Ephedra sinica root.
DB00030 DB01395 Drospirenone The therapeutic efficacy of Insulin human can be decreased when used in combination with Drospirenone.
DB00030 DB01403 Methotrimeprazine The therapeutic efficacy of Insulin human can be decreased when used in combination with Methotrimeprazine.
DB00030 DB01406 Danazol The therapeutic efficacy of Insulin human can be decreased when used in combination with Danazol.
DB00030 DB01590 Everolimus The therapeutic efficacy of Insulin human can be decreased when used in combination with Everolimus.
DB00030 DB01601 Lopinavir The therapeutic efficacy of Insulin human can be decreased when used in combination with Lopinavir.
DB00030 DB01621 Pipotiazine The therapeutic efficacy of Insulin human can be decreased when used in combination with Pipotiazine.
DB00030 DB02546 Vorinostat The therapeutic efficacy of Insulin human can be decreased when used in combination with Vorinostat.
DB00030 DB04574 Estrone sulfate The therapeutic efficacy of Insulin human can be decreased when used in combination with Estrone sulfate.
DB00030 DB04839 Cyproterone acetate The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyproterone acetate.
DB00030 DB04868 Nilotinib The therapeutic efficacy of Insulin human can be decreased when used in combination with Nilotinib.
DB00030 DB04946 Iloperidone The therapeutic efficacy of Insulin human can be decreased when used in combination with Iloperidone.
DB00030 DB06216 Asenapine The therapeutic efficacy of Insulin human can be decreased when used in combination with Asenapine.
DB00030 DB06287 Temsirolimus The therapeutic efficacy of Insulin human can be decreased when used in combination with Temsirolimus.
DB00030 DB06663 Pasireotide The therapeutic efficacy of Insulin human can be decreased when used in combination with Pasireotide.
DB00030 DB06719 Buserelin The therapeutic efficacy of Insulin human can be decreased when used in combination with Buserelin.
DB00030 DB06788 Histrelin The therapeutic efficacy of Insulin human can be decreased when used in combination with Histrelin.
DB00030 DB06789 Hydroxyprogesterone caproate The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydroxyprogesterone caproate.
DB00030 DB06791 Lanreotide The therapeutic efficacy of Insulin human can be decreased when used in combination with Lanreotide.
DB00030 DB06825 Triptorelin The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin.
DB00030 DB08815 Lurasidone The therapeutic efficacy of Insulin human can be decreased when used in combination with Lurasidone.
DB00030 DB08912 Dabrafenib The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib.
DB00030 DB09009 Articaine The therapeutic efficacy of Insulin human can be decreased when used in combination with Articaine.
DB00030 DB09063 Ceritinib The therapeutic efficacy of Insulin human can be decreased when used in combination with Ceritinib.
DB00030 DB09123 Dienogest The therapeutic efficacy of Insulin human can be decreased when used in combination with Dienogest.
DB00030 DB09128 Brexpiprazole The therapeutic efficacy of Insulin human can be decreased when used in combination with Brexpiprazole.
DB00030 DB06343 Teprotumumab The therapeutic efficacy of Insulin human can be decreased when used in combination with Teprotumumab.
DB00030 DB00621 Oxandrolone Oxandrolone may increase the hypoglycemic activities of Insulin human.
DB00030 DB00624 Testosterone Testosterone may increase the hypoglycemic activities of Insulin human.
DB00030 DB00984 Nandrolone phenpropionate Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin human.
DB00030 DB01185 Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Insulin human.
DB00030 DB01420 Testosterone propionate Testosterone propionate may increase the hypoglycemic activities of Insulin human.
DB00030 DB02901 Stanolone Stanolone may increase the hypoglycemic activities of Insulin human.
DB00030 DB06412 Oxymetholone Oxymetholone may increase the hypoglycemic activities of Insulin human.
DB00030 DB06710 Methyltestosterone Methyltestosterone may increase the hypoglycemic activities of Insulin human.
DB00030 DB06718 Stanozolol Stanozolol may increase the hypoglycemic activities of Insulin human.
DB00030 DB08804 Nandrolone decanoate Nandrolone decanoate may increase the hypoglycemic activities of Insulin human.
DB00030 DB12461 GLPG-0492 GLPG-0492 may increase the hypoglycemic activities of Insulin human.
DB00030 DB13169 Nandrolone Nandrolone may increase the hypoglycemic activities of Insulin human.
DB00030 DB13587 Mesterolone Mesterolone may increase the hypoglycemic activities of Insulin human.
DB00030 DB13943 Testosterone cypionate Testosterone cypionate may increase the hypoglycemic activities of Insulin human.
DB00030 DB13944 Testosterone enanthate Testosterone enanthate may increase the hypoglycemic activities of Insulin human.
DB00030 DB00215 Citalopram The risk or severity of hypoglycemia can be increased when Insulin human is combined with Citalopram.
DB00030 DB00230 Pregabalin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Pregabalin.
DB00030 DB00285 Venlafaxine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Venlafaxine.
DB00030 DB00328 Indomethacin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Indomethacin.
DB00030 DB01104 Sertraline The risk or severity of hypoglycemia can be increased when Insulin human is combined with Sertraline.
DB00030 DB01149 Nefazodone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Nefazodone.
DB00030 DB01175 Escitalopram The risk or severity of hypoglycemia can be increased when Insulin human is combined with Escitalopram.
DB00030 DB04832 Zimelidine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Zimelidine.
DB00030 DB04884 Dapoxetine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Dapoxetine.
DB00030 DB04896 Milnacipran The risk or severity of hypoglycemia can be increased when Insulin human is combined with Milnacipran.
DB00030 DB06700 Desvenlafaxine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Desvenlafaxine.
DB00030 DB08918 Levomilnacipran The risk or severity of hypoglycemia can be increased when Insulin human is combined with Levomilnacipran.
DB00030 DB08953 Indalpine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Indalpine.
DB00030 DB09270 Ubidecarenone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ubidecarenone.
DB00030 DB12693 Ritanserin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ritanserin.
DB00030 DB13233 Alaproclate The risk or severity of hypoglycemia can be increased when Insulin human is combined with Alaproclate.
DB00030 DB13358 Cibenzoline The risk or severity of hypoglycemia can be increased when Insulin human is combined with Cibenzoline.
DB00030 DB14025 Clinafloxacin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Clinafloxacin.
DB00030 DB09038 Empagliflozin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Empagliflozin.
DB00030 DB00233 Aminosalicylic acid Aminosalicylic acid may increase the hypoglycemic activities of Insulin human.
DB00030 DB00244 Mesalazine Mesalazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB00795 Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB00861 Diflunisal Diflunisal may increase the hypoglycemic activities of Insulin human.
DB00030 DB00936 Salicylic acid Salicylic acid may increase the hypoglycemic activities of Insulin human.
DB00030 DB01014 Balsalazide Balsalazide may increase the hypoglycemic activities of Insulin human.
DB00030 DB01250 Olsalazine Olsalazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB01294 Bismuth subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Insulin human.
DB00030 DB06251 Dersalazine Dersalazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB06807 Phenyl aminosalicylate Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin human.
DB00030 DB09543 Methyl salicylate Methyl salicylate may increase the hypoglycemic activities of Insulin human.
DB00030 DB11079 Trolamine salicylate Trolamine salicylate may increase the hypoglycemic activities of Insulin human.
DB00030 DB12445 Nitroaspirin Nitroaspirin may increase the hypoglycemic activities of Insulin human.
DB00030 DB13509 Aloxiprin Aloxiprin may increase the hypoglycemic activities of Insulin human.
DB00030 DB13538 Guacetisal Guacetisal may increase the hypoglycemic activities of Insulin human.
DB00030 DB13612 Carbaspirin calcium Carbaspirin calcium may increase the hypoglycemic activities of Insulin human.
DB00030 DB14006 Choline salicylate Choline salicylate may increase the hypoglycemic activities of Insulin human.
DB00030 DB14026 Thiosalicylic acid Thiosalicylic acid may increase the hypoglycemic activities of Insulin human.
DB00030 DB01261 Sitagliptin Sitagliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB04876 Vildagliptin Vildagliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB06011 AMG-222 AMG-222 may increase the hypoglycemic activities of Insulin human.
DB00030 DB06127 Bisegliptin Bisegliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB06203 Alogliptin Alogliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB06335 Saxagliptin Saxagliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB08382 Gosogliptin Gosogliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB08882 Linagliptin Linagliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB11723 Dutogliptin Dutogliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB11950 Teneligliptin Teneligliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB11992 Omarigliptin Omarigliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB12268 Carmegliptin Carmegliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB12412 Gemigliptin Gemigliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB12417 Anagliptin Anagliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB12625 Evogliptin Evogliptin may increase the hypoglycemic activities of Insulin human.
DB00030 DB01276 Exenatide Exenatide may increase the hypoglycemic activities of Insulin human.
DB00030 DB09043 Albiglutide Albiglutide may increase the hypoglycemic activities of Insulin human.
DB00030 DB09045 Dulaglutide Dulaglutide may increase the hypoglycemic activities of Insulin human.
DB00030 DB09265 Lixisenatide Lixisenatide may increase the hypoglycemic activities of Insulin human.
DB00030 DB13928 Semaglutide Semaglutide may increase the hypoglycemic activities of Insulin human.
DB00030 DB14027 Taspoglutide Taspoglutide may increase the hypoglycemic activities of Insulin human.
DB00030 DB00752 Tranylcypromine Tranylcypromine may increase the hypoglycemic activities of Insulin human.
DB00030 DB00780 Phenelzine Phenelzine may increase the hypoglycemic activities of Insulin human.
DB00030 DB01171 Moclobemide Moclobemide may increase the hypoglycemic activities of Insulin human.
DB00030 DB01247 Isocarboxazid Isocarboxazid may increase the hypoglycemic activities of Insulin human.
DB00030 DB01626 Pargyline Pargyline may increase the hypoglycemic activities of Insulin human.
DB00030 DB00805 Minaprine Minaprine may increase the hypoglycemic activities of Insulin human.
DB00030 DB04818 Iproniazid Iproniazid may increase the hypoglycemic activities of Insulin human.
DB00030 DB04820 Nialamide Nialamide may increase the hypoglycemic activities of Insulin human.
DB00030 DB09244 Pirlindole Pirlindole may increase the hypoglycemic activities of Insulin human.
DB00030 DB09245 Toloxatone Toloxatone may increase the hypoglycemic activities of Insulin human.
DB00030 DB09243 Hydracarbazine Hydracarbazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB09241 Methylene blue Methylene blue may increase the hypoglycemic activities of Insulin human.
DB00030 DB09246 Benmoxin Benmoxin may increase the hypoglycemic activities of Insulin human.
DB00030 DB09248 Mebanazine Mebanazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB09249 Octamoxin Octamoxin may increase the hypoglycemic activities of Insulin human.
DB00030 DB09250 Pheniprazine Pheniprazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB09251 Phenoxypropazine Phenoxypropazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB09252 Pivhydrazine Pivhydrazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB09253 Safrazine Safrazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB09254 Caroxazone Caroxazone may increase the hypoglycemic activities of Insulin human.
DB00030 DB00614 Furazolidone Furazolidone may increase the hypoglycemic activities of Insulin human.
DB00030 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin human.
DB00030 DB13875 Harmaline Harmaline may increase the hypoglycemic activities of Insulin human.
DB00030 DB13876 Brofaromine Brofaromine may increase the hypoglycemic activities of Insulin human.
DB00030 DB00721 Procaine Procaine may increase the hypoglycemic activities of Insulin human.
DB00030 DB00182 Amphetamine Amphetamine may increase the hypoglycemic activities of Insulin human.
DB00030 DB01168 Procarbazine Procarbazine may increase the hypoglycemic activities of Insulin human.
DB00030 DB00601 Linezolid Linezolid may increase the hypoglycemic activities of Insulin human.
DB00030 DB06654 Safinamide Safinamide may increase the hypoglycemic activities of Insulin human.
DB00030 DB04017 Clorgiline Clorgiline may increase the hypoglycemic activities of Insulin human.
DB00030 DB11827 Ertugliflozin The therapeutic efficacy of Insulin human can be increased when used in combination with Ertugliflozin.
DB00030 DB00203 Sildenafil The therapeutic efficacy of Insulin human can be increased when used in combination with Sildenafil.
DB00030 DB00214 Torasemide The therapeutic efficacy of Insulin human can be increased when used in combination with Torasemide.
DB00030 DB00263 Sulfisoxazole The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfisoxazole.
DB00030 DB00311 Ethoxzolamide The therapeutic efficacy of Insulin human can be increased when used in combination with Ethoxzolamide.
DB00030 DB00359 Sulfadiazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadiazine.
DB00030 DB00482 Celecoxib The therapeutic efficacy of Insulin human can be increased when used in combination with Celecoxib.
DB00030 DB00559 Bosentan The therapeutic efficacy of Insulin human can be increased when used in combination with Bosentan.
DB00030 DB00576 Sulfamethizole The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethizole.
DB00030 DB00606 Cyclothiazide The therapeutic efficacy of Insulin human can be increased when used in combination with Cyclothiazide.
DB00030 DB00664 Sulfametopyrazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfametopyrazine.
DB00030 DB00669 Sumatriptan The therapeutic efficacy of Insulin human can be increased when used in combination with Sumatriptan.
DB00030 DB00695 Furosemide The therapeutic efficacy of Insulin human can be increased when used in combination with Furosemide.
DB00030 DB00706 Tamsulosin The therapeutic efficacy of Insulin human can be increased when used in combination with Tamsulosin.
DB00030 DB00819 Acetazolamide The therapeutic efficacy of Insulin human can be increased when used in combination with Acetazolamide.
DB00030 DB00887 Bumetanide The therapeutic efficacy of Insulin human can be increased when used in combination with Bumetanide.
DB00030 DB00891 Sulfapyridine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfapyridine.
DB00030 DB00909 Zonisamide The therapeutic efficacy of Insulin human can be increased when used in combination with Zonisamide.
DB00030 DB01015 Sulfamethoxazole The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethoxazole.
DB00030 DB01032 Probenecid The therapeutic efficacy of Insulin human can be increased when used in combination with Probenecid.
DB00030 DB01098 Rosuvastatin The therapeutic efficacy of Insulin human can be increased when used in combination with Rosuvastatin.
DB00030 DB01119 Diazoxide The therapeutic efficacy of Insulin human can be increased when used in combination with Diazoxide.
DB00030 DB01144 Diclofenamide The therapeutic efficacy of Insulin human can be increased when used in combination with Diclofenamide.
DB00030 DB01264 Darunavir The therapeutic efficacy of Insulin human can be increased when used in combination with Darunavir.
DB00030 DB01298 Sulfacytine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfacytine.
DB00030 DB01299 Sulfadoxine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadoxine.
DB00030 DB01382 Glymidine The therapeutic efficacy of Insulin human can be increased when used in combination with Glymidine.
DB00030 DB01581 Sulfamerazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamerazine.
DB00030 DB01582 Sulfamethazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethazine.
DB00030 DB02925 Piretanide The therapeutic efficacy of Insulin human can be increased when used in combination with Piretanide.
DB00030 DB04707 Hydroxyfasudil The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxyfasudil.
DB00030 DB06150 Sulfadimethoxine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadimethoxine.
DB00030 DB06290 Simeprevir The therapeutic efficacy of Insulin human can be increased when used in combination with Simeprevir.
DB00030 DB06729 Sulfaphenazole The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaphenazole.
DB00030 DB06821 Sulfameter The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfameter.
DB00030 DB07996 5-(2-methylpiperazine-1-sulfonyl)isoquinoline The therapeutic efficacy of Insulin human can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
DB00030 DB08162 Fasudil The therapeutic efficacy of Insulin human can be increased when used in combination with Fasudil.
DB00030 DB08798 Sulfamoxole The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamoxole.
DB00030 DB08881 Vemurafenib The therapeutic efficacy of Insulin human can be increased when used in combination with Vemurafenib.
DB00030 DB08961 Azosemide The therapeutic efficacy of Insulin human can be increased when used in combination with Azosemide.
DB00030 DB11389 Clorsulon The therapeutic efficacy of Insulin human can be increased when used in combination with Clorsulon.
DB00030 DB11461 Sulfachlorpyridazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfachlorpyridazine.
DB00030 DB11462 Sulfaethoxypyridazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaethoxypyridazine.
DB00030 DB11463 Sulfanitran The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfanitran.
DB00030 DB11464 Sulfaquinoxaline The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaquinoxaline.
DB00030 DB12051 Setrobuvir The therapeutic efficacy of Insulin human can be increased when used in combination with Setrobuvir.
DB00030 DB12921 Chlorsulfaquinoxaline The therapeutic efficacy of Insulin human can be increased when used in combination with Chlorsulfaquinoxaline.
DB00030 DB13214 Sulfadicramide The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadicramide.
DB00030 DB13248 Phthalylsulfathiazole The therapeutic efficacy of Insulin human can be increased when used in combination with Phthalylsulfathiazole.
DB00030 DB13283 Sulfaisodimidine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaisodimidine.
DB00030 DB13284 Meticrane The therapeutic efficacy of Insulin human can be increased when used in combination with Meticrane.
DB00030 DB13320 Sulfaperin The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaperin.
DB00030 DB13405 Mefruside The therapeutic efficacy of Insulin human can be increased when used in combination with Mefruside.
DB00030 DB13430 Mebutizide The therapeutic efficacy of Insulin human can be increased when used in combination with Mebutizide.
DB00030 DB13485 Sulfametomidine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfametomidine.
DB00030 DB13547 Sulfatolamide The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfatolamide.
DB00030 DB13556 Sulfamazone The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamazone.
DB00030 DB13580 Succinylsulfathiazole The therapeutic efficacy of Insulin human can be increased when used in combination with Succinylsulfathiazole.
DB00030 DB13617 Clorexolone The therapeutic efficacy of Insulin human can be increased when used in combination with Clorexolone.
DB00030 DB13663 Clofenamide The therapeutic efficacy of Insulin human can be increased when used in combination with Clofenamide.
DB00030 DB13699 Sulfathiourea The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfathiourea.
DB00030 DB13708 Fenquizone The therapeutic efficacy of Insulin human can be increased when used in combination with Fenquizone.
DB00030 DB13726 Sulfaguanidine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaguanidine.
DB00030 DB13773 Sulfamethoxypyridazine The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethoxypyridazine.
DB00030 DB13792 Clopamide The therapeutic efficacy of Insulin human can be increased when used in combination with Clopamide.
DB00030 DB13803 Xipamide The therapeutic efficacy of Insulin human can be increased when used in combination with Xipamide.
DB00030 DB14033 Acetyl sulfisoxazole The therapeutic efficacy of Insulin human can be increased when used in combination with Acetyl sulfisoxazole.
DB00030 DB14708 Tosylchloramide The therapeutic efficacy of Insulin human can be increased when used in combination with Tosylchloramide.
DB00030 DB00703 Methazolamide The therapeutic efficacy of Insulin human can be increased when used in combination with Methazolamide.
DB00030 DB06370 Indisulam The therapeutic efficacy of Insulin human can be increased when used in combination with Indisulam.
DB00030 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Insulin human.
DB00030 DB00184 Nicotine The metabolism of Nicotine can be increased when combined with Insulin human.
DB00030 DB00188 Bortezomib The metabolism of Bortezomib can be increased when combined with Insulin human.
DB00030 DB00201 Caffeine The metabolism of Caffeine can be increased when combined with Insulin human.
DB00030 DB00261 Anagrelide The metabolism of Anagrelide can be increased when combined with Insulin human.
DB00030 DB00262 Carmustine The metabolism of Carmustine can be increased when combined with Insulin human.
DB00030 DB00281 Lidocaine The metabolism of Lidocaine can be increased when combined with Insulin human.
DB00030 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Insulin human.
DB00030 DB00296 Ropivacaine The metabolism of Ropivacaine can be increased when combined with Insulin human.
DB00030 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be increased when combined with Insulin human.
DB00030 DB00316 Acetaminophen The metabolism of Acetaminophen can be increased when combined with Insulin human.
DB00030 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Insulin human.
DB00030 DB00370 Mirtazapine The metabolism of Mirtazapine can be increased when combined with Insulin human.
DB00030 DB00379 Mexiletine The metabolism of Mexiletine can be increased when combined with Insulin human.
DB00030 DB00382 Tacrine The metabolism of Tacrine can be increased when combined with Insulin human.
DB00030 DB00384 Triamterene The metabolism of Triamterene can be increased when combined with Insulin human.
DB00030 DB00420 Promazine The metabolism of Promazine can be increased when combined with Insulin human.
DB00030 DB00425 Zolpidem The metabolism of Zolpidem can be increased when combined with Insulin human.
DB00030 DB00442 Entecavir The metabolism of Entecavir can be increased when combined with Insulin human.
DB00030 DB00461 Nabumetone The metabolism of Nabumetone can be increased when combined with Insulin human.
DB00030 DB00472 Fluoxetine The metabolism of Fluoxetine can be increased when combined with Insulin human.
DB00030 DB00476 Duloxetine The metabolism of Duloxetine can be increased when combined with Insulin human.
DB00030 DB00499 Flutamide The metabolism of Flutamide can be increased when combined with Insulin human.
DB00030 DB00518 Albendazole The metabolism of Albendazole can be increased when combined with Insulin human.
DB00030 DB00533 Rofecoxib The metabolism of Rofecoxib can be increased when combined with Insulin human.
DB00030 DB00544 Fluorouracil The metabolism of Fluorouracil can be increased when combined with Insulin human.
DB00030 DB00568 Cinnarizine The metabolism of Cinnarizine can be increased when combined with Insulin human.
DB00030 DB00586 Diclofenac The metabolism of Diclofenac can be increased when combined with Insulin human.
DB00030 DB00619 Imatinib The metabolism of Imatinib can be increased when combined with Insulin human.
DB00030 DB00629 Guanabenz The metabolism of Guanabenz can be increased when combined with Insulin human.
DB00030 DB00642 Pemetrexed The metabolism of Pemetrexed can be increased when combined with Insulin human.
DB00030 DB00661 Verapamil The metabolism of Verapamil can be increased when combined with Insulin human.
DB00030 DB00715 Paroxetine The metabolism of Paroxetine can be increased when combined with Insulin human.
DB00030 DB00730 Thiabendazole The metabolism of Thiabendazole can be increased when combined with Insulin human.
DB00030 DB00740 Riluzole The metabolism of Riluzole can be increased when combined with Insulin human.
DB00030 DB00744 Zileuton The metabolism of Zileuton can be increased when combined with Insulin human.
DB00030 DB00758 Clopidogrel The metabolism of Clopidogrel can be increased when combined with Insulin human.
DB00030 DB00787 Acyclovir The metabolism of Acyclovir can be increased when combined with Insulin human.
DB00030 DB00788 Naproxen The metabolism of Naproxen can be increased when combined with Insulin human.
DB00030 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be increased when combined with Insulin human.
DB00030 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Insulin human.
DB00030 DB00850 Perphenazine The metabolism of Perphenazine can be increased when combined with Insulin human.
DB00030 DB00857 Terbinafine The metabolism of Terbinafine can be increased when combined with Insulin human.
DB00030 DB00863 Ranitidine The metabolism of Ranitidine can be increased when combined with Insulin human.
DB00030 DB00898 Ethanol The metabolism of Ethanol can be increased when combined with Insulin human.
DB00030 DB00934 Maprotiline The metabolism of Maprotiline can be increased when combined with Insulin human.
DB00030 DB00969 Alosetron The metabolism of Alosetron can be increased when combined with Insulin human.
DB00030 DB00980 Ramelteon The metabolism of Ramelteon can be increased when combined with Insulin human.
DB00030 DB00993 Azathioprine The metabolism of Azathioprine can be increased when combined with Insulin human.
DB00030 DB00998 Frovatriptan The metabolism of Frovatriptan can be increased when combined with Insulin human.
DB00030 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Insulin human.
DB00030 DB01012 Cinacalcet The metabolism of Cinacalcet can be increased when combined with Insulin human.
DB00030 DB01037 Selegiline The metabolism of Selegiline can be increased when combined with Insulin human.
DB00030 DB01056 Tocainide The metabolism of Tocainide can be increased when combined with Insulin human.
DB00030 DB01058 Praziquantel The metabolism of Praziquantel can be increased when combined with Insulin human.
DB00030 DB01065 Melatonin The metabolism of Melatonin can be increased when combined with Insulin human.
DB00030 DB01087 Primaquine The metabolism of Primaquine can be increased when combined with Insulin human.
DB00030 DB01094 Hesperetin The metabolism of Hesperetin can be increased when combined with Insulin human.
DB00030 DB01097 Leflunomide The metabolism of Leflunomide can be increased when combined with Insulin human.
DB00030 DB01166 Cilostazol The metabolism of Cilostazol can be increased when combined with Insulin human.
DB00030 DB01184 Domperidone The metabolism of Domperidone can be increased when combined with Insulin human.
DB00030 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Insulin human.
DB00030 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Insulin human.
DB00030 DB01367 Rasagiline The metabolism of Rasagiline can be increased when combined with Insulin human.
DB00030 DB01412 Theobromine The metabolism of Theobromine can be increased when combined with Insulin human.
DB00030 DB01424 Aminophenazone The metabolism of Aminophenazone can be increased when combined with Insulin human.
DB00030 DB01435 Antipyrine The metabolism of Antipyrine can be increased when combined with Insulin human.
DB00030 DB01482 Fenethylline The metabolism of Fenethylline can be increased when combined with Insulin human.
DB00030 DB01558 Bromazepam The metabolism of Bromazepam can be increased when combined with Insulin human.
DB00030 DB01623 Thiothixene The metabolism of Thiothixene can be increased when combined with Insulin human.
DB00030 DB01628 Etoricoxib The metabolism of Etoricoxib can be increased when combined with Insulin human.
DB00030 DB01645 Genistein The metabolism of Genistein can be increased when combined with Insulin human.
DB00030 DB01667 8-azaguanine The metabolism of 8-azaguanine can be increased when combined with Insulin human.
DB00030 DB02134 Xanthine The metabolism of Xanthine can be increased when combined with Insulin human.
DB00030 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be increased when combined with Insulin human.
DB00030 DB02568 Peldesine The metabolism of Peldesine can be increased when combined with Insulin human.
DB00030 DB02709 Resveratrol The metabolism of Resveratrol can be increased when combined with Insulin human.
DB00030 DB03783 Phenacetin The metabolism of Phenacetin can be increased when combined with Insulin human.
DB00030 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be increased when combined with Insulin human.
DB00030 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be increased when combined with Insulin human.
DB00030 DB04841 Flunarizine The metabolism of Flunarizine can be increased when combined with Insulin human.
DB00030 DB04871 Lorcaserin The metabolism of Lorcaserin can be increased when combined with Insulin human.
DB00030 DB04948 Lofexidine The metabolism of Lofexidine can be increased when combined with Insulin human.
DB00030 DB04951 Pirfenidone The metabolism of Pirfenidone can be increased when combined with Insulin human.
DB00030 DB05676 Apremilast The metabolism of Apremilast can be increased when combined with Insulin human.
DB00030 DB06148 Mianserin The metabolism of Mianserin can be increased when combined with Insulin human.
DB00030 DB06210 Eltrombopag The metabolism of Eltrombopag can be increased when combined with Insulin human.
DB00030 DB06235 Vadimezan The metabolism of Vadimezan can be increased when combined with Insulin human.
DB00030 DB06479 Propentofylline The metabolism of Propentofylline can be increased when combined with Insulin human.
DB00030 DB06589 Pazopanib The metabolism of Pazopanib can be increased when combined with Insulin human.
DB00030 DB06594 Agomelatine The metabolism of Agomelatine can be increased when combined with Insulin human.
DB00030 DB06626 Axitinib The metabolism of Axitinib can be increased when combined with Insulin human.
DB00030 DB06769 Bendamustine The metabolism of Bendamustine can be increased when combined with Insulin human.
DB00030 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be increased when combined with Insulin human.
DB00030 DB06774 Capsaicin The metabolism of Capsaicin can be increased when combined with Insulin human.
DB00030 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Insulin human.
DB00030 DB08883 Perampanel The metabolism of Perampanel can be increased when combined with Insulin human.
DB00030 DB09071 Tasimelteon The metabolism of Tasimelteon can be increased when combined with Insulin human.
DB00030 DB09118 Stiripentol The metabolism of Stiripentol can be increased when combined with Insulin human.
DB00030 DB09225 Zotepine The metabolism of Zotepine can be increased when combined with Insulin human.
DB00030 DB09273 Doxofylline The metabolism of Doxofylline can be increased when combined with Insulin human.
DB00030 DB09288 Propacetamol The metabolism of Propacetamol can be increased when combined with Insulin human.
DB00030 DB09290 Ramosetron The metabolism of Ramosetron can be increased when combined with Insulin human.
DB00030 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be increased when combined with Insulin human.
DB00030 DB11967 Binimetinib The metabolism of Binimetinib can be increased when combined with Insulin human.
DB00030 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be increased when combined with Insulin human.
DB00030 DB12245 Triclabendazole The metabolism of Triclabendazole can be increased when combined with Insulin human.
DB00030 DB12332 Rucaparib The metabolism of Rucaparib can be increased when combined with Insulin human.
DB00030 DB12406 Lisofylline The metabolism of Lisofylline can be increased when combined with Insulin human.
DB00030 DB12531 Lobucavir The metabolism of Lobucavir can be increased when combined with Insulin human.
DB00030 DB12926 Cafedrine The metabolism of Cafedrine can be increased when combined with Insulin human.
DB00030 DB12927 Theodrenaline The metabolism of Theodrenaline can be increased when combined with Insulin human.
DB00030 DB12945 Dihydralazine The metabolism of Dihydralazine can be increased when combined with Insulin human.
DB00030 DB13203 Bamifylline The metabolism of Bamifylline can be increased when combined with Insulin human.
DB00030 DB13449 Proxyphylline The metabolism of Proxyphylline can be increased when combined with Insulin human.
DB00030 DB13573 Acefylline The metabolism of Acefylline can be increased when combined with Insulin human.
DB00030 DB13592 Etamiphylline The metabolism of Etamiphylline can be increased when combined with Insulin human.
DB00030 DB13634 Pentifylline The metabolism of Pentifylline can be increased when combined with Insulin human.
DB00030 DB13812 Bufylline The metabolism of Bufylline can be increased when combined with Insulin human.
DB00030 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Insulin human.
DB00030 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Insulin human.
DB00030 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Insulin human.
DB00030 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Insulin human.
DB00030 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Insulin human.
DB00030 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Insulin human.
DB00030 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be increased when combined with Insulin human.
DB00030 DB01115 Nifedipine The metabolism of Nifedipine can be increased when combined with Insulin human.
DB00030 DB11757 Istradefylline The metabolism of Istradefylline can be increased when combined with Insulin human.
DB00030 DB00972 Azelastine The metabolism of Azelastine can be increased when combined with Insulin human.
DB00030 DB00625 Efavirenz The metabolism of Efavirenz can be increased when combined with Insulin human.
DB00030 DB04889 Bicifadine The metabolism of Bicifadine can be increased when combined with Insulin human.
DB00030 DB05708 GTS-21 The metabolism of GTS-21 can be increased when combined with Insulin human.
DB00030 DB01195 Flecainide The metabolism of Flecainide can be increased when combined with Insulin human.
DB00030 DB00783 Estradiol The metabolism of Estradiol can be increased when combined with Insulin human.
DB00030 DB00321 Amitriptyline The metabolism of Amitriptyline can be increased when combined with Insulin human.
DB00030 DB00458 Imipramine The metabolism of Imipramine can be increased when combined with Insulin human.
DB00030 DB01142 Doxepin The metabolism of Doxepin can be increased when combined with Insulin human.
DB00030 DB00532 Mephenytoin The metabolism of Mephenytoin can be increased when combined with Insulin human.
DB00030 DB00540 Nortriptyline The metabolism of Nortriptyline can be increased when combined with Insulin human.
DB00030 DB00575 Clonidine The metabolism of Clonidine can be increased when combined with Insulin human.
DB00030 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Insulin human.
DB00030 DB01151 Desipramine The metabolism of Desipramine can be increased when combined with Insulin human.
DB00030 DB01242 Clomipramine The metabolism of Clomipramine can be increased when combined with Insulin human.
DB00030 DB11689 Selumetinib The metabolism of Selumetinib can be increased when combined with Insulin human.
DB00030 DB00277 Theophylline The metabolism of Theophylline can be increased when combined with Insulin human.
DB00030 DB00398 Sorafenib The metabolism of Sorafenib can be increased when combined with Insulin human.
DB00030 DB00530 Erlotinib The metabolism of Erlotinib can be increased when combined with Insulin human.
DB00030 DB00564 Carbamazepine The metabolism of Carbamazepine can be increased when combined with Insulin human.
DB00030 DB00682 Warfarin The metabolism of Warfarin can be increased when combined with Insulin human.
DB00030 DB00697 Tizanidine The metabolism of Tizanidine can be increased when combined with Insulin human.
DB00030 DB00773 Etoposide The metabolism of Etoposide can be increased when combined with Insulin human.
DB00030 DB00851 Dacarbazine The metabolism of Dacarbazine can be increased when combined with Insulin human.
DB00030 DB01100 Pimozide The metabolism of Pimozide can be increased when combined with Insulin human.
DB00030 DB01223 Aminophylline The metabolism of Aminophylline can be increased when combined with Insulin human.
DB00030 DB01254 Dasatinib The metabolism of Dasatinib can be increased when combined with Insulin human.
DB00030 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Insulin human.
DB00030 DB08910 Pomalidomide The metabolism of Pomalidomide can be increased when combined with Insulin human.
DB00030 DB09256 Tegafur The metabolism of Tegafur can be increased when combined with Insulin human.
DB00030 DB13874 Enasidenib The metabolism of Enasidenib can be increased when combined with Insulin human.
DB00030 DB00675 Tamoxifen The metabolism of Tamoxifen can be increased when combined with Insulin human.
DB00030 DB00046 Insulin lispro The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin lispro.
DB00030 DB00047 Insulin glargine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glargine.
DB00030 DB00071 Insulin pork The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork.
DB00030 DB00197 Troglitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Troglitazone.
DB00030 DB00222 Glimepiride The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glimepiride.
DB00030 DB00280 Disopyramide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Disopyramide.
DB00030 DB00284 Acarbose The risk or severity of hypoglycemia can be increased when Insulin human is combined with Acarbose.
DB00030 DB00414 Acetohexamide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Acetohexamide.
DB00030 DB00468 Quinine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Quinine.
DB00030 DB00491 Miglitol The risk or severity of hypoglycemia can be increased when Insulin human is combined with Miglitol.
DB00030 DB00672 Chlorpropamide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Chlorpropamide.
DB00030 DB00731 Nateglinide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Nateglinide.
DB00030 DB00834 Mifepristone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Mifepristone.
DB00030 DB00839 Tolazamide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tolazamide.
DB00030 DB00912 Repaglinide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Repaglinide.
DB00030 DB00914 Phenformin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Phenformin.
DB00030 DB01016 Glyburide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glyburide.
DB00030 DB01067 Glipizide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glipizide.
DB00030 DB01120 Gliclazide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Gliclazide.
DB00030 DB01124 Tolbutamide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tolbutamide.
DB00030 DB01200 Bromocriptine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Bromocriptine.
DB00030 DB01251 Gliquidone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Gliquidone.
DB00030 DB01252 Mitiglinide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Mitiglinide.
DB00030 DB01268 Sunitinib The risk or severity of hypoglycemia can be increased when Insulin human is combined with Sunitinib.
DB00030 DB01277 Mecasermin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Mecasermin.
DB00030 DB01289 Glisoxepide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glisoxepide.
DB00030 DB01306 Insulin aspart The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin aspart.
DB00030 DB01307 Insulin detemir The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin detemir.
DB00030 DB01309 Insulin glulisine The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glulisine.
DB00030 DB01700 AICA ribonucleotide The risk or severity of hypoglycemia can be increased when Insulin human is combined with AICA ribonucleotide.
DB00030 DB04830 Buformin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Buformin.
DB00030 DB04878 Voglibose The risk or severity of hypoglycemia can be increased when Insulin human is combined with Voglibose.
DB00030 DB05115 NN344 The risk or severity of hypoglycemia can be increased when Insulin human is combined with NN344.
DB00030 DB05819 NBI-6024 The risk or severity of hypoglycemia can be increased when Insulin human is combined with NBI-6024.
DB00030 DB08962 Glibornuride The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glibornuride.
DB00030 DB09022 Benfluorex The risk or severity of hypoglycemia can be increased when Insulin human is combined with Benfluorex.
DB00030 DB09198 Lobeglitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Lobeglitazone.
DB00030 DB09199 Netoglitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Netoglitazone.
DB00030 DB09200 Rivoglitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Rivoglitazone.
DB00030 DB09201 Ciglitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ciglitazone.
DB00030 DB09456 Insulin beef The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin beef.
DB00030 DB09564 Insulin degludec The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin degludec.
DB00030 DB11567 Insulin peglispro The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin peglispro.
DB00030 DB11568 Insulin tregopil The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin tregopil.
DB00030 DB11698 Ipragliflozin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ipragliflozin.
DB00030 DB11780 Allicin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Allicin.
DB00030 DB11824 Tofogliflozin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tofogliflozin.
DB00030 DB11898 2,4-thiazolidinedione The risk or severity of hypoglycemia can be increased when Insulin human is combined with 2,4-thiazolidinedione.
DB00030 DB12713 Sotagliflozin The risk or severity of hypoglycemia can be increased when Insulin human is combined with Sotagliflozin.
DB00030 DB12781 Balaglitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Balaglitazone.
DB00030 DB12935 Remogliflozin etabonate The risk or severity of hypoglycemia can be increased when Insulin human is combined with Remogliflozin etabonate.
DB00030 DB13406 Carbutamide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Carbutamide.
DB00030 DB13446 Guar gum The risk or severity of hypoglycemia can be increased when Insulin human is combined with Guar gum.
DB00030 DB13675 Metahexamide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Metahexamide.
DB00030 DB14035 Englitazone The risk or severity of hypoglycemia can be increased when Insulin human is combined with Englitazone.
DB00030 DB15171 Tirzepatide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tirzepatide.
DB00030 DB15217 Gastric inhibitory polypeptide The risk or severity of hypoglycemia can be increased when Insulin human is combined with Gastric inhibitory polypeptide.
DB00030 DB00270 Isradipine The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin human.
DB00030 DB00343 Diltiazem The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin human.
DB00030 DB00347 Trimethadione The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin human.
DB00030 DB00381 Amlodipine The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin human.
DB00030 DB00393 Nimodipine The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin human.
DB00030 DB00401 Nisoldipine The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin human.
DB00030 DB00528 Lercanidipine The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin human.
DB00030 DB00555 Lamotrigine The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin human.
DB00030 DB00593 Ethosuximide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin human.
DB00030 DB00622 Nicardipine The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin human.
DB00030 DB00653 Magnesium sulfate The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin human.
DB00030 DB00836 Loperamide The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin human.
DB00030 DB01054 Nitrendipine The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin human.
DB00030 DB01074 Perhexiline The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin human.
DB00030 DB01244 Bepridil The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin human.
DB00030 DB01388 Mibefradil The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin human.
DB00030 DB04743 Nimesulide The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin human.
DB00030 DB04825 Prenylamine The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin human.
DB00030 DB04838 Cyclandelate The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin human.
DB00030 DB04842 Fluspirilene The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin human.
DB00030 DB04920 Clevidipine The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin human.
DB00030 DB05246 Methsuximide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin human.
DB00030 DB05885 Seletracetam The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin human.
DB00030 DB06152 Nylidrin The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin human.
DB00030 DB06283 Ziconotide The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin human.
DB00030 DB06446 Dotarizine The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin human.
DB00030 DB06694 Xylometazoline The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin human.
DB00030 DB06712 Nilvadipine The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin human.
DB00030 DB07615 Tranilast The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin human.
DB00030 DB08838 Agmatine The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin human.
DB00030 DB08980 Fendiline The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin human.
DB00030 DB08992 Eperisone The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin human.
DB00030 DB09089 Trimebutine The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin human.
DB00030 DB09090 Pinaverium The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin human.
DB00030 DB09216 Tolfenamic acid The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin human.
DB00030 DB09227 Barnidipine The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin human.
DB00030 DB09229 Aranidipine The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin human.
DB00030 DB09230 Azelnidipine The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin human.
DB00030 DB09231 Benidipine The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin human.
DB00030 DB09232 Cilnidipine The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin human.
DB00030 DB09234 Darodipine The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin human.
DB00030 DB09235 Efonidipine The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin human.
DB00030 DB09236 Lacidipine The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin human.
DB00030 DB09238 Manidipine The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin human.
DB00030 DB09239 Niguldipine The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin human.
DB00030 DB09240 Niludipine The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin human.
DB00030 DB11960 Carboxyamidotriazole The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin human.
DB00030 DB12092 Naftopidil The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin human.
DB00030 DB12093 Tetrahydropalmatine The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin human.
DB00030 DB12131 Vinpocetine The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin human.
DB00030 DB12923 Gallopamil The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin human.
DB00030 DB13488 Bencyclane The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin human.
DB00030 DB13500 Otilonium The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin human.
DB00030 DB13725 Terodiline The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin human.
DB00030 DB13766 Lidoflazine The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin human.
DB00030 DB13791 Penfluridol The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin human.
DB00030 DB13835 Caroverine The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin human.
DB00030 DB13950 WIN 55212-2 The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin human.
DB00030 DB13961 Fish oil The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin human.
DB00030 DB14063 Dexverapamil The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin human.
DB00030 DB14064 Emopamil The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin human.
DB00030 DB14065 Lomerizine The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin human.
DB00030 DB14066 Tetrandrine The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin human.
DB00030 DB14068 Dexniguldipine The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin human.
DB00030 DB01023 Felodipine The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin human.
DB00030 DB01118 Amiodarone The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin human.
DB00030 DB00191 Phentermine The therapeutic efficacy of Insulin human can be increased when used in combination with Phentermine.
DB00030 DB00268 Ropinirole The metabolism of Ropinirole can be increased when combined with Insulin human.
DB00030 DB13074 Macimorelin The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin human.
DB00030 DB00279 Liothyronine The therapeutic efficacy of Insulin human can be decreased when used in combination with Liothyronine.
DB00030 DB00331 Metformin The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.
DB00030 DB00542 Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin human.
DB00030 DB13946 Testosterone undecanoate The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin human.
DB00030 DB00945 Acetylsalicylic acid The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin human.
DB00030 DB00181 Baclofen The therapeutic efficacy of Insulin human can be decreased when used in combination with Baclofen.
DB00030 DB00489 Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin human.
DB00030 DB00196 Fluconazole The risk or severity of hypoglycemia can be increased when Insulin human is combined with Fluconazole.
DB00030 DB00040 Glucagon The therapeutic efficacy of Insulin human can be decreased when used in combination with Glucagon.
DB00030 DB00264 Metoprolol The therapeutic efficacy of Insulin human can be increased when used in combination with Metoprolol.
DB00030 DB00335 Atenolol The therapeutic efficacy of Insulin human can be increased when used in combination with Atenolol.
DB00030 DB00373 Timolol The therapeutic efficacy of Insulin human can be increased when used in combination with Timolol.
DB00030 DB00598 Labetalol The therapeutic efficacy of Insulin human can be increased when used in combination with Labetalol.
DB00030 DB00612 Bisoprolol The therapeutic efficacy of Insulin human can be increased when used in combination with Bisoprolol.
DB00030 DB00866 Alprenolol The therapeutic efficacy of Insulin human can be increased when used in combination with Alprenolol.
DB00030 DB00960 Pindolol The therapeutic efficacy of Insulin human can be increased when used in combination with Pindolol.
DB00030 DB01193 Acebutolol The therapeutic efficacy of Insulin human can be increased when used in combination with Acebutolol.
DB00030 DB01203 Nadolol The therapeutic efficacy of Insulin human can be increased when used in combination with Nadolol.
DB00030 DB01295 Bevantolol The therapeutic efficacy of Insulin human can be increased when used in combination with Bevantolol.
DB00030 DB01297 Practolol The therapeutic efficacy of Insulin human can be increased when used in combination with Practolol.
DB00030 DB01359 Penbutolol The therapeutic efficacy of Insulin human can be increased when used in combination with Penbutolol.
DB00030 DB01580 Oxprenolol The therapeutic efficacy of Insulin human can be increased when used in combination with Oxprenolol.
DB00030 DB03322 Dexpropranolol The therapeutic efficacy of Insulin human can be increased when used in combination with Dexpropranolol.
DB00030 DB04846 Celiprolol The therapeutic efficacy of Insulin human can be increased when used in combination with Celiprolol.
DB00030 DB04861 Nebivolol The therapeutic efficacy of Insulin human can be increased when used in combination with Nebivolol.
DB00030 DB06726 Bufuralol The therapeutic efficacy of Insulin human can be increased when used in combination with Bufuralol.
DB00030 DB08807 Bopindolol The therapeutic efficacy of Insulin human can be increased when used in combination with Bopindolol.
DB00030 DB08808 Bupranolol The therapeutic efficacy of Insulin human can be increased when used in combination with Bupranolol.
DB00030 DB08952 Indenolol The therapeutic efficacy of Insulin human can be increased when used in combination with Indenolol.
DB00030 DB09013 Befunolol The therapeutic efficacy of Insulin human can be increased when used in combination with Befunolol.
DB00030 DB09204 Arotinolol The therapeutic efficacy of Insulin human can be increased when used in combination with Arotinolol.
DB00030 DB09351 Levobetaxolol The therapeutic efficacy of Insulin human can be increased when used in combination with Levobetaxolol.
DB00030 DB11770 Talinolol The therapeutic efficacy of Insulin human can be increased when used in combination with Talinolol.
DB00030 DB11785 Anisodamine The therapeutic efficacy of Insulin human can be increased when used in combination with Anisodamine.
DB00030 DB12212 Landiolol The therapeutic efficacy of Insulin human can be increased when used in combination with Landiolol.
DB00030 DB12752 Bucindolol The therapeutic efficacy of Insulin human can be increased when used in combination with Bucindolol.
DB00030 DB13443 Esatenolol The therapeutic efficacy of Insulin human can be increased when used in combination with Esatenolol.
DB00030 DB13508 Cloranolol The therapeutic efficacy of Insulin human can be increased when used in combination with Cloranolol.
DB00030 DB13530 Mepindolol The therapeutic efficacy of Insulin human can be increased when used in combination with Mepindolol.
DB00030 DB13757 Epanolol The therapeutic efficacy of Insulin human can be increased when used in combination with Epanolol.
DB00030 DB13775 Tertatolol The therapeutic efficacy of Insulin human can be increased when used in combination with Tertatolol.
DB00030 DB00195 Betaxolol The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin human.
DB00030 DB00571 Propranolol The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin human.
DB00030 DB01136 Carvedilol The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin human.
DB00030 DB01182 Propafenone The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin human.
DB00030 DB01611 Hydroxychloroquine The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxychloroquine.
DB00030 DB01233 Metoclopramide The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin human.
DB00030 DB00394 Beclomethasone dipropionate The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin human.
DB00030 DB00443 Betamethasone The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin human.
DB00030 DB00620 Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin human.
DB00030 DB00635 Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin human.
DB00030 DB00687 Fludrocortisone The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin human.
DB00030 DB00741 Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin human.
DB00030 DB00764 Mometasone The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin human.
DB00030 DB00860 Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin human.
DB00030 DB00959 Methylprednisolone The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin human.
DB00030 DB01234 Dexamethasone The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin human.
DB00030 DB01285 Corticotropin The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin human.
DB00030 DB01380 Cortisone acetate The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin human.
DB00030 DB01384 Paramethasone The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin human.
DB00030 DB01410 Ciclesonide The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin human.
DB00030 DB08906 Fluticasone furoate The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin human.
DB00030 DB08970 Fluprednidene The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin human.
DB00030 DB08971 Fluocortolone The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin human.
DB00030 DB09383 Meprednisone The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin human.
DB00030 DB11487 Dexamethasone isonicotinate The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin human.
DB00030 DB11750 Clobetasol The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin human.
DB00030 DB11921 Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin human.
DB00030 DB13003 Cortivazol The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin human.
DB00030 DB13208 Prednylidene The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin human.
DB00030 DB13843 Cloprednol The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin human.
DB00030 DB13867 Fluticasone The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin human.
DB00030 DB14512 Mometasone furoate The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin human.
DB00030 DB00180 Flunisolide The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin human.
DB00030 DB01108 Trilostane The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin human.
DB00030 DB01222 Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin human.
DB00030 DB04630 Aldosterone The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin human.
DB00030 DB09378 Fluprednisolone The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin human.
DB00030 DB11529 Melengestrol The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin human.
DB00030 DB14681 Cortisone The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin human.
DB00030 DB00223 Diflorasone The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin human.
DB00030 DB00240 Alclometasone The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin human.
DB00030 DB00253 Medrysone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin human.
DB00030 DB00288 Amcinonide The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin human.
DB00030 DB00324 Fluorometholone The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin human.
DB00030 DB00547 Desoximetasone The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin human.
DB00030 DB00588 Fluticasone propionate The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin human.
DB00030 DB00591 Fluocinolone acetonide The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin human.
DB00030 DB00596 Ulobetasol The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin human.
DB00030 DB00663 Flumethasone The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin human.
DB00030 DB00838 Clocortolone The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin human.
DB00030 DB00846 Flurandrenolide The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin human.
DB00030 DB14596 Loteprednol etabonate The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin human.
DB00030 DB00896 Rimexolone The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin human.
DB00030 DB01013 Clobetasol propionate The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin human.
DB00030 DB01047 Fluocinonide The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin human.
DB00030 DB01130 Prednicarbate The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin human.
DB00030 DB01260 Desonide The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin human.
DB00030 DB06781 Difluprednate The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin human.
DB00030 DB06786 Halcinonide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin human.
DB00030 DB09091 Tixocortol The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin human.
DB00030 DB09095 Difluocortolone The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin human.
DB00030 DB13158 Clobetasone The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin human.
DB00030 DB13223 Fluocortin The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin human.
DB00030 DB13491 Fluperolone The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin human.
DB00030 DB13664 Formocortal The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin human.
DB00030 DB13728 Halometasone The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin human.
DB00030 DB13856 Fluclorolone The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin human.
DB00030 DB14538 Hydrocortisone aceponate The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin human.
DB00030 DB14539 Hydrocortisone acetate The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin human.
DB00030 DB14540 Hydrocortisone butyrate The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin human.
DB00030 DB14541 Hydrocortisone cypionate The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin human.
DB00030 DB14543 Hydrocortisone probutate The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin human.
DB00030 DB14544 Hydrocortisone valerate The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin human.
DB00030 DB14545 Hydrocortisone succinate The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin human.
DB00030 DB00873 Loteprednol The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin human.
DB00030 DB14631 Prednisolone phosphate The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin human.
DB00030 DB14633 Prednisolone hemisuccinate The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin human.
DB00030 DB14634 Fluprednidene acetate The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin human.
DB00030 DB14643 Methylprednisolone aceponate The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin human.
DB00030 DB14644 Methylprednisolone hemisuccinate The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin human.
DB00030 DB14646 Prednisone acetate The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin human.
DB00030 DB14652 Clocortolone acetate The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin human.
DB00030 DB14659 Melengestrol acetate The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin human.
DB00030 DB14669 Betamethasone phosphate The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin human.
DB00030 DB15566 Prednisolone acetate The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin human.
DB00030 DB00451 Levothyroxine The therapeutic efficacy of Insulin human can be decreased when used in combination with Levothyroxine.
DB00030 DB00024 Thyrotropin alfa Thyrotropin alfa may decrease the hypoglycemic activities of Insulin human.
DB00030 DB01583 Liotrix Liotrix may decrease the hypoglycemic activities of Insulin human.
DB00030 DB03604 Tiratricol Tiratricol may decrease the hypoglycemic activities of Insulin human.
DB00030 DB09100 Thyroid, porcine Thyroid, porcine may decrease the hypoglycemic activities of Insulin human.
DB00031 DB06605 Apixaban Apixaban may increase the anticoagulant activities of Tenecteplase.
DB00031 DB06695 Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01254 Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tenecteplase.
DB00031 DB01609 Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Tenecteplase is combined with Deferasirox.
DB00031 DB01586 Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Ursodeoxycholic acid.
DB00031 DB02123 Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Glycochenodeoxycholic Acid.
DB00031 DB02659 Cholic Acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Cholic Acid.
DB00031 DB02691 Glycocholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Glycocholic acid.
DB00031 DB03619 Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Deoxycholic acid.
DB00031 DB04348 Taurocholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Taurocholic acid.
DB00031 DB05990 Obeticholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Obeticholic acid.
DB00031 DB06777 Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Chenodeoxycholic acid.
DB00031 DB08833 Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Taurochenodeoxycholic acid.
DB00031 DB08834 Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Tauroursodeoxycholic acid.
DB00031 DB08857 Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Bamet-UD2.
DB00031 DB11622 Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Dehydrocholic acid.
DB00031 DB11789 Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Hyodeoxycholic Acid.
DB00031 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Tenecteplase.
DB00031 DB09053 Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Tenecteplase.
DB00031 DB08935 Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Obinutuzumab.
DB00031 DB06228 Rivaroxaban Tenecteplase may increase the anticoagulant activities of Rivaroxaban.
DB00031 DB06206 Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Sugammadex.
DB00031 DB09070 Tibolone Tibolone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00932 Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tenecteplase.
DB00031 DB00013 Urokinase Urokinase may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00163 Vitamin E Vitamin E may increase the anticoagulant activities of Tenecteplase.
DB00031 DB09030 Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Tenecteplase.
DB00031 DB06692 Aprotinin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.
DB00031 DB01381 Ginkgo biloba The therapeutic efficacy of Tenecteplase can be increased when used in combination with Ginkgo biloba.
DB00031 DB01181 Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Tenecteplase.
DB00031 DB00468 Quinine The therapeutic efficacy of Tenecteplase can be increased when used in combination with Quinine.
DB00031 DB00908 Quinidine The therapeutic efficacy of Tenecteplase can be increased when used in combination with Quinidine.
DB00031 DB00675 Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Tenecteplase.
DB00031 DB00539 Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Tenecteplase.
DB00031 DB00806 Pentoxifylline The therapeutic efficacy of Tenecteplase can be increased when used in combination with Pentoxifylline.
DB00031 DB00686 Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00583 Levocarnitine The therapeutic efficacy of Tenecteplase can be increased when used in combination with Levocarnitine.
DB00031 DB00255 Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00269 Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00286 Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00783 Estradiol Estradiol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00977 Ethinylestradiol Ethinylestradiol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB01357 Mestranol Mestranol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB04573 Estriol Estriol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB04574 Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB04575 Quinestrol Quinestrol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB07931 Hexestrol Hexestrol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09369 Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09381 Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB11478 Zeranol Zeranol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB11674 Equol Equol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB12487 Promestriene Promestriene may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13143 Methallenestril Methallenestril may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13386 Epimestrol Epimestrol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13418 Moxestrol Moxestrol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13952 Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13953 Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13954 Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13956 Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB15334 Biochanin A Biochanin A may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB15335 Formononetin Formononetin may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00159 Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Tenecteplase.
DB00031 DB00244 Mesalazine The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tenecteplase.
DB00031 DB00328 Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Tenecteplase.
DB00031 DB00461 Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Tenecteplase.
DB00031 DB00465 Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Tenecteplase.
DB00031 DB00469 Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Tenecteplase.
DB00031 DB00482 Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Tenecteplase.
DB00031 DB00500 Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Tenecteplase.
DB00031 DB00533 Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Tenecteplase.
DB00031 DB00554 Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Tenecteplase.
DB00031 DB00573 Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Tenecteplase.
DB00031 DB00580 Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Tenecteplase.
DB00031 DB00586 Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Tenecteplase.
DB00031 DB00605 Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Tenecteplase.
DB00031 DB00712 Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Tenecteplase.
DB00031 DB00749 Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Tenecteplase.
DB00031 DB00784 Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Tenecteplase.
DB00031 DB00788 Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Tenecteplase.
DB00031 DB00795 Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Tenecteplase.
DB00031 DB00812 Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Tenecteplase.
DB00031 DB00814 Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Tenecteplase.
DB00031 DB00821 Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Tenecteplase.
DB00031 DB00861 Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Tenecteplase.
DB00031 DB00936 Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Tenecteplase.
DB00031 DB00939 Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Tenecteplase.
DB00031 DB00991 Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Tenecteplase.
DB00031 DB01009 Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Tenecteplase.
DB00031 DB01014 Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Tenecteplase.
DB00031 DB01250 Olsalazine The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Tenecteplase.
DB00031 DB01283 Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Tenecteplase.
DB00031 DB01397 Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Tenecteplase.
DB00031 DB01399 Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Tenecteplase.
DB00031 DB01401 Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Tenecteplase.
DB00031 DB01419 Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Tenecteplase.
DB00031 DB01424 Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Tenecteplase.
DB00031 DB01435 Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Tenecteplase.
DB00031 DB01600 Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Tenecteplase.
DB00031 DB01628 Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Tenecteplase.
DB00031 DB02224 Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Tenecteplase.
DB00031 DB03585 Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Tenecteplase.
DB00031 DB04552 Niflumic acid The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Tenecteplase.
DB00031 DB04725 Licofelone The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Tenecteplase.
DB00031 DB04812 Benoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Tenecteplase.
DB00031 DB04817 Metamizole The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Tenecteplase.
DB00031 DB04828 Zomepirac The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Tenecteplase.
DB00031 DB05095 Cimicoxib The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Tenecteplase.
DB00031 DB06725 Lornoxicam The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Tenecteplase.
DB00031 DB06736 Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Tenecteplase.
DB00031 DB06737 Zaltoprofen The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Tenecteplase.
DB00031 DB07402 Azapropazone The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Tenecteplase.
DB00031 DB07477 Felbinac The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Tenecteplase.
DB00031 DB08439 Parecoxib The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Tenecteplase.
DB00031 DB08797 Salicylamide The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Tenecteplase.
DB00031 DB08940 Kebuzone The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Tenecteplase.
DB00031 DB08942 Isoxicam The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Tenecteplase.
DB00031 DB08951 Indoprofen The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Tenecteplase.
DB00031 DB08955 Ibuproxam The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Tenecteplase.
DB00031 DB08976 Floctafenine The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Tenecteplase.
DB00031 DB08981 Fenbufen The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Tenecteplase.
DB00031 DB08984 Etofenamate The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Tenecteplase.
DB00031 DB08991 Epirizole The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Tenecteplase.
DB00031 DB09084 Benzydamine The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Tenecteplase.
DB00031 DB09212 Loxoprofen The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Tenecteplase.
DB00031 DB09214 Dexketoprofen The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Tenecteplase.
DB00031 DB09215 Droxicam The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Tenecteplase.
DB00031 DB09216 Tolfenamic acid The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Tenecteplase.
DB00031 DB09217 Firocoxib The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Tenecteplase.
DB00031 DB09218 Clonixin The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Tenecteplase.
DB00031 DB09285 Morniflumate The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Tenecteplase.
DB00031 DB09288 Propacetamol The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Tenecteplase.
DB00031 DB09295 Talniflumate The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Tenecteplase.
DB00031 DB11455 Robenacoxib The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Tenecteplase.
DB00031 DB11466 Tepoxalin The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Tenecteplase.
DB00031 DB11518 Flunixin The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Tenecteplase.
DB00031 DB12399 Polmacoxib The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Tenecteplase.
DB00031 DB12480 Betulinic Acid The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Tenecteplase.
DB00031 DB12610 Ebselen The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Tenecteplase.
DB00031 DB13001 Tinoridine The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Tenecteplase.
DB00031 DB13167 Alclofenac The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Tenecteplase.
DB00031 DB13217 Fentiazac The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Tenecteplase.
DB00031 DB13232 Suxibuzone The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Tenecteplase.
DB00031 DB13286 Bumadizone The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Tenecteplase.
DB00031 DB13314 Alminoprofen The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Tenecteplase.
DB00031 DB13317 Flunoxaprofen The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Tenecteplase.
DB00031 DB13364 Feprazone The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Tenecteplase.
DB00031 DB13371 Difenpiramide The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Tenecteplase.
DB00031 DB13407 Nifenazone The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Tenecteplase.
DB00031 DB13432 Lonazolac The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Tenecteplase.
DB00031 DB13481 Tenidap The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Tenecteplase.
DB00031 DB13501 Bendazac The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Tenecteplase.
DB00031 DB13514 Pranoprofen The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Tenecteplase.
DB00031 DB13524 Propyphenazone The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Tenecteplase.
DB00031 DB13527 Proglumetacin The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Tenecteplase.
DB00031 DB13538 Guacetisal The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Tenecteplase.
DB00031 DB13544 Ethenzamide The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Tenecteplase.
DB00031 DB13612 Carbaspirin calcium The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Tenecteplase.
DB00031 DB13629 Mofebutazone The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Tenecteplase.
DB00031 DB13649 Proquazone The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Tenecteplase.
DB00031 DB13657 Benorilate The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Tenecteplase.
DB00031 DB13722 Pirprofen The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Tenecteplase.
DB00031 DB13860 Imidazole salicylate The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Tenecteplase.
DB00031 DB14059 SC-236 The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Tenecteplase.
DB00031 DB14060 NS-398 The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Tenecteplase.
DB00031 DB14938 Flurbiprofen axetil The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Tenecteplase.
DB00031 DB04865 Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Tenecteplase is combined with Omacetaxine mepesuccinate.
DB00031 DB11133 Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00081 Tositumomab The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Tositumomab.
DB00031 DB09211 Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Tenecteplase.
DB00031 DB00048 Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Tenecteplase is combined with Collagenase clostridium histolyticum.
DB00031 DB00389 Carbimazole Carbimazole may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00550 Propylthiouracil Propylthiouracil may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00763 Methimazole Methimazole may increase the anticoagulant activities of Tenecteplase.
DB00031 DB03374 3,5-Diiodotyrosine 3,5-Diiodotyrosine may increase the anticoagulant activities of Tenecteplase.
DB00031 DB06715 Potassium Iodide Potassium Iodide may increase the anticoagulant activities of Tenecteplase.
DB00031 DB07637 Dibromotyrosine Dibromotyrosine may increase the anticoagulant activities of Tenecteplase.
DB00031 DB09418 Potassium perchlorate Potassium perchlorate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13644 Methylthiouracil Methylthiouracil may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13804 Benzylthiouracil Benzylthiouracil may increase the anticoagulant activities of Tenecteplase.
DB00031 DB00834 Mifepristone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Mifepristone.
DB00031 DB04066 p-Coumaric acid The therapeutic efficacy of Tenecteplase can be decreased when used in combination with p-Coumaric acid.
DB00031 DB04682 Octylphenoxy polyethoxyethanol The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Octylphenoxy polyethoxyethanol.
DB00031 DB05830 Trestolone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Trestolone.
DB00031 DB06266 Lonidamine The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Lonidamine.
DB00031 DB08867 Ulipristal The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ulipristal.
DB00031 DB09401 Isosorbide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Isosorbide.
DB00031 DB11507 Cloprostenol The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cloprostenol.
DB00031 DB12025 Triptolide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Triptolide.
DB00031 DB13044 Gossypol The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Gossypol.
DB00031 DB13310 Ormeloxifene The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ormeloxifene.
DB00031 DB00294 Etonogestrel Etonogestrel may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00304 Desogestrel Desogestrel may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00351 Megestrol acetate Megestrol acetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00367 Levonorgestrel Levonorgestrel may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00378 Dydrogesterone Dydrogesterone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00396 Progesterone Progesterone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00603 Medroxyprogesterone acetate Medroxyprogesterone acetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00717 Norethisterone Norethisterone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00823 Ethynodiol diacetate Ethynodiol diacetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00957 Norgestimate Norgestimate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB01395 Drospirenone Drospirenone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB01431 Allylestrenol Allylestrenol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB04839 Cyproterone acetate Cyproterone acetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB06713 Norelgestromin Norelgestromin may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB06730 Gestodene Gestodene may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB06789 Hydroxyprogesterone caproate Hydroxyprogesterone caproate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09123 Dienogest Dienogest may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09124 Medrogestone Medrogestone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09371 Norethynodrel Norethynodrel may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB09389 Norgestrel Norgestrel may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB11372 Altrenogest Altrenogest may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB11619 Gestrinone Gestrinone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB11636 Nomegestrol Nomegestrol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB12474 Lynestrenol Lynestrenol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13230 Gestonorone Gestonorone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13528 Chlormadinone Chlormadinone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13533 Methylestrenolone Methylestrenolone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13563 Norgestrienone Norgestrienone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13602 Promegestone Promegestone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13685 Quingestanol Quingestanol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13857 Demegestone Demegestone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13866 Etynodiol Etynodiol may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB13981 Nomegestrol acetate Nomegestrol acetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB14570 Hydroxyprogesterone Hydroxyprogesterone may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB14678 Norethindrone enanthate Norethindrone enanthate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB14679 Quingestanol acetate Quingestanol acetate may decrease the anticoagulant activities of Tenecteplase.
DB00031 DB00233 Aminosalicylic acid The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tenecteplase.
DB00031 DB01294 Bismuth subsalicylate The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Tenecteplase.
DB00031 DB06251 Dersalazine The risk or severity of bleeding can be increased when Dersalazine is combined with Tenecteplase.
DB00031 DB06807 Phenyl aminosalicylate The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Tenecteplase.
DB00031 DB09543 Methyl salicylate The risk or severity of bleeding can be increased when Methyl salicylate is combined with Tenecteplase.
DB00031 DB11079 Trolamine salicylate The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Tenecteplase.
DB00031 DB13509 Aloxiprin The risk or severity of bleeding can be increased when Aloxiprin is combined with Tenecteplase.
DB00031 DB14006 Choline salicylate The risk or severity of bleeding can be increased when Choline salicylate is combined with Tenecteplase.
DB00031 DB14026 Thiosalicylic acid The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Tenecteplase.
DB00031 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Tenecteplase.
DB00031 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Tenecteplase.
DB00031 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Tenecteplase.
DB00031 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Tenecteplase.
DB00031 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Tenecteplase.
DB00031 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Tenecteplase.
DB00031 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Tenecteplase.
DB00031 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Tenecteplase.
DB00031 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tenecteplase.
DB00031 DB01166 Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Tenecteplase.
DB00031 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Tenecteplase.
DB00031 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Tenecteplase.
DB00031 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Tenecteplase.
DB00031 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Tenecteplase.
DB00031 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Tenecteplase.
DB00031 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Tenecteplase.
DB00031 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Tenecteplase.
DB00031 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Tenecteplase.
DB00031 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Tenecteplase.
DB00031 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Tenecteplase.
DB00031 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Tenecteplase.
DB00031 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Tenecteplase.
DB00031 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Tenecteplase.
DB00031 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Tenecteplase.
DB00031 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Tenecteplase.
DB00031 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Tenecteplase.
DB00031 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tenecteplase.
DB00031 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Tenecteplase.
DB00031 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Tenecteplase.
DB00031 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Tenecteplase.
DB00031 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Tenecteplase.
DB00031 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Tenecteplase.
DB00031 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Tenecteplase.
DB00031 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Tenecteplase.
DB00031 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Tenecteplase.
DB00031 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Tenecteplase.
DB00031 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Tenecteplase.
DB00031 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Tenecteplase.
DB00031 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Tenecteplase.
DB00031 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Tenecteplase.
DB00031 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Tenecteplase.
DB00031 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Tenecteplase.
DB00031 DB00374 Treprostinil The risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.
DB00031 DB03404 Hemin Hemin may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13783 Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Tenecteplase.
DB00031 DB00624 Testosterone Testosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01420 Testosterone propionate Testosterone propionate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01481 1-Testosterone 1-Testosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01485 4-Hydroxytestosterone 4-Hydroxytestosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01510 Dehydrochloromethyltestosterone Dehydrochloromethyltestosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01541 Boldenone Boldenone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01543 18-methyl-19-nortestosterone 18-methyl-19-nortestosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01564 Calusterone Calusterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01569 Formebolone Formebolone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01572 Methyl-1-testosterone Methyl-1-testosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB02901 Stanolone Stanolone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB07447 5beta-dihydrotestosterone 5beta-dihydrotestosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB08619 Testosterone succinate Testosterone succinate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB11429 Mibolerone Mibolerone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13943 Testosterone cypionate Testosterone cypionate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13944 Testosterone enanthate Testosterone enanthate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13947 Testosterone enantate benzilic acid hydrazone Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13951 Stanolone acetate Stanolone acetate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB13958 Trestolone acetate Trestolone acetate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB14093 (1,2,6,7-3H)Testosterone (1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Tenecteplase.
DB00031 DB14655 Drostanolone propionate Drostanolone propionate may increase the anticoagulant activities of Tenecteplase.
DB00031 DB11051 Azficel-T The risk or severity of adverse effects can be increased when Tenecteplase is combined with Azficel-T.
DB00031 DB09568 Omega-3-carboxylic acids The therapeutic efficacy of Tenecteplase can be increased when used in combination with Omega-3-carboxylic acids.
DB00031 DB00258 Calcium acetate The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Tenecteplase.
DB00031 DB01164 Calcium chloride The therapeutic efficacy of Calcium chloride can be decreased when used in combination with Tenecteplase.
DB00031 DB01373 Calcium The therapeutic efficacy of Calcium can be decreased when used in combination with Tenecteplase.
DB00031 DB11126 Calcium gluconate The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Tenecteplase.
DB00031 DB11608 Eftrenonacog alfa The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB13884 Albutrepenonacog alfa The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB13923 Emicizumab The therapeutic efficacy of Emicizumab can be decreased when used in combination with Tenecteplase.
DB00031 DB14738 Turoctocog alfa pegol The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Tenecteplase.
DB00031 DB00025 Antihemophilic factor, human recombinant The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Tenecteplase.
DB00031 DB00036 Coagulation factor VIIa Recombinant Human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tenecteplase.
DB00031 DB00100 Coagulation Factor IX (Recombinant) The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Tenecteplase.
DB00031 DB01783 Pantothenic acid The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Tenecteplase.
DB00031 DB01942 Formic acid The therapeutic efficacy of Formic acid can be decreased when used in combination with Tenecteplase.
DB00031 DB02261 Platelet Activating Factor The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Tenecteplase.
DB00031 DB06724 Calcium carbonate The therapeutic efficacy of Calcium carbonate can be decreased when used in combination with Tenecteplase.
DB00031 DB09109 Turoctocog alfa The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB09222 Fibrinogen human The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Tenecteplase.
DB00031 DB09310 Catridecacog The therapeutic efficacy of Catridecacog can be decreased when used in combination with Tenecteplase.
DB00031 DB09329 Antihemophilic Factor (Recombinant), PEGylated The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Tenecteplase.
DB00031 DB11093 Calcium citrate The therapeutic efficacy of Calcium citrate can be decreased when used in combination with Tenecteplase.
DB00031 DB11168 Calcium threonate The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Tenecteplase.
DB00031 DB11311 Prothrombin The therapeutic efficacy of Prothrombin can be decreased when used in combination with Tenecteplase.
DB00031 DB11330 Factor IX Complex (Human) The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Tenecteplase.
DB00031 DB11348 Calcium Phosphate The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Tenecteplase.
DB00031 DB11606 Susoctocog alfa The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB11668 Rusalatide acetate The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Tenecteplase.
DB00031 DB12409 Vatreptacog alfa The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB12909 Factor XIII (human) The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Tenecteplase.
DB00031 DB13133 Von Willebrand Factor Human The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Tenecteplase.
DB00031 DB13148 Coagulation factor X human The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Tenecteplase.
DB00031 DB13150 Coagulation factor VII human The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Tenecteplase.
DB00031 DB13151 Anti-inhibitor coagulant complex The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tenecteplase.
DB00031 DB13152 Coagulation Factor IX Human The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Tenecteplase.
DB00031 DB13192 Antihemophilic factor human The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tenecteplase.
DB00031 DB13197 Kallidinogenase The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Tenecteplase.
DB00031 DB13201 Trenonacog alfa The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB13933 Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Tenecteplase.
DB00031 DB13999 Moroctocog alfa The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB14473 Beroctocog alfa The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB14562 Andexanet alfa The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Tenecteplase.
DB00031 DB14577 Calcium cation The therapeutic efficacy of Calcium cation can be decreased when used in combination with Tenecteplase.
DB00031 DB14700 Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Tenecteplase.
DB00031 DB00176 Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Tenecteplase.
DB00031 DB00215 Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Tenecteplase.
DB00031 DB00472 Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Tenecteplase.
DB00031 DB00715 Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Tenecteplase.
DB00031 DB01149 Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Tenecteplase.
DB00031 DB04832 Zimelidine The risk or severity of hemorrhage can be increased when Zimelidine is combined with Tenecteplase.
DB00031 DB04884 Dapoxetine The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Tenecteplase.
DB00031 DB06731 Seproxetine The risk or severity of hemorrhage can be increased when Seproxetine is combined with Tenecteplase.
DB00031 DB08953 Indalpine The risk or severity of hemorrhage can be increased when Indalpine is combined with Tenecteplase.
DB00031 DB12693 Ritanserin The risk or severity of hemorrhage can be increased when Ritanserin is combined with Tenecteplase.
DB00031 DB13233 Alaproclate The risk or severity of hemorrhage can be increased when Alaproclate is combined with Tenecteplase.
DB00031 DB00476 Duloxetine The risk or severity of hemorrhage can be increased when Duloxetine is combined with Tenecteplase.
DB00031 DB01105 Sibutramine The risk or severity of hemorrhage can be increased when Sibutramine is combined with Tenecteplase.
DB00031 DB04896 Milnacipran The risk or severity of hemorrhage can be increased when Milnacipran is combined with Tenecteplase.
DB00031 DB06700 Desvenlafaxine The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Tenecteplase.
DB00031 DB08918 Levomilnacipran The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Tenecteplase.
DB00031 DB00285 Venlafaxine Venlafaxine may increase the antiplatelet activities of Tenecteplase.
DB00031 DB00182 Amphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Tenecteplase.
DB00031 DB00601 Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Tenecteplase.
DB00031 DB00614 Furazolidone The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Tenecteplase.
DB00031 DB00721 Procaine The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Tenecteplase.
DB00031 DB00752 Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Tenecteplase.
DB00031 DB00780 Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Tenecteplase.
DB00031 DB00805 Minaprine The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Tenecteplase.
DB00031 DB01037 Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Tenecteplase.
DB00031 DB01168 Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Tenecteplase.
DB00031 DB01171 Moclobemide The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Tenecteplase.
DB00031 DB01247 Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Tenecteplase.
DB00031 DB01367 Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Tenecteplase.
DB00031 DB01626 Pargyline The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Tenecteplase.
DB00031 DB04017 Clorgiline The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Tenecteplase.
DB00031 DB04818 Iproniazid The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Tenecteplase.
DB00031 DB04820 Nialamide The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Tenecteplase.
DB00031 DB06654 Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Tenecteplase.
DB00031 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Tenecteplase.
DB00031 DB09241 Methylene blue The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Tenecteplase.
DB00031 DB09243 Hydracarbazine The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Tenecteplase.
DB00031 DB09244 Pirlindole The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Tenecteplase.
DB00031 DB09245 Toloxatone The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Tenecteplase.
DB00031 DB09246 Benmoxin The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Tenecteplase.
DB00031 DB09248 Mebanazine The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Tenecteplase.
DB00031 DB09249 Octamoxin The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Tenecteplase.
DB00031 DB09250 Pheniprazine The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Tenecteplase.
DB00031 DB09251 Phenoxypropazine The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Tenecteplase.
DB00031 DB09252 Pivhydrazine The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Tenecteplase.
DB00031 DB09253 Safrazine The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Tenecteplase.
DB00031 DB09254 Caroxazone The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Tenecteplase.
DB00031 DB13875 Harmaline The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Tenecteplase.
DB00031 DB13876 Brofaromine The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Tenecteplase.
DB00031 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Tenecteplase.
DB00031 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Tenecteplase.
DB00031 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Tenecteplase.
DB00031 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Tenecteplase.
DB00031 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Tenecteplase.
DB00031 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Tenecteplase.
DB00031 DB00682 Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Tenecteplase.
DB00031 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Tenecteplase.
DB00031 DB00974 Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Tenecteplase.
DB00031 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Tenecteplase.
DB00031 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Tenecteplase.
DB00031 DB01418 Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Tenecteplase.
DB00031 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Tenecteplase.
DB00031 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Tenecteplase.
DB00031 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Tenecteplase.
DB00031 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Tenecteplase.
DB00031 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Tenecteplase.
DB00031 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Tenecteplase.
DB00031 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Tenecteplase.
DB00031 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Tenecteplase.
DB00031 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Tenecteplase.
DB00031 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Tenecteplase.
DB00031 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Tenecteplase.
DB00031 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Tenecteplase.
DB00031 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Tenecteplase.
DB00031 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Tenecteplase.
DB00031 DB11268 Protocatechualdehyde The risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Tenecteplase.
DB00031 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Tenecteplase.
DB00031 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Tenecteplase.
DB00031 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Tenecteplase.
DB00031 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Tenecteplase.
DB00031 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Tenecteplase.
DB00031 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Tenecteplase.
DB00031 DB13124 Troxerutin The risk or severity of bleeding can be increased when Troxerutin is combined with Tenecteplase.
DB00031 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Tenecteplase.
DB00031 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Tenecteplase.
DB00031 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Tenecteplase.
DB00031 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Tenecteplase.
DB00031 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Tenecteplase.
DB00031 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Tenecteplase is combined with Drotrecogin alfa.
DB00031 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tenecteplase is combined with Tinzaparin.
DB00031 DB13199 Brinase The risk or severity of bleeding can be increased when Tenecteplase is combined with Brinase.
DB00031 DB13646 Saruplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Saruplase.
DB00031 DB00086 Streptokinase The risk or severity of bleeding can be increased when Tenecteplase is combined with Streptokinase.
DB00031 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Desmoteplase.
DB00031 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Tenecteplase is combined with Fibrinolysin.
DB00031 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Tenecteplase is combined with Astaxanthin.
DB00031 DB08994 Ditazole The risk or severity of bleeding can be increased when Tenecteplase is combined with Ditazole.
DB00031 DB09258 Bemiparin The risk or severity of bleeding can be increased when Tenecteplase is combined with Bemiparin.
DB00031 DB09260 Parnaparin The risk or severity of bleeding can be increased when Tenecteplase is combined with Parnaparin.
DB00031 DB13275 Clorindione The risk or severity of bleeding can be increased when Tenecteplase is combined with Clorindione.
DB00031 DB13347 Diphenadione The risk or severity of bleeding can be increased when Tenecteplase is combined with Diphenadione.
DB00031 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tenecteplase is combined with Tioclomarol.
DB00031 DB00001 Lepirudin The risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin.
DB00031 DB00009 Alteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Alteplase.
DB00031 DB00015 Reteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Reteplase.
DB00031 DB00029 Anistreplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Anistreplase.
DB00031 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tenecteplase is combined with Tocopherylquinone.
DB00031 DB06679 Amediplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Amediplase.
DB00031 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when Tenecteplase is combined with 4-hydroxycoumarin.
DB00031 DB08496 (R)-warfarin The risk or severity of bleeding can be increased when Tenecteplase is combined with (R)-warfarin.
DB00031 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when Tenecteplase is combined with (S)-Warfarin.
DB00031 DB12364 Betrixaban The risk or severity of bleeding can be increased when Tenecteplase is combined with Betrixaban.
DB00031 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Tenecteplase is combined with Edetate calcium disodium anhydrous.
DB00031 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Tenecteplase is combined with Zinc citrate.
DB00031 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Tenecteplase is combined with Antithrombin Alfa.
DB00031 DB04665 Coumarin The risk or severity of bleeding can be increased when Tenecteplase is combined with Coumarin.
DB00031 DB14726 Dabigatran The risk or severity of bleeding can be increased when Tenecteplase is combined with Dabigatran.
DB00031 DB06294 Semuloparin The risk or severity of bleeding can be increased when Tenecteplase is combined with Semuloparin.
DB00031 DB12726 Monteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Monteplase.
DB00031 DB00177 Valsartan The risk or severity of angioedema can be increased when Tenecteplase is combined with Valsartan.
DB00031 DB00178 Ramipril The risk or severity of angioedema can be increased when Tenecteplase is combined with Ramipril.
DB00031 DB00230 Pregabalin The risk or severity of angioedema can be increased when Tenecteplase is combined with Pregabalin.
DB00031 DB00492 Fosinopril The risk or severity of angioedema can be increased when Tenecteplase is combined with Fosinopril.
DB00031 DB00519 Trandolapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Trandolapril.
DB00031 DB00542 Benazepril The risk or severity of angioedema can be increased when Tenecteplase is combined with Benazepril.
DB00031 DB00584 Enalapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Enalapril.
DB00031 DB00678 Losartan The risk or severity of angioedema can be increased when Tenecteplase is combined with Losartan.
DB00031 DB00691 Moexipril The risk or severity of angioedema can be increased when Tenecteplase is combined with Moexipril.
DB00031 DB00722 Lisinopril The risk or severity of angioedema can be increased when Tenecteplase is combined with Lisinopril.
DB00031 DB00790 Perindopril The risk or severity of angioedema can be increased when Tenecteplase is combined with Perindopril.
DB00031 DB00876 Eprosartan The risk or severity of angioedema can be increased when Tenecteplase is combined with Eprosartan.
DB00031 DB00877 Sirolimus The risk or severity of angioedema can be increased when Tenecteplase is combined with Sirolimus.
DB00031 DB00881 Quinapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Quinapril.
DB00031 DB00886 Omapatrilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Omapatrilat.
DB00031 DB00966 Telmisartan The risk or severity of angioedema can be increased when Tenecteplase is combined with Telmisartan.
DB00031 DB01050 Ibuprofen The risk or severity of angioedema can be increased when Tenecteplase is combined with Ibuprofen.
DB00031 DB01180 Rescinnamine The risk or severity of angioedema can be increased when Tenecteplase is combined with Rescinnamine.
DB00031 DB01197 Captopril The risk or severity of angioedema can be increased when Tenecteplase is combined with Captopril.
DB00031 DB01261 Sitagliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Sitagliptin.
DB00031 DB01340 Cilazapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Cilazapril.
DB00031 DB01342 Forasartan The risk or severity of angioedema can be increased when Tenecteplase is combined with Forasartan.
DB00031 DB01347 Saprisartan The risk or severity of angioedema can be increased when Tenecteplase is combined with Saprisartan.
DB00031 DB01348 Spirapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Spirapril.
DB00031 DB04876 Vildagliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Vildagliptin.
DB00031 DB06011 AMG-222 The risk or severity of angioedema can be increased when Tenecteplase is combined with AMG-222.
DB00031 DB06127 Bisegliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Bisegliptin.
DB00031 DB06196 Icatibant The risk or severity of angioedema can be increased when Tenecteplase is combined with Icatibant.
DB00031 DB06203 Alogliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Alogliptin.
DB00031 DB06245 Lanoteplase The risk or severity of angioedema can be increased when Tenecteplase is combined with Lanoteplase.
DB00031 DB06287 Temsirolimus The risk or severity of angioedema can be increased when Tenecteplase is combined with Temsirolimus.
DB00031 DB06335 Saxagliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Saxagliptin.
DB00031 DB08382 Gosogliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Gosogliptin.
DB00031 DB08822 Azilsartan medoxomil The risk or severity of angioedema can be increased when Tenecteplase is combined with Azilsartan medoxomil.
DB00031 DB08836 Temocapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Temocapril.
DB00031 DB08882 Linagliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Linagliptin.
DB00031 DB09292 Sacubitril The risk or severity of angioedema can be increased when Tenecteplase is combined with Sacubitril.
DB00031 DB09477 Enalaprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Enalaprilat.
DB00031 DB11723 Dutogliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Dutogliptin.
DB00031 DB11783 Imidapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Imidapril.
DB00031 DB11950 Teneligliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Teneligliptin.
DB00031 DB11992 Omarigliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Omarigliptin.
DB00031 DB12268 Carmegliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Carmegliptin.
DB00031 DB12412 Gemigliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Gemigliptin.
DB00031 DB12417 Anagliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Anagliptin.
DB00031 DB12625 Evogliptin The risk or severity of angioedema can be increased when Tenecteplase is combined with Evogliptin.
DB00031 DB13166 Zofenopril The risk or severity of angioedema can be increased when Tenecteplase is combined with Zofenopril.
DB00031 DB13312 Delapril The risk or severity of angioedema can be increased when Tenecteplase is combined with Delapril.
DB00031 DB14125 Benazeprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Benazeprilat.
DB00031 DB14207 Fosinoprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Fosinoprilat.
DB00031 DB14208 Ramiprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Ramiprilat.
DB00031 DB14209 Trandolaprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Trandolaprilat.
DB00031 DB14210 Moexiprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Moexiprilat.
DB00031 DB14213 Perindoprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Perindoprilat.
DB00031 DB14217 Quinaprilat The risk or severity of angioedema can be increased when Tenecteplase is combined with Quinaprilat.
DB00031 DB14231 Quinoline Yellow WS The risk or severity of angioedema can be increased when Tenecteplase is combined with Quinoline Yellow WS.
DB00031 DB00203 Sildenafil The risk or severity of hemorrhage can be increased when Tenecteplase is combined with Sildenafil.
DB00031 DB00008 Peginterferon alfa-2a The risk or severity of bleeding can be increased when Tenecteplase is combined with Peginterferon alfa-2a.
DB00031 DB00011 Interferon alfa-n1 The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-n1.
DB00031 DB00018 Interferon alfa-n3 The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-n3.
DB00031 DB00022 Peginterferon alfa-2b The risk or severity of bleeding can be increased when Tenecteplase is combined with Peginterferon alfa-2b.
DB00031 DB00033 Interferon gamma-1b The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon gamma-1b.
DB00031 DB00034 Interferon alfa-2a, Recombinant The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-2a, Recombinant.
DB00031 DB00041 Aldesleukin The risk or severity of bleeding can be increased when Tenecteplase is combined with Aldesleukin.
DB00031 DB00056 Gemtuzumab ozogamicin The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemtuzumab ozogamicin.
DB00031 DB00068 Interferon beta-1b The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon beta-1b.
DB00031 DB00069 Interferon alfacon-1 The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfacon-1.
DB00031 DB00073 Rituximab The risk or severity of bleeding can be increased when Tenecteplase is combined with Rituximab.
DB00031 DB00078 Ibritumomab tiuxetan The risk or severity of bleeding can be increased when Tenecteplase is combined with Ibritumomab tiuxetan.
DB00031 DB00087 Alemtuzumab The risk or severity of bleeding can be increased when Tenecteplase is combined with Alemtuzumab.
DB00031 DB00105 Interferon alfa-2b The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-2b.
DB00031 DB00120 Phenylalanine The risk or severity of bleeding can be increased when Tenecteplase is combined with Phenylalanine.
DB00031 DB00188 Bortezomib The risk or severity of bleeding can be increased when Tenecteplase is combined with Bortezomib.
DB00031 DB00242 Cladribine The risk or severity of bleeding can be increased when Tenecteplase is combined with Cladribine.
DB00031 DB00262 Carmustine The risk or severity of bleeding can be increased when Tenecteplase is combined with Carmustine.
DB00031 DB00276 Amsacrine The risk or severity of bleeding can be increased when Tenecteplase is combined with Amsacrine.
DB00031 DB00291 Chlorambucil The risk or severity of bleeding can be increased when Tenecteplase is combined with Chlorambucil.
DB00031 DB00293 Raltitrexed The risk or severity of bleeding can be increased when Tenecteplase is combined with Raltitrexed.
DB00031 DB00305 Mitomycin The risk or severity of bleeding can be increased when Tenecteplase is combined with Mitomycin.
DB00031 DB00307 Bexarotene The risk or severity of bleeding can be increased when Tenecteplase is combined with Bexarotene.
DB00031 DB00309 Vindesine The risk or severity of bleeding can be increased when Tenecteplase is combined with Vindesine.
DB00031 DB00322 Floxuridine The risk or severity of bleeding can be increased when Tenecteplase is combined with Floxuridine.
DB00031 DB00352 Tioguanine The risk or severity of bleeding can be increased when Tenecteplase is combined with Tioguanine.
DB00031 DB00361 Vinorelbine The risk or severity of bleeding can be increased when Tenecteplase is combined with Vinorelbine.
DB00031 DB00380 Dexrazoxane The risk or severity of bleeding can be increased when Tenecteplase is combined with Dexrazoxane.
DB00031 DB00398 Sorafenib The risk or severity of bleeding can be increased when Tenecteplase is combined with Sorafenib.
DB00031 DB00428 Streptozocin The risk or severity of bleeding can be increased when Tenecteplase is combined with Streptozocin.
DB00031 DB00441 Gemcitabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Gemcitabine.
DB00031 DB00444 Teniposide The risk or severity of bleeding can be increased when Tenecteplase is combined with Teniposide.
DB00031 DB00445 Epirubicin The risk or severity of bleeding can be increased when Tenecteplase is combined with Epirubicin.
DB00031 DB00446 Chloramphenicol The risk or severity of bleeding can be increased when Tenecteplase is combined with Chloramphenicol.
DB00031 DB00480 Lenalidomide The risk or severity of bleeding can be increased when Tenecteplase is combined with Lenalidomide.
DB00031 DB00488 Altretamine The risk or severity of bleeding can be increased when Tenecteplase is combined with Altretamine.
DB00031 DB00495 Zidovudine The risk or severity of bleeding can be increased when Tenecteplase is combined with Zidovudine.
DB00031 DB00515 Cisplatin The risk or severity of bleeding can be increased when Tenecteplase is combined with Cisplatin.
DB00031 DB00526 Oxaliplatin The risk or severity of bleeding can be increased when Tenecteplase is combined with Oxaliplatin.
DB00031 DB00531 Cyclophosphamide The risk or severity of bleeding can be increased when Tenecteplase is combined with Cyclophosphamide.
DB00031 DB00544 Fluorouracil The risk or severity of bleeding can be increased when Tenecteplase is combined with Fluorouracil.
DB00031 DB00552 Pentostatin The risk or severity of bleeding can be increased when Tenecteplase is combined with Pentostatin.
DB00031 DB00563 Methotrexate The risk or severity of bleeding can be increased when Tenecteplase is combined with Methotrexate.
DB00031 DB00564 Carbamazepine The risk or severity of bleeding can be increased when Tenecteplase is combined with Carbamazepine.
DB00031 DB00570 Vinblastine The risk or severity of bleeding can be increased when Tenecteplase is combined with Vinblastine.
DB00031 DB00619 Imatinib The risk or severity of bleeding can be increased when Tenecteplase is combined with Imatinib.
DB00031 DB00631 Clofarabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Clofarabine.
DB00031 DB00642 Pemetrexed The risk or severity of bleeding can be increased when Tenecteplase is combined with Pemetrexed.
DB00031 DB00694 Daunorubicin The risk or severity of bleeding can be increased when Tenecteplase is combined with Daunorubicin.
DB00031 DB00762 Irinotecan The risk or severity of bleeding can be increased when Tenecteplase is combined with Irinotecan.
DB00031 DB00773 Etoposide The risk or severity of bleeding can be increased when Tenecteplase is combined with Etoposide.
DB00031 DB00851 Dacarbazine The risk or severity of bleeding can be increased when Tenecteplase is combined with Dacarbazine.
DB00031 DB00853 Temozolomide The risk or severity of bleeding can be increased when Tenecteplase is combined with Temozolomide.
DB00031 DB00859 Penicillamine The risk or severity of bleeding can be increased when Tenecteplase is combined with Penicillamine.
DB00031 DB00864 Tacrolimus The risk or severity of bleeding can be increased when Tenecteplase is combined with Tacrolimus.
DB00031 DB00888 Mechlorethamine The risk or severity of bleeding can be increased when Tenecteplase is combined with Mechlorethamine.
DB00031 DB00928 Azacitidine The risk or severity of bleeding can be increased when Tenecteplase is combined with Azacitidine.
DB00031 DB00958 Carboplatin The risk or severity of bleeding can be increased when Tenecteplase is combined with Carboplatin.
DB00031 DB00970 Dactinomycin The risk or severity of bleeding can be increased when Tenecteplase is combined with Dactinomycin.
DB00031 DB00987 Cytarabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Cytarabine.
DB00031 DB00997 Doxorubicin The risk or severity of bleeding can be increased when Tenecteplase is combined with Doxorubicin.
DB00031 DB01005 Hydroxyurea The risk or severity of bleeding can be increased when Tenecteplase is combined with Hydroxyurea.
DB00031 DB01008 Busulfan The risk or severity of bleeding can be increased when Tenecteplase is combined with Busulfan.
DB00031 DB01030 Topotecan The risk or severity of bleeding can be increased when Tenecteplase is combined with Topotecan.
DB00031 DB01033 Mercaptopurine The risk or severity of bleeding can be increased when Tenecteplase is combined with Mercaptopurine.
DB00031 DB01041 Thalidomide The risk or severity of bleeding can be increased when Tenecteplase is combined with Thalidomide.
DB00031 DB01042 Melphalan The risk or severity of bleeding can be increased when Tenecteplase is combined with Melphalan.
DB00031 DB01073 Fludarabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Fludarabine.
DB00031 DB01099 Flucytosine The risk or severity of bleeding can be increased when Tenecteplase is combined with Flucytosine.
DB00031 DB01101 Capecitabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Capecitabine.
DB00031 DB01169 Arsenic trioxide The risk or severity of bleeding can be increased when Tenecteplase is combined with Arsenic trioxide.
DB00031 DB01177 Idarubicin The risk or severity of bleeding can be increased when Tenecteplase is combined with Idarubicin.
DB00031 DB01204 Mitoxantrone The risk or severity of bleeding can be increased when Tenecteplase is combined with Mitoxantrone.
DB00031 DB01206 Lomustine The risk or severity of bleeding can be increased when Tenecteplase is combined with Lomustine.
DB00031 DB01229 Paclitaxel The risk or severity of bleeding can be increased when Tenecteplase is combined with Paclitaxel.
DB00031 DB01248 Docetaxel The risk or severity of bleeding can be increased when Tenecteplase is combined with Docetaxel.
DB00031 DB01262 Decitabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Decitabine.
DB00031 DB01280 Nelarabine The risk or severity of bleeding can be increased when Tenecteplase is combined with Nelarabine.
DB00031 DB01590 Everolimus The risk or severity of bleeding can be increased when Tenecteplase is combined with Everolimus.
DB00031 DB02546 Vorinostat The risk or severity of bleeding can be increased when Tenecteplase is combined with Vorinostat.
DB00031 DB04572 Thiotepa The risk or severity of bleeding can be increased when Tenecteplase is combined with Thiotepa.
DB00031 DB04845 Ixabepilone The risk or severity of bleeding can be increased when Tenecteplase is combined with Ixabepilone.
DB00031 DB04868 Nilotinib The risk or severity of bleeding can be increased when Tenecteplase is combined with Nilotinib.
DB00031 DB05015 Belinostat The risk or severity of bleeding can be increased when Tenecteplase is combined with Belinostat.
DB00031 DB05109 Trabectedin The risk or severity of bleeding can be increased when Tenecteplase is combined with Trabectedin.
DB00031 DB05258 Interferon alfa The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa.
DB00031 DB05472 omega interferon The risk or severity of bleeding can be increased when Tenecteplase is combined with omega interferon.
DB00031 DB05773 Trastuzumab emtansine The risk or severity of bleeding can be increased when Tenecteplase is combined with Trastuzumab emtansine.
DB00031 DB06616 Bosutinib The risk or severity of bleeding can be increased when Tenecteplase is combined with Bosutinib.
DB00031 DB06769 Bendamustine The risk or severity of bleeding can be increased when Tenecteplase is combined with Bendamustine.
DB00031 DB06772 Cabazitaxel The risk or severity of bleeding can be increased when Tenecteplase is combined with Cabazitaxel.
DB00031 DB08871 Eribulin The risk or severity of bleeding can be increased when Tenecteplase is combined with Eribulin.
DB00031 DB08877 Ruxolitinib The risk or severity of bleeding can be increased when Tenecteplase is combined with Ruxolitinib.
DB00031 DB08889 Carfilzomib The risk or severity of bleeding can be increased when Tenecteplase is combined with Carfilzomib.
DB00031 DB08895 Tofacitinib The risk or severity of bleeding can be increased when Tenecteplase is combined with Tofacitinib.
DB00031 DB08901 Ponatinib The risk or severity of bleeding can be increased when Tenecteplase is combined with Ponatinib.
DB00031 DB08910 Pomalidomide The risk or severity of bleeding can be increased when Tenecteplase is combined with Pomalidomide.
DB00031 DB09042 Tedizolid phosphate The risk or severity of bleeding can be increased when Tenecteplase is combined with Tedizolid phosphate.
DB00031 DB09052 Blinatumomab The risk or severity of bleeding can be increased when Tenecteplase is combined with Blinatumomab.
DB00031 DB09073 Palbociclib The risk or severity of bleeding can be increased when Tenecteplase is combined with Palbociclib.
DB00031 DB09074 Olaparib The risk or severity of bleeding can be increased when Tenecteplase is combined with Olaparib.
DB00031 DB09077 Dinutuximab The risk or severity of bleeding can be increased when Tenecteplase is combined with Dinutuximab.
DB00031 DB09122 Peginterferon beta-1a The risk or severity of bleeding can be increased when Tenecteplase is combined with Peginterferon beta-1a.
DB00031 DB12814 Cepeginterferon alfa-2B The risk or severity of bleeding can be increased when Tenecteplase is combined with Cepeginterferon alfa-2B.
DB00031 DB00229 Cefotiam The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefotiam.
DB00031 DB00267 Cefmenoxime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefmenoxime.
DB00031 DB00274 Cefmetazole The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefmetazole.
DB00031 DB00430 Cefpiramide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefpiramide.
DB00031 DB00438 Ceftazidime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftazidime.
DB00031 DB00447 Loracarbef The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Loracarbef.
DB00031 DB00456 Cefalotin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefalotin.
DB00031 DB00493 Cefotaxime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefotaxime.
DB00031 DB00535 Cefdinir The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefdinir.
DB00031 DB00567 Cephalexin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cephalexin.
DB00031 DB00671 Cefixime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefixime.
DB00031 DB00689 Cephaloglycin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cephaloglycin.
DB00031 DB00833 Cefaclor The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefaclor.
DB00031 DB00923 Ceforanide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceforanide.
DB00031 DB01066 Cefditoren The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefditoren.
DB00031 DB01112 Cefuroxime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefuroxime.
DB00031 DB01139 Cefapirin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefapirin.
DB00031 DB01140 Cefadroxil The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefadroxil.
DB00031 DB01150 Cefprozil The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefprozil.
DB00031 DB01212 Ceftriaxone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftriaxone.
DB00031 DB01326 Cefamandole The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefamandole.
DB00031 DB01327 Cefazolin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefazolin.
DB00031 DB01328 Cefonicid The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefonicid.
DB00031 DB01329 Cefoperazone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefoperazone.
DB00031 DB01330 Cefotetan The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefotetan.
DB00031 DB01331 Cefoxitin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefoxitin.
DB00031 DB01332 Ceftizoxime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftizoxime.
DB00031 DB01333 Cefradine The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefradine.
DB00031 DB01413 Cefepime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefepime.
DB00031 DB01414 Cefacetrile The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefacetrile.
DB00031 DB01415 Ceftibuten The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftibuten.
DB00031 DB01416 Cefpodoxime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefpodoxime.
DB00031 DB04570 Latamoxef The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Latamoxef.
DB00031 DB04918 Ceftobiprole The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftobiprole.
DB00031 DB06590 Ceftaroline fosamil The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftaroline fosamil.
DB00031 DB09008 Cefaloridine The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefaloridine.
DB00031 DB09050 Ceftolozane The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftolozane.
DB00031 DB09062 Cefminox The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefminox.
DB00031 DB11367 Cefroxadine The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefroxadine.
DB00031 DB11935 Flomoxef The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Flomoxef.
DB00031 DB13266 Cefatrizine The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefatrizine.
DB00031 DB13461 Cefcapene The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefcapene.
DB00031 DB13470 Cefodizime The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefodizime.
DB00031 DB13499 Cefsulodin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefsulodin.
DB00031 DB13504 Cefetamet The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefetamet.
DB00031 DB13638 Cefbuperazone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefbuperazone.
DB00031 DB13667 Cefozopran The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefozopran.
DB00031 DB13682 Cefpirome The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefpirome.
DB00031 DB13778 Cefazedone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefazedone.
DB00031 DB13821 Ceftezole The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Ceftezole.
DB00031 DB14725 Cefamandole nafate The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cefamandole nafate.
DB00031 DB00254 Doxycycline The risk or severity of bleeding can be increased when Doxycycline is combined with Tenecteplase.
DB00031 DB00207 Azithromycin The risk or severity of adverse effects can be increased when Azithromycin is combined with Tenecteplase.
DB00031 DB09539 Omega-3-acid ethyl esters The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tenecteplase.
DB00031 DB00945 Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Tenecteplase.
DB00031 DB01606 Tazobactam The risk or severity of bleeding can be increased when Tazobactam is combined with Tenecteplase.
DB00031 DB00727 Nitroglycerin The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Nitroglycerin.
DB00031 DB00199 Erythromycin The risk or severity of bleeding can be increased when Erythromycin is combined with Tenecteplase.
DB00031 DB00656 Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Tenecteplase.
DB00031 DB00620 Triamcinolone The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Triamcinolone.
DB00031 DB09079 Nintedanib The risk or severity of bleeding can be increased when Tenecteplase is combined with Nintedanib.
DB00031 DB01175 Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Tenecteplase.
DB00031 DB01104 Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Tenecteplase.
DB00031 DB00232 Methyclothiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Methyclothiazide.
DB00031 DB00436 Bendroflumethiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Bendroflumethiazide.
DB00031 DB00562 Benzthiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Benzthiazide.
DB00031 DB00606 Cyclothiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cyclothiazide.
DB00031 DB00774 Hydroflumethiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Hydroflumethiazide.
DB00031 DB00880 Chlorothiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Chlorothiazide.
DB00031 DB00999 Hydrochlorothiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Hydrochlorothiazide.
DB00031 DB01021 Trichlormethiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Trichlormethiazide.
DB00031 DB01324 Polythiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Polythiazide.
DB00031 DB13430 Mebutizide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Mebutizide.
DB00031 DB13532 Cyclopenthiazide The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Cyclopenthiazide.
DB00033 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon gamma-1b.
DB00033 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon gamma-1b.
DB00033 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon gamma-1b.
DB00033 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon gamma-1b.
DB00033 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon gamma-1b.
DB00033 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon gamma-1b.
DB00033 DB00026 Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon gamma-1b.
DB00033 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2a, Recombinant.
DB00033 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Aldesleukin.
DB00033 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Adalimumab.
DB00033 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemtuzumab ozogamicin.
DB00033 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pegaspargase.
DB00033 DB00065 Infliximab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Infliximab.
DB00033 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon beta-1b.
DB00033 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfacon-1.
DB00033 DB00073 Rituximab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rituximab.
DB00033 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Basiliximab.
DB00033 DB00075 Muromonab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Muromonab.
DB00033 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibritumomab tiuxetan.
DB00033 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tositumomab.
DB00033 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alemtuzumab.
DB00033 DB00092 Alefacept The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Alefacept.
DB00033 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Efalizumab.
DB00033 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antithymocyte immunoglobulin (rabbit).
DB00033 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2b.
DB00033 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daclizumab.
DB00033 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bevacizumab.
DB00033 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Phenylalanine.
DB00033 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Flunisolide.
DB00033 DB00188 Bortezomib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bortezomib.
DB00033 DB00242 Cladribine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cladribine.
DB00033 DB00262 Carmustine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carmustine.
DB00033 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Amsacrine.
DB00033 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bleomycin.
DB00033 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Chlorambucil.
DB00033 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Raltitrexed.
DB00033 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mitomycin.
DB00033 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bexarotene.
DB00033 DB00309 Vindesine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vindesine.
DB00033 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Floxuridine.
DB00033 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Indomethacin.
DB00033 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tioguanine.
DB00033 DB00361 Vinorelbine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vinorelbine.
DB00033 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dexrazoxane.
DB00033 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Beclomethasone dipropionate.
DB00033 DB00398 Sorafenib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sorafenib.
DB00033 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Streptozocin.
DB00033 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trifluridine.
DB00033 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gemcitabine.
DB00033 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Betamethasone.
DB00033 DB00444 Teniposide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Teniposide.
DB00033 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Epirubicin.
DB00033 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Chloramphenicol.
DB00033 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Lenalidomide.
DB00033 DB00488 Altretamine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Altretamine.
DB00033 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Zidovudine.
DB00033 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cisplatin.
DB00033 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Oxaliplatin.
DB00033 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cyclophosphamide.
DB00033 DB00541 Vincristine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vincristine.
DB00033 DB00544 Fluorouracil The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluorouracil.
DB00033 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Propylthiouracil.
DB00033 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pentostatin.
DB00033 DB00563 Methotrexate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Methotrexate.
DB00033 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carbamazepine.
DB00033 DB00570 Vinblastine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vinblastine.
DB00033 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluticasone propionate.
DB00033 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocinolone acetonide.
DB00033 DB00601 Linezolid The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Linezolid.
DB00033 DB00619 Imatinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Imatinib.
DB00033 DB00620 Triamcinolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Triamcinolone.
DB00033 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Clofarabine.
DB00033 DB00635 Prednisone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Prednisone.
DB00033 DB00642 Pemetrexed The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pemetrexed.
DB00033 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fludrocortisone.
DB00033 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mycophenolate mofetil.
DB00033 DB00694 Daunorubicin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daunorubicin.
DB00033 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tretinoin.
DB00033 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Irinotecan.
DB00033 DB00763 Methimazole The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Methimazole.
DB00033 DB00764 Mometasone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mometasone.
DB00033 DB00773 Etoposide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Etoposide.
DB00033 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sulfasalazine.
DB00033 DB00851 Dacarbazine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dacarbazine.
DB00033 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Temozolomide.
DB00033 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Penicillamine.
DB00033 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Prednisolone.
DB00033 DB00877 Sirolimus The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sirolimus.
DB00033 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mechlorethamine.
DB00033 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Azacitidine.
DB00033 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carboplatin.
DB00033 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Methylprednisolone.
DB00033 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dactinomycin.
DB00033 DB00987 Cytarabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cytarabine.
DB00033 DB00993 Azathioprine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Azathioprine.
DB00033 DB00997 Doxorubicin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Doxorubicin.
DB00033 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hydroxyurea.
DB00033 DB01008 Busulfan The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Busulfan.
DB00033 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mycophenolic acid.
DB00033 DB01030 Topotecan The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Topotecan.
DB00033 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mercaptopurine.
DB00033 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Thalidomide.
DB00033 DB01042 Melphalan The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Melphalan.
DB00033 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fludarabine.
DB00033 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Flucytosine.
DB00033 DB01101 Capecitabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Capecitabine.
DB00033 DB01108 Trilostane The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trilostane.
DB00033 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Procarbazine.
DB00033 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Arsenic trioxide.
DB00033 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Idarubicin.
DB00033 DB01181 Ifosfamide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ifosfamide.
DB00033 DB01196 Estramustine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Estramustine.
DB00033 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mitoxantrone.
DB00033 DB01206 Lomustine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Lomustine.
DB00033 DB01222 Budesonide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Budesonide.
DB00033 DB01229 Paclitaxel The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Paclitaxel.
DB00033 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dexamethasone.
DB00033 DB01248 Docetaxel The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Docetaxel.
DB00033 DB01254 Dasatinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dasatinib.
DB00033 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Eculizumab.
DB00033 DB01262 Decitabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Decitabine.
DB00033 DB01268 Sunitinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sunitinib.
DB00033 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Nelarabine.
DB00033 DB01281 Abatacept The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Abatacept.
DB00033 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Corticotropin.
DB00033 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cortisone acetate.
DB00033 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Paramethasone.
DB00033 DB01394 Colchicine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Colchicine.
DB00033 DB01410 Ciclesonide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ciclesonide.
DB00033 DB01423 Stepronin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Stepronin.
DB00033 DB01590 Everolimus The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Everolimus.
DB00033 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hydroxychloroquine.
DB00033 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Castanospermine.
DB00033 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vorinostat.
DB00033 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with 2-Methoxyethanol.
DB00033 DB03523 Brequinar The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Brequinar.
DB00033 DB04572 Thiotepa The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Thiotepa.
DB00033 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Aldosterone.
DB00033 DB04845 Ixabepilone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ixabepilone.
DB00033 DB04868 Nilotinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Nilotinib.
DB00033 DB04951 Pirfenidone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pirfenidone.
DB00033 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Afelimomab.
DB00033 DB05015 Belinostat The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Belinostat.
DB00033 DB05109 Trabectedin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trabectedin.
DB00033 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa.
DB00033 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Glatiramer.
DB00033 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gallium nitrate.
DB00033 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Briakinumab.
DB00033 DB05472 omega interferon The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with omega interferon.
DB00033 DB05676 Apremilast The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Apremilast.
DB00033 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trastuzumab emtansine.
DB00033 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Canakinumab.
DB00033 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tocilizumab.
DB00033 DB06287 Temsirolimus The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Temsirolimus.
DB00033 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rilonacept.
DB00033 DB06589 Pazopanib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pazopanib.
DB00033 DB06603 Panobinostat The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Panobinostat.
DB00033 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mepolizumab.
DB00033 DB06616 Bosutinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bosutinib.
DB00033 DB06662 Abetimus The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Abetimus.
DB00033 DB06674 Golimumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Golimumab.
DB00033 DB06681 Belatacept The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Belatacept.
DB00033 DB06769 Bendamustine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bendamustine.
DB00033 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cabazitaxel.
DB00033 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pralatrexate.
DB00033 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Wortmannin.
DB00033 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Brentuximab vedotin.
DB00033 DB08871 Eribulin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Eribulin.
DB00033 DB08877 Ruxolitinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ruxolitinib.
DB00033 DB08879 Belimumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Belimumab.
DB00033 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Teriflunomide.
DB00033 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Carfilzomib.
DB00033 DB08901 Ponatinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ponatinib.
DB00033 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Certolizumab pegol.
DB00033 DB08906 Fluticasone furoate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluticasone furoate.
DB00033 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dimethyl fumarate.
DB00033 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pomalidomide.
DB00033 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Obinutuzumab.
DB00033 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluprednidene.
DB00033 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocortolone.
DB00033 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Secukinumab.
DB00033 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vedolizumab.
DB00033 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Siltuximab.
DB00033 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Blinatumomab.
DB00033 DB09053 Ibrutinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ibrutinib.
DB00033 DB09054 Idelalisib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Idelalisib.
DB00033 DB09073 Palbociclib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Palbociclib.
DB00033 DB09074 Olaparib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Olaparib.
DB00033 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dinutuximab.
DB00033 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vilanterol.
DB00033 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tixocortol.
DB00033 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Peginterferon beta-1a.
DB00033 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antilymphocyte immunoglobulin (horse).
DB00033 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluprednisolone.
DB00033 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Meprednisone.
DB00033 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tepoxalin.
DB00033 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dexamethasone isonicotinate.
DB00033 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Melengestrol.
DB00033 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ixekizumab.
DB00033 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ravulizumab.
DB00033 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pirarubicin.
DB00033 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Voclosporin.
DB00033 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Peficitinib.
DB00033 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Clobetasol.
DB00033 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sarilumab.
DB00033 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Brodalumab.
DB00033 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sirukumab.
DB00033 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Baricitinib.
DB00033 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Guselkumab.
DB00033 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Deflazacort.
DB00033 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ocrelizumab.
DB00033 DB12025 Triptolide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Triptolide.
DB00033 DB12371 Siponimod The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Siponimod.
DB00033 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ozanimod.
DB00033 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mizoribine.
DB00033 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Gusperimus.
DB00033 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cepeginterferon alfa-2B.
DB00033 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Trofosfamide.
DB00033 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Doxifluridine.
DB00033 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Deoxyspergualin.
DB00033 DB12996 Acteoside The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Acteoside.
DB00033 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cortivazol.
DB00033 DB13014 Hypericin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hypericin.
DB00033 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00033 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Prednylidene.
DB00033 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocortin.
DB00033 DB13241 Begelomab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Begelomab.
DB00033 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluperolone.
DB00033 DB13664 Formocortal The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Formocortal.
DB00033 DB13728 Halometasone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Halometasone.
DB00033 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cloprednol.
DB00033 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluclorolone.
DB00033 DB13867 Fluticasone The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluticasone.
DB00033 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Tetrandrine.
DB00033 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Monomethyl fumarate.
DB00033 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mometasone furoate.
DB00033 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hydrocortisone aceponate.
DB00033 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hydrocortisone acetate.
DB00033 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hydrocortisone succinate.
DB00033 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Emapalumab.
DB00033 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Risankizumab.
DB00033 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Rozanolixizumab.
DB00033 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bleselumab.
DB00033 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Natalizumab.
DB00033 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon gamma-1b.
DB00033 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Interferon gamma-1b.
DB00033 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB00363 Clozapine The risk or severity of neutropenia can be increased when Interferon gamma-1b is combined with Clozapine.
DB00033 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Interferon gamma-1b.
DB00033 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon gamma-1b.
DB00033 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Leflunomide.
DB00033 DB08895 Tofacitinib Interferon gamma-1b may increase the immunosuppressive activities of Tofacitinib.
DB00033 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Interferon gamma-1b.
DB00033 DB08868 Fingolimod Interferon gamma-1b may increase the immunosuppressive activities of Fingolimod.
DB00033 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Interferon gamma-1b.
DB00033 DB00201 Caffeine The metabolism of Caffeine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00651 Dyphylline The metabolism of Dyphylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB01412 Theobromine The metabolism of Theobromine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01482 Fenethylline The metabolism of Fenethylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB01667 8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01978 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB02134 Xanthine The metabolism of Xanthine can be decreased when combined with Interferon gamma-1b.
DB00033 DB02245 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB02377 Guanine The metabolism of Guanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB02568 Peldesine The metabolism of Peldesine can be decreased when combined with Interferon gamma-1b.
DB00033 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Interferon gamma-1b.
DB00033 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB06479 Propentofylline The metabolism of Propentofylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB06575 Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Interferon gamma-1b.
DB00033 DB07954 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon gamma-1b.
DB00033 DB08844 Uric acid The metabolism of Uric acid can be decreased when combined with Interferon gamma-1b.
DB00033 DB09273 Doxofylline The metabolism of Doxofylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon gamma-1b.
DB00033 DB12406 Lisofylline The metabolism of Lisofylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB12531 Lobucavir The metabolism of Lobucavir can be decreased when combined with Interferon gamma-1b.
DB00033 DB12926 Cafedrine The metabolism of Cafedrine can be decreased when combined with Interferon gamma-1b.
DB00033 DB12927 Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Interferon gamma-1b.
DB00033 DB13203 Bamifylline The metabolism of Bamifylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB13449 Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB13573 Acefylline The metabolism of Acefylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB13592 Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB13634 Pentifylline The metabolism of Pentifylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB13812 Bufylline The metabolism of Bufylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB14029 Furafylline The metabolism of Furafylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB15122 PCS-499 The metabolism of PCS-499 can be decreased when combined with Interferon gamma-1b.
DB00033 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Interferon gamma-1b.
DB00033 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon gamma-1b.
DB00033 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon gamma-1b.
DB00033 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon gamma-1b.
DB00033 DB00945 Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon gamma-1b.
DB00033 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon gamma-1b.
DB00033 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Interferon gamma-1b.
DB00033 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon gamma-1b.
DB00033 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon gamma-1b.
DB00033 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon gamma-1b.
DB00033 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon gamma-1b.
DB00033 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon gamma-1b.
DB00033 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon gamma-1b.
DB00033 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon gamma-1b.
DB00033 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Interferon gamma-1b.
DB00033 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon gamma-1b.
DB00033 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon gamma-1b.
DB00033 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon gamma-1b.
DB00033 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon gamma-1b.
DB00033 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon gamma-1b.
DB00033 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Interferon gamma-1b.
DB00033 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Interferon gamma-1b.
DB00033 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon gamma-1b.
DB00033 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon gamma-1b.
DB00033 DB09030 Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon gamma-1b.
DB00033 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Interferon gamma-1b.
DB00033 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon gamma-1b.
DB00033 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon gamma-1b.
DB00033 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon gamma-1b.
DB00033 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon gamma-1b.
DB00033 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon gamma-1b.
DB00033 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Interferon gamma-1b.
DB00033 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon gamma-1b.
DB00033 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon gamma-1b.
DB00033 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon gamma-1b.
DB00033 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Interferon gamma-1b.
DB00033 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon gamma-1b.
DB00033 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon gamma-1b.
DB00033 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon gamma-1b.
DB00033 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon gamma-1b.
DB00033 DB13200 Lipegfilgrastim Interferon gamma-1b may increase the myelosuppressive activities of Lipegfilgrastim.
DB00033 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon gamma-1b.
DB00033 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon gamma-1b.
DB00033 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon gamma-1b.
DB00033 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon gamma-1b.
DB00033 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon gamma-1b.
DB00033 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon gamma-1b.
DB00033 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon gamma-1b.
DB00033 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon gamma-1b.
DB00033 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Interferon gamma-1b.
DB00033 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon gamma-1b.
DB00033 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon gamma-1b.
DB00033 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon gamma-1b.
DB00033 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00184 Nicotine The metabolism of Nicotine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00195 Betaxolol The metabolism of Betaxolol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00261 Anagrelide The metabolism of Anagrelide can be decreased when combined with Interferon gamma-1b.
DB00033 DB00280 Disopyramide The metabolism of Disopyramide can be decreased when combined with Interferon gamma-1b.
DB00033 DB00281 Lidocaine The metabolism of Lidocaine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Interferon gamma-1b.
DB00033 DB00296 Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00316 Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Interferon gamma-1b.
DB00033 DB00334 Olanzapine The metabolism of Olanzapine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Interferon gamma-1b.
DB00033 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Interferon gamma-1b.
DB00033 DB00370 Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00379 Mexiletine The metabolism of Mexiletine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00382 Tacrine The metabolism of Tacrine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00384 Triamterene The metabolism of Triamterene can be decreased when combined with Interferon gamma-1b.
DB00033 DB00420 Promazine The metabolism of Promazine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00425 Zolpidem The metabolism of Zolpidem can be decreased when combined with Interferon gamma-1b.
DB00033 DB00442 Entecavir The metabolism of Entecavir can be decreased when combined with Interferon gamma-1b.
DB00033 DB00461 Nabumetone The metabolism of Nabumetone can be decreased when combined with Interferon gamma-1b.
DB00033 DB00468 Quinine The metabolism of Quinine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00472 Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00476 Duloxetine The metabolism of Duloxetine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00499 Flutamide The metabolism of Flutamide can be decreased when combined with Interferon gamma-1b.
DB00033 DB00502 Haloperidol The metabolism of Haloperidol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00518 Albendazole The metabolism of Albendazole can be decreased when combined with Interferon gamma-1b.
DB00033 DB00533 Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Interferon gamma-1b.
DB00033 DB00568 Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00571 Propranolol The metabolism of Propranolol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00586 Diclofenac The metabolism of Diclofenac can be decreased when combined with Interferon gamma-1b.
DB00033 DB00629 Guanabenz The metabolism of Guanabenz can be decreased when combined with Interferon gamma-1b.
DB00033 DB00661 Verapamil The metabolism of Verapamil can be decreased when combined with Interferon gamma-1b.
DB00033 DB00715 Paroxetine The metabolism of Paroxetine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00730 Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Interferon gamma-1b.
DB00033 DB00740 Riluzole The metabolism of Riluzole can be decreased when combined with Interferon gamma-1b.
DB00033 DB00744 Zileuton The metabolism of Zileuton can be decreased when combined with Interferon gamma-1b.
DB00033 DB00758 Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Interferon gamma-1b.
DB00033 DB00783 Estradiol The metabolism of Estradiol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00787 Acyclovir The metabolism of Acyclovir can be decreased when combined with Interferon gamma-1b.
DB00033 DB00788 Naproxen The metabolism of Naproxen can be decreased when combined with Interferon gamma-1b.
DB00033 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00850 Perphenazine The metabolism of Perphenazine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00857 Terbinafine The metabolism of Terbinafine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00863 Ranitidine The metabolism of Ranitidine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00898 Ethanol The metabolism of Ethanol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00934 Maprotiline The metabolism of Maprotiline can be decreased when combined with Interferon gamma-1b.
DB00033 DB00969 Alosetron The metabolism of Alosetron can be decreased when combined with Interferon gamma-1b.
DB00033 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Interferon gamma-1b.
DB00033 DB00980 Ramelteon The metabolism of Ramelteon can be decreased when combined with Interferon gamma-1b.
DB00033 DB00998 Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Interferon gamma-1b.
DB00033 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01012 Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Interferon gamma-1b.
DB00033 DB01037 Selegiline The metabolism of Selegiline can be decreased when combined with Interferon gamma-1b.
DB00033 DB01056 Tocainide The metabolism of Tocainide can be decreased when combined with Interferon gamma-1b.
DB00033 DB01058 Praziquantel The metabolism of Praziquantel can be decreased when combined with Interferon gamma-1b.
DB00033 DB01065 Melatonin The metabolism of Melatonin can be decreased when combined with Interferon gamma-1b.
DB00033 DB01087 Primaquine The metabolism of Primaquine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01094 Hesperetin The metabolism of Hesperetin can be decreased when combined with Interferon gamma-1b.
DB00033 DB01115 Nifedipine The metabolism of Nifedipine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01136 Carvedilol The metabolism of Carvedilol can be decreased when combined with Interferon gamma-1b.
DB00033 DB01166 Cilostazol The metabolism of Cilostazol can be decreased when combined with Interferon gamma-1b.
DB00033 DB01182 Propafenone The metabolism of Propafenone can be decreased when combined with Interferon gamma-1b.
DB00033 DB01184 Domperidone The metabolism of Domperidone can be decreased when combined with Interferon gamma-1b.
DB00033 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01367 Rasagiline The metabolism of Rasagiline can be decreased when combined with Interferon gamma-1b.
DB00033 DB01405 Temafloxacin The metabolism of Temafloxacin can be decreased when combined with Interferon gamma-1b.
DB00033 DB01424 Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Interferon gamma-1b.
DB00033 DB01435 Antipyrine The metabolism of Antipyrine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01558 Bromazepam The metabolism of Bromazepam can be decreased when combined with Interferon gamma-1b.
DB00033 DB01623 Thiothixene The metabolism of Thiothixene can be decreased when combined with Interferon gamma-1b.
DB00033 DB01628 Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Interferon gamma-1b.
DB00033 DB01645 Genistein The metabolism of Genistein can be decreased when combined with Interferon gamma-1b.
DB00033 DB02709 Resveratrol The metabolism of Resveratrol can be decreased when combined with Interferon gamma-1b.
DB00033 DB03783 Phenacetin The metabolism of Phenacetin can be decreased when combined with Interferon gamma-1b.
DB00033 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Interferon gamma-1b.
DB00033 DB04841 Flunarizine The metabolism of Flunarizine can be decreased when combined with Interferon gamma-1b.
DB00033 DB04871 Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Interferon gamma-1b.
DB00033 DB04948 Lofexidine The metabolism of Lofexidine can be decreased when combined with Interferon gamma-1b.
DB00033 DB06148 Mianserin The metabolism of Mianserin can be decreased when combined with Interferon gamma-1b.
DB00033 DB06210 Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Interferon gamma-1b.
DB00033 DB06216 Asenapine The metabolism of Asenapine can be decreased when combined with Interferon gamma-1b.
DB00033 DB06235 Vadimezan The metabolism of Vadimezan can be decreased when combined with Interferon gamma-1b.
DB00033 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Interferon gamma-1b.
DB00033 DB06594 Agomelatine The metabolism of Agomelatine can be decreased when combined with Interferon gamma-1b.
DB00033 DB06626 Axitinib The metabolism of Axitinib can be decreased when combined with Interferon gamma-1b.
DB00033 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Interferon gamma-1b.
DB00033 DB06774 Capsaicin The metabolism of Capsaicin can be decreased when combined with Interferon gamma-1b.
DB00033 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be decreased when combined with Interferon gamma-1b.
DB00033 DB08883 Perampanel The metabolism of Perampanel can be decreased when combined with Interferon gamma-1b.
DB00033 DB09071 Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Interferon gamma-1b.
DB00033 DB09118 Stiripentol The metabolism of Stiripentol can be decreased when combined with Interferon gamma-1b.
DB00033 DB09225 Zotepine The metabolism of Zotepine can be decreased when combined with Interferon gamma-1b.
DB00033 DB09288 Propacetamol The metabolism of Propacetamol can be decreased when combined with Interferon gamma-1b.
DB00033 DB09290 Ramosetron The metabolism of Ramosetron can be decreased when combined with Interferon gamma-1b.
DB00033 DB11967 Binimetinib The metabolism of Binimetinib can be decreased when combined with Interferon gamma-1b.
DB00033 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Interferon gamma-1b.
DB00033 DB12245 Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Interferon gamma-1b.
DB00033 DB12332 Rucaparib The metabolism of Rucaparib can be decreased when combined with Interferon gamma-1b.
DB00033 DB12945 Dihydralazine The metabolism of Dihydralazine can be decreased when combined with Interferon gamma-1b.
DB00033 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Interferon gamma-1b.
DB00033 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Interferon gamma-1b.
DB00033 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Interferon gamma-1b.
DB00033 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Interferon gamma-1b.
DB00033 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Interferon gamma-1b.
DB00033 DB11757 Istradefylline The metabolism of Istradefylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB00972 Azelastine The metabolism of Azelastine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00625 Efavirenz The metabolism of Efavirenz can be decreased when combined with Interferon gamma-1b.
DB00033 DB01233 Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Interferon gamma-1b.
DB00033 DB04889 Bicifadine The metabolism of Bicifadine can be decreased when combined with Interferon gamma-1b.
DB00033 DB05708 GTS-21 The metabolism of GTS-21 can be decreased when combined with Interferon gamma-1b.
DB00033 DB01195 Flecainide The metabolism of Flecainide can be decreased when combined with Interferon gamma-1b.
DB00033 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00321 Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Interferon gamma-1b.
DB00033 DB00458 Imipramine The metabolism of Imipramine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01142 Doxepin The metabolism of Doxepin can be decreased when combined with Interferon gamma-1b.
DB00033 DB00532 Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Interferon gamma-1b.
DB00033 DB00540 Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Interferon gamma-1b.
DB00033 DB00575 Clonidine The metabolism of Clonidine can be decreased when combined with Interferon gamma-1b.
DB00033 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01151 Desipramine The metabolism of Desipramine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01242 Clomipramine The metabolism of Clomipramine can be decreased when combined with Interferon gamma-1b.
DB00033 DB11689 Selumetinib The metabolism of Selumetinib can be decreased when combined with Interferon gamma-1b.
DB00033 DB00277 Theophylline The metabolism of Theophylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB00682 Warfarin The metabolism of Warfarin can be decreased when combined with Interferon gamma-1b.
DB00033 DB00697 Tizanidine The metabolism of Tizanidine can be decreased when combined with Interferon gamma-1b.
DB00033 DB01100 Pimozide The metabolism of Pimozide can be decreased when combined with Interferon gamma-1b.
DB00033 DB01223 Aminophylline The metabolism of Aminophylline can be decreased when combined with Interferon gamma-1b.
DB00033 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Interferon gamma-1b.
DB00033 DB00530 Erlotinib The metabolism of Erlotinib can be decreased when combined with Interferon gamma-1b.
DB00033 DB09256 Tegafur The metabolism of Tegafur can be decreased when combined with Interferon gamma-1b.
DB00033 DB13874 Enasidenib The metabolism of Enasidenib can be decreased when combined with Interferon gamma-1b.
DB00033 DB00675 Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Interferon gamma-1b.
DB00033 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b.
DB00033 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon gamma-1b.
DB00033 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Interferon gamma-1b.
DB00033 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Interferon gamma-1b.
DB00033 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Interferon gamma-1b.
DB00033 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon gamma-1b.
DB00033 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon gamma-1b.
DB00033 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon gamma-1b.
DB00033 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon gamma-1b.
DB00033 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon gamma-1b.
DB00033 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Interferon gamma-1b.
DB00033 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon gamma-1b.
DB00033 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Interferon gamma-1b.
DB00033 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon gamma-1b.
DB00033 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon gamma-1b.
DB00033 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon gamma-1b.
DB00033 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Interferon gamma-1b.
DB00033 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon gamma-1b.
DB00033 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon gamma-1b.
DB00033 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Interferon gamma-1b.
DB00033 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon gamma-1b.
DB00033 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon gamma-1b.
DB00033 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Interferon gamma-1b.
DB00033 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon gamma-1b.
DB00033 DB06228 Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon gamma-1b.
DB00033 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon gamma-1b.
DB00033 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon gamma-1b.
DB00033 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon gamma-1b.
DB00033 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon gamma-1b.
DB00033 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Interferon gamma-1b.
DB00033 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon gamma-1b.
DB00033 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Interferon gamma-1b.
DB00033 DB06695 Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon gamma-1b.
DB00033 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon gamma-1b.
DB00033 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon gamma-1b.
DB00033 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon gamma-1b.
DB00033 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon gamma-1b.
DB00033 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon gamma-1b.
DB00033 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon gamma-1b.
DB00033 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Interferon gamma-1b.
DB00033 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon gamma-1b.
DB00033 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon gamma-1b.
DB00033 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon gamma-1b.
DB00033 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Interferon gamma-1b.
DB00033 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon gamma-1b.
DB00033 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Interferon gamma-1b.
DB00033 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon gamma-1b.
DB00033 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Interferon gamma-1b.
DB00033 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Interferon gamma-1b.
DB00033 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon gamma-1b.
DB00033 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon gamma-1b.
DB00033 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Interferon gamma-1b.
DB00033 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon gamma-1b.
DB00033 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon gamma-1b.
DB00033 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Interferon gamma-1b.
DB00033 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon gamma-1b.
DB00033 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon gamma-1b.
DB00033 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Interferon gamma-1b.
DB00033 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Interferon gamma-1b.
DB00033 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Interferon gamma-1b.
DB00033 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Interferon gamma-1b.
DB00033 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Interferon gamma-1b.
DB00033 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Interferon gamma-1b.
DB00033 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon gamma-1b.
DB00033 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon gamma-1b.
DB00033 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Interferon gamma-1b.
DB00033 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Interferon gamma-1b.
DB00033 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon gamma-1b.
DB00033 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon gamma-1b.
DB00033 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon gamma-1b.
DB00033 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon gamma-1b.
DB00033 DB00232 Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon gamma-1b.
DB00033 DB00436 Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon gamma-1b.
DB00033 DB00562 Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon gamma-1b.
DB00033 DB00606 Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon gamma-1b.
DB00033 DB00774 Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon gamma-1b.
DB00033 DB00880 Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon gamma-1b.
DB00033 DB00999 Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon gamma-1b.
DB00033 DB01021 Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon gamma-1b.
DB00033 DB01324 Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon gamma-1b.
DB00033 DB13430 Mebutizide The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon gamma-1b.
DB00033 DB13532 Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon gamma-1b.
DB00033 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Interferon gamma-1b is combined with Tedizolid phosphate.
DB00033 DB00091 Cyclosporine Interferon gamma-1b may increase the immunosuppressive activities of Cyclosporine.
DB00033 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ropinirole.
DB00033 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon gamma-1b.
DB00033 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon gamma-1b.
DB00033 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Interferon gamma-1b.
DB00033 DB01601 Lopinavir The serum concentration of Interferon gamma-1b can be increased when it is combined with Lopinavir.
DB00033 DB12530 Inebilizumab The risk or severity of infection can be increased when Interferon gamma-1b is combined with Inebilizumab.
DB00034 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00026 Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Adalimumab.
DB00034 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gemtuzumab ozogamicin.
DB00034 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pegaspargase.
DB00034 DB00065 Infliximab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Infliximab.
DB00034 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon beta-1b.
DB00034 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfacon-1.
DB00034 DB00073 Rituximab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Rituximab.
DB00034 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Basiliximab.
DB00034 DB00075 Muromonab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Muromonab.
DB00034 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ibritumomab tiuxetan.
DB00034 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tositumomab.
DB00034 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alemtuzumab.
DB00034 DB00092 Alefacept The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Alefacept.
DB00034 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Efalizumab.
DB00034 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Antithymocyte immunoglobulin (rabbit).
DB00034 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfa-2b.
DB00034 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Daclizumab.
DB00034 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bevacizumab.
DB00034 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Phenylalanine.
DB00034 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Flunisolide.
DB00034 DB00188 Bortezomib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bortezomib.
DB00034 DB00242 Cladribine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cladribine.
DB00034 DB00262 Carmustine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Carmustine.
DB00034 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Amsacrine.
DB00034 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bleomycin.
DB00034 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Chlorambucil.
DB00034 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Raltitrexed.
DB00034 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mitomycin.
DB00034 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bexarotene.
DB00034 DB00309 Vindesine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vindesine.
DB00034 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Floxuridine.
DB00034 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Indomethacin.
DB00034 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tioguanine.
DB00034 DB00361 Vinorelbine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vinorelbine.
DB00034 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dexrazoxane.
DB00034 DB00394 Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Beclomethasone dipropionate.
DB00034 DB00398 Sorafenib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Sorafenib.
DB00034 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Streptozocin.
DB00034 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Trifluridine.
DB00034 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gemcitabine.
DB00034 DB00443 Betamethasone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Betamethasone.
DB00034 DB00444 Teniposide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Teniposide.
DB00034 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Epirubicin.
DB00034 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Chloramphenicol.
DB00034 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Lenalidomide.
DB00034 DB00488 Altretamine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Altretamine.
DB00034 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Zidovudine.
DB00034 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cisplatin.
DB00034 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Oxaliplatin.
DB00034 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cyclophosphamide.
DB00034 DB00541 Vincristine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vincristine.
DB00034 DB00544 Fluorouracil The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluorouracil.
DB00034 DB00550 Propylthiouracil The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Propylthiouracil.
DB00034 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pentostatin.
DB00034 DB00563 Methotrexate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Methotrexate.
DB00034 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Carbamazepine.
DB00034 DB00570 Vinblastine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vinblastine.
DB00034 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluticasone propionate.
DB00034 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluocinolone acetonide.
DB00034 DB00601 Linezolid The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Linezolid.
DB00034 DB00619 Imatinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Imatinib.
DB00034 DB00620 Triamcinolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Triamcinolone.
DB00034 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Clofarabine.
DB00034 DB00635 Prednisone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Prednisone.
DB00034 DB00642 Pemetrexed The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pemetrexed.
DB00034 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fludrocortisone.
DB00034 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mycophenolate mofetil.
DB00034 DB00694 Daunorubicin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Daunorubicin.
DB00034 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tretinoin.
DB00034 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Irinotecan.
DB00034 DB00763 Methimazole The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Methimazole.
DB00034 DB00764 Mometasone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mometasone.
DB00034 DB00773 Etoposide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Etoposide.
DB00034 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Sulfasalazine.
DB00034 DB00851 Dacarbazine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dacarbazine.
DB00034 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Temozolomide.
DB00034 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Penicillamine.
DB00034 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Prednisolone.
DB00034 DB00877 Sirolimus The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Sirolimus.
DB00034 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mechlorethamine.
DB00034 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Azacitidine.
DB00034 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Carboplatin.
DB00034 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Methylprednisolone.
DB00034 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dactinomycin.
DB00034 DB00987 Cytarabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cytarabine.
DB00034 DB00993 Azathioprine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Azathioprine.
DB00034 DB00997 Doxorubicin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Doxorubicin.
DB00034 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Hydroxyurea.
DB00034 DB01008 Busulfan The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Busulfan.
DB00034 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mycophenolic acid.
DB00034 DB01030 Topotecan The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Topotecan.
DB00034 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mercaptopurine.
DB00034 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Thalidomide.
DB00034 DB01042 Melphalan The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Melphalan.
DB00034 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fludarabine.
DB00034 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Flucytosine.
DB00034 DB01101 Capecitabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Capecitabine.
DB00034 DB01108 Trilostane The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Trilostane.
DB00034 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Procarbazine.
DB00034 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Arsenic trioxide.
DB00034 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Idarubicin.
DB00034 DB01181 Ifosfamide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ifosfamide.
DB00034 DB01196 Estramustine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Estramustine.
DB00034 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mitoxantrone.
DB00034 DB01206 Lomustine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Lomustine.
DB00034 DB01222 Budesonide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Budesonide.
DB00034 DB01229 Paclitaxel The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Paclitaxel.
DB00034 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dexamethasone.
DB00034 DB01248 Docetaxel The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Docetaxel.
DB00034 DB01254 Dasatinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dasatinib.
DB00034 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Eculizumab.
DB00034 DB01262 Decitabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Decitabine.
DB00034 DB01268 Sunitinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Sunitinib.
DB00034 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Nelarabine.
DB00034 DB01281 Abatacept The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Abatacept.
DB00034 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Corticotropin.
DB00034 DB01380 Cortisone acetate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cortisone acetate.
DB00034 DB01384 Paramethasone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Paramethasone.
DB00034 DB01394 Colchicine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Colchicine.
DB00034 DB01410 Ciclesonide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ciclesonide.
DB00034 DB01423 Stepronin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Stepronin.
DB00034 DB01590 Everolimus The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Everolimus.
DB00034 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Hydroxychloroquine.
DB00034 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Castanospermine.
DB00034 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vorinostat.
DB00034 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with 2-Methoxyethanol.
DB00034 DB03523 Brequinar The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Brequinar.
DB00034 DB04572 Thiotepa The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Thiotepa.
DB00034 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Aldosterone.
DB00034 DB04845 Ixabepilone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ixabepilone.
DB00034 DB04868 Nilotinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Nilotinib.
DB00034 DB04951 Pirfenidone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pirfenidone.
DB00034 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Afelimomab.
DB00034 DB05015 Belinostat The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Belinostat.
DB00034 DB05109 Trabectedin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Trabectedin.
DB00034 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Interferon alfa.
DB00034 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Glatiramer.
DB00034 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gallium nitrate.
DB00034 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Briakinumab.
DB00034 DB05472 omega interferon The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with omega interferon.
DB00034 DB05676 Apremilast The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Apremilast.
DB00034 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Trastuzumab emtansine.
DB00034 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Canakinumab.
DB00034 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tocilizumab.
DB00034 DB06287 Temsirolimus The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Temsirolimus.
DB00034 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Rilonacept.
DB00034 DB06589 Pazopanib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pazopanib.
DB00034 DB06603 Panobinostat The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Panobinostat.
DB00034 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mepolizumab.
DB00034 DB06616 Bosutinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bosutinib.
DB00034 DB06662 Abetimus The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Abetimus.
DB00034 DB06674 Golimumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Golimumab.
DB00034 DB06681 Belatacept The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Belatacept.
DB00034 DB06769 Bendamustine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bendamustine.
DB00034 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cabazitaxel.
DB00034 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pralatrexate.
DB00034 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Wortmannin.
DB00034 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Brentuximab vedotin.
DB00034 DB08871 Eribulin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Eribulin.
DB00034 DB08877 Ruxolitinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ruxolitinib.
DB00034 DB08879 Belimumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Belimumab.
DB00034 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Teriflunomide.
DB00034 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Carfilzomib.
DB00034 DB08901 Ponatinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ponatinib.
DB00034 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Certolizumab pegol.
DB00034 DB08906 Fluticasone furoate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluticasone furoate.
DB00034 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dimethyl fumarate.
DB00034 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pomalidomide.
DB00034 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Obinutuzumab.
DB00034 DB08970 Fluprednidene The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluprednidene.
DB00034 DB08971 Fluocortolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluocortolone.
DB00034 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Secukinumab.
DB00034 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vedolizumab.
DB00034 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Siltuximab.
DB00034 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Blinatumomab.
DB00034 DB09053 Ibrutinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ibrutinib.
DB00034 DB09054 Idelalisib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Idelalisib.
DB00034 DB09073 Palbociclib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Palbociclib.
DB00034 DB09074 Olaparib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Olaparib.
DB00034 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dinutuximab.
DB00034 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Vilanterol.
DB00034 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tixocortol.
DB00034 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Peginterferon beta-1a.
DB00034 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Antilymphocyte immunoglobulin (horse).
DB00034 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluprednisolone.
DB00034 DB09383 Meprednisone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Meprednisone.
DB00034 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tepoxalin.
DB00034 DB11487 Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Dexamethasone isonicotinate.
DB00034 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Melengestrol.
DB00034 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ixekizumab.
DB00034 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ravulizumab.
DB00034 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Pirarubicin.
DB00034 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Voclosporin.
DB00034 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Peficitinib.
DB00034 DB11750 Clobetasol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Clobetasol.
DB00034 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Sarilumab.
DB00034 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Brodalumab.
DB00034 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Sirukumab.
DB00034 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Baricitinib.
DB00034 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Guselkumab.
DB00034 DB11921 Deflazacort The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Deflazacort.
DB00034 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ocrelizumab.
DB00034 DB12025 Triptolide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Triptolide.
DB00034 DB12371 Siponimod The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Siponimod.
DB00034 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ozanimod.
DB00034 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mizoribine.
DB00034 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Gusperimus.
DB00034 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cepeginterferon alfa-2B.
DB00034 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Trofosfamide.
DB00034 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Doxifluridine.
DB00034 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Deoxyspergualin.
DB00034 DB12996 Acteoside The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Acteoside.
DB00034 DB13003 Cortivazol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cortivazol.
DB00034 DB13014 Hypericin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Hypericin.
DB00034 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00034 DB13208 Prednylidene The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Prednylidene.
DB00034 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluocortin.
DB00034 DB13241 Begelomab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Begelomab.
DB00034 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluperolone.
DB00034 DB13664 Formocortal The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Formocortal.
DB00034 DB13728 Halometasone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Halometasone.
DB00034 DB13843 Cloprednol The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Cloprednol.
DB00034 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluclorolone.
DB00034 DB13867 Fluticasone The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluticasone.
DB00034 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Tetrandrine.
DB00034 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Monomethyl fumarate.
DB00034 DB14512 Mometasone furoate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Mometasone furoate.
DB00034 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Hydrocortisone aceponate.
DB00034 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Hydrocortisone acetate.
DB00034 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Hydrocortisone succinate.
DB00034 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Emapalumab.
DB00034 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Risankizumab.
DB00034 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Rozanolixizumab.
DB00034 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Bleselumab.
DB00034 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Natalizumab.
DB00034 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Interferon alfa-2a, Recombinant.
DB00034 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB00041 Aldesleukin The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Aldesleukin.
DB00034 DB00363 Clozapine The risk or severity of neutropenia can be increased when Interferon alfa-2a, Recombinant is combined with Clozapine.
DB00034 DB00333 Methadone The serum concentration of Methadone can be increased when it is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00811 Ribavirin The risk or severity of anemia can be increased when Interferon alfa-2a, Recombinant is combined with Ribavirin.
DB00034 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01265 Telbivudine The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Telbivudine.
DB00034 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Leflunomide.
DB00034 DB08895 Tofacitinib Interferon alfa-2a, Recombinant may increase the immunosuppressive activities of Tofacitinib.
DB00034 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Interferon alfa-2a, Recombinant.
DB00034 DB08868 Fingolimod Interferon alfa-2a, Recombinant may increase the immunosuppressive activities of Fingolimod.
DB00034 DB00864 Tacrolimus Tacrolimus may increase the immunosuppressive activities of Interferon alfa-2a, Recombinant.
DB00034 DB00201 Caffeine The metabolism of Caffeine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00651 Dyphylline The metabolism of Dyphylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01412 Theobromine The metabolism of Theobromine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01482 Fenethylline The metabolism of Fenethylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01667 8-azaguanine The metabolism of 8-azaguanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01978 7,9-Dimethylguanine The metabolism of 7,9-Dimethylguanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB02134 Xanthine The metabolism of Xanthine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB02245 7-Deazaguanine The metabolism of 7-Deazaguanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB02377 Guanine The metabolism of Guanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB02568 Peldesine The metabolism of Peldesine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06479 Propentofylline The metabolism of Propentofylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06575 Valomaciclovir The metabolism of Valomaciclovir can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB07954 3-isobutyl-1-methyl-7H-xanthine The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB08844 Uric acid The metabolism of Uric acid can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09273 Doxofylline The metabolism of Doxofylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12406 Lisofylline The metabolism of Lisofylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12531 Lobucavir The metabolism of Lobucavir can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12926 Cafedrine The metabolism of Cafedrine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12927 Theodrenaline The metabolism of Theodrenaline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13203 Bamifylline The metabolism of Bamifylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13449 Proxyphylline The metabolism of Proxyphylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13573 Acefylline The metabolism of Acefylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13592 Etamiphylline The metabolism of Etamiphylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13634 Pentifylline The metabolism of Pentifylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13812 Bufylline The metabolism of Bufylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB14029 Furafylline The metabolism of Furafylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB15122 PCS-499 The metabolism of PCS-499 can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00208 Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00775 Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00945 Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01236 Sevoflurane The risk or severity of bleeding can be increased when Sevoflurane is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01240 Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Interferon alfa-2a, Recombinant.
DB00034 DB04743 Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Interferon alfa-2a, Recombinant.
DB00034 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Interferon alfa-2a, Recombinant.
DB00034 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Interferon alfa-2a, Recombinant.
DB00034 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06209 Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Interferon alfa-2a, Recombinant.
DB00034 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Interferon alfa-2a, Recombinant.
DB00034 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Interferon alfa-2a, Recombinant.
DB00034 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Interferon alfa-2a, Recombinant.
DB00034 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09030 Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12092 Naftopidil The risk or severity of bleeding can be increased when Naftopidil is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12445 Nitroaspirin The risk or severity of bleeding can be increased when Nitroaspirin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12465 Ketanserin The risk or severity of bleeding can be increased when Ketanserin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12545 Indobufen The risk or severity of bleeding can be increased when Indobufen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13400 Linsidomine The risk or severity of bleeding can be increased when Linsidomine is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13200 Lipegfilgrastim Interferon alfa-2a, Recombinant may increase the myelosuppressive activities of Lipegfilgrastim.
DB00034 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Interferon alfa-2a, Recombinant.
DB00034 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Interferon alfa-2a, Recombinant.
DB00034 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00184 Nicotine The metabolism of Nicotine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00195 Betaxolol The metabolism of Betaxolol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00261 Anagrelide The metabolism of Anagrelide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00280 Disopyramide The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00281 Lidocaine The metabolism of Lidocaine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00296 Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00316 Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00334 Olanzapine The metabolism of Olanzapine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00370 Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00379 Mexiletine The metabolism of Mexiletine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00382 Tacrine The metabolism of Tacrine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00384 Triamterene The metabolism of Triamterene can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00420 Promazine The metabolism of Promazine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00425 Zolpidem The metabolism of Zolpidem can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00442 Entecavir The metabolism of Entecavir can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00461 Nabumetone The metabolism of Nabumetone can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00468 Quinine The metabolism of Quinine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00472 Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00476 Duloxetine The metabolism of Duloxetine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00499 Flutamide The metabolism of Flutamide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00502 Haloperidol The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00518 Albendazole The metabolism of Albendazole can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00533 Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00568 Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00571 Propranolol The metabolism of Propranolol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00586 Diclofenac The metabolism of Diclofenac can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00629 Guanabenz The metabolism of Guanabenz can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00661 Verapamil The metabolism of Verapamil can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00715 Paroxetine The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00730 Thiabendazole The metabolism of Thiabendazole can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00740 Riluzole The metabolism of Riluzole can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00744 Zileuton The metabolism of Zileuton can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00758 Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00783 Estradiol The metabolism of Estradiol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00787 Acyclovir The metabolism of Acyclovir can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00788 Naproxen The metabolism of Naproxen can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00850 Perphenazine The metabolism of Perphenazine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00857 Terbinafine The metabolism of Terbinafine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00863 Ranitidine The metabolism of Ranitidine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00898 Ethanol The metabolism of Ethanol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00934 Maprotiline The metabolism of Maprotiline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00969 Alosetron The metabolism of Alosetron can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00980 Ramelteon The metabolism of Ramelteon can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00998 Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01012 Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01037 Selegiline The metabolism of Selegiline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01056 Tocainide The metabolism of Tocainide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01058 Praziquantel The metabolism of Praziquantel can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01065 Melatonin The metabolism of Melatonin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01087 Primaquine The metabolism of Primaquine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01094 Hesperetin The metabolism of Hesperetin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01115 Nifedipine The metabolism of Nifedipine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01136 Carvedilol The metabolism of Carvedilol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01166 Cilostazol The metabolism of Cilostazol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01182 Propafenone The metabolism of Propafenone can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01184 Domperidone The metabolism of Domperidone can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01367 Rasagiline The metabolism of Rasagiline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01405 Temafloxacin The metabolism of Temafloxacin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01424 Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01435 Antipyrine The metabolism of Antipyrine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01558 Bromazepam The metabolism of Bromazepam can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01623 Thiothixene The metabolism of Thiothixene can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01628 Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01645 Genistein The metabolism of Genistein can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB02709 Resveratrol The metabolism of Resveratrol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB03783 Phenacetin The metabolism of Phenacetin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04574 Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04841 Flunarizine The metabolism of Flunarizine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04871 Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04948 Lofexidine The metabolism of Lofexidine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06148 Mianserin The metabolism of Mianserin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06210 Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06216 Asenapine The metabolism of Asenapine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06235 Vadimezan The metabolism of Vadimezan can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06292 Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06594 Agomelatine The metabolism of Agomelatine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06626 Axitinib The metabolism of Axitinib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB06774 Capsaicin The metabolism of Capsaicin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB08883 Perampanel The metabolism of Perampanel can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09071 Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09118 Stiripentol The metabolism of Stiripentol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09225 Zotepine The metabolism of Zotepine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09288 Propacetamol The metabolism of Propacetamol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09290 Ramosetron The metabolism of Ramosetron can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB11967 Binimetinib The metabolism of Binimetinib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12245 Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12332 Rucaparib The metabolism of Rucaparib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB12945 Dihydralazine The metabolism of Dihydralazine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB11757 Istradefylline The metabolism of Istradefylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00972 Azelastine The metabolism of Azelastine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00625 Efavirenz The metabolism of Efavirenz can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01233 Metoclopramide The metabolism of Metoclopramide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB04889 Bicifadine The metabolism of Bicifadine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB05708 GTS-21 The metabolism of GTS-21 can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01195 Flecainide The metabolism of Flecainide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00977 Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00321 Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00458 Imipramine The metabolism of Imipramine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01142 Doxepin The metabolism of Doxepin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00532 Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00540 Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00575 Clonidine The metabolism of Clonidine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01151 Desipramine The metabolism of Desipramine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01242 Clomipramine The metabolism of Clomipramine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB11689 Selumetinib The metabolism of Selumetinib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00277 Theophylline The metabolism of Theophylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00682 Warfarin The metabolism of Warfarin can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00697 Tizanidine The metabolism of Tizanidine can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01100 Pimozide The metabolism of Pimozide can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01223 Aminophylline The metabolism of Aminophylline can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00530 Erlotinib The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB09256 Tegafur The metabolism of Tegafur can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB13874 Enasidenib The metabolism of Enasidenib can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00675 Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Interferon alfa-2a, Recombinant.
DB00034 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00086 Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00569 Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00946 Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB03410 4-hydroxycoumarin The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Interferon alfa-2a, Recombinant.
DB00034 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Interferon alfa-2a, Recombinant.
DB00034 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06228 Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06695 Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Ferulic acid is combined with Interferon alfa-2a, Recombinant.
DB00034 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09075 Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09125 Potassium citrate The risk or severity of bleeding can be increased when Potassium citrate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09255 Dextran The risk or severity of bleeding can be increased when Dextran is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11598 Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Interferon alfa-2a, Recombinant.
DB00034 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13136 Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13275 Clorindione The risk or severity of bleeding can be increased when Clorindione is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14055 (S)-Warfarin The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00232 Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00436 Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00562 Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00606 Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00774 Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00880 Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB00999 Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01021 Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01324 Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13430 Mebutizide The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB13532 Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Interferon alfa-2a, Recombinant.
DB00034 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Interferon alfa-2a, Recombinant is combined with Tedizolid phosphate.
DB00034 DB00091 Cyclosporine Interferon alfa-2a, Recombinant may increase the immunosuppressive activities of Cyclosporine.
DB00034 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Ropinirole.
DB00034 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00034 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Interferon alfa-2a, Recombinant.
DB00034 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Interferon alfa-2a, Recombinant.
DB00034 DB01601 Lopinavir The serum concentration of Interferon alfa-2a, Recombinant can be increased when it is combined with Lopinavir.
DB00034 DB12530 Inebilizumab The risk or severity of infection can be increased when Interferon alfa-2a, Recombinant is combined with Inebilizumab.
DB00035 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.
DB00035 DB00477 Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.
DB00035 DB00618 Demeclocycline The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.
DB00035 DB00555 Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.
DB00035 DB01356 Lithium cation The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium cation.
DB00035 DB14507 Lithium citrate The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium citrate.
DB00035 DB14509 Lithium carbonate The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium carbonate.
DB00035 DB14506 Lithium hydroxide The therapeutic efficacy of Lithium hydroxide can be decreased when used in combination with Desmopressin.
DB00035 DB06212 Tolvaptan The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.
DB00035 DB00176 Fluvoxamine The risk or severity of hyponatremia can be increased when Fluvoxamine is combined with Desmopressin.
DB00035 DB00215 Citalopram The risk or severity of hyponatremia can be increased when Citalopram is combined with Desmopressin.
DB00035 DB00472 Fluoxetine The risk or severity of hyponatremia can be increased when Fluoxetine is combined with Desmopressin.
DB00035 DB00476 Duloxetine The risk or severity of hyponatremia can be increased when Duloxetine is combined with Desmopressin.
DB00035 DB00656 Trazodone The risk or severity of hyponatremia can be increased when Trazodone is combined with Desmopressin.
DB00035 DB00715 Paroxetine The risk or severity of hyponatremia can be increased when Paroxetine is combined with Desmopressin.
DB00035 DB01104 Sertraline The risk or severity of hyponatremia can be increased when Sertraline is combined with Desmopressin.
DB00035 DB01105 Sibutramine The risk or severity of hyponatremia can be increased when Sibutramine is combined with Desmopressin.
DB00035 DB01149 Nefazodone The risk or severity of hyponatremia can be increased when Nefazodone is combined with Desmopressin.
DB00035 DB01175 Escitalopram The risk or severity of hyponatremia can be increased when Escitalopram is combined with Desmopressin.
DB00035 DB04832 Zimelidine The risk or severity of hyponatremia can be increased when Zimelidine is combined with Desmopressin.
DB00035 DB04884 Dapoxetine The risk or severity of hyponatremia can be increased when Dapoxetine is combined with Desmopressin.
DB00035 DB04896 Milnacipran The risk or severity of hyponatremia can be increased when Milnacipran is combined with Desmopressin.
DB00035 DB06700 Desvenlafaxine The risk or severity of hyponatremia can be increased when Desvenlafaxine is combined with Desmopressin.
DB00035 DB06731 Seproxetine The risk or severity of hyponatremia can be increased when Seproxetine is combined with Desmopressin.
DB00035 DB08918 Levomilnacipran The risk or severity of hyponatremia can be increased when Levomilnacipran is combined with Desmopressin.
DB00035 DB08953 Indalpine The risk or severity of hyponatremia can be increased when Indalpine is combined with Desmopressin.
DB00035 DB12693 Ritanserin The risk or severity of hyponatremia can be increased when Ritanserin is combined with Desmopressin.
DB00035 DB13233 Alaproclate The risk or severity of hyponatremia can be increased when Alaproclate is combined with Desmopressin.
DB00035 DB00177 Valsartan Desmopressin may decrease the antihypertensive activities of Valsartan.
DB00035 DB00178 Ramipril Desmopressin may decrease the antihypertensive activities of Ramipril.
DB00035 DB00187 Esmolol Desmopressin may decrease the antihypertensive activities of Esmolol.
DB00035 DB00195 Betaxolol Desmopressin may decrease the antihypertensive activities of Betaxolol.
DB00035 DB00212 Remikiren Desmopressin may decrease the antihypertensive activities of Remikiren.
DB00035 DB00226 Guanadrel Desmopressin may decrease the antihypertensive activities of Guanadrel.
DB00035 DB00275 Olmesartan Desmopressin may decrease the antihypertensive activities of Olmesartan.
DB00035 DB00335 Atenolol Desmopressin may decrease the antihypertensive activities of Atenolol.
DB00035 DB00343 Diltiazem Desmopressin may decrease the antihypertensive activities of Diltiazem.
DB00035 DB00350 Minoxidil Desmopressin may decrease the antihypertensive activities of Minoxidil.
DB00035 DB00374 Treprostinil Desmopressin may decrease the antihypertensive activities of Treprostinil.
DB00035 DB00381 Amlodipine Desmopressin may decrease the antihypertensive activities of Amlodipine.
DB00035 DB00393 Nimodipine Desmopressin may decrease the antihypertensive activities of Nimodipine.
DB00035 DB00457 Prazosin Desmopressin may decrease the antihypertensive activities of Prazosin.
DB00035 DB00519 Trandolapril Desmopressin may decrease the antihypertensive activities of Trandolapril.
DB00035 DB00528 Lercanidipine Desmopressin may decrease the antihypertensive activities of Lercanidipine.
DB00035 DB00542 Benazepril Desmopressin may decrease the antihypertensive activities of Benazepril.
DB00035 DB00559 Bosentan Desmopressin may decrease the antihypertensive activities of Bosentan.
DB00035 DB00584 Enalapril Desmopressin may decrease the antihypertensive activities of Enalapril.
DB00035 DB00590 Doxazosin Desmopressin may decrease the antihypertensive activities of Doxazosin.
DB00035 DB00616 Candoxatril Desmopressin may decrease the antihypertensive activities of Candoxatril.
DB00035 DB00622 Nicardipine Desmopressin may decrease the antihypertensive activities of Nicardipine.
DB00035 DB00678 Losartan Desmopressin may decrease the antihypertensive activities of Losartan.
DB00035 DB00691 Moexipril Desmopressin may decrease the antihypertensive activities of Moexipril.
DB00035 DB00727 Nitroglycerin Desmopressin may decrease the antihypertensive activities of Nitroglycerin.
DB00035 DB00765 Metyrosine Desmopressin may decrease the antihypertensive activities of Metyrosine.
DB00035 DB00785 Cryptenamine Desmopressin may decrease the antihypertensive activities of Cryptenamine.
DB00035 DB00796 Candesartan cilexetil Desmopressin may decrease the antihypertensive activities of Candesartan cilexetil.
DB00035 DB00866 Alprenolol Desmopressin may decrease the antihypertensive activities of Alprenolol.
DB00035 DB00876 Eprosartan Desmopressin may decrease the antihypertensive activities of Eprosartan.
DB00035 DB00881 Quinapril Desmopressin may decrease the antihypertensive activities of Quinapril.
DB00035 DB00966 Telmisartan Desmopressin may decrease the antihypertensive activities of Telmisartan.
DB00035 DB01023 Felodipine Desmopressin may decrease the antihypertensive activities of Felodipine.
DB00035 DB01029 Irbesartan Desmopressin may decrease the antihypertensive activities of Irbesartan.
DB00035 DB01054 Nitrendipine Desmopressin may decrease the antihypertensive activities of Nitrendipine.
DB00035 DB01089 Deserpidine Desmopressin may decrease the antihypertensive activities of Deserpidine.
DB00035 DB01090 Pentolinium Desmopressin may decrease the antihypertensive activities of Pentolinium.
DB00035 DB01116 Trimethaphan Desmopressin may decrease the antihypertensive activities of Trimethaphan.
DB00035 DB01136 Carvedilol Desmopressin may decrease the antihypertensive activities of Carvedilol.
DB00035 DB01158 Bretylium Desmopressin may decrease the antihypertensive activities of Bretylium.
DB00035 DB01162 Terazosin Desmopressin may decrease the antihypertensive activities of Terazosin.
DB00035 DB01193 Acebutolol Desmopressin may decrease the antihypertensive activities of Acebutolol.
DB00035 DB01197 Captopril Desmopressin may decrease the antihypertensive activities of Captopril.
DB00035 DB01244 Bepridil Desmopressin may decrease the antihypertensive activities of Bepridil.
DB00035 DB01295 Bevantolol Desmopressin may decrease the antihypertensive activities of Bevantolol.
DB00035 DB01297 Practolol Desmopressin may decrease the antihypertensive activities of Practolol.
DB00035 DB01340 Cilazapril Desmopressin may decrease the antihypertensive activities of Cilazapril.
DB00035 DB01347 Saprisartan Desmopressin may decrease the antihypertensive activities of Saprisartan.
DB00035 DB01348 Spirapril Desmopressin may decrease the antihypertensive activities of Spirapril.
DB00035 DB01388 Mibefradil Desmopressin may decrease the antihypertensive activities of Mibefradil.
DB00035 DB01580 Oxprenolol Desmopressin may decrease the antihypertensive activities of Oxprenolol.
DB00035 DB03322 Dexpropranolol Desmopressin may decrease the antihypertensive activities of Dexpropranolol.
DB00035 DB04840 Debrisoquine Desmopressin may decrease the antihypertensive activities of Debrisoquine.
DB00035 DB04846 Celiprolol Desmopressin may decrease the antihypertensive activities of Celiprolol.
DB00035 DB04861 Nebivolol Desmopressin may decrease the antihypertensive activities of Nebivolol.
DB00035 DB06268 Sitaxentan Desmopressin may decrease the antihypertensive activities of Sitaxentan.
DB00035 DB06403 Ambrisentan Desmopressin may decrease the antihypertensive activities of Ambrisentan.
DB00035 DB06445 Diethylnorspermine Desmopressin may decrease the antihypertensive activities of Diethylnorspermine.
DB00035 DB06712 Nilvadipine Desmopressin may decrease the antihypertensive activities of Nilvadipine.
DB00035 DB06762 Pinacidil Desmopressin may decrease the antihypertensive activities of Pinacidil.
DB00035 DB07767 Ferulic acid Desmopressin may decrease the antihypertensive activities of Ferulic acid.
DB00035 DB08808 Bupranolol Desmopressin may decrease the antihypertensive activities of Bupranolol.
DB00035 DB08836 Temocapril Desmopressin may decrease the antihypertensive activities of Temocapril.
DB00035 DB08931 Riociguat Desmopressin may decrease the antihypertensive activities of Riociguat.
DB00035 DB08952 Indenolol Desmopressin may decrease the antihypertensive activities of Indenolol.
DB00035 DB08960 Hexamethonium Desmopressin may decrease the antihypertensive activities of Hexamethonium.
DB00035 DB09026 Aliskiren Desmopressin may decrease the antihypertensive activities of Aliskiren.
DB00035 DB09206 Trimazosin Desmopressin may decrease the antihypertensive activities of Trimazosin.
DB00035 DB09236 Lacidipine Desmopressin may decrease the antihypertensive activities of Lacidipine.
DB00035 DB09238 Manidipine Desmopressin may decrease the antihypertensive activities of Manidipine.
DB00035 DB09239 Niguldipine Desmopressin may decrease the antihypertensive activities of Niguldipine.
DB00035 DB09363 Rauwolfia serpentina root Desmopressin may decrease the antihypertensive activities of Rauwolfia serpentina root.
DB00035 DB11362 Selexipag Desmopressin may decrease the antihypertensive activities of Selexipag.
DB00035 DB11720 Angiotensin 1-7 Desmopressin may decrease the antihypertensive activities of Angiotensin 1-7.
DB00035 DB11770 Talinolol Desmopressin may decrease the antihypertensive activities of Talinolol.
DB00035 DB11783 Imidapril Desmopressin may decrease the antihypertensive activities of Imidapril.
DB00035 DB12054 BQ-123 Desmopressin may decrease the antihypertensive activities of BQ-123.
DB00035 DB12093 Tetrahydropalmatine Desmopressin may decrease the antihypertensive activities of Tetrahydropalmatine.
DB00035 DB12212 Landiolol Desmopressin may decrease the antihypertensive activities of Landiolol.
DB00035 DB12465 Ketanserin Desmopressin may decrease the antihypertensive activities of Ketanserin.
DB00035 DB12945 Dihydralazine Desmopressin may decrease the antihypertensive activities of Dihydralazine.
DB00035 DB13166 Zofenopril Desmopressin may decrease the antihypertensive activities of Zofenopril.
DB00035 DB13211 Guanoxan Desmopressin may decrease the antihypertensive activities of Guanoxan.
DB00035 DB13312 Delapril Desmopressin may decrease the antihypertensive activities of Delapril.
DB00035 DB13374 Vincamine Desmopressin may decrease the antihypertensive activities of Vincamine.
DB00035 DB13400 Linsidomine Desmopressin may decrease the antihypertensive activities of Linsidomine.
DB00035 DB13410 Guanoxabenz Desmopressin may decrease the antihypertensive activities of Guanoxabenz.
DB00035 DB13429 Tolonidine Desmopressin may decrease the antihypertensive activities of Tolonidine.
DB00035 DB13435 Endralazine Desmopressin may decrease the antihypertensive activities of Endralazine.
DB00035 DB13443 Esatenolol Desmopressin may decrease the antihypertensive activities of Esatenolol.
DB00035 DB13452 Cadralazine Desmopressin may decrease the antihypertensive activities of Cadralazine.
DB00035 DB13508 Cloranolol Desmopressin may decrease the antihypertensive activities of Cloranolol.
DB00035 DB13575 Bietaserpine Desmopressin may decrease the antihypertensive activities of Bietaserpine.
DB00035 DB13604 Guanazodine Desmopressin may decrease the antihypertensive activities of Guanazodine.
DB00035 DB13631 Methoserpidine Desmopressin may decrease the antihypertensive activities of Methoserpidine.
DB00035 DB13757 Epanolol Desmopressin may decrease the antihypertensive activities of Epanolol.
DB00035 DB13779 Guanoclor Desmopressin may decrease the antihypertensive activities of Guanoclor.
DB00035 DB13919 Candesartan Desmopressin may decrease the antihypertensive activities of Candesartan.
DB00035 DB14068 Dexniguldipine Desmopressin may decrease the antihypertensive activities of Dexniguldipine.
DB00035 DB14094 Tocopherylquinone Desmopressin may decrease the antihypertensive activities of Tocopherylquinone.
DB00035 DB14125 Benazeprilat Desmopressin may decrease the antihypertensive activities of Benazeprilat.
DB00035 DB14207 Fosinoprilat Desmopressin may decrease the antihypertensive activities of Fosinoprilat.
DB00035 DB14208 Ramiprilat Desmopressin may decrease the antihypertensive activities of Ramiprilat.
DB00035 DB14213 Perindoprilat Desmopressin may decrease the antihypertensive activities of Perindoprilat.
DB00035 DB14217 Quinaprilat Desmopressin may decrease the antihypertensive activities of Quinaprilat.
DB00035 DB00193 Tramadol The risk or severity of hyponatremia can be increased when Tramadol is combined with Desmopressin.
DB00035 DB00295 Morphine The risk or severity of hyponatremia can be increased when Morphine is combined with Desmopressin.
DB00035 DB00318 Codeine The risk or severity of hyponatremia can be increased when Codeine is combined with Desmopressin.
DB00035 DB00327 Hydromorphone The risk or severity of hyponatremia can be increased when Hydromorphone is combined with Desmopressin.
DB00035 DB00333 Methadone The risk or severity of hyponatremia can be increased when Methadone is combined with Desmopressin.
DB00035 DB00454 Meperidine The risk or severity of hyponatremia can be increased when Meperidine is combined with Desmopressin.
DB00035 DB00497 Oxycodone The risk or severity of hyponatremia can be increased when Oxycodone is combined with Desmopressin.
DB00035 DB00611 Butorphanol The risk or severity of hyponatremia can be increased when Butorphanol is combined with Desmopressin.
DB00035 DB00647 Dextropropoxyphene The risk or severity of hyponatremia can be increased when Dextropropoxyphene is combined with Desmopressin.
DB00035 DB00652 Pentazocine The risk or severity of hyponatremia can be increased when Pentazocine is combined with Desmopressin.
DB00035 DB00704 Naltrexone The risk or severity of hyponatremia can be increased when Naltrexone is combined with Desmopressin.
DB00035 DB00708 Sufentanil The risk or severity of hyponatremia can be increased when Sufentanil is combined with Desmopressin.
DB00035 DB00802 Alfentanil The risk or severity of hyponatremia can be increased when Alfentanil is combined with Desmopressin.
DB00035 DB00813 Fentanyl The risk or severity of hyponatremia can be increased when Fentanyl is combined with Desmopressin.
DB00035 DB00844 Nalbuphine The risk or severity of hyponatremia can be increased when Nalbuphine is combined with Desmopressin.
DB00035 DB00854 Levorphanol The risk or severity of hyponatremia can be increased when Levorphanol is combined with Desmopressin.
DB00035 DB00899 Remifentanil The risk or severity of hyponatremia can be increased when Remifentanil is combined with Desmopressin.
DB00035 DB00921 Buprenorphine The risk or severity of hyponatremia can be increased when Buprenorphine is combined with Desmopressin.
DB00035 DB00956 Hydrocodone The risk or severity of hyponatremia can be increased when Hydrocodone is combined with Desmopressin.
DB00035 DB01081 Diphenoxylate The risk or severity of hyponatremia can be increased when Diphenoxylate is combined with Desmopressin.
DB00035 DB01192 Oxymorphone The risk or severity of hyponatremia can be increased when Oxymorphone is combined with Desmopressin.
DB00035 DB01209 Dezocine The risk or severity of hyponatremia can be increased when Dezocine is combined with Desmopressin.
DB00035 DB01227 Levacetylmethadol The risk or severity of hyponatremia can be increased when Levacetylmethadol is combined with Desmopressin.
DB00035 DB01433 Methadyl acetate The risk or severity of hyponatremia can be increased when Methadyl acetate is combined with Desmopressin.
DB00035 DB01450 Dihydroetorphine The risk or severity of hyponatremia can be increased when Dihydroetorphine is combined with Desmopressin.
DB00035 DB01452 Diamorphine The risk or severity of hyponatremia can be increased when Diamorphine is combined with Desmopressin.
DB00035 DB01459 Bezitramide The risk or severity of hyponatremia can be increased when Bezitramide is combined with Desmopressin.
DB00035 DB01466 Ethylmorphine The risk or severity of hyponatremia can be increased when Ethylmorphine is combined with Desmopressin.
DB00035 DB01497 Etorphine The risk or severity of hyponatremia can be increased when Etorphine is combined with Desmopressin.
DB00035 DB01529 Dextromoramide The risk or severity of hyponatremia can be increased when Dextromoramide is combined with Desmopressin.
DB00035 DB01531 Desomorphine The risk or severity of hyponatremia can be increased when Desomorphine is combined with Desmopressin.
DB00035 DB01535 Carfentanil The risk or severity of hyponatremia can be increased when Carfentanil is combined with Desmopressin.
DB00035 DB01551 Dihydrocodeine The risk or severity of hyponatremia can be increased when Dihydrocodeine is combined with Desmopressin.
DB00035 DB01555 Alphacetylmethadol The risk or severity of hyponatremia can be increased when Alphacetylmethadol is combined with Desmopressin.
DB00035 DB01565 Dihydromorphine The risk or severity of hyponatremia can be increased when Dihydromorphine is combined with Desmopressin.
DB00035 DB06204 Tapentadol The risk or severity of hyponatremia can be increased when Tapentadol is combined with Desmopressin.
DB00035 DB06738 Ketobemidone The risk or severity of hyponatremia can be increased when Ketobemidone is combined with Desmopressin.
DB00035 DB08861 DPDPE The risk or severity of hyponatremia can be increased when DPDPE is combined with Desmopressin.
DB00035 DB09174 Lofentanil The risk or severity of hyponatremia can be increased when Lofentanil is combined with Desmopressin.
DB00035 DB09272 Eluxadoline The risk or severity of hyponatremia can be increased when Eluxadoline is combined with Desmopressin.
DB00035 DB11130 Opium The risk or severity of hyponatremia can be increased when Opium is combined with Desmopressin.
DB00035 DB11609 Normethadone The risk or severity of hyponatremia can be increased when Normethadone is combined with Desmopressin.
DB00035 DB12492 Piritramide The risk or severity of hyponatremia can be increased when Piritramide is combined with Desmopressin.
DB00035 DB13160 Alphaprodine The risk or severity of hyponatremia can be increased when Alphaprodine is combined with Desmopressin.
DB00035 DB13454 Nicomorphine The risk or severity of hyponatremia can be increased when Nicomorphine is combined with Desmopressin.
DB00035 DB13478 Meptazinol The risk or severity of hyponatremia can be increased when Meptazinol is combined with Desmopressin.
DB00035 DB13605 Phenoperidine The risk or severity of hyponatremia can be increased when Phenoperidine is combined with Desmopressin.
DB00035 DB13606 Phenazocine The risk or severity of hyponatremia can be increased when Phenazocine is combined with Desmopressin.
DB00035 DB13787 Tilidine The risk or severity of hyponatremia can be increased when Tilidine is combined with Desmopressin.
DB00035 DB15360 Carfentanil, C-11 The risk or severity of hyponatremia can be increased when Carfentanil, C-11 is combined with Desmopressin.
DB00035 DB15465 Benzhydrocodone The risk or severity of hyponatremia can be increased when Benzhydrocodone is combined with Desmopressin.
DB00035 DB00191 Phentermine The risk or severity of hypertension can be increased when Desmopressin is combined with Phentermine.
DB00035 DB00211 Midodrine The risk or severity of hypertension can be increased when Desmopressin is combined with Midodrine.
DB00035 DB00216 Eletriptan The risk or severity of hypertension can be increased when Desmopressin is combined with Eletriptan.
DB00035 DB00217 Bethanidine The risk or severity of hypertension can be increased when Desmopressin is combined with Bethanidine.
DB00035 DB00221 Isoetharine The risk or severity of hypertension can be increased when Desmopressin is combined with Isoetharine.
DB00035 DB00246 Ziprasidone The risk or severity of hypertension can be increased when Desmopressin is combined with Ziprasidone.
DB00035 DB00247 Methysergide The risk or severity of hypertension can be increased when Desmopressin is combined with Methysergide.
DB00035 DB00248 Cabergoline The risk or severity of hypertension can be increased when Desmopressin is combined with Cabergoline.
DB00035 DB00315 Zolmitriptan The risk or severity of hypertension can be increased when Desmopressin is combined with Zolmitriptan.
DB00035 DB00320 Dihydroergotamine The risk or severity of hypertension can be increased when Desmopressin is combined with Dihydroergotamine.
DB00035 DB00353 Methylergometrine The risk or severity of hypertension can be increased when Desmopressin is combined with Methylergometrine.
DB00035 DB00368 Norepinephrine The risk or severity of hypertension can be increased when Desmopressin is combined with Norepinephrine.
DB00035 DB00370 Mirtazapine The risk or severity of hypertension can be increased when Desmopressin is combined with Mirtazapine.
DB00035 DB00388 Phenylephrine The risk or severity of hypertension can be increased when Desmopressin is combined with Phenylephrine.
DB00035 DB00397 Phenylpropanolamine The risk or severity of hypertension can be increased when Desmopressin is combined with Phenylpropanolamine.
DB00035 DB00420 Promazine The risk or severity of hypertension can be increased when Desmopressin is combined with Promazine.
DB00035 DB00450 Droperidol The risk or severity of hypertension can be increased when Desmopressin is combined with Droperidol.
DB00035 DB00561 Doxapram The risk or severity of hypertension can be increased when Desmopressin is combined with Doxapram.
DB00035 DB00572 Atropine The risk or severity of hypertension can be increased when Desmopressin is combined with Atropine.
DB00035 DB00575 Clonidine The risk or severity of hypertension can be increased when Desmopressin is combined with Clonidine.
DB00035 DB00589 Lisuride The risk or severity of hypertension can be increased when Desmopressin is combined with Lisuride.
DB00035 DB00601 Linezolid The risk or severity of hypertension can be increased when Desmopressin is combined with Linezolid.
DB00035 DB00610 Metaraminol The risk or severity of hypertension can be increased when Desmopressin is combined with Metaraminol.
DB00035 DB00614 Furazolidone The risk or severity of hypertension can be increased when Desmopressin is combined with Furazolidone.
DB00035 DB00629 Guanabenz The risk or severity of hypertension can be increased when Desmopressin is combined with Guanabenz.
DB00035 DB00668 Epinephrine The risk or severity of hypertension can be increased when Desmopressin is combined with Epinephrine.
DB00035 DB00679 Thioridazine The risk or severity of hypertension can be increased when Desmopressin is combined with Thioridazine.
DB00035 DB00696 Ergotamine The risk or severity of hypertension can be increased when Desmopressin is combined with Ergotamine.
DB00035 DB00699 Nicergoline The risk or severity of hypertension can be increased when Desmopressin is combined with Nicergoline.
DB00035 DB00723 Methoxamine The risk or severity of hypertension can be increased when Desmopressin is combined with Methoxamine.
DB00035 DB00734 Risperidone The risk or severity of hypertension can be increased when Desmopressin is combined with Risperidone.
DB00035 DB00752 Tranylcypromine The risk or severity of hypertension can be increased when Desmopressin is combined with Tranylcypromine.
DB00035 DB00753 Isoflurane The risk or severity of hypertension can be increased when Desmopressin is combined with Isoflurane.
DB00035 DB00777 Propiomazine The risk or severity of hypertension can be increased when Desmopressin is combined with Propiomazine.
DB00035 DB00797 Tolazoline The risk or severity of hypertension can be increased when Desmopressin is combined with Tolazoline.
DB00035 DB00805 Minaprine The risk or severity of hypertension can be increased when Desmopressin is combined with Minaprine.
DB00035 DB00816 Orciprenaline The risk or severity of hypertension can be increased when Desmopressin is combined with Orciprenaline.
DB00035 DB00818 Propofol The risk or severity of hypertension can be increased when Desmopressin is combined with Propofol.
DB00035 DB00830 Phenmetrazine The risk or severity of hypertension can be increased when Desmopressin is combined with Phenmetrazine.
DB00035 DB00831 Trifluoperazine The risk or severity of hypertension can be increased when Desmopressin is combined with Trifluoperazine.
DB00035 DB00852 Pseudoephedrine The risk or severity of hypertension can be increased when Desmopressin is combined with Pseudoephedrine.
DB00035 DB00865 Benzphetamine The risk or severity of hypertension can be increased when Desmopressin is combined with Benzphetamine.
DB00035 DB00867 Ritodrine The risk or severity of hypertension can be increased when Desmopressin is combined with Ritodrine.
DB00035 DB00875 Flupentixol The risk or severity of hypertension can be increased when Desmopressin is combined with Flupentixol.
DB00035 DB00886 Omapatrilat The risk or severity of hypertension can be increased when Desmopressin is combined with Omapatrilat.
DB00035 DB00901 Bitolterol The risk or severity of hypertension can be increased when Desmopressin is combined with Bitolterol.
DB00035 DB00925 Phenoxybenzamine The risk or severity of hypertension can be increased when Desmopressin is combined with Phenoxybenzamine.
DB00035 DB00935 Oxymetazoline The risk or severity of hypertension can be increased when Desmopressin is combined with Oxymetazoline.
DB00035 DB00937 Diethylpropion The risk or severity of hypertension can be increased when Desmopressin is combined with Diethylpropion.
DB00035 DB00938 Salmeterol The risk or severity of hypertension can be increased when Desmopressin is combined with Salmeterol.
DB00035 DB00952 Naratriptan The risk or severity of hypertension can be increased when Desmopressin is combined with Naratriptan.
DB00035 DB00983 Formoterol The risk or severity of hypertension can be increased when Desmopressin is combined with Formoterol.
DB00035 DB00998 Frovatriptan The risk or severity of hypertension can be increased when Desmopressin is combined with Frovatriptan.
DB00035 DB01028 Methoxyflurane The risk or severity of hypertension can be increased when Desmopressin is combined with Methoxyflurane.
DB00035 DB01037 Selegiline The risk or severity of hypertension can be increased when Desmopressin is combined with Selegiline.
DB00035 DB01049 Ergoloid mesylate The risk or severity of hypertension can be increased when Desmopressin is combined with Ergoloid mesylate.
DB00035 DB01064 Isoprenaline The risk or severity of hypertension can be increased when Desmopressin is combined with Isoprenaline.
DB00035 DB01102 Arbutamine The risk or severity of hypertension can be increased when Desmopressin is combined with Arbutamine.
DB00035 DB01126 Dutasteride The risk or severity of hypertension can be increased when Desmopressin is combined with Dutasteride.
DB00035 DB01159 Halothane The risk or severity of hypertension can be increased when Desmopressin is combined with Halothane.
DB00035 DB01171 Moclobemide The risk or severity of hypertension can be increased when Desmopressin is combined with Moclobemide.
DB00035 DB01180 Rescinnamine The risk or severity of hypertension can be increased when Desmopressin is combined with Rescinnamine.
DB00035 DB01182 Propafenone The risk or severity of hypertension can be increased when Desmopressin is combined with Propafenone.
DB00035 DB01186 Pergolide The risk or severity of hypertension can be increased when Desmopressin is combined with Pergolide.
DB00035 DB01189 Desflurane The risk or severity of hypertension can be increased when Desmopressin is combined with Desflurane.
DB00035 DB01200 Bromocriptine The risk or severity of hypertension can be increased when Desmopressin is combined with Bromocriptine.
DB00035 DB01216 Finasteride The risk or severity of hypertension can be increased when Desmopressin is combined with Finasteride.
DB00035 DB01236 Sevoflurane The risk or severity of hypertension can be increased when Desmopressin is combined with Sevoflurane.
DB00035 DB01238 Aripiprazole The risk or severity of hypertension can be increased when Desmopressin is combined with Aripiprazole.
DB00035 DB01247 Isocarboxazid The risk or severity of hypertension can be increased when Desmopressin is combined with Isocarboxazid.
DB00035 DB01253 Ergometrine The risk or severity of hypertension can be increased when Desmopressin is combined with Ergometrine.
DB00035 DB01255 Lisdexamfetamine The risk or severity of hypertension can be increased when Desmopressin is combined with Lisdexamfetamine.
DB00035 DB01288 Fenoterol The risk or severity of hypertension can be increased when Desmopressin is combined with Fenoterol.
DB00035 DB01291 Pirbuterol The risk or severity of hypertension can be increased when Desmopressin is combined with Pirbuterol.
DB00035 DB01363 Ephedra sinica root The risk or severity of hypertension can be increased when Desmopressin is combined with Ephedra sinica root.
DB00035 DB01364 Ephedrine The risk or severity of hypertension can be increased when Desmopressin is combined with Ephedrine.
DB00035 DB01365 Mephentermine The risk or severity of hypertension can be increased when Desmopressin is combined with Mephentermine.
DB00035 DB01366 Procaterol The risk or severity of hypertension can be increased when Desmopressin is combined with Procaterol.
DB00035 DB01392 Yohimbine The risk or severity of hypertension can be increased when Desmopressin is combined with Yohimbine.
DB00035 DB01403 Methotrimeprazine The risk or severity of hypertension can be increased when Desmopressin is combined with Methotrimeprazine.
DB00035 DB01407 Clenbuterol The risk or severity of hypertension can be increased when Desmopressin is combined with Clenbuterol.
DB00035 DB01408 Bambuterol The risk or severity of hypertension can be increased when Desmopressin is combined with Bambuterol.
DB00035 DB01442 MMDA The risk or severity of hypertension can be increased when Desmopressin is combined with MMDA.
DB00035 DB01454 Midomafetamine The risk or severity of hypertension can be increased when Desmopressin is combined with Midomafetamine.
DB00035 DB01467 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylamphetamine.
DB00035 DB01472 4-Methoxyamphetamine The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Methoxyamphetamine.
DB00035 DB01484 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB00035 DB01509 Tenamfetamine The risk or severity of hypertension can be increased when Desmopressin is combined with Tenamfetamine.
DB00035 DB01556 Chlorphentermine The risk or severity of hypertension can be increased when Desmopressin is combined with Chlorphentermine.
DB00035 DB01576 Dextroamphetamine The risk or severity of hypertension can be increased when Desmopressin is combined with Dextroamphetamine.
DB00035 DB01579 Phendimetrazine The risk or severity of hypertension can be increased when Desmopressin is combined with Phendimetrazine.
DB00035 DB01591 Solifenacin The risk or severity of hypertension can be increased when Desmopressin is combined with Solifenacin.
DB00035 DB01608 Periciazine The risk or severity of hypertension can be increased when Desmopressin is combined with Periciazine.
DB00035 DB01614 Acepromazine The risk or severity of hypertension can be increased when Desmopressin is combined with Acepromazine.
DB00035 DB01622 Thioproperazine The risk or severity of hypertension can be increased when Desmopressin is combined with Thioproperazine.
DB00035 DB01624 Zuclopenthixol The risk or severity of hypertension can be increased when Desmopressin is combined with Zuclopenthixol.
DB00035 DB01626 Pargyline The risk or severity of hypertension can be increased when Desmopressin is combined with Pargyline.
DB00035 DB02032 Epicaptopril The risk or severity of hypertension can be increased when Desmopressin is combined with Epicaptopril.
DB00035 DB04017 Clorgiline The risk or severity of hypertension can be increased when Desmopressin is combined with Clorgiline.
DB00035 DB04581 1-benzylimidazole The risk or severity of hypertension can be increased when Desmopressin is combined with 1-benzylimidazole.
DB00035 DB04818 Iproniazid The risk or severity of hypertension can be increased when Desmopressin is combined with Iproniazid.
DB00035 DB04820 Nialamide The risk or severity of hypertension can be increased when Desmopressin is combined with Nialamide.
DB00035 DB04829 Lysergic acid diethylamide The risk or severity of hypertension can be increased when Desmopressin is combined with Lysergic acid diethylamide.
DB00035 DB04855 Dronedarone The risk or severity of hypertension can be increased when Desmopressin is combined with Dronedarone.
DB00035 DB04908 Flibanserin The risk or severity of hypertension can be increased when Desmopressin is combined with Flibanserin.
DB00035 DB04946 Iloperidone The risk or severity of hypertension can be increased when Desmopressin is combined with Iloperidone.
DB00035 DB05039 Indacaterol The risk or severity of hypertension can be increased when Desmopressin is combined with Indacaterol.
DB00035 DB05271 Rotigotine The risk or severity of hypertension can be increased when Desmopressin is combined with Rotigotine.
DB00035 DB05395 Amibegron The risk or severity of hypertension can be increased when Desmopressin is combined with Amibegron.
DB00035 DB05562 Naluzotan The risk or severity of hypertension can be increased when Desmopressin is combined with Naluzotan.
DB00035 DB06016 Cariprazine The risk or severity of hypertension can be increased when Desmopressin is combined with Cariprazine.
DB00035 DB06148 Mianserin The risk or severity of hypertension can be increased when Desmopressin is combined with Mianserin.
DB00035 DB06152 Nylidrin The risk or severity of hypertension can be increased when Desmopressin is combined with Nylidrin.
DB00035 DB06153 Pizotifen The risk or severity of hypertension can be increased when Desmopressin is combined with Pizotifen.
DB00035 DB06190 Solabegron The risk or severity of hypertension can be increased when Desmopressin is combined with Solabegron.
DB00035 DB06216 Asenapine The risk or severity of hypertension can be increased when Desmopressin is combined with Asenapine.
DB00035 DB06654 Safinamide The risk or severity of hypertension can be increased when Desmopressin is combined with Safinamide.
DB00035 DB06678 Esmirtazapine The risk or severity of hypertension can be increased when Desmopressin is combined with Esmirtazapine.
DB00035 DB06684 Vilazodone The risk or severity of hypertension can be increased when Desmopressin is combined with Vilazodone.
DB00035 DB06690 Nitrous oxide The risk or severity of hypertension can be increased when Desmopressin is combined with Nitrous oxide.
DB00035 DB06694 Xylometazoline The risk or severity of hypertension can be increased when Desmopressin is combined with Xylometazoline.
DB00035 DB06701 Dexmethylphenidate The risk or severity of hypertension can be increased when Desmopressin is combined with Dexmethylphenidate.
DB00035 DB06706 Isometheptene The risk or severity of hypertension can be increased when Desmopressin is combined with Isometheptene.
DB00035 DB06707 Levonordefrin The risk or severity of hypertension can be increased when Desmopressin is combined with Levonordefrin.
DB00035 DB06711 Naphazoline The risk or severity of hypertension can be increased when Desmopressin is combined with Naphazoline.
DB00035 DB06763 Saralasin The risk or severity of hypertension can be increased when Desmopressin is combined with Saralasin.
DB00035 DB06764 Tetryzoline The risk or severity of hypertension can be increased when Desmopressin is combined with Tetryzoline.
DB00035 DB08810 Cinitapride The risk or severity of hypertension can be increased when Desmopressin is combined with Cinitapride.
DB00035 DB08815 Lurasidone The risk or severity of hypertension can be increased when Desmopressin is combined with Lurasidone.
DB00035 DB08841 Tyramine The risk or severity of hypertension can be increased when Desmopressin is combined with Tyramine.
DB00035 DB08925 Adrafinil The risk or severity of hypertension can be increased when Desmopressin is combined with Adrafinil.
DB00035 DB08941 Isoxsuprine The risk or severity of hypertension can be increased when Desmopressin is combined with Isoxsuprine.
DB00035 DB08950 Indoramin The risk or severity of hypertension can be increased when Desmopressin is combined with Indoramin.
DB00035 DB08954 Ifenprodil The risk or severity of hypertension can be increased when Desmopressin is combined with Ifenprodil.
DB00035 DB08957 Hexoprenaline The risk or severity of hypertension can be increased when Desmopressin is combined with Hexoprenaline.
DB00035 DB08985 Etilefrine The risk or severity of hypertension can be increased when Desmopressin is combined with Etilefrine.
DB00035 DB09061 Cannabidiol The risk or severity of hypertension can be increased when Desmopressin is combined with Cannabidiol.
DB00035 DB09080 Olodaterol The risk or severity of hypertension can be increased when Desmopressin is combined with Olodaterol.
DB00035 DB09128 Brexpiprazole The risk or severity of hypertension can be increased when Desmopressin is combined with Brexpiprazole.
DB00035 DB09202 Cirazoline The risk or severity of hypertension can be increased when Desmopressin is combined with Cirazoline.
DB00035 DB09203 Synephrine The risk or severity of hypertension can be increased when Desmopressin is combined with Synephrine.
DB00035 DB09242 Moxonidine The risk or severity of hypertension can be increased when Desmopressin is combined with Moxonidine.
DB00035 DB09243 Hydracarbazine The risk or severity of hypertension can be increased when Desmopressin is combined with Hydracarbazine.
DB00035 DB09246 Benmoxin The risk or severity of hypertension can be increased when Desmopressin is combined with Benmoxin.
DB00035 DB09248 Mebanazine The risk or severity of hypertension can be increased when Desmopressin is combined with Mebanazine.
DB00035 DB09249 Octamoxin The risk or severity of hypertension can be increased when Desmopressin is combined with Octamoxin.
DB00035 DB09250 Pheniprazine The risk or severity of hypertension can be increased when Desmopressin is combined with Pheniprazine.
DB00035 DB09251 Phenoxypropazine The risk or severity of hypertension can be increased when Desmopressin is combined with Phenoxypropazine.
DB00035 DB09252 Pivhydrazine The risk or severity of hypertension can be increased when Desmopressin is combined with Pivhydrazine.
DB00035 DB09253 Safrazine The risk or severity of hypertension can be increased when Desmopressin is combined with Safrazine.
DB00035 DB09254 Caroxazone The risk or severity of hypertension can be increased when Desmopressin is combined with Caroxazone.
DB00035 DB09273 Doxofylline The risk or severity of hypertension can be increased when Desmopressin is combined with Doxofylline.
DB00035 DB09480 Iofetamine I-123 The risk or severity of hypertension can be increased when Desmopressin is combined with Iofetamine I-123.
DB00035 DB11124 Racepinephrine The risk or severity of hypertension can be increased when Desmopressin is combined with Racepinephrine.
DB00035 DB11273 Dihydroergocornine The risk or severity of hypertension can be increased when Desmopressin is combined with Dihydroergocornine.
DB00035 DB11373 Amitraz The risk or severity of hypertension can be increased when Desmopressin is combined with Amitraz.
DB00035 DB11428 Medetomidine The risk or severity of hypertension can be increased when Desmopressin is combined with Medetomidine.
DB00035 DB11477 Xylazine The risk or severity of hypertension can be increased when Desmopressin is combined with Xylazine.
DB00035 DB11481 Atipamezole The risk or severity of hypertension can be increased when Desmopressin is combined with Atipamezole.
DB00035 DB11541 Ractopamine The risk or severity of hypertension can be increased when Desmopressin is combined with Ractopamine.
DB00035 DB11543 Romifidine The risk or severity of hypertension can be increased when Desmopressin is combined with Romifidine.
DB00035 DB11556 Detomidine The risk or severity of hypertension can be increased when Desmopressin is combined with Detomidine.
DB00035 DB11738 Rilmenidine The risk or severity of hypertension can be increased when Desmopressin is combined with Rilmenidine.
DB00035 DB11755 Tetrahydrocannabivarin The risk or severity of hypertension can be increased when Desmopressin is combined with Tetrahydrocannabivarin.
DB00035 DB11785 Anisodamine The risk or severity of hypertension can be increased when Desmopressin is combined with Anisodamine.
DB00035 DB11871 PF-00610355 The risk or severity of hypertension can be increased when Desmopressin is combined with PF-00610355.
DB00035 DB12080 Ritobegron The risk or severity of hypertension can be increased when Desmopressin is combined with Ritobegron.
DB00035 DB12092 Naftopidil The risk or severity of hypertension can be increased when Desmopressin is combined with Naftopidil.
DB00035 DB12100 Abediterol The risk or severity of hypertension can be increased when Desmopressin is combined with Abediterol.
DB00035 DB12248 Tulobuterol The risk or severity of hypertension can be increased when Desmopressin is combined with Tulobuterol.
DB00035 DB12313 Dopexamine The risk or severity of hypertension can be increased when Desmopressin is combined with Dopexamine.
DB00035 DB12361 Piclozotan The risk or severity of hypertension can be increased when Desmopressin is combined with Piclozotan.
DB00035 DB12371 Siponimod The risk or severity of hypertension can be increased when Desmopressin is combined with Siponimod.
DB00035 DB12551 Idazoxan The risk or severity of hypertension can be increased when Desmopressin is combined with Idazoxan.
DB00035 DB12661 Urapidil The risk or severity of hypertension can be increased when Desmopressin is combined with Urapidil.
DB00035 DB12779 Higenamine The risk or severity of hypertension can be increased when Desmopressin is combined with Higenamine.
DB00035 DB12846 Reproterol The risk or severity of hypertension can be increased when Desmopressin is combined with Reproterol.
DB00035 DB12927 Theodrenaline The risk or severity of hypertension can be increased when Desmopressin is combined with Theodrenaline.
DB00035 DB13064 Tramazoline The risk or severity of hypertension can be increased when Desmopressin is combined with Tramazoline.
DB00035 DB13108 Mephedrone The risk or severity of hypertension can be increased when Desmopressin is combined with Mephedrone.
DB00035 DB13251 Octopamine The risk or severity of hypertension can be increased when Desmopressin is combined with Octopamine.
DB00035 DB13323 Trichloroethylene The risk or severity of hypertension can be increased when Desmopressin is combined with Trichloroethylene.
DB00035 DB13341 Fenozolone The risk or severity of hypertension can be increased when Desmopressin is combined with Fenozolone.
DB00035 DB13345 Dihydroergocristine The risk or severity of hypertension can be increased when Desmopressin is combined with Dihydroergocristine.
DB00035 DB13378 Norfenefrine The risk or severity of hypertension can be increased when Desmopressin is combined with Norfenefrine.
DB00035 DB13385 Dihydroergocryptine The risk or severity of hypertension can be increased when Desmopressin is combined with Dihydroergocryptine.
DB00035 DB13398 Oxyfedrine The risk or severity of hypertension can be increased when Desmopressin is combined with Oxyfedrine.
DB00035 DB13399 Terguride The risk or severity of hypertension can be increased when Desmopressin is combined with Terguride.
DB00035 DB13453 Xenon The risk or severity of hypertension can be increased when Desmopressin is combined with Xenon.
DB00035 DB13510 Buflomedil The risk or severity of hypertension can be increased when Desmopressin is combined with Buflomedil.
DB00035 DB13520 Metergoline The risk or severity of hypertension can be increased when Desmopressin is combined with Metergoline.
DB00035 DB13559 Rimiterol The risk or severity of hypertension can be increased when Desmopressin is combined with Rimiterol.
DB00035 DB13598 Diethyl ether The risk or severity of hypertension can be increased when Desmopressin is combined with Diethyl ether.
DB00035 DB13624 Methoxyphenamine The risk or severity of hypertension can be increased when Desmopressin is combined with Methoxyphenamine.
DB00035 DB13692 Tretoquinol The risk or severity of hypertension can be increased when Desmopressin is combined with Tretoquinol.
DB00035 DB13703 Gepefrine The risk or severity of hypertension can be increased when Desmopressin is combined with Gepefrine.
DB00035 DB13777 Prenalterol The risk or severity of hypertension can be increased when Desmopressin is combined with Prenalterol.
DB00035 DB13781 Xamoterol The risk or severity of hypertension can be increased when Desmopressin is combined with Xamoterol.
DB00035 DB13852 Mefenorex The risk or severity of hypertension can be increased when Desmopressin is combined with Mefenorex.
DB00035 DB13875 Harmaline The risk or severity of hypertension can be increased when Desmopressin is combined with Harmaline.
DB00035 DB13917 Deoxyepinephrine The risk or severity of hypertension can be increased when Desmopressin is combined with Deoxyepinephrine.
DB00035 DB13940 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB00035 DB14010 5-methoxy-N,N-dimethyltryptamine The risk or severity of hypertension can be increased when Desmopressin is combined with 5-methoxy-N,N-dimethyltryptamine.
DB00035 DB14185 Aripiprazole lauroxil The risk or severity of hypertension can be increased when Desmopressin is combined with Aripiprazole lauroxil.
DB00035 DB14231 Quinoline Yellow WS The risk or severity of hypertension can be increased when Desmopressin is combined with Quinoline Yellow WS.
DB00035 DB15685 Selpercatinib The risk or severity of hypertension can be increased when Desmopressin is combined with Selpercatinib.
DB00035 DB00321 Amitriptyline The risk or severity of hyponatremia and water intoxication can be increased when Amitriptyline is combined with Desmopressin.
DB00035 DB00344 Protriptyline The risk or severity of hyponatremia and water intoxication can be increased when Protriptyline is combined with Desmopressin.
DB00035 DB00458 Imipramine The risk or severity of hyponatremia and water intoxication can be increased when Imipramine is combined with Desmopressin.
DB00035 DB00540 Nortriptyline The risk or severity of hyponatremia and water intoxication can be increased when Nortriptyline is combined with Desmopressin.
DB00035 DB00543 Amoxapine The risk or severity of hyponatremia and water intoxication can be increased when Amoxapine is combined with Desmopressin.
DB00035 DB00726 Trimipramine The risk or severity of hyponatremia and water intoxication can be increased when Trimipramine is combined with Desmopressin.
DB00035 DB01142 Doxepin The risk or severity of hyponatremia and water intoxication can be increased when Doxepin is combined with Desmopressin.
DB00035 DB01151 Desipramine The risk or severity of hyponatremia and water intoxication can be increased when Desipramine is combined with Desmopressin.
DB00035 DB01242 Clomipramine The risk or severity of hyponatremia and water intoxication can be increased when Clomipramine is combined with Desmopressin.
DB00035 DB04836 Amineptine The risk or severity of hyponatremia and water intoxication can be increased when Amineptine is combined with Desmopressin.
DB00035 DB08996 Dimetacrine The risk or severity of hyponatremia and water intoxication can be increased when Dimetacrine is combined with Desmopressin.
DB00035 DB09016 Butriptyline The risk or severity of hyponatremia and water intoxication can be increased when Butriptyline is combined with Desmopressin.
DB00035 DB09167 Dosulepin The risk or severity of hyponatremia and water intoxication can be increased when Dosulepin is combined with Desmopressin.
DB00035 DB09289 Tianeptine The risk or severity of hyponatremia and water intoxication can be increased when Tianeptine is combined with Desmopressin.
DB00035 DB09307 Oxaprotiline The risk or severity of hyponatremia and water intoxication can be increased when Oxaprotiline is combined with Desmopressin.
DB00035 DB12930 Opipramol The risk or severity of hyponatremia and water intoxication can be increased when Opipramol is combined with Desmopressin.
DB00035 DB13114 Amitriptylinoxide The risk or severity of hyponatremia and water intoxication can be increased when Amitriptylinoxide is combined with Desmopressin.
DB00035 DB13225 Dibenzepin The risk or severity of hyponatremia and water intoxication can be increased when Dibenzepin is combined with Desmopressin.
DB00035 DB13246 Quinupramine The risk or severity of hyponatremia and water intoxication can be increased when Quinupramine is combined with Desmopressin.
DB00035 DB13384 Melitracen The risk or severity of hyponatremia and water intoxication can be increased when Melitracen is combined with Desmopressin.
DB00035 DB13411 Lofepramine The risk or severity of hyponatremia and water intoxication can be increased when Lofepramine is combined with Desmopressin.
DB00035 DB13496 Iprindole The risk or severity of hyponatremia and water intoxication can be increased when Iprindole is combined with Desmopressin.
DB00035 DB13782 Imipramine oxide The risk or severity of hyponatremia and water intoxication can be increased when Imipramine oxide is combined with Desmopressin.
DB00035 DB00159 Icosapent The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Icosapent is combined with Desmopressin.
DB00035 DB00244 Mesalazine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Mesalazine is combined with Desmopressin.
DB00035 DB00328 Indomethacin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Indomethacin is combined with Desmopressin.
DB00035 DB00461 Nabumetone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Nabumetone is combined with Desmopressin.
DB00035 DB00465 Ketorolac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ketorolac is combined with Desmopressin.
DB00035 DB00469 Tenoxicam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tenoxicam is combined with Desmopressin.
DB00035 DB00482 Celecoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Celecoxib is combined with Desmopressin.
DB00035 DB00500 Tolmetin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tolmetin is combined with Desmopressin.
DB00035 DB00533 Rofecoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Rofecoxib is combined with Desmopressin.
DB00035 DB00554 Piroxicam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Piroxicam is combined with Desmopressin.
DB00035 DB00573 Fenoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Fenoprofen is combined with Desmopressin.
DB00035 DB00580 Valdecoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Valdecoxib is combined with Desmopressin.
DB00035 DB00586 Diclofenac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Diclofenac is combined with Desmopressin.
DB00035 DB00605 Sulindac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Sulindac is combined with Desmopressin.
DB00035 DB00712 Flurbiprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Flurbiprofen is combined with Desmopressin.
DB00035 DB00749 Etodolac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Etodolac is combined with Desmopressin.
DB00035 DB00784 Mefenamic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Mefenamic acid is combined with Desmopressin.
DB00035 DB00788 Naproxen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Naproxen is combined with Desmopressin.
DB00035 DB00795 Sulfasalazine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Sulfasalazine is combined with Desmopressin.
DB00035 DB00812 Phenylbutazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Phenylbutazone is combined with Desmopressin.
DB00035 DB00814 Meloxicam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Meloxicam is combined with Desmopressin.
DB00035 DB00821 Carprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Carprofen is combined with Desmopressin.
DB00035 DB00861 Diflunisal The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Diflunisal is combined with Desmopressin.
DB00035 DB00936 Salicylic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Salicylic acid is combined with Desmopressin.
DB00035 DB00939 Meclofenamic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Meclofenamic acid is combined with Desmopressin.
DB00035 DB00945 Acetylsalicylic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Acetylsalicylic acid is combined with Desmopressin.
DB00035 DB00991 Oxaprozin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Oxaprozin is combined with Desmopressin.
DB00035 DB01009 Ketoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ketoprofen is combined with Desmopressin.
DB00035 DB01014 Balsalazide The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Balsalazide is combined with Desmopressin.
DB00035 DB01050 Ibuprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ibuprofen is combined with Desmopressin.
DB00035 DB01250 Olsalazine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Olsalazine is combined with Desmopressin.
DB00035 DB01283 Lumiracoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Lumiracoxib is combined with Desmopressin.
DB00035 DB01397 Magnesium salicylate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Magnesium salicylate is combined with Desmopressin.
DB00035 DB01399 Salsalate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Salsalate is combined with Desmopressin.
DB00035 DB01401 Choline magnesium trisalicylate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Choline magnesium trisalicylate is combined with Desmopressin.
DB00035 DB01419 Antrafenine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Antrafenine is combined with Desmopressin.
DB00035 DB01424 Aminophenazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Aminophenazone is combined with Desmopressin.
DB00035 DB01435 Antipyrine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Antipyrine is combined with Desmopressin.
DB00035 DB01600 Tiaprofenic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tiaprofenic acid is combined with Desmopressin.
DB00035 DB01628 Etoricoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Etoricoxib is combined with Desmopressin.
DB00035 DB02224 Taxifolin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Taxifolin is combined with Desmopressin.
DB00035 DB03585 Oxyphenbutazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Oxyphenbutazone is combined with Desmopressin.
DB00035 DB04552 Niflumic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Niflumic acid is combined with Desmopressin.
DB00035 DB04725 Licofelone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Licofelone is combined with Desmopressin.
DB00035 DB04743 Nimesulide The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Nimesulide is combined with Desmopressin.
DB00035 DB04812 Benoxaprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Benoxaprofen is combined with Desmopressin.
DB00035 DB04817 Metamizole The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Metamizole is combined with Desmopressin.
DB00035 DB04828 Zomepirac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Zomepirac is combined with Desmopressin.
DB00035 DB05095 Cimicoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Cimicoxib is combined with Desmopressin.
DB00035 DB06725 Lornoxicam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Lornoxicam is combined with Desmopressin.
DB00035 DB06736 Aceclofenac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Aceclofenac is combined with Desmopressin.
DB00035 DB06737 Zaltoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Zaltoprofen is combined with Desmopressin.
DB00035 DB07402 Azapropazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Azapropazone is combined with Desmopressin.
DB00035 DB07477 Felbinac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Felbinac is combined with Desmopressin.
DB00035 DB08439 Parecoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Parecoxib is combined with Desmopressin.
DB00035 DB08797 Salicylamide The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Salicylamide is combined with Desmopressin.
DB00035 DB08940 Kebuzone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Kebuzone is combined with Desmopressin.
DB00035 DB08942 Isoxicam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Isoxicam is combined with Desmopressin.
DB00035 DB08951 Indoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Indoprofen is combined with Desmopressin.
DB00035 DB08955 Ibuproxam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ibuproxam is combined with Desmopressin.
DB00035 DB08976 Floctafenine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Floctafenine is combined with Desmopressin.
DB00035 DB08981 Fenbufen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Fenbufen is combined with Desmopressin.
DB00035 DB08984 Etofenamate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Etofenamate is combined with Desmopressin.
DB00035 DB08991 Epirizole The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Epirizole is combined with Desmopressin.
DB00035 DB09084 Benzydamine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Benzydamine is combined with Desmopressin.
DB00035 DB09212 Loxoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Loxoprofen is combined with Desmopressin.
DB00035 DB09213 Dexibuprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Dexibuprofen is combined with Desmopressin.
DB00035 DB09214 Dexketoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Dexketoprofen is combined with Desmopressin.
DB00035 DB09215 Droxicam The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Droxicam is combined with Desmopressin.
DB00035 DB09216 Tolfenamic acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tolfenamic acid is combined with Desmopressin.
DB00035 DB09217 Firocoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Firocoxib is combined with Desmopressin.
DB00035 DB09218 Clonixin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Clonixin is combined with Desmopressin.
DB00035 DB09285 Morniflumate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Morniflumate is combined with Desmopressin.
DB00035 DB09288 Propacetamol The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Propacetamol is combined with Desmopressin.
DB00035 DB09295 Talniflumate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Talniflumate is combined with Desmopressin.
DB00035 DB11455 Robenacoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Robenacoxib is combined with Desmopressin.
DB00035 DB11466 Tepoxalin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tepoxalin is combined with Desmopressin.
DB00035 DB11518 Flunixin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Flunixin is combined with Desmopressin.
DB00035 DB12399 Polmacoxib The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Polmacoxib is combined with Desmopressin.
DB00035 DB12445 Nitroaspirin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Nitroaspirin is combined with Desmopressin.
DB00035 DB12480 Betulinic Acid The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Betulinic Acid is combined with Desmopressin.
DB00035 DB12545 Indobufen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Indobufen is combined with Desmopressin.
DB00035 DB12610 Ebselen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ebselen is combined with Desmopressin.
DB00035 DB13001 Tinoridine The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tinoridine is combined with Desmopressin.
DB00035 DB13167 Alclofenac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Alclofenac is combined with Desmopressin.
DB00035 DB13217 Fentiazac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Fentiazac is combined with Desmopressin.
DB00035 DB13232 Suxibuzone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Suxibuzone is combined with Desmopressin.
DB00035 DB13286 Bumadizone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Bumadizone is combined with Desmopressin.
DB00035 DB13314 Alminoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Alminoprofen is combined with Desmopressin.
DB00035 DB13317 Flunoxaprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Flunoxaprofen is combined with Desmopressin.
DB00035 DB13364 Feprazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Feprazone is combined with Desmopressin.
DB00035 DB13371 Difenpiramide The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Difenpiramide is combined with Desmopressin.
DB00035 DB13407 Nifenazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Nifenazone is combined with Desmopressin.
DB00035 DB13432 Lonazolac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Lonazolac is combined with Desmopressin.
DB00035 DB13481 Tenidap The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Tenidap is combined with Desmopressin.
DB00035 DB13501 Bendazac The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Bendazac is combined with Desmopressin.
DB00035 DB13514 Pranoprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Pranoprofen is combined with Desmopressin.
DB00035 DB13524 Propyphenazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Propyphenazone is combined with Desmopressin.
DB00035 DB13527 Proglumetacin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Proglumetacin is combined with Desmopressin.
DB00035 DB13538 Guacetisal The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Guacetisal is combined with Desmopressin.
DB00035 DB13544 Ethenzamide The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ethenzamide is combined with Desmopressin.
DB00035 DB13612 Carbaspirin calcium The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Carbaspirin calcium is combined with Desmopressin.
DB00035 DB13629 Mofebutazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Mofebutazone is combined with Desmopressin.
DB00035 DB13649 Proquazone The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Proquazone is combined with Desmopressin.
DB00035 DB13657 Benorilate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Benorilate is combined with Desmopressin.
DB00035 DB13722 Pirprofen The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Pirprofen is combined with Desmopressin.
DB00035 DB13783 Acemetacin The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Acemetacin is combined with Desmopressin.
DB00035 DB13860 Imidazole salicylate The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Imidazole salicylate is combined with Desmopressin.
DB00035 DB14059 SC-236 The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when SC-236 is combined with Desmopressin.
DB00035 DB14060 NS-398 The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when NS-398 is combined with Desmopressin.
DB00035 DB14938 Flurbiprofen axetil The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Flurbiprofen axetil is combined with Desmopressin.
DB00035 DB00091 Cyclosporine Cyclosporine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00229 Cefotiam Cefotiam may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00267 Cefmenoxime Cefmenoxime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00274 Cefmetazole Cefmetazole may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00282 Pamidronic acid Pamidronic acid may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00300 Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00369 Cidofovir Cidofovir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00384 Triamterene Triamterene may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00430 Cefpiramide Cefpiramide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00438 Ceftazidime Ceftazidime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00447 Loracarbef Loracarbef may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00456 Cefalotin Cefalotin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00493 Cefotaxime Cefotaxime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00529 Foscarnet Foscarnet may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00563 Methotrexate Methotrexate may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00567 Cephalexin Cephalexin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00577 Valaciclovir Valaciclovir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00626 Bacitracin Bacitracin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00681 Amphotericin B Amphotericin B may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00689 Cephaloglycin Cephaloglycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00718 Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00738 Pentamidine Pentamidine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00742 Mannitol Mannitol may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00787 Acyclovir Acyclovir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00833 Cefaclor Cefaclor may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00864 Tacrolimus Tacrolimus may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00903 Etacrynic acid Etacrynic acid may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00923 Ceforanide Ceforanide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00958 Carboplatin Carboplatin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00999 Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01066 Cefditoren Cefditoren may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01072 Atazanavir Atazanavir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01111 Colistimethate Colistimethate may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01112 Cefuroxime Cefuroxime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01139 Cefapirin Cefapirin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01140 Cefadroxil Cefadroxil may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01150 Cefprozil Cefprozil may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01212 Ceftriaxone Ceftriaxone may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01326 Cefamandole Cefamandole may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01327 Cefazolin Cefazolin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01328 Cefonicid Cefonicid may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01329 Cefoperazone Cefoperazone may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01330 Cefotetan Cefotetan may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01331 Cefoxitin Cefoxitin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01332 Ceftizoxime Ceftizoxime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01333 Cefradine Cefradine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01413 Cefepime Cefepime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01414 Cefacetrile Cefacetrile may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01415 Ceftibuten Ceftibuten may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01416 Cefpodoxime Cefpodoxime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01601 Lopinavir Lopinavir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB02247 Hydrolyzed Cephalothin Hydrolyzed Cephalothin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB03450 Cephalothin Group Cephalothin Group may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB04570 Latamoxef Latamoxef may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB04918 Ceftobiprole Ceftobiprole may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB06590 Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB09008 Cefaloridine Cefaloridine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB09062 Cefminox Cefminox may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB09299 Tenofovir alafenamide Tenofovir alafenamide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB11367 Cefroxadine Cefroxadine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB11935 Flomoxef Flomoxef may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB12151 Brincidofovir Brincidofovir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13266 Cefatrizine Cefatrizine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13461 Cefcapene Cefcapene may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13470 Cefodizime Cefodizime may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13499 Cefsulodin Cefsulodin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13504 Cefetamet Cefetamet may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13638 Cefbuperazone Cefbuperazone may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13667 Cefozopran Cefozopran may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13682 Cefpirome Cefpirome may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13778 Cefazedone Cefazedone may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13821 Ceftezole Ceftezole may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13868 Adefovir Adefovir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB14126 Tenofovir Tenofovir may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB14713 Inotersen Inotersen may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01438 Phenazopyridine Phenazopyridine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB15066 Givosiran Givosiran may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00007 Leuprolide Leuprolide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00014 Goserelin Goserelin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00017 Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00041 Aldesleukin Desmopressin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00035 DB00080 Daptomycin Desmopressin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
DB00035 DB00081 Tositumomab Desmopressin may decrease the excretion rate of Tositumomab which could result in a higher serum level.
DB00035 DB00115 Cyanocobalamin Desmopressin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
DB00035 DB00158 Folic acid Desmopressin may decrease the excretion rate of Folic acid which could result in a higher serum level.
DB00035 DB00165 Pyridoxine Desmopressin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
DB00035 DB00181 Baclofen Desmopressin may decrease the excretion rate of Baclofen which could result in a higher serum level.
DB00035 DB00182 Amphetamine Desmopressin may decrease the excretion rate of Amphetamine which could result in a higher serum level.
DB00035 DB00185 Cevimeline Desmopressin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
DB00035 DB00186 Lorazepam Desmopressin may decrease the excretion rate of Lorazepam which could result in a higher serum level.
DB00035 DB00190 Carbidopa Desmopressin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00035 DB00196 Fluconazole Desmopressin may decrease the excretion rate of Fluconazole which could result in a higher serum level.
DB00035 DB00198 Oseltamivir Desmopressin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00035 DB00200 Hydroxocobalamin Desmopressin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00035 DB00206 Reserpine Desmopressin may decrease the excretion rate of Reserpine which could result in a higher serum level.
DB00035 DB00208 Ticlopidine Desmopressin may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
DB00035 DB00213 Pantoprazole Desmopressin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00035 DB00225 Gadodiamide Desmopressin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00035 DB00230 Pregabalin Desmopressin may decrease the excretion rate of Pregabalin which could result in a higher serum level.
DB00035 DB00231 Temazepam Desmopressin may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00035 DB00235 Milrinone Desmopressin may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00035 DB00237 Butabarbital Desmopressin may decrease the excretion rate of Butabarbital which could result in a higher serum level.
DB00035 DB00243 Ranolazine Desmopressin may decrease the excretion rate of Ranolazine which could result in a higher serum level.
DB00035 DB00245 Benzatropine Desmopressin may decrease the excretion rate of Benzatropine which could result in a higher serum level.
DB00035 DB00254 Doxycycline Desmopressin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00035 DB00262 Carmustine Desmopressin may decrease the excretion rate of Carmustine which could result in a higher serum level.
DB00035 DB00264 Metoprolol Desmopressin may decrease the excretion rate of Metoprolol which could result in a higher serum level.
DB00035 DB00270 Isradipine Desmopressin may decrease the excretion rate of Isradipine which could result in a higher serum level.
DB00035 DB00271 Diatrizoate Desmopressin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
DB00035 DB00273 Topiramate Desmopressin may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00035 DB00279 Liothyronine Desmopressin may decrease the excretion rate of Liothyronine which could result in a higher serum level.
DB00035 DB00280 Disopyramide Desmopressin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
DB00035 DB00284 Acarbose Desmopressin may decrease the excretion rate of Acarbose which could result in a higher serum level.
DB00035 DB00285 Venlafaxine Desmopressin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
DB00035 DB00286 Conjugated estrogens Desmopressin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00035 DB00289 Atomoxetine Desmopressin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
DB00035 DB00290 Bleomycin Desmopressin may decrease the excretion rate of Bleomycin which could result in a higher serum level.
DB00035 DB00292 Etomidate Desmopressin may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00035 DB00294 Etonogestrel Desmopressin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00035 DB00296 Ropivacaine Desmopressin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00035 DB00303 Ertapenem Desmopressin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00035 DB00308 Ibutilide Desmopressin may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00035 DB00312 Pentobarbital Desmopressin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
DB00035 DB00316 Acetaminophen Desmopressin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
DB00035 DB00319 Piperacillin Desmopressin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00035 DB00322 Floxuridine Desmopressin may decrease the excretion rate of Floxuridine which could result in a higher serum level.
DB00035 DB00323 Tolcapone Desmopressin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00035 DB00325 Nitroprusside Desmopressin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00035 DB00330 Ethambutol Desmopressin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00035 DB00331 Metformin Desmopressin may decrease the excretion rate of Metformin which could result in a higher serum level.
DB00035 DB00339 Pyrazinamide Desmopressin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00035 DB00341 Cetirizine Desmopressin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
DB00035 DB00349 Clobazam Desmopressin may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00035 DB00351 Megestrol acetate Desmopressin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00035 DB00355 Aztreonam Desmopressin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00035 DB00356 Chlorzoxazone Desmopressin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
DB00035 DB00359 Sulfadiazine Desmopressin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
DB00035 DB00363 Clozapine Desmopressin may decrease the excretion rate of Clozapine which could result in a higher serum level.
DB00035 DB00364 Sucralfate Desmopressin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00035 DB00372 Thiethylperazine Desmopressin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00035 DB00373 Timolol Desmopressin may decrease the excretion rate of Timolol which could result in a higher serum level.
DB00035 DB00377 Palonosetron Desmopressin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00035 DB00380 Dexrazoxane Desmopressin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
DB00035 DB00398 Sorafenib Desmopressin may decrease the excretion rate of Sorafenib which could result in a higher serum level.
DB00035 DB00401 Nisoldipine Desmopressin may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
DB00035 DB00402 Eszopiclone Desmopressin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
DB00035 DB00404 Alprazolam Desmopressin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
DB00035 DB00412 Rosiglitazone Desmopressin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
DB00035 DB00413 Pramipexole Desmopressin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00035 DB00415 Ampicillin Desmopressin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00035 DB00418 Secobarbital Desmopressin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
DB00035 DB00422 Methylphenidate Desmopressin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00035 DB00432 Trifluridine Desmopressin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
DB00035 DB00435 Nitric Oxide Desmopressin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00035 DB00437 Allopurinol Desmopressin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
DB00035 DB00440 Trimethoprim Desmopressin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00035 DB00441 Gemcitabine Desmopressin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
DB00035 DB00480 Lenalidomide Desmopressin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
DB00035 DB00490 Buspirone Desmopressin may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00035 DB00492 Fosinopril Desmopressin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00035 DB00499 Flutamide Desmopressin may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00035 DB00501 Cimetidine Desmopressin may decrease the excretion rate of Cimetidine which could result in a higher serum level.
DB00035 DB00502 Haloperidol Desmopressin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
DB00035 DB00535 Cefdinir Desmopressin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00035 DB00537 Ciprofloxacin Desmopressin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
DB00035 DB00548 Azelaic acid Desmopressin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00035 DB00553 Methoxsalen Desmopressin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00035 DB00558 Zanamivir Desmopressin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00035 DB00569 Fondaparinux Desmopressin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00035 DB00571 Propranolol Desmopressin may decrease the excretion rate of Propranolol which could result in a higher serum level.
DB00035 DB00583 Levocarnitine Desmopressin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00035 DB00591 Fluocinolone acetonide Desmopressin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
DB00035 DB00597 Gadoteridol Desmopressin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00035 DB00598 Labetalol Desmopressin may decrease the excretion rate of Labetalol which could result in a higher serum level.
DB00035 DB00603 Medroxyprogesterone acetate Desmopressin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00035 DB00608 Chloroquine Desmopressin may decrease the excretion rate of Chloroquine which could result in a higher serum level.
DB00035 DB00612 Bisoprolol Desmopressin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00035 DB00624 Testosterone Desmopressin may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00035 DB00628 Clorazepic acid Desmopressin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00035 DB00631 Clofarabine Desmopressin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
DB00035 DB00633 Dexmedetomidine Desmopressin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00035 DB00635 Prednisone Desmopressin may decrease the excretion rate of Prednisone which could result in a higher serum level.
DB00035 DB00651 Dyphylline Desmopressin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00035 DB00657 Mecamylamine Desmopressin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
DB00035 DB00660 Metaxalone Desmopressin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00035 DB00661 Verapamil Desmopressin may decrease the excretion rate of Verapamil which could result in a higher serum level.
DB00035 DB00665 Nilutamide Desmopressin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00035 DB00669 Sumatriptan Desmopressin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00035 DB00672 Chlorpropamide Desmopressin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
DB00035 DB00683 Midazolam Desmopressin may decrease the excretion rate of Midazolam which could result in a higher serum level.
DB00035 DB00688 Mycophenolate mofetil Desmopressin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
DB00035 DB00690 Flurazepam Desmopressin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00035 DB00692 Phentolamine Desmopressin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00035 DB00698 Nitrofurantoin Desmopressin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00035 DB00706 Tamsulosin Desmopressin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00035 DB00709 Lamivudine Desmopressin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00035 DB00713 Oxacillin Desmopressin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00035 DB00716 Nedocromil Desmopressin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00035 DB00722 Lisinopril Desmopressin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00035 DB00730 Thiabendazole Desmopressin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00035 DB00731 Nateglinide Desmopressin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
DB00035 DB00733 Pralidoxime Desmopressin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00035 DB00743 Gadobenic acid Desmopressin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00035 DB00759 Tetracycline Desmopressin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00035 DB00760 Meropenem Desmopressin may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00035 DB00761 Potassium chloride Desmopressin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00035 DB00763 Methimazole Desmopressin may decrease the excretion rate of Methimazole which could result in a higher serum level.
DB00035 DB00775 Tirofiban Desmopressin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00035 DB00780 Phenelzine Desmopressin may decrease the excretion rate of Phenelzine which could result in a higher serum level.
DB00035 DB00782 Propantheline Desmopressin may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00035 DB00783 Estradiol Desmopressin may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00035 DB00789 Gadopentetic acid Desmopressin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00035 DB00790 Perindopril Desmopressin may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB00035 DB00800 Fenoldopam Desmopressin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00035 DB00804 Dicyclomine Desmopressin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00035 DB00806 Pentoxifylline Desmopressin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00035 DB00811 Ribavirin Desmopressin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00035 DB00820 Tadalafil Desmopressin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00035 DB00828 Fosfomycin Desmopressin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00035 DB00829 Diazepam Desmopressin may decrease the excretion rate of Diazepam which could result in a higher serum level.
DB00035 DB00839 Tolazamide Desmopressin may decrease the excretion rate of Tolazamide which could result in a higher serum level.
DB00035 DB00841 Dobutamine Desmopressin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00035 DB00842 Oxazepam Desmopressin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00035 DB00851 Dacarbazine Desmopressin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
DB00035 DB00853 Temozolomide Desmopressin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
DB00035 DB00863 Ranitidine Desmopressin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
DB00035 DB00871 Terbutaline Desmopressin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
DB00035 DB00894 Testolactone Desmopressin may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00035 DB00897 Triazolam Desmopressin may decrease the excretion rate of Triazolam which could result in a higher serum level.
DB00035 DB00900 Didanosine Desmopressin may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00035 DB00911 Tinidazole Desmopressin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00035 DB00915 Amantadine Desmopressin may decrease the excretion rate of Amantadine which could result in a higher serum level.
DB00035 DB00918 Almotriptan Desmopressin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00035 DB00928 Azacitidine Desmopressin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
DB00035 DB00934 Maprotiline Desmopressin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
DB00035 DB00951 Isoniazid Desmopressin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
DB00035 DB00953 Rizatriptan Desmopressin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00035 DB00960 Pindolol Desmopressin may decrease the excretion rate of Pindolol which could result in a higher serum level.
DB00035 DB00961 Mepivacaine Desmopressin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00035 DB00962 Zaleplon Desmopressin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00035 DB00968 Methyldopa Desmopressin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
DB00035 DB00980 Ramelteon Desmopressin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00035 DB00988 Dopamine Desmopressin may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00035 DB00993 Azathioprine Desmopressin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
DB00035 DB00995 Auranofin Desmopressin may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB00035 DB01001 Salbutamol Desmopressin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB00035 DB01002 Levobupivacaine Desmopressin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB00035 DB01004 Ganciclovir Desmopressin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB00035 DB01010 Edrophonium Desmopressin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB00035 DB01011 Metyrapone Desmopressin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB00035 DB01015 Sulfamethoxazole Desmopressin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.
DB00035 DB01018 Guanfacine Desmopressin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
DB00035 DB01020 Isosorbide mononitrate Desmopressin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB00035 DB01022 Phylloquinone Desmopressin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB00035 DB01024 Mycophenolic acid Desmopressin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
DB00035 DB01030 Topotecan Desmopressin may decrease the excretion rate of Topotecan which could result in a higher serum level.
DB00035 DB01032 Probenecid Desmopressin may decrease the excretion rate of Probenecid which could result in a higher serum level.
DB00035 DB01036 Tolterodine Desmopressin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
DB00035 DB01039 Fenofibrate Desmopressin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
DB00035 DB01043 Memantine Desmopressin may decrease the excretion rate of Memantine which could result in a higher serum level.
DB00035 DB01046 Lubiprostone Desmopressin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB00035 DB01048 Abacavir Desmopressin may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB00035 DB01060 Amoxicillin Desmopressin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB00035 DB01067 Glipizide Desmopressin may decrease the excretion rate of Glipizide which could result in a higher serum level.
DB00035 DB01068 Clonazepam Desmopressin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB00035 DB01069 Promethazine Desmopressin may decrease the excretion rate of Promethazine which could result in a higher serum level.
DB00035 DB01093 Dimethyl sulfoxide Desmopressin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB00035 DB01099 Flucytosine Desmopressin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
DB00035 DB01101 Capecitabine Desmopressin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
DB00035 DB01115 Nifedipine Desmopressin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
DB00035 DB01124 Tolbutamide Desmopressin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
DB00035 DB01129 Rabeprazole Desmopressin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
DB00035 DB01133 Tiludronic acid Desmopressin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB00035 DB01135 Doxacurium Desmopressin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB00035 DB01137 Levofloxacin Desmopressin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB00035 DB01148 Flavoxate Desmopressin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB00035 DB01156 Bupropion Desmopressin may decrease the excretion rate of Bupropion which could result in a higher serum level.
DB00035 DB01157 Trimetrexate Desmopressin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB00035 DB01166 Cilostazol Desmopressin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
DB00035 DB01169 Arsenic trioxide Desmopressin may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.
DB00035 DB01170 Guanethidine Desmopressin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB00035 DB01181 Ifosfamide Desmopressin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
DB00035 DB01203 Nadolol Desmopressin may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB00035 DB01205 Flumazenil Desmopressin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB00035 DB01213 Fomepizole Desmopressin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB00035 DB01215 Estazolam Desmopressin may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB00035 DB01221 Ketamine Desmopressin may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB00035 DB01222 Budesonide Desmopressin may decrease the excretion rate of Budesonide which could result in a higher serum level.
DB00035 DB01224 Quetiapine Desmopressin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
DB00035 DB01233 Metoclopramide Desmopressin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
DB00035 DB01240 Epoprostenol Desmopressin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB00035 DB01241 Gemfibrozil Desmopressin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB00035 DB01249 Iodixanol Desmopressin may decrease the excretion rate of Iodixanol which could result in a higher serum level.
DB00035 DB01261 Sitagliptin Desmopressin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
DB00035 DB01267 Paliperidone Desmopressin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
DB00035 DB01273 Varenicline Desmopressin may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB00035 DB01274 Arformoterol Desmopressin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB00035 DB01275 Hydralazine Desmopressin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
DB00035 DB01359 Penbutolol Desmopressin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
DB00035 DB01367 Rasagiline Desmopressin may decrease the excretion rate of Rasagiline which could result in a higher serum level.
DB00035 DB01394 Colchicine Desmopressin may decrease the excretion rate of Colchicine which could result in a higher serum level.
DB00035 DB01409 Tiotropium Desmopressin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB00035 DB01420 Testosterone propionate Desmopressin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB00035 DB01427 Amrinone Desmopressin may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB00035 DB01428 Oxybenzone Desmopressin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB00035 DB01431 Allylestrenol Desmopressin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
DB00035 DB01550 Fenproporex Desmopressin may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB00035 DB01558 Bromazepam Desmopressin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB00035 DB01563 Chloral hydrate Desmopressin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB00035 DB01577 Metamfetamine Desmopressin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
DB00035 DB01587 Ketazolam Desmopressin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB00035 DB01610 Valganciclovir Desmopressin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB00035 DB01638 Sorbitol Desmopressin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB00035 DB01656 Roflumilast Desmopressin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
DB00035 DB01685 Topiroxostat Desmopressin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB00035 DB04574 Estrone sulfate Desmopressin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB00035 DB04871 Lorcaserin Desmopressin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB00035 DB04895 Pegaptanib Desmopressin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB00035 DB04920 Clevidipine Desmopressin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB00035 DB04948 Lofexidine Desmopressin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
DB00035 DB04953 Ezogabine Desmopressin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
DB00035 DB05018 Migalastat Desmopressin may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB00035 DB05541 Brivaracetam Desmopressin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB00035 DB05676 Apremilast Desmopressin may decrease the excretion rate of Apremilast which could result in a higher serum level.
DB00035 DB06154 Pentaerythritol tetranitrate Desmopressin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB00035 DB06186 Ipilimumab Desmopressin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB00035 DB06196 Icatibant Desmopressin may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB00035 DB06203 Alogliptin Desmopressin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
DB00035 DB06209 Prasugrel Desmopressin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB00035 DB06211 Doripenem Desmopressin may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB00035 DB06228 Rivaroxaban Desmopressin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB00035 DB06230 Nalmefene Desmopressin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB00035 DB06262 Droxidopa Desmopressin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB00035 DB06282 Levocetirizine Desmopressin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
DB00035 DB06335 Saxagliptin Desmopressin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
DB00035 DB06402 Telavancin Desmopressin may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB00035 DB06480 Prucalopride Desmopressin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
DB00035 DB06623 Flupirtine Desmopressin may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB00035 DB06637 Dalfampridine Desmopressin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB00035 DB06695 Dabigatran etexilate Desmopressin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB00035 DB06702 Fesoterodine Desmopressin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB00035 DB06705 Gadofosveset trisodium Desmopressin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB00035 DB06710 Methyltestosterone Desmopressin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB00035 DB06767 Ammonium chloride Desmopressin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB00035 DB06782 Dimercaprol Desmopressin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB00035 DB06796 Mangafodipir Desmopressin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB00035 DB06800 Methylnaltrexone Desmopressin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB00035 DB06809 Plerixafor Desmopressin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB00035 DB06813 Pralatrexate Desmopressin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
DB00035 DB06823 Tiopronin Desmopressin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB00035 DB06824 Triethylenetetramine Desmopressin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB00035 DB08824 Ioflupane I-123 Desmopressin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB00035 DB08826 Deferiprone Desmopressin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB00035 DB08840 N-methylnicotinamide Desmopressin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB00035 DB08872 Gabapentin enacarbil Desmopressin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB00035 DB08877 Ruxolitinib Desmopressin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
DB00035 DB08893 Mirabegron Desmopressin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
DB00035 DB08894 Peginesatide Desmopressin may decrease the excretion rate of Peginesatide which could result in a higher serum level.
DB00035 DB08897 Aclidinium Desmopressin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB00035 DB08899 Enzalutamide Desmopressin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB00035 DB08900 Teduglutide Desmopressin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB00035 DB08904 Certolizumab pegol Desmopressin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
DB00035 DB08905 Formestane Desmopressin may decrease the excretion rate of Formestane which could result in a higher serum level.
DB00035 DB08909 Glycerol phenylbutyrate Desmopressin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB00035 DB08910 Pomalidomide Desmopressin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
DB00035 DB08911 Trametinib Desmopressin may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB00035 DB08932 Macitentan Desmopressin may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB00035 DB08934 Sofosbuvir Desmopressin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB00035 DB08964 Gemeprost Desmopressin may decrease the excretion rate of Gemeprost which could result in a higher serum level.
DB00035 DB09027 Ledipasvir Desmopressin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB00035 DB09050 Ceftolozane Desmopressin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB00035 DB09066 Corifollitropin alfa Desmopressin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB00035 DB09068 Vortioxetine Desmopressin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB00035 DB09071 Tasimelteon Desmopressin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
DB00035 DB09075 Edoxaban Desmopressin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB00035 DB09081 Idebenone Desmopressin may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB00035 DB09082 Vilanterol Desmopressin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
DB00035 DB09089 Trimebutine Desmopressin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
DB00035 DB09091 Tixocortol Desmopressin may decrease the excretion rate of Tixocortol which could result in a higher serum level.
DB00035 DB09103 Ancestim Desmopressin may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB00035 DB09104 Magnesium hydroxide Desmopressin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB00035 DB09106 Hydroxyethyl Starch Desmopressin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB00035 DB09111 Pentastarch Desmopressin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB00035 DB09118 Stiripentol Desmopressin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB00035 DB09121 Aurothioglucose Desmopressin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB00035 DB09123 Dienogest Desmopressin may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB00035 DB09129 Chromic chloride Desmopressin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB00035 DB09132 Gadoteric acid Desmopressin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB00035 DB09133 Iothalamic acid Desmopressin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB00035 DB09134 Ioversol Desmopressin may decrease the excretion rate of Ioversol which could result in a higher serum level.
DB00035 DB09135 Ioxilan Desmopressin may decrease the excretion rate of Ioxilan which could result in a higher serum level.
DB00035 DB09136 Isosulfan blue Desmopressin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB00035 DB09137 Technetium Tc-99m mebrofenin Desmopressin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB00035 DB09139 Technetium Tc-99m oxidronate Desmopressin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB00035 DB09148 Florbetaben (18F) Desmopressin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB00035 DB09149 Florbetapir (18F) Desmopressin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB00035 DB09156 Iopromide Desmopressin may decrease the excretion rate of Iopromide which could result in a higher serum level.
DB00035 DB09163 Technetium Tc-99m exametazime Desmopressin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB00035 DB09165 Technetium Tc-99m pyrophosphate Desmopressin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB00035 DB09185 Viloxazine Desmopressin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB00035 DB09194 Etoperidone Desmopressin may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB00035 DB09195 Lorpiprazole Desmopressin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB00035 DB09204 Arotinolol Desmopressin may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB00035 DB09205 Moxisylyte Desmopressin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB00035 DB09209 Pholcodine Desmopressin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB00035 DB09210 Piracetam Desmopressin may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB00035 DB09219 Bisoxatin Desmopressin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB00035 DB09220 Nicorandil Desmopressin may decrease the excretion rate of Nicorandil which could result in a higher serum level.
DB00035 DB09223 Blonanserin Desmopressin may decrease the excretion rate of Blonanserin which could result in a higher serum level.
DB00035 DB09224 Melperone Desmopressin may decrease the excretion rate of Melperone which could result in a higher serum level.
DB00035 DB09241 Methylene blue Desmopressin may decrease the excretion rate of Methylene blue which could result in a higher serum level.
DB00035 DB09244 Pirlindole Desmopressin may decrease the excretion rate of Pirlindole which could result in a higher serum level.
DB00035 DB09245 Toloxatone Desmopressin may decrease the excretion rate of Toloxatone which could result in a higher serum level.
DB00035 DB09255 Dextran Desmopressin may decrease the excretion rate of Dextran which could result in a higher serum level.
DB00035 DB09256 Tegafur Desmopressin may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB00035 DB09257 Gimeracil Desmopressin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB00035 DB09262 Imidafenacin Desmopressin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB00035 DB09264 Idarucizumab Desmopressin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB00035 DB09265 Lixisenatide Desmopressin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
DB00035 DB09268 Picosulfuric acid Desmopressin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB00035 DB09276 Sodium aurothiomalate Desmopressin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB00035 DB09277 Choline C 11 Desmopressin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB00035 DB09281 Magnesium trisilicate Desmopressin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB00035 DB09292 Sacubitril Desmopressin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB00035 DB09301 Chondroitin sulfate Desmopressin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB00035 DB09317 Synthetic Conjugated Estrogens, A Desmopressin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB00035 DB09318 Synthetic Conjugated Estrogens, B Desmopressin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB00035 DB09320 Procaine benzylpenicillin Desmopressin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB00035 DB09324 Sulbactam Desmopressin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB00035 DB09325 Sodium fluoride Desmopressin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB00035 DB09329 Antihemophilic Factor (Recombinant), PEGylated Desmopressin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB00035 DB09344 Invert sugar Desmopressin may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB00035 DB09357 Dexpanthenol Desmopressin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB00035 DB09394 Phosphoric acid Desmopressin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB00035 DB09395 Sodium acetate Desmopressin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB00035 DB09407 Magnesium chloride Desmopressin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB00035 DB09418 Potassium perchlorate Desmopressin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
DB00035 DB09472 Sodium sulfate Desmopressin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB00035 DB09477 Enalaprilat Desmopressin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB00035 DB09481 Magnesium carbonate Desmopressin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB00035 DB09488 Acrivastine Desmopressin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB00035 DB09496 Octinoxate Desmopressin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB00035 DB09502 Fludeoxyglucose (18F) Desmopressin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB00035 DB09546 Iobenguane sulfate I-123 Desmopressin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB00035 DB09570 Ixazomib Desmopressin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
DB00035 DB11077 Polyethylene glycol 400 Desmopressin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB00035 DB11090 Potassium nitrate Desmopressin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB00035 DB11098 Potassium bicarbonate Desmopressin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB00035 DB11102 N-acetyltyrosine Desmopressin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB00035 DB11114 Eucalyptus oil Desmopressin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB00035 DB11127 Selenious acid Desmopressin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB00035 DB11135 Selenium Desmopressin may decrease the excretion rate of Selenium which could result in a higher serum level.
DB00035 DB11136 Chromium Desmopressin may decrease the excretion rate of Chromium which could result in a higher serum level.
DB00035 DB11145 Oxyquinoline Desmopressin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB00035 DB11156 Pyrantel Desmopressin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB00035 DB11164 Bicisate Desmopressin may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB00035 DB11251 Tocopherol Desmopressin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB00035 DB11278 DL-Methylephedrine Desmopressin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB00035 DB11328 Tetradecyl hydrogen sulfate (ester) Desmopressin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB00035 DB11338 Clove oil Desmopressin may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB00035 DB11358 Evening primrose oil Desmopressin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB00035 DB11364 Pidotimod Desmopressin may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB00035 DB11560 Lesinurad Desmopressin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB00035 DB11577 Indigotindisulfonic acid Desmopressin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB00035 DB11587 Etafedrine Desmopressin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB00035 DB11598 Antithrombin III human Desmopressin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB00035 DB11642 Pitolisant Desmopressin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
DB00035 DB11691 Naldemedine Desmopressin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB00035 DB11699 Tropisetron Desmopressin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB00035 DB11817 Baricitinib Desmopressin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
DB00035 DB11901 Apalutamide Desmopressin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB00035 DB11915 Valbenazine Desmopressin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB00035 DB11943 Delafloxacin Desmopressin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
DB00035 DB11989 Benznidazole Desmopressin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB00035 DB12007 Isoflavone Desmopressin may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB00035 DB12107 Vaborbactam Desmopressin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB00035 DB12161 Deutetrabenazine Desmopressin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
DB00035 DB12278 Propiverine Desmopressin may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB00035 DB12783 Benserazide Desmopressin may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB00035 DB13025 Tiapride Desmopressin may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB00035 DB13139 Levosalbutamol Desmopressin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB00035 DB13156 Inosine pranobex Desmopressin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB00035 DB13178 Inositol Desmopressin may decrease the excretion rate of Inositol which could result in a higher serum level.
DB00035 DB13185 Oxabolone cipionate Desmopressin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB00035 DB13191 Phosphocreatine Desmopressin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB00035 DB13269 Dichlorobenzyl alcohol Desmopressin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB00035 DB13293 Ipecac Desmopressin may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB00035 DB13595 Almasilate Desmopressin may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB00035 DB13873 Fenofibric acid Desmopressin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB00035 DB13884 Albutrepenonacog alfa Desmopressin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB00035 DB13909 Bismuth subgallate Desmopressin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB00035 DB13943 Testosterone cypionate Desmopressin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB00035 DB13944 Testosterone enanthate Desmopressin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB00035 DB13952 Estradiol acetate Desmopressin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB00035 DB13954 Estradiol cypionate Desmopressin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB00035 DB13955 Estradiol dienanthate Desmopressin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB00035 DB13956 Estradiol valerate Desmopressin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB00035 DB13967 Patent Blue Desmopressin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB00035 DB14006 Choline salicylate Desmopressin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB00035 DB14007 Pentetic acid Desmopressin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB00035 DB14498 Potassium acetate Desmopressin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB00035 DB14499 Potassium sulfate Desmopressin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB00035 DB14526 Chromic citrate Desmopressin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB00035 DB14527 Chromic nitrate Desmopressin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB00035 DB14528 Chromium gluconate Desmopressin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB00035 DB14529 Chromium nicotinate Desmopressin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB00035 DB14530 Chromous sulfate Desmopressin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB00035 DB06815 Pyrithione Desmopressin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB00035 DB11121 Chloroxylenol Desmopressin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB00035 DB01183 Naloxone Desmopressin may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB00035 DB11085 Resorcinol Desmopressin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB00035 DB15593 Golodirsen Desmopressin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00035 DB00879 Emtricitabine Desmopressin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB00035 DB00452 Framycetin Framycetin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00479 Amikacin Amikacin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00684 Tobramycin Tobramycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00798 Gentamicin Gentamicin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00955 Netilmicin Netilmicin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00994 Neomycin Neomycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01082 Streptomycin Streptomycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01172 Kanamycin Kanamycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB01421 Paromomycin Paromomycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB03615 Ribostamycin Ribostamycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB04263 Geneticin Geneticin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB04626 Apramycin Apramycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB04729 Gentamicin C1a Gentamicin C1a may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB04808 Neamine Neamine may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB06696 Arbekacin Arbekacin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB08437 Puromycin Puromycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB11512 Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB11520 Hygromycin B Hygromycin B may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB12604 Sisomicin Sisomicin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13270 Dibekacin Dibekacin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13274 Micronomicin Micronomicin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13540 Isepamicin Isepamicin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB13673 Bekanamycin Bekanamycin may decrease the excretion rate of Desmopressin which could result in a higher serum level.
DB00035 DB00552 Pentostatin Desmopressin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
DB00035 DB13145 Nedaplatin Desmopressin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00035 DB00314 Capreomycin Desmopressin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00035 DB00390 Digoxin Desmopressin may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00035 DB00512 Vancomycin Desmopressin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00035 DB00515 Cisplatin Desmopressin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
DB00035 DB00642 Pemetrexed Desmopressin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
DB00035 DB00682 Warfarin Desmopressin may decrease the excretion rate of Warfarin which could result in a higher serum level.
DB00035 DB00908 Quinidine Desmopressin may decrease the excretion rate of Quinidine which could result in a higher serum level.
DB00035 DB00982 Isotretinoin Desmopressin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB00035 DB01035 Procainamide Desmopressin may decrease the excretion rate of Procainamide which could result in a higher serum level.
DB00035 DB12615 Plazomicin Desmopressin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00035 DB13316 Ibopamine Desmopressin may increase the excretion rate of Ibopamine which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00524 Metolazone Desmopressin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00695 Furosemide Desmopressin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00808 Indapamide Desmopressin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00887 Bumetanide Desmopressin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00909 Zonisamide Desmopressin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB08907 Canagliflozin Desmopressin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB09338 Mersalyl Desmopressin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00214 Torasemide Torasemide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00232 Methyclothiazide Methyclothiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00310 Chlorthalidone Chlorthalidone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00311 Ethoxzolamide Ethoxzolamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00421 Spironolactone Spironolactone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00436 Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00562 Benzthiazide Benzthiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00594 Amiloride Amiloride may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00606 Cyclothiazide Cyclothiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00700 Eplerenone Eplerenone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00703 Methazolamide Methazolamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00774 Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00819 Acetazolamide Acetazolamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00872 Conivaptan Conivaptan may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB00880 Chlorothiazide Chlorothiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01021 Trichlormethiazide Trichlormethiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01119 Diazoxide Diazoxide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01144 Diclofenamide Diclofenamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01324 Polythiazide Polythiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01325 Quinethazone Quinethazone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01395 Drospirenone Drospirenone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB01412 Theobromine Theobromine may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB02925 Piretanide Piretanide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB04831 Tienilic acid Tienilic acid may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB05034 Ularitide Ularitide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB06292 Dapagliflozin Dapagliflozin may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB06370 Indisulam Indisulam may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB08961 Azosemide Azosemide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB09015 Canrenoic acid Canrenoic acid may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB09125 Potassium citrate Potassium citrate may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB09235 Efonidipine Efonidipine may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB09401 Isosorbide Isosorbide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB11827 Ertugliflozin Ertugliflozin may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB12221 Canrenone Canrenone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB12670 Rolofylline Rolofylline may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB12704 Spiradoline Spiradoline may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB12766 Cicletanine Cicletanine may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13284 Meticrane Meticrane may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13405 Mefruside Mefruside may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13430 Mebutizide Mebutizide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13532 Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13617 Clorexolone Clorexolone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13663 Clofenamide Clofenamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13708 Fenquizone Fenquizone may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13792 Clopamide Clopamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13801 Muzolimine Muzolimine may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13803 Xipamide Xipamide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB13989 Epitizide Epitizide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB14018 Bromotheophylline Bromotheophylline may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB14500 Potassium Potassium may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.
DB00035 DB11823 Esketamine The risk or severity of hypertension can be increased when Esketamine is combined with Desmopressin.
DB00035 DB14754 Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Desmopressin.
DB00035 DB13946 Testosterone undecanoate Testosterone undecanoate may increase the hypertensive activities of Desmopressin.
DB00036 DB09310 Catridecacog Catridecacog may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB00513 Aminocaproic acid The risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor VIIa Recombinant Human.
DB00036 DB00058 Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB00170 Menadione Menadione may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB00302 Tranexamic acid Tranexamic acid may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB06692 Aprotinin Aprotinin may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB11091 Hydrogen peroxide Hydrogen peroxide may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB13244 Aminomethylbenzoic acid Aminomethylbenzoic acid may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB13729 Camostat Camostat may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
DB00036 DB12726 Monteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Monteplase.
DB00036 DB00001 Lepirudin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.
DB00036 DB00006 Bivalirudin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Bivalirudin.
DB00036 DB00009 Alteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Alteplase.
DB00036 DB00013 Urokinase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Urokinase.
DB00036 DB00015 Reteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reteplase.
DB00036 DB00029 Anistreplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Anistreplase.
DB00036 DB00031 Tenecteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tenecteplase.
DB00036 DB00054 Abciximab The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Abciximab.
DB00036 DB00055 Drotrecogin alfa The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Drotrecogin alfa.
DB00036 DB00086 Streptokinase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Streptokinase.
DB00036 DB00266 Dicoumarol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dicoumarol.
DB00036 DB00278 Argatroban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Argatroban.
DB00036 DB00407 Ardeparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ardeparin.
DB00036 DB00498 Phenindione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Phenindione.
DB00036 DB00569 Fondaparinux The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Fondaparinux.
DB00036 DB00682 Warfarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Warfarin.
DB00036 DB00686 Pentosan polysulfate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Pentosan polysulfate.
DB00036 DB00945 Acetylsalicylic acid The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Acetylsalicylic acid.
DB00036 DB00946 Phenprocoumon The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Phenprocoumon.
DB00036 DB00975 Dipyridamole The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dipyridamole.
DB00036 DB01088 Iloprost The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Iloprost.
DB00036 DB01109 Heparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Heparin.
DB00036 DB01225 Enoxaparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Enoxaparin.
DB00036 DB01240 Epoprostenol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Epoprostenol.
DB00036 DB01418 Acenocoumarol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Acenocoumarol.
DB00036 DB03410 4-hydroxycoumarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with 4-hydroxycoumarin.
DB00036 DB04665 Coumarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Coumarin.
DB00036 DB04898 Ximelagatran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ximelagatran.
DB00036 DB04925 Desmoteplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Desmoteplase.
DB00036 DB04932 Defibrotide The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Defibrotide.
DB00036 DB05099 Ancrod The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ancrod.
DB00036 DB05229 Beraprost The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Beraprost.
DB00036 DB05254 Fibrinolysin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Fibrinolysin.
DB00036 DB06209 Prasugrel The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Prasugrel.
DB00036 DB06228 Rivaroxaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Rivaroxaban.
DB00036 DB06271 Sulodexide The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Sulodexide.
DB00036 DB06406 Idraparinux The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Idraparinux.
DB00036 DB06441 Cangrelor The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Cangrelor.
DB00036 DB06543 Astaxanthin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Astaxanthin.
DB00036 DB06605 Apixaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Apixaban.
DB00036 DB06635 Otamixaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Otamixaban.
DB00036 DB06679 Amediplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Amediplase.
DB00036 DB06695 Dabigatran etexilate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dabigatran etexilate.
DB00036 DB06754 Danaparoid The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Danaparoid.
DB00036 DB06779 Dalteparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dalteparin.
DB00036 DB06822 Tinzaparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tinzaparin.
DB00036 DB07767 Ferulic acid The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ferulic acid.
DB00036 DB08496 (R)-warfarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with (R)-warfarin.
DB00036 DB08794 Ethyl biscoumacetate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ethyl biscoumacetate.
DB00036 DB08813 Nadroparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Nadroparin.
DB00036 DB08814 Triflusal The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Triflusal.
DB00036 DB08816 Ticagrelor The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ticagrelor.
DB00036 DB08994 Ditazole The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ditazole.
DB00036 DB09030 Vorapaxar The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Vorapaxar.
DB00036 DB09075 Edoxaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Edoxaban.
DB00036 DB09125 Potassium citrate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Potassium citrate.
DB00036 DB09154 Sodium citrate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Sodium citrate.
DB00036 DB09255 Dextran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dextran.
DB00036 DB09258 Bemiparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Bemiparin.
DB00036 DB09259 Reviparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Reviparin.
DB00036 DB09260 Parnaparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Parnaparin.
DB00036 DB09261 Certoparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Certoparin.
DB00036 DB11095 Desirudin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Desirudin.
DB00036 DB11154 Zinc citrate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Zinc citrate.
DB00036 DB11166 Antithrombin Alfa The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin Alfa.
DB00036 DB11312 Protein C The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Protein C.
DB00036 DB11598 Antithrombin III human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin III human.
DB00036 DB11984 Letaxaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Letaxaban.
DB00036 DB12289 Darexaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Darexaban.
DB00036 DB12364 Betrixaban The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Betrixaban.
DB00036 DB12598 Nafamostat The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Nafamostat.
DB00036 DB12831 Gabexate The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Gabexate.
DB00036 DB13136 Fluindione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Fluindione.
DB00036 DB13149 Protein S human The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Protein S human.
DB00036 DB13199 Brinase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Brinase.
DB00036 DB13275 Clorindione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Clorindione.
DB00036 DB13347 Diphenadione The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Diphenadione.
DB00036 DB13451 Tioclomarol The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tioclomarol.
DB00036 DB13616 Melagatran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Melagatran.
DB00036 DB13646 Saruplase The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Saruplase.
DB00036 DB14055 (S)-Warfarin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with (S)-Warfarin.
DB00036 DB14094 Tocopherylquinone The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Tocopherylquinone.
DB00036 DB14598 Edetate calcium disodium anhydrous The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Edetate calcium disodium anhydrous.
DB00036 DB14726 Dabigatran The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dabigatran.
DB00036 DB06294 Semuloparin The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Semuloparin.
DB00039 DB00407 Ardeparin The serum concentration of Palifermin can be increased when it is combined with Ardeparin.
DB00039 DB01109 Heparin The serum concentration of Palifermin can be increased when it is combined with Heparin.
DB00039 DB01225 Enoxaparin The serum concentration of Palifermin can be increased when it is combined with Enoxaparin.
DB00039 DB06271 Sulodexide The serum concentration of Palifermin can be increased when it is combined with Sulodexide.
DB00039 DB06294 Semuloparin The serum concentration of Palifermin can be increased when it is combined with Semuloparin.
DB00039 DB06754 Danaparoid The serum concentration of Palifermin can be increased when it is combined with Danaparoid.
DB00039 DB06779 Dalteparin The serum concentration of Palifermin can be increased when it is combined with Dalteparin.
DB00039 DB06822 Tinzaparin The serum concentration of Palifermin can be increased when it is combined with Tinzaparin.
DB00039 DB08813 Nadroparin The serum concentration of Palifermin can be increased when it is combined with Nadroparin.
DB00039 DB09258 Bemiparin The serum concentration of Palifermin can be increased when it is combined with Bemiparin.
DB00039 DB09259 Reviparin The serum concentration of Palifermin can be increased when it is combined with Reviparin.
DB00039 DB09260 Parnaparin The serum concentration of Palifermin can be increased when it is combined with Parnaparin.
DB00039 DB09261 Certoparin The serum concentration of Palifermin can be increased when it is combined with Certoparin.
DB00039 DB00008 Peginterferon alfa-2a The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2a.
DB00039 DB00011 Interferon alfa-n1 The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-n1.
DB00039 DB00018 Interferon alfa-n3 The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-n3.
DB00039 DB00022 Peginterferon alfa-2b The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon alfa-2b.
DB00039 DB00033 Interferon gamma-1b The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon gamma-1b.
DB00039 DB00034 Interferon alfa-2a, Recombinant The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2a, Recombinant.
DB00039 DB00041 Aldesleukin The therapeutic efficacy of Palifermin can be decreased when used in combination with Aldesleukin.
DB00039 DB00056 Gemtuzumab ozogamicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemtuzumab ozogamicin.
DB00039 DB00068 Interferon beta-1b The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon beta-1b.
DB00039 DB00069 Interferon alfacon-1 The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfacon-1.
DB00039 DB00073 Rituximab The therapeutic efficacy of Palifermin can be decreased when used in combination with Rituximab.
DB00039 DB00078 Ibritumomab tiuxetan The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibritumomab tiuxetan.
DB00039 DB00081 Tositumomab The therapeutic efficacy of Palifermin can be decreased when used in combination with Tositumomab.
DB00039 DB00087 Alemtuzumab The therapeutic efficacy of Palifermin can be decreased when used in combination with Alemtuzumab.
DB00039 DB00105 Interferon alfa-2b The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa-2b.
DB00039 DB00120 Phenylalanine The therapeutic efficacy of Palifermin can be decreased when used in combination with Phenylalanine.
DB00039 DB00188 Bortezomib The therapeutic efficacy of Palifermin can be decreased when used in combination with Bortezomib.
DB00039 DB00242 Cladribine The therapeutic efficacy of Palifermin can be decreased when used in combination with Cladribine.
DB00039 DB00262 Carmustine The therapeutic efficacy of Palifermin can be decreased when used in combination with Carmustine.
DB00039 DB00276 Amsacrine The therapeutic efficacy of Palifermin can be decreased when used in combination with Amsacrine.
DB00039 DB00291 Chlorambucil The therapeutic efficacy of Palifermin can be decreased when used in combination with Chlorambucil.
DB00039 DB00293 Raltitrexed The therapeutic efficacy of Palifermin can be decreased when used in combination with Raltitrexed.
DB00039 DB00305 Mitomycin The therapeutic efficacy of Palifermin can be decreased when used in combination with Mitomycin.
DB00039 DB00307 Bexarotene The therapeutic efficacy of Palifermin can be decreased when used in combination with Bexarotene.
DB00039 DB00309 Vindesine The therapeutic efficacy of Palifermin can be decreased when used in combination with Vindesine.
DB00039 DB00322 Floxuridine The therapeutic efficacy of Palifermin can be decreased when used in combination with Floxuridine.
DB00039 DB00328 Indomethacin The therapeutic efficacy of Palifermin can be decreased when used in combination with Indomethacin.
DB00039 DB00352 Tioguanine The therapeutic efficacy of Palifermin can be decreased when used in combination with Tioguanine.
DB00039 DB00361 Vinorelbine The therapeutic efficacy of Palifermin can be decreased when used in combination with Vinorelbine.
DB00039 DB00380 Dexrazoxane The therapeutic efficacy of Palifermin can be decreased when used in combination with Dexrazoxane.
DB00039 DB00398 Sorafenib The therapeutic efficacy of Palifermin can be decreased when used in combination with Sorafenib.
DB00039 DB00428 Streptozocin The therapeutic efficacy of Palifermin can be decreased when used in combination with Streptozocin.
DB00039 DB00441 Gemcitabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Gemcitabine.
DB00039 DB00444 Teniposide The therapeutic efficacy of Palifermin can be decreased when used in combination with Teniposide.
DB00039 DB00445 Epirubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Epirubicin.
DB00039 DB00446 Chloramphenicol The therapeutic efficacy of Palifermin can be decreased when used in combination with Chloramphenicol.
DB00039 DB00480 Lenalidomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Lenalidomide.
DB00039 DB00488 Altretamine The therapeutic efficacy of Palifermin can be decreased when used in combination with Altretamine.
DB00039 DB00495 Zidovudine The therapeutic efficacy of Palifermin can be decreased when used in combination with Zidovudine.
DB00039 DB00515 Cisplatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Cisplatin.
DB00039 DB00526 Oxaliplatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Oxaliplatin.
DB00039 DB00531 Cyclophosphamide The therapeutic efficacy of Palifermin can be decreased when used in combination with Cyclophosphamide.
DB00039 DB00544 Fluorouracil The therapeutic efficacy of Palifermin can be decreased when used in combination with Fluorouracil.
DB00039 DB00550 Propylthiouracil The therapeutic efficacy of Palifermin can be decreased when used in combination with Propylthiouracil.
DB00039 DB00552 Pentostatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Pentostatin.
DB00039 DB00563 Methotrexate The therapeutic efficacy of Palifermin can be decreased when used in combination with Methotrexate.
DB00039 DB00564 Carbamazepine The therapeutic efficacy of Palifermin can be decreased when used in combination with Carbamazepine.
DB00039 DB00570 Vinblastine The therapeutic efficacy of Palifermin can be decreased when used in combination with Vinblastine.
DB00039 DB00601 Linezolid The therapeutic efficacy of Palifermin can be decreased when used in combination with Linezolid.
DB00039 DB00619 Imatinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Imatinib.
DB00039 DB00631 Clofarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Clofarabine.
DB00039 DB00642 Pemetrexed The therapeutic efficacy of Palifermin can be decreased when used in combination with Pemetrexed.
DB00039 DB00694 Daunorubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Daunorubicin.
DB00039 DB00762 Irinotecan The therapeutic efficacy of Palifermin can be decreased when used in combination with Irinotecan.
DB00039 DB00763 Methimazole The therapeutic efficacy of Palifermin can be decreased when used in combination with Methimazole.
DB00039 DB00773 Etoposide The therapeutic efficacy of Palifermin can be decreased when used in combination with Etoposide.
DB00039 DB00851 Dacarbazine The therapeutic efficacy of Palifermin can be decreased when used in combination with Dacarbazine.
DB00039 DB00853 Temozolomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Temozolomide.
DB00039 DB00859 Penicillamine The therapeutic efficacy of Palifermin can be decreased when used in combination with Penicillamine.
DB00039 DB00864 Tacrolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Tacrolimus.
DB00039 DB00877 Sirolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Sirolimus.
DB00039 DB00888 Mechlorethamine The therapeutic efficacy of Palifermin can be decreased when used in combination with Mechlorethamine.
DB00039 DB00928 Azacitidine The therapeutic efficacy of Palifermin can be decreased when used in combination with Azacitidine.
DB00039 DB00958 Carboplatin The therapeutic efficacy of Palifermin can be decreased when used in combination with Carboplatin.
DB00039 DB00970 Dactinomycin The therapeutic efficacy of Palifermin can be decreased when used in combination with Dactinomycin.
DB00039 DB00987 Cytarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Cytarabine.
DB00039 DB00997 Doxorubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Doxorubicin.
DB00039 DB01005 Hydroxyurea The therapeutic efficacy of Palifermin can be decreased when used in combination with Hydroxyurea.
DB00039 DB01008 Busulfan The therapeutic efficacy of Palifermin can be decreased when used in combination with Busulfan.
DB00039 DB01030 Topotecan The therapeutic efficacy of Palifermin can be decreased when used in combination with Topotecan.
DB00039 DB01033 Mercaptopurine The therapeutic efficacy of Palifermin can be decreased when used in combination with Mercaptopurine.
DB00039 DB01041 Thalidomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Thalidomide.
DB00039 DB01042 Melphalan The therapeutic efficacy of Palifermin can be decreased when used in combination with Melphalan.
DB00039 DB01073 Fludarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Fludarabine.
DB00039 DB01099 Flucytosine The therapeutic efficacy of Palifermin can be decreased when used in combination with Flucytosine.
DB00039 DB01101 Capecitabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Capecitabine.
DB00039 DB01168 Procarbazine The therapeutic efficacy of Palifermin can be decreased when used in combination with Procarbazine.
DB00039 DB01169 Arsenic trioxide The therapeutic efficacy of Palifermin can be decreased when used in combination with Arsenic trioxide.
DB00039 DB01177 Idarubicin The therapeutic efficacy of Palifermin can be decreased when used in combination with Idarubicin.
DB00039 DB01181 Ifosfamide The therapeutic efficacy of Palifermin can be decreased when used in combination with Ifosfamide.
DB00039 DB01204 Mitoxantrone The therapeutic efficacy of Palifermin can be decreased when used in combination with Mitoxantrone.
DB00039 DB01206 Lomustine The therapeutic efficacy of Palifermin can be decreased when used in combination with Lomustine.
DB00039 DB01229 Paclitaxel The therapeutic efficacy of Palifermin can be decreased when used in combination with Paclitaxel.
DB00039 DB01248 Docetaxel The therapeutic efficacy of Palifermin can be decreased when used in combination with Docetaxel.
DB00039 DB01254 Dasatinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Dasatinib.
DB00039 DB01262 Decitabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Decitabine.
DB00039 DB01280 Nelarabine The therapeutic efficacy of Palifermin can be decreased when used in combination with Nelarabine.
DB00039 DB01590 Everolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Everolimus.
DB00039 DB02546 Vorinostat The therapeutic efficacy of Palifermin can be decreased when used in combination with Vorinostat.
DB00039 DB04572 Thiotepa The therapeutic efficacy of Palifermin can be decreased when used in combination with Thiotepa.
DB00039 DB04845 Ixabepilone The therapeutic efficacy of Palifermin can be decreased when used in combination with Ixabepilone.
DB00039 DB04868 Nilotinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Nilotinib.
DB00039 DB05015 Belinostat The therapeutic efficacy of Palifermin can be decreased when used in combination with Belinostat.
DB00039 DB05109 Trabectedin The therapeutic efficacy of Palifermin can be decreased when used in combination with Trabectedin.
DB00039 DB05258 Interferon alfa The therapeutic efficacy of Palifermin can be decreased when used in combination with Interferon alfa.
DB00039 DB05472 omega interferon The therapeutic efficacy of Palifermin can be decreased when used in combination with omega interferon.
DB00039 DB05773 Trastuzumab emtansine The therapeutic efficacy of Palifermin can be decreased when used in combination with Trastuzumab emtansine.
DB00039 DB06287 Temsirolimus The therapeutic efficacy of Palifermin can be decreased when used in combination with Temsirolimus.
DB00039 DB06616 Bosutinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Bosutinib.
DB00039 DB06769 Bendamustine The therapeutic efficacy of Palifermin can be decreased when used in combination with Bendamustine.
DB00039 DB06772 Cabazitaxel The therapeutic efficacy of Palifermin can be decreased when used in combination with Cabazitaxel.
DB00039 DB08871 Eribulin The therapeutic efficacy of Palifermin can be decreased when used in combination with Eribulin.
DB00039 DB08877 Ruxolitinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Ruxolitinib.
DB00039 DB08889 Carfilzomib The therapeutic efficacy of Palifermin can be decreased when used in combination with Carfilzomib.
DB00039 DB08895 Tofacitinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Tofacitinib.
DB00039 DB08901 Ponatinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Ponatinib.
DB00039 DB08910 Pomalidomide The therapeutic efficacy of Palifermin can be decreased when used in combination with Pomalidomide.
DB00039 DB08935 Obinutuzumab The therapeutic efficacy of Palifermin can be decreased when used in combination with Obinutuzumab.
DB00039 DB09042 Tedizolid phosphate The therapeutic efficacy of Palifermin can be decreased when used in combination with Tedizolid phosphate.
DB00039 DB09052 Blinatumomab The therapeutic efficacy of Palifermin can be decreased when used in combination with Blinatumomab.
DB00039 DB09053 Ibrutinib The therapeutic efficacy of Palifermin can be decreased when used in combination with Ibrutinib.
DB00039 DB09073 Palbociclib The therapeutic efficacy of Palifermin can be decreased when used in combination with Palbociclib.
DB00039 DB09074 Olaparib The therapeutic efficacy of Palifermin can be decreased when used in combination with Olaparib.
DB00039 DB09077 Dinutuximab The therapeutic efficacy of Palifermin can be decreased when used in combination with Dinutuximab.
DB00039 DB09122 Peginterferon beta-1a The therapeutic efficacy of Palifermin can be decreased when used in combination with Peginterferon beta-1a.
DB00039 DB12814 Cepeginterferon alfa-2B The therapeutic efficacy of Palifermin can be decreased when used in combination with Cepeginterferon alfa-2B.
DB00040 DB00193 Tramadol Tramadol may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00209 Trospium Trospium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00219 Oxyphenonium Oxyphenonium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00245 Benzatropine Benzatropine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00246 Ziprasidone Ziprasidone may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00280 Disopyramide Disopyramide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00321 Amitriptyline Amitriptyline may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00332 Ipratropium Ipratropium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00334 Olanzapine Olanzapine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00340 Metixene Metixene may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00342 Terfenadine Terfenadine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00354 Buclizine Buclizine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00363 Clozapine Clozapine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00366 Doxylamine Doxylamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00376 Trihexyphenidyl Trihexyphenidyl may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00383 Oxyphencyclimine Oxyphencyclimine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00387 Procyclidine Procyclidine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00392 Profenamine Profenamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00420 Promazine Promazine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00424 Hyoscyamine Hyoscyamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00434 Cyproheptadine Cyproheptadine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00458 Imipramine Imipramine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00462 Methscopolamine bromide Methscopolamine bromide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00477 Chlorpromazine Chlorpromazine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00483 Gallamine triethiodide Gallamine triethiodide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00496 Darifenacin Darifenacin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00505 Tridihexethyl Tridihexethyl may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00508 Triflupromazine Triflupromazine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00517 Anisotropine methylbromide Anisotropine methylbromide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00540 Nortriptyline Nortriptyline may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00543 Amoxapine Amoxapine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00555 Lamotrigine Lamotrigine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00572 Atropine Atropine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00622 Nicardipine Nicardipine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00670 Pirenzepine Pirenzepine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00715 Paroxetine Paroxetine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00725 Homatropine methylbromide Homatropine methylbromide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00728 Rocuronium Rocuronium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00747 Scopolamine Scopolamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00767 Benzquinamide Benzquinamide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00771 Clidinium Clidinium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00777 Propiomazine Propiomazine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00782 Propantheline Propantheline may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00804 Dicyclomine Dicyclomine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00810 Biperiden Biperiden may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00835 Brompheniramine Brompheniramine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00875 Flupentixol Flupentixol may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00907 Cocaine Cocaine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00908 Quinidine Quinidine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00934 Maprotiline Maprotiline may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00940 Methantheline Methantheline may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00942 Cycrimine Cycrimine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00986 Glycopyrronium Glycopyrronium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01036 Tolterodine Tolterodine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01062 Oxybutynin Oxybutynin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01069 Promethazine Promethazine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01075 Diphenhydramine Diphenhydramine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01135 Doxacurium Doxacurium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01142 Doxepin Doxepin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01148 Flavoxate Flavoxate may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01151 Desipramine Desipramine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01173 Orphenadrine Orphenadrine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01175 Escitalopram Escitalopram may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01224 Quetiapine Quetiapine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01226 Mivacurium Mivacurium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01231 Diphenidol Diphenidol may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01238 Aripiprazole Aripiprazole may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01239 Chlorprothixene Chlorprothixene may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01336 Metocurine Metocurine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01337 Pancuronium Pancuronium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01338 Pipecuronium Pipecuronium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01403 Methotrimeprazine Methotrimeprazine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01409 Tiotropium Tiotropium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01591 Solifenacin Solifenacin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB01625 Isopropamide Isopropamide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB04834 Rapacuronium Rapacuronium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB04843 Mepenzolate Mepenzolate may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB06153 Pizotifen Pizotifen may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB06702 Fesoterodine Fesoterodine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB06787 Hexocyclium Hexocyclium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB08801 Dimetindene Dimetindene may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB08897 Aclidinium Aclidinium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB08997 Dexetimide Dexetimide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09007 Chlorphenoxamine Chlorphenoxamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09023 Benactyzine Benactyzine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09076 Umeclidinium Umeclidinium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09089 Trimebutine Trimebutine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09167 Dosulepin Dosulepin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09262 Imidafenacin Imidafenacin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB09300 Butylscopolamine Butylscopolamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB11235 Thonzylamine Thonzylamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB11315 Methscopolamine Methscopolamine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB11855 Revefenacin Revefenacin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB12086 Oxitropium Oxitropium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB12278 Propiverine Propiverine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB12526 Batefenterol Batefenterol may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB12554 Mebeverine Mebeverine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13252 Tropatepine Tropatepine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13254 Prifinium Prifinium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13351 Piperidolate Piperidolate may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13369 Benzilone Benzilone may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13380 Difemerine Difemerine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13413 Phenglutarimide Phenglutarimide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13448 Mazaticol Mazaticol may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13468 Etybenzatropine Etybenzatropine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13500 Otilonium Otilonium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13505 Emepronium Emepronium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13507 Poldine Poldine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13542 Bevonium Bevonium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13581 Rociverine Rociverine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13619 Bornaprine Bornaprine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13636 Etanautine Etanautine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13666 Tiemonium iodide Tiemonium iodide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13678 Dihexyverine Dihexyverine may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13695 Penthienate Penthienate may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13720 Diphemanil Diphemanil may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13738 Camylofin Camylofin may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13759 Fenpiverinium Fenpiverinium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13769 Emetonium iodide Emetonium iodide may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13844 Pipenzolate Pipenzolate may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB13850 Timepidium Timepidium may increase the gastrointestinal motility reducing activities of Glucagon.
DB00040 DB00328 Indomethacin The therapeutic efficacy of Glucagon can be decreased when used in combination with Indomethacin.
DB00040 DB00266 Dicoumarol The therapeutic efficacy of Dicoumarol can be increased when used in combination with Glucagon.
DB00040 DB00498 Phenindione The therapeutic efficacy of Phenindione can be increased when used in combination with Glucagon.
DB00040 DB00682 Warfarin The therapeutic efficacy of Warfarin can be increased when used in combination with Glucagon.
DB00040 DB00946 Phenprocoumon The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Glucagon.
DB00040 DB01418 Acenocoumarol The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Glucagon.
DB00040 DB03410 4-hydroxycoumarin The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Glucagon.
DB00040 DB04665 Coumarin The therapeutic efficacy of Coumarin can be increased when used in combination with Glucagon.
DB00040 DB08496 (R)-warfarin The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Glucagon.
DB00040 DB08794 Ethyl biscoumacetate The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Glucagon.
DB00040 DB13136 Fluindione The therapeutic efficacy of Fluindione can be increased when used in combination with Glucagon.
DB00040 DB13275 Clorindione The therapeutic efficacy of Clorindione can be increased when used in combination with Glucagon.
DB00040 DB13347 Diphenadione The therapeutic efficacy of Diphenadione can be increased when used in combination with Glucagon.
DB00040 DB13451 Tioclomarol The therapeutic efficacy of Tioclomarol can be increased when used in combination with Glucagon.
DB00040 DB14055 (S)-Warfarin The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Glucagon.
DB00040 DB00187 Esmolol The therapeutic efficacy of Esmolol can be decreased when used in combination with Glucagon.
DB00040 DB00195 Betaxolol The therapeutic efficacy of Betaxolol can be decreased when used in combination with Glucagon.
DB00040 DB00264 Metoprolol The therapeutic efficacy of Metoprolol can be decreased when used in combination with Glucagon.
DB00040 DB00335 Atenolol The therapeutic efficacy of Atenolol can be decreased when used in combination with Glucagon.
DB00040 DB00373 Timolol The therapeutic efficacy of Timolol can be decreased when used in combination with Glucagon.
DB00040 DB00489 Sotalol The therapeutic efficacy of Sotalol can be decreased when used in combination with Glucagon.
DB00040 DB00571 Propranolol The therapeutic efficacy of Propranolol can be decreased when used in combination with Glucagon.
DB00040 DB00598 Labetalol The therapeutic efficacy of Labetalol can be decreased when used in combination with Glucagon.
DB00040 DB00612 Bisoprolol The therapeutic efficacy of Bisoprolol can be decreased when used in combination with Glucagon.
DB00040 DB00866 Alprenolol The therapeutic efficacy of Alprenolol can be decreased when used in combination with Glucagon.
DB00040 DB00960 Pindolol The therapeutic efficacy of Pindolol can be decreased when used in combination with Glucagon.
DB00040 DB01136 Carvedilol The therapeutic efficacy of Carvedilol can be decreased when used in combination with Glucagon.
DB00040 DB01182 Propafenone The therapeutic efficacy of Propafenone can be decreased when used in combination with Glucagon.
DB00040 DB01193 Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Glucagon.
DB00040 DB01203 Nadolol The therapeutic efficacy of Nadolol can be decreased when used in combination with Glucagon.
DB00040 DB01295 Bevantolol The therapeutic efficacy of Bevantolol can be decreased when used in combination with Glucagon.
DB00040 DB01297 Practolol The therapeutic efficacy of Practolol can be decreased when used in combination with Glucagon.
DB00040 DB01359 Penbutolol The therapeutic efficacy of Penbutolol can be decreased when used in combination with Glucagon.
DB00040 DB01580 Oxprenolol The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Glucagon.
DB00040 DB03322 Dexpropranolol The therapeutic efficacy of Dexpropranolol can be decreased when used in combination with Glucagon.
DB00040 DB04846 Celiprolol The therapeutic efficacy of Celiprolol can be decreased when used in combination with Glucagon.
DB00040 DB04861 Nebivolol The therapeutic efficacy of Nebivolol can be decreased when used in combination with Glucagon.
DB00040 DB06726 Bufuralol The therapeutic efficacy of Bufuralol can be decreased when used in combination with Glucagon.
DB00040 DB08807 Bopindolol The therapeutic efficacy of Bopindolol can be decreased when used in combination with Glucagon.
DB00040 DB08808 Bupranolol The therapeutic efficacy of Bupranolol can be decreased when used in combination with Glucagon.
DB00040 DB08952 Indenolol The therapeutic efficacy of Indenolol can be decreased when used in combination with Glucagon.
DB00040 DB09013 Befunolol The therapeutic efficacy of Befunolol can be decreased when used in combination with Glucagon.
DB00040 DB09204 Arotinolol The therapeutic efficacy of Arotinolol can be decreased when used in combination with Glucagon.
DB00040 DB09351 Levobetaxolol The therapeutic efficacy of Levobetaxolol can be decreased when used in combination with Glucagon.
DB00040 DB11770 Talinolol The therapeutic efficacy of Talinolol can be decreased when used in combination with Glucagon.
DB00040 DB11785 Anisodamine The therapeutic efficacy of Anisodamine can be decreased when used in combination with Glucagon.
DB00040 DB12212 Landiolol The therapeutic efficacy of Landiolol can be decreased when used in combination with Glucagon.
DB00040 DB12752 Bucindolol The therapeutic efficacy of Bucindolol can be decreased when used in combination with Glucagon.
DB00040 DB13443 Esatenolol The therapeutic efficacy of Esatenolol can be decreased when used in combination with Glucagon.
DB00040 DB13508 Cloranolol The therapeutic efficacy of Cloranolol can be decreased when used in combination with Glucagon.
DB00040 DB13530 Mepindolol The therapeutic efficacy of Mepindolol can be decreased when used in combination with Glucagon.
DB00040 DB13757 Epanolol The therapeutic efficacy of Epanolol can be decreased when used in combination with Glucagon.
DB00040 DB13775 Tertatolol The therapeutic efficacy of Tertatolol can be decreased when used in combination with Glucagon.
DB00040 DB00030 Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Glucagon.
DB00040 DB00046 Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Glucagon.
DB00040 DB00047 Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Glucagon.
DB00040 DB00071 Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Glucagon.
DB00040 DB01306 Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Glucagon.
DB00040 DB01307 Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Glucagon.
DB00040 DB01309 Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Glucagon.
DB00040 DB05115 NN344 The therapeutic efficacy of NN344 can be decreased when used in combination with Glucagon.
DB00040 DB09456 Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Glucagon.
DB00040 DB09564 Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Glucagon.
DB00040 DB11567 Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Glucagon.
DB00040 DB11568 Insulin tregopil The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Glucagon.
DB00040 DB11564 Insulin argine The therapeutic efficacy of Insulin argine can be decreased when used in combination with Glucagon.
DB00040 DB14513 Magnesium The serum concentration of Magnesium can be increased when it is combined with Glucagon.
DB00041 DB06643 Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Aldesleukin.
DB00041 DB00005 Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Aldesleukin.
DB00041 DB00011 Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Aldesleukin.
DB00041 DB00026 Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Aldesleukin.
DB00041 DB00033 Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Aldesleukin.
DB00041 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Adalimumab.
DB00041 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin.
DB00041 DB00059 Pegaspargase The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pegaspargase.
DB00041 DB00065 Infliximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Infliximab.
DB00041 DB00068 Interferon beta-1b The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon beta-1b.
DB00041 DB00073 Rituximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rituximab.
DB00041 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Basiliximab.
DB00041 DB00075 Muromonab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Muromonab.
DB00041 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.
DB00041 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tositumomab.
DB00041 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alemtuzumab.
DB00041 DB00092 Alefacept The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alefacept.
DB00041 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efalizumab.
DB00041 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antithymocyte immunoglobulin (rabbit).
DB00041 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.
DB00041 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bevacizumab.
DB00041 DB00120 Phenylalanine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenylalanine.
DB00041 DB00180 Flunisolide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Flunisolide.
DB00041 DB00242 Cladribine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cladribine.
DB00041 DB00262 Carmustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carmustine.
DB00041 DB00276 Amsacrine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amsacrine.
DB00041 DB00290 Bleomycin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bleomycin.
DB00041 DB00291 Chlorambucil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorambucil.
DB00041 DB00293 Raltitrexed The risk or severity of adverse effects can be increased when Aldesleukin is combined with Raltitrexed.
DB00041 DB00305 Mitomycin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitomycin.
DB00041 DB00307 Bexarotene The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bexarotene.
DB00041 DB00322 Floxuridine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Floxuridine.
DB00041 DB00328 Indomethacin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indomethacin.
DB00041 DB00352 Tioguanine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tioguanine.
DB00041 DB00380 Dexrazoxane The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexrazoxane.
DB00041 DB00428 Streptozocin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptozocin.
DB00041 DB00432 Trifluridine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trifluridine.
DB00041 DB00441 Gemcitabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemcitabine.
DB00041 DB00445 Epirubicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Epirubicin.
DB00041 DB00446 Chloramphenicol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chloramphenicol.
DB00041 DB00480 Lenalidomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lenalidomide.
DB00041 DB00488 Altretamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Altretamine.
DB00041 DB00495 Zidovudine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Zidovudine.
DB00041 DB00515 Cisplatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin.
DB00041 DB00526 Oxaliplatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxaliplatin.
DB00041 DB00531 Cyclophosphamide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cyclophosphamide.
DB00041 DB00544 Fluorouracil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluorouracil.
DB00041 DB00552 Pentostatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pentostatin.
DB00041 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluticasone propionate.
DB00041 DB00591 Fluocinolone acetonide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluocinolone acetonide.
DB00041 DB00601 Linezolid The risk or severity of adverse effects can be increased when Aldesleukin is combined with Linezolid.
DB00041 DB00631 Clofarabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine.
DB00041 DB00642 Pemetrexed The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pemetrexed.
DB00041 DB00687 Fludrocortisone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fludrocortisone.
DB00041 DB00688 Mycophenolate mofetil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mycophenolate mofetil.
DB00041 DB00755 Tretinoin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tretinoin.
DB00041 DB00762 Irinotecan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irinotecan.
DB00041 DB00795 Sulfasalazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sulfasalazine.
DB00041 DB00851 Dacarbazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dacarbazine.
DB00041 DB00853 Temozolomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Temozolomide.
DB00041 DB00859 Penicillamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Penicillamine.
DB00041 DB00860 Prednisolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prednisolone.
DB00041 DB00888 Mechlorethamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mechlorethamine.
DB00041 DB00928 Azacitidine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azacitidine.
DB00041 DB00958 Carboplatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carboplatin.
DB00041 DB00959 Methylprednisolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methylprednisolone.
DB00041 DB00970 Dactinomycin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dactinomycin.
DB00041 DB00993 Azathioprine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azathioprine.
DB00041 DB01005 Hydroxyurea The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroxyurea.
DB00041 DB01024 Mycophenolic acid The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mycophenolic acid.
DB00041 DB01030 Topotecan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Topotecan.
DB00041 DB01033 Mercaptopurine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mercaptopurine.
DB00041 DB01041 Thalidomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.
DB00041 DB01042 Melphalan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Melphalan.
DB00041 DB01073 Fludarabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fludarabine.
DB00041 DB01099 Flucytosine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Flucytosine.
DB00041 DB01101 Capecitabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Capecitabine.
DB00041 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Procarbazine.
DB00041 DB01169 Arsenic trioxide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.
DB00041 DB01177 Idarubicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Idarubicin.
DB00041 DB01196 Estramustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Estramustine.
DB00041 DB01204 Mitoxantrone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitoxantrone.
DB00041 DB01206 Lomustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lomustine.
DB00041 DB01234 Dexamethasone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexamethasone.
DB00041 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eculizumab.
DB00041 DB01262 Decitabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Decitabine.
DB00041 DB01280 Nelarabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nelarabine.
DB00041 DB01281 Abatacept The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abatacept.
DB00041 DB01285 Corticotropin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Corticotropin.
DB00041 DB01423 Stepronin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Stepronin.
DB00041 DB01611 Hydroxychloroquine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroxychloroquine.
DB00041 DB01816 Castanospermine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Castanospermine.
DB00041 DB02546 Vorinostat The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vorinostat.
DB00041 DB02806 2-Methoxyethanol The risk or severity of adverse effects can be increased when Aldesleukin is combined with 2-Methoxyethanol.
DB00041 DB03523 Brequinar The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brequinar.
DB00041 DB04630 Aldosterone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aldosterone.
DB00041 DB04951 Pirfenidone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pirfenidone.
DB00041 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Afelimomab.
DB00041 DB05258 Interferon alfa The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon alfa.
DB00041 DB05259 Glatiramer The risk or severity of adverse effects can be increased when Aldesleukin is combined with Glatiramer.
DB00041 DB05260 Gallium nitrate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gallium nitrate.
DB00041 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Briakinumab.
DB00041 DB05472 omega interferon The risk or severity of adverse effects can be increased when Aldesleukin is combined with omega interferon.
DB00041 DB05676 Apremilast The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apremilast.
DB00041 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trastuzumab emtansine.
DB00041 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canakinumab.
DB00041 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tocilizumab.
DB00041 DB06372 Rilonacept The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rilonacept.
DB00041 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mepolizumab.
DB00041 DB06662 Abetimus The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus.
DB00041 DB06674 Golimumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Golimumab.
DB00041 DB06681 Belatacept The risk or severity of adverse effects can be increased when Aldesleukin is combined with Belatacept.
DB00041 DB06769 Bendamustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendamustine.
DB00041 DB06772 Cabazitaxel The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cabazitaxel.
DB00041 DB06813 Pralatrexate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pralatrexate.
DB00041 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Wortmannin.
DB00041 DB08871 Eribulin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eribulin.
DB00041 DB08879 Belimumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Belimumab.
DB00041 DB08880 Teriflunomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Teriflunomide.
DB00041 DB08889 Carfilzomib The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carfilzomib.
DB00041 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Certolizumab pegol.
DB00041 DB08908 Dimethyl fumarate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dimethyl fumarate.
DB00041 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pomalidomide.
DB00041 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Obinutuzumab.
DB00041 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Secukinumab.
DB00041 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vedolizumab.
DB00041 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Siltuximab.
DB00041 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Blinatumomab.
DB00041 DB09074 Olaparib The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olaparib.
DB00041 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.
DB00041 DB09082 Vilanterol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vilanterol.
DB00041 DB09091 Tixocortol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tixocortol.
DB00041 DB09122 Peginterferon beta-1a The risk or severity of adverse effects can be increased when Aldesleukin is combined with Peginterferon beta-1a.
DB00041 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antilymphocyte immunoglobulin (horse).
DB00041 DB09378 Fluprednisolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluprednisolone.
DB00041 DB11466 Tepoxalin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tepoxalin.
DB00041 DB11529 Melengestrol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Melengestrol.
DB00041 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ixekizumab.
DB00041 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ravulizumab.
DB00041 DB11616 Pirarubicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pirarubicin.
DB00041 DB11693 Voclosporin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Voclosporin.
DB00041 DB11708 Peficitinib The risk or severity of adverse effects can be increased when Aldesleukin is combined with Peficitinib.
DB00041 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sarilumab.
DB00041 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brodalumab.
DB00041 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sirukumab.
DB00041 DB11817 Baricitinib The risk or severity of adverse effects can be increased when Aldesleukin is combined with Baricitinib.
DB00041 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guselkumab.
DB00041 DB12025 Triptolide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triptolide.
DB00041 DB12612 Ozanimod The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ozanimod.
DB00041 DB12617 Mizoribine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mizoribine.
DB00041 DB12692 Gusperimus The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gusperimus.
DB00041 DB12814 Cepeginterferon alfa-2B The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cepeginterferon alfa-2B.
DB00041 DB12902 Trofosfamide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trofosfamide.
DB00041 DB12947 Doxifluridine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxifluridine.
DB00041 DB12991 Deoxyspergualin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Deoxyspergualin.
DB00041 DB12996 Acteoside The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acteoside.
DB00041 DB13014 Hypericin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hypericin.
DB00041 DB13068 9-(N-methyl-L-isoleucine)-cyclosporin A The risk or severity of adverse effects can be increased when Aldesleukin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB00041 DB13223 Fluocortin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluocortin.
DB00041 DB13241 Begelomab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Begelomab.
DB00041 DB13491 Fluperolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluperolone.
DB00041 DB13664 Formocortal The risk or severity of adverse effects can be increased when Aldesleukin is combined with Formocortal.
DB00041 DB13856 Fluclorolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluclorolone.
DB00041 DB14066 Tetrandrine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tetrandrine.
DB00041 DB14219 Monomethyl fumarate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Monomethyl fumarate.
DB00041 DB14538 Hydrocortisone aceponate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrocortisone aceponate.
DB00041 DB14539 Hydrocortisone acetate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrocortisone acetate.
DB00041 DB14545 Hydrocortisone succinate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrocortisone succinate.
DB00041 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Emapalumab.
DB00041 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Risankizumab.
DB00041 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rozanolixizumab.
DB00041 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bleselumab.
DB00041 DB01222 Budesonide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Budesonide.
DB00041 DB12371 Siponimod The risk or severity of adverse effects can be increased when Aldesleukin is combined with Siponimod.
DB00041 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Natalizumab.
DB00041 DB00337 Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Aldesleukin.
DB00041 DB01656 Roflumilast Roflumilast may increase the immunosuppressive activities of Aldesleukin.
DB00041 DB06688 Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Aldesleukin.
DB00041 DB00008 Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.
DB00041 DB00018 Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.
DB00041 DB00022 Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.
DB00041 DB00034 Interferon alfa-2a, Recombinant The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Aldesleukin.
DB00041 DB00069 Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.
DB00041 DB00105 Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Aldesleukin.
DB00041 DB00363 Clozapine The risk or severity of neutropenia can be increased when Aldesleukin is combined with Clozapine.
DB00041 DB08894 Peginesatide The risk or severity of Thrombosis can be increased when Aldesleukin is combined with Peginesatide.
DB00041 DB00012 Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Aldesleukin.
DB00041 DB00016 Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Aldesleukin.
DB00041 DB09107 Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Aldesleukin.
DB00041 DB00476 Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Aldesleukin is combined with Duloxetine.
DB00041 DB01235 Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Aldesleukin is combined with Levodopa.
DB00041 DB00734 Risperidone Aldesleukin may increase the hypotensive activities of Risperidone.
DB00041 DB09039 Eliglustat The metabolism of Eliglustat can be decreased when combined with Aldesleukin.
DB00041 DB09053 Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Aldesleukin.
DB00041 DB01166 Cilostazol The metabolism of Cilostazol can be decreased when combined with Aldesleukin.
DB00041 DB01394 Colchicine The metabolism of Colchicine can be decreased when combined with Aldesleukin.
DB00041 DB00813 Fentanyl The metabolism of Fentanyl can be decreased when combined with Aldesleukin.
DB00041 DB04946 Iloperidone The metabolism of Iloperidone can be decreased when combined with Aldesleukin.
DB00041 DB01256 Retapamulin The metabolism of Retapamulin can be decreased when combined with Aldesleukin.
DB00041 DB08895 Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Aldesleukin.
DB00041 DB00862 Vardenafil The metabolism of Vardenafil can be decreased when combined with Aldesleukin.
DB00041 DB00402 Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Aldesleukin.
DB00041 DB01198 Zopiclone The metabolism of Zopiclone can be decreased when combined with Aldesleukin.
DB00041 DB00394 Beclomethasone dipropionate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Beclomethasone dipropionate.
DB00041 DB00443 Betamethasone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Betamethasone.
DB00041 DB00620 Triamcinolone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Triamcinolone.
DB00041 DB00635 Prednisone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Prednisone.
DB00041 DB00764 Mometasone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Mometasone.
DB00041 DB01380 Cortisone acetate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Cortisone acetate.
DB00041 DB01384 Paramethasone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Paramethasone.
DB00041 DB01410 Ciclesonide The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Ciclesonide.
DB00041 DB08906 Fluticasone furoate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluticasone furoate.
DB00041 DB08970 Fluprednidene The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluprednidene.
DB00041 DB08971 Fluocortolone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluocortolone.
DB00041 DB09383 Meprednisone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Meprednisone.
DB00041 DB11487 Dexamethasone isonicotinate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Dexamethasone isonicotinate.
DB00041 DB11750 Clobetasol The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Clobetasol.
DB00041 DB11921 Deflazacort The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Deflazacort.
DB00041 DB13003 Cortivazol The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Cortivazol.
DB00041 DB13208 Prednylidene The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Prednylidene.
DB00041 DB13728 Halometasone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Halometasone.
DB00041 DB13843 Cloprednol The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Cloprednol.
DB00041 DB13867 Fluticasone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluticasone.
DB00041 DB14512 Mometasone furoate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Mometasone furoate.
DB00041 DB14631 Prednisolone phosphate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Prednisolone phosphate.
DB00041 DB14633 Prednisolone hemisuccinate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Prednisolone hemisuccinate.
DB00041 DB14634 Fluprednidene acetate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluprednidene acetate.
DB00041 DB14644 Methylprednisolone hemisuccinate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Methylprednisolone hemisuccinate.
DB00041 DB14646 Prednisone acetate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Prednisone acetate.
DB00041 DB14652 Clocortolone acetate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Clocortolone acetate.
DB00041 DB14659 Melengestrol acetate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Melengestrol acetate.
DB00041 DB14669 Betamethasone phosphate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Betamethasone phosphate.
DB00041 DB14681 Cortisone The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Cortisone.
DB00041 DB00227 Lovastatin The metabolism of Lovastatin can be decreased when combined with Aldesleukin.
DB00041 DB00271 Diatrizoate The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.
DB00041 DB00965 Ethiodized oil The risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.
DB00041 DB01249 Iodixanol The risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.
DB00041 DB01362 Iohexol The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.
DB00041 DB04711 Iodipamide The risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.
DB00041 DB08947 Iopamidol The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.
DB00041 DB09134 Ioversol The risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.
DB00041 DB09135 Ioxilan The risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.
DB00041 DB09156 Iopromide The risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.
DB00041 DB00346 Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Aldesleukin.
DB00041 DB00404 Alprazolam The metabolism of Alprazolam can be decreased when combined with Aldesleukin.
DB00041 DB00682 Warfarin The serum concentration of Warfarin can be increased when it is combined with Aldesleukin.
DB00041 DB01418 Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Aldesleukin.
DB00041 DB08496 (R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Aldesleukin.
DB00041 DB08735 R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Aldesleukin.
DB00041 DB08736 S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Aldesleukin.
DB00041 DB14055 (S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Aldesleukin.
DB00041 DB00683 Midazolam The serum concentration of Midazolam can be increased when it is combined with Aldesleukin.
DB00041 DB00864 Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Aldesleukin.
DB00041 DB01015 Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Aldesleukin.
DB00041 DB01076 Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Aldesleukin.
DB00041 DB01097 Leflunomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Leflunomide.
DB00041 DB00072 Trastuzumab Trastuzumab may increase the neutropenic activities of Aldesleukin.
DB00041 DB08868 Fingolimod Aldesleukin may increase the immunosuppressive activities of Fingolimod.
DB00041 DB09220 Nicorandil Nicorandil may increase the hypotensive activities of Aldesleukin.
DB00041 DB00614 Furazolidone Furazolidone may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB00721 Procaine Procaine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB00752 Tranylcypromine Tranylcypromine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB00780 Phenelzine Phenelzine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB00805 Minaprine Minaprine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB01037 Selegiline Selegiline may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB01171 Moclobemide Moclobemide may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB01247 Isocarboxazid Isocarboxazid may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB01367 Rasagiline Rasagiline may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB01626 Pargyline Pargyline may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB04017 Clorgiline Clorgiline may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB04818 Iproniazid Iproniazid may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB04820 Nialamide Nialamide may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB06654 Safinamide Safinamide may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09241 Methylene blue Methylene blue may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09243 Hydracarbazine Hydracarbazine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09244 Pirlindole Pirlindole may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09245 Toloxatone Toloxatone may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09246 Benmoxin Benmoxin may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09248 Mebanazine Mebanazine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09249 Octamoxin Octamoxin may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09250 Pheniprazine Pheniprazine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09251 Phenoxypropazine Phenoxypropazine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09252 Pivhydrazine Pivhydrazine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09253 Safrazine Safrazine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB09254 Caroxazone Caroxazone may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB13875 Harmaline Harmaline may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB13876 Brofaromine Brofaromine may increase the orthostatic hypotensive activities of Aldesleukin.
DB00041 DB00182 Amphetamine Aldesleukin may increase the orthostatic hypotensive activities of Amphetamine.
DB00041 DB00241 Butalbital Butalbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB00312 Pentobarbital Pentobarbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB00418 Secobarbital Secobarbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB00474 Methohexital Methohexital may increase the hypotensive activities of Aldesleukin.
DB00041 DB00599 Thiopental Thiopental may increase the hypotensive activities of Aldesleukin.
DB00041 DB00794 Primidone Primidone may increase the hypotensive activities of Aldesleukin.
DB00041 DB00849 Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB01154 Thiamylal Thiamylal may increase the hypotensive activities of Aldesleukin.
DB00041 DB01174 Phenobarbital Phenobarbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB01351 Amobarbital Amobarbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB01355 Hexobarbital Hexobarbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB01483 Barbital Barbital may increase the hypotensive activities of Aldesleukin.
DB00041 DB09001 Barbexaclone Barbexaclone may increase the hypotensive activities of Aldesleukin.
DB00041 DB00237 Butabarbital Aldesleukin may increase the hypotensive activities of Butabarbital.
DB00041 DB00086 Streptokinase The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.
DB00041 DB00268 Ropinirole The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropinirole.
DB00041 DB00334 Olanzapine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olanzapine.
DB00041 DB00486 Nabilone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nabilone.
DB00041 DB00489 Sotalol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.
DB00041 DB00679 Thioridazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Thioridazine.
DB00041 DB00697 Tizanidine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.
DB00041 DB00714 Apomorphine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine.
DB00041 DB00818 Propofol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.
DB00041 DB00899 Remifentanil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Remifentanil.
DB00041 DB00922 Levosimendan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levosimendan.
DB00041 DB01113 Papaverine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.
DB00041 DB01143 Amifostine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amifostine.
DB00041 DB01189 Desflurane The risk or severity of adverse effects can be increased when Aldesleukin is combined with Desflurane.
DB00041 DB01282 Carbetocin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carbetocin.
DB00041 DB01612 Amyl Nitrite The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.
DB00041 DB04899 Nesiritide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.
DB00041 DB08822 Azilsartan medoxomil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.
DB00041 DB08941 Isoxsuprine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.
DB00041 DB09112 Nitrous acid The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrous acid.
DB00041 DB09279 Fimasartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fimasartan.
DB00041 DB09286 Pipamperone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pipamperone.
DB00041 DB00177 Valsartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.
DB00041 DB00178 Ramipril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.
DB00041 DB00187 Esmolol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.
DB00041 DB00195 Betaxolol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.
DB00041 DB00275 Olmesartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.
DB00041 DB00335 Atenolol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.
DB00041 DB00350 Minoxidil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.
DB00041 DB00457 Prazosin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.
DB00041 DB00519 Trandolapril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.
DB00041 DB00542 Benazepril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.
DB00041 DB00691 Moexipril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.
DB00041 DB00727 Nitroglycerin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.
DB00041 DB00796 Candesartan cilexetil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan cilexetil.
DB00041 DB00797 Tolazoline The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolazoline.
DB00041 DB00876 Eprosartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.
DB00041 DB00881 Quinapril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.
DB00041 DB00925 Phenoxybenzamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenoxybenzamine.
DB00041 DB00966 Telmisartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.
DB00041 DB01029 Irbesartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.
DB00041 DB01158 Bretylium The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.
DB00041 DB01162 Terazosin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.
DB00041 DB01193 Acebutolol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.
DB00041 DB01197 Captopril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.
DB00041 DB01340 Cilazapril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.
DB00041 DB01580 Oxprenolol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxprenolol.
DB00041 DB08950 Indoramin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indoramin.
DB00041 DB09242 Moxonidine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moxonidine.
DB00041 DB11783 Imidapril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Imidapril.
DB00041 DB00584 Enalapril The risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.
DB00041 DB00343 Diltiazem The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.
DB00041 DB00381 Amlodipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.
DB00041 DB00393 Nimodipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.
DB00041 DB00528 Lercanidipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lercanidipine.
DB00041 DB00622 Nicardipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.
DB00041 DB00678 Losartan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.
DB00041 DB01054 Nitrendipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrendipine.
DB00041 DB01244 Bepridil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bepridil.
DB00041 DB04861 Nebivolol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.
DB00041 DB08931 Riociguat The risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.
DB00041 DB09026 Aliskiren The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.
DB00041 DB00295 Morphine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Morphine.
DB00041 DB00297 Bupivacaine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bupivacaine.
DB00041 DB00708 Sufentanil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.
DB00041 DB00883 Isosorbide dinitrate The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide dinitrate.
DB00041 DB05271 Rotigotine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rotigotine.
DB00041 DB09227 Barnidipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Barnidipine.
DB00041 DB09232 Cilnidipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilnidipine.
DB00041 DB00401 Nisoldipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.
DB00041 DB00575 Clonidine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.
DB00041 DB01023 Felodipine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.
DB00041 DB01200 Bromocriptine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.
DB00041 DB01242 Clomipramine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clomipramine.
DB00041 DB09038 Empagliflozin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.
DB00041 DB04914 G17DT The therapeutic efficacy of G17DT can be decreased when used in combination with Aldesleukin.
DB00041 DB05144 PEV3A The therapeutic efficacy of PEV3A can be decreased when used in combination with Aldesleukin.
DB00041 DB05325 INGN 225 The therapeutic efficacy of INGN 225 can be decreased when used in combination with Aldesleukin.
DB00041 DB05374 Rindopepimut The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Aldesleukin.
DB00041 DB05440 SRP 299 The therapeutic efficacy of SRP 299 can be decreased when used in combination with Aldesleukin.
DB00041 DB05942 GI-5005 The therapeutic efficacy of GI-5005 can be decreased when used in combination with Aldesleukin.
DB00041 DB06400 Vitespen The therapeutic efficacy of Vitespen can be decreased when used in combination with Aldesleukin.
DB00041 DB06584 TG4010 The therapeutic efficacy of TG4010 can be decreased when used in combination with Aldesleukin.
DB00041 DB09057 Anthrax immune globulin human The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Aldesleukin.
DB00041 DB10062 Rabies virus inactivated antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Aldesleukin.
DB00041 DB10076 Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
DB00041 DB10276 Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Aldesleukin.
DB00041 DB10283 Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Aldesleukin.
DB00041 DB10342 Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Aldesleukin.
DB00041 DB10583 Clostridium tetani toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB10584 Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB10600 Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB10769 Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB10794 Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB10803 Typhoid Vi polysaccharide vaccine The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Aldesleukin.
DB00041 DB10989 Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Aldesleukin.
DB00041 DB10990 Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Aldesleukin.
DB00041 DB11038 Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB11040 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB11041 Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB11044 Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB11603 Human rabies virus immune globulin The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Aldesleukin.
DB00041 DB11627 Hepatitis B Vaccine (Recombinant) The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Aldesleukin.
DB00041 DB12568 Tecemotide The therapeutic efficacy of Tecemotide can be decreased when used in combination with Aldesleukin.
DB00041 DB14022 Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Aldesleukin.
DB00041 DB14384 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB14385 Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB14394 Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Aldesleukin.
DB00041 DB14445 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB14449 Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Aldesleukin.
DB00041 DB14619 Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB14620 Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB14711 Vaccinia virus strain new york city board of health live antigen The therapeutic efficacy of Vaccinia virus strain new york city board of health live antigen can be decreased when used in combination with Aldesleukin.
DB00041 DB15274 Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Aldesleukin.
DB00041 DB15461 Yersinia pestis 195/p antigen (formaldehyde inactivated) The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
DB00041 DB13924 Varicella Zoster Vaccine (Recombinant) The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Aldesleukin.
DB00041 DB15483 Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldesleukin.
DB00041 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Aldesleukin.
DB00041 DB00054 Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Aldesleukin.
DB00041 DB00063 Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Aldesleukin.
DB00041 DB00261 Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Aldesleukin.
DB00041 DB00975 Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Aldesleukin.
DB00041 DB01088 Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Aldesleukin.
DB00041 DB01207 Ridogrel The risk or severity of bleeding can be increased when Ridogrel is combined with Aldesleukin.
DB00041 DB02709 Resveratrol The risk or severity of bleeding can be increased when Resveratrol is combined with Aldesleukin.
DB00041 DB04932 Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Aldesleukin.
DB00041 DB05229 Beraprost The risk or severity of bleeding can be increased when Beraprost is combined with Aldesleukin.
DB00041 DB05266 Ibudilast The risk or severity of bleeding can be increased when Ibudilast is combined with Aldesleukin.
DB00041 DB05767 Andrographolide The risk or severity of bleeding can be increased when Andrographolide is combined with Aldesleukin.
DB00041 DB06081 Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Aldesleukin.
DB00041 DB06441 Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Aldesleukin.
DB00041 DB08814 Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Aldesleukin.
DB00041 DB08887 Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Aldesleukin.
DB00041 DB09283 Trapidil The risk or severity of bleeding can be increased when Trapidil is combined with Aldesleukin.
DB00041 DB12163 Sarpogrelate The risk or severity of bleeding can be increased when Sarpogrelate is combined with Aldesleukin.
DB00041 DB12321 Ifetroban The risk or severity of bleeding can be increased when Ifetroban is combined with Aldesleukin.
DB00041 DB12749 Butylphthalide The risk or severity of bleeding can be increased when Butylphthalide is combined with Aldesleukin.
DB00041 DB12771 Hydroxytyrosol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Aldesleukin.
DB00041 DB13036 Ramatroban The risk or severity of bleeding can be increased when Ramatroban is combined with Aldesleukin.
DB00041 DB13327 Picotamide The risk or severity of bleeding can be increased when Picotamide is combined with Aldesleukin.
DB00041 DB13367 Cloricromen The risk or severity of bleeding can be increased when Cloricromen is combined with Aldesleukin.
DB00041 DB13510 Buflomedil The risk or severity of bleeding can be increased when Buflomedil is combined with Aldesleukin.
DB00041 DB13929 Relcovaptan The risk or severity of bleeding can be increased when Relcovaptan is combined with Aldesleukin.
DB00041 DB12465 Ketanserin The risk or severity of bleeding can be increased when Aldesleukin is combined with Ketanserin.
DB00041 DB13400 Linsidomine The risk or severity of bleeding can be increased when Aldesleukin is combined with Linsidomine.
DB00041 DB12092 Naftopidil The risk or severity of bleeding can be increased when Aldesleukin is combined with Naftopidil.
DB00041 DB00758 Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Aldesleukin.
DB00041 DB01138 Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Aldesleukin.
DB00041 DB04905 Tesmilifene The risk or severity of bleeding can be increased when Tesmilifene is combined with Aldesleukin.
DB00041 DB07615 Tranilast The risk or severity of bleeding can be increased when Tranilast is combined with Aldesleukin.
DB00041 DB08816 Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Aldesleukin.
DB00041 DB09236 Lacidipine Aldesleukin may increase the hypotensive activities of Lacidipine.
DB00041 DB00898 Ethanol Ethanol may increase the hypotensive activities of Aldesleukin.
DB00041 DB11988 Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Aldesleukin.
DB00041 DB13200 Lipegfilgrastim Aldesleukin may increase the myelosuppressive activities of Lipegfilgrastim.
DB00041 DB10317 Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin.
DB00041 DB10318 Varicella Zoster Vaccine (Live/attenuated) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Aldesleukin.
DB00041 DB10343 Bacillus calmette-guerin substrain tice live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Aldesleukin.
DB00041 DB10804 Bacillus calmette-guerin substrain connaught live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Aldesleukin.
DB00041 DB10805 Yellow Fever Vaccine The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Aldesleukin.
DB00041 DB11003 Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Aldesleukin.
DB00041 DB11050 Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Aldesleukin.
DB00041 DB12386 Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Aldesleukin.
DB00041 DB12768 BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Aldesleukin.
DB00041 DB14409 Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Aldesleukin.
DB00041 DB14443 Vibrio cholerae CVD 103-HgR strain live antigen The risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Aldesleukin.
DB00041 DB14685 Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Aldesleukin.
DB00041 DB01238 Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Aldesleukin.
DB00041 DB14185 Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Aldesleukin.
DB00041 DB00039 Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Aldesleukin.
DB00041 DB00159 Icosapent Icosapent may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00229 Cefotiam Cefotiam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00244 Mesalazine Mesalazine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00267 Cefmenoxime Cefmenoxime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00274 Cefmetazole Cefmetazole may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00282 Pamidronic acid Pamidronic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00300 Tenofovir disoproxil Tenofovir disoproxil may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00369 Cidofovir Cidofovir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00384 Triamterene Triamterene may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00430 Cefpiramide Cefpiramide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00438 Ceftazidime Ceftazidime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00447 Loracarbef Loracarbef may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00456 Cefalotin Cefalotin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00461 Nabumetone Nabumetone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00465 Ketorolac Ketorolac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00469 Tenoxicam Tenoxicam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00482 Celecoxib Celecoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00493 Cefotaxime Cefotaxime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00500 Tolmetin Tolmetin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00529 Foscarnet Foscarnet may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00533 Rofecoxib Rofecoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00554 Piroxicam Piroxicam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00567 Cephalexin Cephalexin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00573 Fenoprofen Fenoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00577 Valaciclovir Valaciclovir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00580 Valdecoxib Valdecoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00586 Diclofenac Diclofenac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00605 Sulindac Sulindac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00626 Bacitracin Bacitracin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00681 Amphotericin B Amphotericin B may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00689 Cephaloglycin Cephaloglycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00712 Flurbiprofen Flurbiprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00718 Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00738 Pentamidine Pentamidine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00742 Mannitol Mannitol may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00749 Etodolac Etodolac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00784 Mefenamic acid Mefenamic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00787 Acyclovir Acyclovir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00788 Naproxen Naproxen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00812 Phenylbutazone Phenylbutazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00814 Meloxicam Meloxicam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00821 Carprofen Carprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00833 Cefaclor Cefaclor may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00861 Diflunisal Diflunisal may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00903 Etacrynic acid Etacrynic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00923 Ceforanide Ceforanide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00936 Salicylic acid Salicylic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00939 Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00945 Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00991 Oxaprozin Oxaprozin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00999 Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01009 Ketoprofen Ketoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01014 Balsalazide Balsalazide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01050 Ibuprofen Ibuprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01066 Cefditoren Cefditoren may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01072 Atazanavir Atazanavir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01111 Colistimethate Colistimethate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01112 Cefuroxime Cefuroxime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01139 Cefapirin Cefapirin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01140 Cefadroxil Cefadroxil may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01150 Cefprozil Cefprozil may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01212 Ceftriaxone Ceftriaxone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01250 Olsalazine Olsalazine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01283 Lumiracoxib Lumiracoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01326 Cefamandole Cefamandole may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01327 Cefazolin Cefazolin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01328 Cefonicid Cefonicid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01329 Cefoperazone Cefoperazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01330 Cefotetan Cefotetan may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01331 Cefoxitin Cefoxitin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01332 Ceftizoxime Ceftizoxime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01333 Cefradine Cefradine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01397 Magnesium salicylate Magnesium salicylate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01399 Salsalate Salsalate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01401 Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01413 Cefepime Cefepime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01414 Cefacetrile Cefacetrile may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01415 Ceftibuten Ceftibuten may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01416 Cefpodoxime Cefpodoxime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01419 Antrafenine Antrafenine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01424 Aminophenazone Aminophenazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01435 Antipyrine Antipyrine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01600 Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01628 Etoricoxib Etoricoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB02247 Hydrolyzed Cephalothin Hydrolyzed Cephalothin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB03450 Cephalothin Group Cephalothin Group may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB03585 Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04552 Niflumic acid Niflumic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04570 Latamoxef Latamoxef may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04743 Nimesulide Nimesulide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04812 Benoxaprofen Benoxaprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04817 Metamizole Metamizole may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04828 Zomepirac Zomepirac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04918 Ceftobiprole Ceftobiprole may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB05095 Cimicoxib Cimicoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB06590 Ceftaroline fosamil Ceftaroline fosamil may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB06725 Lornoxicam Lornoxicam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB06736 Aceclofenac Aceclofenac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB06737 Zaltoprofen Zaltoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB07402 Azapropazone Azapropazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB07477 Felbinac Felbinac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08439 Parecoxib Parecoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08797 Salicylamide Salicylamide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08940 Kebuzone Kebuzone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08942 Isoxicam Isoxicam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08951 Indoprofen Indoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08955 Ibuproxam Ibuproxam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08976 Floctafenine Floctafenine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08981 Fenbufen Fenbufen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08984 Etofenamate Etofenamate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08991 Epirizole Epirizole may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09008 Cefaloridine Cefaloridine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09062 Cefminox Cefminox may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09084 Benzydamine Benzydamine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09212 Loxoprofen Loxoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09213 Dexibuprofen Dexibuprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09214 Dexketoprofen Dexketoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09215 Droxicam Droxicam may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09216 Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09217 Firocoxib Firocoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09218 Clonixin Clonixin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09285 Morniflumate Morniflumate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09295 Talniflumate Talniflumate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB09299 Tenofovir alafenamide Tenofovir alafenamide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB11367 Cefroxadine Cefroxadine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB11455 Robenacoxib Robenacoxib may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB11518 Flunixin Flunixin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB11935 Flomoxef Flomoxef may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB12151 Brincidofovir Brincidofovir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB12445 Nitroaspirin Nitroaspirin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB12545 Indobufen Indobufen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13001 Tinoridine Tinoridine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13167 Alclofenac Alclofenac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13217 Fentiazac Fentiazac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13232 Suxibuzone Suxibuzone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13266 Cefatrizine Cefatrizine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13286 Bumadizone Bumadizone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13314 Alminoprofen Alminoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13317 Flunoxaprofen Flunoxaprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13364 Feprazone Feprazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13371 Difenpiramide Difenpiramide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13407 Nifenazone Nifenazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13432 Lonazolac Lonazolac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13461 Cefcapene Cefcapene may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13470 Cefodizime Cefodizime may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13481 Tenidap Tenidap may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13499 Cefsulodin Cefsulodin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13501 Bendazac Bendazac may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13504 Cefetamet Cefetamet may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13514 Pranoprofen Pranoprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13524 Propyphenazone Propyphenazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13527 Proglumetacin Proglumetacin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13538 Guacetisal Guacetisal may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13544 Ethenzamide Ethenzamide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13612 Carbaspirin calcium Carbaspirin calcium may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13629 Mofebutazone Mofebutazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13638 Cefbuperazone Cefbuperazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13649 Proquazone Proquazone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13657 Benorilate Benorilate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13667 Cefozopran Cefozopran may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13682 Cefpirome Cefpirome may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13722 Pirprofen Pirprofen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13778 Cefazedone Cefazedone may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13783 Acemetacin Acemetacin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13821 Ceftezole Ceftezole may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13860 Imidazole salicylate Imidazole salicylate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13868 Adefovir Adefovir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB14059 SC-236 SC-236 may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB14060 NS-398 NS-398 may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB14126 Tenofovir Tenofovir may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB14713 Inotersen Inotersen may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01438 Phenazopyridine Phenazopyridine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB15066 Givosiran Givosiran may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01356 Lithium cation Lithium cation may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB14507 Lithium citrate Lithium citrate may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00007 Leuprolide Leuprolide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00014 Goserelin Goserelin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00035 Desmopressin Desmopressin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00080 Daptomycin Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level.
DB00041 DB00158 Folic acid Aldesleukin may decrease the excretion rate of Folic acid which could result in a higher serum level.
DB00041 DB00165 Pyridoxine Aldesleukin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
DB00041 DB00176 Fluvoxamine Aldesleukin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
DB00041 DB00181 Baclofen Aldesleukin may decrease the excretion rate of Baclofen which could result in a higher serum level.
DB00041 DB00185 Cevimeline Aldesleukin may decrease the excretion rate of Cevimeline which could result in a higher serum level.
DB00041 DB00190 Carbidopa Aldesleukin may decrease the excretion rate of Carbidopa which could result in a higher serum level.
DB00041 DB00196 Fluconazole Aldesleukin may decrease the excretion rate of Fluconazole which could result in a higher serum level.
DB00041 DB00198 Oseltamivir Aldesleukin may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
DB00041 DB00200 Hydroxocobalamin Aldesleukin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
DB00041 DB00206 Reserpine Aldesleukin may decrease the excretion rate of Reserpine which could result in a higher serum level.
DB00041 DB00213 Pantoprazole Aldesleukin may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
DB00041 DB00225 Gadodiamide Aldesleukin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
DB00041 DB00230 Pregabalin Aldesleukin may decrease the excretion rate of Pregabalin which could result in a higher serum level.
DB00041 DB00231 Temazepam Aldesleukin may decrease the excretion rate of Temazepam which could result in a higher serum level.
DB00041 DB00235 Milrinone Aldesleukin may decrease the excretion rate of Milrinone which could result in a higher serum level.
DB00041 DB00243 Ranolazine Aldesleukin may decrease the excretion rate of Ranolazine which could result in a higher serum level.
DB00041 DB00245 Benzatropine Aldesleukin may decrease the excretion rate of Benzatropine which could result in a higher serum level.
DB00041 DB00254 Doxycycline Aldesleukin may decrease the excretion rate of Doxycycline which could result in a higher serum level.
DB00041 DB00270 Isradipine Aldesleukin may decrease the excretion rate of Isradipine which could result in a higher serum level.
DB00041 DB00273 Topiramate Aldesleukin may decrease the excretion rate of Topiramate which could result in a higher serum level.
DB00041 DB00280 Disopyramide Aldesleukin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
DB00041 DB00284 Acarbose Aldesleukin may decrease the excretion rate of Acarbose which could result in a higher serum level.
DB00041 DB00285 Venlafaxine Aldesleukin may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
DB00041 DB00286 Conjugated estrogens Aldesleukin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
DB00041 DB00289 Atomoxetine Aldesleukin may decrease the excretion rate of Atomoxetine which could result in a higher serum level.
DB00041 DB00292 Etomidate Aldesleukin may decrease the excretion rate of Etomidate which could result in a higher serum level.
DB00041 DB00294 Etonogestrel Aldesleukin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
DB00041 DB00296 Ropivacaine Aldesleukin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.
DB00041 DB00303 Ertapenem Aldesleukin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
DB00041 DB00308 Ibutilide Aldesleukin may decrease the excretion rate of Ibutilide which could result in a higher serum level.
DB00041 DB00319 Piperacillin Aldesleukin may decrease the excretion rate of Piperacillin which could result in a higher serum level.
DB00041 DB00323 Tolcapone Aldesleukin may decrease the excretion rate of Tolcapone which could result in a higher serum level.
DB00041 DB00325 Nitroprusside Aldesleukin may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
DB00041 DB00327 Hydromorphone Aldesleukin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
DB00041 DB00330 Ethambutol Aldesleukin may decrease the excretion rate of Ethambutol which could result in a higher serum level.
DB00041 DB00331 Metformin Aldesleukin may decrease the excretion rate of Metformin which could result in a higher serum level.
DB00041 DB00333 Methadone Aldesleukin may decrease the excretion rate of Methadone which could result in a higher serum level.
DB00041 DB00339 Pyrazinamide Aldesleukin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
DB00041 DB00341 Cetirizine Aldesleukin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
DB00041 DB00349 Clobazam Aldesleukin may decrease the excretion rate of Clobazam which could result in a higher serum level.
DB00041 DB00351 Megestrol acetate Aldesleukin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
DB00041 DB00355 Aztreonam Aldesleukin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
DB00041 DB00359 Sulfadiazine Aldesleukin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.
DB00041 DB00364 Sucralfate Aldesleukin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
DB00041 DB00372 Thiethylperazine Aldesleukin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
DB00041 DB00373 Timolol Aldesleukin may decrease the excretion rate of Timolol which could result in a higher serum level.
DB00041 DB00377 Palonosetron Aldesleukin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
DB00041 DB00412 Rosiglitazone Aldesleukin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.
DB00041 DB00413 Pramipexole Aldesleukin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
DB00041 DB00415 Ampicillin Aldesleukin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
DB00041 DB00422 Methylphenidate Aldesleukin may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
DB00041 DB00435 Nitric Oxide Aldesleukin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
DB00041 DB00440 Trimethoprim Aldesleukin may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
DB00041 DB00492 Fosinopril Aldesleukin may decrease the excretion rate of Fosinopril which could result in a higher serum level.
DB00041 DB00499 Flutamide Aldesleukin may decrease the excretion rate of Flutamide which could result in a higher serum level.
DB00041 DB00535 Cefdinir Aldesleukin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
DB00041 DB00537 Ciprofloxacin Aldesleukin may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.
DB00041 DB00548 Azelaic acid Aldesleukin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
DB00041 DB00553 Methoxsalen Aldesleukin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
DB00041 DB00555 Lamotrigine Aldesleukin may decrease the excretion rate of Lamotrigine which could result in a higher serum level.
DB00041 DB00558 Zanamivir Aldesleukin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
DB00041 DB00569 Fondaparinux Aldesleukin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
DB00041 DB00571 Propranolol Aldesleukin may decrease the excretion rate of Propranolol which could result in a higher serum level.
DB00041 DB00583 Levocarnitine Aldesleukin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
DB00041 DB00597 Gadoteridol Aldesleukin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
DB00041 DB00598 Labetalol Aldesleukin may decrease the excretion rate of Labetalol which could result in a higher serum level.
DB00041 DB00603 Medroxyprogesterone acetate Aldesleukin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
DB00041 DB00608 Chloroquine Aldesleukin may decrease the excretion rate of Chloroquine which could result in a higher serum level.
DB00041 DB00612 Bisoprolol Aldesleukin may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
DB00041 DB00624 Testosterone Aldesleukin may decrease the excretion rate of Testosterone which could result in a higher serum level.
DB00041 DB00628 Clorazepic acid Aldesleukin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
DB00041 DB00633 Dexmedetomidine Aldesleukin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
DB00041 DB00651 Dyphylline Aldesleukin may decrease the excretion rate of Dyphylline which could result in a higher serum level.
DB00041 DB00657 Mecamylamine Aldesleukin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
DB00041 DB00660 Metaxalone Aldesleukin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
DB00041 DB00661 Verapamil Aldesleukin may decrease the excretion rate of Verapamil which could result in a higher serum level.
DB00041 DB00665 Nilutamide Aldesleukin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
DB00041 DB00669 Sumatriptan Aldesleukin may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
DB00041 DB00672 Chlorpropamide Aldesleukin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
DB00041 DB00690 Flurazepam Aldesleukin may decrease the excretion rate of Flurazepam which could result in a higher serum level.
DB00041 DB00692 Phentolamine Aldesleukin may decrease the excretion rate of Phentolamine which could result in a higher serum level.
DB00041 DB00698 Nitrofurantoin Aldesleukin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
DB00041 DB00706 Tamsulosin Aldesleukin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
DB00041 DB00709 Lamivudine Aldesleukin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
DB00041 DB00713 Oxacillin Aldesleukin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
DB00041 DB00716 Nedocromil Aldesleukin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
DB00041 DB00722 Lisinopril Aldesleukin may decrease the excretion rate of Lisinopril which could result in a higher serum level.
DB00041 DB00730 Thiabendazole Aldesleukin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
DB00041 DB00731 Nateglinide Aldesleukin may decrease the excretion rate of Nateglinide which could result in a higher serum level.
DB00041 DB00733 Pralidoxime Aldesleukin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
DB00041 DB00743 Gadobenic acid Aldesleukin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
DB00041 DB00759 Tetracycline Aldesleukin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
DB00041 DB00760 Meropenem Aldesleukin may decrease the excretion rate of Meropenem which could result in a higher serum level.
DB00041 DB00761 Potassium chloride Aldesleukin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
DB00041 DB00775 Tirofiban Aldesleukin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
DB00041 DB00782 Propantheline Aldesleukin may decrease the excretion rate of Propantheline which could result in a higher serum level.
DB00041 DB00783 Estradiol Aldesleukin may decrease the excretion rate of Estradiol which could result in a higher serum level.
DB00041 DB00789 Gadopentetic acid Aldesleukin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
DB00041 DB00790 Perindopril Aldesleukin may decrease the excretion rate of Perindopril which could result in a higher serum level.
DB00041 DB00800 Fenoldopam Aldesleukin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
DB00041 DB00804 Dicyclomine Aldesleukin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
DB00041 DB00806 Pentoxifylline Aldesleukin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
DB00041 DB00811 Ribavirin Aldesleukin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
DB00041 DB00828 Fosfomycin Aldesleukin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
DB00041 DB00829 Diazepam Aldesleukin may decrease the excretion rate of Diazepam which could result in a higher serum level.
DB00041 DB00839 Tolazamide Aldesleukin may decrease the excretion rate of Tolazamide which could result in a higher serum level.
DB00041 DB00841 Dobutamine Aldesleukin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
DB00041 DB00842 Oxazepam Aldesleukin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
DB00041 DB00863 Ranitidine Aldesleukin may decrease the excretion rate of Ranitidine which could result in a higher serum level.
DB00041 DB00871 Terbutaline Aldesleukin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
DB00041 DB00894 Testolactone Aldesleukin may decrease the excretion rate of Testolactone which could result in a higher serum level.
DB00041 DB00900 Didanosine Aldesleukin may decrease the excretion rate of Didanosine which could result in a higher serum level.
DB00041 DB00911 Tinidazole Aldesleukin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
DB00041 DB00915 Amantadine Aldesleukin may decrease the excretion rate of Amantadine which could result in a higher serum level.
DB00041 DB00918 Almotriptan Aldesleukin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
DB00041 DB00934 Maprotiline Aldesleukin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
DB00041 DB00951 Isoniazid Aldesleukin may decrease the excretion rate of Isoniazid which could result in a higher serum level.
DB00041 DB00953 Rizatriptan Aldesleukin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
DB00041 DB00960 Pindolol Aldesleukin may decrease the excretion rate of Pindolol which could result in a higher serum level.
DB00041 DB00961 Mepivacaine Aldesleukin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
DB00041 DB00962 Zaleplon Aldesleukin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
DB00041 DB00968 Methyldopa Aldesleukin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
DB00041 DB00980 Ramelteon Aldesleukin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
DB00041 DB00988 Dopamine Aldesleukin may decrease the excretion rate of Dopamine which could result in a higher serum level.
DB00041 DB00995 Auranofin Aldesleukin may decrease the excretion rate of Auranofin which could result in a higher serum level.
DB00041 DB01001 Salbutamol Aldesleukin may decrease the excretion rate of Salbutamol which could result in a higher serum level.
DB00041 DB01002 Levobupivacaine Aldesleukin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.
DB00041 DB01004 Ganciclovir Aldesleukin may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
DB00041 DB01010 Edrophonium Aldesleukin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
DB00041 DB01011 Metyrapone Aldesleukin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
DB00041 DB01018 Guanfacine Aldesleukin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
DB00041 DB01020 Isosorbide mononitrate Aldesleukin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
DB00041 DB01022 Phylloquinone Aldesleukin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
DB00041 DB01032 Probenecid Aldesleukin may decrease the excretion rate of Probenecid which could result in a higher serum level.
DB00041 DB01036 Tolterodine Aldesleukin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
DB00041 DB01043 Memantine Aldesleukin may decrease the excretion rate of Memantine which could result in a higher serum level.
DB00041 DB01046 Lubiprostone Aldesleukin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
DB00041 DB01048 Abacavir Aldesleukin may decrease the excretion rate of Abacavir which could result in a higher serum level.
DB00041 DB01060 Amoxicillin Aldesleukin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
DB00041 DB01067 Glipizide Aldesleukin may decrease the excretion rate of Glipizide which could result in a higher serum level.
DB00041 DB01068 Clonazepam Aldesleukin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
DB00041 DB01069 Promethazine Aldesleukin may decrease the excretion rate of Promethazine which could result in a higher serum level.
DB00041 DB01093 Dimethyl sulfoxide Aldesleukin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
DB00041 DB01105 Sibutramine Aldesleukin may decrease the excretion rate of Sibutramine which could result in a higher serum level.
DB00041 DB01115 Nifedipine Aldesleukin may decrease the excretion rate of Nifedipine which could result in a higher serum level.
DB00041 DB01124 Tolbutamide Aldesleukin may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
DB00041 DB01129 Rabeprazole Aldesleukin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
DB00041 DB01133 Tiludronic acid Aldesleukin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
DB00041 DB01135 Doxacurium Aldesleukin may decrease the excretion rate of Doxacurium which could result in a higher serum level.
DB00041 DB01137 Levofloxacin Aldesleukin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.
DB00041 DB01148 Flavoxate Aldesleukin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
DB00041 DB01149 Nefazodone Aldesleukin may decrease the excretion rate of Nefazodone which could result in a higher serum level.
DB00041 DB01156 Bupropion Aldesleukin may decrease the excretion rate of Bupropion which could result in a higher serum level.
DB00041 DB01157 Trimetrexate Aldesleukin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
DB00041 DB01170 Guanethidine Aldesleukin may decrease the excretion rate of Guanethidine which could result in a higher serum level.
DB00041 DB01183 Naloxone Aldesleukin may decrease the excretion rate of Naloxone which could result in a higher serum level.
DB00041 DB01203 Nadolol Aldesleukin may decrease the excretion rate of Nadolol which could result in a higher serum level.
DB00041 DB01205 Flumazenil Aldesleukin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
DB00041 DB01213 Fomepizole Aldesleukin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
DB00041 DB01215 Estazolam Aldesleukin may decrease the excretion rate of Estazolam which could result in a higher serum level.
DB00041 DB01221 Ketamine Aldesleukin may decrease the excretion rate of Ketamine which could result in a higher serum level.
DB00041 DB01233 Metoclopramide Aldesleukin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
DB00041 DB01240 Epoprostenol Aldesleukin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
DB00041 DB01241 Gemfibrozil Aldesleukin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
DB00041 DB01261 Sitagliptin Aldesleukin may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
DB00041 DB01267 Paliperidone Aldesleukin may decrease the excretion rate of Paliperidone which could result in a higher serum level.
DB00041 DB01273 Varenicline Aldesleukin may decrease the excretion rate of Varenicline which could result in a higher serum level.
DB00041 DB01274 Arformoterol Aldesleukin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
DB00041 DB01275 Hydralazine Aldesleukin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
DB00041 DB01359 Penbutolol Aldesleukin may decrease the excretion rate of Penbutolol which could result in a higher serum level.
DB00041 DB01409 Tiotropium Aldesleukin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
DB00041 DB01420 Testosterone propionate Aldesleukin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
DB00041 DB01427 Amrinone Aldesleukin may decrease the excretion rate of Amrinone which could result in a higher serum level.
DB00041 DB01428 Oxybenzone Aldesleukin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
DB00041 DB01550 Fenproporex Aldesleukin may decrease the excretion rate of Fenproporex which could result in a higher serum level.
DB00041 DB01558 Bromazepam Aldesleukin may decrease the excretion rate of Bromazepam which could result in a higher serum level.
DB00041 DB01563 Chloral hydrate Aldesleukin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
DB00041 DB01577 Metamfetamine Aldesleukin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
DB00041 DB01587 Ketazolam Aldesleukin may decrease the excretion rate of Ketazolam which could result in a higher serum level.
DB00041 DB01610 Valganciclovir Aldesleukin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
DB00041 DB01638 Sorbitol Aldesleukin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
DB00041 DB01685 Topiroxostat Aldesleukin may decrease the excretion rate of Topiroxostat which could result in a higher serum level.
DB00041 DB04574 Estrone sulfate Aldesleukin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
DB00041 DB04871 Lorcaserin Aldesleukin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
DB00041 DB04895 Pegaptanib Aldesleukin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
DB00041 DB04896 Milnacipran Aldesleukin may decrease the excretion rate of Milnacipran which could result in a higher serum level.
DB00041 DB04920 Clevidipine Aldesleukin may decrease the excretion rate of Clevidipine which could result in a higher serum level.
DB00041 DB04948 Lofexidine Aldesleukin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
DB00041 DB04953 Ezogabine Aldesleukin may decrease the excretion rate of Ezogabine which could result in a higher serum level.
DB00041 DB05018 Migalastat Aldesleukin may decrease the excretion rate of Migalastat which could result in a higher serum level.
DB00041 DB05541 Brivaracetam Aldesleukin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
DB00041 DB06154 Pentaerythritol tetranitrate Aldesleukin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
DB00041 DB06186 Ipilimumab Aldesleukin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
DB00041 DB06196 Icatibant Aldesleukin may decrease the excretion rate of Icatibant which could result in a higher serum level.
DB00041 DB06203 Alogliptin Aldesleukin may decrease the excretion rate of Alogliptin which could result in a higher serum level.
DB00041 DB06209 Prasugrel Aldesleukin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
DB00041 DB06211 Doripenem Aldesleukin may decrease the excretion rate of Doripenem which could result in a higher serum level.
DB00041 DB06230 Nalmefene Aldesleukin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
DB00041 DB06262 Droxidopa Aldesleukin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
DB00041 DB06282 Levocetirizine Aldesleukin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
DB00041 DB06335 Saxagliptin Aldesleukin may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
DB00041 DB06402 Telavancin Aldesleukin may decrease the excretion rate of Telavancin which could result in a higher serum level.
DB00041 DB06623 Flupirtine Aldesleukin may decrease the excretion rate of Flupirtine which could result in a higher serum level.
DB00041 DB06637 Dalfampridine Aldesleukin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
DB00041 DB06695 Dabigatran etexilate Aldesleukin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
DB00041 DB06700 Desvenlafaxine Aldesleukin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
DB00041 DB06702 Fesoterodine Aldesleukin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
DB00041 DB06705 Gadofosveset trisodium Aldesleukin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
DB00041 DB06710 Methyltestosterone Aldesleukin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
DB00041 DB06767 Ammonium chloride Aldesleukin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
DB00041 DB06782 Dimercaprol Aldesleukin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
DB00041 DB06796 Mangafodipir Aldesleukin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
DB00041 DB06800 Methylnaltrexone Aldesleukin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
DB00041 DB06809 Plerixafor Aldesleukin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
DB00041 DB06823 Tiopronin Aldesleukin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
DB00041 DB06824 Triethylenetetramine Aldesleukin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
DB00041 DB08824 Ioflupane I-123 Aldesleukin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
DB00041 DB08826 Deferiprone Aldesleukin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
DB00041 DB08840 N-methylnicotinamide Aldesleukin may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.
DB00041 DB08872 Gabapentin enacarbil Aldesleukin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
DB00041 DB08893 Mirabegron Aldesleukin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
DB00041 DB08897 Aclidinium Aldesleukin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
DB00041 DB08899 Enzalutamide Aldesleukin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
DB00041 DB08900 Teduglutide Aldesleukin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
DB00041 DB08905 Formestane Aldesleukin may decrease the excretion rate of Formestane which could result in a higher serum level.
DB00041 DB08909 Glycerol phenylbutyrate Aldesleukin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
DB00041 DB08911 Trametinib Aldesleukin may decrease the excretion rate of Trametinib which could result in a higher serum level.
DB00041 DB08918 Levomilnacipran Aldesleukin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
DB00041 DB08932 Macitentan Aldesleukin may decrease the excretion rate of Macitentan which could result in a higher serum level.
DB00041 DB08934 Sofosbuvir Aldesleukin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
DB00041 DB08964 Gemeprost Aldesleukin may decrease the excretion rate of Gemeprost which could result in a higher serum level.
DB00041 DB09027 Ledipasvir Aldesleukin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
DB00041 DB09050 Ceftolozane Aldesleukin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
DB00041 DB09066 Corifollitropin alfa Aldesleukin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.
DB00041 DB09068 Vortioxetine Aldesleukin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
DB00041 DB09075 Edoxaban Aldesleukin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
DB00041 DB09081 Idebenone Aldesleukin may decrease the excretion rate of Idebenone which could result in a higher serum level.
DB00041 DB09089 Trimebutine Aldesleukin may decrease the excretion rate of Trimebutine which could result in a higher serum level.
DB00041 DB09103 Ancestim Aldesleukin may decrease the excretion rate of Ancestim which could result in a higher serum level.
DB00041 DB09104 Magnesium hydroxide Aldesleukin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
DB00041 DB09106 Hydroxyethyl Starch Aldesleukin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
DB00041 DB09111 Pentastarch Aldesleukin may decrease the excretion rate of Pentastarch which could result in a higher serum level.
DB00041 DB09118 Stiripentol Aldesleukin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
DB00041 DB09121 Aurothioglucose Aldesleukin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
DB00041 DB09123 Dienogest Aldesleukin may decrease the excretion rate of Dienogest which could result in a higher serum level.
DB00041 DB09129 Chromic chloride Aldesleukin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
DB00041 DB09132 Gadoteric acid Aldesleukin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
DB00041 DB09133 Iothalamic acid Aldesleukin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
DB00041 DB09136 Isosulfan blue Aldesleukin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
DB00041 DB09137 Technetium Tc-99m mebrofenin Aldesleukin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
DB00041 DB09139 Technetium Tc-99m oxidronate Aldesleukin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
DB00041 DB09148 Florbetaben (18F) Aldesleukin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
DB00041 DB09149 Florbetapir (18F) Aldesleukin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
DB00041 DB09163 Technetium Tc-99m exametazime Aldesleukin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
DB00041 DB09165 Technetium Tc-99m pyrophosphate Aldesleukin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
DB00041 DB09185 Viloxazine Aldesleukin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
DB00041 DB09194 Etoperidone Aldesleukin may decrease the excretion rate of Etoperidone which could result in a higher serum level.
DB00041 DB09195 Lorpiprazole Aldesleukin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
DB00041 DB09204 Arotinolol Aldesleukin may decrease the excretion rate of Arotinolol which could result in a higher serum level.
DB00041 DB09205 Moxisylyte Aldesleukin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
DB00041 DB09209 Pholcodine Aldesleukin may decrease the excretion rate of Pholcodine which could result in a higher serum level.
DB00041 DB09210 Piracetam Aldesleukin may decrease the excretion rate of Piracetam which could result in a higher serum level.
DB00041 DB09219 Bisoxatin Aldesleukin may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
DB00041 DB09223 Blonanserin Aldesleukin may decrease the excretion rate of Blonanserin which could result in a higher serum level.
DB00041 DB09224 Melperone Aldesleukin may decrease the excretion rate of Melperone which could result in a higher serum level.
DB00041 DB09255 Dextran Aldesleukin may decrease the excretion rate of Dextran which could result in a higher serum level.
DB00041 DB09256 Tegafur Aldesleukin may decrease the excretion rate of Tegafur which could result in a higher serum level.
DB00041 DB09257 Gimeracil Aldesleukin may decrease the excretion rate of Gimeracil which could result in a higher serum level.
DB00041 DB09262 Imidafenacin Aldesleukin may decrease the excretion rate of Imidafenacin which could result in a higher serum level.
DB00041 DB09264 Idarucizumab Aldesleukin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
DB00041 DB09265 Lixisenatide Aldesleukin may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
DB00041 DB09268 Picosulfuric acid Aldesleukin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
DB00041 DB09276 Sodium aurothiomalate Aldesleukin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
DB00041 DB09277 Choline C 11 Aldesleukin may decrease the excretion rate of Choline C 11 which could result in a higher serum level.
DB00041 DB09281 Magnesium trisilicate Aldesleukin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
DB00041 DB09292 Sacubitril Aldesleukin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
DB00041 DB09301 Chondroitin sulfate Aldesleukin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
DB00041 DB09317 Synthetic Conjugated Estrogens, A Aldesleukin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
DB00041 DB09318 Synthetic Conjugated Estrogens, B Aldesleukin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
DB00041 DB09320 Procaine benzylpenicillin Aldesleukin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
DB00041 DB09324 Sulbactam Aldesleukin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
DB00041 DB09325 Sodium fluoride Aldesleukin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
DB00041 DB09329 Antihemophilic Factor (Recombinant), PEGylated Aldesleukin may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.
DB00041 DB09344 Invert sugar Aldesleukin may decrease the excretion rate of Invert sugar which could result in a higher serum level.
DB00041 DB09357 Dexpanthenol Aldesleukin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
DB00041 DB09394 Phosphoric acid Aldesleukin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
DB00041 DB09395 Sodium acetate Aldesleukin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
DB00041 DB09407 Magnesium chloride Aldesleukin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
DB00041 DB09472 Sodium sulfate Aldesleukin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
DB00041 DB09477 Enalaprilat Aldesleukin may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
DB00041 DB09481 Magnesium carbonate Aldesleukin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
DB00041 DB09488 Acrivastine Aldesleukin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
DB00041 DB09496 Octinoxate Aldesleukin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
DB00041 DB09502 Fludeoxyglucose (18F) Aldesleukin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
DB00041 DB09546 Iobenguane sulfate I-123 Aldesleukin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
DB00041 DB11077 Polyethylene glycol 400 Aldesleukin may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.
DB00041 DB11090 Potassium nitrate Aldesleukin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
DB00041 DB11098 Potassium bicarbonate Aldesleukin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
DB00041 DB11102 N-acetyltyrosine Aldesleukin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
DB00041 DB11114 Eucalyptus oil Aldesleukin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
DB00041 DB11127 Selenious acid Aldesleukin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
DB00041 DB11130 Opium Aldesleukin may decrease the excretion rate of Opium which could result in a higher serum level.
DB00041 DB11135 Selenium Aldesleukin may decrease the excretion rate of Selenium which could result in a higher serum level.
DB00041 DB11136 Chromium Aldesleukin may decrease the excretion rate of Chromium which could result in a higher serum level.
DB00041 DB11145 Oxyquinoline Aldesleukin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
DB00041 DB11156 Pyrantel Aldesleukin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
DB00041 DB11164 Bicisate Aldesleukin may decrease the excretion rate of Bicisate which could result in a higher serum level.
DB00041 DB11251 Tocopherol Aldesleukin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
DB00041 DB11278 DL-Methylephedrine Aldesleukin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DB00041 DB11328 Tetradecyl hydrogen sulfate (ester) Aldesleukin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
DB00041 DB11338 Clove oil Aldesleukin may decrease the excretion rate of Clove oil which could result in a higher serum level.
DB00041 DB11358 Evening primrose oil Aldesleukin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
DB00041 DB11364 Pidotimod Aldesleukin may decrease the excretion rate of Pidotimod which could result in a higher serum level.
DB00041 DB11560 Lesinurad Aldesleukin may decrease the excretion rate of Lesinurad which could result in a higher serum level.
DB00041 DB11577 Indigotindisulfonic acid Aldesleukin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
DB00041 DB11587 Etafedrine Aldesleukin may decrease the excretion rate of Etafedrine which could result in a higher serum level.
DB00041 DB11598 Antithrombin III human Aldesleukin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
DB00041 DB11642 Pitolisant Aldesleukin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
DB00041 DB11691 Naldemedine Aldesleukin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
DB00041 DB11699 Tropisetron Aldesleukin may decrease the excretion rate of Tropisetron which could result in a higher serum level.
DB00041 DB11901 Apalutamide Aldesleukin may decrease the excretion rate of Apalutamide which could result in a higher serum level.
DB00041 DB11915 Valbenazine Aldesleukin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
DB00041 DB11943 Delafloxacin Aldesleukin may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
DB00041 DB11989 Benznidazole Aldesleukin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
DB00041 DB12007 Isoflavone Aldesleukin may decrease the excretion rate of Isoflavone which could result in a higher serum level.
DB00041 DB12107 Vaborbactam Aldesleukin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
DB00041 DB12161 Deutetrabenazine Aldesleukin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
DB00041 DB12278 Propiverine Aldesleukin may decrease the excretion rate of Propiverine which could result in a higher serum level.
DB00041 DB12783 Benserazide Aldesleukin may decrease the excretion rate of Benserazide which could result in a higher serum level.
DB00041 DB13025 Tiapride Aldesleukin may decrease the excretion rate of Tiapride which could result in a higher serum level.
DB00041 DB13139 Levosalbutamol Aldesleukin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
DB00041 DB13156 Inosine pranobex Aldesleukin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
DB00041 DB13178 Inositol Aldesleukin may decrease the excretion rate of Inositol which could result in a higher serum level.
DB00041 DB13185 Oxabolone cipionate Aldesleukin may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.
DB00041 DB13191 Phosphocreatine Aldesleukin may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.
DB00041 DB13269 Dichlorobenzyl alcohol Aldesleukin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
DB00041 DB13293 Ipecac Aldesleukin may decrease the excretion rate of Ipecac which could result in a higher serum level.
DB00041 DB13595 Almasilate Aldesleukin may decrease the excretion rate of Almasilate which could result in a higher serum level.
DB00041 DB13873 Fenofibric acid Aldesleukin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
DB00041 DB13884 Albutrepenonacog alfa Aldesleukin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
DB00041 DB13909 Bismuth subgallate Aldesleukin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
DB00041 DB13943 Testosterone cypionate Aldesleukin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
DB00041 DB13944 Testosterone enanthate Aldesleukin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
DB00041 DB13946 Testosterone undecanoate Aldesleukin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
DB00041 DB13952 Estradiol acetate Aldesleukin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
DB00041 DB13954 Estradiol cypionate Aldesleukin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
DB00041 DB13955 Estradiol dienanthate Aldesleukin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
DB00041 DB13956 Estradiol valerate Aldesleukin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
DB00041 DB13967 Patent Blue Aldesleukin may decrease the excretion rate of Patent Blue which could result in a higher serum level.
DB00041 DB14006 Choline salicylate Aldesleukin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
DB00041 DB14007 Pentetic acid Aldesleukin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
DB00041 DB14498 Potassium acetate Aldesleukin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
DB00041 DB14499 Potassium sulfate Aldesleukin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
DB00041 DB14526 Chromic citrate Aldesleukin may decrease the excretion rate of Chromic citrate which could result in a higher serum level.
DB00041 DB14527 Chromic nitrate Aldesleukin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
DB00041 DB14528 Chromium gluconate Aldesleukin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
DB00041 DB14529 Chromium nicotinate Aldesleukin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
DB00041 DB14530 Chromous sulfate Aldesleukin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
DB00041 DB14754 Solriamfetol Aldesleukin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
DB00041 DB06815 Pyrithione Aldesleukin may decrease the excretion rate of Pyrithione which could result in a higher serum level.
DB00041 DB11121 Chloroxylenol Aldesleukin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.
DB00041 DB11085 Resorcinol Aldesleukin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
DB00041 DB01224 Quetiapine Aldesleukin may decrease the excretion rate of Quetiapine which could result in a higher serum level.
DB00041 DB00501 Cimetidine Aldesleukin may decrease the excretion rate of Cimetidine which could result in a higher serum level.
DB00041 DB15593 Golodirsen Aldesleukin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
DB00041 DB00321 Amitriptyline Aldesleukin may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
DB00041 DB00458 Imipramine Aldesleukin may decrease the excretion rate of Imipramine which could result in a higher serum level.
DB00041 DB00490 Buspirone Aldesleukin may decrease the excretion rate of Buspirone which could result in a higher serum level.
DB00041 DB00820 Tadalafil Aldesleukin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
DB00041 DB01142 Doxepin Aldesleukin may decrease the excretion rate of Doxepin which could result in a higher serum level.
DB00041 DB00318 Codeine Aldesleukin may decrease the excretion rate of Codeine which could result in a higher serum level.
DB00041 DB00879 Emtricitabine Aldesleukin may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
DB00041 DB00897 Triazolam Aldesleukin may decrease the excretion rate of Triazolam which could result in a higher serum level.
DB00041 DB06228 Rivaroxaban Aldesleukin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
DB00041 DB08996 Dimetacrine Aldesleukin may decrease the excretion rate of Dimetacrine which could result in a higher serum level.
DB00041 DB14506 Lithium hydroxide Aldesleukin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.
DB00041 DB00452 Framycetin Framycetin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00479 Amikacin Amikacin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00684 Tobramycin Tobramycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00798 Gentamicin Gentamicin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00955 Netilmicin Netilmicin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB00994 Neomycin Neomycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01082 Streptomycin Streptomycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01172 Kanamycin Kanamycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB01421 Paromomycin Paromomycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB03615 Ribostamycin Ribostamycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04263 Geneticin Geneticin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04626 Apramycin Apramycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04729 Gentamicin C1a Gentamicin C1a may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB04808 Neamine Neamine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB06696 Arbekacin Arbekacin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB08437 Puromycin Puromycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB11512 Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB11520 Hygromycin B Hygromycin B may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB12604 Sisomicin Sisomicin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13270 Dibekacin Dibekacin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13274 Micronomicin Micronomicin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13540 Isepamicin Isepamicin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13673 Bekanamycin Bekanamycin may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
DB00041 DB13145 Nedaplatin Aldesleukin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
DB00041 DB00314 Capreomycin Aldesleukin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
DB00041 DB00390 Digoxin Aldesleukin may decrease the excretion rate of Digoxin which could result in a higher serum level.
DB00041 DB00512 Vancomycin Aldesleukin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
DB00041 DB00982 Isotretinoin Aldesleukin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
DB00041 DB01035 Procainamide Aldesleukin may decrease the excretion rate of Procainamide which could result in a higher serum level.
DB00041 DB12615 Plazomicin Aldesleukin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
DB00041 DB14509 Lithium carbonate Aldesleukin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
DB00041 DB00232 Methyclothiazide Aldesleukin may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00421 Spironolactone Aldesleukin may increase the excretion rate of Spironolactone which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00594 Amiloride Aldesleukin may increase the excretion rate of Amiloride which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00703 Methazolamide Aldesleukin may increase the excretion rate of Methazolamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB01144 Diclofenamide Aldesleukin may increase the excretion rate of Diclofenamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB09125 Potassium citrate Potassium citrate may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00562 Benzthiazide Benzthiazide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13430 Mebutizide Mebutizide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00214 Torasemide Aldesleukin may increase the excretion rate of Torasemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00310 Chlorthalidone Aldesleukin may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00436 Bendroflumethiazide Aldesleukin may increase the excretion rate of Bendroflumethiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00606 Cyclothiazide Aldesleukin may increase the excretion rate of Cyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00774 Hydroflumethiazide Aldesleukin may increase the excretion rate of Hydroflumethiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00880 Chlorothiazide Aldesleukin may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB01021 Trichlormethiazide Aldesleukin may increase the excretion rate of Trichlormethiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB01119 Diazoxide Aldesleukin may increase the excretion rate of Diazoxide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB01324 Polythiazide Aldesleukin may increase the excretion rate of Polythiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB04831 Tienilic acid Aldesleukin may increase the excretion rate of Tienilic acid which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB12766 Cicletanine Aldesleukin may increase the excretion rate of Cicletanine which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13532 Cyclopenthiazide Aldesleukin may increase the excretion rate of Cyclopenthiazide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13801 Muzolimine Aldesleukin may increase the excretion rate of Muzolimine which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13803 Xipamide Aldesleukin may increase the excretion rate of Xipamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00524 Metolazone Aldesleukin may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00695 Furosemide Aldesleukin may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00808 Indapamide Aldesleukin may increase the excretion rate of Indapamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00887 Bumetanide Aldesleukin may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00909 Zonisamide Aldesleukin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB08907 Canagliflozin Aldesleukin may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB09338 Mersalyl Aldesleukin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00311 Ethoxzolamide Ethoxzolamide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00819 Acetazolamide Acetazolamide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB01325 Quinethazone Quinethazone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB01412 Theobromine Theobromine may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB02925 Piretanide Piretanide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB05034 Ularitide Ularitide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB06370 Indisulam Indisulam may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB08961 Azosemide Azosemide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB09015 Canrenoic acid Canrenoic acid may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB09401 Isosorbide Isosorbide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB11827 Ertugliflozin Ertugliflozin may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB12221 Canrenone Canrenone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB12670 Rolofylline Rolofylline may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB12704 Spiradoline Spiradoline may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13284 Meticrane Meticrane may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13316 Ibopamine Ibopamine may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13405 Mefruside Mefruside may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13617 Clorexolone Clorexolone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13663 Clofenamide Clofenamide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13708 Fenquizone Fenquizone may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13792 Clopamide Clopamide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB13989 Epitizide Epitizide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB14018 Bromotheophylline Bromotheophylline may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB14500 Potassium Potassium may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB09235 Efonidipine Aldesleukin may increase the excretion rate of Efonidipine which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB06292 Dapagliflozin Dapagliflozin may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00700 Eplerenone Aldesleukin may increase the excretion rate of Eplerenone which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00872 Conivaptan Aldesleukin may increase the excretion rate of Conivaptan which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB06212 Tolvaptan Tolvaptan may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.
DB00041 DB00228 Enflurane The metabolism of Enflurane can be decreased when combined with Aldesleukin.
DB00041 DB00347 Trimethadione The metabolism of Trimethadione can be decreased when combined with Aldesleukin.
DB00041 DB00753 Isoflurane The metabolism of Isoflurane can be decreased when combined with Aldesleukin.
DB00041 DB01028 Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Aldesleukin.
DB00041 DB01159 Halothane The metabolism of Halothane can be decreased when combined with Aldesleukin.
DB00041 DB01236 Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Aldesleukin.
DB00041 DB06712 Nilvadipine The metabolism of Nilvadipine can be decreased when combined with Aldesleukin.
DB00041 DB06728 Aniline The metabolism of Aniline can be decreased when combined with Aldesleukin.
DB00041 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Aldesleukin.
DB00041 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Aldesleukin.
DB00041 DB00949 Felbamate The metabolism of Felbamate can be decreased when combined with Aldesleukin.
DB00041 DB01136 Carvedilol The metabolism of Carvedilol can be decreased when combined with Aldesleukin.
DB00041 DB06119 Cenobamate The metabolism of Cenobamate can be decreased when combined with Aldesleukin.
DB00041 DB00252 Phenytoin The metabolism of Phenytoin can be decreased when combined with Aldesleukin.
DB00041 DB00593 Ethosuximide The metabolism of Ethosuximide can be decreased when combined with Aldesleukin.
DB00041 DB11689 Selumetinib The metabolism of Selumetinib can be decreased when combined with Aldesleukin.
DB00041 DB00908 Quinidine The metabolism of Quinidine can be decreased when combined with Aldesleukin.
DB00041 DB00001 Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin.
DB00041 DB00006 Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Aldesleukin.
DB00041 DB00009 Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Aldesleukin.
DB00041 DB00013 Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Aldesleukin.
DB00041 DB00015 Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Aldesleukin.
DB00041 DB00029 Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Aldesleukin.
DB00041 DB00031 Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Aldesleukin.
DB00041 DB00055 Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Aldesleukin.
DB00041 DB00266 Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Aldesleukin.
DB00041 DB00407 Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Aldesleukin.
DB00041 DB00498 Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Aldesleukin.
DB00041 DB00686 Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Aldesleukin.
DB00041 DB01109 Heparin The risk or severity of bleeding can be increased when Heparin is combined with Aldesleukin.
DB00041 DB01225 Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Aldesleukin.
DB00041 DB04665 Coumarin The risk or severity of bleeding can be increased when Coumarin is combined with Aldesleukin.
DB00041 DB04898 Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Aldesleukin.
DB00041 DB04925 Desmoteplase The risk or severity of bleeding can be increased when Desmoteplase is combined with Aldesleukin.
DB00041 DB05099 Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Aldesleukin.
DB00041 DB05254 Fibrinolysin The risk or severity of bleeding can be increased when Fibrinolysin is combined with Aldesleukin.
DB00041 DB06271 Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Aldesleukin.
DB00041 DB06294 Semuloparin The risk or severity of bleeding can be increased when Semuloparin is combined with Aldesleukin.
DB00041 DB06406 Idraparinux The risk or severity of bleeding can be increased when Idraparinux is combined with Aldesleukin.
DB00041 DB06543 Astaxanthin The risk or severity of bleeding can be increased when Astaxanthin is combined with Aldesleukin.
DB00041 DB06635 Otamixaban The risk or severity of bleeding can be increased when Otamixaban is combined with Aldesleukin.
DB00041 DB06679 Amediplase The risk or severity of bleeding can be increased when Amediplase is combined with Aldesleukin.
DB00041 DB06754 Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Aldesleukin.
DB00041 DB06779 Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Aldesleukin.
DB00041 DB06822 Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Aldesleukin.
DB00041 DB08813 Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Aldesleukin.
DB00041 DB08994 Ditazole The risk or severity of bleeding can be increased when Ditazole is combined with Aldesleukin.
DB00041 DB09154 Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Aldesleukin.
DB00041 DB09258 Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Aldesleukin.
DB00041 DB09259 Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Aldesleukin.
DB00041 DB09260 Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Aldesleukin.
DB00041 DB09261 Certoparin The risk or severity of bleeding can be increased when Certoparin is combined with Aldesleukin.
DB00041 DB11095 Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Aldesleukin.
DB00041 DB11154 Zinc citrate The risk or severity of bleeding can be increased when Zinc citrate is combined with Aldesleukin.
DB00041 DB11166 Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Aldesleukin.
DB00041 DB11312 Protein C The risk or severity of bleeding can be increased when Protein C is combined with Aldesleukin.
DB00041 DB11984 Letaxaban The risk or severity of bleeding can be increased when Letaxaban is combined with Aldesleukin.
DB00041 DB12289 Darexaban The risk or severity of bleeding can be increased when Darexaban is combined with Aldesleukin.
DB00041 DB12364 Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Aldesleukin.
DB00041 DB12598 Nafamostat The risk or severity of bleeding can be increased when Nafamostat is combined with Aldesleukin.
DB00041 DB12726 Monteplase The risk or severity of bleeding can be increased when Monteplase is combined with Aldesleukin.
DB00041 DB12831 Gabexate The risk or severity of bleeding can be increased when Gabexate is combined with Aldesleukin.
DB00041 DB13149 Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Aldesleukin.
DB00041 DB13199 Brinase The risk or severity of bleeding can be increased when Brinase is combined with Aldesleukin.
DB00041 DB13451 Tioclomarol The risk or severity of bleeding can be increased when Tioclomarol is combined with Aldesleukin.
DB00041 DB13616 Melagatran The risk or severity of bleeding can be increased when Melagatran is combined with Aldesleukin.
DB00041 DB13646 Saruplase The risk or severity of bleeding can be increased when Saruplase is combined with Aldesleukin.
DB00041 DB14598 Edetate calcium disodium anhydrous The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Aldesleukin.
DB00041 DB14726 Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Aldesleukin.
DB00041 DB07767 Ferulic acid The risk or severity of bleeding can be increased when Aldesleukin is combined with Ferulic acid.
DB00041 DB14094 Tocopherylquinone The risk or severity of bleeding can be increased when Aldesleukin is combined with Tocopherylquinone.
DB00041 DB00278 Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Aldesleukin.
DB00041 DB06605 Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Aldesleukin.
DB00041 DB08794 Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Aldesleukin.
DB00041 DB13347 Diphenadione The risk or severity of bleeding can be increased when Diphenadione is combined with Aldesleukin.
DB00041 DB09042 Tedizolid phosphate The risk or severity of myelosuppression can be increased when Aldesleukin is combined with Tedizolid phosphate.
DB00041 DB06480 Prucalopride The metabolism of Prucalopride can be decreased when combined with Aldesleukin.
DB00041 DB00091 Cyclosporine Aldesleukin may increase the immunosuppressive activities of Cyclosporine.
DB00041 DB00115 Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Aldesleukin.
DB00041 DB00017 Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Aldesleukin.
DB00041 DB00024 Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Aldesleukin.
DB00041 DB00066 Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Aldesleukin.
DB00041 DB00279 Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Aldesleukin.
DB00041 DB00389 Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Aldesleukin.
DB00041 DB00451 Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Aldesleukin.
DB00041 DB00550 Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aldesleukin.
DB00041 DB00763 Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Aldesleukin.
DB00041 DB01583 Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Aldesleukin.
DB00041 DB03374 3,5-Diiodotyrosine The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Aldesleukin.
DB00041 DB03604 Tiratricol The therapeutic efficacy of Tiratricol can be decreased when used in combination with Aldesleukin.
DB00041 DB05084 Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Aldesleukin.
DB00041 DB05829 Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Aldesleukin.
DB00041 DB06285 Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Aldesleukin.
DB00041 DB06715 Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Aldesleukin.
DB00041 DB07637 Dibromotyrosine The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Aldesleukin.
DB00041 DB09100 Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Aldesleukin.
DB00041 DB09418 Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Aldesleukin.
DB00041 DB09421 Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Aldesleukin.
DB00041 DB12629 3,5-diiodothyropropionic acid The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Aldesleukin.
DB00041 DB13644 Methylthiouracil The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Aldesleukin.
DB00041 DB13742 Elcatonin The therapeutic efficacy of Elcatonin can be decreased when used in combination with Aldesleukin.
DB00041 DB13804 Benzylthiouracil The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Aldesleukin.
DB00041 DB15263 Thyrotropin The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Aldesleukin.
DB00041 DB00437 Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Aldesleukin.
DB00041 DB00316 Acetaminophen Aldesleukin may increase the hepatotoxic activities of Acetaminophen.
DB00041 DB09288 Propacetamol Aldesleukin may increase the hepatotoxic activities of Propacetamol.
DB00041 DB00212 Remikiren Aldesleukin may increase the hypotensive activities of Remikiren.
DB00041 DB00217 Bethanidine Aldesleukin may increase the hypotensive activities of Bethanidine.
DB00041 DB00226 Guanadrel Aldesleukin may increase the hypotensive activities of Guanadrel.
DB00041 DB00374 Treprostinil Aldesleukin may increase the hypotensive activities of Treprostinil.
DB00041 DB00616 Candoxatril Aldesleukin may increase the hypotensive activities of Candoxatril.
DB00041 DB00629 Guanabenz Aldesleukin may increase the hypotensive activities of Guanabenz.
DB00041 DB00765 Metyrosine Aldesleukin may increase the hypotensive activities of Metyrosine.
DB00041 DB00785 Cryptenamine Aldesleukin may increase the hypotensive activities of Cryptenamine.
DB00041 DB00866 Alprenolol Aldesleukin may increase the hypotensive activities of Alprenolol.
DB00041 DB00886 Omapatrilat Aldesleukin may increase the hypotensive activities of Omapatrilat.
DB00041 DB01089 Deserpidine Aldesleukin may increase the hypotensive activities of Deserpidine.
DB00041 DB01090 Pentolinium Aldesleukin may increase the hypotensive activities of Pentolinium.
DB00041 DB01116 Trimethaphan Aldesleukin may increase the hypotensive activities of Trimethaphan.
DB00041 DB01180 Rescinnamine Aldesleukin may increase the hypotensive activities of Rescinnamine.
DB00041 DB01295 Bevantolol Aldesleukin may increase the hypotensive activities of Bevantolol.
DB00041 DB01297 Practolol Aldesleukin may increase the hypotensive activities of Practolol.
DB00041 DB01347 Saprisartan Aldesleukin may increase the hypotensive activities of Saprisartan.
DB00041 DB01348 Spirapril Aldesleukin may increase the hypotensive activities of Spirapril.
DB00041 DB03322 Dexpropranolol Aldesleukin may increase the hypotensive activities of Dexpropranolol.
DB00041 DB04840 Debrisoquine Aldesleukin may increase the hypotensive activities of Debrisoquine.
DB00041 DB04846 Celiprolol Aldesleukin may increase the hypotensive activities of Celiprolol.
DB00041 DB06268 Sitaxentan Aldesleukin may increase the hypotensive activities of Sitaxentan.
DB00041 DB06445 Diethylnorspermine Aldesleukin may increase the hypotensive activities of Diethylnorspermine.
DB00041 DB08808 Bupranolol Aldesleukin may increase the hypotensive activities of Bupranolol.
DB00041 DB08836 Temocapril Aldesleukin may increase the hypotensive activities of Temocapril.
DB00041 DB08952 Indenolol Aldesleukin may increase the hypotensive activities of Indenolol.
DB00041 DB08960 Hexamethonium Aldesleukin may increase the hypotensive activities of Hexamethonium.
DB00041 DB09206 Trimazosin Aldesleukin may increase the hypotensive activities of Trimazosin.
DB00041 DB09363 Rauwolfia serpentina root Aldesleukin may increase the hypotensive activities of Rauwolfia serpentina root.
DB00041 DB11720 Angiotensin 1-7 Aldesleukin may increase the hypotensive activities of Angiotensin 1-7.
DB00041 DB11738 Rilmenidine Aldesleukin may increase the hypotensive activities of Rilmenidine.
DB00041 DB11770 Talinolol Aldesleukin may increase the hypotensive activities of Talinolol.
DB00041 DB12054 BQ-123 Aldesleukin may increase the hypotensive activities of BQ-123.
DB00041 DB12212 Landiolol Aldesleukin may increase the hypotensive activities of Landiolol.
DB00041 DB12661 Urapidil Aldesleukin may increase the hypotensive activities of Urapidil.
DB00041 DB12945 Dihydralazine Aldesleukin may increase the hypotensive activities of Dihydralazine.
DB00041 DB13166 Zofenopril Aldesleukin may increase the hypotensive activities of Zofenopril.
DB00041 DB13211 Guanoxan Aldesleukin may increase the hypotensive activities of Guanoxan.
DB00041 DB13312 Delapril Aldesleukin may increase the hypotensive activities of Delapril.
DB00041 DB13374 Vincamine Aldesleukin may increase the hypotensive activities of Vincamine.
DB00041 DB13410 Guanoxabenz Aldesleukin may increase the hypotensive activities of Guanoxabenz.
DB00041 DB13429 Tolonidine Aldesleukin may increase the hypotensive activities of Tolonidine.
DB00041 DB13435 Endralazine Aldesleukin may increase the hypotensive activities of Endralazine.
DB00041 DB13443 Esatenolol Aldesleukin may increase the hypotensive activities of Esatenolol.
DB00041 DB13452 Cadralazine Aldesleukin may increase the hypotensive activities of Cadralazine.
DB00041 DB13508 Cloranolol Aldesleukin may increase the hypotensive activities of Cloranolol.
DB00041 DB13575 Bietaserpine Aldesleukin may increase the hypotensive activities of Bietaserpine.
DB00041 DB13604 Guanazodine Aldesleukin may increase the hypotensive activities of Guanazodine.
DB00041 DB13631 Methoserpidine Aldesleukin may increase the hypotensive activities of Methoserpidine.
DB00041 DB13757 Epanolol Aldesleukin may increase the hypotensive activities of Epanolol.
DB00041 DB13779 Guanoclor Aldesleukin may increase the hypotensive activities of Guanoclor.
DB00041 DB13919 Candesartan Aldesleukin may increase the hypotensive activities of Candesartan.
DB00041 DB14125 Benazeprilat Aldesleukin may increase the hypotensive activities of Benazeprilat.
DB00041 DB14207 Fosinoprilat Aldesleukin may increase the hypotensive activities of Fosinoprilat.
DB00041 DB14208 Ramiprilat Aldesleukin may increase the hypotensive activities of Ramiprilat.
DB00041 DB14213 Perindoprilat Aldesleukin may increase the hypotensive activities of Perindoprilat.
DB00041 DB14217 Quinaprilat Aldesleukin may increase the hypotensive activities of Quinaprilat.
DB00041 DB00559 Bosentan Aldesleukin may increase the hypotensive activities of Bosentan.
DB00041 DB01388 Mibefradil Aldesleukin may increase the hypotensive activities of Mibefradil.
DB00041 DB06403 Ambrisentan Aldesleukin may increase the hypotensive activities of Ambrisentan.
DB00041 DB06762 Pinacidil Aldesleukin may increase the hypotensive activities of Pinacidil.
DB00041 DB09238 Manidipine Aldesleukin may increase the hypotensive activities of Manidipine.
DB00041 DB09239 Niguldipine Aldesleukin may increase the hypotensive activities of Niguldipine.
DB00041 DB11362 Selexipag Aldesleukin may increase the hypotensive activities of Selexipag.
DB00041 DB12093 Tetrahydropalmatine Aldesleukin may increase the hypotensive activities of Tetrahydropalmatine.
DB00041 DB14068 Dexniguldipine Aldesleukin may increase the hypotensive activities of Dexniguldipine.
DB00041 DB14975 Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Aldesleukin.
DB00041 DB09237 Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Aldesleukin.
DB00041 DB00193 Tramadol The metabolism of Tramadol can be decreased when combined with Aldesleukin.
DB00041 DB14513 Magnesium The serum concentration of Magnesium can be decreased when it is combined with Aldesleukin.
DB00041 DB01601 Lopinavir The serum concentration of Aldesleukin can be increased when it is combined with Lopinavir.
DB00041 DB00502 Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Aldesleukin.
DB00041 DB12530 Inebilizumab The risk or severity of infection can be increased when Aldesleukin is combined with Inebilizumab.
DB00041 DB00186 Lorazepam The metabolism of Lorazepam can be decreased when combined with Aldesleukin.
DB00041 DB00208 Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Aldesleukin.
DB00041 DB00264 Metoprolol The metabolism of Metoprolol can be decreased when combined with Aldesleukin.
DB00041 DB00477 Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Aldesleukin.
DB00041 DB01039 Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Aldesleukin.
DB00041 DB01431 Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Aldesleukin.
DB00041 DB09071 Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Aldesleukin.
DB00041 DB00191 Phentermine The metabolism of Phentermine can be decreased when combined with Aldesleukin.
DB00041 DB00207 Azithromycin The metabolism of Azithromycin can be decreased when combined with Aldesleukin.
DB00041 DB00246 Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Aldesleukin.
DB00041 DB00426 Famciclovir The metabolism of Famciclovir can be decreased when combined with Aldesleukin.
DB00041 DB00433 Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Aldesleukin.
DB00041 DB00518 Albendazole The metabolism of Albendazole can be decreased when combined with Aldesleukin.
DB00041 DB00590 Doxazosin The metabolism of Doxazosin can be decreased when combined with Aldesleukin.
DB00041 DB00717 Norethisterone The metabolism of Norethisterone can be decreased when combined with Aldesleukin.
DB00041 DB01098 Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Aldesleukin.
DB00041 DB01323 St. John's Wort The metabolism of St. John's Wort can be decreased when combined with Aldesleukin.
DB00041 DB01395 Drospirenone The metabolism of Drospirenone can be decreased when combined with Aldesleukin.
DB00041 DB01411 Pranlukast The metabolism of Pranlukast can be decreased when combined with Aldesleukin.
DB00041 DB01624 Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Aldesleukin.
DB00041 DB06201 Rufinamide The metabolism of Rufinamide can be decreased when combined with Aldesleukin.
DB00041 DB06218 Lacosamide The metabolism of Lacosamide can be decreased when combined with Aldesleukin.
DB00041 DB08882 Linagliptin The metabolism of Linagliptin can be decreased when combined with Aldesleukin.
DB00041 DB09030 Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Aldesleukin.
DB00041 DB09034 Suvorexant The metabolism of Suvorexant can be decreased when combined with Aldesleukin.
DB00041 DB09048 Netupitant The metabolism of Netupitant can be decreased when combined with Aldesleukin.
DB00041 DB09079 Nintedanib The metabolism of Nintedanib can be decreased when combined with Aldesleukin.
DB00041 DB09330 Osimertinib The metabolism of Osimertinib can be decreased when combined with Aldesleukin.
DB00041 DB11094 Vitamin D The metabolism of Vitamin D can be decreased when combined with Aldesleukin.
DB00041 DB11273 Dihydroergocornine The metabolism of Dihydroergocornine can be decreased when combined with Aldesleukin.
DB00041 DB11730 Ribociclib The metabolism of Ribociclib can be decreased when combined with Aldesleukin.
DB00041 DB11952 Duvelisib The metabolism of Duvelisib can be decreased when combined with Aldesleukin.
DB00041 DB12141 Gilteritinib The metabolism of Gilteritinib can be decreased when combined with Aldesleukin.
DB00041 DB12515 9-aminocamptothecin The metabolism of 9-aminocamptothecin can be decreased when combined with Aldesleukin.
DB00041 DB12952 Methylprednisone The metabolism of Methylprednisone can be decreased when combined with Aldesleukin.
DB00041 DB13345 Dihydroergocristine The metabolism of Dihydroergocristine can be decreased when combined with Aldesleukin.
DB00041 DB13385 Dihydroergocryptine The metabolism of Dihydroergocryptine can be decreased when combined with Aldesleukin.
DB00041 DB14009 Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Aldesleukin.
DB00041 DB00549 Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Aldesleukin.
DB00041 DB15444 Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Aldesleukin.
DB00041 DB12887 Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Aldesleukin.
DB00041 DB06717 Fosaprepitant The metabolism of Fosaprepitant can be decreased when combined with Aldesleukin.
DB00041 DB12825 Lefamulin The metabolism of Lefamulin can be decreased when combined with Aldesleukin.
DB00041 DB01151 Desipramine The metabolism of Desipramine can be decreased when combined with Aldesleukin.
DB00041 DB00454 Meperidine The metabolism of Meperidine can be decreased when combined with Aldesleukin.
DB00041 DB00247 Methysergide The metabolism of Methysergide can be decreased when combined with Aldesleukin.
DB00041 DB00637 Astemizole The metabolism of Astemizole can be decreased when combined with Aldesleukin.
DB00041 DB08827 Lomitapide The metabolism of Lomitapide can be decreased when combined with Aldesleukin.
DB00041 DB11742 Ebastine The metabolism of Ebastine can be decreased when combined with Aldesleukin.
DB00041 DB00188 Bortezomib The metabolism of Bortezomib can be decreased when combined with Aldesleukin.
DB00041 DB00309 Vindesine The metabolism of Vindesine can be decreased when combined with Aldesleukin.
DB00041 DB00361 Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Aldesleukin.
DB00041 DB00398 Sorafenib The metabolism of Sorafenib can be decreased when combined with Aldesleukin.
DB00041 DB00444 Teniposide The metabolism of Teniposide can be decreased when combined with Aldesleukin.
DB00041 DB00541 Vincristine The metabolism of Vincristine can be decreased when combined with Aldesleukin.
DB00041 DB00563 Methotrexate The metabolism of Methotrexate can be decreased when combined with Aldesleukin.
DB00041 DB00570 Vinblastine The metabolism of Vinblastine can be decreased when combined with Aldesleukin.
DB00041 DB00619 Imatinib The metabolism of Imatinib can be decreased when combined with Aldesleukin.
DB00041 DB00694 Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Aldesleukin.
DB00041 DB00773 Etoposide The metabolism of Etoposide can be decreased when combined with Aldesleukin.
DB00041 DB00987 Cytarabine The metabolism of Cytarabine can be decreased when combined with Aldesleukin.
DB00041 DB00997 Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Aldesleukin.
DB00041 DB01108 Trilostane The metabolism of Trilostane can be decreased when combined with Aldesleukin.
DB00041 DB01181 Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Aldesleukin.
DB00041 DB01248 Docetaxel The metabolism of Docetaxel can be decreased when combined with Aldesleukin.
DB00041 DB01268 Sunitinib The metabolism of Sunitinib can be decreased when combined with Aldesleukin.
DB00041 DB04572 Thiotepa The metabolism of Thiotepa can be decreased when combined with Aldesleukin.
DB00041 DB04845 Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Aldesleukin.
DB00041 DB04868 Nilotinib The metabolism of Nilotinib can be decreased when combined with Aldesleukin.
DB00041 DB05015 Belinostat The metabolism of Belinostat can be decreased when combined with Aldesleukin.
DB00041 DB05109 Trabectedin The metabolism of Trabectedin can be decreased when combined with Aldesleukin.
DB00041 DB06589 Pazopanib The metabolism of Pazopanib can be decreased when combined with Aldesleukin.
DB00041 DB06603 Panobinostat The metabolism of Panobinostat can be decreased when combined with Aldesleukin.
DB00041 DB06616 Bosutinib The metabolism of Bosutinib can be decreased when combined with Aldesleukin.
DB00041 DB08870 Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Aldesleukin.
DB00041 DB08877 Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Aldesleukin.
DB00041 DB08901 Ponatinib The metabolism of Ponatinib can be decreased when combined with Aldesleukin.
DB00041 DB09054 Idelalisib The metabolism of Idelalisib can be decreased when combined with Aldesleukin.
DB00041 DB09073 Palbociclib The metabolism of Palbociclib can be decreased when combined with Aldesleukin.
DB00041 DB09570 Ixazomib The metabolism of Ixazomib can be decreased when combined with Aldesleukin.
DB00041 DB00564 Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Aldesleukin.
DB00041 DB00204 Dofetilide The metabolism of Dofetilide can be decreased when combined with Aldesleukin.
DB00041 DB00277 Theophylline The metabolism of Theophylline can be decreased when combined with Aldesleukin.
DB00041 DB00342 Terfenadine The metabolism of Terfenadine can be decreased when combined with Aldesleukin.
DB00041 DB00604 Cisapride The metabolism of Cisapride can be decreased when combined with Aldesleukin.
DB00041 DB00877 Sirolimus The metabolism of Sirolimus can be decreased when combined with Aldesleukin.
DB00041 DB00946 Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Aldesleukin.
DB00041 DB01008 Busulfan The metabolism of Busulfan can be decreased when combined with Aldesleukin.
DB00041 DB01100 Pimozide The metabolism of Pimozide can be decreased when combined with Aldesleukin.
DB00041 DB01118 Amiodarone The metabolism of Amiodarone can be decreased when combined with Aldesleukin.
DB00041 DB01223 Aminophylline The metabolism of Aminophylline can be decreased when combined with Aldesleukin.
DB00041 DB01229 Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Aldesleukin.
DB00041 DB01254 Dasatinib The metabolism of Dasatinib can be decreased when combined with Aldesleukin.
DB00041 DB01320 Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Aldesleukin.
DB00041 DB01396 Digitoxin The metabolism of Digitoxin can be decreased when combined with Aldesleukin.
DB00041 DB01590 Everolimus The metabolism of Everolimus can be decreased when combined with Aldesleukin.
DB00041 DB03410 4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be decreased when combined with Aldesleukin.
DB00041 DB04855 Dronedarone The metabolism of Dronedarone can be decreased when combined with Aldesleukin.
DB00041 DB05239 Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Aldesleukin.
DB00041 DB06287 Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Aldesleukin.
DB00041 DB09063 Ceritinib The metabolism of Ceritinib can be decreased when combined with Aldesleukin.
DB00041 DB09289 Tianeptine The metabolism of Tianeptine can be decreased when combined with Aldesleukin.
DB00041 DB11633 Isavuconazole The metabolism of Isavuconazole can be decreased when combined with Aldesleukin.
DB00041 DB11963 Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Aldesleukin.
DB00041 DB12015 Alpelisib The metabolism of Alpelisib can be decreased when combined with Aldesleukin.
DB00041 DB13136 Fluindione The metabolism of Fluindione can be decreased when combined with Aldesleukin.
DB00041 DB13275 Clorindione The metabolism of Clorindione can be decreased when combined with Aldesleukin.
DB00041 DB00675 Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Aldesleukin.
DB00041 DB05294 Vandetanib The metabolism of Vandetanib can be decreased when combined with Aldesleukin.
DB00041 DB05812 Abiraterone The metabolism of Abiraterone can be decreased when combined with Aldesleukin.
DB00041 DB08881 Vemurafenib The metabolism of Vemurafenib can be decreased when combined with Aldesleukin.
DB00041 DB11363 Alectinib The metabolism of Alectinib can be decreased when combined with Aldesleukin.
DB00041 DB11581 Venetoclax The metabolism of Venetoclax can be decreased when combined with Aldesleukin.
DB00041 DB11641 Vinflunine The metabolism of Vinflunine can be decreased when combined with Aldesleukin.
DB00041 DB11703 Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Aldesleukin.
DB00041 DB13874 Enasidenib The metabolism of Enasidenib can be decreased when combined with Aldesleukin.
DB00041 DB15035 Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Aldesleukin.
DB00041 DB00248 Cabergoline The metabolism of Cabergoline can be decreased when combined with Aldesleukin.
DB00041 DB00530 Erlotinib The metabolism of Erlotinib can be decreased when combined with Aldesleukin.
DB00041 DB06595 Midostaurin The metabolism of Midostaurin can be decreased when combined with Aldesleukin.
DB00041 DB06626 Axitinib The metabolism of Axitinib can be decreased when combined with Aldesleukin.
DB00041 DB08865 Crizotinib The metabolism of Crizotinib can be decreased when combined with Aldesleukin.
DB00041 DB08912 Dabrafenib The metabolism of Dabrafenib can be decreased when combined with Aldesleukin.
DB00041 DB09143 Sonidegib The metabolism of Sonidegib can be decreased when combined with Aldesleukin.
DB00041 DB11718 Encorafenib The metabolism of Encorafenib can be decreased when combined with Aldesleukin.
DB00041 DB11828 Neratinib The metabolism of Neratinib can be decreased when combined with Aldesleukin.
DB00041 DB12147 Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Aldesleukin.
DB00041 DB12267 Brigatinib The metabolism of Brigatinib can be decreased when combined with Aldesleukin.
DB00041 DB12483 Copanlisib The metabolism of Copanlisib can be decreased when combined with Aldesleukin.
DB00041 DB12978 Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Aldesleukin.
DB00041 DB14568 Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Aldesleukin.
DB00041 DB11986 Entrectinib The metabolism of Entrectinib can be decreased when combined with Aldesleukin.
DB00042 DB00921 Buprenorphine Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
DB00042 DB00366 Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00470 Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00450 Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00956 Hydrocodone Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DB00042 DB00557 Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00653 Magnesium sulfate The therapeutic efficacy of Botulinum Toxin Type B can be increased when used in combination with Magnesium sulfate.
DB00042 DB01403 Methotrimeprazine Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
DB00042 DB00765 Metyrosine Botulinum Toxin Type B may increase the sedative activities of Metyrosine.
DB00042 DB01017 Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00370 Mirtazapine Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DB00042 DB00486 Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB01173 Orphenadrine Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
DB00042 DB09117 Paraldehyde Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
DB00042 DB08883 Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00413 Pramipexole Botulinum Toxin Type B may increase the sedative activities of Pramipexole.
DB00042 DB00268 Ropinirole Botulinum Toxin Type B may increase the sedative activities of Ropinirole.
DB00042 DB05271 Rotigotine Botulinum Toxin Type B may increase the sedative activities of Rotigotine.
DB00042 DB06201 Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Botulinum Toxin Type B.
DB00042 DB09072 Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB09034 Suvorexant Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
DB00042 DB06204 Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB01041 Thalidomide Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
DB00042 DB00425 Zolpidem Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
DB00042 DB00202 Succinylcholine The therapeutic efficacy of Succinylcholine can be increased when used in combination with Botulinum Toxin Type B.
DB00042 DB01245 Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Botulinum Toxin Type B.
DB00042 DB11156 Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Botulinum Toxin Type B.
DB00042 DB12989 Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Botulinum Toxin Type B.
DB00042 DB00333 Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Botulinum Toxin Type B.
DB00042 DB00209 Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Botulinum Toxin Type B.
DB00042 DB00219 Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Botulinum Toxin Type B.
DB00042 DB00237 Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum Toxin Type B.
DB00042 DB00241 Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Botulinum Toxin Type B.
DB00042 DB00245 Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Botulinum Toxin Type B.
DB00042 DB00280 Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum Toxin Type B.
DB00042 DB00306 Talbutal The risk or severity of adverse effects can be increased when Talbutal is combined with Botulinum Toxin Type B.
DB00042 DB00312 Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Botulinum Toxin Type B.
DB00042 DB00321 Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Botulinum Toxin Type B.
DB00042 DB00332 Ipratropium The risk or severity of adverse effects can be increased when Ipratropium is combined with Botulinum Toxin Type B.
DB00042 DB00334 Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Botulinum Toxin Type B.
DB00042 DB00340 Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Botulinum Toxin Type B.
DB00042 DB00342 Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Botulinum Toxin Type B.
DB00042 DB00354 Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Botulinum Toxin Type B.
DB00042 DB00363 Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Botulinum Toxin Type B.
DB00042 DB00376 Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Botulinum Toxin Type B.
DB00042 DB00383 Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Botulinum Toxin Type B.
DB00042 DB00387 Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Botulinum Toxin Type B.
DB00042 DB00392 Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Botulinum Toxin Type B.
DB00042 DB00416 Metocurine iodide The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Botulinum Toxin Type B.
DB00042 DB00418 Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Botulinum Toxin Type B.
DB00042 DB00420 Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Botulinum Toxin Type B.
DB00042 DB00424 Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Botulinum Toxin Type B.
DB00042 DB00434 Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Botulinum Toxin Type B.
DB00042 DB00458 Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Botulinum Toxin Type B.
DB00042 DB00462 Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Botulinum Toxin Type B.
DB00042 DB00463 Metharbital The risk or severity of adverse effects can be increased when Metharbital is combined with Botulinum Toxin Type B.
DB00042 DB00477 Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Botulinum Toxin Type B.
DB00042 DB00483 Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Botulinum Toxin Type B.
DB00042 DB00496 Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Botulinum Toxin Type B.
DB00042 DB00505 Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Botulinum Toxin Type B.
DB00042 DB00508 Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum Toxin Type B.
DB00042 DB00514 Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Botulinum Toxin Type B.
DB00042 DB00517 Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Botulinum Toxin Type B.
DB00042 DB00540 Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Botulinum Toxin Type B.
DB00042 DB00543 Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Botulinum Toxin Type B.
DB00042 DB00555 Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Botulinum Toxin Type B.
DB00042 DB00565 Cisatracurium The risk or severity of adverse effects can be increased when Cisatracurium is combined with Botulinum Toxin Type B.
DB00042 DB00572 Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Botulinum Toxin Type B.
DB00042 DB00599 Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Botulinum Toxin Type B.
DB00042 DB00622 Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Botulinum Toxin Type B.
DB00042 DB00657 Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Botulinum Toxin Type B.
DB00042 DB00670 Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Botulinum Toxin Type B.
DB00042 DB00715 Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum Toxin Type B.
DB00042 DB00721 Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Botulinum Toxin Type B.
DB00042 DB00725 Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Botulinum Toxin Type B.
DB00042 DB00728 Rocuronium The risk or severity of adverse effects can be increased when Rocuronium is combined with Botulinum Toxin Type B.
DB00042 DB00732 Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Botulinum Toxin Type B.
DB00042 DB00747 Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Botulinum Toxin Type B.
DB00042 DB00753 Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Botulinum Toxin Type B.
DB00042 DB00767 Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Botulinum Toxin Type B.
DB00042 DB00771 Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Botulinum Toxin Type B.
DB00042 DB00777 Propiomazine The risk or severity of adverse effects can be increased when Propiomazine is combined with Botulinum Toxin Type B.
DB00042 DB00782 Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Botulinum Toxin Type B.
DB00042 DB00794 Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Botulinum Toxin Type B.
DB00042 DB00804 Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Botulinum Toxin Type B.
DB00042 DB00810 Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Botulinum Toxin Type B.
DB00042 DB00835 Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Botulinum Toxin Type B.
DB00042 DB00849 Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Botulinum Toxin Type B.
DB00042 DB00875 Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Botulinum Toxin Type B.
DB00042 DB00907 Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Botulinum Toxin Type B.
DB00042 DB00908 Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Botulinum Toxin Type B.
DB00042 DB00915 Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Botulinum Toxin Type B.
DB00042 DB00934 Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum Toxin Type B.
DB00042 DB00940 Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Botulinum Toxin Type B.
DB00042 DB00941 Hexafluronium The risk or severity of adverse effects can be increased when Hexafluronium is combined with Botulinum Toxin Type B.
DB00042 DB00942 Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum Toxin Type B.
DB00042 DB00967 Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Botulinum Toxin Type B.
DB00042 DB00986 Glycopyrronium The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Botulinum Toxin Type B.
DB00042 DB01036 Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Botulinum Toxin Type B.
DB00042 DB01062 Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Botulinum Toxin Type B.
DB00042 DB01069 Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Botulinum Toxin Type B.
DB00042 DB01075 Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Botulinum Toxin Type B.
DB00042 DB01090 Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Botulinum Toxin Type B.
DB00042 DB01116 Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Botulinum Toxin Type B.
DB00042 DB01135 Doxacurium The risk or severity of adverse effects can be increased when Doxacurium is combined with Botulinum Toxin Type B.
DB00042 DB01142 Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Botulinum Toxin Type B.
DB00042 DB01148 Flavoxate The risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum Toxin Type B.
DB00042 DB01151 Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Botulinum Toxin Type B.
DB00042 DB01161 Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Botulinum Toxin Type B.
DB00042 DB01174 Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Botulinum Toxin Type B.
DB00042 DB01175 Escitalopram The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum Toxin Type B.
DB00042 DB01199 Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Botulinum Toxin Type B.
DB00042 DB01224 Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Botulinum Toxin Type B.
DB00042 DB01226 Mivacurium The risk or severity of adverse effects can be increased when Mivacurium is combined with Botulinum Toxin Type B.
DB00042 DB01227 Levacetylmethadol The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Botulinum Toxin Type B.
DB00042 DB01231 Diphenidol The risk or severity of adverse effects can be increased when Diphenidol is combined with Botulinum Toxin Type B.
DB00042 DB01238 Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum Toxin Type B.
DB00042 DB01239 Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum Toxin Type B.
DB00042 DB01288 Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Botulinum Toxin Type B.
DB00042 DB01336 Metocurine The risk or severity of adverse effects can be increased when Metocurine is combined with Botulinum Toxin Type B.
DB00042 DB01337 Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Botulinum Toxin Type B.
DB00042 DB01338 Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Botulinum Toxin Type B.
DB00042 DB01339 Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with Botulinum Toxin Type B.
DB00042 DB01351 Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Botulinum Toxin Type B.
DB00042 DB01352 Aprobarbital The risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum Toxin Type B.
DB00042 DB01353 Butobarbital The risk or severity of adverse effects can be increased when Butobarbital is combined with Botulinum Toxin Type B.
DB00042 DB01354 Heptabarbital The risk or severity of adverse effects can be increased when Heptabarbital is combined with Botulinum Toxin Type B.
DB00042 DB01355 Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Botulinum Toxin Type B.
DB00042 DB01409 Tiotropium The risk or severity of adverse effects can be increased when Tiotropium is combined with Botulinum Toxin Type B.
DB00042 DB01483 Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Botulinum Toxin Type B.
DB00042 DB01496 Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione The risk or severity of adverse effects can be increased when Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione is combined with Botulinum Toxin Type B.
DB00042 DB01591 Solifenacin The risk or severity of adverse effects can be increased when Solifenacin is combined with Botulinum Toxin Type B.
DB00042 DB01625 Isopropamide The risk or severity of adverse effects can be increased when Isopropamide is combined with Botulinum Toxin Type B.
DB00042 DB04834 Rapacuronium The risk or severity of adverse effects can be increased when Rapacuronium is combined with Botulinum Toxin Type B.
DB00042 DB04843 Mepenzolate The risk or severity of adverse effects can be increased when Mepenzolate is combined with Botulinum Toxin Type B.
DB00042 DB05710 Gantacurium The risk or severity of adverse effects can be increased when Gantacurium is combined with Botulinum Toxin Type B.
DB00042 DB06153 Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Botulinum Toxin Type B.
DB00042 DB06702 Fesoterodine The risk or severity of adverse effects can be increased when Fesoterodine is combined with Botulinum Toxin Type B.
DB00042 DB06787 Hexocyclium The risk or severity of adverse effects can be increased when Hexocyclium is combined with Botulinum Toxin Type B.
DB00042 DB08801 Dimetindene The risk or severity of adverse effects can be increased when Dimetindene is combined with Botulinum Toxin Type B.
DB00042 DB08838 Agmatine The risk or severity of adverse effects can be increased when Agmatine is combined with Botulinum Toxin Type B.
DB00042 DB08897 Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Botulinum Toxin Type B.
DB00042 DB08960 Hexamethonium The risk or severity of adverse effects can be increased when Hexamethonium is combined with Botulinum Toxin Type B.
DB00042 DB08997 Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Botulinum Toxin Type B.
DB00042 DB09007 Chlorphenoxamine The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Botulinum Toxin Type B.
DB00042 DB09023 Benactyzine The risk or severity of adverse effects can be increased when Benactyzine is combined with Botulinum Toxin Type B.
DB00042 DB09076 Umeclidinium The risk or severity of adverse effects can be increased when Umeclidinium is combined with Botulinum Toxin Type B.
DB00042 DB09089 Trimebutine The risk or severity of adverse effects can be increased when Trimebutine is combined with Botulinum Toxin Type B.
DB00042 DB09167 Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Botulinum Toxin Type B.
DB00042 DB09262 Imidafenacin The risk or severity of adverse effects can be increased when Imidafenacin is combined with Botulinum Toxin Type B.
DB00042 DB09300 Butylscopolamine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum Toxin Type B.
DB00042 DB11235 Thonzylamine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum Toxin Type B.
DB00042 DB11315 Methscopolamine The risk or severity of adverse effects can be increased when Methscopolamine is combined with Botulinum Toxin Type B.
DB00042 DB11855 Revefenacin The risk or severity of adverse effects can be increased when Revefenacin is combined with Botulinum Toxin Type B.
DB00042 DB12086 Oxitropium The risk or severity of adverse effects can be increased when Oxitropium is combined with Botulinum Toxin Type B.
DB00042 DB12278 Propiverine The risk or severity of adverse effects can be increased when Propiverine is combined with Botulinum Toxin Type B.
DB00042 DB12526 Batefenterol The risk or severity of adverse effects can be increased when Batefenterol is combined with Botulinum Toxin Type B.
DB00042 DB12554 Mebeverine The risk or severity of adverse effects can be increased when Mebeverine is combined with Botulinum Toxin Type B.
DB00042 DB13252 Tropatepine The risk or severity of adverse effects can be increased when Tropatepine is combined with Botulinum Toxin Type B.
DB00042 DB13254 Prifinium The risk or severity of adverse effects can be increased when Prifinium is combined with Botulinum Toxin Type B.
DB00042 DB13295 Atracurium The risk or severity of adverse effects can be increased when Atracurium is combined with Botulinum Toxin Type B.
DB00042 DB13351 Piperidolate The risk or severity of adverse effects can be increased when Piperidolate is combined with Botulinum Toxin Type B.
DB00042 DB13369 Benzilone The risk or severity of adverse effects can be increased when Benzilone is combined with Botulinum Toxin Type B.
DB00042 DB13380 Difemerine The risk or severity of adverse effects can be increased when Difemerine is combined with Botulinum Toxin Type B.
DB00042 DB13413 Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Botulinum Toxin Type B.
DB00042 DB13448 Mazaticol The risk or severity of adverse effects can be increased when Mazaticol is combined with Botulinum Toxin Type B.
DB00042 DB13468 Etybenzatropine The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Botulinum Toxin Type B.
DB00042 DB13500 Otilonium The risk or severity of adverse effects can be increased when Otilonium is combined with Botulinum Toxin Type B.
DB00042 DB13505 Emepronium The risk or severity of adverse effects can be increased when Emepronium is combined with Botulinum Toxin Type B.
DB00042 DB13507 Poldine The risk or severity of adverse effects can be increased when Poldine is combined with Botulinum Toxin Type B.
DB00042 DB13542 Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum Toxin Type B.
DB00042 DB13581 Rociverine The risk or severity of adverse effects can be increased when Rociverine is combined with Botulinum Toxin Type B.
DB00042 DB13584 Gallamine The risk or severity of adverse effects can be increased when Gallamine is combined with Botulinum Toxin Type B.
DB00042 DB13619 Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Botulinum Toxin Type B.
DB00042 DB13636 Etanautine The risk or severity of adverse effects can be increased when Etanautine is combined with Botulinum Toxin Type B.
DB00042 DB13648 Alcuronium The risk or severity of adverse effects can be increased when Alcuronium is combined with Botulinum Toxin Type B.
DB00042 DB13666 Tiemonium iodide The risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Botulinum Toxin Type B.
DB00042 DB13678 Dihexyverine The risk or severity of adverse effects can be increased when Dihexyverine is combined with Botulinum Toxin Type B.
DB00042 DB13695 Penthienate The risk or severity of adverse effects can be increased when Penthienate is combined with Botulinum Toxin Type B.
DB00042 DB13720 Diphemanil The risk or severity of adverse effects can be increased when Diphemanil is combined with Botulinum Toxin Type B.
DB00042 DB13738 Camylofin The risk or severity of adverse effects can be increased when Camylofin is combined with Botulinum Toxin Type B.
DB00042 DB13759 Fenpiverinium The risk or severity of adverse effects can be increased when Fenpiverinium is combined with Botulinum Toxin Type B.
DB00042 DB13769 Emetonium iodide The risk or severity of adverse effects can be increased when Emetonium iodide is combined with Botulinum Toxin Type B.
DB00042 DB13844 Pipenzolate The risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum Toxin Type B.
DB00042 DB13850 Timepidium The risk or severity of adverse effects can be increased when Timepidium is combined with Botulinum Toxin Type B.
DB00042 DB00898 Ethanol Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
DB00042 DB00972 Azelastine Botulinum Toxin Type B may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
DB00042 DB00484 Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00042 DB00176 Fluvoxamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fluvoxamine.
DB00042 DB00215 Citalopram The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Citalopram.
DB00042 DB00476 Duloxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Duloxetine.
DB00042 DB00656 Trazodone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trazodone.
DB00042 DB01104 Sertraline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sertraline.
DB00042 DB01105 Sibutramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sibutramine.
DB00042 DB01149 Nefazodone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nefazodone.
DB00042 DB04832 Zimelidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zimelidine.
DB00042 DB04884 Dapoxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dapoxetine.
DB00042 DB04896 Milnacipran The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Milnacipran.
DB00042 DB06700 Desvenlafaxine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Desvenlafaxine.
DB00042 DB06731 Seproxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Seproxetine.
DB00042 DB08918 Levomilnacipran The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Levomilnacipran.
DB00042 DB08953 Indalpine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Indalpine.
DB00042 DB12693 Ritanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ritanserin.
DB00042 DB13233 Alaproclate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alaproclate.
DB00042 DB01198 Zopiclone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zopiclone.
DB00042 DB00150 Tryptophan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tryptophan.
DB00042 DB00181 Baclofen The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Baclofen.
DB00042 DB00182 Amphetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Amphetamine.
DB00042 DB00186 Lorazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lorazepam.
DB00042 DB00189 Ethchlorvynol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethchlorvynol.
DB00042 DB00206 Reserpine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Reserpine.
DB00042 DB00216 Eletriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eletriptan.
DB00042 DB00228 Enflurane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Enflurane.
DB00042 DB00231 Temazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Temazepam.
DB00042 DB00234 Reboxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Reboxetine.
DB00042 DB00247 Methysergide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methysergide.
DB00042 DB00248 Cabergoline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cabergoline.
DB00042 DB00252 Phenytoin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenytoin.
DB00042 DB00273 Topiramate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Topiramate.
DB00042 DB00283 Clemastine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clemastine.
DB00042 DB00285 Venlafaxine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Venlafaxine.
DB00042 DB00289 Atomoxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Atomoxetine.
DB00042 DB00292 Etomidate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Etomidate.
DB00042 DB00295 Morphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Morphine.
DB00042 DB00313 Valproic acid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Valproic acid.
DB00042 DB00315 Zolmitriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zolmitriptan.
DB00042 DB00318 Codeine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Codeine.
DB00042 DB00320 Dihydroergotamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dihydroergotamine.
DB00042 DB00323 Tolcapone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tolcapone.
DB00042 DB00327 Hydromorphone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Hydromorphone.
DB00042 DB00341 Cetirizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cetirizine.
DB00042 DB00344 Protriptyline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Protriptyline.
DB00042 DB00347 Trimethadione The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trimethadione.
DB00042 DB00349 Clobazam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clobazam.
DB00042 DB00356 Chlorzoxazone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlorzoxazone.
DB00042 DB00371 Meprobamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Meprobamate.
DB00042 DB00372 Thiethylperazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thiethylperazine.
DB00042 DB00377 Palonosetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Palonosetron.
DB00042 DB00391 Sulpiride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sulpiride.
DB00042 DB00404 Alprazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alprazolam.
DB00042 DB00405 Dexbrompheniramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dexbrompheniramine.
DB00042 DB00408 Loxapine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Loxapine.
DB00042 DB00409 Remoxipride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Remoxipride.
DB00042 DB00423 Methocarbamol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methocarbamol.
DB00042 DB00427 Triprolidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Triprolidine.
DB00042 DB00433 Prochlorperazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Prochlorperazine.
DB00042 DB00454 Meperidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Meperidine.
DB00042 DB00474 Methohexital The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methohexital.
DB00042 DB00475 Chlordiazepoxide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlordiazepoxide.
DB00042 DB00494 Entacapone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Entacapone.
DB00042 DB00497 Oxycodone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxycodone.
DB00042 DB00532 Mephenytoin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mephenytoin.
DB00042 DB00546 Adinazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Adinazolam.
DB00042 DB00564 Carbamazepine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Carbamazepine.
DB00042 DB00574 Fenfluramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fenfluramine.
DB00042 DB00579 Mazindol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mazindol.
DB00042 DB00588 Fluticasone propionate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fluticasone propionate.
DB00042 DB00589 Lisuride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lisuride.
DB00042 DB00593 Ethosuximide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethosuximide.
DB00042 DB00601 Linezolid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Linezolid.
DB00042 DB00604 Cisapride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cisapride.
DB00042 DB00611 Butorphanol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Butorphanol.
DB00042 DB00614 Furazolidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Furazolidone.
DB00042 DB00617 Paramethadione The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Paramethadione.
DB00042 DB00623 Fluphenazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fluphenazine.
DB00042 DB00625 Efavirenz The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Efavirenz.
DB00042 DB00628 Clorazepic acid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clorazepic acid.
DB00042 DB00633 Dexmedetomidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dexmedetomidine.
DB00042 DB00645 Dyclonine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dyclonine.
DB00042 DB00647 Dextropropoxyphene The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dextropropoxyphene.
DB00042 DB00652 Pentazocine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pentazocine.
DB00042 DB00660 Metaxalone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Metaxalone.
DB00042 DB00662 Trimethobenzamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trimethobenzamide.
DB00042 DB00669 Sumatriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sumatriptan.
DB00042 DB00679 Thioridazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thioridazine.
DB00042 DB00680 Moricizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Moricizine.
DB00042 DB00683 Midazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Midazolam.
DB00042 DB00690 Flurazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Flurazepam.
DB00042 DB00696 Ergotamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ergotamine.
DB00042 DB00697 Tizanidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tizanidine.
DB00042 DB00708 Sufentanil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sufentanil.
DB00042 DB00714 Apomorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Apomorphine.
DB00042 DB00726 Trimipramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trimipramine.
DB00042 DB00734 Risperidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Risperidone.
DB00042 DB00737 Meclizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Meclizine.
DB00042 DB00740 Riluzole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Riluzole.
DB00042 DB00748 Carbinoxamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Carbinoxamine.
DB00042 DB00752 Tranylcypromine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tranylcypromine.
DB00042 DB00754 Ethotoin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethotoin.
DB00042 DB00757 Dolasetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dolasetron.
DB00042 DB00776 Oxcarbazepine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxcarbazepine.
DB00042 DB00780 Phenelzine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenelzine.
DB00042 DB00801 Halazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Halazepam.
DB00042 DB00802 Alfentanil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alfentanil.
DB00042 DB00805 Minaprine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Minaprine.
DB00042 DB00813 Fentanyl The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fentanyl.
DB00042 DB00818 Propofol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Propofol.
DB00042 DB00819 Acetazolamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Acetazolamide.
DB00042 DB00829 Diazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Diazepam.
DB00042 DB00831 Trifluoperazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trifluoperazine.
DB00042 DB00832 Phensuximide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phensuximide.
DB00042 DB00837 Progabide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Progabide.
DB00042 DB00842 Oxazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxazepam.
DB00042 DB00843 Donepezil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Donepezil.
DB00042 DB00844 Nalbuphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nalbuphine.
DB00042 DB00850 Perphenazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Perphenazine.
DB00042 DB00854 Levorphanol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Levorphanol.
DB00042 DB00865 Benzphetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Benzphetamine.
DB00042 DB00866 Alprenolol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alprenolol.
DB00042 DB00889 Granisetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Granisetron.
DB00042 DB00897 Triazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Triazolam.
DB00042 DB00899 Remifentanil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Remifentanil.
DB00042 DB00904 Ondansetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ondansetron.
DB00042 DB00906 Tiagabine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tiagabine.
DB00042 DB00909 Zonisamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zonisamide.
DB00042 DB00918 Almotriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Almotriptan.
DB00042 DB00933 Mesoridazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mesoridazine.
DB00042 DB00937 Diethylpropion The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Diethylpropion.
DB00042 DB00949 Felbamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Felbamate.
DB00042 DB00952 Naratriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Naratriptan.
DB00042 DB00953 Rizatriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Rizatriptan.
DB00042 DB00960 Pindolol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pindolol.
DB00042 DB00962 Zaleplon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zaleplon.
DB00042 DB00969 Alosetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alosetron.
DB00042 DB00980 Ramelteon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ramelteon.
DB00042 DB00985 Dimenhydrinate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dimenhydrinate.
DB00042 DB00996 Gabapentin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Gabapentin.
DB00042 DB00998 Frovatriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Frovatriptan.
DB00042 DB01018 Guanfacine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Guanfacine.
DB00042 DB01028 Methoxyflurane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methoxyflurane.
DB00042 DB01037 Selegiline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Selegiline.
DB00042 DB01049 Ergoloid mesylate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ergoloid mesylate.
DB00042 DB01063 Acetophenazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Acetophenazine.
DB00042 DB01065 Melatonin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Melatonin.
DB00042 DB01068 Clonazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clonazepam.
DB00042 DB01080 Vigabatrin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vigabatrin.
DB00042 DB01081 Diphenoxylate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Diphenoxylate.
DB00042 DB01100 Pimozide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pimozide.
DB00042 DB01107 Methyprylon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methyprylon.
DB00042 DB01114 Chlorpheniramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlorpheniramine.
DB00042 DB01121 Phenacemide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenacemide.
DB00042 DB01154 Thiamylal The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thiamylal.
DB00042 DB01156 Bupropion The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bupropion.
DB00042 DB01159 Halothane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Halothane.
DB00042 DB01168 Procarbazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Procarbazine.
DB00042 DB01171 Moclobemide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Moclobemide.
DB00042 DB01176 Cyclizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cyclizine.
DB00042 DB01178 Chlormezanone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlormezanone.
DB00042 DB01186 Pergolide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pergolide.
DB00042 DB01189 Desflurane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Desflurane.
DB00042 DB01192 Oxymorphone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxymorphone.
DB00042 DB01200 Bromocriptine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bromocriptine.
DB00042 DB01202 Levetiracetam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Levetiracetam.
DB00042 DB01209 Dezocine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dezocine.
DB00042 DB01215 Estazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Estazolam.
DB00042 DB01221 Ketamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ketamine.
DB00042 DB01235 Levodopa The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Levodopa.
DB00042 DB01236 Sevoflurane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sevoflurane.
DB00042 DB01242 Clomipramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clomipramine.
DB00042 DB01246 Alimemazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alimemazine.
DB00042 DB01247 Isocarboxazid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Isocarboxazid.
DB00042 DB01253 Ergometrine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ergometrine.
DB00042 DB01267 Paliperidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Paliperidone.
DB00042 DB01320 Fosphenytoin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fosphenytoin.
DB00042 DB01323 St. John's Wort The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with St. John's Wort.
DB00042 DB01356 Lithium cation The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lithium cation.
DB00042 DB01359 Penbutolol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Penbutolol.
DB00042 DB01367 Rasagiline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Rasagiline.
DB00042 DB01392 Yohimbine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Yohimbine.
DB00042 DB01433 Methadyl acetate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methadyl acetate.
DB00042 DB01437 Glutethimide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Glutethimide.
DB00042 DB01440 gamma-Hydroxybutyric acid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with gamma-Hydroxybutyric acid.
DB00042 DB01442 MMDA The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with MMDA.
DB00042 DB01445 Bufotenine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bufotenine.
DB00042 DB01450 Dihydroetorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dihydroetorphine.
DB00042 DB01452 Diamorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Diamorphine.
DB00042 DB01454 Midomafetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Midomafetamine.
DB00042 DB01463 Fencamfamin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fencamfamin.
DB00042 DB01466 Ethylmorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethylmorphine.
DB00042 DB01472 4-Methoxyamphetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with 4-Methoxyamphetamine.
DB00042 DB01484 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with 4-Bromo-2,5-dimethoxyamphetamine.
DB00042 DB01488 Dimethyltryptamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dimethyltryptamine.
DB00042 DB01489 Camazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Camazepam.
DB00042 DB01495 Dichloralphenazone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dichloralphenazone.
DB00042 DB01497 Etorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Etorphine.
DB00042 DB01501 Difenoxin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Difenoxin.
DB00042 DB01509 Tenamfetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tenamfetamine.
DB00042 DB01511 Delorazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Delorazepam.
DB00042 DB01529 Dextromoramide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dextromoramide.
DB00042 DB01531 Desomorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Desomorphine.
DB00042 DB01534 Chlorhexadol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlorhexadol.
DB00042 DB01535 Carfentanil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Carfentanil.
DB00042 DB01544 Flunitrazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Flunitrazepam.
DB00042 DB01545 Ethyl loflazepate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethyl loflazepate.
DB00042 DB01547 Drotebanol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Drotebanol.
DB00042 DB01551 Dihydrocodeine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dihydrocodeine.
DB00042 DB01553 Cloxazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cloxazolam.
DB00042 DB01555 Alphacetylmethadol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alphacetylmethadol.
DB00042 DB01558 Bromazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bromazepam.
DB00042 DB01559 Clotiazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clotiazepam.
DB00042 DB01560 Cathinone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cathinone.
DB00042 DB01563 Chloral hydrate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chloral hydrate.
DB00042 DB01565 Dihydromorphine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dihydromorphine.
DB00042 DB01567 Fludiazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fludiazepam.
DB00042 DB01577 Metamfetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Metamfetamine.
DB00042 DB01580 Oxprenolol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxprenolol.
DB00042 DB01587 Ketazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ketazolam.
DB00042 DB01588 Prazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Prazepam.
DB00042 DB01589 Quazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Quazepam.
DB00042 DB01594 Cinolazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cinolazepam.
DB00042 DB01595 Nitrazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nitrazepam.
DB00042 DB01608 Periciazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Periciazine.
DB00042 DB01614 Acepromazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Acepromazine.
DB00042 DB01615 Aceprometazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Aceprometazine.
DB00042 DB01616 Alverine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alverine.
DB00042 DB01618 Molindone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Molindone.
DB00042 DB01621 Pipotiazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pipotiazine.
DB00042 DB01622 Thioproperazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thioproperazine.
DB00042 DB01623 Thiothixene The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thiothixene.
DB00042 DB01624 Zuclopenthixol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zuclopenthixol.
DB00042 DB01626 Pargyline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pargyline.
DB00042 DB01954 Rolipram The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Rolipram.
DB00042 DB02207 7-Nitroindazole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with 7-Nitroindazole.
DB00042 DB02234 S-Ethylisothiourea The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with S-Ethylisothiourea.
DB00042 DB02852 Domoic Acid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Domoic Acid.
DB00042 DB02959 Oxitriptan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxitriptan.
DB00042 DB03575 Phencyclidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phencyclidine.
DB00042 DB04017 Clorgiline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clorgiline.
DB00042 DB04165 Valpromide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Valpromide.
DB00042 DB04325 Phenethylamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenethylamine.
DB00042 DB04599 Aniracetam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Aniracetam.
DB00042 DB04818 Iproniazid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Iproniazid.
DB00042 DB04819 Methapyrilene The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methapyrilene.
DB00042 DB04820 Nialamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nialamide.
DB00042 DB04821 Nomifensine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nomifensine.
DB00042 DB04827 Urethane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Urethane.
DB00042 DB04829 Lysergic acid diethylamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lysergic acid diethylamide.
DB00042 DB04833 Methaqualone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methaqualone.
DB00042 DB04836 Amineptine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Amineptine.
DB00042 DB04841 Flunarizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Flunarizine.
DB00042 DB04842 Fluspirilene The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fluspirilene.
DB00042 DB04871 Lorcaserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lorcaserin.
DB00042 DB04872 Osanetant The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Osanetant.
DB00042 DB04885 Cilansetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cilansetron.
DB00042 DB04888 Bifeprunox The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bifeprunox.
DB00042 DB04903 Pagoclone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pagoclone.
DB00042 DB04908 Flibanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Flibanserin.
DB00042 DB04917 Renzapride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Renzapride.
DB00042 DB04946 Iloperidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Iloperidone.
DB00042 DB04953 Ezogabine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ezogabine.
DB00042 DB05227 APD791 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with APD791.
DB00042 DB05232 Tetrodotoxin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tetrodotoxin.
DB00042 DB05246 Methsuximide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methsuximide.
DB00042 DB05316 Pimavanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pimavanserin.
DB00042 DB05541 Brivaracetam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Brivaracetam.
DB00042 DB05542 Naronapride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Naronapride.
DB00042 DB05562 Naluzotan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Naluzotan.
DB00042 DB05607 PRX-08066 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with PRX-08066.
DB00042 DB05687 BL-1020 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with BL-1020.
DB00042 DB06016 Cariprazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cariprazine.
DB00042 DB06077 Lumateperone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lumateperone.
DB00042 DB06109 YKP-1358 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with YKP-1358.
DB00042 DB06144 Sertindole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sertindole.
DB00042 DB06148 Mianserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mianserin.
DB00042 DB06216 Asenapine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Asenapine.
DB00042 DB06218 Lacosamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lacosamide.
DB00042 DB06264 Tolperisone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tolperisone.
DB00042 DB06282 Levocetirizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Levocetirizine.
DB00042 DB06283 Ziconotide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ziconotide.
DB00042 DB06288 Amisulpride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Amisulpride.
DB00042 DB06446 Dotarizine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dotarizine.
DB00042 DB06458 Remacemide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Remacemide.
DB00042 DB06470 Clomethiazole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clomethiazole.
DB00042 DB06512 Deramciclane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Deramciclane.
DB00042 DB06527 Tramiprosate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tramiprosate.
DB00042 DB06529 Ocinaplon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ocinaplon.
DB00042 DB06554 Gaboxadol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Gaboxadol.
DB00042 DB06579 Adipiplon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Adipiplon.
DB00042 DB06582 Dextofisopam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dextofisopam.
DB00042 DB06594 Agomelatine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Agomelatine.
DB00042 DB06654 Safinamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Safinamide.
DB00042 DB06660 Saredutant The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Saredutant.
DB00042 DB06678 Esmirtazapine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Esmirtazapine.
DB00042 DB06684 Vilazodone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vilazodone.
DB00042 DB06690 Nitrous oxide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nitrous oxide.
DB00042 DB06691 Mepyramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mepyramine.
DB00042 DB06701 Dexmethylphenidate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dexmethylphenidate.
DB00042 DB06716 Fospropofol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fospropofol.
DB00042 DB06738 Ketobemidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ketobemidone.
DB00042 DB06753 Triclofos The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Triclofos.
DB00042 DB06770 Benzyl alcohol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Benzyl alcohol.
DB00042 DB06797 Mebutamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mebutamate.
DB00042 DB08059 Wortmannin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Wortmannin.
DB00042 DB08329 Sulthiame The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sulthiame.
DB00042 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
DB00042 DB08810 Cinitapride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cinitapride.
DB00042 DB08811 Tofisopam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tofisopam.
DB00042 DB08815 Lurasidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lurasidone.
DB00042 DB08839 Serotonin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Serotonin.
DB00042 DB08861 DPDPE The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with DPDPE.
DB00042 DB08872 Gabapentin enacarbil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Gabapentin enacarbil.
DB00042 DB08892 Arbaclofen Placarbil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Arbaclofen Placarbil.
DB00042 DB08910 Pomalidomide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pomalidomide.
DB00042 DB08922 Perospirone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Perospirone.
DB00042 DB08927 Amperozide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Amperozide.
DB00042 DB08954 Ifenprodil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ifenprodil.
DB00042 DB08986 Etifoxine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Etifoxine.
DB00042 DB08992 Eperisone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eperisone.
DB00042 DB08996 Dimetacrine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dimetacrine.
DB00042 DB09000 Cyamemazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cyamemazine.
DB00042 DB09001 Barbexaclone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Barbexaclone.
DB00042 DB09011 Beclamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Beclamide.
DB00042 DB09014 Captodiame The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Captodiame.
DB00042 DB09016 Butriptyline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Butriptyline.
DB00042 DB09017 Brotizolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Brotizolam.
DB00042 DB09021 Benzoctamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Benzoctamine.
DB00042 DB09068 Vortioxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vortioxetine.
DB00042 DB09071 Tasimelteon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tasimelteon.
DB00042 DB09118 Stiripentol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Stiripentol.
DB00042 DB09119 Eslicarbazepine acetate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eslicarbazepine acetate.
DB00042 DB09128 Brexpiprazole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Brexpiprazole.
DB00042 DB09166 Etizolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Etizolam.
DB00042 DB09174 Lofentanil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lofentanil.
DB00042 DB09184 Edivoxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Edivoxetine.
DB00042 DB09185 Viloxazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Viloxazine.
DB00042 DB09186 Nisoxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nisoxetine.
DB00042 DB09187 Lortalamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lortalamine.
DB00042 DB09190 Talopram The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Talopram.
DB00042 DB09194 Etoperidone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Etoperidone.
DB00042 DB09223 Blonanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Blonanserin.
DB00042 DB09224 Melperone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Melperone.
DB00042 DB09225 Zotepine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zotepine.
DB00042 DB09226 Brilaroxazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Brilaroxazine.
DB00042 DB09241 Methylene blue The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methylene blue.
DB00042 DB09243 Hydracarbazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Hydracarbazine.
DB00042 DB09244 Pirlindole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pirlindole.
DB00042 DB09245 Toloxatone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Toloxatone.
DB00042 DB09246 Benmoxin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Benmoxin.
DB00042 DB09247 Iproclozide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Iproclozide.
DB00042 DB09248 Mebanazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mebanazine.
DB00042 DB09249 Octamoxin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Octamoxin.
DB00042 DB09250 Pheniprazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pheniprazine.
DB00042 DB09251 Phenoxypropazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenoxypropazine.
DB00042 DB09252 Pivhydrazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pivhydrazine.
DB00042 DB09253 Safrazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Safrazine.
DB00042 DB09254 Caroxazone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Caroxazone.
DB00042 DB09286 Pipamperone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pipamperone.
DB00042 DB09289 Tianeptine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tianeptine.
DB00042 DB09290 Ramosetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ramosetron.
DB00042 DB09307 Oxaprotiline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxaprotiline.
DB00042 DB11130 Opium The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Opium.
DB00042 DB11371 Alfaxalone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alfaxalone.
DB00042 DB11376 Azaperone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Azaperone.
DB00042 DB11400 Doramectin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Doramectin.
DB00042 DB11428 Medetomidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Medetomidine.
DB00042 DB11477 Xylazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Xylazine.
DB00042 DB11540 Propiopromazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Propiopromazine.
DB00042 DB11543 Romifidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Romifidine.
DB00042 DB11549 Tiletamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tiletamine.
DB00042 DB11552 Tricaine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tricaine.
DB00042 DB11555 Zolazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Zolazepam.
DB00042 DB11556 Detomidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Detomidine.
DB00042 DB11582 Thiocolchicoside The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thiocolchicoside.
DB00042 DB11609 Normethadone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Normethadone.
DB00042 DB11664 Psilocybin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Psilocybin.
DB00042 DB11675 Mosapride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mosapride.
DB00042 DB11686 Iferanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Iferanserin.
DB00042 DB11699 Tropisetron The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tropisetron.
DB00042 DB11755 Tetrahydrocannabivarin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tetrahydrocannabivarin.
DB00042 DB11859 Brexanolone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Brexanolone.
DB00042 DB11868 Etiracetam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Etiracetam.
DB00042 DB11889 Lanicemine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lanicemine.
DB00042 DB11957 Idalopirdine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Idalopirdine.
DB00042 DB12071 Vabicaserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vabicaserin.
DB00042 DB12093 Tetrahydropalmatine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tetrahydropalmatine.
DB00042 DB12105 Imagabalin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Imagabalin.
DB00042 DB12110 m-Chlorophenylpiperazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with m-Chlorophenylpiperazine.
DB00042 DB12111 MK-212 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with MK-212.
DB00042 DB12131 Vinpocetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vinpocetine.
DB00042 DB12163 Sarpogrelate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sarpogrelate.
DB00042 DB12177 Eplivanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eplivanserin.
DB00042 DB12184 Gepirone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Gepirone.
DB00042 DB12229 Cerlapirdine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cerlapirdine.
DB00042 DB12273 Ecopipam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ecopipam.
DB00042 DB12308 Eltanolone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eltanolone.
DB00042 DB12327 Salvinorin A The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Salvinorin A.
DB00042 DB12338 Carisbamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Carisbamate.
DB00042 DB12361 Piclozotan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Piclozotan.
DB00042 DB12395 Esreboxetine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Esreboxetine.
DB00042 DB12401 Bromperidol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bromperidol.
DB00042 DB12427 Orvepitant The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Orvepitant.
DB00042 DB12465 Ketanserin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ketanserin.
DB00042 DB12492 Piritramide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Piritramide.
DB00042 DB12518 Raclopride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Raclopride.
DB00042 DB12537 Benzodiazepine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Benzodiazepine.
DB00042 DB12576 AZD-3043 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with AZD-3043.
DB00042 DB12590 Indiplon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Indiplon.
DB00042 DB12661 Urapidil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Urapidil.
DB00042 DB12710 Perazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Perazine.
DB00042 DB12725 TD-8954 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with TD-8954.
DB00042 DB12833 Tandospirone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tandospirone.
DB00042 DB12867 Benperidol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Benperidol.
DB00042 DB12883 Eltoprazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eltoprazine.
DB00042 DB12930 Opipramol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Opipramol.
DB00042 DB12951 Pivagabine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pivagabine.
DB00042 DB12958 Prothipendyl The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Prothipendyl.
DB00042 DB13014 Hypericin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Hypericin.
DB00042 DB13025 Tiapride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tiapride.
DB00042 DB13082 Nefiracetam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nefiracetam.
DB00042 DB13099 Valnoctamide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Valnoctamide.
DB00042 DB13114 Amitriptylinoxide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Amitriptylinoxide.
DB00042 DB13160 Alphaprodine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Alphaprodine.
DB00042 DB13213 Butaperazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Butaperazine.
DB00042 DB13219 Medifoxamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Medifoxamine.
DB00042 DB13221 Apronalide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Apronalide.
DB00042 DB13225 Dibenzepin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dibenzepin.
DB00042 DB13234 Propanidid The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Propanidid.
DB00042 DB13246 Quinupramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Quinupramine.
DB00042 DB13253 Proxibarbal The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Proxibarbal.
DB00042 DB13256 Clothiapine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clothiapine.
DB00042 DB13273 Sultopride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Sultopride.
DB00042 DB13303 Febarbamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Febarbamate.
DB00042 DB13323 Trichloroethylene The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trichloroethylene.
DB00042 DB13324 Tetrazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tetrazepam.
DB00042 DB13331 Pyrithyldione The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pyrithyldione.
DB00042 DB13335 Pinazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pinazepam.
DB00042 DB13352 Deanol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Deanol.
DB00042 DB13354 Phenprobamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenprobamate.
DB00042 DB13357 Styramate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Styramate.
DB00042 DB13362 Pheneturide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pheneturide.
DB00042 DB13370 Bromisoval The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bromisoval.
DB00042 DB13377 Vinbarbital The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vinbarbital.
DB00042 DB13382 Chlorproethazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Chlorproethazine.
DB00042 DB13384 Melitracen The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Melitracen.
DB00042 DB13396 Neocitrullamon The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Neocitrullamon.
DB00042 DB13402 Acetylglycinamide chloral hydrate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Acetylglycinamide chloral hydrate.
DB00042 DB13403 Oxypertine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxypertine.
DB00042 DB13411 Lofepramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lofepramine.
DB00042 DB13414 Fenyramidol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fenyramidol.
DB00042 DB13420 Thiazinam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thiazinam.
DB00042 DB13437 Medazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Medazepam.
DB00042 DB13455 Phenibut The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenibut.
DB00042 DB13457 Oxaflozane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxaflozane.
DB00042 DB13478 Meptazinol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Meptazinol.
DB00042 DB13496 Iprindole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Iprindole.
DB00042 DB13520 Metergoline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Metergoline.
DB00042 DB13522 Mebicar The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mebicar.
DB00042 DB13523 Veralipride The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Veralipride.
DB00042 DB13534 Gedocarnil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Gedocarnil.
DB00042 DB13541 Iprazochrome The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Iprazochrome.
DB00042 DB13550 Bifemelane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bifemelane.
DB00042 DB13552 Trifluperidol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Trifluperidol.
DB00042 DB13554 Moperone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Moperone.
DB00042 DB13557 Thiopropazate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Thiopropazate.
DB00042 DB13572 Emylcamate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Emylcamate.
DB00042 DB13577 Allobarbital The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Allobarbital.
DB00042 DB13588 Naftidrofuryl The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Naftidrofuryl.
DB00042 DB13598 Diethyl ether The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Diethyl ether.
DB00042 DB13601 Oxiracetam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxiracetam.
DB00042 DB13605 Phenoperidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenoperidine.
DB00042 DB13606 Phenazocine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Phenazocine.
DB00042 DB13623 Fabomotizole The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fabomotizole.
DB00042 DB13642 Pridinol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pridinol.
DB00042 DB13643 Loprazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Loprazolam.
DB00042 DB13662 Hexapropymate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Hexapropymate.
DB00042 DB13665 Fluanisone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fluanisone.
DB00042 DB13676 Mosapramine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mosapramine.
DB00042 DB13687 Niaprazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Niaprazine.
DB00042 DB13690 Vinyl ether The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vinyl ether.
DB00042 DB13733 Methylpentynol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Methylpentynol.
DB00042 DB13737 Cyclobarbital The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cyclobarbital.
DB00042 DB13745 Fazadinium bromide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Fazadinium bromide.
DB00042 DB13754 Mephenoxalone The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Mephenoxalone.
DB00042 DB13770 Vinylbital The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Vinylbital.
DB00042 DB13782 Imipramine oxide The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Imipramine oxide.
DB00042 DB13784 Dixyrazine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Dixyrazine.
DB00042 DB13787 Tilidine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tilidine.
DB00042 DB13791 Penfluridol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Penfluridol.
DB00042 DB13799 Ethadione The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Ethadione.
DB00042 DB13805 Reposal The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Reposal.
DB00042 DB13817 Carbromal The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Carbromal.
DB00042 DB13837 Doxefazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Doxefazepam.
DB00042 DB13841 Clopenthixol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Clopenthixol.
DB00042 DB13872 Lormetazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lormetazepam.
DB00042 DB13875 Harmaline The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Harmaline.
DB00042 DB13876 Brofaromine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Brofaromine.
DB00042 DB13940 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
DB00042 DB13948 N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DB00042 DB13984 Cyclopropane The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cyclopropane.
DB00042 DB13993 MRK-409 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with MRK-409.
DB00042 DB14010 5-methoxy-N,N-dimethyltryptamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with 5-methoxy-N,N-dimethyltryptamine.
DB00042 DB14028 Nordazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nordazepam.
DB00042 DB14050 Cannabidivarin The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cannabidivarin.
DB00042 DB14185 Aripiprazole lauroxil The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Aripiprazole lauroxil.
DB00042 DB14509 Lithium carbonate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lithium carbonate.
DB00042 DB14575 Eslicarbazepine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Eslicarbazepine.
DB00042 DB14651 Perphenazine enanthate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Perphenazine enanthate.
DB00042 DB14672 Oxazepam acetate The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Oxazepam acetate.
DB00042 DB14715 Cinazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cinazepam.
DB00042 DB14718 Pyrazolam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Pyrazolam.
DB00042 DB14719 Bentazepam The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bentazepam.
DB00042 DB14754 Solriamfetol The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Solriamfetol.
DB00042 DB15203 JNJ-26489112 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with JNJ-26489112.
DB00042 DB15360 Carfentanil, C-11 The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Carfentanil, C-11.
DB00042 DB11951 Lemborexant The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lemborexant.
DB00042 DB00230 Pregabalin The therapeutic efficacy of Botulinum Toxin Type B can be increased when used in combination with Pregabalin.
DB00042 DB04948 Lofexidine The therapeutic efficacy of Botulinum Toxin Type B can be increased when used in combination with Lofexidine.
DB00042 DB00083 Botulinum toxin type A The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Botulinum toxin type A.
DB00042 DB00184 Nicotine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Nicotine.
DB00042 DB08837 Tetraethylammonium The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Tetraethylammonium.
DB00042 DB08999 Cyclopentamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cyclopentamine.
DB00042 DB00091 Cyclosporine The risk or severity of adverse effects can be increased when Cyclosporine is combined with Botulinum Toxin Type B.
DB00042 DB00254 Doxycycline The risk or severity of adverse effects can be increased when Doxycycline is combined with Botulinum Toxin Type B.
DB00042 DB00256 Lymecycline The risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum Toxin Type B.
DB00042 DB00314 Capreomycin The risk or severity of adverse effects can be increased when Capreomycin is combined with Botulinum Toxin Type B.
DB00042 DB00319 Piperacillin The risk or severity of adverse effects can be increased when Piperacillin is combined with Botulinum Toxin Type B.
DB00042 DB00452 Framycetin The risk or severity of adverse effects can be increased when Framycetin is combined with Botulinum Toxin Type B.
DB00042 DB00453 Clomocycline The risk or severity of adverse effects can be increased when Clomocycline is combined with Botulinum Toxin Type B.
DB00042 DB00468 Quinine The risk or severity of adverse effects can be increased when Quinine is combined with Botulinum Toxin Type B.
DB00042 DB00512 Vancomycin The risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum Toxin Type B.
DB00042 DB00560 Tigecycline The risk or severity of adverse effects can be increased when Tigecycline is combined with Botulinum Toxin Type B.
DB00042 DB00595 Oxytetracycline The risk or severity of adverse effects can be increased when Oxytetracycline is combined with Botulinum Toxin Type B.
DB00042 DB00608 Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Botulinum Toxin Type B.
DB00042 DB00618 Demeclocycline The risk or severity of adverse effects can be increased when Demeclocycline is combined with Botulinum Toxin Type B.
DB00042 DB00684 Tobramycin The risk or severity of adverse effects can be increased when Tobramycin is combined with Botulinum Toxin Type B.
DB00042 DB00759 Tetracycline The risk or severity of adverse effects can be increased when Tetracycline is combined with Botulinum Toxin Type B.
DB00042 DB00798 Gentamicin The risk or severity of adverse effects can be increased when Gentamicin is combined with Botulinum Toxin Type B.
DB00042 DB00903 Etacrynic acid The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Botulinum Toxin Type B.
DB00042 DB00931 Metacycline The risk or severity of adverse effects can be increased when Metacycline is combined with Botulinum Toxin Type B.
DB00042 DB00955 Netilmicin The risk or severity of adverse effects can be increased when Netilmicin is combined with Botulinum Toxin Type B.
DB00042 DB00994 Neomycin The risk or severity of adverse effects can be increased when Neomycin is combined with Botulinum Toxin Type B.
DB00042 DB01035 Procainamide The risk or severity of adverse effects can be increased when Procainamide is combined with Botulinum Toxin Type B.
DB00042 DB01082 Streptomycin The risk or severity of adverse effects can be increased when Streptomycin is combined with Botulinum Toxin Type B.
DB00042 DB01111 Colistimethate The risk or severity of adverse effects can be increased when Colistimethate is combined with Botulinum Toxin Type B.
DB00042 DB01172 Kanamycin The risk or severity of adverse effects can be increased when Kanamycin is combined with Botulinum Toxin Type B.
DB00042 DB01190 Clindamycin The risk or severity of adverse effects can be increased when Clindamycin is combined with Botulinum Toxin Type B.
DB00042 DB01219 Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Botulinum Toxin Type B.
DB00042 DB01301 Rolitetracycline The risk or severity of adverse effects can be increased when Rolitetracycline is combined with Botulinum Toxin Type B.
DB00042 DB01377 Magnesium oxide The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Botulinum Toxin Type B.
DB00042 DB01378 Magnesium cation The risk or severity of adverse effects can be increased when Magnesium cation is combined with Botulinum Toxin Type B.
DB00042 DB01421 Paromomycin The risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum Toxin Type B.
DB00042 DB01627 Lincomycin The risk or severity of adverse effects can be increased when Lincomycin is combined with Botulinum Toxin Type B.
DB00042 DB03615 Ribostamycin The risk or severity of adverse effects can be increased when Ribostamycin is combined with Botulinum Toxin Type B.
DB00042 DB04263 Geneticin The risk or severity of adverse effects can be increased when Geneticin is combined with Botulinum Toxin Type B.
DB00042 DB04626 Apramycin The risk or severity of adverse effects can be increased when Apramycin is combined with Botulinum Toxin Type B.
DB00042 DB04729 Gentamicin C1a The risk or severity of adverse effects can be increased when Gentamicin C1a is combined with Botulinum Toxin Type B.
DB00042 DB04808 Neamine The risk or severity of adverse effects can be increased when Neamine is combined with Botulinum Toxin Type B.
DB00042 DB06696 Arbekacin The risk or severity of adverse effects can be increased when Arbekacin is combined with Botulinum Toxin Type B.
DB00042 DB06827 Viomycin The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum Toxin Type B.
DB00042 DB08437 Puromycin The risk or severity of adverse effects can be increased when Puromycin is combined with Botulinum Toxin Type B.
DB00042 DB09104 Magnesium hydroxide The risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum Toxin Type B.
DB00042 DB09281 Magnesium trisilicate The risk or severity of adverse effects can be increased when Magnesium trisilicate is combined with Botulinum Toxin Type B.
DB00042 DB09407 Magnesium chloride The risk or severity of adverse effects can be increased when Magnesium chloride is combined with Botulinum Toxin Type B.
DB00042 DB09409 Magnesium acetate tetrahydrate The risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Botulinum Toxin Type B.
DB00042 DB09481 Magnesium carbonate The risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Botulinum Toxin Type B.
DB00042 DB11110 Magnesium citrate The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Botulinum Toxin Type B.
DB00042 DB11189 Magnesium glycinate The risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Botulinum Toxin Type B.
DB00042 DB11230 Magnesium Aluminum Silicate The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum Toxin Type B.
DB00042 DB11512 Dihydrostreptomycin The risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Botulinum Toxin Type B.
DB00042 DB11520 Hygromycin B The risk or severity of adverse effects can be increased when Hygromycin B is combined with Botulinum Toxin Type B.
DB00042 DB12604 Sisomicin The risk or severity of adverse effects can be increased when Sisomicin is combined with Botulinum Toxin Type B.
DB00042 DB12615 Plazomicin The risk or severity of adverse effects can be increased when Plazomicin is combined with Botulinum Toxin Type B.
DB00042 DB13249 Magnesium silicate The risk or severity of adverse effects can be increased when Magnesium silicate is combined with Botulinum Toxin Type B.
DB00042 DB13264 Penimepicycline The risk or severity of adverse effects can be increased when Penimepicycline is combined with Botulinum Toxin Type B.
DB00042 DB13270 Dibekacin The risk or severity of adverse effects can be increased when Dibekacin is combined with Botulinum Toxin Type B.
DB00042 DB13274 Micronomicin The risk or severity of adverse effects can be increased when Micronomicin is combined with Botulinum Toxin Type B.
DB00042 DB13359 Magnesium aspartate The risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Botulinum Toxin Type B.
DB00042 DB13540 Isepamicin The risk or severity of adverse effects can be increased when Isepamicin is combined with Botulinum Toxin Type B.
DB00042 DB13673 Bekanamycin The risk or severity of adverse effects can be increased when Bekanamycin is combined with Botulinum Toxin Type B.
DB00042 DB13749 Magnesium gluconate The risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Botulinum Toxin Type B.
DB00042 DB13786 Magnesium orotate The risk or severity of adverse effects can be increased when Magnesium orotate is combined with Botulinum Toxin Type B.
DB00042 DB13862 Magnesium phosphate The risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Botulinum Toxin Type B.
DB00042 DB13996 Magnesium acetate The risk or severity of adverse effects can be increased when Magnesium acetate is combined with Botulinum Toxin Type B.
DB00042 DB05077 SLV319 The risk or severity of adverse effects can be increased when SLV319 is combined with Botulinum Toxin Type B.
DB00042 DB06155 Rimonabant The risk or severity of adverse effects can be increased when Rimonabant is combined with Botulinum Toxin Type B.
DB00042 DB06624 Taranabant The risk or severity of adverse effects can be increased when Taranabant is combined with Botulinum Toxin Type B.
DB00042 DB09061 Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Botulinum Toxin Type B.
DB00042 DB11903 GW842166 The risk or severity of adverse effects can be increased when GW842166 is combined with Botulinum Toxin Type B.
DB00042 DB12193 Ajulemic acid The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Botulinum Toxin Type B.
DB00042 DB12649 Ibipinabant The risk or severity of adverse effects can be increased when Ibipinabant is combined with Botulinum Toxin Type B.
DB00042 DB13070 Surinabant The risk or severity of adverse effects can be increased when Surinabant is combined with Botulinum Toxin Type B.
DB00042 DB13950 WIN 55212-2 The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with Botulinum Toxin Type B.
DB00042 DB14011 Nabiximols The risk or severity of adverse effects can be increased when Nabiximols is combined with Botulinum Toxin Type B.
DB00042 DB14043 Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with Botulinum Toxin Type B.
DB00042 DB14737 Cannabinol The risk or severity of adverse effects can be increased when Cannabinol is combined with Botulinum Toxin Type B.
DB00042 DB11823 Esketamine The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Esketamine.
DB00042 DB00395 Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Botulinum Toxin Type B.
DB00042 DB00704 Naltrexone The risk or severity of respiratory depression can be increased when Naltrexone is combined with Botulinum Toxin Type B.
DB00042 DB01459 Bezitramide The risk or severity of respiratory depression can be increased when Bezitramide is combined with Botulinum Toxin Type B.
DB00042 DB09272 Eluxadoline The risk or severity of respiratory depression can be increased when Eluxadoline is combined with Botulinum Toxin Type B.
DB00042 DB13454 Nicomorphine The risk or severity of respiratory depression can be increased when Nicomorphine is combined with Botulinum Toxin Type B.
DB00042 DB15465 Benzhydrocodone The risk or severity of respiratory depression can be increased when Benzhydrocodone is combined with Botulinum Toxin Type B.
DB00042 DB00402 Eszopiclone The risk or severity of CNS depression can be increased when Botulinum Toxin Type B is combined with Eszopiclone.
DB00042 DB00575 Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Botulinum Toxin Type B.
DB00042 DB00924 Cyclobenzaprine The risk or severity of CNS depression can be increased when Botulinum Toxin Type B is combined with Cyclobenzaprine.
DB00042 DB01233 Metoclopramide The risk or severity of sedation can be increased when Metoclopramide is combined with Botulinum Toxin Type B.
DB00042 DB11732 Lasmiditan The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Lasmiditan.
DB00042 DB00193 Tramadol The risk or severity of CNS depression can be increased when Tramadol is combined with Botulinum Toxin Type B.
DB00042 DB00246 Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Botulinum Toxin Type B.
DB00042 DB00502 Haloperidol The risk or severity of CNS depression can be increased when Botulinum Toxin Type B is combined with Haloperidol.
DB00042 DB00472 Fluoxetine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Botulinum Toxin Type B.
DB00043 DB00408 Loxapine The therapeutic efficacy of Omalizumab can be decreased when used in combination with Loxapine.
DB00043 DB00255 Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Omalizumab.
DB00043 DB00269 Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Omalizumab.
DB00043 DB00286 Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Omalizumab.
DB00043 DB00655 Estrone Estrone may increase the thrombogenic activities of Omalizumab.
DB00043 DB00783 Estradiol Estradiol may increase the thrombogenic activities of Omalizumab.
DB00043 DB00890 Dienestrol Dienestrol may increase the thrombogenic activities of Omalizumab.
DB00043 DB00977 Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Omalizumab.
DB00043 DB01357 Mestranol Mestranol may increase the thrombogenic activities of Omalizumab.
DB00043 DB04573 Estriol Estriol may increase the thrombogenic activities of Omalizumab.
DB00043 DB04574 Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Omalizumab.
DB00043 DB04575 Quinestrol Quinestrol may increase the thrombogenic activities of Omalizumab.
DB00043 DB07931 Hexestrol Hexestrol may increase the thrombogenic activities of Omalizumab.
DB00043 DB09070 Tibolone Tibolone may increase the thrombogenic activities of Omalizumab.
DB00043 DB09317 Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Omalizumab.
DB00043 DB09318 Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Omalizumab.
DB00043 DB09369 Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Omalizumab.
DB00043 DB09381 Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Omalizumab.
DB00043 DB11478 Zeranol Zeranol may increase the thrombogenic activities of Omalizumab.
DB00043 DB11674 Equol Equol may increase the thrombogenic activities of Omalizumab.
DB00043 DB12487 Promestriene Promestriene may increase the thrombogenic activities of Omalizumab.
DB00043 DB13143 Methallenestril Methallenestril may increase the thrombogenic activities of Omalizumab.
DB00043 DB13386 Epimestrol Epimestrol may increase the thrombogenic activities of Omalizumab.
DB00043 DB13418 Moxestrol Moxestrol may increase the thrombogenic activities of Omalizumab.
DB00043 DB13952 Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Omalizumab.
DB00043 DB13953 Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Omalizumab.
DB00043 DB13954 Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Omalizumab.
DB00043 DB13956 Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Omalizumab.
DB00043 DB15334 Biochanin A Biochanin A may increase the thrombogenic activities of Omalizumab.
DB00043 DB15335 Formononetin Formononetin may increase the thrombogenic activities of Omalizumab.
DB00043 DB00002 Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Omalizumab.
DB00043 DB00028 Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Omalizumab.
DB00043 DB00051 Adalimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Adalimumab.
DB00043 DB00054 Abciximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Abciximab.
DB00043 DB00056 Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Omalizumab is combined with Gemtuzumab ozogamicin.
DB00043 DB00057 Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Omalizumab is combined with Indium In-111 satumomab pendetide.
DB00043 DB00065 Infliximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Infliximab.
DB00043 DB00072 Trastuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Trastuzumab.
DB00043 DB00073 Rituximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Rituximab.
DB00043 DB00074 Basiliximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Basiliximab.
DB00043 DB00075 Muromonab The risk or severity of adverse effects can be increased when Omalizumab is combined with Muromonab.
DB00043 DB00076 Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Omalizumab is combined with Digoxin Immune Fab (Ovine).
DB00043 DB00078 Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibritumomab tiuxetan.
DB00043 DB00081 Tositumomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tositumomab.
DB00043 DB00087 Alemtuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Alemtuzumab.
DB00043 DB00089 Capromab pendetide The risk or severity of adverse effects can be increased when Omalizumab is combined with Capromab pendetide.
DB00043 DB00095 Efalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Efalizumab.
DB00043 DB00098 Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Omalizumab is combined with Antithymocyte immunoglobulin (rabbit).
DB00043 DB00108 Natalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Natalizumab.
DB00043 DB00110 Palivizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Palivizumab.
DB00043 DB00111 Daclizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Daclizumab.
DB00043 DB00112 Bevacizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab.
DB00043 DB00113 Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Technetium Tc-99m arcitumomab.
DB00043 DB01257 Eculizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Eculizumab.
DB00043 DB01269 Panitumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Panitumumab.
DB00043 DB01270 Ranibizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ranibizumab.
DB00043 DB04901 Galiximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Galiximab.
DB00043 DB04949 Pexelizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pexelizumab.
DB00043 DB04956 Afelimomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Afelimomab.
DB00043 DB04958 Epratuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Epratuzumab.
DB00043 DB04962 Bectumomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bectumomab.
DB00043 DB04964 Oregovomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Oregovomab.
DB00043 DB04988 IGN311 The risk or severity of adverse effects can be increased when Omalizumab is combined with IGN311.
DB00043 DB05006 Adecatumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Adecatumumab.
DB00043 DB05097 Labetuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Labetuzumab.
DB00043 DB05101 Matuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Matuzumab.
DB00043 DB05111 Fontolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fontolizumab.
DB00043 DB05136 Bavituximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bavituximab.
DB00043 DB05139 CR002 The risk or severity of adverse effects can be increased when Omalizumab is combined with CR002.
DB00043 DB05209 Rozrolimupab The risk or severity of adverse effects can be increased when Omalizumab is combined with Rozrolimupab.
DB00043 DB05304 Girentuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Girentuximab.
DB00043 DB05336 Obiltoxaximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Obiltoxaximab.
DB00043 DB05405 XTL-001 The risk or severity of adverse effects can be increased when Omalizumab is combined with XTL-001.
DB00043 DB05437 NAV 1800 The risk or severity of adverse effects can be increased when Omalizumab is combined with NAV 1800.
DB00043 DB05459 Briakinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Briakinumab.
DB00043 DB05496 Otelixizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Otelixizumab.
DB00043 DB05545 AMG 108 The risk or severity of adverse effects can be increased when Omalizumab is combined with AMG 108.
DB00043 DB05550 Iratumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Iratumumab.
DB00043 DB05555 Enokizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Enokizumab.
DB00043 DB05578 Ramucirumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ramucirumab.
DB00043 DB05595 Farletuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Farletuzumab.
DB00043 DB05656 Veltuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Veltuzumab.
DB00043 DB05679 Ustekinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ustekinumab.
DB00043 DB05773 Trastuzumab emtansine The risk or severity of adverse effects can be increased when Omalizumab is combined with Trastuzumab emtansine.
DB00043 DB05793 PRO-542 The risk or severity of adverse effects can be increased when Omalizumab is combined with PRO-542.
DB00043 DB05797 TNX-901 The risk or severity of adverse effects can be increased when Omalizumab is combined with TNX-901.
DB00043 DB05889 Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Omalizumab is combined with Inotuzumab ozogamicin.
DB00043 DB05892 RI 624 The risk or severity of adverse effects can be increased when Omalizumab is combined with RI 624.
DB00043 DB05915 MYO-029 The risk or severity of adverse effects can be increased when Omalizumab is combined with MYO-029.
DB00043 DB05916 CT-011 The risk or severity of adverse effects can be increased when Omalizumab is combined with CT-011.
DB00043 DB05941 Leronlimab The risk or severity of adverse effects can be increased when Omalizumab is combined with Leronlimab.
DB00043 DB05996 Glembatumumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Glembatumumab vedotin.
DB00043 DB06043 Olaratumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Olaratumab.
DB00043 DB06049 IPH 2101 The risk or severity of adverse effects can be increased when Omalizumab is combined with IPH 2101.
DB00043 DB06050 TB-402 The risk or severity of adverse effects can be increased when Omalizumab is combined with TB-402.
DB00043 DB06081 Caplacizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Caplacizumab.
DB00043 DB06101 IMC-1C11 The risk or severity of adverse effects can be increased when Omalizumab is combined with IMC-1C11.
DB00043 DB06116 Eldelumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Eldelumab.
DB00043 DB06162 Lumiliximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lumiliximab.
DB00043 DB06168 Canakinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Canakinumab.
DB00043 DB06186 Ipilimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ipilimumab.
DB00043 DB06192 Nimotuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Nimotuzumab.
DB00043 DB06241 Clenoliximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Clenoliximab.
DB00043 DB06273 Tocilizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tocilizumab.
DB00043 DB06304 BIIB015 The risk or severity of adverse effects can be increased when Omalizumab is combined with BIIB015.
DB00043 DB06305 Sonepcizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sonepcizumab.
DB00043 DB06310 Motavizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Motavizumab.
DB00043 DB06317 Elotuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Elotuzumab.
DB00043 DB06318 AVE9633 The risk or severity of adverse effects can be increased when Omalizumab is combined with AVE9633.
DB00043 DB06322 Carotuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Carotuximab.
DB00043 DB06324 XmAb 2513 The risk or severity of adverse effects can be increased when Omalizumab is combined with XmAb 2513.
DB00043 DB06342 Coltuximab ravtansine The risk or severity of adverse effects can be increased when Omalizumab is combined with Coltuximab ravtansine.
DB00043 DB06343 Teprotumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Teprotumumab.
DB00043 DB06360 Lucatumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lucatumumab.
DB00043 DB06366 Pertuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pertuzumab.
DB00043 DB06371 Siplizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Siplizumab.
DB00043 DB06467 Apolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Apolizumab.
DB00043 DB06474 Sibrotuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sibrotuzumab.
DB00043 DB06550 Bivatuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bivatuzumab.
DB00043 DB06557 Lerdelimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lerdelimumab.
DB00043 DB06599 Lexatumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lexatumumab.
DB00043 DB06602 Reslizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Reslizumab.
DB00043 DB06606 Teplizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Teplizumab.
DB00043 DB06607 Catumaxomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Catumaxomab.
DB00043 DB06612 Mepolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Mepolizumab.
DB00043 DB06643 Denosumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Denosumab.
DB00043 DB06647 Volociximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Volociximab.
DB00043 DB06650 Ofatumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ofatumumab.
DB00043 DB06674 Golimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Golimumab.
DB00043 DB08870 Brentuximab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Brentuximab vedotin.
DB00043 DB08879 Belimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Belimumab.
DB00043 DB08902 Raxibacumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Raxibacumab.
DB00043 DB08904 Certolizumab pegol The risk or severity of adverse effects can be increased when Omalizumab is combined with Certolizumab pegol.
DB00043 DB08935 Obinutuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Obinutuzumab.
DB00043 DB09029 Secukinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Secukinumab.
DB00043 DB09033 Vedolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Vedolizumab.
DB00043 DB09035 Nivolumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Nivolumab.
DB00043 DB09036 Siltuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Siltuximab.
DB00043 DB09037 Pembrolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pembrolizumab.
DB00043 DB09045 Dulaglutide The risk or severity of adverse effects can be increased when Omalizumab is combined with Dulaglutide.
DB00043 DB09052 Blinatumomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Blinatumomab.
DB00043 DB09057 Anthrax immune globulin human The risk or severity of adverse effects can be increased when Omalizumab is combined with Anthrax immune globulin human.
DB00043 DB09077 Dinutuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dinutuximab.
DB00043 DB09105 Asfotase alfa The risk or severity of adverse effects can be increased when Omalizumab is combined with Asfotase alfa.
DB00043 DB09264 Idarucizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Idarucizumab.
DB00043 DB09302 Alirocumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Alirocumab.
DB00043 DB09303 Evolocumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Evolocumab.
DB00043 DB09312 Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Omalizumab is combined with Antilymphocyte immunoglobulin (horse).
DB00043 DB09331 Daratumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Daratumumab.
DB00043 DB09559 Necitumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Necitumumab.
DB00043 DB11569 Ixekizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ixekizumab.
DB00043 DB11580 Ravulizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ravulizumab.
DB00043 DB11595 Atezolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Atezolizumab.
DB00043 DB11604 Tetanus Immune Globulin The risk or severity of adverse effects can be increased when Omalizumab is combined with Tetanus Immune Globulin.
DB00043 DB11608 Eftrenonacog alfa The risk or severity of adverse effects can be increased when Omalizumab is combined with Eftrenonacog alfa.
DB00043 DB11621 Human Varicella-Zoster Immune Globulin The risk or severity of adverse effects can be increased when Omalizumab is combined with Human Varicella-Zoster Immune Globulin.
DB00043 DB11646 Conatumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Conatumumab.
DB00043 DB11657 Tabalumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tabalumab.
DB00043 DB11680 Ficlatuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ficlatuzumab.
DB00043 DB11685 Figitumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Figitumumab.
DB00043 DB11714 Durvalumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Durvalumab.
DB00043 DB11715 Bapineuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bapineuzumab.
DB00043 DB11731 Depatuxizumab mafodotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Depatuxizumab mafodotin.
DB00043 DB11746 Onartuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Onartuzumab.
DB00043 DB11756 Solanezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Solanezumab.
DB00043 DB11767 Sarilumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sarilumab.
DB00043 DB11771 Tremelimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tremelimumab.
DB00043 DB11776 Brodalumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Brodalumab.
DB00043 DB11803 Sirukumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sirukumab.
DB00043 DB11826 Lampalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lampalizumab.
DB00043 DB11834 Guselkumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Guselkumab.
DB00043 DB11840 Dalotuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dalotuzumab.
DB00043 DB11849 Emibetuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Emibetuzumab.
DB00043 DB11850 Ublituximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ublituximab.
DB00043 DB11856 Ligelizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ligelizumab.
DB00043 DB11857 Seribantumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Seribantumab.
DB00043 DB11862 Landogrozumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Landogrozumab.
DB00043 DB11866 Romosozumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Romosozumab.
DB00043 DB11884 Vadastuximab Talirine The risk or severity of adverse effects can be increased when Omalizumab is combined with Vadastuximab Talirine.
DB00043 DB11914 Lebrikizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lebrikizumab.
DB00043 DB11930 Varlilumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Varlilumab.
DB00043 DB11945 Avelumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Avelumab.
DB00043 DB11959 Crenezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Crenezumab.
DB00043 DB11972 Rilotumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Rilotumumab.
DB00043 DB11976 Anifrolumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Anifrolumab.
DB00043 DB11988 Ocrelizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ocrelizumab.
DB00043 DB12023 Benralizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Benralizumab.
DB00043 DB12034 Gantenerumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Gantenerumab.
DB00043 DB12053 Visilizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Visilizumab.
DB00043 DB12077 Urelumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Urelumab.
DB00043 DB12089 Lorvotuzumab mertansine The risk or severity of adverse effects can be increased when Omalizumab is combined with Lorvotuzumab mertansine.
DB00043 DB12090 Patritumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Patritumab.
DB00043 DB12102 Fulranumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fulranumab.
DB00043 DB12104 Tarextumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tarextumab.
DB00043 DB12118 Sotatercept The risk or severity of adverse effects can be increased when Omalizumab is combined with Sotatercept.
DB00043 DB12119 Gevokizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Gevokizumab.
DB00043 DB12142 Duligotuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Duligotuzumab.
DB00043 DB12152 Simtuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Simtuzumab.
DB00043 DB12157 Fasinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fasinumab.
DB00043 DB12159 Dupilumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dupilumab.
DB00043 DB12169 Tralokinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tralokinumab.
DB00043 DB12189 Etrolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Etrolizumab.
DB00043 DB12202 Zalutumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Zalutumumab.
DB00043 DB12205 Ganitumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ganitumab.
DB00043 DB12213 Etaracizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Etaracizumab.
DB00043 DB12240 Polatuzumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Polatuzumab vedotin.
DB00043 DB12246 Inclacumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Inclacumab.
DB00043 DB12250 Cixutumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Cixutumumab.
DB00043 DB12261 Ascrinvacumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ascrinvacumab.
DB00043 DB12274 Aducanumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Aducanumab.
DB00043 DB12281 Luspatercept The risk or severity of adverse effects can be increased when Omalizumab is combined with Luspatercept.
DB00043 DB12296 GS-5745 The risk or severity of adverse effects can be increased when Omalizumab is combined with GS-5745.
DB00043 DB12317 Vanucizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Vanucizumab.
DB00043 DB12331 Labetuzumab govitecan The risk or severity of adverse effects can be increased when Omalizumab is combined with Labetuzumab govitecan.
DB00043 DB12335 Tanezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tanezumab.
DB00043 DB12342 Ensituximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ensituximab.
DB00043 DB12344 Fezakinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fezakinumab.
DB00043 DB12363 Dusigitumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dusigitumab.
DB00043 DB12396 Fresolimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fresolimumab.
DB00043 DB12413 Indusatumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Indusatumab vedotin.
DB00043 DB12456 Bococizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bococizumab.
DB00043 DB12489 Mirvetuximab Soravtansine The risk or severity of adverse effects can be increased when Omalizumab is combined with Mirvetuximab Soravtansine.
DB00043 DB12498 Mogamulizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Mogamulizumab.
DB00043 DB12520 Plozalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Plozalizumab.
DB00043 DB12530 Inebilizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Inebilizumab.
DB00043 DB12534 Mavrilimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Mavrilimumab.
DB00043 DB12560 Blosozumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Blosozumab.
DB00043 DB12584 Bimagrumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bimagrumab.
DB00043 DB12589 Dacetuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dacetuzumab.
DB00043 DB12609 Tovetumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tovetumab.
DB00043 DB12683 Lumretuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lumretuzumab.
DB00043 DB12698 Ibalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ibalizumab.
DB00043 DB12701 Intetumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Intetumumab.
DB00043 DB12718 Carlumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Carlumab.
DB00043 DB12734 Demcizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Demcizumab.
DB00043 DB12773 Sifalimumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sifalimumab.
DB00043 DB12775 Abituzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Abituzumab.
DB00043 DB12797 Ecromeximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ecromeximab.
DB00043 DB12807 Naptumomab Estafenatox The risk or severity of adverse effects can be increased when Omalizumab is combined with Naptumomab Estafenatox.
DB00043 DB12815 Crotedumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Crotedumab.
DB00043 DB12820 Concizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Concizumab.
DB00043 DB12826 Depatuxizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Depatuxizumab.
DB00043 DB12844 Rontalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Rontalizumab.
DB00043 DB12845 Amatuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Amatuximab.
DB00043 DB12849 Clazakizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Clazakizumab.
DB00043 DB12891 Ozanezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ozanezumab.
DB00043 DB12893 Sacituzumab govitecan The risk or severity of adverse effects can be increased when Omalizumab is combined with Sacituzumab govitecan.
DB00043 DB12917 Bimekizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bimekizumab.
DB00043 DB12943 Milatuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Milatuzumab.
DB00043 DB12976 Robatumumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Robatumumab.
DB00043 DB13017 Rovalpituzumab Tesirine The risk or severity of adverse effects can be increased when Omalizumab is combined with Rovalpituzumab Tesirine.
DB00043 DB13037 Namilumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Namilumab.
DB00043 DB13045 Racotumomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Racotumomab.
DB00043 DB13073 Tregalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tregalizumab.
DB00043 DB13127 Olokizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Olokizumab.
DB00043 DB13140 Bezlotoxumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bezlotoxumab.
DB00043 DB13375 Edrecolomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Edrecolomab.
DB00043 DB13535 Nebacumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Nebacumab.
DB00043 DB13886 Human cytomegalovirus immune globulin The risk or severity of adverse effects can be increased when Omalizumab is combined with Human cytomegalovirus immune globulin.
DB00043 DB13923 Emicizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Emicizumab.
DB00043 DB13976 Sulesomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Sulesomab.
DB00043 DB13979 Besilesomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Besilesomab.
DB00043 DB14004 Tildrakizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tildrakizumab.
DB00043 DB14012 Burosumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Burosumab.
DB00043 DB14039 Erenumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Erenumab.
DB00043 DB14040 Eptinezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Eptinezumab.
DB00043 DB14041 Fremanezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fremanezumab.
DB00043 DB14042 Galcanezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Galcanezumab.
DB00043 DB14211 Fanolesomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Fanolesomab.
DB00043 DB14580 Lecanemab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lecanemab.
DB00043 DB14597 Lanadelumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lanadelumab.
DB00043 DB14707 Cemiplimab The risk or severity of adverse effects can be increased when Omalizumab is combined with Cemiplimab.
DB00043 DB14724 Emapalumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Emapalumab.
DB00043 DB14762 Risankizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Risankizumab.
DB00043 DB14776 Camrelizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Camrelizumab.
DB00043 DB14778 Setrusumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Setrusumab.
DB00043 DB14784 Gancotamab The risk or severity of adverse effects can be increased when Omalizumab is combined with Gancotamab.
DB00043 DB14809 Anetumab ravtansine The risk or severity of adverse effects can be increased when Omalizumab is combined with Anetumab ravtansine.
DB00043 DB14811 Isatuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Isatuximab.
DB00043 DB14824 Icrucumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Icrucumab.
DB00043 DB14843 Codrituzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Codrituzumab.
DB00043 DB14864 Brolucizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Brolucizumab.
DB00043 DB14871 Xentuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Xentuzumab.
DB00043 DB14877 Lintuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Lintuzumab.
DB00043 DB14891 Vobarilizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Vobarilizumab.
DB00043 DB14897 Parsatuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Parsatuzumab.
DB00043 DB14905 Emactuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Emactuzumab.
DB00043 DB14907 Bevacizumab zirconium Zr-89 The risk or severity of adverse effects can be increased when Omalizumab is combined with Bevacizumab zirconium Zr-89.
DB00043 DB14908 Refanezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Refanezumab.
DB00043 DB14919 Rozanolixizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Rozanolixizumab.
DB00043 DB14947 Bermekimab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bermekimab.
DB00043 DB14952 Pamrevlumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pamrevlumab.
DB00043 DB14959 Opicinumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Opicinumab.
DB00043 DB14962 Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Omalizumab is combined with Trastuzumab deruxtecan.
DB00043 DB14967 Margetuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Margetuximab.
DB00043 DB14988 Dalantercept The risk or severity of adverse effects can be increased when Omalizumab is combined with Dalantercept.
DB00043 DB14997 Pateclizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pateclizumab.
DB00043 DB15014 Gremubamab The risk or severity of adverse effects can be increased when Omalizumab is combined with Gremubamab.
DB00043 DB15022 Apomab The risk or severity of adverse effects can be increased when Omalizumab is combined with Apomab.
DB00043 DB15044 Tafasitamab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tafasitamab.
DB00043 DB15045 Ipafricept The risk or severity of adverse effects can be increased when Omalizumab is combined with Ipafricept.
DB00043 DB15076 Abrilumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Abrilumab.
DB00043 DB15089 Frovocimab The risk or severity of adverse effects can be increased when Omalizumab is combined with Frovocimab.
DB00043 DB15090 Tezepelumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tezepelumab.
DB00043 DB15101 Tigatuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tigatuzumab.
DB00043 DB15104 Telisotuzumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Telisotuzumab vedotin.
DB00043 DB15113 Utomilumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Utomilumab.
DB00043 DB15118 Zolbetuximab The risk or severity of adverse effects can be increased when Omalizumab is combined with Zolbetuximab.
DB00043 DB15135 Ponezumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ponezumab.
DB00043 DB15160 Asunercept The risk or severity of adverse effects can be increased when Omalizumab is combined with Asunercept.
DB00043 DB15172 Suvratoxumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Suvratoxumab.
DB00043 DB15225 Mitazalimab The risk or severity of adverse effects can be increased when Omalizumab is combined with Mitazalimab.
DB00043 DB15252 Nemolizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Nemolizumab.
DB00043 DB15253 Bleselumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Bleselumab.
DB00043 DB15277 Gedivumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Gedivumab.
DB00043 DB15336 Valanafusp alfa The risk or severity of adverse effects can be increased when Omalizumab is combined with Valanafusp alfa.
DB00043 DB15349 Sofituzumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Sofituzumab vedotin.
DB00043 DB15354 Evinacumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Evinacumab.
DB00043 DB15363 Istiratumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Istiratumab.
DB00043 DB15383 Pidilizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Pidilizumab.
DB00043 DB15397 GMA-161 The risk or severity of adverse effects can be increased when Omalizumab is combined with GMA-161.
DB00043 DB15409 Ladiratuzumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Ladiratuzumab vedotin.
DB00043 DB15415 Tomaralimab The risk or severity of adverse effects can be increased when Omalizumab is combined with Tomaralimab.
DB00043 DB15428 Vesencumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Vesencumab.
DB00043 DB15432 Pinatuzumab vedotin The risk or severity of adverse effects can be increased when Omalizumab is combined with Pinatuzumab vedotin.
DB00043 DB15441 Lulizumab pegol The risk or severity of adverse effects can be increased when Omalizumab is combined with Lulizumab pegol.
DB00043 DB15443 Lorukafusp alfa The risk or severity of adverse effects can be increased when Omalizumab is combined with Lorukafusp alfa.
DB00043 DB15453 Naratuximab emtansine The risk or severity of adverse effects can be increased when Omalizumab is combined with Naratuximab emtansine.
DB00043 DB15559 Zenocutuzumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Zenocutuzumab.
DB00043 DB15595 Ebola Zaire vaccine (live, attenuated) The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Omalizumab.
DB00046 DB06655 Liraglutide Liraglutide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09046 Metreleptin Metreleptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00082 Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin lispro.
DB00046 DB01132 Pioglitazone The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin lispro.
DB00046 DB01278 Pramlintide Pramlintide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00412 Rosiglitazone The risk or severity of congestive heart failure can be increased when Insulin lispro is combined with Rosiglitazone.
DB00046 DB00166 Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin lispro.
DB00046 DB00974 Edetic acid Edetic acid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00187 Esmolol Esmolol may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00218 Moxifloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Moxifloxacin.
DB00046 DB00365 Grepafloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Grepafloxacin.
DB00046 DB00467 Enoxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Enoxacin.
DB00046 DB00487 Pefloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Pefloxacin.
DB00046 DB00537 Ciprofloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Ciprofloxacin.
DB00046 DB00685 Trovafloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Trovafloxacin.
DB00046 DB00779 Nalidixic acid The therapeutic efficacy of Insulin lispro can be increased when used in combination with Nalidixic acid.
DB00046 DB00817 Rosoxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Rosoxacin.
DB00046 DB00827 Cinoxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Cinoxacin.
DB00046 DB00978 Lomefloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Lomefloxacin.
DB00046 DB01044 Gatifloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Gatifloxacin.
DB00046 DB01059 Norfloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Norfloxacin.
DB00046 DB01137 Levofloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Levofloxacin.
DB00046 DB01155 Gemifloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Gemifloxacin.
DB00046 DB01165 Ofloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Ofloxacin.
DB00046 DB01208 Sparfloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sparfloxacin.
DB00046 DB01405 Temafloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Temafloxacin.
DB00046 DB04576 Fleroxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Fleroxacin.
DB00046 DB05488 Technetium Tc-99m ciprofloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
DB00046 DB06160 Garenoxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Garenoxacin.
DB00046 DB06600 Nemonoxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Nemonoxacin.
DB00046 DB08972 Flumequine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Flumequine.
DB00046 DB11404 Enrofloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Enrofloxacin.
DB00046 DB11443 Orbifloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Orbifloxacin.
DB00046 DB11491 Sarafloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sarafloxacin.
DB00046 DB11511 Difloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Difloxacin.
DB00046 DB11774 Pazufloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Pazufloxacin.
DB00046 DB11892 Prulifloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Prulifloxacin.
DB00046 DB11943 Delafloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Delafloxacin.
DB00046 DB13261 Sitafloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sitafloxacin.
DB00046 DB13627 Oxolinic acid The therapeutic efficacy of Insulin lispro can be increased when used in combination with Oxolinic acid.
DB00046 DB13772 Rufloxacin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Rufloxacin.
DB00046 DB13823 Pipemidic acid The therapeutic efficacy of Insulin lispro can be increased when used in combination with Pipemidic acid.
DB00046 DB00232 Methyclothiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Methyclothiazide.
DB00046 DB00310 Chlorthalidone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Chlorthalidone.
DB00046 DB00436 Bendroflumethiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Bendroflumethiazide.
DB00046 DB00524 Metolazone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Metolazone.
DB00046 DB00562 Benzthiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Benzthiazide.
DB00046 DB00774 Hydroflumethiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Hydroflumethiazide.
DB00046 DB00808 Indapamide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Indapamide.
DB00046 DB00880 Chlorothiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Chlorothiazide.
DB00046 DB00999 Hydrochlorothiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Hydrochlorothiazide.
DB00046 DB01021 Trichlormethiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Trichlormethiazide.
DB00046 DB01324 Polythiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Polythiazide.
DB00046 DB01325 Quinethazone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Quinethazone.
DB00046 DB13532 Cyclopenthiazide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Cyclopenthiazide.
DB00046 DB13989 Epitizide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Epitizide.
DB00046 DB00344 Protriptyline Protriptyline may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB00543 Amoxapine Amoxapine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB00726 Trimipramine Trimipramine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB04836 Amineptine Amineptine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB08996 Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB09016 Butriptyline Butriptyline may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB09167 Dosulepin Dosulepin may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB09289 Tianeptine Tianeptine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB09307 Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB12930 Opipramol Opipramol may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13114 Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13225 Dibenzepin Dibenzepin may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13246 Quinupramine Quinupramine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13384 Melitracen Melitracen may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13411 Lofepramine Lofepramine may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13496 Iprindole Iprindole may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB13782 Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB06292 Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB08907 Canagliflozin Canagliflozin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00007 Leuprolide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Leuprolide.
DB00046 DB00014 Goserelin The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Goserelin.
DB00046 DB00104 Octreotide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Octreotide.
DB00046 DB00220 Nelfinavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Nelfinavir.
DB00046 DB00224 Indinavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Indinavir.
DB00046 DB00246 Ziprasidone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ziprasidone.
DB00046 DB00294 Etonogestrel The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Etonogestrel.
DB00046 DB00304 Desogestrel The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Desogestrel.
DB00046 DB00334 Olanzapine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Olanzapine.
DB00046 DB00351 Megestrol acetate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Megestrol acetate.
DB00046 DB00363 Clozapine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Clozapine.
DB00046 DB00367 Levonorgestrel The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Levonorgestrel.
DB00046 DB00396 Progesterone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Progesterone.
DB00046 DB00477 Chlorpromazine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Chlorpromazine.
DB00046 DB00502 Haloperidol The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Haloperidol.
DB00046 DB00503 Ritonavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ritonavir.
DB00046 DB00592 Piperazine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Piperazine.
DB00046 DB00603 Medroxyprogesterone acetate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Medroxyprogesterone acetate.
DB00046 DB00627 Niacin The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Niacin.
DB00046 DB00668 Epinephrine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Epinephrine.
DB00046 DB00717 Norethisterone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Norethisterone.
DB00046 DB00734 Risperidone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Risperidone.
DB00046 DB00738 Pentamidine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Pentamidine.
DB00046 DB00823 Ethynodiol diacetate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ethynodiol diacetate.
DB00046 DB00852 Pseudoephedrine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Pseudoephedrine.
DB00046 DB00864 Tacrolimus The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Tacrolimus.
DB00046 DB00877 Sirolimus The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Sirolimus.
DB00046 DB00903 Etacrynic acid The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Etacrynic acid.
DB00046 DB00932 Tipranavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Tipranavir.
DB00046 DB00957 Norgestimate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Norgestimate.
DB00046 DB00977 Ethinylestradiol The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ethinylestradiol.
DB00046 DB01072 Atazanavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Atazanavir.
DB00046 DB01169 Arsenic trioxide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Arsenic trioxide.
DB00046 DB01224 Quetiapine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Quetiapine.
DB00046 DB01232 Saquinavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Saquinavir.
DB00046 DB01238 Aripiprazole The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Aripiprazole.
DB00046 DB01267 Paliperidone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Paliperidone.
DB00046 DB01319 Fosamprenavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Fosamprenavir.
DB00046 DB01323 St. John's Wort The therapeutic efficacy of Insulin lispro can be decreased when used in combination with St. John's Wort.
DB00046 DB01357 Mestranol The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Mestranol.
DB00046 DB01363 Ephedra sinica root The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ephedra sinica root.
DB00046 DB01395 Drospirenone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Drospirenone.
DB00046 DB01403 Methotrimeprazine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Methotrimeprazine.
DB00046 DB01406 Danazol The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Danazol.
DB00046 DB01590 Everolimus The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Everolimus.
DB00046 DB01601 Lopinavir The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Lopinavir.
DB00046 DB01621 Pipotiazine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Pipotiazine.
DB00046 DB02546 Vorinostat The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Vorinostat.
DB00046 DB04574 Estrone sulfate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Estrone sulfate.
DB00046 DB04839 Cyproterone acetate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Cyproterone acetate.
DB00046 DB04868 Nilotinib The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Nilotinib.
DB00046 DB04946 Iloperidone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Iloperidone.
DB00046 DB06216 Asenapine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Asenapine.
DB00046 DB06287 Temsirolimus The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Temsirolimus.
DB00046 DB06663 Pasireotide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Pasireotide.
DB00046 DB06719 Buserelin The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Buserelin.
DB00046 DB06788 Histrelin The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Histrelin.
DB00046 DB06789 Hydroxyprogesterone caproate The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Hydroxyprogesterone caproate.
DB00046 DB06791 Lanreotide The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Lanreotide.
DB00046 DB06825 Triptorelin The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Triptorelin.
DB00046 DB08815 Lurasidone The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Lurasidone.
DB00046 DB08912 Dabrafenib The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Dabrafenib.
DB00046 DB09009 Articaine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Articaine.
DB00046 DB09063 Ceritinib The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ceritinib.
DB00046 DB09123 Dienogest The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Dienogest.
DB00046 DB09128 Brexpiprazole The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Brexpiprazole.
DB00046 DB06343 Teprotumumab The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Teprotumumab.
DB00046 DB00621 Oxandrolone Oxandrolone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00624 Testosterone Testosterone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00984 Nandrolone phenpropionate Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01185 Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01420 Testosterone propionate Testosterone propionate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB02901 Stanolone Stanolone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06412 Oxymetholone Oxymetholone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06710 Methyltestosterone Methyltestosterone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06718 Stanozolol Stanozolol may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB08804 Nandrolone decanoate Nandrolone decanoate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB12461 GLPG-0492 GLPG-0492 may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13169 Nandrolone Nandrolone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13587 Mesterolone Mesterolone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13943 Testosterone cypionate Testosterone cypionate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13944 Testosterone enanthate Testosterone enanthate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00215 Citalopram The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Citalopram.
DB00046 DB00230 Pregabalin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Pregabalin.
DB00046 DB00285 Venlafaxine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Venlafaxine.
DB00046 DB00328 Indomethacin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Indomethacin.
DB00046 DB01104 Sertraline The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Sertraline.
DB00046 DB01149 Nefazodone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Nefazodone.
DB00046 DB01175 Escitalopram The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Escitalopram.
DB00046 DB04832 Zimelidine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Zimelidine.
DB00046 DB04884 Dapoxetine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Dapoxetine.
DB00046 DB04896 Milnacipran The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Milnacipran.
DB00046 DB06700 Desvenlafaxine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Desvenlafaxine.
DB00046 DB08918 Levomilnacipran The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Levomilnacipran.
DB00046 DB08953 Indalpine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Indalpine.
DB00046 DB09270 Ubidecarenone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Ubidecarenone.
DB00046 DB12693 Ritanserin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Ritanserin.
DB00046 DB13233 Alaproclate The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Alaproclate.
DB00046 DB13358 Cibenzoline The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Cibenzoline.
DB00046 DB14025 Clinafloxacin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Clinafloxacin.
DB00046 DB09038 Empagliflozin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Empagliflozin.
DB00046 DB00233 Aminosalicylic acid Aminosalicylic acid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00244 Mesalazine Mesalazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00795 Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00861 Diflunisal Diflunisal may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00936 Salicylic acid Salicylic acid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01014 Balsalazide Balsalazide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01250 Olsalazine Olsalazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01294 Bismuth subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06251 Dersalazine Dersalazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06807 Phenyl aminosalicylate Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09543 Methyl salicylate Methyl salicylate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB11079 Trolamine salicylate Trolamine salicylate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB12445 Nitroaspirin Nitroaspirin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13509 Aloxiprin Aloxiprin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13538 Guacetisal Guacetisal may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13612 Carbaspirin calcium Carbaspirin calcium may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB14006 Choline salicylate Choline salicylate may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB14026 Thiosalicylic acid Thiosalicylic acid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01261 Sitagliptin Sitagliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB04876 Vildagliptin Vildagliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06011 AMG-222 AMG-222 may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06127 Bisegliptin Bisegliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06203 Alogliptin Alogliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06335 Saxagliptin Saxagliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB08382 Gosogliptin Gosogliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB08882 Linagliptin Linagliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB11723 Dutogliptin Dutogliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB11950 Teneligliptin Teneligliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB11992 Omarigliptin Omarigliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB12268 Carmegliptin Carmegliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB12412 Gemigliptin Gemigliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB12417 Anagliptin Anagliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB12625 Evogliptin Evogliptin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01276 Exenatide Exenatide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09043 Albiglutide Albiglutide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09045 Dulaglutide Dulaglutide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09265 Lixisenatide Lixisenatide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13928 Semaglutide Semaglutide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB14027 Taspoglutide Taspoglutide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00752 Tranylcypromine Tranylcypromine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00780 Phenelzine Phenelzine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01171 Moclobemide Moclobemide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01247 Isocarboxazid Isocarboxazid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01626 Pargyline Pargyline may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00805 Minaprine Minaprine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB04818 Iproniazid Iproniazid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB04820 Nialamide Nialamide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09244 Pirlindole Pirlindole may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09245 Toloxatone Toloxatone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09243 Hydracarbazine Hydracarbazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09241 Methylene blue Methylene blue may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09246 Benmoxin Benmoxin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09248 Mebanazine Mebanazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09249 Octamoxin Octamoxin may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09250 Pheniprazine Pheniprazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09251 Phenoxypropazine Phenoxypropazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09252 Pivhydrazine Pivhydrazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09253 Safrazine Safrazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB09254 Caroxazone Caroxazone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00614 Furazolidone Furazolidone may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13875 Harmaline Harmaline may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB13876 Brofaromine Brofaromine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00721 Procaine Procaine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00182 Amphetamine Amphetamine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB01168 Procarbazine Procarbazine may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB00601 Linezolid Linezolid may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB06654 Safinamide Safinamide may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB04017 Clorgiline Clorgiline may increase the hypoglycemic activities of Insulin lispro.
DB00046 DB11827 Ertugliflozin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Ertugliflozin.
DB00046 DB00203 Sildenafil The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sildenafil.
DB00046 DB00214 Torasemide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Torasemide.
DB00046 DB00263 Sulfisoxazole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfisoxazole.
DB00046 DB00311 Ethoxzolamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Ethoxzolamide.
DB00046 DB00359 Sulfadiazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfadiazine.
DB00046 DB00482 Celecoxib The therapeutic efficacy of Insulin lispro can be increased when used in combination with Celecoxib.
DB00046 DB00559 Bosentan The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bosentan.
DB00046 DB00576 Sulfamethizole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamethizole.
DB00046 DB00606 Cyclothiazide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Cyclothiazide.
DB00046 DB00664 Sulfametopyrazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfametopyrazine.
DB00046 DB00669 Sumatriptan The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sumatriptan.
DB00046 DB00695 Furosemide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Furosemide.
DB00046 DB00706 Tamsulosin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Tamsulosin.
DB00046 DB00819 Acetazolamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Acetazolamide.
DB00046 DB00887 Bumetanide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bumetanide.
DB00046 DB00891 Sulfapyridine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfapyridine.
DB00046 DB00909 Zonisamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Zonisamide.
DB00046 DB01015 Sulfamethoxazole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamethoxazole.
DB00046 DB01032 Probenecid The therapeutic efficacy of Insulin lispro can be increased when used in combination with Probenecid.
DB00046 DB01098 Rosuvastatin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Rosuvastatin.
DB00046 DB01119 Diazoxide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Diazoxide.
DB00046 DB01144 Diclofenamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Diclofenamide.
DB00046 DB01264 Darunavir The therapeutic efficacy of Insulin lispro can be increased when used in combination with Darunavir.
DB00046 DB01298 Sulfacytine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfacytine.
DB00046 DB01299 Sulfadoxine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfadoxine.
DB00046 DB01382 Glymidine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Glymidine.
DB00046 DB01581 Sulfamerazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamerazine.
DB00046 DB01582 Sulfamethazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamethazine.
DB00046 DB02925 Piretanide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Piretanide.
DB00046 DB04707 Hydroxyfasudil The therapeutic efficacy of Insulin lispro can be increased when used in combination with Hydroxyfasudil.
DB00046 DB06150 Sulfadimethoxine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfadimethoxine.
DB00046 DB06290 Simeprevir The therapeutic efficacy of Insulin lispro can be increased when used in combination with Simeprevir.
DB00046 DB06729 Sulfaphenazole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaphenazole.
DB00046 DB06821 Sulfameter The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfameter.
DB00046 DB07996 5-(2-methylpiperazine-1-sulfonyl)isoquinoline The therapeutic efficacy of Insulin lispro can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
DB00046 DB08162 Fasudil The therapeutic efficacy of Insulin lispro can be increased when used in combination with Fasudil.
DB00046 DB08798 Sulfamoxole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamoxole.
DB00046 DB08881 Vemurafenib The therapeutic efficacy of Insulin lispro can be increased when used in combination with Vemurafenib.
DB00046 DB08961 Azosemide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Azosemide.
DB00046 DB11389 Clorsulon The therapeutic efficacy of Insulin lispro can be increased when used in combination with Clorsulon.
DB00046 DB11461 Sulfachlorpyridazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfachlorpyridazine.
DB00046 DB11462 Sulfaethoxypyridazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaethoxypyridazine.
DB00046 DB11463 Sulfanitran The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfanitran.
DB00046 DB11464 Sulfaquinoxaline The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaquinoxaline.
DB00046 DB12051 Setrobuvir The therapeutic efficacy of Insulin lispro can be increased when used in combination with Setrobuvir.
DB00046 DB12921 Chlorsulfaquinoxaline The therapeutic efficacy of Insulin lispro can be increased when used in combination with Chlorsulfaquinoxaline.
DB00046 DB13214 Sulfadicramide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfadicramide.
DB00046 DB13248 Phthalylsulfathiazole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Phthalylsulfathiazole.
DB00046 DB13283 Sulfaisodimidine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaisodimidine.
DB00046 DB13284 Meticrane The therapeutic efficacy of Insulin lispro can be increased when used in combination with Meticrane.
DB00046 DB13320 Sulfaperin The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaperin.
DB00046 DB13405 Mefruside The therapeutic efficacy of Insulin lispro can be increased when used in combination with Mefruside.
DB00046 DB13430 Mebutizide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Mebutizide.
DB00046 DB13485 Sulfametomidine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfametomidine.
DB00046 DB13547 Sulfatolamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfatolamide.
DB00046 DB13556 Sulfamazone The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamazone.
DB00046 DB13580 Succinylsulfathiazole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Succinylsulfathiazole.
DB00046 DB13617 Clorexolone The therapeutic efficacy of Insulin lispro can be increased when used in combination with Clorexolone.
DB00046 DB13663 Clofenamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Clofenamide.
DB00046 DB13699 Sulfathiourea The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfathiourea.
DB00046 DB13708 Fenquizone The therapeutic efficacy of Insulin lispro can be increased when used in combination with Fenquizone.
DB00046 DB13726 Sulfaguanidine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaguanidine.
DB00046 DB13773 Sulfamethoxypyridazine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfamethoxypyridazine.
DB00046 DB13792 Clopamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Clopamide.
DB00046 DB13803 Xipamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Xipamide.
DB00046 DB14033 Acetyl sulfisoxazole The therapeutic efficacy of Insulin lispro can be increased when used in combination with Acetyl sulfisoxazole.
DB00046 DB14708 Tosylchloramide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Tosylchloramide.
DB00046 DB00703 Methazolamide The therapeutic efficacy of Insulin lispro can be increased when used in combination with Methazolamide.
DB00046 DB06370 Indisulam The therapeutic efficacy of Insulin lispro can be increased when used in combination with Indisulam.
DB00046 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Insulin lispro.
DB00046 DB00184 Nicotine The metabolism of Nicotine can be increased when combined with Insulin lispro.
DB00046 DB00188 Bortezomib The metabolism of Bortezomib can be increased when combined with Insulin lispro.
DB00046 DB00201 Caffeine The metabolism of Caffeine can be increased when combined with Insulin lispro.
DB00046 DB00261 Anagrelide The metabolism of Anagrelide can be increased when combined with Insulin lispro.
DB00046 DB00262 Carmustine The metabolism of Carmustine can be increased when combined with Insulin lispro.
DB00046 DB00281 Lidocaine The metabolism of Lidocaine can be increased when combined with Insulin lispro.
DB00046 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Insulin lispro.
DB00046 DB00296 Ropivacaine The metabolism of Ropivacaine can be increased when combined with Insulin lispro.
DB00046 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be increased when combined with Insulin lispro.
DB00046 DB00316 Acetaminophen The metabolism of Acetaminophen can be increased when combined with Insulin lispro.
DB00046 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Insulin lispro.
DB00046 DB00370 Mirtazapine The metabolism of Mirtazapine can be increased when combined with Insulin lispro.
DB00046 DB00379 Mexiletine The metabolism of Mexiletine can be increased when combined with Insulin lispro.
DB00046 DB00382 Tacrine The metabolism of Tacrine can be increased when combined with Insulin lispro.
DB00046 DB00384 Triamterene The metabolism of Triamterene can be increased when combined with Insulin lispro.
DB00046 DB00420 Promazine The metabolism of Promazine can be increased when combined with Insulin lispro.
DB00046 DB00425 Zolpidem The metabolism of Zolpidem can be increased when combined with Insulin lispro.
DB00046 DB00442 Entecavir The metabolism of Entecavir can be increased when combined with Insulin lispro.
DB00046 DB00461 Nabumetone The metabolism of Nabumetone can be increased when combined with Insulin lispro.
DB00046 DB00472 Fluoxetine The metabolism of Fluoxetine can be increased when combined with Insulin lispro.
DB00046 DB00476 Duloxetine The metabolism of Duloxetine can be increased when combined with Insulin lispro.
DB00046 DB00499 Flutamide The metabolism of Flutamide can be increased when combined with Insulin lispro.
DB00046 DB00518 Albendazole The metabolism of Albendazole can be increased when combined with Insulin lispro.
DB00046 DB00533 Rofecoxib The metabolism of Rofecoxib can be increased when combined with Insulin lispro.
DB00046 DB00544 Fluorouracil The metabolism of Fluorouracil can be increased when combined with Insulin lispro.
DB00046 DB00568 Cinnarizine The metabolism of Cinnarizine can be increased when combined with Insulin lispro.
DB00046 DB00586 Diclofenac The metabolism of Diclofenac can be increased when combined with Insulin lispro.
DB00046 DB00619 Imatinib The metabolism of Imatinib can be increased when combined with Insulin lispro.
DB00046 DB00629 Guanabenz The metabolism of Guanabenz can be increased when combined with Insulin lispro.
DB00046 DB00642 Pemetrexed The metabolism of Pemetrexed can be increased when combined with Insulin lispro.
DB00046 DB00661 Verapamil The metabolism of Verapamil can be increased when combined with Insulin lispro.
DB00046 DB00715 Paroxetine The metabolism of Paroxetine can be increased when combined with Insulin lispro.
DB00046 DB00730 Thiabendazole The metabolism of Thiabendazole can be increased when combined with Insulin lispro.
DB00046 DB00740 Riluzole The metabolism of Riluzole can be increased when combined with Insulin lispro.
DB00046 DB00744 Zileuton The metabolism of Zileuton can be increased when combined with Insulin lispro.
DB00046 DB00758 Clopidogrel The metabolism of Clopidogrel can be increased when combined with Insulin lispro.
DB00046 DB00787 Acyclovir The metabolism of Acyclovir can be increased when combined with Insulin lispro.
DB00046 DB00788 Naproxen The metabolism of Naproxen can be increased when combined with Insulin lispro.
DB00046 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be increased when combined with Insulin lispro.
DB00046 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Insulin lispro.
DB00046 DB00850 Perphenazine The metabolism of Perphenazine can be increased when combined with Insulin lispro.
DB00046 DB00857 Terbinafine The metabolism of Terbinafine can be increased when combined with Insulin lispro.
DB00046 DB00863 Ranitidine The metabolism of Ranitidine can be increased when combined with Insulin lispro.
DB00046 DB00898 Ethanol The metabolism of Ethanol can be increased when combined with Insulin lispro.
DB00046 DB00934 Maprotiline The metabolism of Maprotiline can be increased when combined with Insulin lispro.
DB00046 DB00969 Alosetron The metabolism of Alosetron can be increased when combined with Insulin lispro.
DB00046 DB00980 Ramelteon The metabolism of Ramelteon can be increased when combined with Insulin lispro.
DB00046 DB00993 Azathioprine The metabolism of Azathioprine can be increased when combined with Insulin lispro.
DB00046 DB00998 Frovatriptan The metabolism of Frovatriptan can be increased when combined with Insulin lispro.
DB00046 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Insulin lispro.
DB00046 DB01012 Cinacalcet The metabolism of Cinacalcet can be increased when combined with Insulin lispro.
DB00046 DB01037 Selegiline The metabolism of Selegiline can be increased when combined with Insulin lispro.
DB00046 DB01056 Tocainide The metabolism of Tocainide can be increased when combined with Insulin lispro.
DB00046 DB01058 Praziquantel The metabolism of Praziquantel can be increased when combined with Insulin lispro.
DB00046 DB01065 Melatonin The metabolism of Melatonin can be increased when combined with Insulin lispro.
DB00046 DB01087 Primaquine The metabolism of Primaquine can be increased when combined with Insulin lispro.
DB00046 DB01094 Hesperetin The metabolism of Hesperetin can be increased when combined with Insulin lispro.
DB00046 DB01097 Leflunomide The metabolism of Leflunomide can be increased when combined with Insulin lispro.
DB00046 DB01166 Cilostazol The metabolism of Cilostazol can be increased when combined with Insulin lispro.
DB00046 DB01184 Domperidone The metabolism of Domperidone can be increased when combined with Insulin lispro.
DB00046 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Insulin lispro.
DB00046 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Insulin lispro.
DB00046 DB01367 Rasagiline The metabolism of Rasagiline can be increased when combined with Insulin lispro.
DB00046 DB01412 Theobromine The metabolism of Theobromine can be increased when combined with Insulin lispro.
DB00046 DB01424 Aminophenazone The metabolism of Aminophenazone can be increased when combined with Insulin lispro.
DB00046 DB01435 Antipyrine The metabolism of Antipyrine can be increased when combined with Insulin lispro.
DB00046 DB01482 Fenethylline The metabolism of Fenethylline can be increased when combined with Insulin lispro.
DB00046 DB01558 Bromazepam The metabolism of Bromazepam can be increased when combined with Insulin lispro.
DB00046 DB01623 Thiothixene The metabolism of Thiothixene can be increased when combined with Insulin lispro.
DB00046 DB01628 Etoricoxib The metabolism of Etoricoxib can be increased when combined with Insulin lispro.
DB00046 DB01645 Genistein The metabolism of Genistein can be increased when combined with Insulin lispro.
DB00046 DB01667 8-azaguanine The metabolism of 8-azaguanine can be increased when combined with Insulin lispro.
DB00046 DB02134 Xanthine The metabolism of Xanthine can be increased when combined with Insulin lispro.
DB00046 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be increased when combined with Insulin lispro.
DB00046 DB02568 Peldesine The metabolism of Peldesine can be increased when combined with Insulin lispro.
DB00046 DB02709 Resveratrol The metabolism of Resveratrol can be increased when combined with Insulin lispro.
DB00046 DB03783 Phenacetin The metabolism of Phenacetin can be increased when combined with Insulin lispro.
DB00046 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be increased when combined with Insulin lispro.
DB00046 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be increased when combined with Insulin lispro.
DB00046 DB04841 Flunarizine The metabolism of Flunarizine can be increased when combined with Insulin lispro.
DB00046 DB04871 Lorcaserin The metabolism of Lorcaserin can be increased when combined with Insulin lispro.
DB00046 DB04948 Lofexidine The metabolism of Lofexidine can be increased when combined with Insulin lispro.
DB00046 DB04951 Pirfenidone The metabolism of Pirfenidone can be increased when combined with Insulin lispro.
DB00046 DB05676 Apremilast The metabolism of Apremilast can be increased when combined with Insulin lispro.
DB00046 DB06148 Mianserin The metabolism of Mianserin can be increased when combined with Insulin lispro.
DB00046 DB06210 Eltrombopag The metabolism of Eltrombopag can be increased when combined with Insulin lispro.
DB00046 DB06235 Vadimezan The metabolism of Vadimezan can be increased when combined with Insulin lispro.
DB00046 DB06479 Propentofylline The metabolism of Propentofylline can be increased when combined with Insulin lispro.
DB00046 DB06589 Pazopanib The metabolism of Pazopanib can be increased when combined with Insulin lispro.
DB00046 DB06594 Agomelatine The metabolism of Agomelatine can be increased when combined with Insulin lispro.
DB00046 DB06626 Axitinib The metabolism of Axitinib can be increased when combined with Insulin lispro.
DB00046 DB06769 Bendamustine The metabolism of Bendamustine can be increased when combined with Insulin lispro.
DB00046 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be increased when combined with Insulin lispro.
DB00046 DB06774 Capsaicin The metabolism of Capsaicin can be increased when combined with Insulin lispro.
DB00046 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Insulin lispro.
DB00046 DB08883 Perampanel The metabolism of Perampanel can be increased when combined with Insulin lispro.
DB00046 DB09071 Tasimelteon The metabolism of Tasimelteon can be increased when combined with Insulin lispro.
DB00046 DB09118 Stiripentol The metabolism of Stiripentol can be increased when combined with Insulin lispro.
DB00046 DB09225 Zotepine The metabolism of Zotepine can be increased when combined with Insulin lispro.
DB00046 DB09273 Doxofylline The metabolism of Doxofylline can be increased when combined with Insulin lispro.
DB00046 DB09288 Propacetamol The metabolism of Propacetamol can be increased when combined with Insulin lispro.
DB00046 DB09290 Ramosetron The metabolism of Ramosetron can be increased when combined with Insulin lispro.
DB00046 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be increased when combined with Insulin lispro.
DB00046 DB11967 Binimetinib The metabolism of Binimetinib can be increased when combined with Insulin lispro.
DB00046 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be increased when combined with Insulin lispro.
DB00046 DB12245 Triclabendazole The metabolism of Triclabendazole can be increased when combined with Insulin lispro.
DB00046 DB12332 Rucaparib The metabolism of Rucaparib can be increased when combined with Insulin lispro.
DB00046 DB12406 Lisofylline The metabolism of Lisofylline can be increased when combined with Insulin lispro.
DB00046 DB12531 Lobucavir The metabolism of Lobucavir can be increased when combined with Insulin lispro.
DB00046 DB12926 Cafedrine The metabolism of Cafedrine can be increased when combined with Insulin lispro.
DB00046 DB12927 Theodrenaline The metabolism of Theodrenaline can be increased when combined with Insulin lispro.
DB00046 DB12945 Dihydralazine The metabolism of Dihydralazine can be increased when combined with Insulin lispro.
DB00046 DB13203 Bamifylline The metabolism of Bamifylline can be increased when combined with Insulin lispro.
DB00046 DB13449 Proxyphylline The metabolism of Proxyphylline can be increased when combined with Insulin lispro.
DB00046 DB13573 Acefylline The metabolism of Acefylline can be increased when combined with Insulin lispro.
DB00046 DB13592 Etamiphylline The metabolism of Etamiphylline can be increased when combined with Insulin lispro.
DB00046 DB13634 Pentifylline The metabolism of Pentifylline can be increased when combined with Insulin lispro.
DB00046 DB13812 Bufylline The metabolism of Bufylline can be increased when combined with Insulin lispro.
DB00046 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Insulin lispro.
DB00046 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Insulin lispro.
DB00046 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Insulin lispro.
DB00046 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Insulin lispro.
DB00046 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Insulin lispro.
DB00046 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Insulin lispro.
DB00046 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be increased when combined with Insulin lispro.
DB00046 DB01115 Nifedipine The metabolism of Nifedipine can be increased when combined with Insulin lispro.
DB00046 DB11757 Istradefylline The metabolism of Istradefylline can be increased when combined with Insulin lispro.
DB00046 DB00972 Azelastine The metabolism of Azelastine can be increased when combined with Insulin lispro.
DB00046 DB00625 Efavirenz The metabolism of Efavirenz can be increased when combined with Insulin lispro.
DB00046 DB04889 Bicifadine The metabolism of Bicifadine can be increased when combined with Insulin lispro.
DB00046 DB05708 GTS-21 The metabolism of GTS-21 can be increased when combined with Insulin lispro.
DB00046 DB01195 Flecainide The metabolism of Flecainide can be increased when combined with Insulin lispro.
DB00046 DB00783 Estradiol The metabolism of Estradiol can be increased when combined with Insulin lispro.
DB00046 DB00321 Amitriptyline The metabolism of Amitriptyline can be increased when combined with Insulin lispro.
DB00046 DB00458 Imipramine The metabolism of Imipramine can be increased when combined with Insulin lispro.
DB00046 DB01142 Doxepin The metabolism of Doxepin can be increased when combined with Insulin lispro.
DB00046 DB00532 Mephenytoin The metabolism of Mephenytoin can be increased when combined with Insulin lispro.
DB00046 DB00540 Nortriptyline The metabolism of Nortriptyline can be increased when combined with Insulin lispro.
DB00046 DB00575 Clonidine The metabolism of Clonidine can be increased when combined with Insulin lispro.
DB00046 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Insulin lispro.
DB00046 DB01151 Desipramine The metabolism of Desipramine can be increased when combined with Insulin lispro.
DB00046 DB01242 Clomipramine The metabolism of Clomipramine can be increased when combined with Insulin lispro.
DB00046 DB11689 Selumetinib The metabolism of Selumetinib can be increased when combined with Insulin lispro.
DB00046 DB00277 Theophylline The metabolism of Theophylline can be increased when combined with Insulin lispro.
DB00046 DB00398 Sorafenib The metabolism of Sorafenib can be increased when combined with Insulin lispro.
DB00046 DB00530 Erlotinib The metabolism of Erlotinib can be increased when combined with Insulin lispro.
DB00046 DB00564 Carbamazepine The metabolism of Carbamazepine can be increased when combined with Insulin lispro.
DB00046 DB00682 Warfarin The metabolism of Warfarin can be increased when combined with Insulin lispro.
DB00046 DB00697 Tizanidine The metabolism of Tizanidine can be increased when combined with Insulin lispro.
DB00046 DB00773 Etoposide The metabolism of Etoposide can be increased when combined with Insulin lispro.
DB00046 DB00851 Dacarbazine The metabolism of Dacarbazine can be increased when combined with Insulin lispro.
DB00046 DB01100 Pimozide The metabolism of Pimozide can be increased when combined with Insulin lispro.
DB00046 DB01223 Aminophylline The metabolism of Aminophylline can be increased when combined with Insulin lispro.
DB00046 DB01254 Dasatinib The metabolism of Dasatinib can be increased when combined with Insulin lispro.
DB00046 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Insulin lispro.
DB00046 DB08910 Pomalidomide The metabolism of Pomalidomide can be increased when combined with Insulin lispro.
DB00046 DB09256 Tegafur The metabolism of Tegafur can be increased when combined with Insulin lispro.
DB00046 DB13874 Enasidenib The metabolism of Enasidenib can be increased when combined with Insulin lispro.
DB00046 DB00675 Tamoxifen The metabolism of Tamoxifen can be increased when combined with Insulin lispro.
DB00046 DB00030 Insulin human The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin lispro.
DB00046 DB00047 Insulin glargine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin glargine.
DB00046 DB00071 Insulin pork The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin pork.
DB00046 DB00197 Troglitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Troglitazone.
DB00046 DB00222 Glimepiride The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Glimepiride.
DB00046 DB00280 Disopyramide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Disopyramide.
DB00046 DB00284 Acarbose The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Acarbose.
DB00046 DB00414 Acetohexamide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Acetohexamide.
DB00046 DB00468 Quinine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Quinine.
DB00046 DB00491 Miglitol The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Miglitol.
DB00046 DB00672 Chlorpropamide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Chlorpropamide.
DB00046 DB00731 Nateglinide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Nateglinide.
DB00046 DB00834 Mifepristone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Mifepristone.
DB00046 DB00839 Tolazamide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Tolazamide.
DB00046 DB00912 Repaglinide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Repaglinide.
DB00046 DB00914 Phenformin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Phenformin.
DB00046 DB01016 Glyburide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Glyburide.
DB00046 DB01067 Glipizide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Glipizide.
DB00046 DB01120 Gliclazide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Gliclazide.
DB00046 DB01124 Tolbutamide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Tolbutamide.
DB00046 DB01200 Bromocriptine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Bromocriptine.
DB00046 DB01251 Gliquidone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Gliquidone.
DB00046 DB01252 Mitiglinide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Mitiglinide.
DB00046 DB01268 Sunitinib The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Sunitinib.
DB00046 DB01277 Mecasermin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Mecasermin.
DB00046 DB01289 Glisoxepide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Glisoxepide.
DB00046 DB01306 Insulin aspart The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin aspart.
DB00046 DB01307 Insulin detemir The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin detemir.
DB00046 DB01309 Insulin glulisine The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin glulisine.
DB00046 DB01700 AICA ribonucleotide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with AICA ribonucleotide.
DB00046 DB04830 Buformin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Buformin.
DB00046 DB04878 Voglibose The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Voglibose.
DB00046 DB05115 NN344 The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with NN344.
DB00046 DB05819 NBI-6024 The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with NBI-6024.
DB00046 DB08962 Glibornuride The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Glibornuride.
DB00046 DB09022 Benfluorex The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Benfluorex.
DB00046 DB09198 Lobeglitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Lobeglitazone.
DB00046 DB09199 Netoglitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Netoglitazone.
DB00046 DB09200 Rivoglitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Rivoglitazone.
DB00046 DB09201 Ciglitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Ciglitazone.
DB00046 DB09456 Insulin beef The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin beef.
DB00046 DB09564 Insulin degludec The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin degludec.
DB00046 DB11567 Insulin peglispro The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin peglispro.
DB00046 DB11568 Insulin tregopil The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin tregopil.
DB00046 DB11698 Ipragliflozin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Ipragliflozin.
DB00046 DB11780 Allicin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Allicin.
DB00046 DB11824 Tofogliflozin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Tofogliflozin.
DB00046 DB11898 2,4-thiazolidinedione The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with 2,4-thiazolidinedione.
DB00046 DB12713 Sotagliflozin The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Sotagliflozin.
DB00046 DB12781 Balaglitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Balaglitazone.
DB00046 DB12935 Remogliflozin etabonate The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Remogliflozin etabonate.
DB00046 DB13406 Carbutamide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Carbutamide.
DB00046 DB13446 Guar gum The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Guar gum.
DB00046 DB13675 Metahexamide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Metahexamide.
DB00046 DB14035 Englitazone The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Englitazone.
DB00046 DB15171 Tirzepatide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Tirzepatide.
DB00046 DB15217 Gastric inhibitory polypeptide The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Gastric inhibitory polypeptide.
DB00046 DB00270 Isradipine The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin lispro.
DB00046 DB00343 Diltiazem The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin lispro.
DB00046 DB00347 Trimethadione The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin lispro.
DB00046 DB00381 Amlodipine The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin lispro.
DB00046 DB00393 Nimodipine The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin lispro.
DB00046 DB00401 Nisoldipine The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin lispro.
DB00046 DB00528 Lercanidipine The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin lispro.
DB00046 DB00555 Lamotrigine The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin lispro.
DB00046 DB00593 Ethosuximide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin lispro.
DB00046 DB00622 Nicardipine The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin lispro.
DB00046 DB00653 Magnesium sulfate The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin lispro.
DB00046 DB00836 Loperamide The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin lispro.
DB00046 DB01054 Nitrendipine The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin lispro.
DB00046 DB01074 Perhexiline The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin lispro.
DB00046 DB01244 Bepridil The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin lispro.
DB00046 DB01388 Mibefradil The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin lispro.
DB00046 DB04743 Nimesulide The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin lispro.
DB00046 DB04825 Prenylamine The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin lispro.
DB00046 DB04838 Cyclandelate The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin lispro.
DB00046 DB04842 Fluspirilene The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin lispro.
DB00046 DB04920 Clevidipine The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin lispro.
DB00046 DB05246 Methsuximide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin lispro.
DB00046 DB05885 Seletracetam The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin lispro.
DB00046 DB06152 Nylidrin The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin lispro.
DB00046 DB06283 Ziconotide The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin lispro.
DB00046 DB06446 Dotarizine The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin lispro.
DB00046 DB06694 Xylometazoline The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin lispro.
DB00046 DB06712 Nilvadipine The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin lispro.
DB00046 DB07615 Tranilast The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin lispro.
DB00046 DB08838 Agmatine The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin lispro.
DB00046 DB08980 Fendiline The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin lispro.
DB00046 DB08992 Eperisone The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin lispro.
DB00046 DB09089 Trimebutine The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin lispro.
DB00046 DB09090 Pinaverium The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin lispro.
DB00046 DB09216 Tolfenamic acid The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin lispro.
DB00046 DB09227 Barnidipine The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin lispro.
DB00046 DB09229 Aranidipine The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin lispro.
DB00046 DB09230 Azelnidipine The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin lispro.
DB00046 DB09231 Benidipine The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin lispro.
DB00046 DB09232 Cilnidipine The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin lispro.
DB00046 DB09234 Darodipine The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin lispro.
DB00046 DB09235 Efonidipine The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin lispro.
DB00046 DB09236 Lacidipine The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin lispro.
DB00046 DB09238 Manidipine The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin lispro.
DB00046 DB09239 Niguldipine The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin lispro.
DB00046 DB09240 Niludipine The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin lispro.
DB00046 DB11960 Carboxyamidotriazole The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin lispro.
DB00046 DB12092 Naftopidil The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin lispro.
DB00046 DB12093 Tetrahydropalmatine The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin lispro.
DB00046 DB12131 Vinpocetine The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin lispro.
DB00046 DB12923 Gallopamil The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin lispro.
DB00046 DB13488 Bencyclane The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin lispro.
DB00046 DB13500 Otilonium The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin lispro.
DB00046 DB13725 Terodiline The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin lispro.
DB00046 DB13766 Lidoflazine The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin lispro.
DB00046 DB13791 Penfluridol The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin lispro.
DB00046 DB13835 Caroverine The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin lispro.
DB00046 DB13950 WIN 55212-2 The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin lispro.
DB00046 DB13961 Fish oil The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin lispro.
DB00046 DB14063 Dexverapamil The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin lispro.
DB00046 DB14064 Emopamil The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin lispro.
DB00046 DB14065 Lomerizine The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin lispro.
DB00046 DB14066 Tetrandrine The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin lispro.
DB00046 DB14068 Dexniguldipine The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin lispro.
DB00046 DB01023 Felodipine The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin lispro.
DB00046 DB01118 Amiodarone The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin lispro.
DB00046 DB00191 Phentermine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Phentermine.
DB00046 DB00268 Ropinirole The metabolism of Ropinirole can be increased when combined with Insulin lispro.
DB00046 DB13074 Macimorelin The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin lispro.
DB00046 DB00279 Liothyronine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Liothyronine.
DB00046 DB00331 Metformin The risk or severity of adverse effects can be increased when Insulin lispro is combined with Metformin.
DB00046 DB00542 Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin lispro.
DB00046 DB13946 Testosterone undecanoate The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin lispro.
DB00046 DB00945 Acetylsalicylic acid The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin lispro.
DB00046 DB00181 Baclofen The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Baclofen.
DB00046 DB00489 Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin lispro.
DB00046 DB00196 Fluconazole The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Fluconazole.
DB00046 DB00040 Glucagon The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Glucagon.
DB00046 DB00264 Metoprolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Metoprolol.
DB00046 DB00335 Atenolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Atenolol.
DB00046 DB00373 Timolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Timolol.
DB00046 DB00598 Labetalol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Labetalol.
DB00046 DB00612 Bisoprolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bisoprolol.
DB00046 DB00866 Alprenolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Alprenolol.
DB00046 DB00960 Pindolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Pindolol.
DB00046 DB01193 Acebutolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Acebutolol.
DB00046 DB01203 Nadolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Nadolol.
DB00046 DB01295 Bevantolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bevantolol.
DB00046 DB01297 Practolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Practolol.
DB00046 DB01359 Penbutolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Penbutolol.
DB00046 DB01580 Oxprenolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Oxprenolol.
DB00046 DB03322 Dexpropranolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Dexpropranolol.
DB00046 DB04846 Celiprolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Celiprolol.
DB00046 DB04861 Nebivolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Nebivolol.
DB00046 DB06726 Bufuralol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bufuralol.
DB00046 DB08807 Bopindolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bopindolol.
DB00046 DB08808 Bupranolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bupranolol.
DB00046 DB08952 Indenolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Indenolol.
DB00046 DB09013 Befunolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Befunolol.
DB00046 DB09204 Arotinolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Arotinolol.
DB00046 DB09351 Levobetaxolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Levobetaxolol.
DB00046 DB11770 Talinolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Talinolol.
DB00046 DB11785 Anisodamine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Anisodamine.
DB00046 DB12212 Landiolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Landiolol.
DB00046 DB12752 Bucindolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Bucindolol.
DB00046 DB13443 Esatenolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Esatenolol.
DB00046 DB13508 Cloranolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Cloranolol.
DB00046 DB13530 Mepindolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Mepindolol.
DB00046 DB13757 Epanolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Epanolol.
DB00046 DB13775 Tertatolol The therapeutic efficacy of Insulin lispro can be increased when used in combination with Tertatolol.
DB00046 DB00195 Betaxolol The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin lispro.
DB00046 DB00571 Propranolol The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin lispro.
DB00046 DB01136 Carvedilol The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin lispro.
DB00046 DB01182 Propafenone The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin lispro.
DB00046 DB01611 Hydroxychloroquine The therapeutic efficacy of Insulin lispro can be increased when used in combination with Hydroxychloroquine.
DB00046 DB01233 Metoclopramide The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin lispro.
DB00046 DB00394 Beclomethasone dipropionate The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin lispro.
DB00046 DB00443 Betamethasone The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin lispro.
DB00046 DB00620 Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin lispro.
DB00046 DB00635 Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin lispro.
DB00046 DB00687 Fludrocortisone The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin lispro.
DB00046 DB00741 Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin lispro.
DB00046 DB00764 Mometasone The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin lispro.
DB00046 DB00860 Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin lispro.
DB00046 DB00959 Methylprednisolone The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin lispro.
DB00046 DB01234 Dexamethasone The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin lispro.
DB00046 DB01285 Corticotropin The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin lispro.
DB00046 DB01380 Cortisone acetate The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin lispro.
DB00046 DB01384 Paramethasone The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin lispro.
DB00046 DB01410 Ciclesonide The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin lispro.
DB00046 DB08906 Fluticasone furoate The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin lispro.
DB00046 DB08970 Fluprednidene The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin lispro.
DB00046 DB08971 Fluocortolone The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin lispro.
DB00046 DB09383 Meprednisone The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin lispro.
DB00046 DB11487 Dexamethasone isonicotinate The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin lispro.
DB00046 DB11750 Clobetasol The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin lispro.
DB00046 DB11921 Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin lispro.
DB00046 DB13003 Cortivazol The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin lispro.
DB00046 DB13208 Prednylidene The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin lispro.
DB00046 DB13843 Cloprednol The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin lispro.
DB00046 DB13867 Fluticasone The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin lispro.
DB00046 DB14512 Mometasone furoate The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin lispro.
DB00046 DB00180 Flunisolide The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin lispro.
DB00046 DB01108 Trilostane The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin lispro.
DB00046 DB01222 Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin lispro.
DB00046 DB04630 Aldosterone The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin lispro.
DB00046 DB09378 Fluprednisolone The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin lispro.
DB00046 DB11529 Melengestrol The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin lispro.
DB00046 DB14681 Cortisone The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin lispro.
DB00046 DB00223 Diflorasone The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin lispro.
DB00046 DB00240 Alclometasone The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin lispro.
DB00046 DB00253 Medrysone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin lispro.
DB00046 DB00288 Amcinonide The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin lispro.
DB00046 DB00324 Fluorometholone The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin lispro.
DB00046 DB00547 Desoximetasone The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin lispro.
DB00046 DB00588 Fluticasone propionate The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin lispro.
DB00046 DB00591 Fluocinolone acetonide The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin lispro.
DB00046 DB00596 Ulobetasol The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin lispro.
DB00046 DB00663 Flumethasone The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin lispro.
DB00046 DB00838 Clocortolone The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin lispro.
DB00046 DB00846 Flurandrenolide The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin lispro.
DB00046 DB14596 Loteprednol etabonate The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin lispro.
DB00046 DB00896 Rimexolone The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin lispro.
DB00046 DB01013 Clobetasol propionate The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin lispro.
DB00046 DB01047 Fluocinonide The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin lispro.
DB00046 DB01130 Prednicarbate The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin lispro.
DB00046 DB01260 Desonide The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin lispro.
DB00046 DB06781 Difluprednate The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin lispro.
DB00046 DB06786 Halcinonide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin lispro.
DB00046 DB09091 Tixocortol The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin lispro.
DB00046 DB09095 Difluocortolone The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin lispro.
DB00046 DB13158 Clobetasone The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin lispro.
DB00046 DB13223 Fluocortin The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin lispro.
DB00046 DB13491 Fluperolone The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin lispro.
DB00046 DB13664 Formocortal The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin lispro.
DB00046 DB13728 Halometasone The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin lispro.
DB00046 DB13856 Fluclorolone The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin lispro.
DB00046 DB14538 Hydrocortisone aceponate The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin lispro.
DB00046 DB14539 Hydrocortisone acetate The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin lispro.
DB00046 DB14540 Hydrocortisone butyrate The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin lispro.
DB00046 DB14541 Hydrocortisone cypionate The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin lispro.
DB00046 DB14543 Hydrocortisone probutate The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin lispro.
DB00046 DB14544 Hydrocortisone valerate The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin lispro.
DB00046 DB14545 Hydrocortisone succinate The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin lispro.
DB00046 DB00873 Loteprednol The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin lispro.
DB00046 DB14631 Prednisolone phosphate The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin lispro.
DB00046 DB14633 Prednisolone hemisuccinate The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin lispro.
DB00046 DB14634 Fluprednidene acetate The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin lispro.
DB00046 DB14643 Methylprednisolone aceponate The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin lispro.
DB00046 DB14644 Methylprednisolone hemisuccinate The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin lispro.
DB00046 DB14646 Prednisone acetate The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin lispro.
DB00046 DB14652 Clocortolone acetate The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin lispro.
DB00046 DB14659 Melengestrol acetate The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin lispro.
DB00046 DB14669 Betamethasone phosphate The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin lispro.
DB00046 DB15566 Prednisolone acetate The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin lispro.
DB00046 DB00451 Levothyroxine The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Levothyroxine.
DB00046 DB00024 Thyrotropin alfa Thyrotropin alfa may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB01583 Liotrix Liotrix may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB03604 Tiratricol Tiratricol may decrease the hypoglycemic activities of Insulin lispro.
DB00046 DB09100 Thyroid, porcine Thyroid, porcine may decrease the hypoglycemic activities of Insulin lispro.
DB00047 DB06655 Liraglutide Liraglutide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09046 Metreleptin Metreleptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00082 Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin glargine.
DB00047 DB01132 Pioglitazone The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin glargine.
DB00047 DB01278 Pramlintide Pramlintide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00412 Rosiglitazone The risk or severity of congestive heart failure can be increased when Insulin glargine is combined with Rosiglitazone.
DB00047 DB00166 Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin glargine.
DB00047 DB00974 Edetic acid Edetic acid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00187 Esmolol Esmolol may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01044 Gatifloxacin The therapeutic efficacy of Gatifloxacin can be increased when used in combination with Insulin glargine.
DB00047 DB00218 Moxifloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Moxifloxacin.
DB00047 DB00467 Enoxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Enoxacin.
DB00047 DB00487 Pefloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Pefloxacin.
DB00047 DB00537 Ciprofloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Ciprofloxacin.
DB00047 DB00685 Trovafloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Trovafloxacin.
DB00047 DB00779 Nalidixic acid The therapeutic efficacy of Insulin glargine can be increased when used in combination with Nalidixic acid.
DB00047 DB00817 Rosoxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Rosoxacin.
DB00047 DB00827 Cinoxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Cinoxacin.
DB00047 DB01059 Norfloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Norfloxacin.
DB00047 DB01137 Levofloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Levofloxacin.
DB00047 DB01155 Gemifloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Gemifloxacin.
DB00047 DB01165 Ofloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Ofloxacin.
DB00047 DB01208 Sparfloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sparfloxacin.
DB00047 DB04576 Fleroxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Fleroxacin.
DB00047 DB05488 Technetium Tc-99m ciprofloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
DB00047 DB06160 Garenoxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Garenoxacin.
DB00047 DB06600 Nemonoxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Nemonoxacin.
DB00047 DB08972 Flumequine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Flumequine.
DB00047 DB11404 Enrofloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Enrofloxacin.
DB00047 DB11443 Orbifloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Orbifloxacin.
DB00047 DB11491 Sarafloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sarafloxacin.
DB00047 DB11511 Difloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Difloxacin.
DB00047 DB11774 Pazufloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Pazufloxacin.
DB00047 DB11892 Prulifloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Prulifloxacin.
DB00047 DB11943 Delafloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Delafloxacin.
DB00047 DB13261 Sitafloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sitafloxacin.
DB00047 DB13627 Oxolinic acid The therapeutic efficacy of Insulin glargine can be increased when used in combination with Oxolinic acid.
DB00047 DB13772 Rufloxacin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Rufloxacin.
DB00047 DB13823 Pipemidic acid The therapeutic efficacy of Insulin glargine can be increased when used in combination with Pipemidic acid.
DB00047 DB00232 Methyclothiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Methyclothiazide.
DB00047 DB00310 Chlorthalidone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Chlorthalidone.
DB00047 DB00436 Bendroflumethiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Bendroflumethiazide.
DB00047 DB00524 Metolazone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Metolazone.
DB00047 DB00562 Benzthiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Benzthiazide.
DB00047 DB00774 Hydroflumethiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Hydroflumethiazide.
DB00047 DB00808 Indapamide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Indapamide.
DB00047 DB00880 Chlorothiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Chlorothiazide.
DB00047 DB00999 Hydrochlorothiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Hydrochlorothiazide.
DB00047 DB01021 Trichlormethiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Trichlormethiazide.
DB00047 DB01324 Polythiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Polythiazide.
DB00047 DB01325 Quinethazone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Quinethazone.
DB00047 DB13532 Cyclopenthiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Cyclopenthiazide.
DB00047 DB13989 Epitizide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Epitizide.
DB00047 DB00344 Protriptyline Protriptyline may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB00543 Amoxapine Amoxapine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB00726 Trimipramine Trimipramine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB04836 Amineptine Amineptine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB08996 Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB09016 Butriptyline Butriptyline may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB09167 Dosulepin Dosulepin may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB09289 Tianeptine Tianeptine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB09307 Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB12930 Opipramol Opipramol may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13114 Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13225 Dibenzepin Dibenzepin may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13246 Quinupramine Quinupramine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13384 Melitracen Melitracen may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13411 Lofepramine Lofepramine may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13496 Iprindole Iprindole may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB13782 Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB06292 Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB08907 Canagliflozin Canagliflozin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00007 Leuprolide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Leuprolide.
DB00047 DB00014 Goserelin The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Goserelin.
DB00047 DB00104 Octreotide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Octreotide.
DB00047 DB00214 Torasemide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Torasemide.
DB00047 DB00220 Nelfinavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Nelfinavir.
DB00047 DB00224 Indinavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Indinavir.
DB00047 DB00246 Ziprasidone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ziprasidone.
DB00047 DB00294 Etonogestrel The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Etonogestrel.
DB00047 DB00304 Desogestrel The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Desogestrel.
DB00047 DB00334 Olanzapine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Olanzapine.
DB00047 DB00351 Megestrol acetate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Megestrol acetate.
DB00047 DB00363 Clozapine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Clozapine.
DB00047 DB00367 Levonorgestrel The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Levonorgestrel.
DB00047 DB00396 Progesterone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Progesterone.
DB00047 DB00477 Chlorpromazine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Chlorpromazine.
DB00047 DB00502 Haloperidol The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Haloperidol.
DB00047 DB00503 Ritonavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ritonavir.
DB00047 DB00592 Piperazine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Piperazine.
DB00047 DB00603 Medroxyprogesterone acetate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Medroxyprogesterone acetate.
DB00047 DB00606 Cyclothiazide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Cyclothiazide.
DB00047 DB00627 Niacin The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Niacin.
DB00047 DB00668 Epinephrine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Epinephrine.
DB00047 DB00695 Furosemide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Furosemide.
DB00047 DB00717 Norethisterone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Norethisterone.
DB00047 DB00734 Risperidone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Risperidone.
DB00047 DB00738 Pentamidine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Pentamidine.
DB00047 DB00823 Ethynodiol diacetate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ethynodiol diacetate.
DB00047 DB00852 Pseudoephedrine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Pseudoephedrine.
DB00047 DB00864 Tacrolimus The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Tacrolimus.
DB00047 DB00877 Sirolimus The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Sirolimus.
DB00047 DB00887 Bumetanide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Bumetanide.
DB00047 DB00903 Etacrynic acid The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Etacrynic acid.
DB00047 DB00932 Tipranavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Tipranavir.
DB00047 DB00957 Norgestimate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Norgestimate.
DB00047 DB00977 Ethinylestradiol The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ethinylestradiol.
DB00047 DB01072 Atazanavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Atazanavir.
DB00047 DB01119 Diazoxide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Diazoxide.
DB00047 DB01169 Arsenic trioxide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Arsenic trioxide.
DB00047 DB01224 Quetiapine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Quetiapine.
DB00047 DB01232 Saquinavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Saquinavir.
DB00047 DB01238 Aripiprazole The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Aripiprazole.
DB00047 DB01264 Darunavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Darunavir.
DB00047 DB01267 Paliperidone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Paliperidone.
DB00047 DB01319 Fosamprenavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Fosamprenavir.
DB00047 DB01323 St. John's Wort The therapeutic efficacy of Insulin glargine can be decreased when used in combination with St. John's Wort.
DB00047 DB01357 Mestranol The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Mestranol.
DB00047 DB01363 Ephedra sinica root The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ephedra sinica root.
DB00047 DB01395 Drospirenone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Drospirenone.
DB00047 DB01403 Methotrimeprazine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Methotrimeprazine.
DB00047 DB01406 Danazol The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Danazol.
DB00047 DB01590 Everolimus The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Everolimus.
DB00047 DB01601 Lopinavir The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Lopinavir.
DB00047 DB01621 Pipotiazine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Pipotiazine.
DB00047 DB02546 Vorinostat The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Vorinostat.
DB00047 DB04574 Estrone sulfate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Estrone sulfate.
DB00047 DB04839 Cyproterone acetate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Cyproterone acetate.
DB00047 DB04868 Nilotinib The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Nilotinib.
DB00047 DB04946 Iloperidone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Iloperidone.
DB00047 DB06216 Asenapine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Asenapine.
DB00047 DB06287 Temsirolimus The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Temsirolimus.
DB00047 DB06663 Pasireotide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Pasireotide.
DB00047 DB06719 Buserelin The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Buserelin.
DB00047 DB06788 Histrelin The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Histrelin.
DB00047 DB06789 Hydroxyprogesterone caproate The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Hydroxyprogesterone caproate.
DB00047 DB06791 Lanreotide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Lanreotide.
DB00047 DB06825 Triptorelin The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Triptorelin.
DB00047 DB08815 Lurasidone The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Lurasidone.
DB00047 DB08912 Dabrafenib The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Dabrafenib.
DB00047 DB09009 Articaine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Articaine.
DB00047 DB09063 Ceritinib The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ceritinib.
DB00047 DB09123 Dienogest The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Dienogest.
DB00047 DB09128 Brexpiprazole The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Brexpiprazole.
DB00047 DB13430 Mebutizide The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Mebutizide.
DB00047 DB06343 Teprotumumab The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Teprotumumab.
DB00047 DB00621 Oxandrolone Oxandrolone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00624 Testosterone Testosterone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00984 Nandrolone phenpropionate Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01185 Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01420 Testosterone propionate Testosterone propionate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB02901 Stanolone Stanolone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06412 Oxymetholone Oxymetholone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06710 Methyltestosterone Methyltestosterone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06718 Stanozolol Stanozolol may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB08804 Nandrolone decanoate Nandrolone decanoate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB12461 GLPG-0492 GLPG-0492 may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13169 Nandrolone Nandrolone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13587 Mesterolone Mesterolone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13943 Testosterone cypionate Testosterone cypionate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13944 Testosterone enanthate Testosterone enanthate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00215 Citalopram The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Citalopram.
DB00047 DB00230 Pregabalin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Pregabalin.
DB00047 DB00285 Venlafaxine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Venlafaxine.
DB00047 DB00328 Indomethacin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Indomethacin.
DB00047 DB01104 Sertraline The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Sertraline.
DB00047 DB01149 Nefazodone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Nefazodone.
DB00047 DB01175 Escitalopram The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Escitalopram.
DB00047 DB04832 Zimelidine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Zimelidine.
DB00047 DB04884 Dapoxetine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Dapoxetine.
DB00047 DB04896 Milnacipran The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Milnacipran.
DB00047 DB06700 Desvenlafaxine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Desvenlafaxine.
DB00047 DB08918 Levomilnacipran The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Levomilnacipran.
DB00047 DB08953 Indalpine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Indalpine.
DB00047 DB09270 Ubidecarenone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Ubidecarenone.
DB00047 DB12693 Ritanserin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Ritanserin.
DB00047 DB13233 Alaproclate The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Alaproclate.
DB00047 DB13358 Cibenzoline The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Cibenzoline.
DB00047 DB14025 Clinafloxacin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Clinafloxacin.
DB00047 DB09038 Empagliflozin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Empagliflozin.
DB00047 DB00233 Aminosalicylic acid Aminosalicylic acid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00244 Mesalazine Mesalazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00795 Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00861 Diflunisal Diflunisal may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00936 Salicylic acid Salicylic acid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01014 Balsalazide Balsalazide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01250 Olsalazine Olsalazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01294 Bismuth subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06251 Dersalazine Dersalazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06807 Phenyl aminosalicylate Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09543 Methyl salicylate Methyl salicylate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB11079 Trolamine salicylate Trolamine salicylate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB12445 Nitroaspirin Nitroaspirin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13509 Aloxiprin Aloxiprin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13538 Guacetisal Guacetisal may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13612 Carbaspirin calcium Carbaspirin calcium may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB14006 Choline salicylate Choline salicylate may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB14026 Thiosalicylic acid Thiosalicylic acid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01261 Sitagliptin Sitagliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB04876 Vildagliptin Vildagliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06011 AMG-222 AMG-222 may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06127 Bisegliptin Bisegliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06203 Alogliptin Alogliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06335 Saxagliptin Saxagliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB08382 Gosogliptin Gosogliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB08882 Linagliptin Linagliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB11723 Dutogliptin Dutogliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB11950 Teneligliptin Teneligliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB11992 Omarigliptin Omarigliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB12268 Carmegliptin Carmegliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB12412 Gemigliptin Gemigliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB12417 Anagliptin Anagliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB12625 Evogliptin Evogliptin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01276 Exenatide Exenatide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09043 Albiglutide Albiglutide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09045 Dulaglutide Dulaglutide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13928 Semaglutide Semaglutide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB14027 Taspoglutide Taspoglutide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00752 Tranylcypromine Tranylcypromine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00780 Phenelzine Phenelzine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01171 Moclobemide Moclobemide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01247 Isocarboxazid Isocarboxazid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01626 Pargyline Pargyline may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00805 Minaprine Minaprine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB04818 Iproniazid Iproniazid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB04820 Nialamide Nialamide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09244 Pirlindole Pirlindole may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09245 Toloxatone Toloxatone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09243 Hydracarbazine Hydracarbazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09241 Methylene blue Methylene blue may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09246 Benmoxin Benmoxin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09248 Mebanazine Mebanazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09249 Octamoxin Octamoxin may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09250 Pheniprazine Pheniprazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09251 Phenoxypropazine Phenoxypropazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09252 Pivhydrazine Pivhydrazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09253 Safrazine Safrazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB09254 Caroxazone Caroxazone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00614 Furazolidone Furazolidone may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB08550 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13875 Harmaline Harmaline may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB13876 Brofaromine Brofaromine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00721 Procaine Procaine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00182 Amphetamine Amphetamine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB01168 Procarbazine Procarbazine may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB00601 Linezolid Linezolid may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB06654 Safinamide Safinamide may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB04017 Clorgiline Clorgiline may increase the hypoglycemic activities of Insulin glargine.
DB00047 DB11827 Ertugliflozin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Ertugliflozin.
DB00047 DB00203 Sildenafil The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sildenafil.
DB00047 DB00263 Sulfisoxazole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfisoxazole.
DB00047 DB00311 Ethoxzolamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Ethoxzolamide.
DB00047 DB00359 Sulfadiazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfadiazine.
DB00047 DB00482 Celecoxib The therapeutic efficacy of Insulin glargine can be increased when used in combination with Celecoxib.
DB00047 DB00559 Bosentan The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bosentan.
DB00047 DB00576 Sulfamethizole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamethizole.
DB00047 DB00664 Sulfametopyrazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfametopyrazine.
DB00047 DB00669 Sumatriptan The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sumatriptan.
DB00047 DB00706 Tamsulosin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Tamsulosin.
DB00047 DB00819 Acetazolamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Acetazolamide.
DB00047 DB00891 Sulfapyridine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfapyridine.
DB00047 DB00909 Zonisamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Zonisamide.
DB00047 DB01015 Sulfamethoxazole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamethoxazole.
DB00047 DB01032 Probenecid The therapeutic efficacy of Insulin glargine can be increased when used in combination with Probenecid.
DB00047 DB01144 Diclofenamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Diclofenamide.
DB00047 DB01298 Sulfacytine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfacytine.
DB00047 DB01299 Sulfadoxine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfadoxine.
DB00047 DB01382 Glymidine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Glymidine.
DB00047 DB01581 Sulfamerazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamerazine.
DB00047 DB01582 Sulfamethazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamethazine.
DB00047 DB02925 Piretanide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Piretanide.
DB00047 DB04707 Hydroxyfasudil The therapeutic efficacy of Insulin glargine can be increased when used in combination with Hydroxyfasudil.
DB00047 DB06150 Sulfadimethoxine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfadimethoxine.
DB00047 DB06290 Simeprevir The therapeutic efficacy of Insulin glargine can be increased when used in combination with Simeprevir.
DB00047 DB06729 Sulfaphenazole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaphenazole.
DB00047 DB06821 Sulfameter The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfameter.
DB00047 DB07996 5-(2-methylpiperazine-1-sulfonyl)isoquinoline The therapeutic efficacy of Insulin glargine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
DB00047 DB08162 Fasudil The therapeutic efficacy of Insulin glargine can be increased when used in combination with Fasudil.
DB00047 DB08798 Sulfamoxole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamoxole.
DB00047 DB08881 Vemurafenib The therapeutic efficacy of Insulin glargine can be increased when used in combination with Vemurafenib.
DB00047 DB08961 Azosemide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Azosemide.
DB00047 DB11389 Clorsulon The therapeutic efficacy of Insulin glargine can be increased when used in combination with Clorsulon.
DB00047 DB11461 Sulfachlorpyridazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfachlorpyridazine.
DB00047 DB11462 Sulfaethoxypyridazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaethoxypyridazine.
DB00047 DB11463 Sulfanitran The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfanitran.
DB00047 DB11464 Sulfaquinoxaline The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaquinoxaline.
DB00047 DB12051 Setrobuvir The therapeutic efficacy of Insulin glargine can be increased when used in combination with Setrobuvir.
DB00047 DB12921 Chlorsulfaquinoxaline The therapeutic efficacy of Insulin glargine can be increased when used in combination with Chlorsulfaquinoxaline.
DB00047 DB13214 Sulfadicramide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfadicramide.
DB00047 DB13248 Phthalylsulfathiazole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Phthalylsulfathiazole.
DB00047 DB13283 Sulfaisodimidine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaisodimidine.
DB00047 DB13284 Meticrane The therapeutic efficacy of Insulin glargine can be increased when used in combination with Meticrane.
DB00047 DB13320 Sulfaperin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaperin.
DB00047 DB13405 Mefruside The therapeutic efficacy of Insulin glargine can be increased when used in combination with Mefruside.
DB00047 DB13485 Sulfametomidine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfametomidine.
DB00047 DB13547 Sulfatolamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfatolamide.
DB00047 DB13556 Sulfamazone The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamazone.
DB00047 DB13580 Succinylsulfathiazole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Succinylsulfathiazole.
DB00047 DB13617 Clorexolone The therapeutic efficacy of Insulin glargine can be increased when used in combination with Clorexolone.
DB00047 DB13663 Clofenamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Clofenamide.
DB00047 DB13699 Sulfathiourea The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfathiourea.
DB00047 DB13708 Fenquizone The therapeutic efficacy of Insulin glargine can be increased when used in combination with Fenquizone.
DB00047 DB13726 Sulfaguanidine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaguanidine.
DB00047 DB13773 Sulfamethoxypyridazine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfamethoxypyridazine.
DB00047 DB13792 Clopamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Clopamide.
DB00047 DB13803 Xipamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Xipamide.
DB00047 DB14033 Acetyl sulfisoxazole The therapeutic efficacy of Insulin glargine can be increased when used in combination with Acetyl sulfisoxazole.
DB00047 DB14708 Tosylchloramide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Tosylchloramide.
DB00047 DB01098 Rosuvastatin The therapeutic efficacy of Insulin glargine can be increased when used in combination with Rosuvastatin.
DB00047 DB00703 Methazolamide The therapeutic efficacy of Insulin glargine can be increased when used in combination with Methazolamide.
DB00047 DB06370 Indisulam The therapeutic efficacy of Insulin glargine can be increased when used in combination with Indisulam.
DB00047 DB00176 Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Insulin glargine.
DB00047 DB00184 Nicotine The metabolism of Nicotine can be increased when combined with Insulin glargine.
DB00047 DB00188 Bortezomib The metabolism of Bortezomib can be increased when combined with Insulin glargine.
DB00047 DB00201 Caffeine The metabolism of Caffeine can be increased when combined with Insulin glargine.
DB00047 DB00261 Anagrelide The metabolism of Anagrelide can be increased when combined with Insulin glargine.
DB00047 DB00262 Carmustine The metabolism of Carmustine can be increased when combined with Insulin glargine.
DB00047 DB00281 Lidocaine The metabolism of Lidocaine can be increased when combined with Insulin glargine.
DB00047 DB00286 Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Insulin glargine.
DB00047 DB00296 Ropivacaine The metabolism of Ropivacaine can be increased when combined with Insulin glargine.
DB00047 DB00315 Zolmitriptan The metabolism of Zolmitriptan can be increased when combined with Insulin glargine.
DB00047 DB00316 Acetaminophen The metabolism of Acetaminophen can be increased when combined with Insulin glargine.
DB00047 DB00356 Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Insulin glargine.
DB00047 DB00365 Grepafloxacin The metabolism of Grepafloxacin can be increased when combined with Insulin glargine.
DB00047 DB00370 Mirtazapine The metabolism of Mirtazapine can be increased when combined with Insulin glargine.
DB00047 DB00379 Mexiletine The metabolism of Mexiletine can be increased when combined with Insulin glargine.
DB00047 DB00382 Tacrine The metabolism of Tacrine can be increased when combined with Insulin glargine.
DB00047 DB00384 Triamterene The metabolism of Triamterene can be increased when combined with Insulin glargine.
DB00047 DB00420 Promazine The metabolism of Promazine can be increased when combined with Insulin glargine.
DB00047 DB00425 Zolpidem The metabolism of Zolpidem can be increased when combined with Insulin glargine.
DB00047 DB00442 Entecavir The metabolism of Entecavir can be increased when combined with Insulin glargine.
DB00047 DB00461 Nabumetone The metabolism of Nabumetone can be increased when combined with Insulin glargine.
DB00047 DB00472 Fluoxetine The metabolism of Fluoxetine can be increased when combined with Insulin glargine.
DB00047 DB00476 Duloxetine The metabolism of Duloxetine can be increased when combined with Insulin glargine.
DB00047 DB00499 Flutamide The metabolism of Flutamide can be increased when combined with Insulin glargine.
DB00047 DB00518 Albendazole The metabolism of Albendazole can be increased when combined with Insulin glargine.
DB00047 DB00533 Rofecoxib The metabolism of Rofecoxib can be increased when combined with Insulin glargine.
DB00047 DB00544 Fluorouracil The metabolism of Fluorouracil can be increased when combined with Insulin glargine.
DB00047 DB00568 Cinnarizine The metabolism of Cinnarizine can be increased when combined with Insulin glargine.
DB00047 DB00586 Diclofenac The metabolism of Diclofenac can be increased when combined with Insulin glargine.
DB00047 DB00619 Imatinib The metabolism of Imatinib can be increased when combined with Insulin glargine.
DB00047 DB00629 Guanabenz The metabolism of Guanabenz can be increased when combined with Insulin glargine.
DB00047 DB00642 Pemetrexed The metabolism of Pemetrexed can be increased when combined with Insulin glargine.
DB00047 DB00661 Verapamil The metabolism of Verapamil can be increased when combined with Insulin glargine.
DB00047 DB00715 Paroxetine The metabolism of Paroxetine can be increased when combined with Insulin glargine.
DB00047 DB00730 Thiabendazole The metabolism of Thiabendazole can be increased when combined with Insulin glargine.
DB00047 DB00740 Riluzole The metabolism of Riluzole can be increased when combined with Insulin glargine.
DB00047 DB00744 Zileuton The metabolism of Zileuton can be increased when combined with Insulin glargine.
DB00047 DB00758 Clopidogrel The metabolism of Clopidogrel can be increased when combined with Insulin glargine.
DB00047 DB00787 Acyclovir The metabolism of Acyclovir can be increased when combined with Insulin glargine.
DB00047 DB00788 Naproxen The metabolism of Naproxen can be increased when combined with Insulin glargine.
DB00047 DB00806 Pentoxifylline The metabolism of Pentoxifylline can be increased when combined with Insulin glargine.
DB00047 DB00831 Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Insulin glargine.
DB00047 DB00850 Perphenazine The metabolism of Perphenazine can be increased when combined with Insulin glargine.
DB00047 DB00857 Terbinafine The metabolism of Terbinafine can be increased when combined with Insulin glargine.
DB00047 DB00863 Ranitidine The metabolism of Ranitidine can be increased when combined with Insulin glargine.
DB00047 DB00898 Ethanol The metabolism of Ethanol can be increased when combined with Insulin glargine.
DB00047 DB00934 Maprotiline The metabolism of Maprotiline can be increased when combined with Insulin glargine.
DB00047 DB00969 Alosetron The metabolism of Alosetron can be increased when combined with Insulin glargine.
DB00047 DB00978 Lomefloxacin The metabolism of Lomefloxacin can be increased when combined with Insulin glargine.
DB00047 DB00980 Ramelteon The metabolism of Ramelteon can be increased when combined with Insulin glargine.
DB00047 DB00993 Azathioprine The metabolism of Azathioprine can be increased when combined with Insulin glargine.
DB00047 DB00998 Frovatriptan The metabolism of Frovatriptan can be increased when combined with Insulin glargine.
DB00047 DB01002 Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Insulin glargine.
DB00047 DB01012 Cinacalcet The metabolism of Cinacalcet can be increased when combined with Insulin glargine.
DB00047 DB01037 Selegiline The metabolism of Selegiline can be increased when combined with Insulin glargine.
DB00047 DB01056 Tocainide The metabolism of Tocainide can be increased when combined with Insulin glargine.
DB00047 DB01058 Praziquantel The metabolism of Praziquantel can be increased when combined with Insulin glargine.
DB00047 DB01065 Melatonin The metabolism of Melatonin can be increased when combined with Insulin glargine.
DB00047 DB01087 Primaquine The metabolism of Primaquine can be increased when combined with Insulin glargine.
DB00047 DB01094 Hesperetin The metabolism of Hesperetin can be increased when combined with Insulin glargine.
DB00047 DB01097 Leflunomide The metabolism of Leflunomide can be increased when combined with Insulin glargine.
DB00047 DB01166 Cilostazol The metabolism of Cilostazol can be increased when combined with Insulin glargine.
DB00047 DB01184 Domperidone The metabolism of Domperidone can be increased when combined with Insulin glargine.
DB00047 DB01191 Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Insulin glargine.
DB00047 DB01303 Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Insulin glargine.
DB00047 DB01367 Rasagiline The metabolism of Rasagiline can be increased when combined with Insulin glargine.
DB00047 DB01405 Temafloxacin The metabolism of Temafloxacin can be increased when combined with Insulin glargine.
DB00047 DB01412 Theobromine The metabolism of Theobromine can be increased when combined with Insulin glargine.
DB00047 DB01424 Aminophenazone The metabolism of Aminophenazone can be increased when combined with Insulin glargine.
DB00047 DB01435 Antipyrine The metabolism of Antipyrine can be increased when combined with Insulin glargine.
DB00047 DB01482 Fenethylline The metabolism of Fenethylline can be increased when combined with Insulin glargine.
DB00047 DB01558 Bromazepam The metabolism of Bromazepam can be increased when combined with Insulin glargine.
DB00047 DB01623 Thiothixene The metabolism of Thiothixene can be increased when combined with Insulin glargine.
DB00047 DB01628 Etoricoxib The metabolism of Etoricoxib can be increased when combined with Insulin glargine.
DB00047 DB01645 Genistein The metabolism of Genistein can be increased when combined with Insulin glargine.
DB00047 DB01667 8-azaguanine The metabolism of 8-azaguanine can be increased when combined with Insulin glargine.
DB00047 DB02134 Xanthine The metabolism of Xanthine can be increased when combined with Insulin glargine.
DB00047 DB02489 9-Methylguanine The metabolism of 9-Methylguanine can be increased when combined with Insulin glargine.
DB00047 DB02568 Peldesine The metabolism of Peldesine can be increased when combined with Insulin glargine.
DB00047 DB02709 Resveratrol The metabolism of Resveratrol can be increased when combined with Insulin glargine.
DB00047 DB03783 Phenacetin The metabolism of Phenacetin can be increased when combined with Insulin glargine.
DB00047 DB04076 Hypoxanthine The metabolism of Hypoxanthine can be increased when combined with Insulin glargine.
DB00047 DB04356 9-Deazaguanine The metabolism of 9-Deazaguanine can be increased when combined with Insulin glargine.
DB00047 DB04841 Flunarizine The metabolism of Flunarizine can be increased when combined with Insulin glargine.
DB00047 DB04871 Lorcaserin The metabolism of Lorcaserin can be increased when combined with Insulin glargine.
DB00047 DB04948 Lofexidine The metabolism of Lofexidine can be increased when combined with Insulin glargine.
DB00047 DB04951 Pirfenidone The metabolism of Pirfenidone can be increased when combined with Insulin glargine.
DB00047 DB05676 Apremilast The metabolism of Apremilast can be increased when combined with Insulin glargine.
DB00047 DB06148 Mianserin The metabolism of Mianserin can be increased when combined with Insulin glargine.
DB00047 DB06210 Eltrombopag The metabolism of Eltrombopag can be increased when combined with Insulin glargine.
DB00047 DB06235 Vadimezan The metabolism of Vadimezan can be increased when combined with Insulin glargine.
DB00047 DB06479 Propentofylline The metabolism of Propentofylline can be increased when combined with Insulin glargine.
DB00047 DB06589 Pazopanib The metabolism of Pazopanib can be increased when combined with Insulin glargine.
DB00047 DB06594 Agomelatine The metabolism of Agomelatine can be increased when combined with Insulin glargine.
DB00047 DB06626 Axitinib The metabolism of Axitinib can be increased when combined with Insulin glargine.
DB00047 DB06769 Bendamustine The metabolism of Bendamustine can be increased when combined with Insulin glargine.
DB00047 DB06770 Benzyl alcohol The metabolism of Benzyl alcohol can be increased when combined with Insulin glargine.
DB00047 DB06774 Capsaicin The metabolism of Capsaicin can be increased when combined with Insulin glargine.
DB00047 DB08496 (R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Insulin glargine.
DB00047 DB08883 Perampanel The metabolism of Perampanel can be increased when combined with Insulin glargine.
DB00047 DB09071 Tasimelteon The metabolism of Tasimelteon can be increased when combined with Insulin glargine.
DB00047 DB09118 Stiripentol The metabolism of Stiripentol can be increased when combined with Insulin glargine.
DB00047 DB09225 Zotepine The metabolism of Zotepine can be increased when combined with Insulin glargine.
DB00047 DB09273 Doxofylline The metabolism of Doxofylline can be increased when combined with Insulin glargine.
DB00047 DB09288 Propacetamol The metabolism of Propacetamol can be increased when combined with Insulin glargine.
DB00047 DB09290 Ramosetron The metabolism of Ramosetron can be increased when combined with Insulin glargine.
DB00047 DB11919 6-O-benzylguanine The metabolism of 6-O-benzylguanine can be increased when combined with Insulin glargine.
DB00047 DB11967 Binimetinib The metabolism of Binimetinib can be increased when combined with Insulin glargine.
DB00047 DB12026 Voxilaprevir The metabolism of Voxilaprevir can be increased when combined with Insulin glargine.
DB00047 DB12245 Triclabendazole The metabolism of Triclabendazole can be increased when combined with Insulin glargine.
DB00047 DB12332 Rucaparib The metabolism of Rucaparib can be increased when combined with Insulin glargine.
DB00047 DB12406 Lisofylline The metabolism of Lisofylline can be increased when combined with Insulin glargine.
DB00047 DB12531 Lobucavir The metabolism of Lobucavir can be increased when combined with Insulin glargine.
DB00047 DB12926 Cafedrine The metabolism of Cafedrine can be increased when combined with Insulin glargine.
DB00047 DB12927 Theodrenaline The metabolism of Theodrenaline can be increased when combined with Insulin glargine.
DB00047 DB12945 Dihydralazine The metabolism of Dihydralazine can be increased when combined with Insulin glargine.
DB00047 DB13203 Bamifylline The metabolism of Bamifylline can be increased when combined with Insulin glargine.
DB00047 DB13449 Proxyphylline The metabolism of Proxyphylline can be increased when combined with Insulin glargine.
DB00047 DB13573 Acefylline The metabolism of Acefylline can be increased when combined with Insulin glargine.
DB00047 DB13592 Etamiphylline The metabolism of Etamiphylline can be increased when combined with Insulin glargine.
DB00047 DB13634 Pentifylline The metabolism of Pentifylline can be increased when combined with Insulin glargine.
DB00047 DB13812 Bufylline The metabolism of Bufylline can be increased when combined with Insulin glargine.
DB00047 DB13952 Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Insulin glargine.
DB00047 DB13953 Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Insulin glargine.
DB00047 DB13954 Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Insulin glargine.
DB00047 DB13955 Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Insulin glargine.
DB00047 DB13956 Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Insulin glargine.
DB00047 DB14018 Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Insulin glargine.
DB00047 DB14132 8-chlorotheophylline The metabolism of 8-chlorotheophylline can be increased when combined with Insulin glargine.
DB00047 DB01115 Nifedipine The metabolism of Nifedipine can be increased when combined with Insulin glargine.
DB00047 DB11757 Istradefylline The metabolism of Istradefylline can be increased when combined with Insulin glargine.
DB00047 DB00972 Azelastine The metabolism of Azelastine can be increased when combined with Insulin glargine.
DB00047 DB00625 Efavirenz The metabolism of Efavirenz can be increased when combined with Insulin glargine.
DB00047 DB04889 Bicifadine The metabolism of Bicifadine can be increased when combined with Insulin glargine.
DB00047 DB05708 GTS-21 The metabolism of GTS-21 can be increased when combined with Insulin glargine.
DB00047 DB01195 Flecainide The metabolism of Flecainide can be increased when combined with Insulin glargine.
DB00047 DB00783 Estradiol The metabolism of Estradiol can be increased when combined with Insulin glargine.
DB00047 DB00321 Amitriptyline The metabolism of Amitriptyline can be increased when combined with Insulin glargine.
DB00047 DB00458 Imipramine The metabolism of Imipramine can be increased when combined with Insulin glargine.
DB00047 DB01142 Doxepin The metabolism of Doxepin can be increased when combined with Insulin glargine.
DB00047 DB00532 Mephenytoin The metabolism of Mephenytoin can be increased when combined with Insulin glargine.
DB00047 DB00540 Nortriptyline The metabolism of Nortriptyline can be increased when combined with Insulin glargine.
DB00047 DB00575 Clonidine The metabolism of Clonidine can be increased when combined with Insulin glargine.
DB00047 DB00924 Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Insulin glargine.
DB00047 DB01151 Desipramine The metabolism of Desipramine can be increased when combined with Insulin glargine.
DB00047 DB01242 Clomipramine The metabolism of Clomipramine can be increased when combined with Insulin glargine.
DB00047 DB11689 Selumetinib The metabolism of Selumetinib can be increased when combined with Insulin glargine.
DB00047 DB00277 Theophylline The metabolism of Theophylline can be increased when combined with Insulin glargine.
DB00047 DB00398 Sorafenib The metabolism of Sorafenib can be increased when combined with Insulin glargine.
DB00047 DB00530 Erlotinib The metabolism of Erlotinib can be increased when combined with Insulin glargine.
DB00047 DB00564 Carbamazepine The metabolism of Carbamazepine can be increased when combined with Insulin glargine.
DB00047 DB00682 Warfarin The metabolism of Warfarin can be increased when combined with Insulin glargine.
DB00047 DB00697 Tizanidine The metabolism of Tizanidine can be increased when combined with Insulin glargine.
DB00047 DB00773 Etoposide The metabolism of Etoposide can be increased when combined with Insulin glargine.
DB00047 DB00851 Dacarbazine The metabolism of Dacarbazine can be increased when combined with Insulin glargine.
DB00047 DB01100 Pimozide The metabolism of Pimozide can be increased when combined with Insulin glargine.
DB00047 DB01223 Aminophylline The metabolism of Aminophylline can be increased when combined with Insulin glargine.
DB00047 DB01254 Dasatinib The metabolism of Dasatinib can be increased when combined with Insulin glargine.
DB00047 DB01418 Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Insulin glargine.
DB00047 DB08910 Pomalidomide The metabolism of Pomalidomide can be increased when combined with Insulin glargine.
DB00047 DB09256 Tegafur The metabolism of Tegafur can be increased when combined with Insulin glargine.
DB00047 DB13874 Enasidenib The metabolism of Enasidenib can be increased when combined with Insulin glargine.
DB00047 DB00675 Tamoxifen The metabolism of Tamoxifen can be increased when combined with Insulin glargine.
DB00047 DB00030 Insulin human The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glargine.
DB00047 DB00046 Insulin lispro The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Insulin glargine.
DB00047 DB00071 Insulin pork The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin pork.
DB00047 DB00197 Troglitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Troglitazone.
DB00047 DB00222 Glimepiride The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Glimepiride.
DB00047 DB00280 Disopyramide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Disopyramide.
DB00047 DB00284 Acarbose The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Acarbose.
DB00047 DB00414 Acetohexamide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Acetohexamide.
DB00047 DB00468 Quinine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Quinine.
DB00047 DB00491 Miglitol The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Miglitol.
DB00047 DB00672 Chlorpropamide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Chlorpropamide.
DB00047 DB00731 Nateglinide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Nateglinide.
DB00047 DB00834 Mifepristone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Mifepristone.
DB00047 DB00839 Tolazamide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Tolazamide.
DB00047 DB00912 Repaglinide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Repaglinide.
DB00047 DB00914 Phenformin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Phenformin.
DB00047 DB01016 Glyburide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Glyburide.
DB00047 DB01067 Glipizide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Glipizide.
DB00047 DB01120 Gliclazide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Gliclazide.
DB00047 DB01124 Tolbutamide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Tolbutamide.
DB00047 DB01200 Bromocriptine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Bromocriptine.
DB00047 DB01251 Gliquidone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Gliquidone.
DB00047 DB01252 Mitiglinide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Mitiglinide.
DB00047 DB01268 Sunitinib The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Sunitinib.
DB00047 DB01277 Mecasermin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Mecasermin.
DB00047 DB01289 Glisoxepide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Glisoxepide.
DB00047 DB01306 Insulin aspart The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin aspart.
DB00047 DB01307 Insulin detemir The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin detemir.
DB00047 DB01309 Insulin glulisine The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin glulisine.
DB00047 DB01700 AICA ribonucleotide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with AICA ribonucleotide.
DB00047 DB04830 Buformin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Buformin.
DB00047 DB04878 Voglibose The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Voglibose.
DB00047 DB05115 NN344 The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with NN344.
DB00047 DB05819 NBI-6024 The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with NBI-6024.
DB00047 DB08962 Glibornuride The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Glibornuride.
DB00047 DB09022 Benfluorex The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Benfluorex.
DB00047 DB09198 Lobeglitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Lobeglitazone.
DB00047 DB09199 Netoglitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Netoglitazone.
DB00047 DB09200 Rivoglitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Rivoglitazone.
DB00047 DB09201 Ciglitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Ciglitazone.
DB00047 DB09456 Insulin beef The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin beef.
DB00047 DB09564 Insulin degludec The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin degludec.
DB00047 DB11567 Insulin peglispro The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin peglispro.
DB00047 DB11568 Insulin tregopil The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Insulin tregopil.
DB00047 DB11698 Ipragliflozin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Ipragliflozin.
DB00047 DB11780 Allicin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Allicin.
DB00047 DB11824 Tofogliflozin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Tofogliflozin.
DB00047 DB11898 2,4-thiazolidinedione The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with 2,4-thiazolidinedione.
DB00047 DB12713 Sotagliflozin The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Sotagliflozin.
DB00047 DB12781 Balaglitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Balaglitazone.
DB00047 DB12935 Remogliflozin etabonate The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Remogliflozin etabonate.
DB00047 DB13406 Carbutamide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Carbutamide.
DB00047 DB13446 Guar gum The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Guar gum.
DB00047 DB13675 Metahexamide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Metahexamide.
DB00047 DB14035 Englitazone The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Englitazone.
DB00047 DB15171 Tirzepatide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Tirzepatide.
DB00047 DB15217 Gastric inhibitory polypeptide The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Gastric inhibitory polypeptide.
DB00047 DB00270 Isradipine The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin glargine.
DB00047 DB00343 Diltiazem The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin glargine.
DB00047 DB00347 Trimethadione The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin glargine.
DB00047 DB00381 Amlodipine The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin glargine.
DB00047 DB00393 Nimodipine The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin glargine.
DB00047 DB00401 Nisoldipine The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin glargine.
DB00047 DB00528 Lercanidipine The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin glargine.
DB00047 DB00555 Lamotrigine The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin glargine.
DB00047 DB00593 Ethosuximide The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin glargine.
DB00047 DB00622 Nicardipine The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin glargine.
DB00047 DB00653 Magnesium sulfate The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin glargine.
DB00047 DB00836 Loperamide The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin glargine.
DB00047 DB01054 Nitrendipine The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin glargine.
DB00047 DB01074 Perhexiline The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin glargine.
DB00047 DB01244 Bepridil The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin glargine.
DB00047 DB01388 Mibefradil The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin glargine.
DB00047 DB04743 Nimesulide The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin glargine.
DB00047 DB04825 Prenylamine The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin glargine.
DB00047 DB04838 Cyclandelate The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin glargine.
DB00047 DB04842 Fluspirilene The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin glargine.
DB00047 DB04920 Clevidipine The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin glargine.
DB00047 DB05246 Methsuximide The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin glargine.
DB00047 DB05885 Seletracetam The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin glargine.
DB00047 DB06152 Nylidrin The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin glargine.
DB00047 DB06283 Ziconotide The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin glargine.
DB00047 DB06446 Dotarizine The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin glargine.
DB00047 DB06694 Xylometazoline The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin glargine.
DB00047 DB06712 Nilvadipine The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin glargine.
DB00047 DB07615 Tranilast The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin glargine.
DB00047 DB08838 Agmatine The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin glargine.
DB00047 DB08980 Fendiline The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin glargine.
DB00047 DB08992 Eperisone The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin glargine.
DB00047 DB09089 Trimebutine The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin glargine.
DB00047 DB09090 Pinaverium The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin glargine.
DB00047 DB09216 Tolfenamic acid The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin glargine.
DB00047 DB09227 Barnidipine The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin glargine.
DB00047 DB09229 Aranidipine The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin glargine.
DB00047 DB09230 Azelnidipine The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin glargine.
DB00047 DB09231 Benidipine The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin glargine.
DB00047 DB09232 Cilnidipine The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin glargine.
DB00047 DB09234 Darodipine The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin glargine.
DB00047 DB09235 Efonidipine The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin glargine.
DB00047 DB09236 Lacidipine The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin glargine.
DB00047 DB09238 Manidipine The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin glargine.
DB00047 DB09239 Niguldipine The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin glargine.
DB00047 DB09240 Niludipine The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin glargine.
DB00047 DB11960 Carboxyamidotriazole The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin glargine.
DB00047 DB12092 Naftopidil The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin glargine.
DB00047 DB12093 Tetrahydropalmatine The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin glargine.
DB00047 DB12131 Vinpocetine The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin glargine.
DB00047 DB12923 Gallopamil The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin glargine.
DB00047 DB13488 Bencyclane The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin glargine.
DB00047 DB13500 Otilonium The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin glargine.
DB00047 DB13725 Terodiline The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin glargine.
DB00047 DB13766 Lidoflazine The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin glargine.
DB00047 DB13791 Penfluridol The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin glargine.
DB00047 DB13835 Caroverine The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin glargine.
DB00047 DB13950 WIN 55212-2 The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin glargine.
DB00047 DB13961 Fish oil The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin glargine.
DB00047 DB14063 Dexverapamil The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin glargine.
DB00047 DB14064 Emopamil The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin glargine.
DB00047 DB14065 Lomerizine The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin glargine.
DB00047 DB14066 Tetrandrine The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin glargine.
DB00047 DB14068 Dexniguldipine The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin glargine.
DB00047 DB01023 Felodipine The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin glargine.
DB00047 DB01118 Amiodarone The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin glargine.
DB00047 DB00191 Phentermine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Phentermine.
DB00047 DB00268 Ropinirole The metabolism of Ropinirole can be increased when combined with Insulin glargine.
DB00047 DB13074 Macimorelin The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin glargine.
DB00047 DB00279 Liothyronine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Liothyronine.
DB00047 DB00331 Metformin The risk or severity of adverse effects can be increased when Insulin glargine is combined with Metformin.
DB00047 DB00542 Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin glargine.
DB00047 DB13946 Testosterone undecanoate The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin glargine.
DB00047 DB00945 Acetylsalicylic acid The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin glargine.
DB00047 DB00181 Baclofen The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Baclofen.
DB00047 DB00489 Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin glargine.
DB00047 DB00196 Fluconazole The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Fluconazole.
DB00047 DB00040 Glucagon The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Glucagon.
DB00047 DB00264 Metoprolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Metoprolol.
DB00047 DB00335 Atenolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Atenolol.
DB00047 DB00373 Timolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Timolol.
DB00047 DB00598 Labetalol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Labetalol.
DB00047 DB00612 Bisoprolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bisoprolol.
DB00047 DB00866 Alprenolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Alprenolol.
DB00047 DB00960 Pindolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Pindolol.
DB00047 DB01193 Acebutolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Acebutolol.
DB00047 DB01203 Nadolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Nadolol.
DB00047 DB01295 Bevantolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bevantolol.
DB00047 DB01297 Practolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Practolol.
DB00047 DB01359 Penbutolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Penbutolol.
DB00047 DB01580 Oxprenolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Oxprenolol.
DB00047 DB03322 Dexpropranolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Dexpropranolol.
DB00047 DB04846 Celiprolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Celiprolol.
DB00047 DB04861 Nebivolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Nebivolol.
DB00047 DB06726 Bufuralol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bufuralol.
DB00047 DB08807 Bopindolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bopindolol.
DB00047 DB08808 Bupranolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bupranolol.
DB00047 DB08952 Indenolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Indenolol.
DB00047 DB09013 Befunolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Befunolol.
DB00047 DB09204 Arotinolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Arotinolol.
DB00047 DB09351 Levobetaxolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Levobetaxolol.
DB00047 DB11770 Talinolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Talinolol.
DB00047 DB11785 Anisodamine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Anisodamine.
DB00047 DB12212 Landiolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Landiolol.
DB00047 DB12752 Bucindolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Bucindolol.
DB00047 DB13443 Esatenolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Esatenolol.
DB00047 DB13508 Cloranolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Cloranolol.
DB00047 DB13530 Mepindolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Mepindolol.
DB00047 DB13757 Epanolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Epanolol.
DB00047 DB13775 Tertatolol The therapeutic efficacy of Insulin glargine can be increased when used in combination with Tertatolol.
DB00047 DB00195 Betaxolol The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin glargine.
DB00047 DB00571 Propranolol The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin glargine.
DB00047 DB01136 Carvedilol The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin glargine.
DB00047 DB01182 Propafenone The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin glargine.
DB00047 DB01611 Hydroxychloroquine The therapeutic efficacy of Insulin glargine can be increased when used in combination with Hydroxychloroquine.
DB00047 DB01233 Metoclopramide The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin glargine.
DB00047 DB00394 Beclomethasone dipropionate The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin glargine.
DB00047 DB00443 Betamethasone The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin glargine.
DB00047 DB00620 Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin glargine.
DB00047 DB00635 Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin glargine.
DB00047 DB00687 Fludrocortisone The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin glargine.
DB00047 DB00741 Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin glargine.
DB00047 DB00764 Mometasone The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin glargine.
DB00047 DB00860 Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin glargine.
DB00047 DB00959 Methylprednisolone The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin glargine.
DB00047 DB01234 Dexamethasone The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin glargine.
DB00047 DB01285 Corticotropin The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin glargine.
DB00047 DB01380 Cortisone acetate The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin glargine.
DB00047 DB01384 Paramethasone The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin glargine.
DB00047 DB01410 Ciclesonide The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin glargine.
DB00047 DB08906 Fluticasone furoate The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin glargine.
DB00047 DB08970 Fluprednidene The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin glargine.
DB00047 DB08971 Fluocortolone The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin glargine.
DB00047 DB09383 Meprednisone The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin glargine.
DB00047 DB11487 Dexamethasone isonicotinate The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin glargine.
DB00047 DB11750 Clobetasol The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin glargine.
DB00047 DB11921 Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin glargine.
DB00047 DB13003 Cortivazol The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin glargine.
DB00047 DB13208 Prednylidene The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin glargine.
DB00047 DB13843 Cloprednol The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin glargine.
DB00047 DB13867 Fluticasone The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin glargine.
DB00047 DB14512 Mometasone furoate The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin glargine.
DB00047 DB00180 Flunisolide The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin glargine.
DB00047 DB01108 Trilostane The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin glargine.
DB00047 DB01222 Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin glargine.
DB00047 DB04630 Aldosterone The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin glargine.
DB00047 DB09378 Fluprednisolone The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin glargine.
DB00047 DB11529 Melengestrol The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin glargine.
DB00047 DB14681 Cortisone The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin glargine.
DB00047 DB00223 Diflorasone The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin glargine.
DB00047 DB00240 Alclometasone The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin glargine.
DB00047 DB00253 Medrysone The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin glargine.
DB00047 DB00288 Amcinonide The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin glargine.
DB00047 DB00324 Fluorometholone The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin glargine.
DB00047 DB00547 Desoximetasone The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin glargine.
DB00047 DB00588 Fluticasone propionate The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin glargine.
DB00047 DB00591 Fluocinolone acetonide The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin glargine.
DB00047 DB00596 Ulobetasol The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin glargine.
DB00047 DB00663 Flumethasone The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin glargine.
DB00047 DB00838 Clocortolone The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin glargine.
DB00047 DB00846 Flurandrenolide The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin glargine.
DB00047 DB14596 Loteprednol etabonate The risk or severity of hyperglycemia can be increased when Loteprednol etabonate is combined with Insulin glargine.
DB00047 DB00896 Rimexolone The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin glargine.
DB00047 DB01013 Clobetasol propionate The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin glargine.
DB00047 DB01047 Fluocinonide The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin glargine.
DB00047 DB01130 Prednicarbate The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin glargine.
DB00047 DB01260 Desonide The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin glargine.
DB00047 DB06781 Difluprednate The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin glargine.
DB00047 DB06786 Halcinonide The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin glargine.
DB00047 DB09091 Tixocortol The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin glargine.
DB00047 DB09095 Difluocortolone The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin glargine.
DB00047 DB13158 Clobetasone The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin glargine.
DB00047 DB13223 Fluocortin The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin glargine.
DB00047 DB13491 Fluperolone The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin glargine.
DB00047 DB13664 Formocortal The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin glargine.
DB00047 DB13728 Halometasone The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin glargine.
DB00047 DB13856 Fluclorolone The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin glargine.
DB00047 DB14538 Hydrocortisone aceponate The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin glargine.
DB00047 DB14539 Hydrocortisone acetate The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin glargine.
DB00047 DB14540 Hydrocortisone butyrate The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin glargine.
DB00047 DB14541 Hydrocortisone cypionate The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin glargine.
DB00047 DB14543 Hydrocortisone probutate The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin glargine.
DB00047 DB14544 Hydrocortisone valerate The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin glargine.
DB00047 DB14545 Hydrocortisone succinate The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin glargine.
DB00047 DB00873 Loteprednol The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin glargine.
DB00047 DB14631 Prednisolone phosphate The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin glargine.
DB00047 DB14633 Prednisolone hemisuccinate The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin glargine.
DB00047 DB14634 Fluprednidene acetate The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin glargine.
DB00047 DB14643 Methylprednisolone aceponate The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin glargine.
DB00047 DB14644 Methylprednisolone hemisuccinate The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin glargine.
DB00047 DB14646 Prednisone acetate The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin glargine.
DB00047 DB14652 Clocortolone acetate The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin glargine.
DB00047 DB14659 Melengestrol acetate The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin glargine.
DB00047 DB14669 Betamethasone phosphate The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin glargine.
DB00047 DB15566 Prednisolone acetate The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin glargine.
DB00047 DB00451 Levothyroxine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Levothyroxine.
DB00047 DB00024 Thyrotropin alfa Thyrotropin alfa may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB01583 Liotrix Liotrix may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB03604 Tiratricol Tiratricol may decrease the hypoglycemic activities of Insulin glargine.
DB00047 DB09100 Thyroid, porcine Thyroid, porcine may decrease the hypoglycemic activities of Insulin glargine.
DB00048 DB00006 Bivalirudin The risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase clostridium histolyticum.
DB00048 DB00054 Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Collagenase clostridium histolyticum.
DB00048 DB00266 Dicoumarol The risk or severity of adverse effects can be increased when Dicoumarol is combined with Collagenase clostridium histolyticum.
DB00048 DB00278 Argatroban The risk or severity of adverse effects can be increased when Argatroban is combined with Collagenase clostridium histolyticum.
DB00048 DB00407 Ardeparin The risk or severity of adverse effects can be increased when Ardeparin is combined with Collagenase clostridium histolyticum.
DB00048 DB00498 Phenindione The risk or severity of adverse effects can be increased when Phenindione is combined with Collagenase clostridium histolyticum.
DB00048 DB00569 Fondaparinux The risk or severity of adverse effects can be increased when Fondaparinux is combined with Collagenase clostridium histolyticum.
DB00048 DB00682 Warfarin The risk or severity of adverse effects can be increased when Warfarin is combined with Collagenase clostridium histolyticum.
DB00048 DB00686 Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Collagenase clostridium histolyticum.
DB00048 DB00946 Phenprocoumon The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Collagenase clostridium histolyticum.
DB00048 DB00974 Edetic acid The risk or severity of adverse effects can be increased when Edetic acid is combined with Collagenase clostridium histolyticum.
DB00048 DB01109 Heparin The risk or severity of adverse effects can be increased when Heparin is combined with Collagenase clostridium histolyticum.
DB00048 DB01225 Enoxaparin The risk or severity of adverse effects can be increased when Enoxaparin is combined with Collagenase clostridium histolyticum.
DB00048 DB01418 Acenocoumarol The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Collagenase clostridium histolyticum.
DB00048 DB04898 Ximelagatran The risk or severity of adverse effects can be increased when Ximelagatran is combined with Collagenase clostridium histolyticum.
DB00048 DB05099 Ancrod The risk or severity of adverse effects can be increased when Ancrod is combined with Collagenase clostridium histolyticum.
DB00048 DB06228 Rivaroxaban The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Collagenase clostridium histolyticum.
DB00048 DB06271 Sulodexide The risk or severity of adverse effects can be increased when Sulodexide is combined with Collagenase clostridium histolyticum.
DB00048 DB06406 Idraparinux The risk or severity of adverse effects can be increased when Idraparinux is combined with Collagenase clostridium histolyticum.
DB00048 DB06605 Apixaban The risk or severity of adverse effects can be increased when Apixaban is combined with Collagenase clostridium histolyticum.
DB00048 DB06635 Otamixaban The risk or severity of adverse effects can be increased when Otamixaban is combined with Collagenase clostridium histolyticum.
DB00048 DB06695 Dabigatran etexilate The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase clostridium histolyticum.
DB00048 DB06754 Danaparoid The risk or severity of adverse effects can be increased when Danaparoid is combined with Collagenase clostridium histolyticum.
DB00048 DB06779 Dalteparin The risk or severity of adverse effects can be increased when Dalteparin is combined with Collagenase clostridium histolyticum.
DB00048 DB07767 Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Collagenase clostridium histolyticum.
DB00048 DB08794 Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Collagenase clostridium histolyticum.
DB00048 DB08813 Nadroparin The risk or severity of adverse effects can be increased when Nadroparin is combined with Collagenase clostridium histolyticum.
DB00048 DB09075 Edoxaban The risk or severity of adverse effects can be increased when Edoxaban is combined with Collagenase clostridium histolyticum.
DB00048 DB09255 Dextran The risk or severity of adverse effects can be increased when Dextran is combined with Collagenase clostridium histolyticum.
DB00048 DB09259 Reviparin The risk or severity of adverse effects can be increased when Reviparin is combined with Collagenase clostridium histolyticum.
DB00048 DB09261 Certoparin The risk or severity of adverse effects can be increased when Certoparin is combined with Collagenase clostridium histolyticum.
DB00048 DB11095 Desirudin The risk or severity of adverse effects can be increased when Desirudin is combined with Collagenase clostridium histolyticum.
DB00048 DB11268 Protocatechualdehyde The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Collagenase clostridium histolyticum.
DB00048 DB11312 Protein C The risk or severity of adverse effects can be increased when Protein C is combined with Collagenase clostridium histolyticum.
DB00048 DB11598 Antithrombin III human The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Collagenase clostridium histolyticum.
DB00048 DB11984 Letaxaban The risk or severity of adverse effects can be increased when Letaxaban is combined with Collagenase clostridium histolyticum.
DB00048 DB12289 Darexaban The risk or severity of adverse effects can be increased when Darexaban is combined with Collagenase clostridium histolyticum.
DB00048 DB12598 Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Collagenase clostridium histolyticum.
DB00048 DB12831 Gabexate The risk or severity of adverse effects can be increased when Gabexate is combined with Collagenase clostridium histolyticum.
DB00048 DB13124 Troxerutin The risk or severity of adverse effects can be increased when Troxerutin is combined with Collagenase clostridium histolyticum.
DB00048 DB13136 Fluindione The risk or severity of adverse effects can be increased when Fluindione is combined with Collagenase clostridium histolyticum.
DB00048 DB13149 Protein S human The risk or severity of adverse effects can be increased when Protein S human is combined with Collagenase clostridium histolyticum.
DB00048 DB13616 Melagatran The risk or severity of adverse effects can be increased when Melagatran is combined with Collagenase clostridium histolyticum.
DB00048 DB09125 Potassium citrate The risk or severity of adverse effects can be increased when Potassium citrate is combined with Collagenase clostridium histolyticum.
DB00048 DB09154 Sodium citrate The risk or severity of adverse effects can be increased when Sodium citrate is combined with Collagenase clostridium histolyticum.
DB00048 DB00031 Tenecteplase The risk or severity of adverse effects can be increased when Tenecteplase is combined with Collagenase clostridium histolyticum.
DB00048 DB00055 Drotrecogin alfa The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Collagenase clostridium histolyticum.
DB00048 DB04932 Defibrotide The risk or severity of adverse effects can be increased when Defibrotide is combined with Collagenase clostridium histolyticum.
DB00048 DB06822 Tinzaparin The risk or severity of adverse effects can be increased when Tinzaparin is combined with Collagenase clostridium histolyticum.
DB00048 DB13199 Brinase The risk or severity of adverse effects can be increased when Brinase is combined with Collagenase clostridium histolyticum.
DB00048 DB13646 Saruplase The risk or severity of adverse effects can be increased when Saruplase is combined with Collagenase clostridium histolyticum.
DB00048 DB00086 Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Collagenase clostridium histolyticum.
DB00048 DB00945 Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Collagenase clostridium histolyticum.
DB00048 DB04925 Desmoteplase The risk or severity of adverse effects can be increased when Desmoteplase is combined with Collagenase clostridium histolyticum.
DB00048 DB05254 Fibrinolysin The risk or severity of adverse effects can be increased when Fibrinolysin is combined with Collagenase clostridium histolyticum.
DB00048 DB06543 Astaxanthin The risk or severity of adverse effects can be increased when Astaxanthin is combined with Collagenase clostridium histolyticum.
DB00048 DB00013 Urokinase The risk or severity of adverse effects can be increased when Urokinase is combined with Collagenase clostridium histolyticum.
DB00048 DB00975 Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase clostridium histolyticum.
DB00048 DB01088 Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Collagenase clostridium histolyticum.
DB00048 DB01240 Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase clostridium histolyticum.
DB00048 DB05229 Beraprost The risk or severity of adverse effects can be increased when Beraprost is combined with Collagenase clostridium histolyticum.
DB00048 DB06209 Prasugrel The risk or severity of adverse effects can be increased when Prasugrel is combined with Collagenase clostridium histolyticum.
DB00048 DB06441 Cangrelor The risk or severity of adverse effects can be increased when Cangrelor is combined with Collagenase clostridium histolyticum.
DB00048 DB08814 Triflusal The risk or severity of adverse effects can be increased when Triflusal is combined with Collagenase clostridium histolyticum.
DB00048 DB08816 Ticagrelor The risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum.
DB00048 DB08994 Ditazole The risk or severity of adverse effects can be increased when Ditazole is combined with Collagenase clostridium histolyticum.
DB00048 DB09030 Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Collagenase clostridium histolyticum.
DB00048 DB09258 Bemiparin The risk or severity of adverse effects can be increased when Bemiparin is combined with Collagenase clostridium histolyticum.
DB00048 DB09260 Parnaparin The risk or severity of adverse effects can be increased when Parnaparin is combined with Collagenase clostridium histolyticum.
DB00048 DB13275 Clorindione The risk or severity of adverse effects can be increased when Clorindione is combined with Collagenase clostridium histolyticum.
DB00048 DB13347 Diphenadione The risk or severity of adverse effects can be increased when Diphenadione is combined with Collagenase clostridium histolyticum.
DB00048 DB13451 Tioclomarol The risk or severity of adverse effects can be increased when Tioclomarol is combined with Collagenase clostridium histolyticum.
DB00048 DB00001 Lepirudin The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.
DB00048 DB00009 Alteplase The risk or severity of adverse effects can be increased when Alteplase is combined with Collagenase clostridium histolyticum.
DB00048 DB00015 Reteplase The risk or severity of adverse effects can be increased when Reteplase is combined with Collagenase clostridium histolyticum.
DB00048 DB00029 Anistreplase The risk or severity of adverse effects can be increased when Anistreplase is combined with Collagenase clostridium histolyticum.
DB00048 DB14094 Tocopherylquinone The risk or severity of adverse effects can be increased when Tocopherylquinone is combined with Collagenase clostridium histolyticum.
DB00048 DB06679 Amediplase The risk or severity of adverse effects can be increased when Amediplase is combined with Collagenase clostridium histolyticum.
DB00048 DB03410 4-hydroxycoumarin The risk or severity of adverse effects can be increased when 4-hydroxycoumarin is combined with Collagenase clostridium histolyticum.
DB00048 DB08496 (R)-warfarin The risk or severity of adverse effects can be increased when (R)-warfarin is combined with Collagenase clostridium histolyticum.
DB00048 DB14055 (S)-Warfarin The risk or severity of adverse effects can be increased when (S)-Warfarin is combined with Collagenase clostridium histolyticum.
DB00048 DB12364 Betrixaban The risk or severity of adverse effects can be increased when Betrixaban is combined with Collagenase clostridium histolyticum.
DB00048 DB14598 Edetate calcium disodium anhydrous The risk or severity of adverse effects can be increased when Edetate calcium disodium anhydrous is combined with Collagenase clostridium histolyticum.
DB00048 DB11154 Zinc citrate The risk or severity of adverse effects can be increased when Zinc citrate is combined with Collagenase clostridium histolyticum.
DB00048 DB11166 Antithrombin Alfa The risk or severity of adverse effects can be increased when Antithrombin Alfa is combined with Collagenase clostridium histolyticum.
DB00048 DB04665 Coumarin The risk or severity of adverse effects can be increased when Coumarin is combined with Collagenase clostridium histolyticum.
DB00048 DB14726 Dabigatran The risk or severity of adverse effects can be increased when Dabigatran is combined with Collagenase clostridium histolyticum.
DB00048 DB06294 Semuloparin The risk or severity of adverse effects can be increased when Semuloparin is combined with Collagenase clostridium histolyticum.
DB00048 DB12726 Monteplase The risk or severity of adverse effects can be increased when Monteplase is combined with Collagenase clostridium histolyticum.
DB00049 DB00232 Methyclothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Methyclothiazide.
DB00049 DB00436 Bendroflumethiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Bendroflumethiazide.
DB00049 DB00562 Benzthiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Benzthiazide.
DB00049 DB00606 Cyclothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Cyclothiazide.
DB00049 DB00774 Hydroflumethiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Hydroflumethiazide.
DB00049 DB00880 Chlorothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Chlorothiazide.
DB00049 DB00999 Hydrochlorothiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Hydrochlorothiazide.
DB00049 DB01021 Trichlormethiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Trichlormethiazide.
DB00049 DB01324 Polythiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Polythiazide.
DB00049 DB13430 Mebutizide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Mebutizide.
DB00049 DB13532 Cyclopenthiazide The therapeutic efficacy of Rasburicase can be decreased when used in combination with Cyclopenthiazide.
